The	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
several	O
unsaturated	O
acyclonucleosides	O
related	O
to	O
augustmycin	O
A	O
are	O
described	O
.	O

The	O
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
acyclonucleoside	I-IUPAC
analogues	I-MODIFIER
of	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
adenine	I-IUPAC
,	O
6	I-IUPAC
-	I-IUPAC
methoxypurine	I-IUPAC
,	O
hypoxanthine	I-IUPAC
,	O
6	I-IUPAC
-	I-IUPAC
mercaptopurine	I-IUPAC
,	O
and	O
azathioprine	I-IUPAC
have	O
been	O
prepared	O
.	O

The	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
(	O
5	O
)	O
and	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
hypoxanthine	I-IUPAC
(	O
12	O
)	O
analogues	I-MODIFIER
were	O
converted	O
to	O
the	O
corresponding	O
5'	I-IUPAC
-	I-IUPAC
tributylstannyl	I-IUPAC
intermediates	I-MODIFIER
(	O
9	O
and	O
13	O
)	O
,	O
respectively	O
,	O
which	O
gave	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
(	O
10	O
)	O
and	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
hypoxanthine	I-IUPAC
(	O
14	O
)	O
,	O
respectively	O
,	O
after	O
iododestannylation	O
.	O

The	O
[	O
125I	O
]	O
-	O
radiolabeled	O
congeners	O
of	O
10	O
and	O
14	O
were	O
prepared	O
as	O
potential	O
metabolic	O
markers	O
.	O

Among	O
the	O
unsaturated	O
acyclonucleosides	O
tested	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
3	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
mercaptopurine	I-IUPAC
(	O
15	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
propargyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
azathioprine	I-IUPAC
(	O
17	O
)	O
,	O
and	O
angustmycin	O
A	O
analogue	O
10	O
showed	O
inhibition	O
of	O
cancer	O
cell	O
growth	O
,	O
but	O
only	O
at	O
a	O
minimal	O
level	O
,	O
and	O
17	O
also	O
showed	O
14%	O
cancer	O
cell	O
death	O
in	O
vitro	O
.	O

Compound	O
10	O
provided	O
approximately	O
50%	O
protection	O
against	O
HIV	O
at	O
10	O
(	O
-	O
4	O
)	O
M	O
concentrations	O
.	O

Biodistribution	O
results	O
of	O
[	O
125I	O
]	O
-	O
10	O
in	O
mice	O
indicate	O
that	O
compound	O
10	O
is	O
readily	O
metabolized	O
via	O
deiodination	O
in	O
vivo	O
,	O
possibly	O
by	O
serving	O
as	O
a	O
substrate	O
for	O
the	O
enzyme	O
S	I-IUPAC
-	I-IUPAC
adenosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
hydrolase	O
.	O

Sulfur	O
-	O
bridged	O
pregnanes	O
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
,	O
21	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
,	O
and	O
the	O
corresponding	O
sulfoxides	O
and	O
sulfones	O
were	O
synthesized	O
and	O
tested	O
as	O
blockers	O
of	O
the	O
immunosuppresive	O
activity	O
of	O
dexamethasone	O
in	O
rat	O
thymocytes	O
.	O

A	O
new	O
one	O
-	O
pot	O
procedure	O
is	O
described	O
for	O
the	O
preparation	O
of	O
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
and	O
related	O
compounds	O
by	O
iodocyclization	O
of	O
a	O
19	I-IUPAC
-	I-IUPAC
sulfanylpregn	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
.	O

Antiimmunosuppresive	O
activity	O
was	O
evaluated	O
by	O
the	O
ability	O
of	O
the	O
different	O
steroids	O
to	O
block	O
dexamethasone	O
-	O
mediated	O
apoptosis	O
in	O
thymocytes	O
and	O
dexamethasone	O
-	O
mediated	O
inhibition	O
of	O
the	O
NFkappa	O
-	O
B	O
transcription	O
factor	O
activity	O
.	O

DNA	O
fragmentation	O
and	O
annexin	O
V	O
-	O
FITC	O
positive	O
cells	O
were	O
taken	O
as	O
parameters	O
of	O
apoptosis	O
whereas	O
NFkappa	O
-	O
B	O
activity	O
was	O
tested	O
by	O
the	O
expression	O
of	O
the	O
reporter	O
vector	O
kappaB	O
-	O
luciferase	O
by	O
TNF	O
-	O
alpha	O
in	O
Hela	O
cells	O
.	O

21	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
S	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
had	O
improved	O
activity	O
in	O
both	O
parameters	O
,	O
while	O
21	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,19	I-IUPAC
-	I-IUPAC
epithioprogesterone	I-IUPAC
had	O
improved	O
activity	O
only	O
in	O
blocking	O
dexamethasone	O
-	O
induced	O
programmed	O
cell	O
death	O
.	O

A	O
new	O
procedure	O
for	O
the	O
preparation	O
of	O
the	O
antiviral	O
and	O
antitumor	O
agent	O
3	I-IUPAC
-	I-IUPAC
deazaguanine	I-IUPAC
(	O
1	O
)	O
and	O
its	O
metabolite	O
3	I-IUPAC
-	I-IUPAC
deazaguanosine	I-IUPAC
(	O
2	O
)	O
has	O
been	O
developed	O
by	O
reacting	O
methyl	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
cyanomethyl	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
4	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
cyanomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
6	O
)	O
,	O
respectively	O
,	O
with	O
hydrazine	O
.	O

The	O
3	I-IUPAC
-	I-IUPAC
deazaguanosine	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
cyclic	I-IUPAC
phosphate	I-IUPAC
(	O
13	O
)	O
was	O
prepared	O
from	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
cyanomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
-	I-IUPAC
imidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
phosphate	I-IUPAC
.	O

Glycosylation	O
of	O
the	O
trimethylsilyl	O
4	O
with	O
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranose	I-IUPAC
in	O
the	O
presence	O
of	O
trimethylsilyl	I-IUPAC
trifluoromethanesulfonate	I-IUPAC
gave	O
the	O
corresponding	O
N	I-IUPAC
-	I-IUPAC
1	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
3	I-IUPAC
glycosyl	I-IUPAC
derivatives	I-MODIFIER
with	O
alpha	O
-	O
configuration	O
(	O
18	O
and	O
20	O
)	O
as	O
the	O
major	O
products	O
,	O
along	O
with	O
minor	O
amounts	O
of	O
the	O
beta	O
-	O
anomers	O
(	O
19	O
and	O
21	O
)	O
.	O

However	O
,	O
glycosylation	O
of	O
the	O
sodium	O
salt	O
of	O
4	O
with	O
1	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofurano	I-IUPAC
se	I-IUPAC
(	O
17	O
)	O
gave	O
exclusively	O
the	O
beta	O
-	O
anomers	O
(	O
19	O
and	O
21	O
)	O
in	O
good	O
yield	O
.	O

Base	O
-	O
catalyzed	O
ring	O
closure	O
of	O
these	O
imidazole	O
nucleosides	O
gave	O
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
deazaguanosine	I-IUPAC
(	O
29	O
)	O
,	O
the	O
alpha	O
-	O
anomer	O
28	O
,	O
and	O
the	O
corresponding	O
N	O
-	O
3	O
positional	O
isomers	O
27	O
and	O
26	O
.	O

The	O
site	O
of	O
glycosylation	O
and	O
the	O
anomeric	O
configuration	O
of	O
these	O
nucleosides	O
have	O
been	O
assigned	O
on	O
the	O
basis	O
of	O
1'	O
NMR	O
and	O
UV	O
spectral	O
characteristics	O
and	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
for	O
27-29	O
.	O

In	O
a	O
preliminary	O
screening	O
,	O
several	O
of	O
these	O
compounds	O
have	O
demonstrated	O
significant	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
against	O
certain	O
DNA	O
and	O
RNA	O
viruses	O
in	O
vitro	O
,	O
as	O
well	O
as	O
moderate	O
activity	O
against	O
L1210	O
and	O
P388	O
leukemia	O
in	O
cell	O
culture	O
.	O

To	O
synthesize	O
potent	O
antagonists	O
of	O
the	O
mu	O
-	O
opioid	O
receptor	O
,	O
we	O
prepared	O
a	O
series	O
of	O
endomorphin	O
-	O
1	O
and	O
endomorphin	O
-	O
2	O
analogues	O
with	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
(	O
d	O
-	O
1	O
-	O
Nal	O
)	O
or	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
(	O
d	O
-	O
2	O
-	O
Nal	O
)	O
in	O
position	O
4	O
.	O

Some	O
of	O
these	O
analogues	O
displayed	O
weak	O
antagonist	O
properties	O
.	O

We	O
tried	O
to	O
strengthen	O
these	O
properties	O
by	O
introducing	O
the	O
structurally	O
modified	O
tyrosine	O
residue	O
2,6	I-IUPAC
-	I-IUPAC
dimethyltyrosine	I-IUPAC
(	O
Dmt	O
)	O
in	O
place	O
of	O
Tyr1	O
.	O

Among	O
the	O
synthesized	O
compounds	O
,	O
[	O
Dmt1	O
,	O
d	O
-	O
2	O
-	O
Nal4	O
]	O
endomorphin	O
-	O
1	O
,	O
designated	O
antanal	O
-	O
1	O
,	O
and	O
[	O
Dmt1	O
,	O
d	O
-	O
2	O
-	O
Nal4	O
]	O
endomorphin	O
-	O
2	O
,	O
designated	O
antanal	O
-	O
2	O
,	O
turned	O
out	O
to	O
be	O
highly	O
potent	O
and	O
selective	O
mu	O
-	O
opioid	O
receptor	O
antagonists	O
,	O
as	O
judged	O
on	O
the	O
basis	O
of	O
two	O
functional	O
assays	O
,	O
the	O
receptor	O
binding	O
assay	O
and	O
the	O
hot	O
plate	O
test	O
of	O
analgesia	O
.	O

Interestingly	O
,	O
another	O
analogue	O
of	O
this	O
series	O
,	O
[	O
Dmt1	O
,	O
d	O
-	O
1	O
-	O
Nal4	O
]	O
endomorphin	O
-	O
1	O
,	O
turned	O
out	O
to	O
be	O
a	O
moderately	O
potent	O
mixed	O
mu	O
-	O
agonist	O
/	O
delta	O
-	O
antagonist	O
.	O

A	O
family	O
of	O
analogues	O
of	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
/	O
D2Nal	O
(	O
8	O
)	O
]	O
-	O
SRIF	O
that	O
contain	O
a	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminomethylphenylalanine	I-IUPAC
(	O
IAmp	O
)	O
at	O
position	O
9	O
was	O
identified	O
that	O
has	O
high	O
affinity	O
and	O
selectivity	O
for	O
human	O
somatostatin	O
receptor	O
subtype	O
1	O
(	O
sst1	O
)	O
.	O

The	O
binding	O
affinities	O
of	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
c	O
[	O
H	O
-	O
Cys	O
-	O
Lys	O
-	O
Phe	O
-	O
Phe	O
-	O
DTrp	O
-	O
IAmp	O
-	O
Thr	O
-	O
Phe	O
-	O
Thr	O
-	O
Ser	O
-	O
Cys	O
-	O
OH	O
]	O
,	O
CH	O
-	O
275	O
)	O
(	O
7	O
)	O
,	O
des	O
-	O
AA	O
(	O
1,5	O
)	O
-	O
[	O
Tyr	O
(	O
2	O
)	O
,	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
CH	O
-	O
288	O
)	O
(	O
16	O
)	O
,	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
Tyr	O
(	O
7	O
)	O
,	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
23	O
)	O
,	O
and	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
Tyr	O
(	O
11	O
)	O
]	O
-	O
SRIF	O
(	O
25	O
)	O
are	O
about	O
(	O
1	O
)	O
/	O
(	O
7	O
)	O
,	O
(	O
1	O
)	O
/	O
(	O
4	O
)	O
,	O
(	O
1	O
)	O
/	O
(	O
125	O
)	O
,	O
and	O
(	O
1	O
)	O
/	O
(	O
4	O
)	O
that	O
of	O
SRIF	O
-	O
28	O
(	O
1	O
)	O
to	O
sst1	O
,	O
respectively	O
,	O
about	O
(	O
1	O
)	O
/	O
(	O
65	O
)	O
,	O
(	O
1	O
)	O
/	O
(	O
130	O
)	O
,	O
&	O
lt	O
;	O
(	O
1	O
)	O
/	O
(	O
1000	O
)	O
,	O
and	O
&	O
lt	O
;	O
(	O
1	O
)	O
/	O
(	O
150	O
)	O
that	O
of	O
1	O
to	O
sst3	O
,	O
respectively	O
,	O
and	O
about	O
or	O
less	O
than	O
(	O
1	O
)	O
/	O
(	O
1000	O
)	O
that	O
of	O
1	O
to	O
the	O
other	O
three	O
human	O
SRIF	O
receptor	O
subtypes	O
.	O

A	O
substitution	O
of	O
DTrp	O
(	O
8	O
)	O
by	O
D2Nal	O
(	O
8	O
)	O
in	O
7	O
to	O
yield	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
D2Nal	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
13	O
)	O
and	O
in	O
16	O
to	O
yield	O
des	O
-	O
AA	O
(	O
1,5	O
)	O
-	O
[	O
Tyr	O
(	O
2	O
)	O
,	O
D2Nal	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
17	O
)	O
was	O
intended	O
to	O
increase	O
chemical	O
stability	O
,	O
selectivity	O
,	O
and	O
affinity	O
and	O
resulted	O
in	O
two	O
analogues	O
that	O
were	O
less	O
potent	O
or	O
equipotent	O
with	O
similar	O
selectivity	O
,	O
respectively	O
.	O

Carbamoylation	O
of	O
the	O
N	O
-	O
terminus	O
as	O
in	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
Tyr	O
(	O
11	O
)	O
]	O
-	O
Cbm	O
-	O
SRIF	O
(	O
27	O
)	O
increased	O
affinity	O
slightly	O
as	O
well	O
as	O
improved	O
selectivity	O
.	O

Monoiodination	O
of	O
25	O
to	O
yield	O
26	O
and	O
of	O
27	O
to	O
yield	O
28	O
resulted	O
in	O
an	O
additional	O
4	O
-	O
fold	O
increase	O
in	O
affinity	O
at	O
sst1	O
.	O

Desamination	O
of	O
the	O
N	O
-	O
terminus	O
of	O
17	O
to	O
yield	O
18	O
,	O
on	O
the	O
other	O
hand	O
,	O
resulted	O
in	O
significant	O
loss	O
of	O
affinity	O
.	O

Attempts	O
at	O
reducing	O
the	O
size	O
of	O
the	O
ring	O
with	O
maintenance	O
of	O
selectivity	O
failed	O
in	O
that	O
des	O
-	O
AA	O
(	O
1,4,5,13	O
)	O
-	O
[	O
Tyr	O
(	O
2	O
)	O
,	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
33	O
)	O
and	O
des	O
-	O
AA	O
(	O
1,4,5,6,12,13	O
)	O
-	O
[	O
Tyr	O
(	O
2	O
)	O
,	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
34	O
)	O
progressively	O
lost	O
affinity	O
for	O
all	O
receptors	O
.	O

Both	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
Tyr	O
(	O
11	O
)	O
]	O
-	O
Cbm	O
-	O
SRIF	O
(	O
27	O
)	O
and	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DCys	O
(	O
3	O
)	O
,	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
Tyr	O
(	O
11	O
)	O
]	O
-	O
Cbm	O
-	O
SRIF	O
(	O
29	O
)	O
show	O
agonistic	O
activity	O
in	O
a	O
cAMP	O
assay	O
;	O
therefore	O
,	O
the	O
structural	O
basis	O
for	O
the	O
agonist	O
property	O
of	O
this	O
family	O
of	O
analogues	O
is	O
not	O
contingent	O
upon	O
the	O
chirality	O
of	O
the	O
Cys	O
residue	O
at	O
position	O
3	O
as	O
shown	O
to	O
be	O
the	O
case	O
in	O
18	O
-	O
membered	O
ring	O
SRIF	O
octapeptides	O
.	O

None	O
of	O
the	O
high	O
affinity	O
structures	O
described	O
here	O
showed	O
receptor	O
antagonism	O
.	O

We	O
have	O
prepared	O
the	O
radiolabeled	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
(	O
125	O
)	O
ITyr	O
(	O
11	O
)	O
]	O
-	O
SRIF	O
(	O
(	O
125	O
)	O
I	O
-	O
25	O
)	O
and	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
(	O
125	O
)	O
ITyr	O
(	O
11	O
)	O
]	O
-	O
Cbm	O
-	O
SRIF	O
(	O
(	O
125	O
)	O
I	O
-	O
27	O
)	O
,	O
used	O
them	O
as	O
in	O
vitro	O
tracers	O
,	O
and	O
found	O
them	O
to	O
be	O
superior	O
to	O
des	O
-	O
AA	O
(	O
1,5	O
)	O
-	O
[	O
(	O
125	O
)	O
ITyr	O
(	O
2	O
)	O
,	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
(	O
125	O
)	O
I	O
-	O
16	O
)	O
for	O
the	O
detection	O
of	O
sst1	O
tumors	O
in	O
receptor	O
autoradiography	O
studies	O
.	O

2	I-PARTIUPAC
-	I-PARTIUPAC
Fluoro	I-PARTIUPAC
-	I-PARTIUPAC
,	O
5	I-PARTIUPAC
-	I-PARTIUPAC
fluoro	I-PARTIUPAC
-	I-PARTIUPAC
and	O
6	I-IUPAC
-	I-IUPAC
fluorodimethoxybenzaldehydes	I-IUPAC
were	O
prepared	O
by	O
photochemical	O
decomposition	O
of	O
the	O
corresponding	O
diazonium	O
fluoroborates	O
.	O

The	O
aldehydes	O
were	O
converted	O
to	O
the	O
cyanohydrin	I-IUPAC
trimethylsilyl	I-IUPAC
ethers	I-IUPAC
,	O
which	O
,	O
in	O
turn	O
,	O
were	O
reduced	O
to	O
the	O
dimethoxyphenethanolamines	I-IUPAC
.	O

Boron	O
tribromide	O
demethylation	O
afforded	O
the	O
racemic	O
ring	O
-	O
fluorinated	O
norepinephrines	O
.	O

An	O
alternate	O
route	O
,	O
using	O
the	O
dibenzyloxyfluoroaldehyde	I-IUPAC
,	O
was	O
also	O
used	O
to	O
prepare	O
6	I-IUPAC
-	I-IUPAC
fluoronorepinephrine	I-IUPAC
.	O

The	O
fluorine	O
substituent	O
markedly	O
increases	O
the	O
phenolic	O
acidities	O
of	O
these	O
analogues	O
.	O

The	O
biological	O
properties	O
conferred	O
upon	O
norepinephrine	O
by	O
the	O
fluorine	O
substituents	O
in	O
peripheral	O
and	O
central	O
adrenergically	O
responsive	O
systems	O
clearly	O
demonstrate	O
that	O
2	I-IUPAC
-	I-IUPAC
fluoronorepinephrine	I-IUPAC
is	O
a	O
nearly	O
a	O
pure	O
beta	O
-	O
adrenergic	O
agonist	O
,	O
while	O
6	I-IUPAC
-	I-IUPAC
fluoronorepinephrine	I-IUPAC
is	O
an	O
alpha	O
-	O
adrenergic	O
agonist	O
.	O

5	I-IUPAC
-	I-IUPAC
Fluoronorepinephrine	I-IUPAC
retains	O
both	O
beta	O
-	O
and	O
alpha	O
-	O
adrenergic	O
agonist	O
properties	O
.	O

Receptor	O
-	O
binding	O
studies	O
with	O
specific	O
radiolabeled	O
ligands	O
indicate	O
that	O
the	O
specificity	O
conferred	O
by	O
the	O
site	O
of	O
fluorine	O
substituents	O
results	O
from	O
a	O
change	O
in	O
the	O
affinity	O
of	O
these	O
analogues	O
for	O
the	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
receptors	O
.	O

Three	O
N	I-IUPAC
-	I-IUPAC
fluoroethyl	I-IUPAC
-	I-IUPAC
substituted	I-MODIFIER
(	B-IUPAC
imidazolylphenyl	I-IUPAC
)	I-IUPAC
formamidine	I-IUPAC
derivatives	I-MODIFIER
,	O
namely	O
,	O
2	I-IUPAC
-	I-IUPAC
fluoroethyl	I-IUPAC
(	O
3b	O
)	O
,	O
2,2	I-IUPAC
-	I-IUPAC
difluoroethyl	I-IUPAC
(	O
3c	O
)	O
,	O
and	O
2,2,2	I-IUPAC
-	I-IUPAC
trifluoroethyl	I-IUPAC
(	O
3d	O
)	O
,	O
were	O
prepared	O
to	O
test	O
the	O
effect	O
of	O
fluorine	O
substitution	O
on	O
basicity	O
and	O
,	O
then	O
,	O
on	O
H2	O
-	O
antagonist	O
affinity	O
in	O
comparison	O
with	O
the	O
unsubstituted	I-MODIFIER
N	B-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
derivative	I-MODIFIER
(	O
3a	O
)	O
,	O
taken	O
as	O
a	O
model	O
of	O
mifentidine	O
.	O

Imidazolylphenyl	O
isothiocyanate	O
(	O
1	O
)	O
,	O
obtained	O
by	O
reaction	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
with	O
carbon	O
disulfide	O
and	O
ethyl	I-IUPAC
chloroformate	I-IUPAC
,	O
was	O
condensed	O
with	O
the	O
requisite	O
2	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	O
substituted	I-MODIFIER
ethylamines	B-IUPAC
to	O
give	O
the	O
intermediate	O
thioureas	O
(	O
2b	O
-	O
d	O
)	O
.	O

Desulfurization	O
of	O
these	O
thioureas	O
by	O
Raney	O
nickel	O
furnished	O
the	O
desired	O
formamidines	O
(	O
3b	O
-	O
d	O
)	O
.	O

Increasing	O
fluorine	O
substitution	O
was	O
found	O
to	O
decrease	O
basicity	O
of	O
the	O
formamidino	O
group	O
substantially	O
(	O
3a	O
,	O
pKa	O
=	O
8.65	O
;	O
3b	O
,	O
pKa	O
=	O
8.12	O
;	O
3c	O
,	O
pKa	O
=	O
6.60	O
;	O
3d	O
,	O
pKa	O
=	O
6.14	O
)	O
,	O
while	O
having	O
a	O
modest	O
effect	O
on	O
the	O
imidazole	O
portion	O
.	O

Affinity	O
at	O
the	O
H2	O
receptors	O
,	O
evaluated	O
from	O
antagonism	O
of	O
histamine	O
-	O
stimulated	O
chronotropic	O
response	O
on	O
guinea	O
pig	O
atria	O
,	O
increased	O
following	O
fluorine	O
substitution	O
(	O
3a	O
,	O
KB	O
=	O
177	O
;	O
3b	O
,	O
KB	O
=	O
61	O
;	O
3c	O
,	O
KB	O
=	O
21	O
;	O
3d	O
,	O
KB	O
=	O
7.6	O
)	O
.	O

It	O
is	O
concluded	O
that	O
H2	O
-	O
receptor	O
antagonist	O
affinity	O
in	O
the	O
mifentidine	O
series	O
is	O
mostly	O
dependent	O
on	O
the	O
availability	O
of	O
the	O
neutral	O
species	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
mifentidine	O
,	O
like	O
cimetidine	O
,	O
acts	O
through	O
the	O
neutral	O
species	O
.	O

Glycosylation	O
of	O
ethyl	I-IUPAC
3	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
3	O
)	O
and	O
3	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
4	O
)	O
with	O
poly	O
-	O
O	O
-	O
acetylated	O
sugars	O
via	O
an	O
acid	O
-	O
catalyzed	O
fusion	O
method	O
afforded	O
the	O
corresponding	O
ethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
substituted	I-MODIFIER
nucleosides	I-MODIFIER
5	I-MODIFIER
and	O
7	I-MODIFIER
,	O
respectively	O
.	O

In	O
some	O
cases	O
,	O
the	O
positional	O
isomers	O
6	O
and	O
8	O
were	O
also	O
obtained	O
.	O

Treatment	O
of	O
5	O
and	O
7	O
with	O
methanolic	O
ammonia	O
gave	O
the	O
deprotected	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
nucleosides	I-MODIFIER
9	O
.	O

Reaction	O
of	O
3	O
-	O
-	O
5	O
and	O
7	O
with	O
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amine	I-IUPAC
led	O
to	O
the	O
corresponding	O
pyrazole	O
nitrogen	O
mustards	O
10	O
-	O
-	O
13	O
.	O

All	O
the	O
bromomethylpyrazole	O
nucleosides	O
described	O
showed	O
significant	O
cytostatic	O
activity	O
against	O
HeLa	O
cell	O
cultures	O
.	O

2beta	O
-	O
(	O
R	O
)	O
-	O
Carbo	O
-	O
1	O
-	O
fluoro	O
-	O
2	O
-	O
propoxy	O
-	O
3beta	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
tro	O
pane	O
(	O
(	O
R	O
)	O
-	O
FIPCT	O
,	O
R	O
-	O
6	O
)	O
and	O
2beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carbo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
tro	I-IUPAC
pane	I-IUPAC
(	O
(	O
S	O
)	O
-	O
FIPCT	O
,	O
S	O
-	O
6	O
)	O
were	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
selectivity	O
and	O
specificity	O
.	O

High	O
specific	O
activity	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
were	O
synthesized	O
in	O
5%	O
radiochemical	O
yield	O
(	O
decay	O
-	O
corrected	O
to	O
end	O
of	O
bombardment	O
(	O
EOB	O
)	O
)	O
by	O
preparation	O
of	O
the	O
precursors	O
2beta	I-IUPAC
-	I-IUPAC
carbo	I-IUPAC
-	I-IUPAC
R	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mesyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorop	I-IUPAC
hen	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
(	O
R	O
-	O
12	O
)	O
and	O
2beta	I-IUPAC
-	I-IUPAC
carbo	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mesyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorop	I-IUPAC
hen	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
(	O
S	O
-	O
12	O
)	O
followed	O
by	O
treatment	O
with	O
no	O
carrier	O
-	O
added	O
potassium	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoride	O
and	O
kyrptofix	O
K222	O
in	O
acetonitrile	O
.	O

Competition	O
binding	O
in	O
cells	O
stably	O
expressing	O
the	O
transfected	O
human	O
DAT	O
and	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
labeled	O
by	O
[	O
(	O
3	O
)	O
H	O
]	O
WIN	O
35428	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
citalopram	O
,	O
respectively	O
,	O
demonstrated	O
the	O
following	O
order	O
of	O
DAT	O
affinity	O
(	O
K	O
(	O
i	O
)	O
in	O
nM	O
)	O
:	O
GBR	O
12909	O
(	O
0.36	O
)	O
&	O
gt	O
;	O
CIT	O
(	O
0.48	O
)	O
&	O
gt	O
;	O
(	O
S	O
)	O
-	O
FIPCT	O
(	O
0.67	O
)	O
&	O
gt	O
;	O
&	O
gt	O
;	O
(	O
R	O
)	O
-	O
FIPCT	O
(	O
3.2	O
)	O
.	O

The	O
affinity	O
of	O
(	O
S	O
)	O
-	O
FIPCT	O
and	O
(	O
R	O
)	O
-	O
FIPCT	O
for	O
SERT	O
was	O
127	O
-	O
and	O
20	O
-	O
fold	O
lower	O
,	O
respectively	O
,	O
than	O
for	O
DAT	O
.	O

In	O
vivo	O
biodistribution	O
studies	O
were	O
performed	O
in	O
male	O
rats	O
and	O
demonstrated	O
that	O
the	O
brain	O
uptake	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
were	O
selective	O
and	O
specific	O
for	O
DAT	O
rich	O
regions	O
(	O
caudate	O
and	O
putamen	O
)	O
.	O

PET	O
brain	O
imaging	O
studies	O
in	O
monkeys	O
demonstrated	O
high	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
uptake	O
in	O
the	O
caudate	O
and	O
putamen	O
which	O
resulted	O
in	O
caudate	O
-	O
to	O
-	O
cerebellum	O
and	O
putamen	O
-	O
to	O
-	O
cerebellum	O
ratios	O
of	O
2.5-3.5	O
at	O
115	O
min	O
.	O

[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
uptake	O
in	O
the	O
caudate	O
/	O
putamen	O
achieved	O
transient	O
equilibrium	O
at	O
75	O
min	O
.	O

In	O
an	O
imaging	O
experiment	O
with	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
in	O
a	O
rhesus	O
monkey	O
with	O
its	O
left	O
hemisphere	O
lesioned	O
with	O
MPTP	O
,	O
radioactivity	O
was	O
reduced	O
to	O
background	O
in	O
the	O
caudate	O
and	O
putamen	O
of	O
the	O
lesioned	O
hemisphere	O
.	O

The	O
high	O
specific	O
activity	O
one	O
-	O
step	O
radiolabeling	O
preparation	O
and	O
high	O
specificity	O
and	O
selectivity	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
for	O
DAT	O
indicate	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
are	O
potential	O
radioligands	O
for	O
mapping	O
brain	O
DAT	O
in	O
humans	O
using	O
PET	O
.	O

Steric	O
and	O
electrostatic	O
requirements	O
at	O
position	O
6	O
of	O
[	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
,	O
a	O
full	O
agonist	O
of	O
NK	O
-	O
2	O
receptors	O
,	O
for	O
molecular	O
recognition	O
by	O
the	O
receptor	O
were	O
studied	O
.	O

Two	O
series	O
of	O
peptide	O
analogues	O
,	O
(	O
a	O
)	O
p	O
-	O
substituted	O
analogues	O
,	O
[	O
p	O
-	O
X	O
-	O
Phe	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
,	O
where	O
X	O
=	O
F	O
,	O
Cl	O
,	O
Br	O
,	O
I	O
,	O
NH	O
(	O
2	O
)	O
,	O
NO	O
(	O
2	O
)	O
,	O
and	O
(	O
b	O
)	O
[	O
D	O
-	O
Phe	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
,	O
[	O
Trp	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
,	O
and	O
[	O
Chex	O
-	O
Ala	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
,	O
were	O
synthesized	O
,	O
and	O
their	O
biological	O
activity	O
was	O
examined	O
.	O

Competition	O
binding	O
experiments	O
with	O
[	O
(	O
3	O
)	O
H	O
]	O
NKA	O
were	O
performed	O
using	O
cloned	O
human	O
NK	O
-	O
2	O
receptors	O
expressed	O
in	O
CHO	O
cells	O
.	O

Antagonistic	O
and	O
agonistic	O
properties	O
of	O
the	O
analogues	O
were	O
studied	O
using	O
an	O
in	O
vitro	O
functional	O
assay	O
with	O
hamster	O
tracheal	O
rings	O
.	O

The	O
rank	O
order	O
of	O
potency	O
of	O
agonists	O
was	O
[	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
approximately	O
[	O
p	O
-	O
F	O
-	O
Phe	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
&	O
gt	O
;	O
[	O
p	O
-	O
NH	O
(	O
2	O
)	O
-	O
Phe	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
&	O
gt	O
;	O
[	O
p	O
-	O
Cl	O
-	O
Phe	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
&	O
gt	O
;	O
[	O
p	O
-	O
NO	O
(	O
2	O
)	O
-	O
Phe	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
&	O
gt	O
;	O
[	O
Trp	O
(	O
6	O
)	O
,	O
Nle	O
(	O
10	O
)	O
]	O
NKA	O
(	O
4-10	O
)	O
.	O

Size	O
and	O
planarity	O
of	O
the	O
aromatic	O
side	O
chain	O
were	O
crucially	O
important	O
for	O
the	O
biological	O
activity	O
,	O
whereas	O
electron	O
-	O
donating	O
and	O
electron	O
-	O
withdrawing	O
properties	O
of	O
the	O
para	O
-	O
substituent	O
were	O
less	O
important	O
.	O

The	O
results	O
favor	O
the	O
hypothesis	O
that	O
weakly	O
polar	O
pi	O
-	O
pi	O
interactions	O
exist	O
between	O
the	O
aromatic	O
group	O
and	O
the	O
receptor	O
.	O

We	O
have	O
previously	O
described	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
cyclohepta	I-IUPAC
[	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
4	O
-	O
AHCP	O
)	O
as	O
a	O
highly	O
effective	O
agonist	O
at	O
non	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
aspartate	I-IUPAC
(	O
non	O
-	O
NMDA	O
)	O
glutamate	O
(	O
Glu	O
)	O
receptors	O
in	O
vivo	O
,	O
which	O
is	O
more	O
potent	O
than	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
but	O
inactive	O
at	O
NMDA	O
receptors	O
.	O

However	O
,	O
4	O
-	O
AHCP	O
was	O
found	O
to	O
be	O
much	O
weaker	O
than	O
AMPA	O
as	O
an	O
inhibitor	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
AMPA	O
binding	O
and	O
to	O
have	O
limited	O
effect	O
in	O
a	O
[	O
(	O
3	O
)	O
H	O
]	O
kainic	O
acid	O
binding	O
assay	O
using	O
rat	O
cortical	O
membranes	O
.	O

To	O
shed	O
light	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
quite	O
enigmatic	O
pharmacological	O
profile	O
of	O
4	O
-	O
AHCP	O
,	O
we	O
have	O
now	O
developed	O
a	O
synthesis	O
of	O
(	O
S	O
)	O
-	O
4	O
-	O
AHCP	O
(	O
6	O
)	O
and	O
(	O
R	O
)	O
-	O
4	O
-	O
AHCP	O
(	O
7	O
)	O
.	O

At	O
cloned	O
metabotropic	O
Glu	O
receptors	O
mGluR1alpha	O
(	O
group	O
I	O
)	O
,	O
mGluR2	O
(	O
group	O
II	O
)	O
,	O
and	O
mGluR4a	O
(	O
group	O
III	O
)	O
,	O
neither	O
6	O
nor	O
7	O
showed	O
significant	O
agonist	O
or	O
antagonist	O
effects	O
.	O

The	O
stereoisomer	O
6	O
,	O
but	O
not	O
7	O
,	O
activated	O
cloned	O
AMPA	O
receptor	O
subunits	O
GluR1o	O
,	O
GluR3o	O
,	O
and	O
GluR4o	O
with	O
EC	O
(	O
50	O
)	O
values	O
in	O
the	O
range	O
4.5-15	O
microM	O
and	O
the	O
coexpressed	O
kainate	O
-	O
preferring	O
subunits	O
GluR6	O
+	O
KA2	O
(	O
EC	O
(	O
50	O
)	O
=	O
6.4	O
microM	O
)	O
.	O

Compound	O
6	O
,	O
but	O
not	O
7	O
,	O
proved	O
to	O
be	O
a	O
very	O
potent	O
agonist	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.13	O
microM	O
)	O
at	O
the	O
kainate	O
-	O
preferring	O
GluR5	O
subunit	O
,	O
equipotent	O
with	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyisothiazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
Thio	O
-	O
ATPA	O
,	O
4	O
]	O
and	O
almost	O
4	O
times	O
more	O
potent	O
than	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
ATPA	O
,	O
3	O
]	O
.	O

Compound	O
6	O
thus	O
represents	O
a	O
new	O
structural	O
class	O
of	O
GluR5	O
agonists	O
.	O

Molecular	O
modeling	O
and	O
docking	O
to	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
the	O
AMPA	O
subunit	O
GluR2	O
has	O
enabled	O
identification	O
of	O
the	O
probable	O
active	O
conformation	O
and	O
binding	O
mode	O
of	O
6	O
.	O

We	O
are	O
able	O
to	O
rationalize	O
the	O
observed	O
selectivities	O
by	O
comparing	O
the	O
docking	O
of	O
4	O
and	O
6	O
to	O
subtype	O
constructs	O
,	O
i.e.	O
,	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
GluR2	O
and	O
a	O
homology	O
model	O
of	O
GluR5	O
.	O

N	O
-	O
Methylacetazolamide	O
was	O
shown	O
to	O
be	O
active	O
topically	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
to	O
a	O
small	O
but	O
statistically	O
significant	O
level	O
in	O
the	O
normotensive	O
rabbit	O
eye	O
.	O

In	O
vivo	O
experiments	O
with	O
N	I-IUPAC
-	I-IUPAC
methylacetazolamide	I-IUPAC
suggest	O
that	O
ocular	O
metabolism	O
to	O
acetazolamide	O
was	O
responsible	O
for	O
the	O
observed	O
topical	O
activity	O
.	O

Examination	O
of	O
initial	O
rate	O
kinetics	O
of	O
carbonic	O
anhydrase	O
catalyzed	O
p	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
acetate	I-IUPAC
hydrolysis	O
showed	O
that	O
N	I-IUPAC
-	I-IUPAC
methylacetazolamide	I-IUPAC
was	O
a	O
competitive	O
inhibitor	O
,	O
in	O
contrast	O
to	O
noncompetitive	O
inhibition	O
seen	O
with	O
acetazolamide	O
and	O
other	O
primary	O
sulfonamide	O
inhibitors	O
.	O

N	I-MODIFIER
-	I-MODIFIER
Substituted	I-MODIFIER
and	O
unsubstituted	I-MODIFIER
4	B-PARTIUPAC
-	I-PARTIUPAC
chlorobenzene	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
nitrobenzenesulfonamides	I-IUPAC
were	O
also	O
synthesized	O
,	O
and	O
their	O
biochemical	O
characteristics	O
and	O
in	O
vivo	O
ability	O
to	O
lower	O
IOP	O
when	O
applied	O
topically	O
were	O
determined	O
.	O

The	O
primary	O
sulfonamides	O
were	O
reversible	O
noncompetitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
with	O
no	O
effect	O
on	O
IOP	O
after	O
topical	O
administration	O
.	O

4	I-PARTIUPAC
-	I-PARTIUPAC
Nitrobenzene	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
chlorobenzenesulfonamides	I-IUPAC
containing	O
both	O
N	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
substituents	I-MODIFIER
were	O
model	O
irreversible	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
and	O
exhibited	O
a	O
trend	O
toward	O
topical	O
activity	O
in	O
reducing	O
IOP	O
in	O
normotensive	O
rabbit	O
eyes	O
.	O

Therefore	O
,	O
this	O
paper	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
two	O
types	O
of	O
carbonic	O
anhydrase	O
inhibitors	O
;	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
sulfonamides	B-IUPAC
are	O
reversible	O
competitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
while	O
the	O
N	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
sulfonamides	B-IUPAC
are	O
irreversible	O
inhibitors	O
.	O

The	O
synthesis	O
and	O
pharmacological	O
profile	O
of	O
a	O
series	O
of	O
neuroprotective	O
adenosine	O
agonists	O
are	O
described	O
.	O

Novel	O
A	O
(	O
1	O
)	O
agonists	O
with	O
potent	O
central	O
nervous	O
system	O
effects	O
and	O
diminished	O
influence	O
on	O
the	O
cardiovascular	O
system	O
are	O
reported	O
and	O
compared	O
to	O
selected	O
reference	O
adenosine	O
agonists	O
.	O

The	O
novel	O
compounds	O
featured	O
are	O
derived	O
structurally	O
from	O
two	O
key	O
lead	O
structures	O
:	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	O
21-0041	O
,	O
9	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	O
90-1515	O
,	O
4	O
)	O
.	O

The	O
agonists	O
are	O
characterized	O
in	O
terms	O
of	O
their	O
in	O
vitro	O
profiles	O
,	O
both	O
binding	O
and	O
functional	O
,	O
and	O
in	O
vivo	O
activity	O
in	O
relevant	O
animal	O
models	O
.	O

Neuroprotective	O
properties	O
assessed	O
after	O
postischemic	O
dosing	O
in	O
a	O
Mongolian	O
gerbil	O
severe	O
temporary	O
forebrain	O
ischemia	O
paradigm	O
,	O
using	O
hippocampal	O
CA1	O
damage	O
endpoints	O
,	O
and	O
the	O
efficacy	O
of	O
these	O
agonists	O
in	O
an	O
A	O
(	O
1	O
)	O
functional	O
assay	O
show	O
similarities	O
to	O
some	O
reference	O
adenosine	O
agonists	O
.	O

However	O
,	O
the	O
new	O
compounds	O
we	O
describe	O
exhibit	O
diminished	O
cardiovascular	O
effects	O
in	O
both	O
anesthetized	O
and	O
awake	O
rats	O
when	O
compared	O
to	O
reference	O
A	O
(	O
1	O
)	O
agonists	O
such	O
as	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phenylisopropyladenosine	I-IUPAC
(	O
R	O
-	O
PIA	O
,	O
5	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
cyclopentyladenosine	I-IUPAC
(	O
CPA	O
,	O
2	O
)	O
,	O
4	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
trans	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxycyclopentyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
GR	O
79236	O
,	O
26	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyladenosine	I-IUPAC
(	O
SDZ	O
WAG	O
994	O
,	O
27	O
)	O
,	O
and	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
Metrifudil	O
,	O
28	O
)	O
.	O

In	O
mouse	O
permanent	O
middle	O
cerebral	O
artery	O
occlusion	O
focal	O
ischemia	O
,	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzothiazolyl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	O
21-0136	O
,	O
12	O
)	O
exhibited	O
significant	O
neuroprotection	O
at	O
the	O
remarkably	O
low	O
total	O
intraperitoneal	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
,	O
a	O
dose	O
at	O
which	O
no	O
cardiovascular	O
effects	O
are	O
observed	O
in	O
conscious	O
rats	O
.	O

The	O
novel	O
agonists	O
described	O
inhibit	O
6	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
carboline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
-	O
induced	I-MODIFIER
seizures	I-MODIFIER
,	O
and	O
in	O
mouse	O
locomotor	O
activity	O
higher	O
doses	O
are	O
required	O
to	O
reach	O
ED	O
(	O
50	O
)	O
values	O
than	O
for	O
reference	O
A	O
(	O
1	O
)	O
agonists	O
.	O

We	O
conclude	O
that	O
two	O
of	O
the	O
novel	O
adenosine	O
derivatives	O
revealed	O
herein	O
,	O
12	I-PARTIUPAC
and	O
5'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	O
21-0147	O
,	O
13	O
)	O
,	O
representatives	O
of	O
a	O
new	O
series	O
of	O
P	O
(	O
1	O
)	O
ligands	O
,	O
reinforce	O
the	O
fact	O
that	O
novel	O
selective	O
adenosine	O
A	O
(	O
1	O
)	O
agonists	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
cerebral	O
ischemia	O
in	O
humans	O
.	O

Conversion	O
of	O
the	O
8	I-IUPAC
-	I-IUPAC
phenolic	I-IUPAC
1,2,3,4,5,6	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
methano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzazocines	I-IUPAC
to	O
the	O
corresponding	O
8	I-IUPAC
-	I-IUPAC
thiophenolic	I-IUPAC
analogues	I-MODIFIER
was	O
achieved	O
by	O
three	O
different	O
routes	O
.	O

Diazotization	O
of	O
8	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
methano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzazocine	I-IUPAC
(	O
2	O
)	O
followed	O
by	O
the	O
reaction	O
with	O
CH3SNa	O
afforded	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4,5,6	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
methano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzazocine	I-IUPAC
(	O
3	O
)	O
.	O

Another	O
route	O
using	O
Grewe	O
cyclization	O
was	O
also	O
examined	O
for	O
the	O
synthesis	O
of	O
3	O
.	O

As	O
the	O
most	O
effective	O
route	O
,	O
Newman	O
-	O
Kwart	O
rearrangement	O
of	O
benzazocines	O
was	O
selected	O
and	O
closely	O
investigated	O
.	O

8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
Dimethylthiocarbamoyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
derivatives	I-MODIFIER
(	O
6a	O
-	O
e	O
)	O
rearranged	O
to	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylcarbamoyl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
derivatives	I-MODIFIER
(	O
7a	O
-	O
e	O
)	O
in	O
good	O
yields	O
.	O

Reductive	O
cleavage	O
of	O
7a	O
-	O
e	O
and	O
subsequent	O
methylation	O
or	O
acylations	O
gave	O
the	O
title	O
compounds	O
(	O
3	O
,	O
8-24	O
)	O
.	O

Although	O
analgesic	O
activities	O
of	O
sulfur	O
-	O
containing	O
benzazocines	O
decreased	O
compared	O
to	O
the	O
corresponding	O
hydroxy	O
compounds	O
,	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivative	I-MODIFIER
(	O
S	O
-	O
metazocine	O
,	O
8	O
)	O
showed	O
potent	O
analgesic	O
activity	O
.	O

Two	O
alkylating	O
glucocorticoids	O
have	O
been	O
synthesized	O
in	O
order	O
to	O
test	O
the	O
possibility	O
of	O
alkylating	O
glucocorticoid	O
receptors	O
.	O

The	O
title	O
compounds	O
are	O
9alpha	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
11beta	I-IUPAC
,	I-IUPAC
16alpha	I-IUPAC
,	I-IUPAC
17alpha	I-IUPAC
,	I-IUPAC
21	I-IUPAC
-	I-IUPAC
tetrahydroxypregna	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diene	I-IUPAC
-	I-IUPAC
3,20	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
21	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
carbamate	I-IUPAC
]	I-IUPAC
16,17	I-IUPAC
-	I-IUPAC
acetonide	I-IUPAC
(	O
I	O
)	O
and	O
11beta	I-IUPAC
,	I-IUPAC
17alpha	I-IUPAC
,	I-IUPAC
21	I-IUPAC
-	I-IUPAC
trihydroxypregn	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
-	I-IUPAC
3,20	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
21	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
carbamate	I-IUPAC
]	I-IUPAC
(	O
II	O
)	O
,	O
prepared	O
from	O
triamcinolone	O
acetonide	O
and	O
cortisol	O
,	O
respectively	O
,	O
through	O
the	O
reaction	O
of	O
the	O
C	O
-	O
21	O
hydroxyl	I-IUPAC
group	B-MODIFIER
with	O
phosgene	O
and	O
di	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethylamine	I-IUPAC
in	O
the	O
presence	O
of	O
triethylamine	O
.	O

Both	O
compounds	O
are	O
biologically	O
active	O
as	O
inhibitors	O
of	O
the	O
growth	O
of	O
cultured	O
mouse	O
fibroblasts	O
and	O
are	O
able	O
to	O
compete	O
for	O
the	O
specific	O
binding	O
of	O
radiolabeled	O
triamcinolone	O
acetonide	O
to	O
the	O
L929	O
cell	O
receptor	O
.	O

The	O
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
carbamate	I-IUPAC
moiety	I-MODIFIER
is	O
capable	O
of	O
reacting	O
with	O
nucleophilic	O
groups	O
as	O
evidenced	O
by	O
the	O
colorimetric	O
reaction	O
with	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
.	O

Both	O
the	O
interaction	O
with	O
the	O
receptor	O
and	O
inhibition	O
of	O
cell	O
growth	O
by	O
these	O
two	O
glucocorticoids	O
are	O
reversible	O
.	O

Syntheses	O
of	O
the	O
enantiomers	O
of	O
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
trisphosphate	I-IUPAC
are	O
described	O
.	O

1,4	I-IUPAC
-	I-IUPAC
Di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
was	O
regioselectively	O
p	O
-	O
methoxybenzylated	O
at	O
the	O
3	O
-	O
position	O
to	O
give	O
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
followed	O
by	O
benzylation	O
of	O
the	O
remaining	O
free	O
hydroxyl	I-IUPAC
groups	B-MODIFIER
to	O
give	O
the	O
key	O
intermediate	O
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
2,5,6	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
.	O

Removal	O
of	O
the	O
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
and	O
allyl	I-IUPAC
groups	B-MODIFIER
gave	O
2,4,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
which	O
was	O
phosphitylated	O
with	O
bis	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
(	I-IUPAC
diisopropylamino	I-IUPAC
)	I-IUPAC
phosphine	I-IUPAC
to	O
give	O
the	O
fully	O
protected	O
trisphosphite	O
triester	O
.	O

Oxidation	O
using	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
hydroperoxide	I-IUPAC
gave	O
2,5,6	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
tris	I-IUPAC
(	I-IUPAC
dibenzylphospho	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
,	O
and	O
deprotection	O
using	O
sodium	O
in	O
liquid	O
ammonia	O
gave	O
racemic	I-MODIFIER
myo	B-IUPAC
-	I-IUPAC
inositol	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
trisphosphate	I-IUPAC
.	O

Deprotection	O
of	O
the	O
key	O
intermediate	O
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
2,5,6	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
by	O
isomerization	O
of	O
allyl	O
groups	O
followed	O
by	O
mild	O
acid	O
hydrolysis	O
gave	O
2,4,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
,	O
which	O
was	O
converted	O
to	O
the	O
diastereoisomeric	O
(	O
bis	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
camphanates	I-IUPAC
.	O

The	O
diastereoisomers	O
were	O
separated	O
by	O
column	O
chromatography	O
and	O
the	O
camphanates	O
and	O
the	O
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
group	I-MODIFIER
removed	O
by	O
saponification	O
and	O
acid	O
hydrolysis	O
,	O
respectively	O
,	O
for	O
each	O
diastereoisomer	O
to	O
give	O
the	O
enantiomers	O
of	O
2,4,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
.	O

The	O
absolute	O
configurations	O
of	O
the	O
latter	O
were	O
established	O
by	O
conversion	O
of	O
1L	I-IUPAC
-	I-IUPAC
2,5,6	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
to	O
the	O
known	O
1L	I-IUPAC
-	I-IUPAC
1,2,4,5,6	I-IUPAC
-	I-IUPAC
penta	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
.	O

Phosphorylation	O
and	O
deblocking	O
gave	O
the	O
D	O
-	O
and	O
L	O
-	O
enantiomers	O
of	O
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
trisphosphate	I-IUPAC
.	O

Biological	O
evaluation	O
in	O
Limulus	O
photoreceptors	O
showed	O
that	O
1L	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
trisphosphate	I-IUPAC
was	O
much	O
more	O
active	O
than	O
the	O
D	O
-	O
enantiomer	O
,	O
producing	O
repetitive	O
bursts	O
of	O
depolarization	O
due	O
to	O
mobilization	O
of	O
intracellular	O
calcium	O
.	O

The	O
formation	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
followed	O
during	O
the	O
oxidation	O
of	O
37	O
N	I-IUPAC
-	I-IUPAC
hydroxyguanidines	I-IUPAC
or	O
related	O
derivatives	O
,	O
including	O
18	O
new	O
N	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidines	I-IUPAC
,	O
by	O
recombinant	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
II	O
)	O
.	O

Several	O
N	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidines	I-IUPAC
bearing	O
a	O
relatively	O
small	O
,	O
electron	O
-	O
donating	O
para	O
subtituent	O
,	O
such	O
as	O
H	O
,	O
F	O
,	O
Cl	O
,	O
CH	O
(	O
3	O
)	O
,	O
OH	O
,	O
OCH	O
(	O
3	O
)	O
,	O
and	O
NH	O
(	O
2	O
)	O
,	O
led	O
to	O
NO	O
formation	O
rates	O
between	O
8	O
and	O
41%	O
of	O
that	O
of	O
NO	O
formation	O
from	O
the	O
natural	O
NOS	O
substrate	O
,	O
N	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
)	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
(	O
NOHA	O
)	O
.	O

The	O
characteristics	O
of	O
these	O
reactions	O
were	O
very	O
similar	O
to	O
those	O
previously	O
reported	O
for	O
the	O
oxidation	O
of	O
NOHA	O
by	O
NOS	O
:	O
(	O
i	O
)	O
the	O
strict	O
requirement	O
of	O
NOS	O
containing	O
(	I-IUPAC
6R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
biopterin	I-IUPAC
,	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
,	O
and	O
O	O
(	O
2	O
)	O
for	O
the	O
oxidation	O
to	O
occur	O
,	O
(	O
ii	O
)	O
the	O
formation	O
of	O
NO	O
and	O
the	O
corresponding	O
urea	O
in	O
a	O
1	O
:	O
1	O
molar	O
ratio	O
,	O
and	O
(	O
iii	O
)	O
a	O
strong	O
inhibitory	O
effect	O
of	O
the	O
classical	O
NOS	O
inhibitors	O
such	O
as	O
N	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
and	O
S	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
iso	I-IUPAC
-	I-IUPAC
thiourea	I-IUPAC
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
showed	O
that	O
two	O
structural	O
factors	O
are	O
crucial	O
for	O
NO	O
formation	O
from	O
compounds	O
containing	O
a	O
C	O
(	O
triple	O
bond	O
)	O
NOH	O
function	O
.	O

The	O
first	O
one	O
is	O
the	O
presence	O
of	O
a	O
monosubstituted	I-MODIFIER
N	B-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
function	O
,	O
since	O
disubstituted	I-MODIFIER
N	B-IUPAC
-	I-IUPAC
hydroxyguanidines	I-IUPAC
,	O
amidoximes	O
,	O
ketoximes	O
,	O
and	O
aldoximes	O
failed	O
to	O
produce	O
NO	O
.	O

The	O
second	O
one	O
is	O
the	O
presence	O
of	O
a	O
N	O
-	O
phenyl	O
ring	O
bearing	O
a	O
relatively	O
small	O
,	O
not	O
electron	O
-	O
withdrawing	O
para	O
substituent	O
that	O
could	O
favorably	O
interact	O
with	O
a	O
hydrophobic	O
cavity	O
close	O
to	O
the	O
NOS	O
catalytic	O
site	O
.	O

The	O
k	O
(	O
cat	O
)	O
value	O
for	O
NOS	O
II	O
-	O
catalyzed	O
oxidation	O
of	O
N	I-IUPAC
-	I-IUPAC
para	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
was	O
80%	O
of	O
that	O
found	O
for	O
NOHA	O
,	O
and	O
its	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
value	O
was	O
only	O
9	O
-	O
fold	O
lower	O
than	O
that	O
of	O
NOHA	O
.	O

Interestingly	O
,	O
the	O
K	O
(	O
m	O
)	O
value	O
found	O
for	O
NOS	O
II	O
-	O
catalyzed	O
oxidation	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
was	O
25	O
microM	O
,	O
almost	O
identical	O
to	O
that	O
of	O
NOHA	O
.	O

Recombinant	O
NOS	O
I	O
and	O
NOS	O
III	O
also	O
oxidize	O
several	O
N	I-MODIFIER
-	I-MODIFIER
aryl	I-MODIFIER
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidines	I-IUPAC
with	O
the	O
formation	O
of	O
NO	O
,	O
with	O
a	O
clearly	O
different	O
substrate	O
specificity	O
.	O

The	O
best	O
substrates	O
of	O
the	O
studied	O
series	O
for	O
NOS	O
I	O
and	O
NOS	O
III	O
were	O
N	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
para	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
meta	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
,	O
respectively	O
.	O

Among	O
the	O
studied	O
compounds	O
,	O
the	O
para	O
-	O
chlorophenyl	O
and	O
para	O
-	O
methylphenyl	O
derivatives	O
were	O
selective	O
substrates	O
of	O
NOS	O
II	O
.	O

These	O
results	O
open	O
the	O
way	O
toward	O
a	O
new	O
class	O
of	O
selective	O
NO	O
donors	O
after	O
in	O
situ	O
oxidation	O
by	O
each	O
NOS	O
family	O
.	O

Several	O
novel	O
substituted	I-MODIFIER
tetrahydro	B-PARTIUPAC
-	I-PARTIUPAC
and	O
hexahydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
one	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
and	O
thiadiazinones	I-IUPAC
were	O
prepared	O
and	O
examined	O
in	O
a	O
series	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
tests	O
to	O
determine	O
their	O
pharmacological	O
profile	O
.	O

Most	O
compounds	O
were	O
orally	O
active	O
in	O
blocking	O
the	O
conditioned	O
avoidance	O
response	O
(	O
CAR	O
)	O
but	O
did	O
not	O
antagonize	O
apomorphine	O
-	O
induced	O
stereotyped	O
behavior	O
.	O

Several	O
compounds	O
demonstrated	O
moderate	O
to	O
high	O
affinity	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
binding	O
site	O
,	O
with	O
compounds	O
37	O
and	O
38	O
containing	O
2	I-IUPAC
-	I-IUPAC
pyrimidinylpiperazinyl	I-IUPAC
and	O
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
piperazinyl	I-IUPAC
moieties	I-MODIFIER
and	O
compound	O
47	O
containing	O
the	O
2	I-IUPAC
-	I-IUPAC
pyrazinylpiperazinyl	I-IUPAC
moiety	I-MODIFIER
displaying	O
the	O
highest	O
affinity	O
(	O
Ki	O
values	O
of	O
10	O
,	O
4	O
,	O
and	O
9	O
nM	O
,	O
respectively	O
)	O
.	O

Compound	O
37	O
,	O
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrimidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
]	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
etheno	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
cyclobut	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
,	O
buspirone	O
,	O
and	O
ipsapirone	O
showed	O
similarities	O
in	O
their	O
neurochemical	O
and	O
behavioral	O
profiles	O
.	O

They	O
were	O
similar	O
in	O
potency	O
in	O
blocking	O
CAR	O
with	O
AB50	O
values	O
of	O
39	O
,	O
32	O
,	O
and	O
42	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

They	O
also	O
demonstrated	O
high	O
affinity	O
and	O
selectivity	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
site	O
(	O
Ki	O
=	O
10	O
nM	O
)	O
and	O
exhibited	O
partial	O
agonist	O
/	O
antagonist	O
activity	O
in	O
the	O
serotonin	O
syndrome	O
test	O
.	O

In	O
addition	O
,	O
compound	O
37	O
inhibited	O
apomorphine	O
-	O
induced	O
climbing	O
behavior	O
much	O
more	O
potently	O
(	O
ED50	O
of	O
3.4	O
mg	O
/	O
kg	O
)	O
than	O
stereotyped	O
behavior	O
(	O
ED50	O
of	O
32.2	O
mg	O
/	O
kg	O
)	O
and	O
will	O
be	O
evaluated	O
further	O
.	O

Structure	O
-	O
activity	O
relationships	O
within	O
this	O
series	O
of	O
compounds	O
are	O
discussed	O
.	O

The	O
synthesis	O
of	O
various	O
substituted	I-MODIFIER
5	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acids	I-IUPAC
and	O
their	O
derivatives	O
is	O
described	O
by	O
three	O
general	O
methods	O
:	O
(	O
1	O
)	O
reductive	O
alkylation	O
of	O
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylates	I-IUPAC
(	O
2	O
)	O
and	O
subsequent	O
hydrolysis	O
;	O
(	O
2	O
)	O
alkylation	O
of	O
the	O
urethane	O
(	O
9	O
)	O
,	O
followed	O
by	O
hydrolysis	O
;	O
and	O
(	O
3	O
)	O
selective	O
NaBH4	O
reduction	O
of	O
the	O
appropriate	O
amide	O
of	O
(	O
2	O
)	O
,	O
followed	O
by	O
hydrolysis	O
.	O

A	O
more	O
specific	O
process	O
was	O
used	O
for	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
compound	I-MODIFIER
,	O
i.e.	O
,	O
nucleophilic	O
displacement	O
of	O
nitrite	O
from	O
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylate	I-IUPAC
by	O
sodioformanilide	O
and	O
subsequent	O
hydrolysis	O
.	O

Many	O
of	O
these	O
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acid	I-IUPAC
derivatives	I-MODIFIER
were	O
potent	O
antihypertensive	O
agents	O
in	O
the	O
spontaneously	O
hypertensive	O
rat	O
(	O
SHR	O
)	O
.	O

Optimization	O
of	O
structural	O
parameters	O
for	O
this	O
activity	O
yielded	O
compounds	O
54	O
,	O
55	O
,	O
34	O
,	O
65	O
,	O
and	O
22	O
,	O
which	O
were	O
selected	O
for	O
further	O
study	O
in	O
the	O
renal	O
hypertensive	O
dog	O
(	O
RHD	O
)	O
.	O

Based	O
on	O
these	O
studies	O
,	O
one	O
compound	O
,	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorobenzyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
65	O
)	O
,	O
was	O
selected	O
for	O
preclinical	O
toxicity	O
evaluation	O
.	O

Based	O
on	O
the	O
toxicological	O
findings	O
,	O
it	O
was	O
decided	O
not	O
to	O
pursue	O
compound	O
65	O
clinically	O
.	O

The	O
synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
of	O
1	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethylamine	I-IUPAC
derivatives	I-MODIFIER
5-8	O
designed	O
from	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dipropyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethoxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
ethylamine	I-IUPAC
hydrochloride	I-IUPAC
(	O
1	O
,	O
NE	O
-	O
100	O
)	O
are	O
presented	O
.	O

The	O
SAR	O
between	O
compound	O
1	O
and	O
1	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethylamine	I-IUPAC
derivatives	I-MODIFIER
suggested	O
that	O
the	O
alkyl	O
group	O
on	O
the	O
1	O
-	O
position	O
carbon	O
of	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
ethylamine	I-IUPAC
derivatives	I-MODIFIER
played	O
the	O
role	O
of	O
one	O
of	O
the	O
propyl	O
groups	O
on	O
the	O
aminic	O
nitrogen	O
of	O
compound	O
1	O
.	O

(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
Propyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethoxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
ethylam	I-IUPAC
ine	I-IUPAC
hydrochloride	I-IUPAC
(	O
(	O
-	O
)	O
-	O
6d	O
,	O
NE	O
-	O
537	O
)	O
and	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methybutyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethoxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
e	I-IUPAC
thylamine	I-IUPAC
hydrochloride	I-IUPAC
(	O
(	O
-	O
)	O
-	O
6i	O
,	O
NE	O
-	O
535	O
)	O
,	O
typical	O
compounds	O
in	O
this	O
series	O
,	O
have	O
potent	O
and	O
selective	O
sigma	O
(	O
1	O
)	O
affinity	O
.	O

We	O
have	O
previously	O
shown	O
that	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
APPA	O
,	O
2	O
]	O
is	O
a	O
weak	O
agonist	O
at	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
receptors	O
,	O
specifically	O
activated	O
by	O
(	O
S	O
)	O
-	O
AMPA	O
(	O
1	O
)	O
,	O
whereas	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
2	O
-	O
Py	O
-	O
AMPA	O
,	O
5	O
]	O
and	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiazolyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
are	O
potent	O
AMPA	O
agonists	O
.	O

On	O
the	O
other	O
hand	O
,	O
(	O
R	O
)	O
-	O
APPA	O
(	O
3	O
)	O
and	O
(	O
R	O
)	O
-	O
2	O
-	O
Py	O
-	O
AMPA	O
(	O
6	O
)	O
have	O
been	O
shown	O
to	O
be	O
weak	O
AMPA	O
antagonists	O
.	O

We	O
now	O
report	O
the	O
synthesis	O
of	O
2	O
-	O
Py	O
-	O
AMPA	O
(	O
7a	O
)	O
and	O
the	O
isomeric	O
compounds	O
3	O
-	O
Py	O
-	O
AMPA	O
(	O
7b	O
)	O
and	O
4	O
-	O
Py	O
-	O
AMPA	O
(	O
7c	O
)	O
as	O
well	O
as	O
the	O
7a	O
analogues	O
,	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
p	I-IUPAC
ropion	I-IUPAC
ic	I-IUPAC
acid	I-IUPAC
(	O
7d	O
)	O
and	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinolinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
7e	O
)	O
.	O

Furthermore	O
,	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
]	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
2	O
-	O
Fu	O
-	O
AMPA	O
,	O
7f	O
)	O
and	O
its	O
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furyl	I-IUPAC
derivative	I-MODIFIER
(	O
7g	O
)	O
were	O
synthesized	O
,	O
and	O
(	O
S	O
)	O
-	O
2	O
-	O
Fu	O
-	O
AMPA	O
(	O
8	O
)	O
and	O
(	O
R	O
)	O
-	O
2	O
-	O
Fu	O
-	O
AMPA	O
(	O
9	O
)	O
were	O
prepared	O
by	O
semipreparative	O
chiral	O
HPLC	O
resolution	O
of	O
7f	O
.	O

HPLC	O
analyses	O
and	O
circular	O
dichroism	O
spectroscopy	O
indicated	O
the	O
absolute	O
stereochemistry	O
of	O
8	O
and	O
9	O
to	O
be	O
S	O
and	O
R	O
,	O
respectively	O
.	O

This	O
was	O
confirmed	O
by	O
an	O
X	O
-	O
ray	O
crystallographic	O
analysis	O
of	O
9	O
.	O

HCl	O
.	O

In	O
receptor	O
binding	O
(	O
IC50	O
values	O
)	O
and	O
rat	O
cortical	O
wedge	O
electrophysiological	O
(	O
EC50	O
values	O
)	O
studies	O
,	O
7c	O
(	O
IC50	O
=	O
5.5	O
+	O
/	O
-	O
0.6	O
microM	O
;	O
EC50	O
=	O
96	O
+	O
/	O
-	O
5	O
microM	O
)	O
was	O
shown	O
to	O
be	O
markedly	O
weaker	O
than	O
7a	O
(	O
IC50	O
=	O
0.57	O
+	O
/	O
-	O
0.16	O
microM	O
;	O
EC50	O
=	O
7.4	O
+	O
/	O
-	O
0.2	O
microM	O
)	O
as	O
an	O
AMPA	O
agonist	O
,	O
whereas	O
7b	O
,	O
d	O
,	O
e	O
were	O
inactive	O
.	O

The	O
very	O
potent	O
AMPA	O
agonist	O
effect	O
of	O
7f	O
(	O
IC50	O
=	O
0.15	O
+	O
/	O
-	O
0.03	O
microM	O
;	O
EC50	O
=	O
1.7	O
+	O
/	O
-	O
0	O
.	O

2	O
microM	O
)	O
was	O
shown	O
to	O
reside	O
exclusively	O
in	O
8	O
(	O
IC50	O
=	O
0.11	O
+	O
/	O
-	O
0.01	O
microM	O
;	O
EC50	O
=	O
0.71	O
+	O
/	O
-	O
0.11	O
microM	O
)	O
,	O
whereas	O
9	O
did	O
not	O
interact	O
significantly	O
with	O
AMPA	O
receptors	O
,	O
either	O
as	O
an	O
agonist	O
or	O
as	O
an	O
antagonist	O
.	O

8	O
was	O
shown	O
to	O
be	O
photochemically	O
active	O
and	O
is	O
a	O
potential	O
photoaffinity	O
label	O
for	O
the	O
recognition	O
site	O
of	O
the	O
AMPA	O
receptors	O
.	O

Compound	O
7g	O
turned	O
out	O
to	O
be	O
a	O
very	O
weak	O
AMPA	O
receptor	O
agonist	O
(	O
IC50	O
=	O
12	O
+	O
/	O
-	O
0.7	O
microM	O
;	O
EC50	O
=	O
160	O
+	O
/	O
-	O
15	O
microM	O
)	O
.	O

None	O
of	O
these	O
new	O
compounds	O
showed	O
detectable	O
effects	O
at	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
(	O
NMDA	O
)	O
or	O
kainic	O
acid	O
receptors	O
in	O
vitro	O
.	O

The	O
present	O
studies	O
have	O
emphasized	O
that	O
the	O
presence	O
of	O
a	O
heteroatom	O
in	O
the	O
2	O
-	O
position	O
of	O
the	O
heteroaryl	O
5	O
-	O
substituent	O
greatly	O
facilitates	O
AMPA	O
receptor	O
agonist	O
activity	O
.	O

Biological	O
tests	O
indicate	O
hexahydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indeno	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridines	I-IUPAC
to	O
be	O
potential	O
human	O
antidepressants	O
with	O
additional	O
stimulating	O
properties	O
.	O

Two	O
diastereomeric	O
series	O
with	O
H4a	O
,	O
H5	O
-	O
trans	O
,	O
H4a	O
,	O
H9b	O
-	O
cis	O
and	O
H4a	O
,	O
H5	O
-	O
cis	O
,	O
H4a	O
,	O
H9b	O
-	O
cis	O
configurations	O
have	O
been	O
tested	O
biologically	O
.	O

The	O
results	O
revealed	O
that	O
the	O
H4a	O
,	O
H5	O
-	O
cis	O
,	O
H4a	O
,	O
H9b	O
-	O
cis	O
series	O
and	O
the	O
ortho	O
-	O
substituted	O
5	O
-	O
phenyl	O
H4a	O
,	O
H5	O
-	O
trans	O
,	O
H4a	O
,	O
H9b	O
-	O
cis	O
compounds	O
lack	O
activity	O
.	O

Neither	O
the	O
conformation	O
with	O
lowest	O
potential	O
energy	O
nor	O
any	O
other	O
electron	O
-	O
derived	O
parameter	O
correlate	O
with	O
these	O
data	O
.	O

The	O
only	O
relevant	O
difference	O
between	O
the	O
active	O
and	O
the	O
inactive	O
compounds	O
detected	O
thus	O
far	O
is	O
the	O
rotational	O
barrier	O
of	O
the	O
phenyl	O
in	O
the	O
5	O
-	O
position	O
.	O

The	O
conclusion	O
was	O
reached	O
that	O
certain	O
conformations	O
,	O
which	O
do	O
not	O
resemble	O
those	O
of	O
lowest	O
potential	O
energy	O
,	O
cannot	O
be	O
adopted	O
by	O
the	O
inactive	O
compounds	O
.	O

Therefore	O
,	O
the	O
interaction	O
of	O
the	O
drug	O
with	O
the	O
binding	O
site	O
,	O
responsible	O
for	O
its	O
biological	O
activity	O
,	O
appears	O
to	O
be	O
governed	O
by	O
a	O
dynamic	O
process	O
.	O

This	O
process	O
is	O
characterized	O
by	O
a	O
transformation	O
of	O
the	O
conformation	O
of	O
lowest	O
potential	O
energy	O
to	O
one	O
with	O
an	O
energy	O
content	O
above	O
the	O
minimum	O
.	O

A	O
number	O
of	O
4,7	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
benzopyran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
crude	O
rat	O
lens	O
aldose	O
reductase	O
inhibitory	O
activity	O
.	O

Substituents	O
on	O
position	O
4	O
included	O
CH3	O
,	O
CO2H	O
,	O
CH2CO2H	O
,	O
CH	O
=	O
CHCO2H	O
,	O
and	O
CH2CH2CO2H	O
.	O

The	O
aromatic	O
substituents	O
included	O
OH	O
,	O
OCH3	O
,	O
OCOCH3	O
,	O
CH2CH3	O
,	O
and	O
Cl	O
.	O

Also	O
included	O
in	O
the	O
study	O
were	O
3	I-PARTIUPAC
-	I-PARTIUPAC
oxo	I-PARTIUPAC
-	I-PARTIUPAC
3H	I-PARTIUPAC
-	I-PARTIUPAC
naphtho	I-PARTIUPAC
[	I-PARTIUPAC
2,1	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
pyran	I-PARTIUPAC
-	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
acetic	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
oxo	I-PARTIUPAC
-	I-PARTIUPAC
2H	I-PARTIUPAC
-	I-PARTIUPAC
naphtho	I-PARTIUPAC
[	I-PARTIUPAC
1,2	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
pyran	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
acetic	I-PARTIUPAC
,	O
and	O
1	I-IUPAC
-	I-IUPAC
naphthylacetic	I-IUPAC
acids	I-IUPAC
.	O

The	O
benzopyran	O
and	O
naphthopyran	O
derivatives	O
were	O
prepared	O
by	O
the	O
classical	O
von	O
Pechmann	O
reaction	O
.	O

General	O
structure	O
-	O
activity	O
relationships	O
reveal	O
that	O
optimal	O
enzyme	O
inhibitory	O
activity	O
is	O
displayed	O
by	O
those	O
compounds	O
possessing	O
the	O
acetic	I-IUPAC
acid	I-IUPAC
moiety	I-MODIFIER
.	O

For	O
example	O
,	O
the	O
most	O
potent	O
derivative	O
,	O
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
with	O
an	O
IC50	O
of	O
0.020	O
microM	O
,	O
is	O
as	O
potent	O
as	O
sorbinil	O
(	O
IC50	O
=	O
0.017	O
microM	O
)	O
in	O
the	O
crude	O
rat	O
lens	O
aldose	O
reductase	O
assay	O
.	O

Modification	O
of	O
the	O
benzodiazepine	O
(	O
BZ	O
)	O
receptor	O
binding	O
template	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinazolin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
by	O
replacement	O
of	O
the	O
annelated	O
benzene	O
ring	O
with	O
various	O
alicyclic	O
and	O
heterocyclic	O
moieties	O
led	O
to	O
novel	O
structures	O
with	O
potent	O
BZ	O
receptor	O
binding	O
affinity	O
.	O

High	O
affinity	O
was	O
found	O
in	O
some	O
cycloalkyl	I-MODIFIER
-	I-MODIFIER
annelated	I-MODIFIER
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
in	O
some	O
7,8,9,10	I-IUPAC
-	I-IUPAC
tetrahydropyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
in	O
which	O
the	O
degree	O
of	O
activity	O
was	O
strongly	O
dependent	O
on	O
the	O
N	O
-	O
substituent	O
in	O
the	O
9	O
-	O
position	O
.	O

Nine	O
compounds	O
with	O
BZ	O
receptor	O
IC50	O
binding	O
affinity	O
values	O
equal	O
or	O
superior	O
to	O
diazepam	O
were	O
evaluated	O
in	O
secondary	O
screening	O
.	O

One	O
of	O
these	O
,	O
9	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
7,8,9,10	I-IUPAC
-	I-IUPAC
tetrahydropyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
showed	O
good	O
activity	O
in	O
rats	O
as	O
a	O
potential	O
anxiolytic	O
agent	O
without	O
sedative	O
liability	O
.	O

However	O
,	O
it	O
increased	O
the	O
rotorod	O
deficit	O
produced	O
by	O
ethanol	O
at	O
anxiolytic	O
doses	O
,	O
an	O
indication	O
of	O
alcohol	O
interaction	O
.	O

Thus	O
,	O
none	O
of	O
the	O
compounds	O
showed	O
an	O
advantage	O
over	O
CGS	O
9896	O
(	O
Yokoyama	O
et	O
al.	O
J	O
.	O

Med.	O
Chem.	O
1982	O
,	O
25	O
,	O
337-339	O
)	O
,	O
which	O
is	O
free	O
of	O
sedative	O
and	O
alcohol	O
interaction	O
potential	O
as	O
measured	O
by	O
the	O
test	O
procedures	O
described	O
.	O

Appropriately	O
substituted	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
7H	I-IUPAC
-	I-IUPAC
thiazolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
9-12	O
and	O
18	O
were	O
considered	O
as	O
annulated	O
analogues	O
of	O
HEPT	O
(	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
thymine	I-IUPAC
)	O
,	O
and	O
some	O
of	O
these	O
compounds	O
were	O
also	O
found	O
active	O
against	O
HIV	O
-	O
1	O
,	O
the	O
most	O
active	O
one	O
being	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dimethylphenyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
7H	I-IUPAC
-	I-IUPAC
thiazolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
10b	O
)	O
.	O

S	O
-	O
Alkylation	O
of	O
5	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiouracils	I-IUPAC
1-4	O
was	O
performed	O
with	O
2	I-IUPAC
-	I-IUPAC
bromoacetaldehyde	I-IUPAC
acetals	I-IUPAC
to	O
furnish	O
the	O
S	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
alkoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
derivatives	I-MODIFIER
5-8	O
and	O
with	O
allyl	O
bromide	O
to	O
furnish	O
S	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
derivatives	I-MODIFIER
17	O
.	O

The	O
target	O
compounds	O
9-12	O
were	O
obtained	O
by	O
an	O
N1	O
regioselective	O
intramolecular	O
cyclization	O
reaction	O
of	O
silylated	O
5-8	O
using	O
trimethylsilyl	O
trifluoromethanesulfonate	O
(	O
TMS	O
triflate	O
)	O
as	O
the	O
catalyst	O
.	O

Treatment	O
of	O
the	O
S	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
derivatives	I-MODIFIER
17	O
with	O
bromine	O
in	O
dry	O
methylene	O
chloride	O
afforded	O
the	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
18	O
.	O

A	O
novel	O
series	O
of	O
nonpeptide	O
CCK	O
(	O
2	O
)	O
receptor	O
antagonists	O
has	O
been	O
prepared	O
,	O
in	O
which	O
2,7	I-IUPAC
-	I-IUPAC
dioxo	I-IUPAC
-	I-IUPAC
2,3,4,5,6,7	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
h	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1	I-IUPAC
,	I-IUPAC
4	I-IUPAC
]	I-IUPAC
diazonine	I-IUPAC
(	O
5	O
)	O
was	O
used	O
as	O
a	O
chemical	O
template	O
.	O

This	O
uncommon	O
ring	O
system	O
was	O
obtained	O
in	O
a	O
highly	O
substituted	O
form	O
and	O
in	O
high	O
yield	O
by	O
ozonolysis	O
of	O
the	O
enamine	O
bond	O
of	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
derivatives	I-MODIFIER
(	O
4	O
)	O
,	O
in	O
which	O
the	O
configuration	O
of	O
the	O
substituents	O
was	O
established	O
stereoselectively	O
via	O
the	O
Pictet	O
-	O
Spengler	O
reaction	O
.	O

Further	O
structural	O
manipulation	O
was	O
guided	O
by	O
molecular	O
modeling	O
through	O
comparison	O
of	O
fieldpoint	O
-	O
based	O
structures	O
of	O
candidate	O
compounds	O
with	O
a	O
selected	O
low	O
-	O
energy	O
conformation	O
of	O
the	O
representative	O
CCK	O
(	O
2	O
)	O
receptor	O
antagonist	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
dicarboxyphenyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantylmethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
(	O
JB93182	O
(	O
3	O
)	O
)	O
.	O

By	O
this	O
approach	O
compounds	O
such	O
as	O
(	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
5S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chlorobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxymet	I-IUPAC
hyl	I-IUPAC
aminocarbonyl	I-IUPAC
-	I-IUPAC
2,7	I-IUPAC
-	I-IUPAC
dioxo	I-IUPAC
-	I-IUPAC
2,3,4,5,6,7	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
h	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1	I-IUPAC
,	I-IUPAC
4	I-IUPAC
]	I-IUPAC
diazonine	I-IUPAC
(	O
32	O
)	O
were	O
prepared	O
.	O

Compound	O
32	O
behaved	O
as	O
a	O
competitive	O
CCK	O
(	O
2	O
)	O
receptor	O
antagonist	O
in	O
vitro	O
as	O
judged	O
by	O
its	O
inhibition	O
of	O
pentagastrin	O
-	O
stimulated	O
acid	O
secretion	O
in	O
an	O
isolated	O
,	O
lumen	O
-	O
perfused	O
,	O
immature	O
rat	O
stomach	O
assay	O
(	O
pK	O
(	O
B	O
)	O
=	O
6.74	O
+	O
/	O
-	O
0.27	O
)	O
and	O
by	O
its	O
displacement	O
of	O
[	O
(	O
125	O
)	O
I	O
]	O
CCK	O
-	O
8S	O
from	O
CCK	O
(	O
2	O
)	O
sites	O
in	O
mouse	O
cortical	O
homogenates	O
(	O
pK	O
(	O
i	O
)	O
=	O
6.99	O
+	O
/	O
-	O
0.05	O
)	O
.	O

Compound	O
32	O
was	O
100	O
-	O
fold	O
selective	O
for	O
CCK	O
(	O
2	O
)	O
over	O
CCK	O
(	O
1	O
)	O
receptors	O
based	O
on	O
the	O
affinity	O
estimate	O
obtained	O
in	O
a	O
guinea	O
pig	O
pancreas	O
radioligand	O
binding	O
assay	O
(	O
pK	O
(	O
i	O
)	O
=	O
5.0	O
)	O
.	O

A	O
group	O
of	O
racemic	I-MODIFIER
alkyl	B-IUPAC
and	O
2	I-PARTIUPAC
-	I-PARTIUPAC
phenethyl	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
2,6	I-PARTIUPAC
-	I-PARTIUPAC
dimethyl	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-MODIFIER
-	I-MODIFIER
or	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
2	I-PARTIUPAC
-	I-PARTIUPAC
pyridyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
pyridinecarboxylates	I-PARTIUPAC
(	O
13a	O
-	O
q	O
)	O
was	O
prepared	O
using	O
a	O
modified	O
Hantzsch	O
reaction	O
that	O
involved	O
the	O
condensation	O
of	O
a	O
3	I-MODIFIER
-	I-MODIFIER
or	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
2	I-IUPAC
-	I-IUPAC
pyridinecarboxaldehyde	I-IUPAC
(	O
7a	O
-	O
j	O
)	O
with	O
an	O
alkyl	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminocrotonate	I-IUPAC
(	O
11a	O
-	O
d	O
)	O
and	O
nitroacetone	O
(	O
12	O
)	O
.	O

Nuclear	O
Overhauser	O
(	O
NOE	O
)	O
studies	O
indicated	O
there	O
is	O
a	O
significant	O
rotamer	O
fraction	O
in	O
solution	O
where	O
the	O
pyridyl	O
nitrogen	O
is	O
oriented	O
above	O
the	O
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
ring	I-MODIFIER
,	O
irrespective	O
of	O
whether	O
a	O
substituent	O
is	O
located	O
at	O
the	O
3	O
-	O
or	O
6	O
-	O
position	O
.	O

A	O
potential	O
H	O
-	O
bonding	O
interaction	O
between	O
the	O
pyridyl	O
nitrogen	O
free	O
electron	O
pair	O
and	O
the	O
suitably	O
positioned	O
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
NH	I-MODIFIER
moiety	I-MODIFIER
may	O
stablize	O
this	O
rotamer	O
orientation	O
.	O

In	O
vitro	O
calcium	O
channel	O
antagonist	O
and	O
agonist	O
activities	O
were	O
determined	O
using	O
guinea	O
pig	O
ileum	O
longitudinal	O
smooth	O
muscle	O
(	O
GPILSM	O
)	O
and	O
guinea	O
pig	O
left	O
atrium	O
(	O
GPLA	O
)	O
assays	O
,	O
respectively	O
.	O

Compounds	O
having	O
an	O
i	O
-	O
Pr	O
ester	O
substituent	O
acted	O
as	O
dual	O
cardioselective	O
calcium	O
channel	O
agonists	O
(	O
GPLA	O
)	O
/	O
smooth	O
muscle	O
-	O
selective	O
calcium	O
channel	O
antagonists	O
(	O
GPILSM	O
)	O
,	O
except	O
for	O
the	O
C	O
-	O
4	O
3	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
compound	I-MODIFIER
which	O
exhibited	O
an	O
antagonist	O
effect	O
on	O
both	O
GPLA	O
and	O
GPILSM	O
.	O

In	O
contrast	O
,	O
the	O
compounds	O
with	O
a	O
phenethyl	O
ester	O
group	O
,	O
which	O
exhibited	O
antagonist	O
activity	O
(	O
IC50	O
=	O
10	O
(	O
-	O
5	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
M	O
range	O
)	O
on	O
GPILSM	O
,	O
were	O
devoid	O
of	O
cardiac	O
agonist	O
activity	O
on	O
GPLA	O
.	O

Structure	O
-	O
activity	O
relationships	O
showing	O
the	O
effect	O
of	O
a	O
substituent	O
(	O
Me	O
,	O
CF3	O
,	O
Cl	O
,	O
NO2	O
,	O
Ph	O
)	O
at	O
the	O
3	O
-	O
or	O
6	O
-	O
position	O
of	O
a	O
C	O
-	O
4	O
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
moiety	I-MODIFIER
and	O
a	O
variety	O
of	O
ester	O
substituents	O
(	O
Me	O
,	O
Et	O
,	O
i	O
-	O
Pr	O
,	O
PhCH2CH2	O
-	O
)	O
upon	O
calcium	O
channel	O
modulation	O
are	O
described	O
.	O

Compounds	O
possessing	O
a	O
3	I-MODIFIER
-	I-MODIFIER
or	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
moiety	I-MODIFIER
,	O
in	O
conjuction	O
with	O
an	O
i	O
-	O
Pr	O
ester	O
substituent	O
,	O
are	O
novel	O
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
calcium	O
channel	O
modulators	O
that	O
offer	O
a	O
new	O
drug	O
design	O
approach	O
directed	O
to	O
the	O
treatment	O
of	O
congestive	O
heart	O
failure	O
and	O
may	O
also	O
be	O
useful	O
as	O
probes	O
to	O
study	O
the	O
structure	O
-	O
function	O
relationships	O
of	O
calcium	O
channels	O
.	O

A	O
series	O
of	O
4'	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
spiro	I-IUPAC
[	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
3,1	I-IUPAC
-	I-IUPAC
benzoxazine	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidin	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
was	O
prepared	O
and	O
evaluated	O
for	O
antihypertensive	O
activity	O
in	O
the	O
spontaneously	O
hypertensive	O
rat	O
(	O
SHR	O
)	O
.	O

The	O
basic	O
ring	O
system	O
was	O
prepared	O
in	O
one	O
step	O
by	O
condensation	O
of	O
dilithiated	I-MODIFIER
(	B-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
aniline	I-IUPAC
(	O
3	O
)	O
with	O
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
piperidinone	I-IUPAC
.	O

Deprotection	O
afforded	O
6	O
,	O
which	O
was	O
condensed	O
with	O
expoxides	O
or	O
alkyl	O
halides	O
to	O
furnish	O
the	O
title	O
compounds	O
.	O

The	O
most	O
active	O
compound	O
was	O
dl	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
benzodioxan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
3,1	I-IUPAC
-	I-IUPAC
benzoxazine	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidin	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
9	O
)	O
,	O
and	O
various	O
modifications	O
of	O
this	O
compound	O
were	O
made	O
in	O
order	O
to	O
elucidate	O
the	O
structure	O
-	O
activity	O
relationships	O
in	O
the	O
series	O
.	O

Preliminary	O
indications	O
are	O
that	O
9	O
may	O
act	O
by	O
both	O
central	O
and	O
peripheral	O
mechanisms	O
.	O

A	O
number	O
of	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
:	I-IUPAC
N'	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
:	I-IUPAC
N	I-IUPAC
"	I-IUPAC
,	I-IUPAC
N	I-IUPAC
"	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
ethanediylphosphoric	I-IUPAC
triamide	I-IUPAC
(	O
TEPA	O
)	O
and	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
:	I-IUPAC
N'	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
:	I-IUPAC
N	I-IUPAC
"	I-IUPAC
,	I-IUPAC
N	I-IUPAC
"	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
ethanediylphosphorothioic	I-IUPAC
triamide	I-IUPAC
(	O
thio	O
-	O
TEPA	O
)	O
derivatives	O
containing	O
either	O
two	O
aziridine	I-IUPAC
moieties	B-MODIFIER
(	O
1a	O
)	O
or	O
two	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
functions	I-MODIFIER
(	O
1b	O
)	O
and	O
either	O
a	O
2,2,6,6	I-IUPAC
-	I-IUPAC
tetramethylpiperidine	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
oxy	I-IUPAC
-	I-IUPAC
2,2,6,6	I-IUPAC
-	I-IUPAC
tetramethylpiperidine	I-IUPAC
or	O
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2,2,6,6	I-IUPAC
-	I-IUPAC
tetramethylpiperidine	I-IUPAC
component	I-MODIFIER
were	O
synthesized	O
and	O
tested	O
against	O
lymphocytic	O
leukemia	O
P388	O
in	O
mice	O
.	O

In	O
a	O
structure	O
-	O
activity	O
comparison	O
it	O
was	O
found	O
that	O
at	O
optimum	O
dose	O
all	O
compounds	O
containing	O
the	O
nitroxyl	O
radical	O
were	O
more	O
active	O
than	O
the	O
corresponding	O
hydroxylamine	O
derivatives	O
.	O

The	O
open	O
-	O
chain	O
compounds	O
(	O
1b	O
)	O
were	O
less	O
active	O
than	O
the	O
corresponding	O
aziridine	O
ring	O
compounds	O
(	O
1a	O
)	O
.	O

The	O
replacement	O
of	O
the	O
X	O
=	O
bridge	O
in	O
1a	O
with	O
the	O
X	O
=	O
N	O
(	O
CH3	O
)	O
group	O
resulted	O
in	O
lowering	O
of	O
the	O
anticancer	O
activity	O
.	O

A	O
series	O
of	O
esters	O
of	O
6beta	I-IUPAC
-	I-IUPAC
hydroxynortropane	I-IUPAC
and	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	I-MODIFIER
6beta	B-IUPAC
-	I-IUPAC
tropanol	I-IUPAC
were	O
synthesized	O
and	O
screened	O
versus	O
binding	O
of	O
an	O
antagonist	O
(	O
quinuclidinyl	I-IUPAC
benzilate	I-IUPAC
)	O
and	O
an	O
agonist	O
(	O
oxotremorine	O
-	O
M	O
)	O
at	O
sites	O
on	O
human	O
m	O
(	O
1	O
)	O
-	O
,	O
m	O
(	O
2	O
)	O
-	O
,	O
m	O
(	O
3	O
)	O
-	O
,	O
and	O
m	O
(	O
4	O
)	O
-	O
muscarinic	O
receptors	O
in	O
transfected	O
cell	O
membranes	O
and	O
on	O
native	O
M	O
(	O
1	O
)	O
-	O
muscarinic	O
receptors	O
in	O
rat	O
brain	O
membranes	O
and	O
native	O
M	O
(	O
2	O
)	O
-	O
muscarinic	O
receptors	O
in	O
rat	O
heart	O
membranes	O
.	O

Most	O
6beta	I-IUPAC
-	I-IUPAC
acyloxy	I-IUPAC
(	I-IUPAC
nor	I-IUPAC
)	I-IUPAC
tropanes	I-IUPAC
had	O
higher	O
affinity	O
versus	O
oxotremorine	O
-	O
M	O
binding	O
compared	O
to	O
quinuclidinyl	O
benzilate	O
binding	O
at	O
transfected	O
m	O
(	O
1	O
)	O
-	O
and	O
native	O
M	O
(	O
1	O
)	O
-	O
receptors	O
,	O
indicative	O
of	O
agonist	O
activity	O
.	O

6beta	I-IUPAC
-	I-IUPAC
Acetoxynortropane	I-IUPAC
had	O
K	O
(	O
i	O
)	O
values	O
versus	O
oxotremorine	O
-	O
M	O
binding	O
at	O
m	O
(	O
1	O
)	O
-	O
,	O
m	O
(	O
2	O
)	O
-	O
,	O
and	O
m	O
(	O
4	O
)	O
-	O
receptors	O
ranging	O
from	O
4	O
to	O
7	O
nM	O
.	O

N	O
-	O
Methylation	O
reduced	O
affinity	O
greatly	O
as	O
did	O
increasing	O
the	O
size	O
of	O
the	O
acyl	O
moiety	O
.	O

The	O
affinity	O
of	O
6beta	I-IUPAC
-	I-IUPAC
benzoyloxynortropane	I-IUPAC
and	O
other	O
analogues	O
with	O
larger	O
acyl	O
moieties	O
was	O
little	O
affected	O
by	O
N	O
-	O
methylation	O
or	O
in	O
some	O
cases	O
was	O
increased	O
.	O

6beta	I-IUPAC
-	I-IUPAC
Acyloxy	I-IUPAC
(	I-IUPAC
nor	I-IUPAC
)	I-IUPAC
tropanes	I-IUPAC
and	O
classical	O
muscarinic	O
agonists	O
,	O
such	O
as	O
muscarine	O
and	O
oxotremorine	O
,	O
had	O
higher	O
affinity	O
versus	O
oxotremorine	O
-	O
M	O
binding	O
compared	O
to	O
quinuclidinyl	O
benzilate	O
binding	O
at	O
native	O
M	O
(	O
2	O
)	O
-	O
muscarinic	O
receptors	O
of	O
heart	O
,	O
but	O
not	O
at	O
transfected	O
m	O
(	O
2	O
)	O
-	O
muscarinic	O
receptors	O
.	O

Antagonist	O
/	O
agonist	O
binding	O
ratios	O
were	O
not	O
obtained	O
for	O
transfected	O
m	O
(	O
3	O
)	O
-	O
receptors	O
,	O
since	O
significant	O
oxotremorine	O
-	O
M	O
binding	O
could	O
not	O
be	O
detected	O
.	O

6beta	I-IUPAC
-	I-IUPAC
Acyloxy	I-IUPAC
(	I-IUPAC
nor	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
,	O
two	O
other	O
(	O
nor	O
)	O
tropanes	O
,	O
and	O
the	O
classical	O
muscarinic	O
agonists	O
had	O
higher	O
affinity	O
versus	O
agonist	O
binding	O
compared	O
to	O
antagonist	O
binding	O
for	O
transfected	O
m	O
(	O
4	O
)	O
-	O
receptors	O
.	O

The	O
antagonist	O
/	O
agonist	O
binding	O
ratio	O
method	O
is	O
clearly	O
not	O
always	O
reliable	O
for	O
predicting	O
agonist	O
activity	O
at	O
muscarinic	O
receptors	O
.	O

New	O
histamine	O
derivatives	O
characterized	O
by	O
a	O
(	O
substituted	O
)	O
aryl	O
,	O
heteroaryl	O
,	O
benzyl	O
,	O
or	O
heteroarylmethyl	O
substituent	O
in	O
the	O
C2	O
position	O
of	O
the	O
imidazole	O
ring	O
have	O
been	O
prepared	O
from	O
appropriate	O
imidates	O
or	O
amidines	O
,	O
respectively	O
,	O
and	O
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phthalimido	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
acetate	I-IUPAC
(	O
1	O
)	O
.	O

The	O
compounds	O
were	O
screened	O
as	O
potential	O
H1	O
receptor	O
agonists	O
on	O
the	O
isolated	O
guinea	O
pig	O
ileum	O
.	O

The	O
3	I-IUPAC
-	I-IUPAC
halogenated	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylhistamines	I-IUPAC
(	O
halogen	O
=	O
Br	O
(	O
35	O
)	O
and	O
I	O
(	O
36	O
)	O
)	O
were	O
equipotent	O
with	O
histamine	O
,	O
while	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
histamine	I-IUPAC
(	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ethanamine	I-IUPAC
(	O
39	O
)	O
)	O
was	O
significantly	O
more	O
potent	O
than	O
histamine	O
(	O
39	O
:	O
pD2	O
=	O
6.81	O
,	O
relative	O
activity	O
=	O
128%	O
)	O
.	O

The	O
2	O
-	O
substituted	O
histamine	O
analogues	O
were	O
partial	O
H1	O
receptor	O
agonists	O
on	O
the	O
endothelium	O
-	O
denuded	O
isolated	O
guinea	O
pig	O
aorta	O
with	O
pEC50	O
values	O
generally	O
smaller	O
than	O
observed	O
on	O
the	O
guinea	O
pig	O
ileum	O
,	O
but	O
the	O
rank	O
order	O
of	O
potency	O
was	O
found	O
to	O
be	O
similar	O
.	O

The	O
contractile	O
effects	O
on	O
guinea	O
pig	O
ileum	O
and	O
aorta	O
,	O
respectively	O
,	O
could	O
be	O
blocked	O
concentration	O
-	O
dependently	O
by	O
the	O
H1	O
receptor	O
antagonist	O
mepyramine	O
,	O
yielding	O
KB	O
values	O
for	O
mepyramine	O
in	O
the	O
nanomolar	O
range	O
.	O

In	O
vitro	O
compounds	O
35	O
and	O
39	O
bound	O
to	O
[	O
3H	O
]	O
mepyramine	O
-	O
labeled	O
guinea	O
pig	O
cerebellar	O
membranes	O
with	O
a	O
pKi	O
of	O
6.1	O
and	O
5.9	O
,	O
respectively	O
.	O

However	O
,	O
upon	O
iv	O
administration	O
,	O
35	O
(	O
3-100	O
mg	O
/	O
kg	O
)	O
and	O
39	O
(	O
3-300	O
mg	O
/	O
kg	O
)	O
failed	O
to	O
inhibit	O
the	O
binding	O
of	O
[	O
3H	O
]	O
mepyramine	O
to	O
mouse	O
cerebral	O
cortex	O
in	O
vivo	O
,	O
thereby	O
indicating	O
that	O
these	O
histamine	O
derivatives	O
are	O
not	O
able	O
to	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

In	O
functional	O
in	O
vitro	O
studies	O
on	O
histamine	O
H2	O
,	O
H3	O
,	O
and	O
other	O
neurotransmitter	O
receptors	O
the	O
selectivity	O
of	O
39	O
was	O
found	O
to	O
be	O
2138	O
(	O
H1	O
:	O
H2	O
)	O
,	O
&	O
gt	O
;	O
64	O
(	O
H1	O
:	O
H3	O
)	O
,	O
1000	O
(	O
H1	O
:	O
M3	O
)	O
,	O
105	O
(	O
H1	O
:	O
alpha	O
1	O
)	O
,	O
708	O
(	O
H1	O
:	O
beta	O
1	O
)	O
,	O
and	O
71	O
(	O
H1	O
:	O
5HT2A	O
)	O
.	O

Thus	O
compound	O
39	O
is	O
the	O
most	O
potent	O
and	O
selective	O
H1	O
receptor	O
agonist	O
reported	O
so	O
far	O
.	O

These	O
results	O
make	O
meta	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
phenylhistamines	I-IUPAC
,	O
especially	O
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
trifluoromethyl	I-PARTIUPAC
)	I-PARTIUPAC
phenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromophenyl	I-IUPAC
)	I-IUPAC
histamine	I-IUPAC
(	O
39	O
and	O
35	O
,	O
respectively	O
)	O
valuable	O
experimental	O
tools	O
for	O
the	O
selective	O
stimulation	O
of	O
histamine	O
H1	O
receptors	O
and	O
the	O
study	O
of	O
H1	O
receptor	O
-	O
mediated	O
functions	O
.	O

Substrate	O
enantioselectivity	O
in	O
the	O
conjugation	O
of	O
phenethyl	O
halides	O
catalyzed	O
by	O
the	O
glutathione	O
S	O
-	O
transferases	O
was	O
studied	O
with	O
partially	O
purified	O
isozymes	O
from	O
rat	O
liver	O
.	O

All	O
of	O
the	O
isozymes	O
tested	O
possessed	O
measurable	O
activity	O
with	O
phenethyl	O
chloride	O
.	O

Tranferase	O
A	O
was	O
the	O
most	O
active	O
isozyme	O
tested	O
.	O

Each	O
of	O
the	O
isozymes	O
demonstrated	O
a	O
high	O
degree	O
of	O
substrate	O
enantioselectivity	O
,	O
with	O
transferase	O
A	O
being	O
the	O
most	O
enantioselective	O
isozyme	O
.	O

The	O
enantioselectivity	O
was	O
determined	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatographic	O
analysis	O
of	O
the	O
enzymatically	O
formed	O
diastereomeric	O
products	O
.	O

The	O
effect	O
of	O
limiting	O
glutathione	O
concentrations	O
on	O
the	O
stereochemical	O
outcome	O
of	O
the	O
transferase	O
A	O
catalyzed	O
conjugation	O
of	O
the	O
chiral	O
substrate	O
,	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
chloride	I-IUPAC
(	O
4	O
mM	O
)	O
,	O
was	O
investigated	O
.	O

The	O
stereochemical	O
course	O
of	O
the	O
enzymatic	O
reaction	O
was	O
not	O
significantly	O
altered	O
at	O
glutathione	O
concentrations	O
as	O
low	O
as	O
25	O
microM	O
.	O

The	O
major	O
product	O
of	O
conjugation	O
had	O
the	O
opposite	O
stereochemistry	O
at	O
the	O
benzylic	O
carbon	O
,	O
indicating	O
that	O
the	O
reaction	O
proceeded	O
primarily	O
with	O
inversion	O
of	O
configuration	O
.	O

The	O
glutathione	O
conjugates	O
,	O
S	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
glutathione	I-IUPAC
,	O
S	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
glutathione	I-IUPAC
,	O
S	I-IUPAC
-	I-IUPAC
benzylglutathione	I-IUPAC
,	O
and	O
S	I-IUPAC
-	I-IUPAC
methylglutathione	I-IUPAC
were	O
studied	O
as	O
inhibitors	O
of	O
the	O
transferase	O
A	O
catalyzed	O
conjugation	O
of	O
1	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dinitrobenzene	I-IUPAC
.	O

The	O
order	O
of	O
the	O
inhibitory	O
potency	O
was	O
S	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
glutathione	I-IUPAC
=	O
S	I-IUPAC
-	I-IUPAC
benzylglutathione	I-IUPAC
greater	O
than	O
S	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
glutathione	I-IUPAC
greater	O
than	O
S	I-IUPAC
-	I-IUPAC
methylglutathione	I-IUPAC
.	O

This	O
represented	O
the	O
first	O
demonstration	O
of	O
the	O
stereoselective	O
product	O
inhibition	O
of	O
the	O
glutathione	O
S	O
-	O
transferases	O
.	O

Due	O
to	O
the	O
antiviral	O
activity	O
of	O
certain	O
5	O
-	O
substituted	O
imidazole	O
nucleosides	O
related	O
to	O
ribavirin	O
,	O
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
nucleosides	I-MODIFIER
having	O
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
deoxy	I-PARTIUPAC
-	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
alpha	I-PARTIUPAC
-	I-PARTIUPAC
D	I-PARTIUPAC
-	I-PARTIUPAC
ribofuranosyl	I-PARTIUPAC
,	O
and	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
moieties	I-MODIFIER
have	O
been	O
prepared	O
and	O
tested	O
as	O
antiviral	O
agents	O
.	O

1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
Ribofuranosyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
was	O
obtained	O
by	O
deacetylation	O
of	O
the	O
corresponding	O
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
nucleoside	I-IUPAC
11	O
or	O
by	O
deacetylation	O
and	O
ammonolysis	O
of	O
the	O
blocked	O
ethyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
nucleoside	I-IUPAC
10	O
,	O
which	O
was	O
prepared	O
from	O
the	O
stannic	O
chloride	O
catalyzed	O
condensation	O
of	O
the	O
trimethylsilyl	I-IUPAC
derivative	B-MODIFIER
of	O
ethyl	I-IUPAC
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
.	O

Glycosylation	O
of	O
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
with	O
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
chloride	I-IUPAC
via	O
mercuric	O
cyanide	O
method	O
provided	O
an	O
anomeric	O
mixture	O
of	O
the	O
blocked	O
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
deoxynucleoside	I-IUPAC
14	O
along	O
with	O
an	O
anomeric	O
mixture	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
isomer	I-MODIFIER
15	O
.	O

Separation	O
of	O
compound	O
14	O
into	O
the	O
corresponding	O
beta	O
and	O
alpha	O
anomers	O
was	O
achieved	O
by	O
conversion	O
to	O
the	O
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
derivatives	I-MODIFIER
17	O
and	O
18	O
,	O
which	O
after	O
chromatographic	O
separation	O
were	O
deacetylated	O
to	O
give	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxa	I-IUPAC
mid	I-IUPAC
e	I-IUPAC
and	O
its	O
alpha	O
anomer	O
20	O
.	O

1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
Hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
was	O
prepared	O
by	O
alkylation	O
of	O
the	O
imidazole	O
13	O
with	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetoxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
bromide	I-IUPAC
followed	O
by	O
treatment	O
with	O
methanolic	O
ammonia	O
.	O

All	O
these	O
imidazole	O
nucleosides	O
were	O
tested	O
in	O
HeLa	O
cell	O
cultures	O
against	O
type	O
1	O
herpes	O
simplex	O
and	O
vesicular	O
stomatitis	O
viruses	O
.	O

The	O
ribofuranosyl	I-IUPAC
derivative	B-MODIFIER
12	O
showed	O
a	O
significant	O
activity	O
against	O
type	O
1	O
herpes	O
simplex	O
virus	O
.	O

A	O
series	O
of	O
thymidylate	O
synthetase	O
inhibitors	O
was	O
synthesized	O
,	O
some	O
of	O
which	O
were	O
potential	O
irreversible	O
inhibitors	O
.	O

5	I-IUPAC
-	I-IUPAC
Formyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
9	O
)	O
and	O
its	O
dithiolane	I-IUPAC
derivative	B-MODIFIER
11	O
were	O
prepared	O
by	O
condensation	O
of	O
the	O
bis	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
of	O
5	I-IUPAC
-	I-IUPAC
formyluracil	I-IUPAC
dimethyl	I-IUPAC
acetal	I-IUPAC
and	O
the	O
protected	O
chloro	O
sugar	O
followed	O
by	O
saponification	O
of	O
the	O
protective	O
groups	O
.	O

5	I-IUPAC
-	I-IUPAC
Acetyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
15	O
)	O
was	O
prepared	O
in	O
the	O
same	O
way	O
from	O
5	I-IUPAC
-	I-IUPAC
acetyluracil	I-IUPAC
.	O

Treatment	O
of	O
the	O
diester	O
of	O
5	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
17	O
or	O
22	O
)	O
with	O
m	I-IUPAC
-	I-IUPAC
chloroperbenzoic	I-IUPAC
acid	I-IUPAC
gave	O
the	O
corresponding	O
epoxide	O
.	O

Dimethylamine	O
removed	O
the	O
ester	O
groups	O
and	O
opened	O
the	O
epoxide	O
to	O
give	O
the	O
amino	O
alcohol	O
24	O
.	O

The	O
diester	O
of	O
5	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
27	O
)	O
treated	O
with	O
methanol	I-IUPAC
or	O
sodium	O
azide	O
gave	O
5	I-PARTIUPAC
-	I-PARTIUPAC
methoxymethyl	I-PARTIUPAC
-	I-PARTIUPAC
(	O
29	O
)	O
and	O
5	I-PARTIUPAC
-	I-PARTIUPAC
azidomethyl	I-PARTIUPAC
-	I-PARTIUPAC
(	O
31	O
)	O
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
.	O

Compound	O
27	O
also	O
was	O
converted	O
to	O
5	I-IUPAC
-	I-IUPAC
iodoacetamidomethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
by	O
treatment	O
with	O
ammonia	O
,	O
chloroacetyl	O
chloride	O
,	O
base	O
saponification	O
,	O
and	O
finally	O
sodium	O
iodide	O
.	O

Reaction	O
of	O
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydrofolic	I-IUPAC
acid	I-IUPAC
(	O
THF	O
,	O
7	O
)	O
with	O
phosgene	O
,	O
thiophosgene	O
,	O
and	O
cyanogen	O
bromide	O
gave	O
the	O
bridged	O
derivatives	O
,	O
5,10	O
-	O
(	O
CO	O
)	O
-	O
THF	O
(	O
8	O
)	O
,	O
5,10	O
-	O
(	O
CS	O
)	O
-	O
THF	O
(	O
9	O
)	O
,	O
and	O
5,10	O
-	O
(	O
C	O
=	O
NH	O
)	O
-	O
THF	O
(	O
11	O
)	O
,	O
respectively	O
.	O

Catalytic	O
hydrogenation	O
of	O
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloroacetyl	I-IUPAC
)	I-IUPAC
folic	I-IUPAC
acid	I-IUPAC
(	O
2	O
)	O
gave	O
5,10	O
-	O
(	O
CH2CO	O
)	O
-	O
THF	O
(	O
12	O
)	O
.	O

A	O
similar	O
reaction	O
with	O
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloropropionyl	I-IUPAC
)	I-IUPAC
folic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
gave	O
10	O
-	O
(	O
ClCH2CH2CO	O
)	O
-	O
THF	O
(	O
14	O
)	O
rather	O
than	O
5,10	O
-	O
(	O
CH2CH2CO	O
)	O
-	O
THF	O
(	O
13	O
)	O
.	O

In	O
the	O
catalytic	O
hydrogenation	O
of	O
10	I-IUPAC
-	I-IUPAC
ethoxalylfolic	I-IUPAC
acid	I-IUPAC
(	O
5	O
)	O
,	O
the	O
initial	O
product	O
10	O
-	O
(	O
EtO2CCO	O
)	O
-	O
THF	O
(	O
22	O
)	O
rearranged	O
readily	O
to	O
give	O
5	O
-	O
(	O
EtO2CCO	O
)	O
-	O
THF	O
(	O
21	O
)	O
.	O

Acylation	O
of	O
THF	O
with	O
chloroacetyl	O
chloride	O
gave	O
a	O
N5	O
,	O
N10	O
-	O
diacylated	O
product	O
(	O
18	O
or	O
19	O
)	O
,	O
which	O
could	O
not	O
be	O
converted	O
to	O
5,10	O
-	O
COCH2	O
)	O
-	O
THF	O
(	O
17	O
)	O
.	O

Reductive	O
alkylation	O
of	O
THF	O
with	O
glyoxylic	O
acid	O
and	O
5	I-IUPAC
-	I-IUPAC
hydroxypentanal	I-IUPAC
,	O
respectively	O
,	O
gave	O
5	O
-	O
(	O
HO2CCH2	O
)	O
-	O
THF	O
(	O
24	O
)	O
and	O
5	O
-	O
[	O
HO	O
(	O
CH2	O
)	O
5	O
]	O
-	O
THF	O
(	O
25	O
)	O
.	O

Reductive	O
dialkylation	O
of	O
THF	O
with	O
formaldehyde	O
gave	O
5,10	O
-	O
(	O
CH3	O
)	O
2	O
-	O
THF	O
(	O
27	O
)	O
,	O
whereas	O
glyoxal	O
gave	O
5,10	O
-	O
CH2CH2	O
)	O
-	O
THF	O
(	O
10	O
)	O
.	O

Also	O
,	O
both	O
folic	O
acid	O
and	O
5	O
-	O
(	O
CHO	O
)	O
-	O
THF	O
were	O
reductively	O
alkylated	O
with	O
formaldehyde	O
to	O
give	O
10	I-IUPAC
-	I-IUPAC
methylfolic	I-IUPAC
acid	I-IUPAC
(	O
6	O
)	O
and	O
5	O
-	O
(	O
CHO	O
)	O
-	O
10	O
-	O
(	O
CH3	O
)	O
-	O
THF	O
(	O
28	O
)	O
,	O
respectively	O
.	O

These	O
compounds	O
were	O
tested	O
as	O
inhibitors	O
of	O
the	O
enzymes	O
involved	O
in	O
folate	O
metabolism	O
and	O
for	O
activity	O
against	O
lymphocytic	O
leukemia	O
P388	O
in	O
mice	O
.	O

A	O
broad	O
screening	O
of	O
phytochemicals	O
has	O
demonstrated	O
that	O
certain	O
flavone	O
and	O
flavonol	O
derivatives	O
have	O
a	O
relatively	O
high	O
affinity	O
at	O
A3	O
adenosine	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
&	O
gt	O
;	O
or	O
=	O
1	O
microM	O
(	O
Ji	O
et	O
al.	O
J	O
.	O

Med.	O
Chem.	O
1996	O
,	O
39	O
,	O
781-788	O
)	O
.	O

We	O
have	O
further	O
modified	O
the	O
flavone	O
structure	O
to	O
achieve	O
a	O
degree	O
of	O
selectivity	O
for	O
cloned	O
human	O
brain	O
A3	O
receptors	O
,	O
determined	O
in	O
competitive	O
binding	O
assays	O
versus	O
[	O
125I	O
]	O
AB	O
-	O
MECA	O
[	O
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodobenzyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylur	I-IUPAC
onamide	I-IUPAC
)	I-IUPAC
]	O
.	O

Affinity	O
was	O
determined	O
in	O
radioligand	O
binding	O
assays	O
at	O
rat	O
brain	O
A1	O
and	O
A2a	O
receptors	O
using	O
[	O
3H	O
]	O
-	O
N6	O
-	O
PIA	O
(	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
phenylisopropyladenosine	I-IUPAC
)	O
and	O
[	O
3H	O
]	O
CGS21680	O
[	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxyethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
ethylamino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
ethylcarbamoyl+	I-IUPAC
+	I-IUPAC
+	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
]	O
,	O
respectively	O
.	O

The	O
triethyl	O
and	O
tripropyl	O
ether	O
derivatives	O
of	O
the	O
flavonol	O
galangin	O
,	O
4	O
,	O
had	O
Ki	O
values	O
of	O
0.3	O
-	O
0.4	O
microM	O
at	O
human	O
A3	O
receptors	O
.	O

The	O
presence	O
of	O
a	O
5	I-IUPAC
-	I-IUPAC
hydroxyl	I-IUPAC
group	I-MODIFIER
increased	O
selectivity	O
of	O
flavonols	O
for	O
human	O
A3	O
receptors	O
.	O

The	O
2'	I-IUPAC
,	I-IUPAC
3,4	I-IUPAC
'	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
tetraethyl	I-IUPAC
ether	I-IUPAC
derivative	I-MODIFIER
of	O
the	O
flavonol	O
morin	O
,	O
7	O
,	O
displayed	O
a	O
Ki	O
value	O
of	O
4.8	O
microM	O
at	O
human	O
A3	O
receptors	O
and	O
was	O
inactive	O
at	O
rat	O
A1	O
/	O
A2a	O
receptors	O
.	O

3,6	I-IUPAC
-	I-IUPAC
Dichloro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isopropyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
methylflavone	I-IUPAC
,	O
11e	O
,	O
was	O
both	O
potent	O
and	O
highly	O
selective	O
(	O
approximately	O
200	O
-	O
fold	O
)	O
for	O
human	O
A3	O
receptors	O
(	O
Ki	O
=	O
0.56	O
microM	O
)	O
.	O

Among	O
dihydroflavonol	O
analogues	O
,	O
the	O
2	I-IUPAC
-	I-IUPAC
styryl	I-IUPAC
instead	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
substituent	I-MODIFIER
,	O
in	O
15	O
,	O
afforded	O
selectivity	O
for	O
human	O
A3	O
vs	O
rat	O
A1	O
or	O
A2A	O
receptors	O
.	O

The	O
2	I-IUPAC
-	I-IUPAC
styryl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
derivative	I-MODIFIER
,	O
20	O
,	O
of	O
the	O
furanochromone	O
visnagin	O
was	O
30	O
-	O
fold	O
selective	O
for	O
human	O
A3	O
receptors	O
vs	O
either	O
rat	O
A1	O
or	O
A2A	O
receptors	O
.	O

Several	O
of	O
the	O
more	O
potent	O
derivatives	O
effectively	O
antagonized	O
the	O
effects	O
of	O
an	O
agonist	O
in	O
a	O
functional	O
A3	O
receptor	O
assay	O
,	O
i.e.	O
inhibition	O
of	O
adenylyl	I-IUPAC
cyclase	I-IUPAC
in	O
CHO	O
cells	O
expressing	O
cloned	O
rat	O
A3	O
receptors	O
.	O

In	O
conclusion	O
,	O
these	O
series	O
of	O
flavonoids	O
provide	O
leads	O
for	O
the	O
development	O
of	O
novel	O
potent	O
and	O
subtype	O
selective	O
A3	O
antagonists	O
.	O

A	O
number	O
of	O
novel	O
dihydropyridine	O
derivatives	O
based	O
upon	O
1	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diphenylpiperidin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
aminocarbonyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
(	O
4	O
)	O
have	O
been	O
synthesized	O
and	O
tested	O
at	O
cloned	O
human	O
alpha	O
adrenoceptors	O
as	O
well	O
as	O
the	O
rat	O
L	O
-	O
type	O
calcium	O
channel	O
.	O

Within	O
this	O
compound	O
series	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminocarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diphenylpiperidin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
aminocarbonyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
(	O
19	O
)	O
displayed	O
good	O
binding	O
affinity	O
and	O
selectivity	O
for	O
the	O
alpha1a	O
adrenoceptor	O
(	O
pKi	O
=	O
8.73	O
)	O
and	O
potently	O
inhibited	O
(	O
pA2	O
=	O
9.23	O
)	O
phenylephrine	O
-	O
induced	O
contraction	O
of	O
the	O
human	O
prostate	O
.	O

The	O
synthesis	O
of	O
several	O
analogues	O
of	O
(	I-IUPAC
8R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydroimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
pentostatin	O
,	O
1a	O
)	O
is	O
described	O
.	O

Ring	O
closure	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethanone	I-IUPAC
dihydrochloride	I-IUPAC
(	O
3	O
)	O
with	O
triethyl	I-IUPAC
orthoacetate	I-IUPAC
or	O
triethyl	I-IUPAC
orthopropionate	I-IUPAC
gave	O
the	O
C	I-MODIFIER
-	I-MODIFIER
5	I-MODIFIER
methyl	I-IUPAC
and	O
ethyl	I-IUPAC
ketoaglycons	I-IUPAC
,	O
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
4b	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dihydroimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
4c	O
)	O
,	O
respectively	O
.	O

Stannic	O
chloride	O
catalyzed	O
condensation	O
of	O
the	O
pertrimethylsilyl	O
derivatives	O
of	O
4b	O
and	O
4c	O
with	O
a	O
protected	O
glycosyl	O
halide	O
afforded	O
anomeric	O
mixtures	O
of	O
ketonucleosides	O
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
deoxy	I-PARTIUPAC
-	I-PARTIUPAC
3,5	I-PARTIUPAC
-	I-PARTIUPAC
di	I-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
p	I-PARTIUPAC
-	I-PARTIUPAC
toluoyl	I-PARTIUPAC
-	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
alpha	I-PARTIUPAC
-	I-PARTIUPAC
D	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
pentofuranosyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
6,7	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
methylimidazo	I-PARTIUPAC
[	I-PARTIUPAC
4,5	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
[	I-PARTIUPAC
1,3	I-PARTIUPAC
]	I-PARTIUPAC
diazepin	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
(	I-PARTIUPAC
3H	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
one	I-PARTIUPAC
(	O
5b	O
and	O
6b	O
)	O
and	O
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
deoxy	I-PARTIUPAC
-	I-PARTIUPAC
3,5	I-PARTIUPAC
-	I-PARTIUPAC
di	I-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
p	I-PARTIUPAC
-	I-PARTIUPAC
toluoyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
alpha	I-PARTIUPAC
-	I-PARTIUPAC
D	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
pentofuranosyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
ethyl	I-PARTIUPAC
-	I-PARTIUPAC
6,7	I-PARTIUPAC
-	I-PARTIUPAC
dihydroimidazo	I-PARTIUPAC
[	I-PARTIUPAC
4,5	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
1,3	I-PARTIUPAC
]	I-PARTIUPAC
diazepin	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
(	I-PARTIUPAC
3H	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
one	I-PARTIUPAC
(	O
5c	O
and	O
6c	O
)	O
,	O
respectively	O
.	O

Subsequent	O
separation	O
of	O
the	O
anomers	O
,	O
followed	O
by	O
deprotection	O
and	O
reduction	O
of	O
5b	O
,	O
6b	O
,	O
and	O
5c	O
,	O
afforded	O
the	O
respective	O
8R	O
and	O
8S	O
isomers	O
.	O

Stannic	O
chloride	O
catalyzed	O
condensation	O
of	O
pertrimethylsilyl	O
ketoaglycon	O
4a	O
with	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyloxy	I-IUPAC
)	I-IUPAC
ethane	I-IUPAC
to	O
give	O
ketonucleoside	O
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyloxy	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
9a	O
)	O
was	O
followed	O
by	O
deprotection	O
to	O
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
9b	O
)	O
and	O
then	O
reduction	O
to	O
the	O
racemic	O
acyclic	O
pentostatin	O
analogue	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
2	O
)	O
.	O

Ki	O
values	O
for	O
the	O
in	O
vitro	O
adenosine	O
deaminase	O
(	O
EC	O
3.5.4.4	O
;	O
type	O
I	O
;	O
calf	O
intestinal	O
mucosa	O
)	O
inhibitory	O
activities	O
of	O
1b	O
,	O
1c	O
,	O
and	O
2	O
were	O
determined	O
to	O
be	O
1.6	O
X	O
10	O
(	O
-	O
8	O
)	O
,	O
1.5	O
X	O
10	O
(	O
-	O
6	O
)	O
,	O
and	O
9.8	O
X	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
respectively	O
.	O

When	O
compounds	O
2	O
and	O
9b	O
were	O
tested	O
in	O
combination	O
with	O
vidarabine	O
against	O
herpes	O
simplex	O
virus	O
,	O
type	O
1	O
,	O
in	O
an	O
HEp	O
-	O
2	O
plaque	O
reduction	O
assay	O
,	O
only	O
compound	O
2	O
was	O
able	O
to	O
potentiate	O
the	O
antiviral	O
activity	O
of	O
vidarabine	O
.	O

A	O
series	O
of	O
2	I-MODIFIER
-	I-MODIFIER
(	I-MODIFIER
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
homo	I-IUPAC
)	I-IUPAC
piperazinyl	I-IUPAC
)	I-IUPAC
benzimidazoles	I-IUPAC
was	O
prepared	O
and	O
tested	O
for	O
H1	O
-	O
antihistaminic	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Most	O
of	O
the	O
compounds	O
showed	O
antihistaminic	O
activity	O
and	O
some	O
of	O
the	O
1	I-MODIFIER
-	I-MODIFIER
[	I-MODIFIER
2	I-MODIFIER
-	I-MODIFIER
(	I-MODIFIER
substituted	I-MODIFIER
-	I-MODIFIER
oxy	I-MODIFIER
)	I-MODIFIER
ethyl	I-MODIFIER
]	I-MODIFIER
derivatives	B-MODIFIER
exhibited	O
potent	O
activity	O
.	O

In	O
a	O
structure	O
-	O
activity	O
comparison	O
it	O
was	O
found	O
that	O
the	O
oxygen	O
atom	O
in	O
the	O
2	I-MODIFIER
-	I-MODIFIER
(	I-MODIFIER
substituted	I-MODIFIER
-	I-MODIFIER
oxy	I-MODIFIER
)	I-MODIFIER
ethyl	I-MODIFIER
group	B-MODIFIER
at	O
the	O
1	O
-	O
position	O
of	O
the	O
benzimidazole	O
nucleus	O
played	O
an	O
important	O
role	O
for	O
potent	O
antihistaminic	O
activity	O
,	O
especially	O
in	O
vivo	O
.	O

One	O
of	O
the	O
most	O
potent	O
compounds	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethoxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
homopiperazinyl	I-IUPAC
)	I-IUPAC
benzimidazole	I-IUPAC
(	O
69	O
)	O
,	O
was	O
39	O
times	O
more	O
potent	O
than	O
chlorpheniramine	O
maleate	O
in	O
H1	O
-	O
antihistaminic	O
activity	O
in	O
vivo	O
and	O
was	O
selected	O
for	O
clinical	O
evaluation	O
.	O

The	O
structure	O
of	O
compound	O
69	O
is	O
of	O
interest	O
because	O
it	O
provides	O
only	O
a	O
single	O
aromatic	O
unit	O
linked	O
through	O
a	O
chain	O
to	O
a	O
basic	O
nitrogen	O
,	O
while	O
most	O
H1	O
-	O
antihistaminic	O
agents	O
have	O
structures	O
that	O
comprise	O
a	O
double	O
-	O
aromatic	O
unit	O
linked	O
through	O
a	O
chain	O
to	O
a	O
basic	O
tertiary	O
amino	O
group	O
.	O

(	O
E	O
)	O
-	O
4	O
-	O
[	O
4	O
-	O
(	O
Methylthio	O
)	O
phenyl	O
]	O
-	O
1	O
-	O
(	O
2	O
-	O
piperidinyl	O
)	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O
hydrochloride	O
(	O
44	O
,	O
RMI	O
14	O
133A	O
)	O
was	O
found	O
to	O
inhibit	O
ADP	O
-	O
induced	O
aggregation	O
of	O
blood	O
platelets	O
.	O

It	O
was	O
selected	O
from	O
a	O
large	O
series	O
of	O
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
piperidinyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
ethanones	I-IUPAC
synthesized	O
by	O
a	O
modified	O
Schopf	O
reaction	O
from	O
enolate	O
magnesium	O
salts	O
of	O
beta	O
-	O
keto	O
acids	O
and	O
2,3,4,5	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
trimer	I-MODIFIER
or	O
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
pyrrole	I-IUPAC
trimer	I-MODIFIER
,	O
respectively	O
.	O

Evaluation	O
of	O
the	O
compounds	O
was	O
carried	O
out	O
in	O
vitro	O
on	O
human	O
blood	O
platelets	O
.	O

Structure	O
-	O
activity	O
relationships	O
are	O
discussed	O
.	O

44	O
also	O
inhibited	O
platelet	O
aggregation	O
ex	O
vivo	O
in	O
guinea	O
pigs	O
.	O

Subacute	O
toxicity	O
evaluation	O
in	O
dogs	O
and	O
guinea	O
pigs	O
showed	O
it	O
to	O
have	O
an	O
unfavorable	O
therapeutic	O
ratio	O
.	O

1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
Chloro	I-IUPAC
(	I-IUPAC
1,1	I-IUPAC
'	I-IUPAC
-	I-IUPAC
biphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
a1	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
piperdinyl	I-IUPAC
)	I-IUPAC
ethanone	I-IUPAC
hydrochloride	I-IUPAC
(	O
18	O
,	O
RMI	O
12436A	O
)	O
was	O
found	O
to	O
lower	O
serum	O
cholesterol	O
levles	O
in	O
rats	O
with	O
concurrent	O
accumulation	O
of	O
(	I-IUPAC
3beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cholesta	I-IUPAC
-	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
,	O
suggesting	O
inhibition	O
of	O
7	I-IUPAC
-	I-IUPAC
dehydrocholesterol	I-IUPAC
delta7	O
-	O
reductase	O
.	O

A	O
new	O
class	O
of	O
5	I-PARTIUPAC
-	I-PARTIUPAC
halo	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
alkoxy	I-PARTIUPAC
(	O
or	O
azido	I-PARTIUPAC
)	O
-	I-PARTIUPAC
5,6	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
azido	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
deoxythymidines	I-PARTIUPAC
was	O
investigated	O
as	O
potential	O
anti	O
-	O
AIDS	O
drugs	O
.	O

These	O
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
derivatives	I-MODIFIER
,	O
which	O
are	O
also	O
potential	O
prodrugs	O
to	O
3'	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxythymidine	I-IUPAC
(	O
AZT	O
)	O
,	O
were	O
designed	O
in	O
an	O
effort	O
to	O
enhance	O
the	O
duration	O
of	O
action	O
,	O
lipophilicity	O
,	O
and	O
cephalic	O
delivery	O
to	O
the	O
central	O
nervous	O
system	O
.	O

The	O
5	I-PARTIUPAC
-	I-PARTIUPAC
halo	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
alkoxy	I-PARTIUPAC
(	O
or	O
azido	I-PARTIUPAC
)	O
-	I-PARTIUPAC
5,6	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
azido	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
deoxythymidines	I-PARTIUPAC
,	O
which	O
differ	O
in	O
configuration	O
at	O
the	O
C	O
-	O
5	O
and	O
C	O
-	O
6	O
positions	O
,	O
were	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
XR	O
(	O
X	O
=	O
Br	O
,	O
Cl	O
,	O
I	O
;	O
R	O
=	O
alkoxy	O
,	O
azido	O
)	O
to	O
the	O
5,6	O
-	O
olefinic	O
bond	O
of	O
AZT	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
halo	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
derivatives	I-MODIFIER
of	O
AZT	O
are	O
more	O
lipophilic	O
(	O
P	O
=	O
3.3-18.8	O
range	O
)	O
than	O
the	O
parent	O
compound	O
AZT	O
(	O
P	O
=	O
1.29	O
)	O
.	O

These	O
5	I-IUPAC
-	I-IUPAC
halo	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
compounds	I-MODIFIER
,	O
like	O
AZT	O
,	O
did	O
not	O
undergo	O
glycosidic	O
bond	O
cleavage	O
upon	O
incubation	O
with	O
Escherichia	O
coli	O
thymidine	O
phosphorylase	O
.	O

Regeneration	O
of	O
the	O
5,6	O
-	O
olefinic	O
bond	O
to	O
give	O
AZT	O
,	O
upon	O
incubation	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
halo	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
compounds	I-MODIFIER
with	O
glutathione	O
,	O
mouse	O
blood	O
,	O
or	O
mouse	O
liver	O
homogenate	O
,	O
was	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
halo	I-IUPAC
substituent	I-MODIFIER
(	O
I	O
&	O
gt	O
;	O
Br	O
)	O
.	O

No	O
5,6	O
-	O
olefinic	O
bond	O
regeneration	O
was	O
observed	O
for	O
the	O
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
analogs	I-MODIFIER
.	O

The	O
ability	O
of	O
these	O
5	I-PARTIUPAC
-	I-PARTIUPAC
halo	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
alkoxy	I-PARTIUPAC
(	O
or	O
azido	I-PARTIUPAC
)	O
-	I-PARTIUPAC
5,6	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
azido	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
deoxythymidines	I-PARTIUPAC
to	O
protect	O
CEM	O
cells	O
against	O
HIV	O
-	O
induced	O
cytopathogenicity	O
was	O
evaluated	O
.	O

Structure	O
-	O
activity	O
studies	O
showed	O
that	O
the	O
C	O
-	O
5	O
substituent	O
(	O
I	O
,	O
Br	O
,	O
Cl	O
)	O
was	O
a	O
determinant	O
of	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
where	O
the	O
potency	O
order	O
was	O
I	O
&	O
gt	O
;	O
or	O
=	O
Br	O
&	O
gt	O
;	O
Cl	O
.	O

In	O
the	O
5	O
-	O
bromo	O
series	O
of	O
compounds	O
,	O
the	O
C	O
-	O
6	O
substituent	O
was	O
also	O
a	O
determinant	O
of	O
activity	O
where	O
6	O
-	O
OMe	O
and	O
6	O
-	O
OEt	O
substituents	O
exhibited	O
a	O
greater	O
potency	O
than	O
the	O
corresponding	O
6	O
-	O
i	O
-	O
PrO	O
,	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
octyloxy	I-IUPAC
)	I-IUPAC
,	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hexadecyloxy	I-IUPAC
)	I-IUPAC
,	O
and	O
6	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
analogs	I-MODIFIER
.	O

All	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	O
substituted	I-MODIFIER
-	O
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
compounds	I-MODIFIER
were	O
inactive	O
,	O
except	O
for	O
the	O
approximately	O
equipotent	O
6	O
-	O
OMe	O
and	O
6	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
diastereomeric	I-IUPAC
mixtures	I-MODIFIER
which	O
were	O
2-3	O
log	O
units	O
less	O
active	O
than	O
the	O
reference	O
drug	O
AZT	O
.	O

The	O
configuration	O
at	O
the	O
C	O
-	O
5	O
and	O
C	O
-	O
6	O
positions	O
also	O
influenced	O
potency	O
where	O
the	O
activity	O
of	O
the	O
5R	O
,	O
6R	O
-	O
diastereomer	O
was	O
generally	O
greater	O
than	O
that	O
of	O
the	O
corresponding	O
5S	O
,	O
6S	O
-	O
diastereomer	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
synthesis	O
of	O
certain	O
heteroarotinoids	O
has	O
been	O
achieved	O
,	O
namely	O
the	O
systems	O
(	I-IUPAC
2E	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
,	I-IUPAC
6E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
thiochromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
heptatrienoic	I-IUPAC
acid	I-IUPAC
(	O
1a	O
)	O
,	O
ethyl	I-IUPAC
(	I-IUPAC
2E	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
,	I-IUPAC
6E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
teterahydro	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
thiochromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
heptatrienoate	I-IUPAC
(	O
1b	O
)	O
,	O
(	I-IUPAC
2E	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
,	I-IUPAC
6E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
heptatrienoic	I-IUPAC
acid	I-IUPAC
(	O
1c	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
phthalimidoethyl	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
thiochromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
heptatrienoate	I-IUPAC
(	O
1d	O
)	O
,	O
methyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
2a	O
)	O
,	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzyl	I-IUPAC
alcohol	I-IUPAC
(	O
2b	O
)	O
,	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzonitrile	I-IUPAC
(	O
2c	O
)	O
,	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chromanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzaldehyde	I-IUPAC
(	O
2d	O
)	O
,	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
benzofuranyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
3a	O
)	O
,	O
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
benzofuranyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
3b	O
)	O
.	O

Characterization	O
via	O
elemental	O
,	O
IR	O
,	O
1H	O
NMR	O
,	O
and	O
13C	O
NMR	O
analyses	O
was	O
completed	O
for	O
these	O
heterocycles	O
.	O

The	O
biological	O
activity	O
of	O
these	O
heteroarotinoids	O
was	O
assayed	O
by	O
either	O
the	O
suppression	O
of	O
the	O
12	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetradecanoylphorbol	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
(	O
TPA	O
)	O
induced	O
synthesis	O
of	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
in	O
mouse	O
skin	O
or	O
the	O
induction	O
of	O
differentiation	O
of	O
human	O
(	O
HL	O
-	O
60	O
)	O
promyelocytic	O
cells	O
.	O

In	O
the	O
ODC	O
assay	O
,	O
systems	O
1a	O
-	O
c	O
exhibited	O
strong	O
activity	O
(	O
within	O
10%	O
of	O
or	O
less	O
than	O
the	O
control	O
)	O
whereas	O
alcohols	O
2b	O
and	O
3a	O
showed	O
good	O
activity	O
(	O
within	O
50%	O
of	O
the	O
control	O
)	O
as	O
compared	O
to	O
either	O
13	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
or	O
trans	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
.	O

Moderate	O
activity	O
was	O
observed	O
with	O
2a	O
and	O
2b	O
while	O
1d	O
and	O
2c	O
were	O
essentially	O
inactive	O
.	O

With	O
the	O
HL	O
-	O
60	O
assay	O
,	O
1a	O
and	O
1c	O
were	O
approximately	O
2	O
-	O
and	O
5	O
-	O
fold	O
less	O
active	O
,	O
respectively	O
,	O
than	O
trans	O
-	O
retinoic	O
acid	O
.	O

In	O
contrast	O
,	O
2a	O
,	O
3a	O
,	O
and	O
3b	O
induced	O
differentiation	O
of	O
only	O
a	O
very	O
small	O
percentage	O
of	O
the	O
cells	O
.	O

Acids	O
1a	O
and	O
1c	O
were	O
the	O
most	O
active	O
heteroarotinoids	O
in	O
the	O
two	O
biological	O
assays	O
.	O

Consequently	O
,	O
the	O
presence	O
of	O
the	O
heteroatom	O
does	O
not	O
eradicate	O
the	O
activity	O
of	O
the	O
heteroarotinoids	O
and	O
thus	O
they	O
may	O
have	O
potential	O
as	O
chemotherapeutic	O
agents	O
.	O

A	O
number	O
of	O
nucleoside	O
analogues	O
have	O
been	O
either	O
used	O
clinically	O
as	O
anticancer	O
drugs	O
or	O
evaluated	O
in	O
clinical	O
studies	O
,	O
while	O
new	O
nucleoside	O
analogues	O
continue	O
to	O
show	O
promise	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
synthesis	O
and	O
cytotoxicity	O
of	O
a	O
series	O
of	O
new	O
pyrido	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
nucleosides	I-MODIFIER
.	O

2	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxypyridine	I-IUPAC
was	O
converted	O
,	O
in	O
two	O
steps	O
,	O
to	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxopyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
.	O

A	O
variety	O
of	O
1	O
-	O
O	O
-	O
acetylated	O
pentose	O
sugar	O
derivatives	O
were	O
condensed	O
with	O
silylated	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxopyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
,	O
followed	O
by	O
protection	O
,	O
to	O
afford	O
a	O
series	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxopyrido	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
nucleosides	I-MODIFIER
.	O

Further	O
derivatizations	O
provided	O
an	O
additional	O
group	O
of	O
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
nucleosides	I-MODIFIER
.	O

These	O
nucleosides	O
were	O
evaluated	O
for	O
in	O
vitro	O
cytotoxicity	O
to	O
human	O
prostate	O
cancer	O
(	O
HTB	O
-	O
81	O
)	O
and	O
mouse	O
melanoma	O
(	O
B16	O
)	O
cells	O
as	O
well	O
as	O
normal	O
human	O
fibroblasts	O
(	O
NHF	O
)	O
.	O

A	O
number	O
of	O
compounds	O
(	O
1a	O
,	O
b	O
,	O
2a	O
-	O
c	O
,	O
f	O
,	O
3f	O
+	O
4d	O
)	O
showed	O
significant	O
cytotoxicity	O
to	O
cancer	O
cells	O
,	O
with	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
1b	O
)	O
being	O
the	O
most	O
potent	O
proliferation	O
inhibitor	O
(	O
EC	O
(	O
50	O
)	O
:	O
0.06-0.08	O
microM	O
)	O
to	O
all	O
types	O
of	O
cells	O
tested	O
.	O

However	O
,	O
a	O
selective	O
inhibition	O
to	O
the	O
cancer	O
cells	O
was	O
observed	O
for	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
xylofuranosyl	I-IUPAC
)	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
2b	O
)	O
,	O
which	O
is	O
a	O
potent	O
inhibitor	O
of	O
HTB	O
-	O
81	O
(	O
EC	O
(	O
50	O
)	O
:	O
0.73	O
microM	O
)	O
and	O
has	O
a	O
favorable	O
in	O
vitro	O
selectivity	O
index	O
(	O
28	O
)	O
.	O

Two	O
series	O
of	O
compounds	O
that	O
are	O
structurally	O
related	O
to	O
benzomorphans	O
,	O
derived	O
by	O
structural	O
modification	O
of	O
arylpiperazines	O
with	O
high	O
5	O
-	O
HT1A	O
affinity	O
and	O
moderate	O
sigma	O
affinity	O
,	O
were	O
prepared	O
in	O
order	O
to	O
increase	O
sigma	O
affinity	O
and	O
selectivity	O
.	O

All	O
new	O
compounds	O
are	O
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
omega	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
1,2,3,4	I-PARTIUPAC
-	I-PARTIUPAC
tetrahydronaphthalen	I-PARTIUPAC
-	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	I-PARTIUPAC
omega	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
1,2	I-PARTIUPAC
-	I-PARTIUPAC
dihydronaphthalen	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
n	I-PARTIUPAC
-	I-PARTIUPAC
alkylamines	I-PARTIUPAC
with	O
,	O
in	O
some	O
cases	O
,	O
a	O
methoxy	I-IUPAC
group	B-MODIFIER
on	O
the	O
tetralin	O
moiety	O
.	O

They	O
were	O
tested	O
in	O
radioligand	O
binding	O
assays	O
on	O
sigma	O
(	O
[	O
3H	O
]	O
DTG	O
and	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
pentazocine	O
)	O
,	O
D	O
-	O
2	O
dopaminergic	O
,	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2	O
serotonergic	O
,	O
and	O
PCP	O
(	O
phencyclidine	O
)	O
receptors	O
.	O

A	O
first	O
set	O
of	O
compounds	O
bearing	O
a	O
4	I-MODIFIER
-	I-MODIFIER
(	I-MODIFIER
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
)	I-MODIFIER
piperazine	O
moiety	I-MODIFIER
as	O
terminal	O
fragment	O
on	O
the	O
alkyl	I-IUPAC
chain	B-MODIFIER
showed	O
moderate	O
to	O
high	O
sigma	O
affinity	O
(	O
Ki	O
=	O
5.3-139	O
nM	O
)	O
,	O
the	O
most	O
active	O
and	O
selective	O
being	O
1	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
piperazine	I-IUPAC
(	O
14	O
)	O
,	O
with	O
probable	O
pronounced	O
sigma	O
2	O
affinity	O
(	O
Ki	O
=	O
5.3	O
nM	O
on	O
[	O
3H	O
]	O
DTG	O
and	O
Ki	O
=	O
71	O
nM	O
on	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
pentazocine	O
)	O
.	O

Moreover	O
,	O
compound	O
13	O
,	O
a	O
1	I-IUPAC
-	I-IUPAC
benzylpiperazine	I-IUPAC
analogue	I-MODIFIER
of	O
14	O
,	O
preserved	O
a	O
dual	O
high	O
5	O
-	O
HT1A	O
and	O
sigma	O
affinity	O
(	O
Ki	O
=	O
3.6	O
nM	O
on	O
[	O
3H	O
]	O
-	O
5	O
-	O
HT	O
and	O
Ki	O
=	O
7.0	O
nM	O
on	O
[	O
3H	O
]	O
DTG	O
)	O
.	O

The	O
second	O
set	O
of	O
compounds	O
includes	O
some	O
N	I-IUPAC
-	I-IUPAC
phenylalkyl	I-IUPAC
derivatives	I-MODIFIER
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamine	I-IUPAC
that	O
can	O
be	O
considered	O
to	O
be	O
open	O
-	O
chain	O
derivatives	O
of	O
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
1	I-IUPAC
-	I-IUPAC
arylpiperazines	I-IUPAC
.	O

Among	O
these	O
compounds	O
that	O
had	O
a	O
lower	O
activity	O
toward	O
sigma	O
binding	O
sites	O
,	O
a	O
high	O
5	O
-	O
HT1A	O
affinity	O
was	O
found	O
for	O
the	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylpropyl	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
21	O
(	O
Ki	O
=	O
4.4	O
nM	O
)	O
which	O
demonstrated	O
very	O
good	O
selectivity	O
.	O

A	O
series	O
of	O
complexes	O
of	O
the	O
general	O
formula	O
trans	O
-	O
[	O
PtCl2	O
(	O
Am	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
where	O
pip	O
-	O
pip	O
is	O
4	I-IUPAC
-	I-IUPAC
piperidinopiperidine	I-IUPAC
and	O
Am	O
is	O
NH3	O
,	O
methylamine	O
(	O
MA	O
)	O
,	O
dimethylamine	I-IUPAC
(	O
DMA	O
)	O
,	O
n	I-IUPAC
-	I-IUPAC
propylamine	I-IUPAC
(	O
NPA	O
)	O
,	O
isopropylamine	O
(	O
IPA	O
)	O
,	O
n	I-IUPAC
-	I-IUPAC
butylamine	I-IUPAC
(	O
NBA	O
)	O
,	O
or	O
cyclohexylamine	I-IUPAC
(	O
CHA	O
)	O
were	O
prepared	O
and	O
characterized	O
,	O
and	O
their	O
cytotoxic	O
properties	O
against	O
ovarian	O
and	O
colon	O
cancer	O
cells	O
were	O
evaluated	O
.	O

The	O
trans	O
-	O
[	O
PtCl2	O
(	O
NH3	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
was	O
significantly	O
more	O
potent	O
than	O
cisplatin	O
in	O
all	O
the	O
cisplatin	O
-	O
resistant	O
ovarian	O
cancer	O
cell	O
lines	O
and	O
was	O
nearly	O
as	O
cytotoxic	O
as	O
cisplatin	O
against	O
colon	O
cancer	O
cells	O
.	O

In	O
vivo	O
studies	O
in	O
mice	O
showed	O
that	O
the	O
pip	O
-	O
pip	O
complexes	O
are	O
significantly	O
less	O
toxic	O
than	O
cisplatin	O
.	O

Cisplatin	O
was	O
more	O
efficacious	O
than	O
both	O
trans	O
-	O
[	O
PtCl2	O
(	O
NH3	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
and	O
trans	O
-	O
[	O
PtCl2	O
(	O
NBA	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
in	O
the	O
A2780	O
and	O
A2780cisR	O
tumor	O
xenograft	O
models	O
,	O
consistent	O
with	O
its	O
lower	O
IC50	O
values	O
in	O
A2780	O
cells	O
but	O
contrary	O
to	O
the	O
higher	O
IC50	O
values	O
in	O
A2780cisR	O
cells	O
.	O

In	O
the	O
colon	O
cancer	O
cell	O
studies	O
,	O
trans	O
-	O
[	O
PtCl2	O
(	O
NH3	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
was	O
slightly	O
less	O
potent	O
than	O
cisplatin	O
in	O
the	O
in	O
vitro	O
studies	O
but	O
had	O
efficacy	O
comparable	O
to	O
that	O
of	O
cisplatin	O
in	O
the	O
in	O
vivo	O
xenograft	O
model	O
.	O

Palladium	O
(	O
0	O
)	O
-	O
mediated	O
Suzuki	O
-	O
Miyaura	O
and	O
Heck	O
transformations	O
have	O
been	O
exploited	O
to	O
provide	O
examples	O
of	O
8	I-IUPAC
-	I-IUPAC
methylquino	I-IUPAC
[	I-IUPAC
4,3,2	I-IUPAC
-	I-IUPAC
kl	I-IUPAC
]	I-IUPAC
acridines	I-IUPAC
and	O
8,13	I-IUPAC
-	I-IUPAC
dimethylquino	I-IUPAC
[	I-IUPAC
4,3,2	I-IUPAC
-	I-IUPAC
kl	I-IUPAC
]	I-IUPAC
acridinium	I-IUPAC
iodides	I-IUPAC
bearing	O
bulky	O
saturated	O
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
or	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxopropenyl	I-IUPAC
substituents	I-MODIFIER
variously	O
in	O
the	O
3	O
-	O
,	O
6	O
-	O
,	O
or	O
10	O
-	O
positions	O
of	O
the	O
pentacyclic	O
nucleus	O
.	O

The	O
pharmacological	O
/	O
pharmaceutical	O
properties	O
of	O
four	O
compounds	O
(	O
4	O
,	O
RHPS4	O
)	O
,	O
(	O
5	O
,	O
IH383	O
)	O
,	O
(	O
6	O
,	O
RHPS16	O
)	O
,	O
and	O
(	O
17	O
,	O
RHPS19	O
)	O
were	O
measured	O
to	O
assess	O
their	O
clinical	O
potential	O
as	O
DNA	O
G	O
-	O
quadruplex	O
-	O
stabilizing	O
/	O
telomerase	O
inhibitory	O
agents	O
.	O

The	O
following	O
properties	O
were	O
measured	O
:	O
stability	O
in	O
tissue	O
culture	O
media	O
in	O
the	O
presence	O
of	O
A549	O
lung	O
and	O
MCF	O
-	O
7	O
breast	O
tumor	O
cells	O
,	O
metabolic	O
stability	O
when	O
incubated	O
with	O
rat	O
liver	O
microsomes	O
,	O
and	O
rate	O
of	O
uptake	O
and	O
subcellular	O
location	O
in	O
A549	O
and	O
MCF	O
-	O
7	O
cells	O
.	O

Compound	O
17	O
was	O
unstable	O
in	O
tissue	O
culture	O
media	O
,	O
failed	O
to	O
achieve	O
nuclear	O
access	O
,	O
and	O
was	O
excluded	O
from	O
further	O
consideration	O
.	O

Of	O
the	O
other	O
agents	O
,	O
4	O
exhibited	O
the	O
most	O
favorable	O
pharmaceutical	O
profile	O
:	O
the	O
agent	O
has	O
appropriate	O
stability	O
in	O
the	O
presence	O
of	O
tumor	O
cells	O
and	O
rat	O
liver	O
microsomes	O
and	O
achieves	O
rapid	O
ingress	O
into	O
cell	O
nuclei	O
where	O
the	O
putative	O
molecular	O
target	O
is	O
located	O
.	O

N	O
-	O
(	O
2	O
-	O
Naphthyl	O
)	O
glycine	O
hydrazide	O
analogues	I-MODIFIER
were	O
synthesized	O
and	O
tested	O
for	O
possible	O
in	O
vitro	O
antitubercular	O
activity	O
.	O

N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
Naphthyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
hydrazide	I-IUPAC
(	O
3	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
glycine	I-IUPAC
hydrazide	I-IUPAC
(	O
5	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
glycine	I-IUPAC
hydrazide	I-IUPAC
(	O
7	O
)	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthylamino	I-IUPAC
)	I-IUPAC
butyric	I-IUPAC
acid	I-IUPAC
hydrazide	I-IUPAC
(	O
23	O
)	O
showed	O
potent	O
inhibitory	O
action	O
against	O
Mycobacterium	O
tuberculosis	O
H37Rv	O
in	O
Youman	O
's	O
medium	O
at	O
concentrations	O
ranging	O
from	O
0.5	O
to	O
10.0	O
micrograms	O
/	O
mL	O
.	O

These	O
compounds	O
showed	O
significant	O
inhibitory	O
action	O
against	O
isonicotinic	O
acid	O
hydrazide	O
and	O
streptomycin	O
-	O
resistant	O
strains	O
of	O
M	O
.	O

tuberculosis	O
.	O

N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
Quinolyl	I-IUPAC
)	I-IUPAC
glycine	I-IUPAC
hydrazide	I-IUPAC
(	O
18	O
)	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinolylamino	I-IUPAC
)	I-IUPAC
butyric	I-IUPAC
acid	I-IUPAC
hydrazide	I-IUPAC
(	O
24	O
)	O
,	O
which	O
are	O
bioisosteres	O
of	O
compounds	O
1	O
and	O
23	O
,	O
showed	O
loss	O
of	O
antitubercular	O
activity	O
at	O
low	O
concentrations	O
.	O

The	O
pyrimidine	O
acyclonucleoside	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
uracil	I-IUPAC
(	O
3	O
)	O
was	O
synthesized	O
as	O
part	O
of	O
a	O
program	O
aimed	O
at	O
the	O
development	O
of	O
new	O
5	I-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
derivatives	I-MODIFIER
with	O
fewer	O
side	O
effects	O
and	O
a	O
broader	O
margin	O
of	O
safety	O
.	O

Condensation	O
of	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
with	O
2	I-IUPAC
-	I-IUPAC
acetoxyethyl	I-IUPAC
acetoxymethyl	I-IUPAC
ether	I-IUPAC
(	O
6	O
)	O
in	O
the	O
presence	O
of	O
SnCl4	O
afforded	O
the	O
acetate	O
ester	O
7	O
,	O
which	O
on	O
deprotection	O
with	O
NaOMe	O
gave	O
3	O
in	O
50-60%	O
overall	O
yield	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
and	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
analogues	I-MODIFIER
10	O
and	O
11	O
,	O
respectively	O
,	O
were	O
obtained	O
similarly	O
.	O

Reaction	O
of	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
with	O
2	I-IUPAC
-	I-IUPAC
acetoxyethyl	I-IUPAC
acetoxymethyl	I-IUPAC
ether	I-IUPAC
and	O
SnCl4	O
,	O
followed	O
by	O
ammonolysis	O
,	O
yielded	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
cytosine	I-IUPAC
(	O
12	O
)	O
.	O

Deamination	O
of	O
12	O
with	O
nitrous	O
acid	O
produced	O
3	O
,	O
thereby	O
confirming	O
that	O
alkylation	O
of	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
had	O
occurred	O
at	O
N1	O
.	O

The	O
ID50	O
of	O
3	O
against	O
L1210	O
mouse	O
leukemia	O
cells	O
in	O
culture	O
was	O
1.7	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
as	O
compared	O
with	O
1	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
for	O
FU	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
analogue	I-MODIFIER
12	O
was	O
inactive	O
at	O
up	O
to	O
1	O
x	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
and	O
the	O
other	O
halogenated	O
derivatives	O
10	O
and	O
11	O
had	O
no	O
effect	O
even	O
at	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
M	O
.	O

When	O
3	O
was	O
given	O
ip	O
in	O
water	O
to	O
P388	O
leukemic	O
mice	O
at	O
400	O
mg	O
/	O
kg	O
(	O
b	O
.	O

i	O
.	O

d	O
.	O

x	O
4	O
)	O
or	O
240	O
mg	O
/	O
kg	O
(	O
q	O
.	O

d	O
.	O

1-9	O
)	O
,	O
a	O
75%	O
increase	O
in	O
survival	O
was	O
observed	O
relative	O
to	O
untreated	O
controls	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
any	O
host	O
toxicity	O
.	O

A	O
series	O
of	O
21	O
1,3	I-IUPAC
-	I-IUPAC
dialkylpyrazolo	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
substituted	O
in	O
the	O
5	O
-	O
position	O
with	O
various	O
phenyl	I-IUPAC
substituents	B-MODIFIER
has	O
been	O
synthesized	O
and	O
found	O
to	O
have	O
affinity	O
for	O
the	O
adenosine	O
A1	O
receptor	O
.	O

The	O
potency	O
pattern	O
due	O
to	O
substituents	O
of	O
the	O
phenyl	I-IUPAC
ring	B-MODIFIER
was	O
found	O
to	O
parallel	O
that	O
found	O
in	O
a	O
previously	O
reported	O
1,3	I-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
phenylxanthine	I-IUPAC
series	I-MODIFIER
.	O

A	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
was	O
developed	O
between	O
these	O
two	O
series	O
that	O
correctly	O
predicted	O
the	O
potencies	O
of	O
six	O
additional	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
pyrazolo	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
that	O
were	O
synthesized	O
during	O
the	O
course	O
of	O
the	O
analysis	O
.	O

With	O
use	O
of	O
the	O
correlation	O
as	O
a	O
guide	O
,	O
one	O
additional	O
5	I-IUPAC
-	I-IUPAC
phenylpyrazolo	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
containing	O
a	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
sulfonyl	I-IUPAC
substituent	I-MODIFIER
to	O
improve	O
aqueous	O
solubility	O
was	O
prepared	O
.	O

On	O
the	O
basis	O
of	O
the	O
high	O
correlation	O
between	O
adenosine	O
binding	O
affinities	O
of	O
analogously	O
substituted	O
xanthines	O
and	O
pyrazolo	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
and	O
the	O
close	O
superposition	O
of	O
the	O
heterocyclic	O
rings	O
and	O
substituents	O
that	O
is	O
apparent	O
from	O
molecular	O
models	O
of	O
these	O
two	O
series	O
,	O
it	O
is	O
hypothesized	O
they	O
fit	O
the	O
receptor	O
in	O
an	O
analogous	O
fashion	O
.	O

The	O
previously	O
reported	O
diphenyl	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
prolylpyrrolidine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phosphonate	I-IUPAC
(	O
5	O
)	O
was	O
used	O
as	O
a	O
lead	O
compound	O
for	O
the	O
development	O
of	O
potent	O
and	O
irreversible	O
inhibitors	O
of	O
dipeptidyl	I-IUPAC
peptidase	I-IUPAC
IV	I-IUPAC
(	O
DPP	O
IV	O
,	O
EC	O
3.4.14.5	O
)	O
.	O

The	O
synthesis	O
of	O
a	O
series	O
of	O
diaryl	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
prolylpyrrolidine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phosphonates	I-IUPAC
with	O
different	O
substituents	O
on	O
the	O
aryl	O
rings	O
(	O
hydroxyl	I-IUPAC
,	O
methoxy	I-IUPAC
,	O
acylamino	I-IUPAC
,	O
sulfonylamino	I-IUPAC
,	O
ureyl	I-IUPAC
,	O
methoxycarbonyl	I-IUPAC
,	O
and	O
alkylaminocarbonyl	I-IUPAC
)	O
started	O
from	O
the	O
corresponding	O
phosphites	O
.	O

A	O
good	O
correlation	O
was	O
found	O
between	O
the	O
electronic	O
properties	O
of	O
the	O
substituent	O
and	O
the	O
inhibitory	O
activity	O
and	O
stability	O
.	O

The	O
most	O
striking	O
divergence	O
of	O
this	O
correlation	O
was	O
the	O
high	O
potency	O
combined	O
with	O
a	O
high	O
stability	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
acetylamino	I-IUPAC
-	O
substituted	I-MODIFIER
derivative	I-MODIFIER
11e	O
.	O

This	O
compound	O
shows	O
low	O
cytotoxicity	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
also	O
has	O
favorable	O
properties	O
in	O
vivo	O
.	O

Therefore	O
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetamidophenyl	I-IUPAC
)	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
prolylpyrrolidine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phosphonate	I-IUPAC
(	O
11e	O
)	O
is	O
considered	O
as	O
a	O
major	O
improvement	O
and	O
will	O
be	O
a	O
highly	O
valuable	O
DPP	O
IV	O
inhibitor	O
for	O
further	O
studies	O
on	O
the	O
biological	O
function	O
of	O
the	O
enzyme	O
and	O
the	O
therapeutic	O
value	O
of	O
its	O
inhibition	O
.	O

A	O
number	O
of	O
nitrogen	O
analogues	O
of	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
guanine	I-IUPAC
[	O
acylovir	O
,	O
Zovirax	O
]	O
containing	O
amine	O
functions	O
in	O
the	O
side	O
chain	O
were	O
synthesized	O
and	O
tested	O
for	O
antiviral	O
activity	O
.	O

These	O
purine	O
acyclic	O
nucleosides	O
were	O
prepared	O
by	O
reaction	O
of	O
tris	I-PARTIUPAC
(	I-PARTIUPAC
trimethylsilyl	I-PARTIUPAC
)	I-PARTIUPAC
guanine	I-PARTIUPAC
or	O
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
sodium	I-IUPAC
salt	I-IUPAC
with	O
the	O
chloromethyl	O
ethers	O
prepared	O
from	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
phthalimide	I-IUPAC
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
phthalimide	I-IUPAC
,	O
or	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
oxazolidin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
to	O
give	O
the	O
N	O
-	O
blocked	O
intermediates	O
5-8	O
.	O

Deprotection	O
with	O
hydrazine	O
or	O
by	O
alkaline	O
hydrolysis	O
gave	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
guanine	I-IUPAC
(	O
9	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
(	O
10	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethoxy	I-IUPAC
]	I-IUPAC
ethoxymethyl	I-IUPAC
]	I-IUPAC
guanine	I-IUPAC
(	O
11	O
)	O
,	O
and	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
guanine	I-IUPAC
(	O
12	O
)	O
.	O

When	O
tested	O
against	O
herpes	O
simplex	O
virus	O
type	O
1	O
,	O
only	O
9	O
was	O
active	O
with	O
an	O
IC50	O
=	O
8	O
microM	O
.	O

Little	O
or	O
no	O
activity	O
was	O
observed	O
against	O
a	O
range	O
of	O
other	O
DNA	O
and	O
RNA	O
viruses	O
.	O

Seven	O
1,2	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydroacronycine	I-IUPAC
and	O
1,2	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
demethoxyacronycine	I-IUPAC
esters	I-IUPAC
and	O
diesters	O
were	O
synthesized	O
via	O
osmic	O
oxidation	O
of	O
acronycine	O
or	O
6	I-IUPAC
-	I-IUPAC
demethoxyacronycine	I-IUPAC
followed	O
by	O
acylation	O
.	O

The	O
6	I-IUPAC
-	I-IUPAC
demethoxyacronycine	I-IUPAC
derivatives	I-MODIFIER
were	O
found	O
to	O
be	O
inactive	O
,	O
whereas	O
in	O
contrast	O
,	O
all	O
of	O
the	O
acronycine	O
derivatives	O
were	O
more	O
potent	O
than	O
acronycine	O
itself	O
when	O
tested	O
against	O
L1210	O
cells	O
in	O
vitro	O
.	O

Four	O
selected	O
acronycine	O
derivatives	O
(	O
17,19	O
,	O
21	O
,	O
and	O
22	O
)	O
were	O
evaluated	O
in	O
vivo	O
against	O
murine	O
P388	O
leukemia	O
and	O
colon	O
38	O
adenocarcinoma	O
implanted	O
in	O
mice	O
.	O

All	O
compounds	O
were	O
markedly	O
active	O
against	O
P388	O
at	O
doses	O
4-16	O
-	O
fold	O
lower	O
than	O
acronycine	O
itself	O
.	O

Against	O
the	O
colon	O
38	O
adenocarcinoma	O
,	O
the	O
three	O
compounds	O
17	O
,	O
21	O
,	O
and	O
22	O
were	O
highly	O
efficient	O
.	O

1,2	I-IUPAC
-	I-IUPAC
Diacetoxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydroacronycine	I-IUPAC
(	O
17	O
)	O
was	O
the	O
most	O
active	O
,	O
all	O
the	O
treated	O
mice	O
being	O
tumor	O
-	O
free	O
on	O
day	O
23	O
.	O

3,4	O
-	O
Dihydro	O
-	O
2	O
(	O
1H	O
)	O
-	O
quinolones	O
,	O
evolved	O
from	O
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
,	I-IUPAC
-	I-IUPAC
tetrahydroquinolines	I-IUPAC
and	O
3	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
,	O
have	O
been	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
antagonist	O
activity	O
at	O
the	O
glycine	O
site	O
on	O
the	O
NMDA	O
receptor	O
and	O
for	O
AMPA	O
[	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
]	O
antagonist	O
activity	O
.	O

Generally	O
poor	O
potency	O
at	O
the	O
glycine	O
site	O
is	O
observed	O
when	O
a	O
variety	O
of	O
electron	O
-	O
withdrawing	O
substituents	O
are	O
attached	O
to	O
the	O
3	O
-	O
position	O
of	O
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
.	O

The	O
analogues	O
5-9	O
(	O
IC50	O
values	O
&	O
gt	O
;	O
100	O
microM	O
,	O
Table	O
I	O
)	O
exist	O
largely	O
in	O
the	O
3,4	O
-	O
dipseudoaxial	O
conformation	O
(	O
as	O
evidenced	O
by	O
1H	O
NMR	O
spectra	O
)	O
,	O
whereas	O
the	O
3	O
-	O
cyano	O
derivative	O
(	O
10	O
,	O
IC50	O
=	O
12.0	O
microM	O
)	O
has	O
a	O
relatively	O
high	O
population	O
of	O
the	O
3	O
-	O
pseudoequatorial	O
conformer	O
.	O

The	O
3	O
-	O
nitro	O
analogue	O
(	O
4	O
,	O
IC50	O
=	O
1.32	O
microM	O
)	O
has	O
a	O
pKa	O
approximately	O
5	O
and	O
thus	O
exists	O
at	O
physiological	O
pH	O
as	O
an	O
anion	O
with	O
the	O
nitro	O
group	O
planar	O
to	O
the	O
quinolone	O
ring	O
.	O

The	O
general	O
requirement	O
of	O
acidity	O
for	O
high	O
affinity	O
binding	O
at	O
the	O
glycine	O
/	O
NMDA	O
site	O
is	O
supported	O
with	O
the	O
good	O
activity	O
of	O
the	O
other	O
3	I-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
derivatives	I-MODIFIER
(	O
13-21	O
)	O
,	O
all	O
of	O
which	O
are	O
deprotonated	O
at	O
physiological	O
pH	O
.	O

The	O
3	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroquinolines	I-IUPAC
show	O
quite	O
different	O
structure	O
-	O
activity	O
relationships	O
at	O
the	O
4	O
-	O
position	O
.	O

The	O
unselective	O
excitatory	O
amino	O
acid	O
activity	O
of	O
21	O
is	O
comparable	O
with	O
6,7	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
quinoxaline	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
and	O
6,7	I-IUPAC
-	I-IUPAC
dichloroquinoxalic	I-IUPAC
acid	I-IUPAC
and	O
this	O
suggests	O
similarities	O
in	O
their	O
modes	O
of	O
binding	O
to	O
excitatory	O
amino	O
acid	O
receptors	O
.	O

The	O
broad	O
spectrum	O
excitatory	O
amino	O
acid	O
antagonist	O
activity	O
of	O
the	O
4	O
-	O
unsubstituted	O
analogue	O
21	O
(	O
KbNMDA	O
=	O
6.7	O
microM	O
,	O
KbAMPA	O
=	O
9.2	O
microM	O
)	O
and	O
the	O
glycine	O
/	O
NMDA	O
selectivity	O
of	O
the	O
other	O
3	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
derivatives	I-MODIFIER
allows	O
the	O
proposal	O
of	O
a	O
model	O
for	O
AMPA	O
receptor	O
binding	O
which	O
differs	O
from	O
the	O
glycine	O
binding	O
pharmacophore	O
in	O
that	O
there	O
is	O
bulk	O
intolerance	O
adjacent	O
to	O
the	O
4	O
-	O
position	O
.	O

Compound	O
21	O
(	O
L	O
-	O
698,544	O
)	O
is	O
active	O
(	O
ED50	O
=	O
13.2	O
mg	O
/	O
kg	O
)	O
in	O
the	O
DBA	O
/	O
2	O
mouse	O
anticonvulsant	O
model	O
and	O
is	O
the	O
most	O
potent	O
combined	O
glycine	O
/	O
NMDA	O
-	O
AMPA	O
antagonist	O
yet	O
reported	O
,	O
in	O
vivo	O
,	O
and	O
may	O
prove	O
to	O
be	O
a	O
useful	O
pharmacological	O
tool	O
.	O

Antagonists	O
at	O
the	O
1A	O
/	O
2B	O
subtype	O
of	O
the	O
NMDA	O
receptor	O
(	O
NR1A	O
/	O
2B	O
)	O
are	O
typically	O
small	O
molecules	O
that	O
consist	O
of	O
a	O
4	I-PARTIUPAC
-	I-PARTIUPAC
benzyl	I-PARTIUPAC
-	I-PARTIUPAC
or	O
a	O
4	I-IUPAC
-	I-IUPAC
phenylpiperidine	I-IUPAC
with	O
an	O
omega	I-IUPAC
-	I-IUPAC
phenylalkyl	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
heterocyclic	O
nitrogen	O
.	O

Many	O
of	O
these	O
antagonists	O
,	O
for	O
example	O
ifenprodil	O
(	O
1	O
)	O
,	O
incorporate	O
a	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
omega	O
-	O
phenyl	O
group	O
.	O

In	O
this	O
study	O
,	O
the	O
position	O
of	O
this	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
substituent	I-MODIFIER
was	O
transferred	O
from	O
the	O
omega	O
-	O
phenyl	O
group	O
to	O
the	O
benzyl	O
or	O
phenyl	O
group	O
located	O
on	O
the	O
4	O
-	O
position	O
of	O
the	O
piperidine	O
ring	O
.	O

Analogues	O
incorporating	O
pyrrolidine	O
in	O
lieu	O
of	O
piperidine	O
were	O
also	O
prepared	O
.	O

Electrical	O
recordings	O
using	O
cloned	O
receptors	O
expressed	O
in	O
Xenopus	O
oocytes	O
show	O
that	O
high	O
-	O
potency	O
antagonists	O
at	O
the	O
NR1A	O
/	O
2B	O
subtype	O
are	O
obtained	O
employing	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
phenylalkyl	I-IUPAC
)	I-IUPAC
-	O
substituted	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxybenzyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
,	O
and	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
pyrrolidine	I-IUPAC
as	O
exemplified	O
by	O
21	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.022	O
microM	O
)	O
,	O
33	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.059	O
microM	O
)	O
,	O
and	O
40	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.017	O
microM	O
)	O
,	O
respectively	O
.	O

These	O
high	O
-	O
potency	O
antagonists	O
are	O
&	O
gt	O
;	O
1000	O
times	O
more	O
potent	O
at	O
the	O
NR1A	O
/	O
2B	O
subtype	O
than	O
at	O
either	O
the	O
NR1A	O
/	O
2A	O
or	O
NR1A	O
/	O
2C	O
subtypes	O
.	O

The	O
binding	O
affinities	O
of	O
21	O
at	O
alpha	O
(	O
1	O
)	O
-	O
adrenergic	O
receptors	O
(	O
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
H	I-IUPAC
]	I-IUPAC
prazosin	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
0.54	O
microM	O
)	O
and	O
dopamine	O
D2	O
receptors	O
(	O
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
H	I-IUPAC
]	I-IUPAC
raclopride	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.2	O
microM	O
)	O
are	O
reduced	O
by	O
incorporating	O
a	O
hydroxy	O
group	O
onto	O
the	O
4	O
-	O
position	O
of	O
the	O
piperidine	O
ring	O
and	O
the	O
beta	O
-	O
carbon	O
of	O
the	O
N	O
-	O
alkyl	O
spacer	O
to	O
give	O
(	O
+	O
/	O
-	O
)	O
-	O
27	O
:	O
IC	O
(	O
50	O
)	O
NR1A	O
/	O
2B	O
,	O
0.026	O
;	O
alpha	O
(	O
1	O
)	O
,	O
14	O
;	O
D2	O
,	O
105	O
microM	O
.	O

The	O
high	O
-	O
potency	O
phenolic	O
antagonist	O
21	O
and	O
its	O
low	O
-	O
potency	O
O	O
-	O
methylated	O
analogue	O
18	O
are	O
both	O
potent	O
anticonvulsants	O
in	O
a	O
mouse	O
maximal	O
electroshock	O
-	O
induced	O
seizure	O
(	O
MES	O
)	O
study	O
(	O
ED	O
(	O
50	O
)	O
(	O
iv	O
)	O
=	O
0.23	O
and	O
0.56	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
.	O

These	O
data	O
indicate	O
that	O
such	O
compounds	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
but	O
their	O
MES	O
activity	O
may	O
not	O
be	O
related	O
to	O
NMDA	O
receptor	O
antagonism	O
.	O

8	O
-	O
Carbamoyl	O
-	O
3	O
-	O
methylimidazo	O
[	O
5,1	O
-	O
d	O
]	O
-	O
1,2,3,5	O
-	O
tetrazin	O
-	O
4	O
(	O
3H	O
)	O
-	O
one	O
(	O
temozolomide	O
,	O
1	O
)	O
is	O
an	O
anticancer	O
prodrug	O
.	O

As	O
part	O
of	O
investigations	O
to	O
probe	O
its	O
postulated	O
mode	O
of	O
action	O
using	O
PET	O
we	O
have	O
developed	O
two	O
rapid	O
radiosynthetic	O
routes	O
for	O
the	O
preparation	O
of	O
temozolomide	O
labeled	O
with	O
the	O
short	O
-	O
lived	O
positron	O
emitter	O
,	O
carbon	O
-	O
11	O
(	O
t	O
(	O
1/2	O
)	O
=	O
20.4	O
min	O
)	O
.	O

Reaction	O
of	O
5	I-IUPAC
-	I-IUPAC
diazoimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
7	O
)	O
with	O
the	O
novel	O
labeling	O
agent	O
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
isocyanate	I-IUPAC
(	O
8	O
)	O
gave	O
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
temozolomide	I-IUPAC
(	O
9	O
)	O
in	O
14-20%	O
radiochemical	O
yield	O
from	O
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
isocyanate	I-IUPAC
(	O
8	O
)	O
(	O
decay	O
corrected	O
)	O
.	O

The	O
position	O
of	O
radiolabeling	O
in	O
the	O
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
was	O
confirmed	O
by	O
[	O
(	O
11/13	O
)	O
C	O
]	O
colabeling	O
and	O
subsequent	O
carbon	O
-	O
13	O
NMR	O
spectroscopy	O
.	O

Similarly	O
,	O
the	O
reaction	O
of	O
5	I-IUPAC
-	I-IUPAC
diazoimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
7	O
)	O
with	O
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
isocyanate	I-IUPAC
(	O
10	O
)	O
gave	O
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
temozolomide	I-IUPAC
(	O
11	O
)	O
in	O
10-15%	O
radiochemical	O
yield	O
from	O
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
isocyanate	I-IUPAC
(	O
10	O
)	O
(	O
decay	O
corrected	O
)	O
.	O

Apyrogenic	O
samples	O
of	O
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
temozolomide	I-IUPAC
(	O
9	O
)	O
and	O
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
temozolomide	I-IUPAC
(	O
11	O
)	O
,	O
with	O
good	O
chemical	O
and	O
radiochemical	O
purities	O
,	O
have	O
been	O
prepared	O
and	O
used	O
in	O
human	O
PET	O
studies	O
.	O

Alkoxymethyl	O
,	O
acyloxymethyl	O
,	O
and	O
mixed	O
alkylalkoxymethyl	O
or	O
alkylacyloxymethyl	O
derivatives	O
of	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
exhibit	O
anticonvulsant	O
activity	O
.	O

Also	O
effective	O
are	O
bis	O
(	O
alkoxymethyl	O
)	O
and	O
mixed	O
alkylalkoxymethyl	O
derivatives	O
of	O
5,5	I-IUPAC
-	I-IUPAC
diphenylhydantoin	I-IUPAC
.	O

Of	O
particular	O
interest	O
are	O
1,3	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
methoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,5	I-IUPAC
-	I-IUPAC
diphenylhydantoin	I-IUPAC
and	O
3	I-IUPAC
-	I-IUPAC
acetoxymethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
,	O
which	O
show	O
good	O
activity	O
against	O
maximal	O
electroshock	O
seizures	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
methoxymethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
,	O
which	O
is	O
effective	O
against	O
both	O
maximal	O
electroshock	O
and	O
pentylenetetrazole	I-IUPAC
.	O

None	O
of	O
the	O
above	O
compounds	O
show	O
greater	O
activity	O
against	O
maximal	O
electroshock	O
seizures	O
than	O
the	O
parent	O
compounds	O
,	O
however	O
.	O

By	O
a	O
variety	O
of	O
synthetic	O
routes	O
,	O
we	O
have	O
synthesized	O
a	O
series	O
of	O
3,4,5	I-MODIFIER
-	I-MODIFIER
trisubstituted	I-MODIFIER
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazoles	I-IUPAC
and	O
a	O
related	O
series	O
of	O
3H	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazoles	I-IUPAC
and	O
evaluated	O
them	O
in	O
vitro	O
and	O
in	O
vivo	O
as	O
angiotensin	O
II	O
(	O
AII	O
)	O
antagonists	O
.	O

Principal	O
efforts	O
focused	O
on	O
triazoles	O
bearing	O
an	O
n	O
-	O
alkyl	O
substitutent	O
at	O
C3	O
and	O
a	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxybenzoyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
benzyl	I-IUPAC
,	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
carboxybiphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
,	O
or	O
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
side	I-MODIFIER
chain	I-MODIFIER
at	O
N4	O
.	O

Among	O
numerous	O
variations	O
at	O
C5	O
,	O
benzylthio	O
groups	O
gave	O
the	O
best	O
potency	O
.	O

Particularly	O
noteworthy	O
was	O
3	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxybenzyl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
(	O
71	O
,	O
IC50	O
1.4	O
nM	O
)	O
,	O
which	O
blocked	O
the	O
AII	O
pressor	O
response	O
in	O
conscious	O
rats	O
at	O
0.3	O
mg	O
/	O
kg	O
iv	O
with	O
a	O
duration	O
of	O
action	O
of	O
approximately	O
6	O
h	O
,	O
similar	O
to	O
that	O
of	O
DuP	O
753	O
.	O

Although	O
71	O
was	O
active	O
orally	O
only	O
at	O
a	O
10	O
-	O
fold	O
higher	O
dose	O
level	O
,	O
good	O
oral	O
bioavailability	O
was	O
demonstrated	O
for	O
a	O
monoacidic	O
analogue	O
62	O
.	O

Most	O
potent	O
among	O
the	O
bicyclic	O
derivatives	O
was	O
2	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
meth	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazole	I-IUPAC
(	O
93	O
,	O
IC50	O
7.8	O
nM	O
)	O
.	O

The	O
effects	O
of	O
hydrophobic	O
,	O
hydrogen	O
-	O
bonding	O
,	O
and	O
ionic	O
interactions	O
with	O
the	O
AT1	O
receptor	O
are	O
considered	O
.	O

A	O
still	O
unknown	O
tricyclic	O
heterocyclic	O
system	O
(	O
5	O
)	O
was	O
synthesized	O
from	O
6	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylpyridazin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
its	O
structure	O
identified	O
as	O
2,8	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methylpyrrolo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
b	I-IUPAC
:	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d'	I-IUPAC
]	I-IUPAC
dipyridazin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
6H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
by	O
spectroscopic	O
investigations	O
.	O

Selective	O
condensation	O
of	O
5	O
with	O
2	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
substituted	I-MODIFIER
-	O
phenyl	I-IUPAC
)	I-IUPAC
piperazin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ethylamine	I-IUPAC
gave	O
the	O
2	I-IUPAC
-	I-IUPAC
arylpiperazinylethylamino	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivatives	I-MODIFIER
6a	O
-	O
c	O
,	O
which	O
were	O
investigated	O
in	O
binding	O
studies	O
toward	O
the	O
three	O
alpha1	O
-	O
adrenergic	O
and	O
5	O
-	O
HT1A	O
-	O
serotonergic	O
receptor	O
subtypes	O
.	O

They	O
displayed	O
high	O
potency	O
on	O
all	O
the	O
assays	O
and	O
some	O
selectivity	O
for	O
alpha1a	O
and	O
alpha1d	O
subtypes	O
.	O

Five	O
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosylcytosine	I-IUPAC
conjugates	I-MODIFIER
and	O
two	O
cytidine	O
conjugates	O
of	O
thioether	O
lipids	O
(	O
1	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
alkylthioglycerols	I-IUPAC
)	O
linked	O
by	O
a	O
pyrophosphate	O
diester	O
bond	O
have	O
been	O
prepared	O
and	O
their	O
antitumor	O
activity	O
against	O
an	O
ara	O
-	O
C2	O
sensitive	O
(	O
L1210/0	O
)	O
and	O
two	O
ara	O
-	O
C	O
resistant	O
L1210	O
lymphoid	O
leukemia	O
sublines	O
in	O
mice	O
were	O
evaluated	O
.	O

These	O
prodrugs	O
of	O
ara	O
-	O
C	O
include	O
ara	I-IUPAC
-	I-IUPAC
CDP	I-IUPAC
-	I-IUPAC
rac	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
hexadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
palmitoyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
thioglycerol	I-IUPAC
(	O
8a	O
)	O
,	O
ara	I-IUPAC
-	I-IUPAC
CDP	I-IUPAC
-	I-IUPAC
rac	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
octadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
palmitoylthioglycerol	I-IUPAC
(	O
8b	O
)	O
,	O
and	O
ara	I-IUPAC
-	I-IUPAC
CDP	I-IUPAC
-	I-IUPAC
rac	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
octadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
(	O
or	O
-	I-PARTIUPAC
ethyl	I-PARTIUPAC
,	O
-	I-PARTIUPAC
hexadecyl	I-PARTIUPAC
)	O
thioglycerols	I-PARTIUPAC
(	O
8c	O
-	O
e	O
)	O
.	O

The	O
cytidine	O
conjugates	O
include	O
CDP	I-IUPAC
-	I-IUPAC
rac	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
octadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
palmitoyl	I-IUPAC
(	O
or	O
-	I-PARTIUPAC
methyl	I-PARTIUPAC
)	O
-	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
thioglycerols	I-PARTIUPAC
(	O
9a	O
and	O
9b	O
)	O
.	O

Sonicated	O
solutions	O
of	O
the	O
conjugates	O
existed	O
in	O
the	O
form	O
of	O
micellar	O
disks	O
(	O
size	O
0.01-0.04	O
microns	O
)	O
.	O

Single	O
doses	O
(	O
200-400	O
mg	O
/	O
kg	O
)	O
of	O
8a	O
and	O
8b	O
produced	O
significant	O
increase	O
in	O
life	O
span	O
(	O
257-371%	O
)	O
in	O
mice	O
bearing	O
ip	O
implanted	O
L1210/0	O
leukemia	O
.	O

In	O
contrast	O
,	O
conjugates	O
8c	O
-	O
e	O
were	O
less	O
effective	O
(	O
ILS	O
19-75%	O
)	O
and	O
cytidine	O
conjugates	O
(	O
9a	O
and	O
9b	O
)	O
were	O
ineffective	O
.	O

Even	O
though	O
8a	O
and	O
8b	O
were	O
found	O
to	O
be	O
curative	O
in	O
a	O
high	O
percentage	O
of	O
mice	O
bearing	O
ip	O
implanted	O
partially	O
ara	O
-	O
C	O
resistant	O
L1210	O
subline	O
[	O
L1210	O
/	O
ara	O
-	O
C	O
(	O
I	O
)	O
]	O
,	O
they	O
were	O
completely	O
ineffective	O
against	O
deoxycytidine	O
kinase	O
deficient	O
ara	O
-	O
C	O
resistant	O
L1210	O
subline	O
[	O
L1210	O
/	O
ara	O
-	O
C	O
(	O
II	O
)	O
]	O
.	O

However	O
,	O
the	O
present	O
results	O
,	O
together	O
with	O
the	O
previous	O
,	O
demonstrate	O
that	O
8a	O
and	O
8b	O
are	O
promising	O
new	O
prodrugs	O
of	O
ara	O
-	O
C	O
with	O
improved	O
efficacy	O
.	O

Pyrazolo	O
[	O
3,4	O
-	O
d	O
]	O
pyrimidines	O
are	O
pyrazolo	O
analogues	O
of	O
purines	O
.	O

They	O
have	O
been	O
shown	O
to	O
be	O
a	O
general	O
class	O
of	O
compounds	O
which	O
exhibit	O
A1	O
adenosine	O
receptor	O
affinity	O
.	O

Two	O
series	O
of	O
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
analogues	I-MODIFIER
of	O
1	I-IUPAC
-	I-IUPAC
methylisoguanosine	I-IUPAC
have	O
been	O
synthesized	O
.	O

The	O
first	O
involved	O
substitution	O
of	O
the	O
N1	O
-	O
position	O
while	O
the	O
second	O
involved	O
substitution	O
of	O
the	O
N5	O
-	O
position	O
.	O

Both	O
alkyl	O
and	O
aryl	O
substituents	O
were	O
examined	O
.	O

All	O
compounds	O
were	O
tested	O
for	O
A1	O
adenosine	O
receptor	O
affinity	O
by	O
using	O
a	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylisopropyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
binding	O
assay	O
.	O

The	O
3	O
-	O
chlorophenyl	O
group	O
showed	O
the	O
greatest	O
activity	O
in	O
the	O
N1	O
-	O
position	O
and	O
the	O
butyl	O
group	O
produced	O
the	O
greatest	O
activity	O
in	O
the	O
N5	O
-	O
position	O
.	O

Combination	O
of	O
the	O
best	O
substituent	O
in	O
each	O
of	O
these	O
positions	O
enhanced	O
the	O
overall	O
activity	O
.	O

The	O
most	O
potent	O
compound	O
was	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
with	O
an	O
IC50	O
of	O
6.4	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

Selectivity	O
at	O
the	O
receptor	O
subclasses	O
was	O
examined	O
by	O
performing	O
an	O
A2	O
adenosine	O
receptor	O
affinity	O
assay	O
with	O
[	O
3H	O
]	O
CGS	O
21680	O
.	O

This	O
series	O
of	O
compounds	O
were	O
slightly	O
less	O
potent	O
at	O
A2	O
receptors	O
.	O

4	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
was	O
the	O
most	O
potent	O
compound	O
with	O
an	O
IC50	O
of	O
19.2	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

Several	O
new	O
analogues	O
of	O
L	I-IUPAC
-	I-IUPAC
fucose	I-IUPAC
modified	O
in	O
the	O
2	O
position	O
and	O
the	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
have	O
been	O
synthesized	O
as	O
potential	O
plasma	O
-	O
membrane	O
glycoconjugate	O
inhibitors	O
or	O
modifiers	O
,	O
and	O
their	O
biological	O
effects	O
have	O
been	O
studied	O
.	O

2	I-PARTIUPAC
-	I-PARTIUPAC
Chloro	I-PARTIUPAC
-	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
fucose	I-IUPAC
(	O
9a	O
,	O
9b	O
,	O
and	O
13	O
,	O
respectively	O
)	O
have	O
been	O
prepared	O
by	O
addition	O
of	O
the	O
appropriate	O
halogen	O
to	O
3,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
fucal	I-IUPAC
,	O
followed	O
by	O
hydrolysis	O
of	O
the	O
anomeric	O
halogen	O
and	O
the	O
acetyl	O
groups	O
.	O

A	O
series	O
of	O
four	O
halogenated	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogues	I-MODIFIER
of	O
L	I-IUPAC
-	I-IUPAC
fucose	I-IUPAC
(	O
4	O
,	O
X	O
=	O
F	O
,	O
Cl	O
,	O
Br	O
,	O
and	O
I	O
)	O
have	O
been	O
obtained	O
starting	O
from	O
1,2	I-IUPAC
:	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
isopropylidene	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
galactose	I-IUPAC
.	O

The	O
synthesis	O
of	O
this	O
latter	O
compound	O
has	O
been	O
improved	O
.	O

A	O
corresponding	O
series	O
of	O
6	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
halo	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
galactose	I-IUPAC
analogues	I-MODIFIER
,	O
which	O
are	O
enantiomers	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
halomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
fucose	I-IUPAC
analogues	I-MODIFIER
,	O
has	O
also	O
been	O
synthesized	O
.	O

Analogues	O
4b	O
,	O
4c	O
,	O
and	O
9b	O
at	O
1	O
x	O
10	O
(	O
-	O
3	O
)	O
M	O
specifically	O
inhibited	O
the	O
incorporation	O
of	O
L	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
fucose	I-IUPAC
into	O
macromolecular	O
components	O
of	O
SW613	O
human	O
mammary	O
tumor	O
cells	O
.	O

Analogue	O
13	O
inhibited	O
the	O
growth	O
of	O
L1210	O
murine	O
leukemic	O
cells	O
with	O
an	O
IC50	O
of	O
6	O
x	O
10	O
(	O
5	O
)	O
M	O
in	O
culture	O
.	O

6	I-IUPAC
-	I-IUPAC
Deoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
galactose	I-IUPAC
and	O
its	O
enantiomer	O
4a	O
were	O
found	O
to	O
be	O
effective	O
inhibitors	O
of	O
D	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
galactose	I-IUPAC
and	O
L	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
fucose	I-IUPAC
incorporation	O
,	O
respectively	O
,	O
into	O
macromolecular	O
components	O
of	O
human	O
mammary	O
tumor	O
cells	O
.	O

The	O
effectiveness	O
of	O
inhibition	O
was	O
reduced	O
with	O
an	O
increase	O
in	O
size	O
of	O
the	O
halogen	O
atom	O
.	O

Analogue	O
4a	O
and	O
its	O
enantiomer	O
have	O
been	O
tritiated	O
at	O
C	O
-	O
1	O
and	O
both	O
were	O
found	O
to	O
be	O
activated	O
to	O
a	O
nucleotide	O
sugar	O
,	O
which	O
was	O
followed	O
by	O
incorporation	O
into	O
the	O
macromolecular	O
fraction	O
of	O
SW613	O
human	O
mammary	O
tumor	O
cells	O
in	O
vitro	O
.	O

The	O
transition	O
metal	O
complexes	O
[	I-IUPAC
eta	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
phenyltropane	I-IUPAC
)	I-IUPAC
]	I-IUPAC
tricarbonylchromium	I-IUPAC
(	O
3	O
)	O
and	O
[	I-IUPAC
eta	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
phenyltropane	I-IUPAC
)	I-IUPAC
]	I-IUPAC
[	I-IUPAC
eta	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
pentamethylcyclopentadienyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
ruthenium	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
triflate	I-IUPAC
(	O
4	O
)	O
were	O
synthesized	O
from	O
2beta	I-IUPAC
-	I-IUPAC
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
phenyltropane	I-IUPAC
(	O
2	O
,	O
WIN	O
35,065	O
)	O
to	O
further	O
elucidate	O
the	O
influence	O
of	O
substituents	O
on	O
the	O
3beta	O
-	O
aryl	O
on	O
the	O
affinity	O
of	O
the	O
ligand	O
for	O
cocaine	O
-	O
binding	O
sites	O
at	O
the	O
dopamine	O
transporter	O
.	O

The	O
compounds	O
were	O
tested	O
for	O
their	O
ability	O
to	O
displace	O
bound	O
[	O
(	O
3	O
)	O
H	O
]	O
WIN	O
35,428	O
(	O
5	O
)	O
from	O
rat	O
caudate	O
putamen	O
tissue	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
[	O
(	O
3	O
)	O
H	O
]	O
dopamine	O
uptake	O
.	O

The	O
binding	O
affinity	O
for	O
3	O
was	O
2	O
-	O
fold	O
greater	O
than	O
those	O
observed	O
for	O
cocaine	O
(	O
1	O
)	O
and	O
2	O
,	O
while	O
the	O
binding	O
affinity	O
for	O
4	O
was	O
found	O
to	O
be	O
100	O
-	O
fold	O
less	O
than	O
those	O
of	O
1	O
and	O
2	O
.	O

In	O
addition	O
,	O
3	O
was	O
equipotent	O
with	O
1	O
and	O
2	O
in	O
[	O
(	O
3	O
)	O
H	O
]	O
dopamine	O
uptake	O
inhibition	O
studies	O
,	O
while	O
4	O
was	O
10	O
-	O
fold	O
less	O
potent	O
.	O

The	O
potencies	O
of	O
the	O
complexes	O
3	O
and	O
4	O
correlated	O
well	O
with	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
other	O
2beta	I-IUPAC
-	I-IUPAC
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
aryltropane	I-IUPAC
derivatives	I-MODIFIER
.	O

These	O
data	O
further	O
support	O
a	O
pharmacophore	O
model	O
in	O
which	O
the	O
region	O
occupied	O
by	O
the	O
aryl	O
ring	O
is	O
a	O
lipophilic	O
pocket	O
with	O
electropositive	O
character	O
.	O

A	O
variety	O
of	O
mesoionic	O
xanthines	O
including	O
mesoionic	I-MODIFIER
thiazolo	B-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
,	O
benzothiazolopyrimidines	I-IUPAC
,	O
and	O
1,3,4	I-IUPAC
-	I-IUPAC
thiadiazolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
antagonists	O
of	O
A1	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
binding	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
cyclohexyladenosine	I-IUPAC
)	O
and	O
A2	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
2	I-IUPAC
-	I-IUPAC
chloroadenosine	I-IUPAC
-	O
elicited	O
accumulations	O
of	O
cyclic	O
AMP	O
)	O
in	O
brain	O
tissue	O
.	O

Most	O
of	O
the	O
compounds	O
were	O
less	O
potent	O
than	O
theophylline	O
and	O
none	O
were	O
remarkably	O
selective	O
for	O
A1	O
-	O
or	O
A2	O
-	O
adenosine	O
receptors	O
.	O

However	O
,	O
members	O
of	O
the	O
thiadiazolopyrimidine	I-IUPAC
class	O
of	O
mesoionics	O
exhibited	O
very	O
low	O
or	O
no	O
activity	O
as	O
antagonists	O
of	O
A2	O
-	O
adenosine	O
receptors	O
while	O
exhibiting	O
activity	O
only	O
2-4	O
-	O
fold	O
lower	O
than	O
that	O
of	O
theophylline	O
at	O
A1	O
-	O
adenosine	O
receptors	O
.	O

Unlike	O
the	O
case	O
for	O
theophylline	O
,	O
the	O
presence	O
of	O
a	O
phenyl	O
substituent	O
in	O
the	O
five	O
-	O
membered	O
ring	O
did	O
not	O
enhance	O
the	O
potency	O
of	O
a	O
mesoionic	O
thiadiazolopyrimidine	O
.	O

The	O
nature	O
of	O
the	O
substituents	O
on	O
the	O
mesoionic	O
ring	O
did	O
not	O
appear	O
to	O
have	O
marked	O
effects	O
on	O
potency	O
unlike	O
the	O
marked	O
effect	O
of	O
the	O
nature	O
of	O
1,3	O
-	O
substituents	O
on	O
activity	O
of	O
nonmesoionic	O
xanthines	O
.	O

The	O
benzothiazolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
the	O
most	O
potent	O
antagonists	O
,	O
being	O
nearly	O
as	O
potent	O
as	O
theophylline	O
at	O
A1	O
-	O
adenosine	O
receptors	O
and	O
somewhat	O
more	O
potent	O
than	O
theophylline	O
at	O
A2	O
-	O
adenosine	O
receptors	O
.	O

The	O
conformational	O
characteristics	O
of	O
two	O
series	O
of	O
5	I-IUPAC
-	I-IUPAC
hydroxytryptamine	I-IUPAC
(	O
5	O
-	O
HT	O
)	O
receptor	O
agonists	O
,	O
monophenolic	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkylated	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
aminotetralins	I-IUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylcyclopropylamines	I-IUPAC
,	O
have	O
been	O
studied	O
by	O
a	O
combination	O
of	O
experimental	O
(	O
NMR	O
spectroscopy	O
)	O
and	O
theoretical	O
(	O
molecular	O
mechanics	O
and	O
MNDO	O
calculations	O
)	O
methods	O
.	O

In	O
addition	O
,	O
molecular	O
electrostatic	O
potentials	O
have	O
been	O
calculated	O
for	O
selected	O
conformations	O
and	O
the	O
absolute	O
configuration	O
of	O
the	O
potent	O
5	O
-	O
HT	O
-	O
receptor	O
agonist	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
tetralin	I-IUPAC
has	O
been	O
determined	O
,	O
by	O
X	O
-	O
ray	O
crystallography	O
of	O
the	O
synthetic	O
precursor	O
,	O
to	O
be	O
1S	O
,	O
2R	O
.	O

Results	O
obtained	O
are	O
discussed	O
in	O
terms	O
of	O
conformational	O
,	O
steric	O
,	O
and	O
electronic	O
requirements	O
for	O
5	O
-	O
HT	O
-	O
receptor	O
activation	O
.	O

It	O
is	O
suggested	O
that	O
different	O
conformations	O
of	O
the	O
5	O
-	O
HT	O
-	O
receptor	O
agonists	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcyclopropylamine	I-IUPAC
[	O
(	O
1R	O
,	O
2S	O
)	O
-	O
4	O
]	O
and	O
its	O
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
isomer	I-MODIFIER
(	O
1R	O
,	O
2S	O
)	O
-	O
5	O
are	O
able	O
to	O
activate	O
5	O
-	O
HT	O
receptors	O
.	O

The	O
strongly	O
increased	O
stereoselectivity	O
of	O
2	O
,	O
4	O
,	O
and	O
5	O
as	O
compared	O
to	O
that	O
of	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
tetralin	I-IUPAC
(	O
8	O
-	O
OH	O
-	O
DPAT	O
;	O
1	O
)	O
is	O
rationalized	O
on	O
the	O
basis	O
of	O
steric	O
factors	O
.	O

Conformational	O
factors	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
inability	O
of	O
the	O
trans	O
-	O
C1	O
-	O
methyl	O
-	O
substituted	O
derivative	O
of	O
1	O
to	O
activate	O
5	O
-	O
HT	O
receptors	O
.	O

A	O
series	O
of	O
osteotropic	O
(	O
bone	O
-	O
seeking	O
)	O
[	I-IUPAC
(	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
phosphonomethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
kappaN	I-IUPAC
)	I-IUPAC
acetato	I-IUPAC
-	I-IUPAC
kappaO	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
)	I-IUPAC
]	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
attached	O
to	O
diammine	I-IUPAC
,	O
ethane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
cis	I-IUPAC
-	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
trans	I-IUPAC
-	I-IUPAC
S	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
or	O
trans	I-IUPAC
-	I-IUPAC
R	I-IUPAC
,	I-IUPAC
R	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
has	O
been	O
synthesized	O
in	O
accord	O
with	O
the	O
concept	O
of	O
drug	O
targeting	O
and	O
characterized	O
by	O
elemental	O
analysis	O
,	O
(	O
1	O
)	O
H	O
,	O
(	O
13	O
)	O
C	O
,	O
and	O
(	O
31	O
)	O
P	O
NMR	O
spectroscopy	O
.	O

The	O
in	O
vitro	O
antitumor	O
activity	O
in	O
ovarian	O
cancer	O
cells	O
(	O
CH1	O
)	O
has	O
been	O
determined	O
by	O
means	O
of	O
the	O
MTT	O
assay	O
.	O

In	O
this	O
cisplatin	O
-	O
sensitive	O
cell	O
line	O
the	O
complexes	O
containing	O
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
(	O
chxn	O
)	O
displayed	O
a	O
high	O
activity	O
in	O
comparison	O
to	O
the	O
diammine	I-IUPAC
and	O
ethane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
counterparts	O
.	O

In	O
agreement	O
with	O
structure	O
-	O
activity	O
relationships	O
of	O
other	O
chxn	O
-	O
containing	O
platinum	O
(	O
II	O
)	O
complexes	O
both	O
[	I-IUPAC
(	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
phosphonomethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
kappaN	I-IUPAC
)	I-IUPAC
acetato	I-IUPAC
-	I-IUPAC
kappaO	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
)	I-IUPAC
]	I-IUPAC
(	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
)	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
show	O
superior	O
potency	O
than	O
the	O
corresponding	O
cis	O
-	O
congener	O
whereas	O
the	O
trans	O
-	O
R	O
,	O
R	O
isomer	O
displays	O
the	O
highest	O
activity	O
.	O

Within	O
the	O
series	O
of	O
complexes	O
under	O
investigation	O
,	O
potency	O
decreases	O
depending	O
on	O
the	O
coordinated	O
amine	O
ligand	O
in	O
the	O
following	O
order	O
:	O
trans	O
-	O
R	O
,	O
R	O
-	O
chxn	O
&	O
gt	O
;	O
trans	O
-	O
S	O
,	O
S	O
-	O
chxn	O
&	O
gt	O
;	O
NH	O
(	O
3	O
)	O
&	O
gt	O
;	O
or	O
=	O
cis	O
-	O
R	O
,	O
S	O
-	O
chxn	O
&	O
gt	O
;	O
en	O
.	O

Rotationally	O
restricted	O
analogues	O
of	O
5	I-IUPAC
-	I-IUPAC
deazapteroyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
and	O
(	I-IUPAC
6R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydropteroyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
with	O
a	O
one	O
-	O
carbon	O
bridge	O
between	O
the	O
amide	O
nitrogen	O
and	O
the	O
6'	O
-	O
position	O
of	O
the	O
p	I-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
moiety	I-MODIFIER
were	O
synthesized	O
and	O
tested	O
as	O
substrates	O
for	O
folylpolyglutamate	O
synthetase	O
(	O
FPGS	O
)	O
,	O
a	O
key	O
enzyme	O
in	O
folate	O
metabolism	O
and	O
an	O
important	O
determinant	O
of	O
the	O
therapeutic	O
potency	O
and	O
selectivity	O
of	O
classical	O
antifolates	O
.	O

The	O
corresponding	O
bridged	O
analogues	O
of	O
5	I-IUPAC
-	I-IUPAC
deazapteroyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
and	O
(	I-IUPAC
6R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
5,6,7	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydropteroyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
were	O
also	O
synthesized	O
as	O
potential	O
inhibitors	O
.	O

Condensation	O
of	O
diethyl	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
with	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromomethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrobenzoate	I-IUPAC
followed	O
by	O
catalytic	O
reduction	O
of	O
the	O
nitro	O
group	O
,	O
reductive	O
coupling	O
with	O
2	I-IUPAC
-	I-IUPAC
acetamido	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
formylpyrido	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
in	O
the	O
presence	O
of	O
dimethylaminoborane	O
,	O
and	O
acidolysis	O
with	O
HBr	O
/	O
AcOH	O
yielded	O
2	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetamido	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
oxopyrido	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isoindolyl	I-IUPAC
]	I-IUPAC
glutaric	I-IUPAC
acid	I-IUPAC
(	O
1	O
)	O
.	O

When	O
acidolysis	O
was	O
preceded	O
by	O
catalytic	O
hydrogenation	O
,	O
the	O
final	O
product	O
was	O
the	O
corresponding	O
(	O
6R	O
,	O
6S	O
)	O
-	O
tetrahydro	O
derivative	O
2	O
.	O

A	O
similar	O
sequence	O
starting	O
from	O
methyl	I-IUPAC
N	I-IUPAC
(	I-IUPAC
delta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyloxycarbonyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
led	O
to	O
2	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
oxopyrido	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isoindolyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
aminopentanoic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
and	O
the	O
(	I-IUPAC
6R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
derivative	I-MODIFIER
4	O
.	O

Compounds	O
3	O
and	O
4	O
were	O
powerful	O
inhibitors	O
of	O
recombinant	O
human	O
FPGS	O
,	O
whereas	O
1	O
and	O
2	O
were	O
exceptionally	O
efficient	O
FPGS	O
substrates	O
,	O
with	O
the	O
reduced	O
compound	O
2	O
giving	O
a	O
K	O
(	O
m	O
)	O
(	O
0.018	O
microM	O
)	O
lower	O
than	O
that	O
of	O
any	O
other	O
substrate	O
identified	O
to	O
date	O
.	O

(	I-IUPAC
6R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Deazatetrahydrofolate	I-IUPAC
,	O
in	O
which	O
the	O
side	O
chain	O
is	O
free	O
to	O
rotate	O
,	O
was	O
rapidly	O
converted	O
to	O
long	O
-	O
chain	O
polyglutamates	O
.	O

In	O
contrast	O
,	O
the	O
reaction	O
of	O
1	O
and	O
2	O
was	O
limited	O
to	O
the	O
addition	O
of	O
a	O
single	O
molecule	O
of	O
glutamic	O
acid	O
.	O

Hence	O
rotational	O
restriction	O
of	O
the	O
side	O
chain	O
did	O
not	O
interfere	O
with	O
the	O
initial	O
FPGS	O
-	O
catalyzed	O
reaction	O
and	O
indeed	O
seemed	O
to	O
facilitate	O
it	O
,	O
but	O
the	O
ensuing	O
gamma	O
-	O
glutamyl	O
adduct	O
was	O
no	O
longer	O
an	O
efficient	O
substrate	O
for	O
the	O
enzyme	O
.	O

[	I-IUPAC
1	I-IUPAC
]	I-IUPAC
Benzothieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridines	I-IUPAC
(	O
10a	O
-	O
c	O
,	O
11	O
,	O
12a	O
-	O
t	O
,	O
and	O
13a	O
,	O
b	O
)	O
and	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
[	I-IUPAC
1	I-IUPAC
]	I-IUPAC
benzothieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridines	I-IUPAC
(	O
3a	O
-	O
c	O
,	O
7	O
,	O
8a	O
-	O
c	O
,	O
and	O
9	O
)	O
were	O
synthesized	O
.	O

The	O
compounds	O
are	O
bioisosteres	O
of	O
beta	O
-	O
carbolines	O
and	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
carbolines	I-IUPAC
where	O
the	O
indole	O
nitrogen	O
is	O
replaced	O
by	O
sulfur	O
.	O

Their	O
pharmacological	O
activity	O
was	O
evaluated	O
in	O
a	O
water	O
lick	O
conflict	O
test	O
in	O
rats	O
and	O
a	O
passive	O
avoidance	O
test	O
in	O
mice	O
.	O

In	O
the	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
[	I-IUPAC
1	I-IUPAC
]	I-IUPAC
benzothieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
series	I-MODIFIER
,	O
the	O
presence	O
of	O
ethyl	O
ester	O
(	O
3b	O
)	O
or	O
cyclohexyl	O
carboxamide	O
(	O
7	O
)	O
groups	O
at	O
C	O
-	O
3	O
conferred	O
good	O
anticonflict	O
activity	O
and	O
lessening	O
of	O
memory	O
impairment	O
,	O
while	O
N	O
-	O
acylation	O
of	O
3b	O
abolished	O
activity	O
.	O

In	O
the	O
[	I-IUPAC
1	I-IUPAC
]	I-IUPAC
benzothieno	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
series	I-MODIFIER
,	O
the	O
aminoethyl	I-IUPAC
carboxamide	I-IUPAC
(	O
12a	O
)	O
group	I-MODIFIER
at	O
C	O
-	O
3	O
also	O
conferred	O
activity	O
,	O
but	O
other	O
amides	O
studied	O
were	O
not	O
active	O
.	O

The	O
most	O
potent	O
compounds	O
(	O
3b	O
,	O
7	O
,	O
and	O
12a	O
)	O
were	O
also	O
administered	O
orally	O
and	O
had	O
potent	O
anticonflict	O
and	O
antiscopolamine	O
amnesia	O
-	O
reversal	O
activity	O
.	O

These	O
compounds	O
did	O
not	O
bind	O
to	O
the	O
BZP	O
receptor	O
in	O
spite	O
of	O
having	O
structures	O
similar	O
to	O
those	O
of	O
beta	O
-	O
carbolines	O
.	O

Compound	O
7	O
bound	O
strongly	O
to	O
5	O
-	O
HT1A	O
receptors	O
and	O
would	O
be	O
expected	O
to	O
be	O
a	O
novel	O
anxiolytic	O
.	O

A	O
series	O
of	O
new	O
dipeptidyl	O
alpha	O
-	O
keto	O
amides	O
of	O
the	O
general	O
structure	O
R1	O
-	O
L	O
-	O
Leu	O
-	O
D	O
,	O
L	O
-	O
AA	O
-	O
CONH	O
-	O
R2	O
were	O
synthesized	O
and	O
evaluated	O
as	O
inhibitors	O
for	O
the	O
cysteine	O
proteases	O
calpain	O
I	O
,	O
calpain	O
II	O
,	O
and	O
cathepsin	O
B	O
.	O

They	O
combine	O
10	O
different	O
N	O
-	O
protecting	O
groups	O
(	O
R1	O
)	O
,	O
3	O
amino	O
acids	O
residues	O
in	O
P1	O
(	O
AA	O
)	O
,	O
and	O
44	O
distinct	O
substituents	O
on	O
the	O
alpha	O
-	O
keto	O
amide	O
nitrogen	O
(	O
R2	O
)	O
.	O

In	O
general	O
,	O
calpain	O
II	O
was	O
more	O
sensitive	O
to	O
these	O
inhibitors	O
than	O
calpain	O
I	O
,	O
with	O
a	O
large	O
number	O
of	O
inhibitors	O
displaying	O
dissociation	O
constants	O
(	O
Ki	O
)	O
in	O
the	O
10-100	O
nM	O
range	O
.	O

Calpain	O
I	O
was	O
also	O
effectively	O
inhibited	O
,	O
but	O
very	O
low	O
Ki	O
values	O
were	O
observed	O
with	O
a	O
smaller	O
number	O
of	O
inhibitors	O
than	O
with	O
calpain	O
II	O
.	O

Cathepsin	O
B	O
was	O
weakly	O
inhibited	O
by	O
most	O
compounds	O
in	O
this	O
study	O
.	O

The	O
best	O
inhibitors	O
for	O
calpain	O
II	O
were	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
CH2	O
-	O
CHOH	O
-	O
C6H5	O
(	O
Ki	O
=	O
15	O
nM	O
)	O
,	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
CH2	O
-	O
2	O
-	O
pyridyl	O
(	O
Ki	O
=	O
17	O
nM	O
)	O
,	O
and	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
CH2	O
-	O
C6H3	O
(	O
3,5	O
(	O
OMe	O
)	O
2	O
)	O
(	O
Ki	O
=	O
22	O
nM	O
)	O
.	O

The	O
best	O
calpain	O
I	O
inhibitor	O
in	O
this	O
study	O
was	O
Z	O
-	O
Leu	O
-	O
Nva	O
-	O
CONH	O
-	O
CH2	O
-	O
2	O
-	O
pyridyl	O
(	O
Ki	O
=	O
19	O
nM	O
)	O
.	O

The	O
peptide	O
alpha	O
-	O
keto	O
amide	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
(	O
CH2	O
)	O
2-3	O
-	O
indolyl	O
was	O
the	O
best	O
inhibitor	O
for	O
cathepsin	O
B	O
(	O
Ki	O
=	O
31	O
nM	O
)	O
.	O

Some	O
compounds	O
acted	O
as	O
specific	O
calpain	O
inhibitors	O
,	O
with	O
comparable	O
activity	O
on	O
both	O
calpains	O
I	O
and	O
II	O
and	O
a	O
lack	O
of	O
activity	O
on	O
cathepsin	O
B	O
(	O
e.g.	O
,	O
40	O
,	O
42	O
,	O
48	O
,	O
70	O
)	O
.	O

Others	O
were	O
specific	O
inhibitors	O
for	O
calpain	O
I	O
(	O
e.g.	O
,	O
73	O
)	O
or	O
calpain	O
II	O
(	O
e.g.	O
,	O
18	O
,	O
19	O
,	O
33	O
,	O
35	O
,	O
56	O
)	O
.	O

Such	O
inhibitors	O
may	O
be	O
useful	O
in	O
elucidating	O
the	O
physiological	O
and	O
pathological	O
events	O
involving	O
these	O
proteases	O
and	O
may	O
become	O
possible	O
therapeutic	O
agents	O
.	O

Lipophilic	O
methotrexate	O
(	O
MTX	O
)	O
and	O
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dichloromethotrexate	I-IUPAC
(	O
DCM	O
)	O
diesters	I-MODIFIER
were	O
prepared	O
by	O
HCl	O
-	O
catalyzed	O
esterification	O
or	O
by	O
neutral	O
esterification	O
using	O
cesium	O
carbonate	O
and	O
an	O
alkyl	O
or	O
aralkyl	O
halide	O
in	O
Me2SO	O
.	O

The	O
products	O
were	O
tested	O
for	O
in	O
vivo	O
antitumor	O
activity	O
against	O
L1210	O
leukemia	O
in	O
mice	O
to	O
test	O
whether	O
all	O
MTX	O
and	O
DCM	O
diesters	O
are	O
therapeutically	O
equivalent	O
in	O
this	O
species	O
.	O

Contrary	O
to	O
what	O
has	O
been	O
found	O
with	O
simple	O
primary	O
dialkyl	O
esters	O
,	O
ortho	O
-	O
substituted	O
dibenzyl	O
esters	O
of	O
MTX	O
produce	O
longer	O
survival	O
on	O
a	O
q3dX3	O
schedule	O
than	O
does	O
MTX	O
itself	O
and	O
show	O
a	O
dose	O
-	O
sparing	O
effect	O
comparable	O
to	O
that	O
of	O
MTX	O
at	O
shorter	O
treatment	O
intervals	O
.	O

Thus	O
,	O
MTX	O
bis	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropiperonyl	I-IUPAC
)	I-IUPAC
ester	I-IUPAC
at	O
an	O
MTX	O
-	O
equivalent	O
dose	O
of	O
5.5	O
mg	O
/	O
kg	O
gave	O
a	O
+	O
88%	O
increase	O
in	O
median	O
life	O
span	O
(	O
ILS	O
)	O
,	O
whereas	O
for	O
MTX	O
a	O
+	O
88%	O
ILS	O
required	O
30	O
mg	O
/	O
kg	O
.	O

When	O
the	O
MTX	O
-	O
equivalent	O
dose	O
of	O
MTX	O
bis	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropiperonyl	I-IUPAC
)	I-IUPAC
ester	I-IUPAC
was	O
increased	O
to	O
40	O
mg	O
/	O
kg	O
,	O
a	O
+	O
167%	O
ILS	O
was	O
observed	O
,	O
as	O
compared	O
with	O
a	O
+	O
100%	O
ILS	O
with	O
60	O
mg	O
/	O
kg	O
of	O
the	O
parent	O
drug	O
.	O

High	O
activity	O
(	O
greater	O
than	O
100%	O
ILS	O
)	O
was	O
likewise	O
shown	O
by	O
the	O
bis	I-PARTIUPAC
(	I-PARTIUPAC
2,5	I-PARTIUPAC
-	I-PARTIUPAC
dimethylbenzyl	I-PARTIUPAC
)	I-PARTIUPAC
,	O
bis	I-PARTIUPAC
(	I-PARTIUPAC
2,6	I-PARTIUPAC
-	I-PARTIUPAC
dichlorobenzyl	I-PARTIUPAC
)	I-PARTIUPAC
,	O
and	O
di	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
picolyl	I-IUPAC
esters	I-IUPAC
of	O
MTX	O
and	O
by	O
the	O
bis	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
)	I-IUPAC
ester	I-IUPAC
of	O
DCM	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
MTX	O
and	O
DCM	O
esters	O
are	O
not	O
therapeutically	O
equivalent	O
in	O
mice	O
,	O
despite	O
the	O
high	O
serum	O
esterase	O
activity	O
in	O
this	O
species	O
,	O
and	O
that	O
an	O
up	O
to	O
10	O
-	O
fold	O
reduction	O
in	O
total	O
administered	O
dose	O
on	O
the	O
q3dX3	O
schedule	O
is	O
feasible	O
by	O
this	O
approach	O
.	O

The	O
higher	O
toxicity	O
of	O
neonicotinoid	O
insecticides	O
such	O
as	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
nitroiminoimidazolidine	I-IUPAC
(	O
imidacloprid	O
)	O
to	O
insects	O
than	O
mammals	O
is	O
due	O
in	O
large	O
part	O
to	O
target	O
site	O
specificity	O
at	O
the	O
corresponding	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
.	O

We	O
propose	O
that	O
neonicotinoids	O
with	O
a	O
protonated	O
N	O
-	O
unsubstituted	O
imine	O
or	O
equivalent	O
substituent	O
recognize	O
the	O
anionic	O
subsite	O
of	O
the	O
mammalian	O
alpha4beta2	O
nAChR	O
whereas	O
the	O
negatively	O
charged	O
(	O
delta	O
(	O
-	O
)	O
)	O
tip	O
of	O
the	O
neonicotinoid	O
insecticides	O
interacts	O
with	O
a	O
putative	O
cationic	O
subsite	O
of	O
the	O
insect	O
nAChR	O
.	O

This	O
hypothesis	O
can	O
be	O
tested	O
by	O
using	O
two	O
photoaffinity	O
probes	O
that	O
differ	O
only	O
in	O
the	O
N	O
-	O
unsubstituted	O
imine	O
vs	O
negatively	O
charged	O
(	O
delta	O
(	O
-	O
)	O
)	O
tip	O
.	O

Synthesis	O
methodology	O
was	O
developed	O
for	O
compounds	O
combining	O
three	O
moieties	O
:	O
pyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
or	O
6	I-IUPAC
-	I-IUPAC
chloropyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
and	O
their	O
4	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
analogues	I-MODIFIER
;	O
imidazolidine	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
imidazoline	I-IUPAC
or	O
4	I-IUPAC
-	I-IUPAC
thiazoline	I-IUPAC
;	O
and	O
N	I-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
imine	I-IUPAC
,	O
nitroimine	O
,	O
cyanoimine	O
,	O
or	O
nitromethylene	O
.	O

Structure	O
-	O
activity	O
studies	O
compared	O
displacement	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
nicotine	O
binding	O
in	O
mammalian	O
alpha4beta2	O
nAChR	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
imidacloprid	O
binding	O
in	O
Drosophila	O
nAChR	O
.	O

Preferred	O
compounds	O
are	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
with	O
2	I-IUPAC
-	I-IUPAC
iminothiazoline	I-IUPAC
for	O
alpha4beta2	O
(	O
K	O
(	O
i	O
)	O
=	O
0.47	O
nM	O
)	O
and	O
with	O
2	I-IUPAC
-	I-IUPAC
nitroiminothiazoline	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
nitromethyleneimidazolidine	I-IUPAC
for	O
Drosophila	O
(	O
K	O
(	O
i	O
)	O
=	O
0.72-3.9	O
nM	O
)	O
.	O

Improved	O
rationally	O
designed	O
lead	O
drug	O
structures	O
against	O
African	O
trypanosomiasis	O
,	O
Chagas	O
disease	O
,	O
and	O
leishmaniasis	O
were	O
obtained	O
against	O
trypanothione	O
reductase	O
from	O
Trypanosoma	O
cruzi	O
.	O

Substituted	I-MODIFIER
-	I-MODIFIER
benzyl	I-MODIFIER
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4a	I-IUPAC
,	I-IUPAC
10a	I-IUPAC
-	I-IUPAC
dihydrophenothiazin	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
dimethylammonium	I-IUPAC
salts	I-IUPAC
,	O
synthesized	O
by	O
Menschutkin	O
quaternization	O
of	O
the	O
tertiary	O
alkylamine	O
omega	O
-	O
nitrogen	O
atom	O
of	O
chlorpromazine	O
,	O
were	O
linear	O
,	O
competitive	O
inhibitors	O
of	O
recombinant	O
trypanothione	O
reductase	O
from	O
T	O
.	O

cruzi	O
,	O
with	O
either	O
trypanothione	O
disulfide	O
or	O
N	I-IUPAC
-	I-IUPAC
benzyloxycarbonyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
cysteinylglycyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
dimethylaminopropylamide	I-IUPAC
disulfide	I-IUPAC
as	O
substrate	O
.	O

The	O
permanent	O
positive	O
charge	O
on	O
the	O
distal	O
nitrogen	O
atom	O
of	O
the	O
tricyclic	O
side	O
chain	O
contribution	O
to	O
binding	O
was	O
estimated	O
as	O
&	O
gt	O
;	O
/	O
=	O
5.6	O
kcal	O
.	O

mol	O
(	O
-	O
1	O
)	O
by	O
comparison	O
with	O
the	O
analogue	O
with	O
the	O
cationic	O
nitrogen	O
atom	O
of	O
the	O
quaternary	O
replaced	O
by	O
an	O
ether	O
oxygen	O
atom	O
.	O

A	O
further	O
major	O
contribution	O
to	O
improving	O
K	O
(	O
i	O
)	O
values	O
and	O
inhibition	O
strength	O
was	O
the	O
hydrophobic	O
natures	O
and	O
structures	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
substituents	I-MODIFIER
.	O

The	O
strongest	O
inhibitor	O
,	O
the	O
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4a	I-IUPAC
,	I-IUPAC
10a	I-IUPAC
-	I-IUPAC
dihydrophenothiazin	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
dimethylammonium	I-IUPAC
derivative	I-MODIFIER
(	O
K	O
(	O
i	O
)	O
0.12	O
microM	O
)	O
,	O
was	O
approximately	O
2	O
orders	O
of	O
magnitude	O
more	O
inhibitory	O
than	O
the	O
parent	O
chlorpromazine	O
.	O

Several	O
of	O
these	O
quaternary	O
phenothiazines	O
completely	O
inhibited	O
T	O
.	O

brucei	O
parasite	O
growth	O
in	O
vitro	O
at	O
&	O
lt	O
;	O
1	O
microM	O
.	O

Antiparasite	O
activity	O
was	O
not	O
solely	O
determined	O
by	O
inhibition	O
strength	O
against	O
trypanothione	O
reductase	O
,	O
there	O
being	O
a	O
strong	O
contribution	O
from	O
hydrophobicity	O
(	O
for	O
example	O
,	O
benzhydryl	I-IUPAC
-	O
quaternized	I-MODIFIER
chlorpromazime	B-IUPAC
had	O
ED	O
(	O
50	O
)	O
&	O
lt	O
;	O
1	O
microM	O
)	O
.	O

Although	O
active	O
against	O
Leishmania	O
donovani	O
,	O
none	O
of	O
the	O
analogues	O
showed	O
major	O
improvement	O
in	O
this	O
activity	O
relative	O
to	O
chlorpromazine	O
or	O
other	O
nonquaternized	O
phenothiazines	O
.	O

The	O
p	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butylbenzyl	I-IUPAC
-	O
quaternized	I-MODIFIER
analogue	I-MODIFIER
very	O
strongly	O
inhibited	O
(	O
ED	O
(	O
50	O
)	O
&	O
lt	O
;	O
1	O
microM	O
)	O
growth	O
of	O
the	O
amastigote	O
stage	O
of	O
T	O
.	O

cruzi	O
.	O

After	O
our	O
discovery	O
that	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Phe	O
-	O
DNal	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
ODN	O
-	O
8	O
)	O
had	O
high	O
affinity	O
and	O
marginal	O
selectivity	O
for	O
human	O
sst	O
(	O
3	O
)	O
(	O
part	O
2	O
of	O
this	O
series	O
:	O
Erchegyi	O
et	O
al.	O
J	O
.	O

Med.	O
Chem.	O
,	O
preceding	O
paper	O
in	O
this	O
issue	O
)	O
(	O
11	O
)	O
and	O
that	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Phe	O
-	O
DTrp	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
ODT	O
-	O
8	O
,	O
3	O
)	O
had	O
high	O
affinity	O
and	O
marginal	O
selectivity	O
for	O
human	O
sst	O
(	O
4	O
)	O
,	O
that	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Tyr	O
-	O
D	O
-	O
threo	O
-	O
beta	O
-	O
Me2Nal	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
had	O
high	O
affinity	O
for	O
all	O
sst	O
's	O
except	O
for	O
sst	O
(	O
1	O
)	O
,	O
and	O
that	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Tyr	O
-	O
L	O
-	O
threo	O
-	O
beta	O
-	O
Me2Nal	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
had	O
high	O
affinity	O
for	O
sst	O
(	O
4	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
2.1	O
nM	O
)	O
,	O
with	O
more	O
than	O
50	O
-	O
fold	O
selectivity	O
toward	O
the	O
other	O
receptors	O
(	O
parts	O
1	O
and	O
2	O
of	O
this	O
series	O
:	O
Rivier	O
et	O
al.	O
and	O
Erchegyi	O
et	O
al.	O
J	O
.	O

Med.	O
Chem.	O
,	O
preceding	O
papers	O
in	O
this	O
issue	O
)	O
,	O
we	O
found	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Phe	O
-	O
Trp	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
OLT	O
-	O
8	O
,	O
2	O
)	O
,	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Phe	O
-	O
L	O
-	O
threo	O
-	O
beta	O
-	O
MeTrp	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
4	O
)	O
and	O
H	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Phe	O
-	O
D	O
-	O
threo	O
-	O
beta	O
-	O
MeTrp	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
5	O
)	O
to	O
have	O
very	O
high	O
affinity	O
for	O
sst	O
(	O
4	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.7	O
,	O
1.8	O
,	O
and	O
4.0	O
nM	O
,	O
respectively	O
)	O
and	O
5	O
-	O
to	O
10	O
-	O
fold	O
selectivity	O
versus	O
the	O
other	O
sst	O
's	O
.	O

From	O
earlier	O
work	O
,	O
we	O
concluded	O
that	O
an	O
l	O
-	O
amino	O
acid	O
at	O
position	O
8	O
and	O
a	O
tyrosine	I-IUPAC
or	O
4	I-IUPAC
-	I-IUPAC
aminophenylalanine	I-IUPAC
substitution	I-MODIFIER
at	O
position	O
7	O
may	O
lead	O
to	O
high	O
sst	O
(	O
4	O
)	O
selectivity	O
.	O

In	O
fact	O
,	O
[	O
Tyr	O
(	O
7	O
)	O
]	O
-	O
2	O
(	O
6	O
)	O
and	O
[	O
Tyr	O
(	O
7	O
)	O
]	O
-	O
3	O
(	O
7	O
)	O
show	O
ca.	O
5	O
-	O
fold	O
selectivity	O
for	O
sst	O
(	O
4	O
)	O
,	O
and	O
[	O
Aph	O
(	O
7	O
)	O
]	O
-	O
2	O
(	O
8	O
)	O
and	O
[	O
Aph	O
(	O
7	O
)	O
]	O
-	O
3	O
(	O
9	O
)	O
have	O
high	O
sst	O
(	O
4	O
)	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.2	O
and	O
0.88	O
nM	O
,	O
respectively	O
)	O
and	O
selectivity	O
,	O
suggesting	O
that	O
indeed	O
an	O
l	O
-	O
residue	O
at	O
position	O
8	O
will	O
direct	O
selectivity	O
toward	O
sst	O
(	O
4	O
)	O
.	O

Unexpectedly	O
,	O
[	O
Ala	O
(	O
7	O
)	O
]	O
-	O
2	O
(	O
10	O
)	O
and	O
[	O
Ala	O
(	O
7	O
)	O
]	O
-	O
3	O
(	O
11	O
)	O
have	O
very	O
high	O
sst	O
(	O
4	O
)	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.84	O
and	O
0.98	O
nM	O
,	O
respectively	O
)	O
and	O
selectivity	O
(	O
&	O
gt	O
;	O
600	O
-	O
and	O
200	O
-	O
fold	O
,	O
respectively	O
)	O
.	O

The	O
combination	O
of	O
Tyr	O
(	O
2	O
)	O
and	O
dTrp	O
(	O
8	O
)	O
in	O
analogues	O
14	O
and	O
22	O
did	O
not	O
affect	O
the	O
affinity	O
of	O
the	O
analogues	O
for	O
sst	O
(	O
4	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.2	O
and	O
1.1	O
nM	O
,	O
respectively	O
)	O
but	O
resulted	O
in	O
loss	O
of	O
selectivity	O
,	O
whereas	O
the	O
combination	O
of	O
Tyr	O
(	O
2	O
)	O
and	O
LTrp	O
(	O
8	O
)	O
in	O
H	O
-	O
Tyr	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Aph	O
-	O
Trp	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
13	O
)	O
and	O
H	O
-	O
Tyr	O
-	O
c	O
[	O
Cys	O
-	O
Phe	O
-	O
Ala	O
-	O
Trp	O
-	O
Lys	O
-	O
Thr	O
-	O
Phe	O
-	O
Cys	O
]	O
-	O
OH	O
(	O
19	O
)	O
retained	O
high	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.9	O
and	O
1.98	O
nM	O
,	O
respectively	O
)	O
and	O
sst	O
(	O
4	O
)	O
selectivity	O
(	O
&	O
gt	O
;	O
50	O
and	O
&	O
gt	O
;	O
250	O
,	O
respectively	O
)	O
.	O

Interestingly	O
,	O
the	O
same	O
substitutions	O
at	O
positions	O
2	O
and	O
7	O
,	O
with	O
l	O
-	O
threo	O
-	O
beta	O
-	O
MeTrp	O
at	O
position	O
8	O
,	O
yielded	O
a	O
much	O
less	O
selective	O
analogue	O
(	O
20	O
)	O
.	O

Carbamoylation	O
of	O
the	O
N	O
-	O
terminus	O
of	O
most	O
of	O
these	O
analogues	O
resulted	O
in	O
slightly	O
improved	O
affinity	O
,	O
selectivity	O
,	O
or	O
both	O
.	O

Other	O
amino	O
acid	O
substitutions	O
in	O
this	O
series	O
,	O
such	O
as	O
those	O
with	O
Amp	O
(	O
25	O
,	O
26	O
)	O
,	O
Orn	O
(	O
27	O
)	O
,	O
or	O
IAmp	O
(	O
29	O
)	O
at	O
position	O
7	O
,	O
were	O
also	O
tolerated	O
but	O
with	O
a	O
2	O
-	O
to	O
3	O
-	O
fold	O
loss	O
of	O
affinity	O
and	O
concomitant	O
loss	O
of	O
selectivity	O
.	O

Analogous	O
peptides	O
with	O
a	O
tyrosine	O
at	O
position	O
11	O
(	O
31-36	O
)	O
were	O
less	O
selective	O
than	O
the	O
corresponding	O
peptides	O
with	O
a	O
tyrosine	O
at	O
position	O
2	O
.	O

Several	O
analogues	O
in	O
this	O
series	O
compared	O
favorably	O
with	O
the	O
non	O
-	O
peptide	O
L	O
-	O
803,087	O
(	O
37	O
)	O
in	O
terms	O
of	O
affinity	O
and	O
selectivity	O
.	O

Analogues	O
8	O
,	O
10	O
,	O
and	O
21	O
potently	O
inhibited	O
the	O
forskolin	O
-	O
stimulated	O
cAMP	O
production	O
in	O
sst	O
(	O
4	O
)	O
-	O
transfected	O
cells	O
,	O
therefore	O
acting	O
as	O
full	O
agonists	O
.	O

Cold	O
monoiodination	O
of	O
19	O
yielded	O
21	O
,	O
with	O
retention	O
of	O
high	O
sst	O
(	O
4	O
)	O
selectivity	O
and	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
=	O
3.5	O
nM	O
)	O
.	O

(	O
125	O
)	O
Iodinated	O
19	O
selectively	O
binds	O
to	O
sst	O
(	O
4	O
)	O
-	O
transfected	O
cells	O
but	O
not	O
to	O
sst	O
(	O
1-3	O
)	O
-	O
or	O
sst	O
(	O
5	O
)	O
-	O
transfected	O
cells	O
.	O

Binding	O
in	O
sst	O
(	O
4	O
)	O
-	O
transfected	O
cells	O
was	O
completely	O
displaced	O
by	O
SRIF	O
-	O
28	O
or	O
the	O
sst	O
(	O
4	O
)	O
-	O
selective	O
L	O
-	O
803,087	O
.	O

Nineteen	O
previously	O
undescribed	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,6,7	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydroquinazolines	I-IUPAC
(	O
5a	O
-	O
m	O
,	O
10-12	O
)	O
were	O
synthesized	O
as	O
part	O
of	O
a	O
larger	O
effort	O
to	O
assess	O
the	O
therapeutic	O
potential	O
of	O
lipophilic	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
inhibitors	O
against	O
opportunistic	O
infections	O
of	O
AIDS	O
.	O

Condensation	O
of	O
appropriately	O
substituted	O
(	O
arylmethyl	O
)	O
triphenylphosphoranes	O
with	O
4	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ethylenedioxycyclohexanone	I-IUPAC
,	O
followed	O
by	O
hydrogenation	O
(	O
H2	O
/	O
Pd	O
-	O
C	O
)	O
and	O
acidolysis	O
,	O
yielded	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
cyclohexanones	I-IUPAC
,	O
which	O
were	O
then	O
condensed	O
with	O
cyanoguanidine	O
to	O
form	O
the	O
tetrahydroquinazolines	O
.	O

Three	O
simple	O
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydroquinazoline	I-IUPAC
model	I-MODIFIER
compounds	I-MODIFIER
(	O
9a	O
-	O
c	O
)	O
were	O
also	O
prepared	O
in	O
one	O
step	O
from	O
commercially	O
available	O
4	I-IUPAC
-	I-IUPAC
alkylcyclohexanones	I-IUPAC
by	O
this	O
method	O
.	O

Enzyme	O
inhibition	O
assays	O
against	O
rat	O
liver	O
DHFR	O
,	O
Pneumocystis	O
carinii	O
DHFR	O
,	O
and	O
the	O
bifunctional	O
DHFR	O
-	O
TS	O
enzyme	O
from	O
Toxoplasma	O
gondii	O
were	O
carried	O
out	O
,	O
and	O
the	O
selectivity	O
ratios	O
IC50	O
(	O
rat	O
)	O
/	O
IC50	O
(	O
P	O
.	O

carinii	O
)	O
and	O
IC50	O
(	O
rat	O
)	O
/	O
IC50	O
(	O
T	O
.	O

gondii	O
)	O
were	O
compared	O
.	O

The	O
three	O
most	O
potent	O
inhibitors	O
of	O
P	O
.	O

carinii	O
DHFR	O
were	O
the	O
2,5	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
(	O
5j	O
)	O
,	O
3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
(	O
5k	O
)	O
,	O
and	O
3,4,5	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
(	O
5l	O
)	O
analogues	I-MODIFIER
,	O
with	O
IC50	O
values	O
of	O
0.057	O
,	O
0.10	O
,	O
and	O
0.091	O
microM	O
,	O
respectively	O
.	O

The	O
remaining	O
compounds	O
generally	O
had	O
IC50	O
values	O
in	O
the	O
0.1-1.0	O
microM	O
range	O
.	O

However	O
all	O
the	O
compounds	O
were	O
more	O
potent	O
against	O
the	O
rat	O
liver	O
enzyme	O
than	O
the	O
P	O
.	O

carinii	O
enzyme	O
and	O
thus	O
were	O
nonselective	O
.	O

The	O
T	O
.	O

gondii	O
enzyme	O
was	O
always	O
more	O
sensitive	O
than	O
the	O
P	O
.	O

carinii	O
enzyme	O
,	O
with	O
most	O
of	O
the	O
analogues	O
giving	O
IC50	O
values	O
of	O
0.01-0.1	O
microM	O
.	O

Moderate	O
5-10	O
-	O
fold	O
selectivity	O
for	O
T	O
.	O

gondii	O
versus	O
rat	O
liver	O
DHFR	O
was	O
observed	O
with	O
five	O
compounds	O
,	O
the	O
best	O
combination	O
of	O
potency	O
and	O
selectivity	O
being	O
achieved	O
with	O
the	O
2	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
analogue	I-MODIFIER
5d	O
,	O
which	O
had	O
an	O
IC50	O
of	O
0.014	O
microM	O
and	O
a	O
selectivity	O
ratio	O
of	O
8.6	O
.	O

One	O
compound	O
(	O
5l	O
)	O
was	O
tested	O
for	O
antiproliferative	O
activity	O
against	O
P	O
.	O

carinii	O
trophozoites	O
in	O
culture	O
at	O
a	O
concentration	O
of	O
10	O
microgram	O
/	O
mL	O
and	O
was	O
found	O
to	O
completely	O
suppress	O
growth	O
over	O
7	O
days	O
.	O

The	O
suppressive	O
effect	O
of	O
5l	O
was	O
the	O
same	O
as	O
that	O
of	O
trimethoprim	O
(	O
10	O
microgram	O
/	O
mL	O
)	O
+	O
sulfamethoxazole	O
(	O
250	O
microgram	O
/	O
mL	O
)	O
,	O
a	O
standard	O
clinical	O
combination	O
for	O
the	O
treatment	O
of	O
P	O
.	O

carinii	O
pneumonia	O
in	O
AIDS	O
patients	O
.	O

Four	O
compounds	O
(	O
5a	O
,	O
h	O
,	O
k	O
,	O
l	O
)	O
were	O
tested	O
against	O
T	O
.	O

gondii	O
tachyzoites	O
in	O
culture	O
and	O
were	O
found	O
to	O
have	O
a	O
potency	O
(	O
IC50	O
=	O
0.1-0.5	O
microM	O
)	O
similar	O
to	O
that	O
of	O
pyrimethamine	O
(	O
IC50	O
=	O
0.69	O
microM	O
)	O
,	O
a	O
standard	O
clinical	O
agent	O
for	O
the	O
treatment	O
of	O
cerebral	O
toxoplasmosis	O
in	O
AIDS	O
patients	O
.	O

Compound	O
5h	O
was	O
also	O
active	O
against	O
T	O
.	O

gondii	O
infection	O
in	O
mice	O
when	O
given	O
qdx8	O
by	O
peritoneal	O
injection	O
at	O
doses	O
ranging	O
from	O
62.5	O
(	O
initial	O
dose	O
)	O
to	O
25	O
mg	O
/	O
kg	O
.	O

Survival	O
was	O
prolonged	O
to	O
the	O
same	O
degree	O
as	O
with	O
25	O
mg	O
/	O
kg	O
clindamycin	O
,	O
another	O
widely	O
used	O
drug	O
against	O
toxoplasmosis	O
.	O

Three	O
compounds	O
(	O
5j	O
-	O
l	O
)	O
were	O
tested	O
for	O
antiproliferative	O
activity	O
against	O
human	O
tumor	O
cells	O
in	O
culture	O
.	O

Among	O
the	O
25	O
cell	O
lines	O
in	O
the	O
National	O
Cancer	O
Institute	O
panel	O
for	O
which	O
data	O
were	O
confirmed	O
in	O
two	O
independent	O
experiments	O
,	O
the	O
IC50	O
for	O
at	O
least	O
two	O
of	O
these	O
compounds	O
was	O
&	O
lt	O
;	O
10	O
microM	O
against	O
17	O
cell	O
lines	O
(	O
68%	O
)	O
and	O
in	O
the	O
0	O
.	O

1-1	O
microM	O
range	O
against	O
13	O
cell	O
lines	O
(	O
52%	O
)	O
.	O

One	O
compound	O
(	O
5j	O
)	O
had	O
an	O
IC50	O
of	O
&	O
lt	O
;	O
0.01	O
microM	O
against	O
four	O
of	O
the	O
cell	O
lines	O
.	O

The	O
activity	O
profiles	O
of	O
5k	O
,	O
l	O
were	O
generally	O
similar	O
to	O
that	O
of	O
5j	O
except	O
that	O
there	O
were	O
no	O
cells	O
against	O
which	O
the	O
IC50	O
was	O
&	O
lt	O
;	O
0.01	O
microM	O
.	O

A	O
series	O
of	O
novel	O
(	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
arylmethanones	I-IUPAC
was	O
synthesized	O
.	O

Pharmacological	O
evaluation	O
of	O
these	O
compounds	O
demonstrated	O
central	O
nervous	O
system	O
depressant	O
activity	O
,	O
potential	O
anticonvulsant	O
properties	O
,	O
and	O
a	O
low	O
order	O
of	O
acute	O
toxicity	O
.	O

In	O
addition	O
,	O
selected	O
compounds	O
showed	O
potential	O
antipsychotic	O
effects	O
.	O

This	O
report	O
focuses	O
on	O
the	O
synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
these	O
compounds	O
.	O

(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
methanone	I-IUPAC
(	O
21	O
)	O
was	O
the	O
most	O
active	O
compound	O
against	O
pentylenetetrazole	O
-	O
induced	O
convulsions	O
.	O

(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
methanone	I-IUPAC
(	O
4	O
)	O
also	O
has	O
a	O
favorable	O
anticonvulsant	O
depression	O
ratio	O
.	O

(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
trifluoromethylphenyl	I-IUPAC
)	I-IUPAC
methan	I-IUPAC
one	I-IUPAC
(	O
8	O
)	O
,	O
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
methanone	I-IUPAC
(	O
13	O
)	O
,	O
and	O
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
phenylmethanone	I-IUPAC
(	O
14	O
)	O
are	O
very	O
potent	O
depressants	O
.	O

(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
methanone	I-IUPAC
(	O
12	O
)	O
possessed	O
marked	O
central	O
depressant	O
activity	O
without	O
anticonvulsant	O
activity	O
and	O
without	O
impairment	O
of	O
motor	O
functioning	O
.	O

(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
methanone	I-IUPAC
(	O
2	O
)	O
has	O
a	O
behavioral	O
profile	O
suggestive	O
of	O
antipsychotic	O
activity	O
and	O
gave	O
a	O
positive	O
Ames	O
test	O
result	O
.	O

A	O
series	O
of	O
2,4	I-PARTIUPAC
-	I-PARTIUPAC
diamino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
aralkyl	I-PARTIUPAC
and	O
alicyclic	I-PARTIUPAC
)	I-PARTIUPAC
thio	I-PARTIUPAC
-	I-PARTIUPAC
,	O
sulfinyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
sulfonyl	I-PARTIUPAC
]	I-PARTIUPAC
quinazolines	I-PARTIUPAC
was	O
prepared	O
via	O
condensation	O
of	O
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
nitrobenzonitrile	I-IUPAC
or	O
5,6	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
nitrobenzonitrile	I-IUPAC
with	O
the	O
appropriate	O
aralkyl	O
or	O
alicyclic	O
thiopseudourea	O
,	O
reduction	O
of	O
the	O
resulting	O
2	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
aralkyl	I-IUPAC
or	I-IUPAC
alicyclic	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
benzonitrile	I-IUPAC
with	O
stannous	O
chloride	O
to	O
the	O
amine	O
,	O
and	O
cyclization	O
with	O
chloroformamidine	I-IUPAC
hydrochloride	I-IUPAC
.	O

Oxidation	O
was	O
effected	O
with	O
hydrogen	O
peroxide	O
or	O
the	O
bromine	O
complex	O
of	O
1,4	I-IUPAC
-	I-IUPAC
diazabicyclo	I-IUPAC
[	I-IUPAC
2.2.2	I-IUPAC
]	I-IUPAC
octane	I-IUPAC
.	O

These	O
analogues	O
when	O
examined	O
for	O
suppressive	O
activity	O
against	O
drug	O
-	O
sensitive	O
lines	O
of	O
Plasmodium	O
berghei	O
in	O
mice	O
were	O
not	O
as	O
active	O
as	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
Ia	O
)	O
.	O

We	O
describe	O
the	O
synthesis	O
and	O
some	O
pharmacological	O
properties	O
of	O
16	O
new	O
in	O
vivo	O
antagonists	O
of	O
oxytocin	O
.	O

These	O
are	O
based	O
on	O
modifications	O
of	O
three	O
peptides	O
:	O
A	O
,	O
B	O
,	O
and	O
C	O
.	O

A	O
is	O
our	O
previously	O
reported	O
potent	O
and	O
selective	O
antagonist	O
of	O
the	O
vasopressor	O
(	O
V1	O
receptor	O
)	O
responses	O
to	O
arginine	O
-	O
vasopressin	O
(	O
AVP	O
)	O
/	O
weak	O
oxytocin	O
antagonist	O
,	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
pentamethylenepropionic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
]	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
(	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVP	O
.	O

B	O
reported	O
here	O
,	O
the	O
Ile3	O
analogue	O
of	O
A	O
,	O
is	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVT	O
(	O
5	O
below	O
)	O
and	O
C	O
is	O
our	O
previously	O
reported	O
potent	O
nonselective	O
oxytocin	O
antagonist	O
/	O
AVP	O
V1	O
antagonist	O
,	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
pentamethylenepropionic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
]	I-IUPAC
vasotocin	I-IUPAC
(	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
OVT	O
)	O
.	O

The	O
following	O
substitutions	O
and	O
deletions	O
,	O
alone	O
or	O
in	O
combination	O
,	O
were	O
employed	O
in	O
A	O
,	O
B	O
,	O
and	O
C	O
:	O
1	I-IUPAC
-	I-IUPAC
deaminopenicillamine	I-IUPAC
(	O
dP	O
)	O
;	O
D	O
-	O
Tyr	O
(	O
Alk	O
)	O
2	O
(	O
where	O
Alk	O
=	O
Me	O
or	O
Et	O
)	O
,	O
D	O
-	O
Phe2	O
;	O
Val4	O
,	O
Thr4	O
;	O
delta	O
3	O
-	O
Pro7	O
;	O
Lys8	O
,	O
Cit8	O
;	O
desGly9	O
,	O
desGly	O
-	O
NH2	O
(	O
9	O
)	O
,	O
Ala	O
-	O
NH2	O
(	O
9	O
)	O
;	O
Leu	O
-	O
NH2	O
(	O
9	O
)	O
;	O
Arg	O
-	O
NH2	O
(	O
9	O
)	O
.	O

The	O
16	O
new	O
analogues	O
are	O
(	O
1	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
D	O
-	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVP	O
,	O
(	O
2	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
D	O
-	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Val4	O
,	O
delta	O
3	O
-	O
Pro7	O
]	O
AVP	O
,	O
(	O
3	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
D	O
-	O
Tyr	O
-	O
(	O
Et	O
)	O
2	O
,	O
Val4	O
,	O
Lys8	O
]	O
VP	O
,	O
(	O
4	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
D	O
-	O
Tyr	O
(	O
Et	O
)	O
2	O
,	O
Val4	O
,	O
Cit8	O
]	O
VP	O
,	O
(	O
5	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVT	O
,	O
(	O
6	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Lys8	O
]	O
VT	O
,	O
(	O
7	O
)	O
dP	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVT	O
,	O
(	O
8	O
)	O
dP	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Val4	O
]	O
AVT	O
,	O
(	O
9	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
D	O
-	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Val4	O
]	O
AVT	O
,	O
(	O
10	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
D	O
-	O
Phe2	O
,	O
Val4	O
]	O
AVT	O
,	O
(	O
11	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
]	O
OVT	O
,	O
(	O
12	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
,	O
Ala	O
-	O
NH2	O
(	O
9	O
)	O
]	O
OVT	O
,	O
(	O
13	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
,	O
Leu	O
-	O
NH2	O
(	O
9	O
)	O
]	O
OVT	O
,	O
(	O
14	O
)	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
,	O
Arg	O
-	O
NH2	O
(	O
9	O
)	O
]	O
OVT	O
,	O
(	O
15	O
)	O
desGly	O
-	O
NH2	O
(	O
9	O
)	O
,	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
]	O
OVT	O
,	O
(	O
16	O
)	O
desGly9	O
,	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
]	O
OVT	O
.	O

1-4	O
are	O
analogues	O
of	O
A	O
,	O
5-10	O
are	O
analogues	O
of	O
B	O
,	O
and	O
11-16	O
are	O
analogues	O
of	O
C	O
.	O

Their	O
protected	O
precursors	O
were	O
synthesized	O
either	O
entirely	O
by	O
the	O
solid	O
-	O
phase	O
method	O
or	O
by	O
a	O
combination	O
of	O
solid	O
-	O
phase	O
and	O
solution	O
methods	O
(	O
1	O
+	O
8	O
or	O
8	O
+	O
1	O
couplings	O
)	O
.	O

All	O
analogues	O
were	O
tested	O
in	O
rats	O
for	O
agonistic	O
and	O
antagonistic	O
activities	O
in	O
oxytocic	O
(	O
in	O
vitro	O
,	O
without	O
and	O
with	O
Mg2+	O
,	O
and	O
in	O
vivo	O
)	O
assays	O
as	O
well	O
as	O
by	O
antidiuretic	O
and	O
vasopressor	O
assays	O
.	O

All	O
analogues	O
exhibit	O
potent	O
oxytocic	O
antagonism	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

With	O
an	O
in	O
vitro	O
pA2	O
(	O
in	O
the	O
absence	O
of	O
Mg2+	O
)	O
=	O
9.12	O
+	O
/	O
-	O
0.09	O
,	O
dP	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVT	O
is	O
(	O
7	O
)	O
one	O
of	O
the	O
most	O
potent	O
in	O
vitro	O
oxytocin	O
antagonists	O
reported	O
to	O
date	O
.	O

Fifteen	O
of	O
these	O
analogues	O
(	O
all	O
but	O
6	O
)	O
appear	O
as	O
potent	O
or	O
more	O
potent	O
in	O
vivo	O
oxytocin	O
antagonists	O
than	O
C	O
(	O
pA2	O
=	O
7.37	O
+	O
/	O
-	O
0.17	O
)	O
.	O

Analogues	O
1-9	O
and	O
14	O
are	O
potent	O
AVP	O
V1	O
antagonists	O
.	O

Their	O
anti	O
-	O
V1	O
pA2	O
values	O
range	O
from	O
7.92	O
to	O
8.45	O
.	O

They	O
are	O
thus	O
nonselective	O
oxytocin	O
antagonists	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

A	O
series	O
of	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
decahydroisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
were	O
prepared	O
as	O
excitatory	O
amino	O
acid	O
(	O
EAA	O
)	O
receptor	O
antagonists	O
.	O

These	O
compounds	O
are	O
antagonists	O
at	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartate	I-IUPAC
(	O
NMDA	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propanoic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
subclasses	O
of	O
ligand	O
gated	O
ion	O
channel	O
(	O
ionotropic	O
)	O
EAA	O
receptors	O
.	O

(	I-IUPAC
3S	I-IUPAC
,	I-IUPAC
4aR	I-IUPAC
,	I-IUPAC
6R	I-IUPAC
,	I-IUPAC
8aR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4,4	I-IUPAC
a	I-IUPAC
,	I-IUPAC
5,6,7,8,8	I-IUPAC
a	I-IUPAC
-	I-IUPAC
decahydroisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
9	O
)	O
is	O
a	O
potent	O
,	O
selective	O
and	O
systemically	O
active	O
AMPA	O
antagonist	O
.	O

Other	O
analogs	O
from	O
this	O
series	O
,	O
including	O
(	I-IUPAC
3S	I-IUPAC
,	I-IUPAC
4aR	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
,	I-IUPAC
8aR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4,4	I-IUPAC
a	I-IUPAC
,	I-IUPAC
5,6,7,8,8	I-IUPAC
a	I-IUPAC
-	I-IUPAC
decahydroisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
32	O
)	O
and	O
(	I-IUPAC
3S	I-IUPAC
,	I-IUPAC
4aR	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
,	I-IUPAC
8aR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4,4	I-IUPAC
a	I-IUPAC
,	I-IUPAC
5,6,7,8,8	I-IUPAC
a	I-IUPAC
-	I-IUPAC
decahydroisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ca	I-IUPAC
rboxylic	I-IUPAC
acid	I-IUPAC
(	O
61	O
)	O
are	O
potent	O
,	O
selective	O
,	O
and	O
systemically	O
active	O
NMDA	O
antagonists	O
.	O

This	O
and	O
the	O
subsequent	O
publication	O
look	O
at	O
the	O
AMPA	O
antagonist	O
aspects	O
of	O
this	O
SAR	O
.	O

Herein	O
we	O
report	O
the	O
effects	O
of	O
varying	O
stereochemistry	O
around	O
the	O
hydroisoquinoline	O
ring	O
;	O
of	O
tetrahydro	O
-	O
versus	O
decahydroisoquinoline	O
;	O
of	O
having	O
the	O
carboxylic	O
acid	O
at	O
C	O
-	O
1	O
versus	O
C	O
-	O
3	O
;	O
of	O
varying	O
the	O
length	O
of	O
the	O
carbon	O
chain	O
connecting	O
a	O
tetrazole	O
to	O
the	O
bicyclic	O
nucleus	O
;	O
and	O
of	O
holding	O
the	O
connecting	O
chain	O
constant	O
at	O
two	O
atoms	O
,	O
the	O
effect	O
of	O
heteroatom	O
substitution	O
in	O
the	O
position	O
adjacent	O
to	O
the	O
bicyclic	O
nucleus	O
and	O
substitution	O
with	O
methyl	O
or	O
phenyl	O
on	O
the	O
chain	O
.	O

Compounds	O
were	O
evaluated	O
on	O
rat	O
cortical	O
tissue	O
for	O
their	O
ability	O
to	O
inhibit	O
the	O
binding	O
of	O
radioligands	O
selective	O
for	O
AMPA	O
(	O
[	O
3H	O
]	O
AMPA	O
)	O
,	O
NMDA	O
(	O
[	O
3H	O
]	O
CGS	O
19755	O
)	O
,	O
and	O
kainic	O
acid	O
(	O
[	O
3H	O
]	O
-	O
kainic	O
acid	O
)	O
receptors	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
depolarizations	O
induced	O
by	O
AMPA	O
(	O
40	O
microM	O
)	O
,	O
NMDA	O
(	O
40	O
microM	O
)	O
,	O
and	O
kainic	O
acid	O
(	O
10	O
microM	O
)	O
.	O

Our	O
findings	O
revealed	O
that	O
the	O
optimal	O
stereochemical	O
array	O
was	O
the	O
same	O
for	O
both	O
NMDA	O
(	O
32	O
and	O
61	O
)	O
and	O
AMPA	O
(	O
9	O
)	O
antagonists	O
identified	O
in	O
this	O
series	O
and	O
that	O
the	O
tetrahydroisoquinoline	O
(	O
25	O
)	O
and	O
the	O
C	I-MODIFIER
-	I-MODIFIER
1	I-MODIFIER
carboxy	I-IUPAC
(	O
30	O
)	O
analogs	I-MODIFIER
of	O
9	O
are	O
inactive	O
.	O

With	O
a	O
tetrazole	O
in	O
the	O
distal	O
acid	O
position	O
,	O
an	O
ethylene	O
spacer	O
(	O
9	O
)	O
is	O
optimal	O
;	O
substitution	O
with	O
oxygen	O
or	O
nitrogen	O
on	O
the	O
chain	O
in	O
the	O
position	O
adjacent	O
to	O
the	O
bicyclic	O
nucleus	O
significantly	O
reduced	O
activity	O
,	O
while	O
substitution	O
with	O
a	O
methyl	O
or	O
phenyl	O
group	O
on	O
the	O
chain	O
was	O
well	O
tolerated	O
.	O

As	O
part	O
of	O
a	O
program	O
in	O
which	O
we	O
are	O
attempting	O
(	O
a	O
)	O
to	O
delineate	O
the	O
structural	O
features	O
at	O
positions	O
1-9	O
in	O
our	O
previously	O
reported	O
antidiuretic	O
antagonists	O
required	O
for	O
antidiuretic	O
antagonism	O
and	O
(	O
b	O
)	O
to	O
obtain	O
analogues	O
with	O
enhanced	O
antiantidiuretic	O
potency	O
and	O
/	O
or	O
selectivity	O
,	O
we	O
have	O
synthesized	O
14	O
new	O
analogues	O
of	O
the	O
antidiuretic	O
antagonist	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
cyclopentamethylenepropionic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
phenylalanine	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
valine	I-IUPAC
]	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
[	O
d	O
-	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2VAVP	O
)	O
,	O
in	O
which	O
the	O
valine	O
residue	O
at	O
position	O
4	O
was	O
replaced	O
by	O
the	O
following	O
L	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
acids	I-IUPAC
and	O
glycine	I-PARTIUPAC
:	O
Ile	O
,	O
Abu	O
,	O
Thr	O
,	O
Ala	O
,	O
Gln	O
,	O
Lys	O
,	O
Cha	O
,	O
Nle	O
,	O
Nva	O
,	O
Phe	O
,	O
Leu	O
,	O
Gly	O
,	O
Tyr	O
,	O
and	O
Pro	O
.	O

These	O
analogues	O
are	O
1	O
,	O
d	O
-	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Ile4AVP	O
;	O
2	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Abu4AVP	O
;	O
3	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Thr4AVP	O
;	O
4	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Ala4AVP	O
;	O
5	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2AVP	O
;	O
6	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Lys4AVP	O
;	O
7	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Cha4AVP	O
;	O
8	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Nle4AVP	O
;	O
9	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Nva4AVP	O
;	O
10	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Phe4AVP	O
;	O
11	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Leu4AVP	O
;	O
12	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Gly4AVP	O
;	O
13	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Tyr4AVP	O
;	O
14	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Pro4AVP	O
.	O

The	O
protected	O
intermediates	O
required	O
for	O
the	O
synthesis	O
of	O
all	O
of	O
these	O
peptides	O
were	O
prepared	O
by	O
the	O
solid	O
-	O
phase	O
method	O
and	O
cleaved	O
from	O
the	O
resin	O
by	O
ammonolysis	O
.	O

Following	O
deblocking	O
with	O
Na	O
in	O
NH3	O
and	O
oxidizing	O
with	O
K3	O
[	O
Fe	O
(	O
CN	O
)	O
6	O
]	O
,	O
each	O
peptide	O
was	O
purified	O
on	O
Sephadex	O
G	O
-	O
15	O
in	O
a	O
two	O
-	O
step	O
procedure	O
using	O
50%	O
HOAc	O
and	O
0.2	O
M	O
HOAc	O
as	O
eluants	O
.	O

Analogues	O
1-14	O
were	O
tested	O
for	O
agonistic	O
and	O
antagonistic	O
activities	O
by	O
antidiuretic	O
,	O
vasopressor	O
,	O
and	O
oxytocic	O
assays	O
in	O
rats	O
.	O

Analogues	O
1	O
,	O
2	O
,	O
and	O
4-6	O
exhibit	O
no	O
detectable	O
antidiuretic	O
agonistic	O
activity	O
.	O

All	O
analogues	O
,	O
with	O
the	O
exception	O
of	O
the	O
Pro4	O
-	O
containing	O
analogue	O
,	O
are	O
antidiuretic	O
antagonists	O
.	O

Their	O
antiantidiuretic	O
pA2	O
values	O
are	O
as	O
follows	O
:	O
1	O
,	O
8.24	O
+	O
/	O
-	O
0.08	O
;	O
2	O
,	O
7.96	O
+	O
/	O
-	O
0.07	O
;	O
3	O
,	O
7.62	O
+	O
/	O
-	O
0.09	O
;	O
4	O
,	O
7.52	O
+	O
/	O
-	O
0.03	O
;	O
5	O
,	O
7.21	O
+	O
/	O
-	O
0.07	O
;	O
6	O
,	O
7.22	O
+	O
/	O
-	O
0.12	O
;	O
7	O
,	O
7.19	O
+	O
/	O
-	O
0.08	O
;	O
8	O
,	O
7.12	O
+	O
/	O
-	O
0.09	O
;	O
9	O
,	O
6.99	O
+	O
/	O
-	O
0.06	O
;	O
10	O
,	O
6.07	O
+	O
/	O
-	O
0.11	O
;	O
11	O
,	O
6.07	O
+	O
/	O
-	O
0.11	O
;	O
12	O
,	O
5.85	O
+	O
/	O
-	O
0.05	O
;	O
13	O
,	O
approximately	O
5.57	O
;	O
14	O
,	O
a	O
weak	O
agonist	O
(	O
0.004	O
U	O
/	O
mg	O
)	O
.	O

Analogues	O
1-14	O
also	O
antagonize	O
the	O
vascular	O
responses	O
to	O
arginine	O
-	O
vasopressin	O
(	O
AVP	O
)	O
and	O
the	O
in	O
vitro	O
oxytocic	O
responses	O
to	O
oxytocin	O
.	O

Analogues	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
5	O
have	O
also	O
been	O
shown	O
to	O
antagonize	O
the	O
in	O
vivo	O
oxytocic	O
responses	O
to	O
oxytocin	O
.	O

Five	O
of	O
these	O
analogues	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
,	O
and	O
7	O
)	O
exhibit	O
enhanced	O
antiantidiuretic	O
/	O
antivasopressor	O
selectivity	O
.	O

d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Lys4AVP	O
and	O
other	O
position	O
-	O
4	O
analogues	O
with	O
side	O
-	O
chain	O
functional	O
groups	O
may	O
be	O
useful	O
covalent	O
ligands	O
with	O
which	O
to	O
probe	O
the	O
structural	O
characteristics	O
of	O
AVP	O
renal	O
and	O
vascular	O
receptors	O
.	O

With	O
an	O
antiantidiuretic	O
"	O
effective	O
dose	O
"	O
of	O
0.46	O
+	O
/	O
-	O
0.07	O
nmol	O
/	O
kg	O
and	O
a	O
pA2	O
value	O
of	O
8.24	O
+	O
/	O
-	O
0.08	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Ile4AVP	O
(	O
1	O
)	O
appears	O
to	O
be	O
the	O
most	O
potent	O
antidiuretic	O
antagonist	O
reported	O
to	O
date	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
synthesis	O
and	O
alpha	O
2	O
-	O
adrenergic	O
activity	O
of	O
a	O
series	O
of	O
indolin	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
and	O
tetrahydroquinolin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
imidazolines	I-IUPAC
are	O
described	O
.	O

The	O
indolin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
imidazoline	I-IUPAC
4b	O
was	O
found	O
to	O
possess	O
potent	O
alpha	O
2	O
-	O
adrenergic	O
agonist	O
and	O
antagonist	O
activity	O
.	O

The	O
modification	O
of	O
the	O
substituents	O
on	O
the	O
indoline	O
ring	O
of	O
4b	O
has	O
led	O
to	O
the	O
separation	O
of	O
these	O
activities	O
.	O

Substitution	O
on	O
the	O
aromatic	O
ring	O
of	O
4b	O
with	O
halogen	O
or	O
increasing	O
the	O
size	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
substituent	I-MODIFIER
of	O
4b	O
gave	O
alpha	O
2	O
-	O
adrenergic	O
antagonists	O
without	O
agonist	O
activity	O
.	O

The	O
N	I-IUPAC
-	I-IUPAC
allylindoline	I-IUPAC
4d	O
is	O
more	O
potent	O
than	O
idazoxan	O
in	O
vitro	O
and	O
is	O
equipotent	O
in	O
vivo	O
,	O
but	O
is	O
less	O
receptor	O
selective	O
(	O
alpha	O
2	O
vs.	O
alpha	O
1	O
)	O
than	O
idazoxan	O
.	O

The	O
cis	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethylindolin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
imidazoline	I-IUPAC
6a	O
is	O
an	O
alpha	O
2	O
-	O
adrenergic	O
agonist	O
equal	O
in	O
potency	O
to	O
clonidine	O
in	O
vitro	O
,	O
while	O
the	O
trans	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethylindolin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
imidazoline	I-IUPAC
6b	O
is	O
a	O
moderately	O
potent	O
alpha	O
2	O
-	O
adrenergic	O
antagonist	O
.	O

2	O
-	O
Amino	O
-	O
3	O
-	O
aroylthiophenes	O
are	O
agonist	O
allosteric	O
enhancers	O
(	O
AE	O
)	O
at	O
the	O
A	O
(	O
1	O
)	O
adenosine	O
receptor	O
(	O
A	O
(	O
1	O
)	O
AR	O
)	O
.	O

Here	O
we	O
report	O
the	O
syntheses	O
of	O
three	O
kinds	O
of	O
novel	O
2	I-IUPAC
-	I-IUPAC
aminothiophenes	I-IUPAC
and	O
assays	O
of	O
their	O
AE	O
activity	O
at	O
the	O
human	O
A	O
(	O
1	O
)	O
AR	O
(	O
hA	O
(	O
1	O
)	O
AR	O
)	O
,	O
namely	O
,	O
(	O
1	O
)	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
diphenylthiophene	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylates	I-IUPAC
,	O
3a	O
-	O
h	O
,	O
(	O
2	O
)	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
diphenylthiophenes	I-IUPAC
,	O
7a	O
-	O
p	O
,	O
and	O
(	O
3	O
)	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylthiophenes	I-IUPAC
,	O
10a	O
-	O
h	O
.	O

An	O
in	O
vitro	O
assay	O
employing	O
the	O
A	O
(	O
1	O
)	O
AR	O
agonist	O
[	O
(	O
125	O
)	O
I	O
]	O
ABA	O
and	O
membranes	O
from	O
CHO	O
-	O
K1	O
cells	O
stably	O
expressing	O
the	O
hA	O
(	O
1	O
)	O
AR	O
measured	O
an	O
index	O
of	O
AE	O
activity	O
,	O
the	O
ability	O
of	O
a	O
candidate	O
AE	O
to	O
stabilize	O
the	O
agonist	O
-	O
A	O
(	O
1	O
)	O
AR	O
-	O
G	O
protein	O
ternary	O
complex	O
,	O
scored	O
as	O
the	O
percentage	O
of	O
ternary	O
complex	O
remaining	O
after	O
10	O
min	O
of	O
dissociation	O
initiated	O
by	O
CPX	O
and	O
GTPgammaS	O
.	O

The	O
AE	O
activity	O
score	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
trifluoromethylbenzoyl	I-IUPAC
)	I-IUPAC
thiophene	I-IUPAC
(	O
PD	O
81,723	O
)	O
,	O
which	O
was	O
19%	O
,	O
served	O
as	O
a	O
standard	O
for	O
comparison	O
.	O

Two	O
3	I-IUPAC
-	I-IUPAC
carboxythiophene	I-IUPAC
3	I-IUPAC
-	I-IUPAC
trifluoromethylbenzyl	I-IUPAC
esters	I-IUPAC
,	O
3d	O
(	O
49%	O
)	O
and	O
3f	O
(	O
63%	O
)	O
,	O
had	O
substantial	O
AE	O
activity	O
.	O

The	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoyl	I-IUPAC
)	I-IUPAC
substituent	I-MODIFIER
of	O
7e	O
(	O
52%	O
)	O
also	O
supported	O
AE	O
activity	O
.	O

Compounds	O
in	O
series	O
3	O
tended	O
to	O
be	O
more	O
potent	O
,	O
10a	O
and	O
10c	O
having	O
scores	O
of	O
91	O
and	O
80%	O
,	O
respectively	O
.	O

The	O
activity	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
thiophene	I-IUPAC
,	O
10h	O
(	O
26%	O
)	O
,	O
is	O
an	O
exception	O
to	O
the	O
rule	O
that	O
a	O
3	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
substituent	I-MODIFIER
cannot	O
support	O
AE	O
activity	O
.	O

The	O
novel	O
acidic	O
amino	O
acids	O
6a	O
-	O
c	O
,	O
7	O
,	O
and	O
8	O
have	O
been	O
synthesized	O
via	O
1,3	O
-	O
dipolar	O
cycloadditions	O
,	O
using	O
nitrile	O
oxides	O
and	O
alkynes	O
.	O

The	O
prepared	O
compounds	O
are	O
heterocyclic	O
analogues	O
of	O
glutamic	O
acid	O
with	O
differing	O
chain	O
lengths	O
.	O

One	O
of	O
these	O
compounds	O
,	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
ACPA	O
,	O
8	O
)	O
,	O
was	O
shown	O
in	O
[	O
3H	O
]	O
AMPA	O
binding	O
studies	O
to	O
be	O
more	O
active	O
than	O
AMPA	O
itself	O
(	O
IC50	O
=	O
20	O
nM	O
compared	O
to	O
IC50	O
=	O
79	O
nM	O
for	O
AMPA	O
)	O
.	O

No	O
affinity	O
for	O
NMDA	O
receptors	O
(	O
NMDA	O
-	O
sensitive	O
[	O
3H	O
]	O
glutamic	O
acid	O
binding	O
)	O
was	O
found	O
,	O
and	O
only	O
weak	O
affinity	O
in	O
[	O
3H	O
]	O
kainic	O
acid	O
binding	O
(	O
IC50	O
=	O
6.3	O
microM	O
)	O
was	O
detected	O
.	O

The	O
excitatory	O
activity	O
in	O
rat	O
cortical	O
wedge	O
also	O
showed	O
that	O
ACPA	O
was	O
more	O
potent	O
than	O
AMPA	O
(	O
EC50	O
=	O
1.0	O
microM	O
compared	O
to	O
EC50	O
=	O
3.5	O
microM	O
for	O
AMPA	O
)	O
.	O

The	O
depolarizing	O
effect	O
of	O
ACPA	O
could	O
be	O
fully	O
antagonized	O
by	O
the	O
selective	O
non	O
-	O
NMDA	O
antagonist	O
6	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
quinoxazoline	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
CNQX	O
)	O
,	O
but	O
was	O
unaffected	O
by	O
the	O
selective	O
NMDA	O
antagonist	O
D	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phosphonovaleric	I-IUPAC
acid	I-IUPAC
(	O
AP5	O
)	O
.	O

A	O
series	O
of	O
C11	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aporphines	I-IUPAC
and	O
C11	I-MODIFIER
-	I-MODIFIER
oxygenated	I-MODIFIER
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
noraporphines	I-IUPAC
has	O
been	O
synthesized	O
and	O
evaluated	O
for	O
central	O
serotonergic	O
and	O
dopaminergic	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
various	O
C11	O
-	O
substituents	O
were	O
introduced	O
using	O
efficient	O
nickel	O
-	O
and	O
palladium	O
-	O
catalyzed	O
reactions	O
of	O
the	O
corresponding	O
triflate	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
aporphine	I-IUPAC
(	O
6	O
)	O
.	O

Several	O
compounds	O
display	O
high	O
affinity	O
to	O
serotonin	O
5	O
-	O
HT1A	O
receptors	O
in	O
spite	O
of	O
major	O
differences	O
in	O
steric	O
bulk	O
and	O
electronic	O
properties	O
of	O
the	O
various	O
C11	O
-	O
substituents	O
.	O

A	O
change	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
of	O
the	O
nonselective	O
3	O
to	O
H	O
[	O
23	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxynoraporphine	I-IUPAC
]	O
or	O
propyl	O
[	O
2	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propylnoraporphine	I-IUPAC
]	O
increases	O
the	O
selectivity	O
for	O
5	O
-	O
HT1A	O
receptors	O
(	O
100	O
-	O
fold	O
)	O
and	O
dopamine	O
D2A	O
receptors	O
(	O
3	O
-	O
fold	O
)	O
,	O
respectively	O
.	O

Compounds	O
3	O
and	O
23	O
have	O
similar	O
affinities	O
to	O
5	O
-	O
HT1A	O
receptors	O
,	O
whereas	O
the	O
propyl	I-IUPAC
substituent	B-MODIFIER
of	O
2	O
not	O
only	O
enhances	O
the	O
selectivity	O
for	O
D2A	O
receptors	O
but	O
also	O
increases	O
the	O
D2A	O
affinity	O
.	O

Modeling	O
of	O
ligand	O
-	O
receptor	O
binding	O
site	O
interactions	O
yielded	O
an	O
interaction	O
site	O
model	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
that	O
describes	O
a	O
gradual	O
change	O
in	O
binding	O
mode	O
for	O
C11	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
,	O
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
-	I-PARTIUPAC
phenyl	I-PARTIUPAC
-	O
substituted	I-MODIFIER
derivatives	I-MODIFIER
.	O

Hydrogen	O
bonding	O
is	O
hereby	O
gradually	O
replaced	O
by	O
van	O
der	O
Waals	O
interactions	O
involving	O
a	O
relatively	O
large	O
lipophilic	O
pocket	O
.	O

The	O
derived	O
D2A	O
receptor	O
model	O
can	O
accommodate	O
both	O
the	O
N	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
substituent	I-MODIFIER
of	O
2	O
and	O
the	O
C11	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
substituent	I-MODIFIER
of	O
11	O
[	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
ethylaporphine	I-IUPAC
]	O
.	O

Methotrexate	O
poly	O
(	O
gamma	O
-	O
L	O
-	O
glutamate	O
)	O
s	O
bearing	O
two	O
and	O
three	O
glutamate	O
units	O
above	O
that	O
present	O
in	O
methotrexate	O
have	O
been	O
synthesized	O
by	O
extension	O
of	O
a	O
previously	O
described	O
route	O
used	O
to	O
synthesize	O
the	O
lower	O
conjugate	O
bearing	O
one	O
added	O
glutamate	O
unit	O
.	O

Key	O
steps	O
in	O
the	O
sequence	O
are	O
the	O
peptide	O
coupling	O
of	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
ester	I-IUPAC
(	O
5	O
)	O
with	O
oligo	I-IUPAC
(	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
)	I-IUPAC
benzyl	I-IUPAC
esters	I-IUPAC
,	O
removal	O
of	O
blocking	O
groups	O
by	O
catalytic	O
hydrogenolysis	O
,	O
and	O
introduction	O
of	O
the	O
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
pteridinyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
grouping	I-MODIFIER
by	O
alkylation	O
with	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pteridinediamine	I-IUPAC
hydrobromide	I-IUPAC
.	O

Elaboration	O
of	O
the	O
required	O
oligo	I-IUPAC
(	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
)	I-IUPAC
chain	O
was	O
achieved	O
one	O
unit	O
at	O
a	O
time	O
,	O
beginning	O
with	O
the	O
coupling	O
of	O
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
dibenzyl	I-IUPAC
ester	I-IUPAC
with	O
[	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
ester	I-IUPAC
(	O
7	O
)	O
,	O
followed	O
by	O
selective	O
removal	O
of	O
the	O
tert	O
-	O
butyloxycarbonyl	O
grouping	O
and	O
another	O
coupling	O
step	O
with	O
5	O
or	O
7	O
as	O
required	O
.	O

Diphenylphosphoryl	O
azide	O
was	O
used	O
as	O
the	O
coupling	O
reagent	O
in	O
each	O
conversion	O
producing	O
a	O
peptide	O
linkage	O
.	O

The	O
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
derivative	I-MODIFIER
3	O
,	O
more	O
commonly	O
known	O
in	O
the	O
field	O
of	O
adenosine	O
research	O
as	O
ZM	O
-	O
241385	O
,	O
has	O
previously	O
been	O
demonstrated	O
to	O
be	O
a	O
potent	O
and	O
selective	O
adenosine	O
A2a	O
receptor	O
antagonist	O
,	O
although	O
with	O
limited	O
oral	O
bioavailability	O
.	O

This	O
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
core	I-MODIFIER
structure	I-MODIFIER
has	O
now	O
been	O
improved	O
by	O
incorporating	O
various	O
piperazine	O
derivatives	O
.	O

With	O
some	O
preliminary	O
optimization	O
,	O
the	O
A2a	O
binding	O
affinity	O
of	O
some	O
of	O
the	O
best	O
piperazine	O
derivatives	O
is	O
almost	O
as	O
good	O
as	O
that	O
of	O
compound	O
3	O
.	O

The	O
selectivity	O
level	O
over	O
the	O
adenosine	O
A1	O
receptor	O
subtype	O
for	O
some	O
of	O
the	O
more	O
active	O
analogues	O
is	O
also	O
fairly	O
high	O
,	O
&	O
gt	O
;	O
400	O
-	O
fold	O
in	O
some	O
cases	O
.	O

Many	O
compounds	O
within	O
this	O
piperazine	O
series	O
of	O
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
have	O
now	O
been	O
shown	O
to	O
have	O
good	O
oral	O
bioavailability	O
in	O
the	O
rat	O
,	O
with	O
some	O
as	O
high	O
as	O
89%	O
(	O
compound	O
35	O
)	O
.	O

More	O
significantly	O
,	O
some	O
piperazines	O
derivatives	O
of	O
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
also	O
possessed	O
good	O
oral	O
efficacy	O
in	O
rodent	O
models	O
of	O
Parkinson	O
's	O
disease	O
.	O

For	O
instance	O
,	O
compound	O
34	O
was	O
orally	O
active	O
in	O
the	O
rat	O
catalepsy	O
model	O
at	O
3	O
mg	O
/	O
kg	O
.	O

In	O
the	O
6	I-IUPAC
-	I-IUPAC
hydroxydopamine	I-IUPAC
-	O
lesioned	O
rat	O
model	O
,	O
this	O
compound	O
was	O
also	O
quite	O
effective	O
,	O
with	O
a	O
minimum	O
effective	O
dose	O
of	O
3	O
mg	O
/	O
kg	O
po	O
.	O

The	O
racemate	O
and	O
the	O
enantiomers	I-MODIFIER
of	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
6	O
)	O
and	O
racemic	I-MODIFIER
5	B-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoindan	I-IUPAC
(	O
11	O
)	O
were	O
tested	O
for	O
stimulus	O
generalization	O
in	O
the	O
two	O
-	O
lever	O
drug	O
-	O
discrimination	O
paradigm	O
.	O

Both	O
6	O
and	O
11	O
were	O
found	O
to	O
substitute	O
with	O
high	O
potency	O
in	O
3,4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylenedioxy	I-IUPAC
)	I-IUPAC
methamphetamine	I-IUPAC
(	O
1	O
)	O
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
benzodioxol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
butane	I-IUPAC
(	O
2	O
)	O
trained	O
rats	O
.	O

In	O
the	O
latter	O
assay	O
,	O
both	O
enantiomers	O
of	O
6	O
had	O
identical	O
potencies	O
,	O
but	O
their	O
dose	O
-	O
response	O
curves	O
were	O
not	O
parallel	O
.	O

Racemic	O
6	O
,	O
but	O
not	O
11	O
,	O
partially	O
substituted	O
for	O
LSD	O
.	O

Racemic	O
6	O
and	O
11	O
did	O
not	O
substitute	O
in	O
(	O
S	O
)	O
-	O
amphetamine	O
-	O
trained	O
rats	O
.	O

All	O
of	O
the	O
test	O
compounds	O
were	O
potent	O
inhibitors	O
of	O
[	O
3H	O
]	O
-	O
5	O
-	O
HT	O
uptake	O
into	O
synaptosomes	O
in	O
vitro	O
,	O
with	O
the	O
S	O
enantiomer	O
of	O
6	O
being	O
most	O
active	O
.	O

Rat	O
brain	O
monoamine	O
levels	O
were	O
unaltered	O
1	O
week	O
following	O
a	O
single	O
high	O
dose	O
(	O
10	O
or	O
20	O
mg	O
/	O
kg	O
,	O
sc	O
)	O
of	O
6	O
or	O
11	O
,	O
or	O
two	O
weeks	O
following	O
a	O
subacute	O
dosing	O
regimen	O
(	O
20	O
mg	O
/	O
kg	O
,	O
sc	O
,	O
twice	O
a	O
day	O
for	O
4	O
days	O
)	O
.	O

In	O
addition	O
,	O
radioligand	O
-	O
binding	O
parameters	O
in	O
rat	O
brain	O
homogenate	O
with	O
the	O
5	O
-	O
HT	O
uptake	O
inhibitor	O
[	O
3H	O
]	O
paroxetine	O
were	O
unchanged	O
after	O
subacute	O
dosing	O
with	O
either	O
racemic	O
6	O
or	O
11	O
.	O

The	O
results	O
indicate	O
that	O
compounds	O
6	O
and	O
11	O
have	O
animal	O
behavioral	O
pharmacology	O
similar	O
to	O
the	O
methylenedioxy	O
compounds	O
1	O
and	O
2	O
,	O
but	O
that	O
they	O
do	O
not	O
induce	O
the	O
serotonin	O
neurotoxicity	O
that	O
has	O
been	O
observed	O
for	O
the	O
latter	O
two	O
drugs	O
.	O

The	O
development	O
of	O
a	O
prostaglandin	O
PGF2	O
alpha	O
photoaffinity	O
probe	O
led	O
to	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
azide	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
17	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
and	O
16	I-IUPAC
-	I-IUPAC
phenoxy	I-IUPAC
-	I-IUPAC
17,18,19,20	I-IUPAC
-	I-IUPAC
tetranorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
derivatives	O
.	O

Two	O
approaches	O
for	O
the	O
preparation	O
of	O
iodinated	O
versions	O
of	O
these	O
prostaglandins	O
were	O
evaluated	O
:	O
(	O
1	O
)	O
iodination	O
of	O
a	O
phenyl	O
azide	O
bearing	O
an	O
activating	O
hydroxyl	O
group	O
and	O
(	O
2	O
)	O
iodination	O
of	O
an	O
aniline	O
precursor	O
to	O
the	O
phenyl	O
azide	O
group	O
and	O
subsequent	O
conversion	O
of	O
the	O
aniline	O
to	O
the	O
phenyl	O
azide	O
.	O

In	O
the	O
first	O
approach	O
,	O
17	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
,	O
16	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
17,18,19,20	I-IUPAC
-	I-IUPAC
tetranorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
,	O
and	O
16	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyphenoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
17,18,19,20	I-IUPAC
-	I-IUPAC
tetranorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
were	O
prepared	O
by	O
using	O
the	O
Corey	O
synthesis	O
,	O
but	O
were	O
biologically	O
inactive	O
presumably	O
as	O
a	O
result	O
of	O
the	O
hydrophilic	O
phenolic	O
hydroxyl	O
group	O
.	O

In	O
the	O
second	O
approach	O
,	O
the	O
iodination	O
of	O
a	O
17	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
derivative	I-MODIFIER
delivered	O
17	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
,	O
which	O
exhibited	O
competitive	O
binding	O
with	O
natural	O
[	O
3H	O
]	O
PGF2	O
alpha	O
to	O
ovine	O
luteal	O
cells	O
and	O
to	O
plasma	O
membranes	O
of	O
bovine	O
corpora	O
lutea	O
.	O

[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
Azido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
was	O
utilized	O
in	O
a	O
preliminary	O
photoaffinity	O
cross	O
-	O
linking	O
experiment	O
.	O

We	O
have	O
synthesized	O
five	O
fluorinated	O
derivatives	O
of	O
WAY	O
100635	O
,	O
N	I-IUPAC
-	I-IUPAC
{	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
piperazino	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
cyclohe	I-IUPAC
xaneca	I-IUPAC
rboxamide	I-IUPAC
(	O
4a	O
)	O
,	O
using	O
various	O
acids	O
in	O
place	O
of	O
the	O
cyclohexanecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
CHCA	O
,	O
2a	O
)	O
in	O
the	O
reaction	O
scheme	O
.	O

The	O
five	O
acids	O
are	O
4	I-IUPAC
-	I-IUPAC
fluorobenzoic	I-IUPAC
acid	I-IUPAC
(	O
FB	O
,	O
2b	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbenzoic	I-IUPAC
acid	I-IUPAC
(	O
MeFB	O
,	O
2c	O
)	O
,	O
trans	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorocyclohexanecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
FC	O
,	O
2d	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
FMeB	O
,	O
2e	O
)	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
NFMeB	O
,	O
2f	O
)	O
(	O
see	O
Scheme	O
1	O
)	O
.	O

These	O
compounds	O
were	O
radiolabeled	O
with	O
fluorine	O
-	O
18	O
,	O
and	O
their	O
biological	O
properties	O
were	O
evaluated	O
in	O
rats	O
and	O
compared	O
with	O
those	O
of	O
[	O
11C	O
]	O
carbonyl	O
WAY	O
100635	O
(	O
[	O
carbonyl	O
-	O
11C	O
]	O
4a	O
)	O
.	O

[	O
Carbonyl	O
-	O
11C	O
]	O
4a	O
cleared	O
the	O
brain	O
with	O
a	O
biological	O
half	O
-	O
life	O
averaging	O
41	O
min	O
.	O

The	O
metabolite	O
-	O
corrected	O
blood	O
radioactivity	O
had	O
a	O
half	O
-	O
life	O
of	O
29	O
min	O
.	O

[	O
18F	O
]	O
FCWAY	O
(	O
[	O
18F	O
]	O
4d	O
)	O
gave	O
half	O
-	O
lives	O
and	O
intercepts	O
comparable	O
to	O
[	O
carbonyl	O
-	O
11C	O
]	O
4a	O
in	O
the	O
brain	O
,	O
but	O
the	O
blood	O
clearance	O
was	O
faster	O
.	O

[	O
18F	O
]	O
FBWAY	O
(	O
[	O
18F	O
]	O
4b	O
)	O
showed	O
an	O
early	O
rapid	O
net	O
efflux	O
from	O
the	O
whole	O
brain	O
,	O
clearing	O
with	O
a	O
biological	O
half	O
-	O
life	O
of	O
35	O
min	O
.	O

The	O
metabolite	O
-	O
corrected	O
blood	O
half	O
-	O
life	O
was	O
41	O
min	O
.	O

The	O
comparable	O
whole	O
brain	O
and	O
blood	O
half	O
-	O
lives	O
for	O
Me	O
[	O
18F	O
]	O
FBWAY	O
(	O
[	O
18F	O
]	O
4c	O
)	O
were	O
16	O
and	O
18	O
min	O
,	O
respectively	O
.	O

For	O
each	O
compound	O
,	O
the	O
corresponding	O
carboxylic	O
acid	O
was	O
identified	O
as	O
a	O
major	O
metabolite	O
in	O
blood	O
.	O

Fluoride	O
was	O
also	O
found	O
after	O
injection	O
of	O
[	O
18F	O
]	O
4d	O
.	O

However	O
,	O
for	O
all	O
compounds	O
there	O
was	O
a	O
good	O
correlation	O
(	O
R	O
&	O
gt	O
;	O
0.97	O
)	O
between	O
the	O
differential	O
uptake	O
ratio	O
(	O
DUR	O
,	O
(	O
%	O
ID	O
/	O
g	O
)	O
x	O
body	O
weight	O
(	O
g	O
)	O
/	O
100	O
)	O
in	O
individual	O
rat	O
brain	O
regions	O
at	O
30	O
min	O
after	O
injection	O
and	O
the	O
concentration	O
of	O
receptors	O
as	O
determined	O
by	O
in	O
vitro	O
quantitative	O
autoradiography	O
in	O
rat	O
.	O

Specific	O
binding	O
ratios	O
[	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
/	O
cerebellum	O
-	O
1	O
]	O
in	O
control	O
studies	O
for	O
cortex	O
(	O
Ctx	O
)	O
and	O
hippocampus	O
(	O
H	O
)	O
were	O
higher	O
for	O
[	O
carbonyl	O
-	O
11C	O
]	O
4a	O
and	O
[	O
18F	O
]	O
4d	O
compared	O
to	O
[	O
18F	O
]	O
4b	O
and	O
[	O
18F	O
]	O
4c	O
.	O

[	O
18F	O
]	O
4d	O
has	O
similar	O
pharmacokinetic	O
properties	O
and	O
comparable	O
specific	O
binding	O
ratios	O
to	O
[	O
carbonyl	O
-	O
11C	O
]	O
4a	O
.	O

Fifty	O
nanomoles	O
of	O
4a	O
blocked	O
only	O
30%	O
of	O
the	O
specific	O
binding	O
of	O
[	O
18F	O
]	O
4d	O
,	O
while	O
complete	O
blockade	O
was	O
obtained	O
from	O
co	O
-	O
injection	O
of	O
200	O
nmol	O
of	O
4a	O
(	O
H	O
/	O
Cb	O
-	O
1	O
from	O
17.2	O
to	O
0.6	O
)	O
.	O

[	O
18F	O
]	O
4b	O
and	O
[	O
18F	O
]	O
4c	O
showed	O
lower	O
specific	O
binding	O
ratios	O
than	O
[	O
carbonyl	O
-	O
11C	O
]	O
4a	O
and	O
[	O
18F	O
]	O
4d	O
.	O

[	O
18F	O
]	O
4c	O
was	O
superior	O
to	O
[	O
18F	O
]	O
4b	O
since	O
its	O
specific	O
binding	O
was	O
more	O
readily	O
blocked	O
by	O
4a	O
.	O

These	O
studies	O
suggest	O
that	O
[	O
18F	O
]	O
4c	O
should	O
be	O
a	O
useful	O
compound	O
to	O
assess	O
dynamic	O
changes	O
in	O
serotonin	O
levels	O
while	O
[	O
18F	O
]	O
4d	O
,	O
with	O
its	O
high	O
contrast	O
and	O
F	O
-	O
18	O
label	O
,	O
should	O
provide	O
better	O
statistics	O
and	O
quantification	O
for	O
static	O
measurement	O
of	O
5	O
-	O
HT1A	O
receptor	O
distribution	O
.	O

A	O
conformationally	O
defined	O
retinoic	O
acid	O
analog	O
(	O
1	O
)	O
which	O
contains	O
a	O
dimethylene	O
bridge	O
to	O
maintain	O
the	O
6	O
-	O
s	O
-	O
trans	O
orientation	O
for	O
two	O
terminal	O
double	O
bonds	O
in	O
the	O
polyene	O
chain	O
was	O
synthesized	O
.	O

A	O
Reformatsky	O
reaction	O
was	O
utilized	O
to	O
extend	O
the	O
polyene	O
chain	O
of	O
the	O
starting	O
enone	O
,	O
which	O
provided	O
exclusively	O
the	O
9Z	O
-	O
configuration	O
for	O
the	O
intermediate	O
aldehyde	O
.	O

A	O
Horners	O
-	O
Emmons	O
condensation	O
with	O
this	O
aldehyde	O
then	O
produced	O
retinoic	O
acid	O
analogs	O
with	O
both	O
9Z	O
-	O
and	O
9Z	O
,	O
13Z	O
-	O
configurations	O
.	O

An	O
I2	O
-	O
catalyzed	O
isomerization	O
of	O
the	O
intermediate	O
9Z	I-IUPAC
-	I-IUPAC
aldehyde	I-IUPAC
yielded	O
the	O
all	I-IUPAC
-	I-IUPAC
E	I-IUPAC
-	I-IUPAC
aldehyde	I-IUPAC
,	O
which	O
was	O
olefinated	O
as	O
above	O
to	O
yield	O
the	O
(	I-PARTIUPAC
all	I-PARTIUPAC
-	I-PARTIUPAC
E	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
13Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
analogs	I-MODIFIER
of	O
1	O
.	O

Each	O
configurational	O
isomer	O
of	O
1	O
was	O
evaluated	O
for	O
its	O
ability	O
to	O
inhibit	O
the	O
binding	O
of	O
retinoic	O
acid	O
to	O
CRABP	O
(	O
chick	O
skin	O
)	O
and	O
to	O
inhibit	O
the	O
chemical	O
induction	O
of	O
ornithine	O
decarboxylase	O
in	O
mouse	O
skin	O
.	O

In	O
each	O
assay	O
(	O
all	O
-	O
E	O
)	O
-	O
1	O
was	O
the	O
most	O
active	O
isomer	O
,	O
and	O
this	O
activity	O
was	O
comparable	O
to	O
or	O
better	O
than	O
that	O
for	O
(	I-IUPAC
all	I-IUPAC
-	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
.	O

(	O
all	O
-	O
E	O
)	O
-	O
1	O
and	O
(	O
13Z	O
)	O
-	O
1	O
were	O
both	O
shown	O
to	O
be	O
equally	O
effective	O
as	O
(	I-IUPAC
13Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
in	O
suppressing	O
the	O
proliferation	O
of	O
human	O
sebaceous	O
cells	O
in	O
vitro	O
.	O

(	O
all	O
-	O
E	O
)	O
-	O
1	O
was	O
further	O
evaluated	O
for	O
its	O
ability	O
to	O
prevent	O
the	O
induction	O
of	O
mouse	O
skin	O
papillomas	O
and	O
to	O
induce	O
signs	O
of	O
vitamin	O
A	O
toxicity	O
in	O
mice	O
.	O

The	O
cancer	O
chemopreventive	O
activity	O
of	O
(	O
all	O
-	O
E	O
)	O
-	O
1	O
was	O
comparable	O
to	O
that	O
of	O
(	I-IUPAC
all	I-IUPAC
-	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
,	O
and	O
the	O
toxicity	O
was	O
comparable	O
to	O
or	O
slightly	O
better	O
than	O
that	O
of	O
the	O
natural	O
vitamin	O
.	O

A	O
number	O
of	O
3,4	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
ribonucleosides	I-MODIFIER
were	O
synthesized	O
and	O
tested	O
for	O
their	O
biological	O
activity	O
.	O

Glycosylation	O
of	O
persilylated	O
as	O
well	O
as	O
nonsilylated	O
3	I-IUPAC
-	I-IUPAC
bromoallopurinol	I-IUPAC
with	O
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranose	I-IUPAC
(	O
4	O
)	O
provided	O
the	O
key	O
intermediate	O
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
5a	O
)	O
.	O

Similar	O
glycosylations	O
of	O
3	I-IUPAC
-	I-IUPAC
cyanoallopurinol	I-IUPAC
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
allopurinol	I-IUPAC
furnished	O
the	O
corresponding	O
protected	O
N	I-IUPAC
-	I-IUPAC
1	I-IUPAC
glycosyl	I-IUPAC
derivatives	I-MODIFIER
(	O
5b	O
and	O
5c	O
)	O
.	O

Debenzoylation	O
of	O
these	O
nucleosides	O
(	O
5a	O
-	O
c	O
)	O
gave	O
the	O
corresponding	O
3	I-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
cyano	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
allopurinol	I-IUPAC
nucleosides	I-MODIFIER
(	O
6a	O
-	O
c	O
)	O
.	O

The	O
site	O
of	O
glycosylation	O
and	O
anomeric	O
configuration	O
of	O
6a	O
and	O
6c	O
were	O
assigned	O
on	O
the	O
basis	O
of	O
spectral	O
studies	O
as	O
well	O
as	O
conversion	O
to	O
allopurinol	O
ribonucleoside	O
,	O
whereas	O
the	O
structural	O
assignment	O
of	O
6b	O
was	O
made	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
.	O

Conventional	O
functional	O
group	O
transformation	O
of	O
5a	O
and	O
5b	O
provided	O
a	O
number	O
of	O
novel	O
3	O
-	O
substituted	O
allopurinol	O
nucleosides	O
,	O
which	O
included	O
10a	O
and	O
18a	O
-	O
d	O
.	O

Glycosylation	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
14	O
)	O
with	O
4	O
and	O
subsequent	O
debenzoylation	O
gave	O
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
ribonucleoside	I-MODIFIER
(	O
13a	O
)	O
from	O
which	O
3,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
13b	O
)	O
was	O
obtained	O
by	O
amination	O
.	O

Thiation	O
of	O
5b	O
,	O
followed	O
by	O
deblocking	O
,	O
gave	O
3	I-IUPAC
-	I-IUPAC
cyanothiopurinol	I-IUPAC
ribonucleoside	I-MODIFIER
(	O
20	O
)	O
.	O

All	O
of	O
these	O
compounds	O
were	O
tested	O
in	O
vitro	O
against	O
certain	O
viruses	O
,	O
tumor	O
cells	O
,	O
and	O
the	O
parasite	O
Leishmania	O
tropica	O
.	O

Among	O
the	O
3	O
-	O
substituted	O
allopurinol	O
nucleosides	O
,	O
18b	O
and	O
18c	O
showed	O
significant	O
activity	O
against	O
Para	O
3	O
virus	O
and	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
growth	O
of	O
L1210	O
and	O
P388	O
leukemia	O
.	O

Compound	O
20	O
exhibited	O
the	O
most	O
significant	O
broad	O
-	O
spectrum	O
in	O
vitro	O
antiviral	O
and	O
antitumor	O
activity	O
.	O

3	I-IUPAC
-	I-IUPAC
Bromoallopurinol	I-IUPAC
ribonucleoside	I-MODIFIER
(	O
6a	O
)	O
was	O
found	O
to	O
be	O
more	O
active	O
than	O
allopurinol	O
ribonucleoside	O
against	O
Leishmania	O
tropica	O
within	O
human	O
macrophages	O
in	O
vitro	O
.	O

The	O
synthesis	O
of	O
10	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
analogues	I-MODIFIER
of	O
the	O
potent	O
antitumor	O
agent	O
8,10	I-IUPAC
-	I-IUPAC
dideazaminopterin	I-IUPAC
is	O
described	O
.	O

Alkylation	O
of	O
appropriate	O
alpha	O
-	O
alkyl	O
homoterephthalate	O
esters	O
with	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
deazapteridine	I-IUPAC
afforded	O
10	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
8,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acid	I-IUPAC
diesters	I-IUPAC
.	O

Ester	O
cleavage	O
and	O
decarboxylation	O
at	O
C	O
-	O
10	O
were	O
accomplished	O
by	O
heating	O
with	O
sodium	O
cyanide	O
in	O
Me2SO	O
at	O
170-180	O
degrees	O
C	O
to	O
afford	O
the	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
8,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acids	I-IUPAC
.	O

The	O
acids	O
were	O
coupled	O
with	O
diethyl	O
glutamate	O
,	O
followed	O
by	O
saponification	O
,	O
to	O
give	O
the	O
10	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
8,10	I-IUPAC
-	I-IUPAC
dideazaminopterins	I-IUPAC
.	O

The	O
compounds	O
were	O
potent	O
inhibitors	O
of	O
growth	O
in	O
folate	O
-	O
dependent	O
bacteria	O
,	O
Streptococcus	O
faecium	O
and	O
Lactobacillus	O
casei	O
.	O

The	O
10	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
and	O
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
analogues	I-MODIFIER
gave	O
the	O
highest	O
percent	O
increases	O
in	O
life	O
span	O
for	O
mice	O
infected	O
with	O
L1210	O
leukemia	O
with	O
ILS	O
values	O
of	O
+	O
203	O
and	O
+	O
235%	O
,	O
respectively	O
.	O

Of	O
a	O
series	O
of	O
58	O
aliphatic	O
nucleoside	O
analogues	O
,	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydroxypropyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
[	O
(	O
S	O
)	O
-	O
DHPA	O
]	O
proved	O
to	O
be	O
the	O
most	O
active	O
congener	O
,	O
when	O
assayed	O
for	O
antiviral	O
activity	O
in	O
primary	O
rabbit	O
kidney	O
cell	O
cultures	O
challenged	O
with	O
either	O
vaccinia	O
or	O
vesicular	O
stomatitis	O
virus	O
.	O

Whereas	O
most	O
analogues	O
derived	O
from	O
substituted	O
purine	O
and	O
pyrimidine	O
bases	O
and	O
bearing	O
various	O
hydroxy	I-MODIFIER
-	I-MODIFIER
or	O
amino	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
alkyl	I-IUPAC
chains	B-MODIFIER
did	O
not	O
show	O
evidence	O
of	O
antiviral	O
activity	O
at	O
a	O
concentration	O
of	O
2	O
mM	O
,	O
(	O
S	O
)	O
-	O
DHPA	O
inhibited	O
both	O
vaccinia	O
and	O
vesicular	O
stomatitis	O
virus	O
replication	O
at	O
0.05-0.1	O
mM	O
.	O

For	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diazidopropyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
and	O
some	O
di	I-MODIFIER
-	I-MODIFIER
and	O
trihydroxybutyl	I-MODIFIER
analogues	I-MODIFIER
of	O
DHPA	O
,	O
viz	O
.	O

,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2RS	I-IUPAC
,	I-IUPAC
3SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydroxybutylladenine	I-IUPAC
,	O
9	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
RS	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
or	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydroxybutyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
,	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
3R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3,4	I-IUPAC
-	I-IUPAC
trihydroxybutyl	I-IUPAC
]	I-IUPAC
adenine	I-IUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
adenin	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
,	O
an	O
antiviral	O
effect	O
was	O
noted	O
at	O
a	O
concentration	O
of	O
0.5-1	O
mM	O
.	O

Several	O
N	O
(	O
1	O
)	O
-	O
substituted	O
polyamines	O
containing	O
various	O
spacer	O
units	O
between	O
nitrogen	O
centers	O
were	O
synthesized	O
as	O
their	O
respective	O
HCl	O
salts	O
.	O

The	O
N	O
(	O
1	O
)	O
-	O
substituents	O
included	O
benzyl	I-IUPAC
,	O
naphthalen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
,	O
anthracen	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
,	O
and	O
pyren	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
.	O

The	O
polyamine	O
spacer	O
units	O
ranged	O
from	O
generic	O
(	O
4,4	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
,	O
4,3	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
,	O
and	O
diaminooctane	O
)	O
spacers	O
to	O
more	O
exotic	O
[	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
)	I-IUPAC
ethanoxy	I-IUPAC
-	I-IUPAC
containing	I-MODIFIER
diamine	B-IUPAC
,	O
hydroxylated	I-MODIFIER
4,3	B-IUPAC
-	I-IUPAC
triamine	I-IUPAC
,	O
and	O
cyclohexylene	O
-	O
containing	O
triamine	O
]	O
spacers	O
.	O

Two	O
control	O
compounds	O
were	O
also	O
evaluated	O
:	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
anthracen	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
butylamine	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
anthracen	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
butanediamine	I-IUPAC
.	O

Biological	O
activities	O
in	O
L1210	O
(	O
murine	O
leukemia	O
)	O
,	O
alpha	I-IUPAC
-	I-IUPAC
difluoromethylornithine	I-IUPAC
(	O
DFMO	O
)	O
-	O
treated	O
L1210	O
,	O
and	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
and	O
its	O
polyamine	O
transport	O
-	O
deficient	O
mutant	O
(	O
CHO	O
-	O
MG	O
)	O
cell	O
lines	O
were	O
investigated	O
via	O
IC	O
(	O
50	O
)	O
cytotoxicity	O
determinations	O
.	O

K	O
(	O
i	O
)	O
values	O
for	O
spermidine	O
uptake	O
were	O
also	O
determined	O
in	O
L1210	O
cells	O
.	O

Of	O
the	O
series	O
studied	O
,	O
the	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
system	I-MODIFIER
6	O
had	O
significantly	O
higher	O
IC	O
(	O
50	O
)	O
values	O
(	O
lower	O
cytotoxicity	O
)	O
in	O
the	O
L1210	O
,	O
CHO	O
,	O
and	O
CHO	O
-	O
MG	O
cell	O
lines	O
.	O

A	O
cellular	O
debenzylation	O
process	O
was	O
observed	O
in	O
L1210	O
cells	O
with	O
6	O
and	O
generated	O
"	O
free	O
"	O
homospermidine	O
.	O

The	O
size	O
of	O
the	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
arylmethyl	I-IUPAC
substituent	I-MODIFIER
had	O
direct	O
bearing	O
on	O
the	O
observed	O
cytotoxicity	O
in	O
CHO	O
-	O
MG	O
cells	O
.	O

The	O
N	I-PARTIUPAC
(	I-PARTIUPAC
1	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
naphthalenylmethyl	I-PARTIUPAC
,	O
N	I-PARTIUPAC
(	I-PARTIUPAC
1	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
anthracenylmethyl	I-PARTIUPAC
,	O
and	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyrenylmethyl	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
triamines	I-IUPAC
had	O
similar	O
toxicity	O
(	O
IC	O
(	O
50	O
)	O
s	O
:	O
approximately	O
0.5	O
microM	O
)	O
in	O
CHO	O
cells	O
,	O
which	O
have	O
an	O
active	O
polyamine	O
transporter	O
(	O
PAT	O
)	O
.	O

However	O
,	O
this	O
series	O
had	O
IC	O
(	O
50	O
)	O
values	O
of	O
&	O
gt	O
;	O
100	O
microM	O
,	O
66.7	O
microM	O
,	O
and	O
15.5	O
microM	O
,	O
respectively	O
,	O
in	O
CHO	O
-	O
MG	O
cells	O
,	O
which	O
are	O
PAT	O
-	O
deficient	O
.	O

The	O
observed	O
lower	O
cytotoxicity	O
in	O
the	O
PAT	O
-	O
deficient	O
CHO	O
-	O
MG	O
cell	O
line	O
supported	O
the	O
premise	O
that	O
the	O
conjugates	O
use	O
PAT	O
for	O
cellular	O
entry	O
.	O

In	O
general	O
,	O
moderate	O
affinities	O
for	O
the	O
polyamine	O
transporter	O
were	O
observed	O
for	O
the	O
N	I-IUPAC
-	I-IUPAC
arylmethyl	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
series	I-MODIFIER
with	O
their	O
L1210	O
K	O
(	O
i	O
)	O
values	O
all	O
near	O
3	O
microM	O
.	O

In	O
summary	O
,	O
the	O
4,4	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
motif	I-MODIFIER
was	O
shown	O
to	O
facilitate	O
entry	O
of	O
polyamine	O
conjugates	O
into	O
cells	O
containing	O
active	O
polyamine	O
transporters	O
.	O

The	O
utility	O
of	O
polyamines	O
as	O
vectors	O
for	O
the	O
intracellular	O
transport	O
of	O
iron	O
chelators	O
is	O
further	O
described	O
.	O

Consistent	O
with	O
earlier	O
results	O
with	O
polyamine	O
analogues	O
,	O
these	O
studies	O
underscore	O
the	O
importance	O
of	O
charge	O
in	O
the	O
design	O
of	O
polyamine	O
-	O
vectored	O
chelators	O
.	O

Four	O
polyamine	O
conjugates	O
are	O
synthesized	O
,	O
two	O
of	O
terephthalic	O
acid	O
[	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
)	I-IUPAC
benzoylspermine	I-IUPAC
(	O
7	O
)	O
and	O
its	O
methyl	O
ester	O
(	O
6	O
)	O
]	O
and	O
two	O
of	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dihydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
thiazolecarboxylic	I-IUPAC
acid	I-IUPAC
[	O
(	O
S	O
)	O
-	O
4'	O
-	O
(	O
HO	O
)	O
-	O
DADFT	O
]	O
[	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
12	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5,9	I-IUPAC
-	I-IUPAC
diazadodecyl	I-IUPAC
-	I-IUPAC
oxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
thiazolecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
10	O
)	O
and	O
its	O
ethyl	O
ester	O
(	O
9	O
)	O
]	O
.	O

These	O
four	O
molecules	O
were	O
evaluated	O
in	O
murine	O
leukemia	O
L1210	O
cells	O
for	O
their	O
impact	O
on	O
cell	O
proliferation	O
(	O
48	O
-	O
and	O
96	O
-	O
h	O
IC	O
(	O
50	O
)	O
values	O
)	O
,	O
their	O
ability	O
to	O
compete	O
with	O
spermidine	O
for	O
the	O
polyamine	O
transport	O
apparatus	O
(	O
K	O
(	O
i	O
)	O
)	O
,	O
and	O
their	O
intracellular	O
accumulation	O
.	O

The	O
data	O
revealed	O
that	O
when	O
neutral	O
molecules	O
(	O
cargo	O
fragments	O
)	O
were	O
fixed	O
to	O
the	O
polyamine	O
vector	O
,	O
the	O
conjugates	O
competed	O
well	O
with	O
spermidine	O
for	O
transport	O
and	O
were	O
accumulated	O
intracellularly	O
to	O
millimolar	O
levels	O
.	O

However	O
,	O
this	O
was	O
not	O
the	O
case	O
when	O
the	O
cargo	O
fragments	O
were	O
negatively	O
charged	O
.	O

Metabolic	O
studies	O
of	O
the	O
polyamine	O
-	O
vectored	O
(	O
S	O
)	O
-	O
4'	O
-	O
(	O
HO	O
)	O
-	O
DADFTs	O
in	O
rodents	O
indicated	O
that	O
not	O
only	O
did	O
the	O
expected	O
deaminopropylation	O
step	O
occur	O
,	O
but	O
also	O
a	O
surprisingly	O
high	O
level	O
of	O
oxidative	O
deamination	O
at	O
the	O
terminal	O
primary	O
nitrogens	O
took	O
place	O
.	O

Finally	O
,	O
the	O
iron	O
-	O
clearing	O
efficiency	O
of	O
the	O
(	O
S	O
)	O
-	O
4'	O
-	O
(	O
HO	O
)	O
-	O
DADFT	O
conjugates	O
was	O
determined	O
in	O
a	O
bile	O
-	O
duct	O
-	O
cannulated	O
rodent	O
model	O
.	O

Attaching	O
the	O
ligand	O
to	O
a	O
polyamine	O
vector	O
had	O
a	O
profound	O
effect	O
on	O
increasing	O
the	O
iron	O
-	O
clearing	O
efficiency	O
of	O
this	O
chelator	O
relative	O
to	O
its	O
parent	O
drug	O
.	O

This	O
publication	O
describes	O
the	O
synthesis	O
and	O
optimization	O
of	O
a	O
novel	O
series	O
of	O
stilbene	O
endothelin	O
antagonists	O
.	O

Analysis	O
of	O
the	O
SAR	O
established	O
for	O
previous	O
papers	O
in	O
this	O
series	O
prompted	O
the	O
design	O
and	O
synthesis	O
of	O
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzyloxyphenyl	I-IUPAC
)	I-IUPAC
pent	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acid	I-IUPAC
3	O
which	O
was	O
found	O
to	O
be	O
a	O
moderately	O
active	O
inhibitor	O
of	O
the	O
binding	O
of	O
[	O
125I	O
]	O
ET	O
-	O
1	O
to	O
ETA	O
receptors	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O

More	O
interestingly	O
,	O
the	O
intermediate	O
compound	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzyloxyphenyl	I-IUPAC
)	I-IUPAC
propenoic	I-IUPAC
acid	I-IUPAC
5	O
was	O
equiactive	O
with	O
3	O
.	O

Optimization	O
of	O
5	O
resulted	O
in	O
the	O
preparation	O
of	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethoxy	I-IUPAC
)	I-IUPAC
)	I-IUPAC
phenylprope	I-IUPAC
noic	I-IUPAC
acid	I-IUPAC
18	O
(	O
RPR111723	O
)	O
which	O
had	O
an	O
IC50	O
in	O
the	O
binding	O
assay	O
of	O
80	O
nM	O
on	O
the	O
ETA	O
receptor	O
and	O
a	O
pKB	O
of	O
6.5	O
in	O
the	O
functional	O
assay	O
,	O
measured	O
on	O
rat	O
aortic	O
strips	O
.	O

Reduction	O
of	O
the	O
acid	O
group	O
of	O
5	O
gave	O
the	O
first	O
nonacidic	O
ETA	O
antagonist	O
in	O
our	O
series	O
,	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzyloxyphenoxy	I-IUPAC
)	I-IUPAC
prop2	I-IUPAC
-	I-IUPAC
enol	I-IUPAC
6	O
with	O
an	O
IC50	O
of	O
20	O
microM	O
.	O

Optimization	O
of	O
6	O
resulted	O
in	O
the	O
preparation	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
pro	I-IUPAC
p	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enol	I-IUPAC
33	O
with	O
an	O
IC50	O
of	O
300	O
nM	O
on	O
the	O
ETA	O
receptor	O
.	O

Several	O
potentially	O
bis	O
(	O
alkylating	O
)	O
bis	O
(	O
quinones	O
)	O
(	O
3-5	O
)	O
and	O
1,4	I-PARTIUPAC
-	I-PARTIUPAC
and	O
1,3	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
alkylating	I-IUPAC
)	I-IUPAC
monoquinones	I-IUPAC
(	O
6-13	O
)	O
belonging	O
to	O
general	O
structure	O
2,2	I-PARTIUPAC
'	I-PARTIUPAC
-	I-PARTIUPAC
ethylenebis	I-PARTIUPAC
[	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	O
leaving	O
group	O
)	O
methyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
benzoquinone	I-PARTIUPAC
]	I-PARTIUPAC
(	O
3-5	O
)	O
and	O
2,5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2,6	I-PARTIUPAC
-	I-PARTIUPAC
bis	I-PARTIUPAC
[	I-PARTIUPAC
(	O
leaving	O
group	O
)	O
methyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
benzoquinone	I-PARTIUPAC
water	O
-	O
soluble	O
and	O
-	O
insoluble	O
classes	O
were	O
prepared	O
by	O
oxidative	O
demethylation	O
of	O
the	O
corresponding	O
tetramethoxydiphenylethanes	O
(	O
17-19	O
)	O
and	O
dimethoxybenzenes	O
(	O
24	O
,	O
27	O
,	O
36-39	O
)	O
,	O
respectively	O
.	O

Methods	O
employed	O
for	O
the	O
preparation	O
of	O
tetramethoxydiphenylethane	I-IUPAC
intermediates	O
involved	O
(	O
1	O
)	O
arylmethyl	O
bromide	O
coupling	O
and	O
(	O
2	O
)	O
catalytic	O
hydrogenation	O
of	O
stilbene	O
intermediates	O
derived	O
via	O
Wittig	O
reaction	O
of	O
(	O
arylmethyl	O
)	O
phosphonium	O
salts	O
with	O
aryl	O
aldehydes	O
.	O

However	O
,	O
in	O
biological	O
investigations	O
using	O
a	O
subcutaneous	O
B16	O
(	O
hypoxic	O
)	O
melanoma	O
tumor	O
in	O
BDF1	O
hybrid	O
mice	O
with	O
cyclophosphamide	O
as	O
positive	O
control	O
the	O
most	O
interesting	O
series	O
of	O
structurally	O
related	O
analogues	O
were	O
the	O
potentially	O
monoalkylating	O
monoquinones	O
of	O
the	O
2	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	O
leaving	O
group	O
)	O
methyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
benzoquinone	I-PARTIUPAC
type	I-MODIFIER
(	O
i.e.	O
,	O
14	O
and	O
15	O
)	O
having	O
water	O
-	O
insoluble	O
(	O
acetoxy	O
)	O
and	O
water	O
-	O
solubilizing	O
(	O
succinate	O
)	O
groups	O
.	O

Serial	O
measurements	O
of	O
tumor	O
size	O
,	O
and	O
evaluation	O
of	O
increased	O
life	O
span	O
,	O
in	O
response	O
to	O
drug	O
treatment	O
also	O
revealed	O
potentially	O
1,4	I-PARTIUPAC
-	I-PARTIUPAC
bis	I-PARTIUPAC
(	O
alkylating	O
)	O
(	I-PARTIUPAC
bromomethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
quinone	I-PARTIUPAC
7	O
and	O
1,3	I-PARTIUPAC
-	I-PARTIUPAC
bis	I-PARTIUPAC
(	O
alkylating	O
)	O
(	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
quinone	I-PARTIUPAC
10	O
to	O
have	O
variable	O
activity	O
,	O
but	O
none	O
of	O
the	O
potentially	O
bis	O
(	O
alkylating	O
)	O
bis	O
(	O
quinones	O
)	O
showed	O
antitumor	O
properties	O
in	O
this	O
model	O
.	O

The	O
homologous	O
series	O
of	O
acidic	O
amino	O
acids	O
,	O
ranging	O
from	O
aspartic	O
acid	O
(	O
1	O
)	O
to	O
2	I-IUPAC
-	I-IUPAC
aminosuberic	I-IUPAC
acid	I-IUPAC
(	O
5	O
)	O
,	O
and	O
the	O
corresponding	O
series	O
of	O
3	I-IUPAC
-	I-IUPAC
isoxazolol	I-IUPAC
bioisosteres	I-MODIFIER
of	O
these	O
amino	O
acids	O
,	O
ranging	O
from	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
(	O
AMAA	O
,	O
6	O
)	O
to	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
hexanoic	I-IUPAC
acid	I-IUPAC
(	O
10	O
)	O
,	O
were	O
tested	O
as	O
ligands	O
for	O
metabotropic	O
excitatory	O
amino	O
acid	O
receptors	O
(	O
mGlu1	O
alpha	O
,	O
mGlu2	O
,	O
mGlu4a	O
,	O
and	O
mGlu6	O
)	O
.	O

Whereas	O
AMAA	O
(	O
6	O
)	O
and	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propinoic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
,	O
7	O
)	O
are	O
potent	O
and	O
highly	O
selective	O
agonists	O
at	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
(	O
NMDA	O
)	O
and	O
AMPA	O
receptors	O
,	O
respectively	O
,	O
the	O
higher	O
homologue	O
of	O
AMPA	O
(	O
7	O
)	O
,	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
butyric	I-IUPAC
acid	I-IUPAC
(	O
homo	O
-	O
AMPA	O
,	O
8	O
)	O
,	O
is	O
inactive	O
at	O
ionotropic	O
excitatory	O
amino	O
acid	O
receptors	O
.	O

Homo	O
-	O
AMPA	O
(	O
8	O
)	O
,	O
which	O
is	O
a	O
3	I-IUPAC
-	I-IUPAC
isoxazolol	I-IUPAC
bioisostere	I-MODIFIER
of	O
2	I-IUPAC
-	I-IUPAC
aminoadipic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
,	O
was	O
,	O
however	O
,	O
shown	O
to	O
be	O
a	O
specific	O
and	O
rather	O
potent	O
agonist	O
at	O
mGlu6	O
,	O
approximately	O
4	O
times	O
weaker	O
than	O
the	O
nonselective	O
excitatory	O
amino	O
acid	O
receptor	O
agonist	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
.	O

2	I-IUPAC
-	I-IUPAC
Aminoadipic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
,	O
which	O
shows	O
a	O
complex	O
excitatory	O
amino	O
acid	O
synaptic	O
pharmacology	O
,	O
was	O
an	O
agonist	O
at	O
mGlu6	O
as	O
well	O
as	O
mGlu2	O
.	O

AMPA	O
(	O
7	O
)	O
and	O
the	O
higher	O
homologue	O
of	O
homo	O
-	O
AMPA	O
(	O
8	O
)	O
,	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
pentanoic	I-IUPAC
acid	I-IUPAC
(	O
9	O
)	O
,	O
showed	O
relatively	O
weak	O
agonist	O
effects	O
at	O
mGlu6	O
.	O

It	O
is	O
concluded	O
that	O
homo	O
-	O
AMPA	O
(	O
8	O
)	O
is	O
likely	O
to	O
be	O
a	O
useful	O
tool	O
for	O
studies	O
of	O
the	O
pharmacology	O
and	O
physiological	O
role	O
of	O
mGlu6	O
.	O

We	O
describe	O
a	O
new	O
versatile	O
synthesis	O
of	O
this	O
homologue	O
of	O
AMPA	O
and	O
the	O
synthesis	O
of	O
compound	O
10	O
.	O

A	O
novel	O
series	O
of	O
(	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
difluorocyclopentyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylacetamides	I-IUPAC
was	O
designed	O
and	O
synthesized	O
based	O
on	O
the	O
structure	O
and	O
biological	O
profiles	O
of	O
an	O
active	O
metabolite	O
2	O
of	O
our	O
prototype	O
muscarinic	O
M	O
(	O
3	O
)	O
receptor	O
selective	O
antagonist	O
1	O
,	O
to	O
develop	O
a	O
potent	O
,	O
long	O
-	O
acting	O
,	O
orally	O
active	O
M	O
(	O
3	O
)	O
antagonist	O
for	O
the	O
treatment	O
of	O
urinary	O
tract	O
disorders	O
,	O
irritable	O
bowel	O
syndrome	O
,	O
and	O
respiratory	O
disorders	O
.	O

Investigation	O
of	O
(	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
difluorocyclopentyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylacetamides	I-IUPAC
containing	O
a	O
phenyl	I-IUPAC
or	O
heterocyclic	I-IUPAC
ring	B-MODIFIER
as	O
the	O
piperidinyl	I-IUPAC
side	B-MODIFIER
chain	I-MODIFIER
in	O
place	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pentenyl	I-IUPAC
moiety	I-MODIFIER
of	O
15a	O
revealed	O
that	O
this	O
acid	O
moiety	O
was	O
a	O
versatile	O
template	O
for	O
improving	O
the	O
selectivity	O
for	O
M	O
(	O
3	O
)	O
over	O
M	O
(	O
2	O
)	O
receptors	O
in	O
comparison	O
with	O
the	O
corresponding	O
cyclopentylphenylacetic	O
acid	O
group	O
.	O

However	O
,	O
since	O
the	O
in	O
vitro	O
metabolic	O
stability	O
of	O
these	O
analogues	O
was	O
insufficient	O
compared	O
with	O
that	O
of	O
2	O
,	O
further	O
derivatization	O
was	O
performed	O
by	O
introducing	O
an	O
appropriate	O
hydrophilic	O
group	O
into	O
the	O
phenyl	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
ring	I-MODIFIER
.	O

Thus	O
,	O
the	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
aminopyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
analogue	I-MODIFIER
15y	O
exhibiting	O
190	O
-	O
fold	O
selectivity	O
for	O
M	O
(	O
3	O
)	O
receptors	O
(	O
K	O
(	O
i	O
)	O
=	O
2.8	O
nM	O
)	O
over	O
M	O
(	O
2	O
)	O
receptors	O
(	O
K	O
(	O
i	O
)	O
=	O
530	O
nM	O
)	O
in	O
a	O
human	O
binding	O
assay	O
and	O
good	O
in	O
vitro	O
metabolic	O
stability	O
in	O
dog	O
and	O
human	O
hepatic	O
microsomes	O
was	O
identified	O
.	O

This	O
compound	O
has	O
excellent	O
oral	O
activity	O
at	O
4	O
h	O
after	O
oral	O
dosing	O
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
inhibiting	O
methacholine	O
-	O
induced	O
bronchoconstriction	O
in	O
dogs	O
,	O
and	O
may	O
be	O
useful	O
in	O
clinical	O
situations	O
in	O
which	O
M	O
(	O
3	O
)	O
over	O
M	O
(	O
2	O
)	O
selectivity	O
is	O
desirable	O
.	O

3	I-IUPAC
-	I-IUPAC
Methoxy	I-IUPAC
-	I-IUPAC
4,5,6,7	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
20a	O
)	O
,	O
or	O
the	O
corresponding	O
3	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
analogue	I-MODIFIER
(	O
20b	O
)	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4,5,6	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
51	O
)	O
were	O
synthesized	O
by	O
regioselective	O
chromic	O
acid	O
oxidation	O
of	O
the	O
respective	O
bicyclic	O
tetrahydrobenzenes	O
19a	O
,	O
b	O
and	O
50	O
,	O
and	O
they	O
were	O
used	O
as	O
key	O
intermediates	O
for	O
the	O
syntheses	O
of	O
the	O
target	O
zwitterionic	O
3	I-IUPAC
-	I-IUPAC
isoxazolols	I-IUPAC
8-15	O
and	O
3	I-IUPAC
-	I-IUPAC
isothiazolols	I-IUPAC
16	O
and	O
17	O
,	O
respectively	O
.	O

These	O
reaction	O
sequences	O
involved	O
different	O
reductive	O
processes	O
.	O

Whereas	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4,5,6,7	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisoxazole	I-IUPAC
(	O
8	O
,	O
exo	O
-	O
THPO	O
)	O
was	O
synthesized	O
via	O
aluminum	O
amalgam	O
reduction	O
of	O
oxime	O
22a	O
or	O
22b	O
,	O
compounds	O
9	O
,	O
11-13	O
,	O
and	O
15-17	O
were	O
obtained	O
via	O
reductive	O
aminations	O
.	O

Compound	O
10	O
was	O
synthesized	O
via	O
N	O
-	O
ethylation	O
of	O
the	O
N	O
-	O
Boc	O
-	O
protected	O
primary	O
amine	O
25	O
.	O

The	O
enantiomers	O
of	O
8	O
were	O
obtained	O
in	O
high	O
enantiomeric	O
purities	O
(	O
ee	O
&	O
gt	O
;	O
/	O
=	O
99.1%	O
)	O
via	O
the	O
diastereomeric	O
amides	O
32	O
and	O
33	O
,	O
synthesized	O
from	O
the	O
primary	O
amine	O
23b	O
and	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methoxyphenylacetyl	I-IUPAC
chloride	I-IUPAC
and	O
subsequent	O
separation	O
by	O
preparative	O
HPLC	O
.	O

The	O
enantiomers	O
of	O
9	O
were	O
prepared	O
analogously	O
from	O
the	O
secondary	O
amine	O
27	O
.	O

On	O
the	O
basis	O
of	O
X	O
-	O
ray	O
crystallographic	O
analyses	O
,	O
the	O
configuration	O
of	O
oxime	O
22a	O
was	O
shown	O
to	O
be	O
E	O
and	O
the	O
absolute	O
configurations	O
of	O
(	O
-	O
)	O
-	O
8	O
x	O
HCl	O
and	O
(	O
+	O
)	O
-	O
9	O
x	O
HBr	O
were	O
established	O
to	O
be	O
R	O
.	O

The	O
effects	O
of	O
the	O
target	O
compounds	O
on	O
GABA	O
uptake	O
mechanisms	O
in	O
vitro	O
were	O
measured	O
using	O
a	O
rat	O
brain	O
synaptosomal	O
preparation	O
and	O
primary	O
cultures	O
of	O
mouse	O
cortical	O
neurons	O
and	O
glia	O
cells	O
(	O
astrocytes	O
)	O
.	O

Whereas	O
the	O
classical	O
GABA	O
uptake	O
inhibitor	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nipecotic	I-IUPAC
acid	I-IUPAC
(	O
2	O
)	O
,	O
nonselectively	O
inhibits	O
neuronal	O
(	O
IC	O
(	O
50	O
)	O
=	O
12	O
microM	O
)	O
and	O
glial	O
(	O
IC	O
(	O
50	O
)	O
=	O
16	O
microM	O
)	O
GABA	O
uptake	O
and	O
4,5,6,7	I-IUPAC
-	I-IUPAC
tetrahydroisoxazolo	I-IUPAC
	I-IUPAC
	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
cpyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
1	O
,	O
THPO	O
)	O
shows	O
some	O
selectivity	O
for	O
glial	O
(	O
IC	O
(	O
50	O
)	O
=	O
268	O
microM	O
)	O
versus	O
neuronal	O
(	O
IC	O
(	O
50	O
)	O
=	O
530	O
microM	O
)	O
GABA	O
uptake	O
,	O
exo	O
-	O
THPO	O
(	O
8	O
)	O
was	O
shown	O
to	O
be	O
more	O
potent	O
as	O
an	O
inhibitor	O
of	O
glial	O
(	O
IC	O
(	O
50	O
)	O
=	O
200	O
microM	O
)	O
rather	O
than	O
neuronal	O
(	O
IC	O
(	O
50	O
)	O
=	O
900	O
microM	O
)	O
GABA	O
uptake	O
.	O

This	O
selectivity	O
was	O
more	O
pronounced	O
for	O
9	O
,	O
which	O
showed	O
IC	O
(	O
50	O
)	O
values	O
of	O
40	O
and	O
500	O
microM	O
as	O
an	O
inhibitor	O
of	O
glial	O
and	O
neuronal	O
GABA	O
uptake	O
,	O
respectively	O
.	O

These	O
effects	O
of	O
8	O
and	O
9	O
proved	O
to	O
be	O
enantioselective	O
,	O
(	O
R	O
)	O
-	O
(	O
-	O
)	O
-	O
8	O
and	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-	O
9	O
being	O
the	O
active	O
inhibitors	O
of	O
both	O
uptake	O
systems	O
.	O

The	O
selectivity	O
of	O
9	O
as	O
a	O
glial	O
GABA	O
uptake	O
inhibitor	O
was	O
largely	O
lost	O
by	O
replacing	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
of	O
9	O
by	O
an	O
ethyl	I-IUPAC
group	B-MODIFIER
,	O
compound	O
10	O
being	O
an	O
almost	O
equipotent	O
inhibitor	O
of	O
glial	O
(	O
IC	O
(	O
50	O
)	O
=	O
280	O
microM	O
)	O
and	O
neuronal	O
(	O
IC	O
(	O
50	O
)	O
=	O
400	O
microM	O
)	O
GABA	O
uptake	O
.	O

The	O
remaining	O
target	O
compounds	O
,	O
11-17	O
,	O
were	O
very	O
weak	O
or	O
inactive	O
as	O
inhibitors	O
of	O
both	O
uptake	O
systems	O
.	O

Compounds	O
9-13	O
and	O
15	O
were	O
shown	O
to	O
be	O
essentially	O
inactive	O
against	O
isoniazide	O
-	O
induced	O
convulsions	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
.	O

The	O
isomeric	I-MODIFIER
pivaloyloxymethyl	B-IUPAC
derivatives	B-MODIFIER
of	O
9	O
,	O
compounds	O
43	O
and	O
44	O
,	O
were	O
synthesized	O
and	O
tested	O
as	O
potential	O
prodrugs	O
in	O
the	O
isoniazide	O
animal	O
model	O
.	O

Both	O
43	O
(	O
ED	O
(	O
50	O
)	O
=	O
150	O
micromol	O
/	O
kg	O
)	O
and	O
44	O
(	O
ED	O
(	O
50	O
)	O
=	O
220	O
micromol	O
/	O
kg	O
)	O
showed	O
anticonvulsant	O
effects	O
,	O
and	O
this	O
effect	O
of	O
43	O
was	O
shown	O
to	O
reside	O
in	O
the	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-	O
enantiomer	O
,	O
45	O
(	O
ED	O
(	O
50	O
)	O
=	O
44	O
micromol	O
/	O
kg	O
)	O
.	O

Compound	O
9	O
also	O
showed	O
anticonvulsant	O
activity	O
when	O
administered	O
intracerebroventricularly	O
(	O
ED	O
(	O
50	O
)	O
=	O
59	O
nmol	O
)	O
.	O

A	O
series	O
of	O
substituted	O
racemic	O
naphthofurans	O
were	O
synthesized	O
as	O
"	O
hybrid	O
"	O
molecules	O
of	O
the	O
two	O
major	O
prototypical	O
hallucinogenic	O
drug	O
classes	O
,	O
the	O
phenethylamines	O
and	O
the	O
tryptamines	O
/	O
ergolines	O
.	O

Although	O
it	O
was	O
hypothesized	O
that	O
these	O
new	O
agents	O
might	O
possess	O
high	O
affinity	O
for	O
the	O
serotonin	O
5	O
-	O
HT2A	O
/	O
2C	O
receptor	O
subtypes	O
,	O
unexpected	O
affinity	O
for	O
muscarinic	O
receptors	O
was	O
observed	O
.	O

The	O
compounds	O
initially	O
synthesized	O
for	O
this	O
study	O
were	O
(	I-PARTIUPAC
+	I-PARTIUPAC
/	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
anti	I-PARTIUPAC
-	I-PARTIUPAC
and	O
syn	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2a	I-IUPAC
,	I-IUPAC
3,4,5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
furan	I-IUPAC
(	O
4a	O
,	O
b	O
)	O
,	O
respectively	O
,	O
and	O
their	O
8	O
-	O
bromo	O
derivatives	O
4c	O
,	O
d	O
,	O
respectively	O
.	O

The	O
brominated	O
primary	O
amines	O
4c	O
,	O
d	O
were	O
assayed	O
initially	O
for	O
activity	O
in	O
the	O
two	O
-	O
lever	O
drug	O
discrimination	O
(	O
DD	O
)	O
paradigm	O
in	O
rats	O
trained	O
to	O
discriminate	O
saline	O
from	O
LSD	O
tartrate	O
(	O
0	O
.	O

08	O
mg	O
/	O
kg	O
)	O
.	O

Also	O
,	O
4c	O
,	O
d	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
compete	O
against	O
agonist	O
and	O
antagonist	O
radioligands	O
at	O
cloned	O
human	O
5	O
-	O
HT2A	O
,	O
5	O
-	O
HT2B	O
,	O
and	O
5	O
-	O
HT2C	O
receptors	O
.	O

After	O
the	O
syn	O
diastereomers	O
were	O
found	O
to	O
have	O
the	O
highest	O
activity	O
in	O
these	O
preliminary	O
assays	O
,	O
the	O
N	O
-	O
alkylated	O
analogues	O
syn	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2a	I-IUPAC
,	I-IUPAC
3,4	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
furan	I-IUPAC
(	O
4e	O
)	O
and	O
syn	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dipropyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2a	I-IUPAC
,	I-IUPAC
3,4,5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
furan	I-IUPAC
(	O
4f	O
)	O
were	O
prepared	O
and	O
assayed	O
for	O
their	O
affinities	O
at	O
[	O
3H	O
]	O
ketanserin	O
-	O
labeled	O
5	O
-	O
HT2A	O
and	O
[	O
3H	O
]	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
-	O
labeled	O
5	O
-	O
HT1A	O
sites	O
.	O

All	O
of	O
the	O
molecules	O
tested	O
had	O
relatively	O
low	O
affinity	O
for	O
serotonin	O
receptors	O
,	O
yet	O
a	O
preliminary	O
screen	O
indicated	O
that	O
compound	O
4d	O
had	O
affinity	O
for	O
muscarinic	O
receptors	O
.	O

Thus	O
,	O
4b	O
,	O
d	O
,	O
e	O
were	O
evaluated	O
for	O
their	O
affinity	O
at	O
muscarinic	O
M1	O
-	O
M5	O
receptors	O
and	O
also	O
assessed	O
for	O
their	O
functional	O
characteristics	O
at	O
the	O
M1	O
and	O
M2	O
isoforms	O
.	O

Compound	O
4d	O
had	O
affinities	O
of	O
12-33	O
nM	O
at	O
all	O
of	O
the	O
muscarinic	O
sites	O
,	O
with	O
4b	O
,	O
e	O
having	O
much	O
lower	O
affinity	O
.	O

All	O
three	O
compounds	O
fully	O
antagonized	O
the	O
effects	O
of	O
carbachol	O
at	O
the	O
M1	O
receptor	O
,	O
while	O
only	O
4d	O
completely	O
antagonized	O
carbachol	O
at	O
the	O
M2	O
receptor	O
.	O

The	O
fact	O
that	O
the	O
naphthofurans	O
lack	O
LSD	O
-	O
like	O
activity	O
suggests	O
that	O
they	O
do	O
not	O
bind	O
to	O
the	O
serotonin	O
receptor	O
in	O
a	O
way	O
such	O
that	O
the	O
tricyclic	O
naphthofuran	O
nucleus	O
is	O
bioisosteric	O
with	O
,	O
and	O
directly	O
superimposable	O
upon	O
,	O
the	O
A	O
,	O
B	O
,	O
and	O
C	O
rings	O
of	O
LSD	O
.	O

This	O
also	O
implies	O
,	O
therefore	O
,	O
that	O
the	O
hallucinogenic	O
phenethylamines	O
cannot	O
be	O
directly	O
superimposed	O
on	O
LSD	O
in	O
a	O
common	O
binding	O
orientation	O
for	O
these	O
two	O
chemical	O
classes	O
,	O
contrary	O
to	O
previous	O
hypotheses	O
.	O

A	O
Langendorff	O
guinea	O
pig	O
heart	O
preparation	O
served	O
for	O
the	O
assay	O
of	O
agonist	O
potency	O
of	O
a	O
series	O
of	O
26	O
2	I-IUPAC
-	I-IUPAC
aralkoxyadenosines	I-IUPAC
at	O
the	O
A1	O
and	O
A2	O
receptors	O
of	O
,	O
respectively	O
,	O
the	O
atrioventricular	O
node	O
(	O
conduction	O
block	O
)	O
and	O
coronary	O
arteries	O
(	O
vasodilation	O
)	O
.	O

All	O
of	O
the	O
analogues	O
are	O
weak	O
agonists	O
at	O
the	O
A1	O
receptor	O
,	O
requiring	O
concentrations	O
greater	O
than	O
9	O
microM	O
to	O
cause	O
second	O
degree	O
heart	O
block	O
.	O

At	O
the	O
A2	O
receptor	O
2	I-IUPAC
-	I-IUPAC
phenethoxyadenosine	I-IUPAC
is	O
the	O
most	O
potent	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
phenylalkyladenosines	I-IUPAC
.	O

The	O
activity	O
of	O
ring	O
-	O
substituted	O
(	O
F	O
,	O
Cl	O
,	O
CH3	O
,	O
and	O
OCH3	O
)	O
2	I-IUPAC
-	I-IUPAC
phenethoxyadenosines	I-IUPAC
increases	O
ortho	O
less	O
than	O
meta	O
less	O
than	O
para	O
.	O

The	O
EC50s	O
of	O
coronary	O
vasoactivity	O
of	O
several	O
para	O
-	O
substituted	O
analogues	O
are	O
in	O
the	O
subnanomolar	O
range	O
.	O

The	O
most	O
potent	O
analogue	O
,	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
19	O
,	O
has	O
an	O
EC50	O
for	O
coronary	O
vasodilation	O
of	O
190	O
pM	O
and	O
an	O
A1	O
/	O
A2	O
selectivity	O
ratio	O
of	O
44,000	O
.	O

Aryl	O
groups	O
such	O
as	O
thienyl	O
,	O
indoloyl	O
,	O
or	O
naphthyl	O
also	O
support	O
A2	O
agonist	O
activity	O
.	O

Although	O
2	I-IUPAC
-	I-IUPAC
oxoadenosine	I-IUPAC
is	O
3	O
times	O
more	O
vasoactive	O
than	O
2	I-IUPAC
-	I-IUPAC
aminoadenosine	I-IUPAC
,	O
the	O
activities	O
of	O
the	O
phenyl	I-IUPAC
derivatives	B-MODIFIER
are	O
markedly	O
different	O
;	O
2	I-IUPAC
-	I-IUPAC
phenoxyadenosine	I-IUPAC
is	O
23	O
times	O
weaker	O
than	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
CV	O
-	O
1808	O
)	O
.	O

In	O
an	O
attempt	O
to	O
increase	O
the	O
combined	O
toxicity	O
of	O
the	O
metabolic	O
end	O
-	O
products	O
[	O
acrolein	O
(	O
4	O
)	O
and	O
phosphoramide	O
mustard	O
(	O
3	O
)	O
]	O
from	O
cyclophosphamide	O
(	O
1	O
)	O
,	O
the	O
analog	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
trifluoromethyl	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorine	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
2	O
,	O
6	I-IUPAC
-	I-IUPAC
trifluoromethylcyclophosphamide	I-IUPAC
)	O
was	O
synthesized	O
and	O
its	O
metabolism	O
and	O
antitumor	O
activity	O
studied	O
.	O

Following	O
metabolism	O
of	O
2	O
by	O
rat	O
liver	O
microsomes	O
the	O
predicted	O
formation	O
of	O
4,4,4	I-IUPAC
-	I-IUPAC
trifluorocrotonaldehyde	I-IUPAC
(	O
5	O
)	O
was	O
confirmed	O
by	O
isolation	O
and	O
identification	O
,	O
by	O
mass	O
spectrometry	O
,	O
of	O
its	O
dinitrophenylhydrazone	O
.	O

The	O
therapeutic	O
indices	O
(	O
LD50	O
-	O
/	O
ID90	O
)	O
for	O
2	O
against	O
the	O
ADJ	O
/	O
PC6	O
mouse	O
tumor	O
and	O
the	O
Walker	O
256	O
tumor	O
in	O
the	O
rat	O
were	O
28.6	O
and	O
7.7	O
,	O
respectively	O
,	O
and	O
were	O
lower	O
than	O
the	O
corresponding	O
values	O
for	O
1	O
(	O
91.8	O
and	O
33.2	O
,	O
respectively	O
)	O
although	O
the	O
toxicities	O
toward	O
Walker	O
cells	O
in	O
a	O
bioassay	O
system	O
of	O
1	O
and	O
2	O
following	O
microsomal	O
metabolism	O
were	O
similar	O
.	O

In	O
order	O
to	O
study	O
the	O
toxicities	O
of	O
4	O
and	O
5	O
released	O
under	O
drug	O
metabolizing	O
conditions	O
independently	O
of	O
the	O
production	O
of	O
a	O
toxic	O
mustard	O
the	O
analogs	I-MODIFIER
18	O
[	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorine	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
]	O
and	O
6	O
[	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
trifluoromethyl	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorine	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
]	O
were	O
also	O
synthesized	O
.	O

The	O
release	O
of	O
5	O
from	O
6	O
following	O
metabolism	O
was	O
confirmed	O
and	O
shown	O
by	O
use	O
of	O
the	O
bioassay	O
system	O
to	O
be	O
an	O
event	O
of	O
similar	O
toxicity	O
to	O
release	O
of	O
4	O
from	O
18	O
;	O
in	O
vivo	O
,	O
however	O
,	O
6	O
(	O
LD50	O
330	O
mg	O
/	O
kg	O
)	O
was	O
more	O
toxic	O
to	O
mice	O
than	O
18	O
(	O
LD50	O
greater	O
than	O
500	O
mg	O
/	O
kg	O
)	O
.	O

There	O
is	O
reported	O
the	O
first	O
four	O
members	O
of	O
heteroarotinoids	O
,	O
the	O
names	O
of	O
which	O
are	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1b	O
)	O
,	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylchroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1c	O
)	O
,	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxothiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1d	O
)	O
,	O
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylchroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
1e	O
)	O
.	O

IR	O
,	O
1H	O
NMR	O
and	O
13C	O
NMR	O
data	O
have	O
been	O
recorded	O
for	O
each	O
compound	O
and	O
support	O
the	O
structural	O
assignments	O
.	O

To	O
provide	O
a	O
firm	O
basis	O
for	O
comparison	O
purposes	O
of	O
future	O
analogues	O
,	O
an	O
X	O
-	O
ray	O
analysis	O
was	O
performed	O
on	O
a	O
single	O
crystal	O
of	O
ethyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
1b	O
)	O
and	O
a	O
precursor	O
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
methyl	I-IUPAC
ketone	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
(	O
18	O
)	O
.	O

These	O
data	O
for	O
the	O
heteroarotinoid	O
1b	O
revealed	O
that	O
the	O
two	O
aryl	O
ring	O
systems	O
were	O
nearly	O
perpendicular	O
in	O
each	O
of	O
the	O
two	O
molecules	O
present	O
in	O
the	O
unit	O
cell	O
(	O
86.37	O
degrees	O
and	O
84.17	O
degrees	O
,	O
respectively	O
)	O
.	O

The	O
space	O
group	O
for	O
both	O
molecules	O
was	O
P1	O
in	O
triclinic	O
systems	O
.	O

Unit	O
cell	O
dimensions	O
(	O
at	O
15	O
degrees	O
C	O
)	O
are	O
as	O
follows	O
:	O
for	O
1b	O
,	O
a	O
=	O
20.568	O
(	O
6	O
)	O
A	O
,	O
b	O
=	O
14.760	O
(	O
3	O
)	O
A	O
,	O
c	O
=	O
7.679	O
(	O
2	O
)	O
A	O
,	O
alpha	O
=	O
113.33	O
(	O
2	O
)	O
degrees	O
,	O
beta	O
=	O
79.45	O
(	O
2	O
)	O
degrees	O
,	O
gamma	O
=	O
79.98	O
(	O
2	O
)	O
degrees	O
,	O
Z	O
=	O
4	O
;	O
for	O
18	O
,	O
a	O
=	O
9.292	O
(	O
5	O
)	O
A	O
,	O
b	O
=	O
9.291	O
(	O
5	O
)	O
A	O
,	O
c	O
=	O
7.951	O
(	O
3	O
)	O
A	O
,	O
alpha	O
=	O
102.16	O
(	O
3	O
)	O
degrees	O
,	O
beta	O
=	O
77.49	O
(	O
3	O
)	O
degrees	O
,	O
gamma	O
=	O
79.60	O
(	O
4	O
)	O
degrees	O
,	O
Z	O
=	O
2	O
.	O

The	O
sulfur	O
-	O
containing	O
ring	O
is	O
in	O
a	O
distorted	O
half	O
-	O
chair	O
in	O
1b	O
and	O
the	O
methyl	O
carbon	O
C	O
(	O
12	O
)	O
is	O
shown	O
to	O
be	O
trans	O
to	O
H	O
(	O
13	O
)	O
at	O
the	O
C	O
(	O
11	O
)	O
-	O
C	O
(	O
13	O
)	O
bond	O
.	O

The	O
biological	O
activity	O
of	O
these	O
arotinoids	O
was	O
determined	O
in	O
the	O
tracheal	O
organ	O
culture	O
assay	O
and	O
compared	O
with	O
trans	O
-	O
retinoic	O
acid	O
for	O
ability	O
to	O
reverse	O
keratinization	O
in	O
vitamin	O
A	O
deficient	O
hamsters	O
.	O

The	O
ester	O
1b	O
displayed	O
activity	O
about	O
one	O
-	O
half	O
log	O
unit	O
less	O
than	O
that	O
of	O
the	O
reference	O
while	O
1c	O
and	O
1e	O
had	O
activity	O
nearly	O
one	O
log	O
until	O
less	O
than	O
trans	O
-	O
retinoic	O
acid	O
.	O

The	O
sulfoxide	O
was	O
the	O
least	O
active	O
of	O
the	O
heteroretinoids	O
.	O

A	O
series	O
of	O
new	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
and	O
uridine	I-IUPAC
compounds	B-MODIFIER
(	O
11	O
,	O
16	O
)	O
was	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
HOI	O
to	O
the	O
vinyl	O
substituent	O
of	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10a	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10b	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
vinyluridine	I-IUPAC
(	O
10c	O
)	O
,	O
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
4b	O
)	O
.	O

Treatment	O
of	O
the	O
iodohydrins	O
11a	O
-	O
c	O
with	O
methanolic	O
sulfuric	O
acid	O
afforded	O
the	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
(	O
12a	O
-	O
c	O
)	O
.	O

In	O
contrast	O
,	O
reaction	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
11a	O
)	O
with	O
sodium	O
carbonate	O
in	O
methanol	O
afforded	O
a	O
mixture	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
13	O
)	O
and	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
furano	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
14	O
)	O
.	O

The	O
most	O
active	O
compound	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
12a	O
,	O
ID50	O
=	O
0.1	O
micrograms	O
/	O
mL	O
)	O
,	O
which	O
exhibited	O
antiviral	O
activity	O
(	O
HSV	O
-	O
1	O
)	O
100	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
analogue	I-MODIFIER
(	O
11a	O
)	O
,	O
was	O
less	O
active	O
than	O
IVDU	O
or	O
acyclovir	O
(	O
ID50	O
=	O
0.01-0.1	O
micrograms	O
/	O
mL	O
range	O
)	O
.	O

The	O
C	O
-	O
5	O
substituent	O
in	O
the	O
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
series	I-MODIFIER
was	O
a	O
determinant	O
of	O
cytotoxic	O
activity	O
,	O
as	O
determined	O
in	O
the	O
in	O
vitro	O
L1210	O
screen	O
,	O
where	O
the	O
relative	O
activity	O
order	O
was	O
CH	O
(	O
OH	O
)	O
CHI2	O
(	O
16	O
)	O
greater	O
than	O
CH	O
(	O
OMe	O
)	O
CH2I	O
(	O
12a	O
)	O
greater	O
than	O
CH	O
(	O
OH	O
)	O
CH2I	O
(	O
11a	O
)	O
congruent	O
to	O
CH	O
(	O
OH	O
)	O
CH2OMe	O
(	O
13	O
)	O
.	O

The	O
2'	O
-	O
substituent	O
was	O
also	O
a	O
determinant	O
of	O
cytotoxic	O
activity	O
in	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
(	O
11a	O
-	O
c	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
series	I-MODIFIER
of	O
compounds	O
,	O
where	O
the	O
relative	O
activity	O
profile	O
was	O
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
greater	O
than	O
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
greater	O
than	O
uridine	I-IUPAC
(	O
11a	O
greater	O
than	O
11b	O
greater	O
than	O
or	O
equal	O
to	O
11c	O
;	O
12a	O
greater	O
than	O
12b	O
greater	O
than	O
12c	O
)	O
.	O

The	O
most	O
active	O
cytotoxic	O
agent	O
(	O
16	O
)	O
,	O
possessing	O
a	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
diiodoethyl	I-IUPAC
)	I-IUPAC
substituent	I-MODIFIER
(	O
ED50	O
=	O
0.77	O
micrograms	O
/	O
mL	O
)	O
,	O
exhibited	O
an	O
activity	O
approaching	O
that	O
of	O
melphalan	O
(	O
ED50	O
=	O
0.15	O
micrograms	O
/	O
mL	O
)	O
.	O

All	O
compounds	O
tested	O
,	O
except	O
for	O
13	O
and	O
14	O
,	O
exhibited	O
high	O
affinity	O
(	O
Ki	O
=	O
0.035-0.22	O
mM	O
range	O
relative	O
to	O
deoxyuridine	O
,	O
Ki	O
=	O
0.125	O
)	O
for	O
the	O
murine	O
NBMPR	O
-	O
sensitive	O
erythrocyte	O
nucleoside	O
transport	O
system	O
,	O
suggesting	O
that	O
these	O
iodohydrins	O
are	O
good	O
permeants	O
of	O
cell	O
membranes	O
.	O

A	O
number	O
of	O
derivatives	O
structurally	O
related	O
to	O
cirazoline	O
(	O
1	O
)	O
were	O
synthesized	O
and	O
studied	O
with	O
the	O
purpose	O
of	O
modulating	O
alpha2	O
-	O
adrenoreceptors	O
selectivity	O
versus	O
both	O
alpha1	O
-	O
adrenoreceptors	O
and	O
I2	O
imidazoline	O
binding	O
sites	O
.	O

The	O
most	O
potent	O
alpha2	O
-	O
agonist	O
was	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yloxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazole	I-IUPAC
(	O
7	O
)	O
,	O
whose	O
key	O
pharmacophoric	O
features	O
closely	O
matched	O
those	O
found	O
in	O
the	O
alpha2	O
-	O
agonist	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
exo	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylprop	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
exo	I-IUPAC
-	I-IUPAC
norbornyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxazoline	I-IUPAC
(	O
15	O
)	O
.	O

(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
7	O
was	O
the	O
most	O
potent	O
of	O
the	O
two	O
enantiomers	O
,	O
confirming	O
the	O
stereospecificity	O
of	O
the	O
interaction	O
with	O
alpha2	O
-	O
adrenoreceptors	O
.	O

This	O
eutomer	O
was	O
tested	O
on	O
two	O
algesiometric	O
paradigms	O
and	O
,	O
because	O
of	O
the	O
interaction	O
with	O
alpha2	O
-	O
adrenoreceptors	O
,	O
showed	O
a	O
potent	O
and	O
long	O
-	O
lasting	O
antinociceptive	O
activity	O
,	O
since	O
it	O
was	O
abolished	O
by	O
the	O
selective	O
alpha2	O
-	O
antagonist	O
RX821002	O
.	O

A	O
series	O
of	O
substituted	I-MODIFIER
1,4	B-IUPAC
-	I-IUPAC
dihydronaphthoquinones	I-IUPAC
,	O
hydroindoloquinones	O
,	O
benzofuran	I-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydroquinones	I-IUPAC
,	O
and	O
benzothiophene	I-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydroquinones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibitory	O
activity	O
against	O
5	O
-	O
lipoxygenase	O
.	O

These	O
compounds	O
were	O
found	O
to	O
be	O
active	O
in	O
vitro	O
for	O
LTC4	O
/	O
D4	O
inhibition	O
with	O
the	O
potencies	O
(	O
IC50	O
's	O
)	O
ranging	O
from	O
0.2	O
to	O
85	O
microM	O
.	O

Active	O
1,4	I-IUPAC
-	I-IUPAC
dihydronaphthoquinone	I-IUPAC
acetates	I-IUPAC
(	O
IC50	O
less	O
than	O
20	O
microM	O
)	O
were	O
evaluated	O
in	O
an	O
ex	O
vivo	O
LTB4	O
inhibition	O
assay	O
.	O

The	O
acetates	O
of	O
1,4	I-IUPAC
-	I-IUPAC
dihydronaphthoquinones	I-IUPAC
containing	O
the	O
alkyl	O
substituent	O
(	O
s	O
)	O
(	O
2	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
,	O
11	O
,	O
and	O
2,3	I-IUPAC
-	I-IUPAC
diethyl	I-IUPAC
,	O
15	O
)	O
exhibited	O
the	O
best	O
activity	O
in	O
LTC4	O
/	O
D4	O
inhibition	O
(	O
IC50	O
=	O
0.2-0.4	O
microM	O
,	O
in	O
vitro	O
)	O
as	O
well	O
as	O
in	O
LTB4	O
inhibition	O
(	O
60-75%	O
inhibition	O
)	O
.	O

In	O
the	O
present	O
investigation	O
,	O
the	O
last	O
two	O
possible	O
modes	O
of	O
generating	O
conformationally	O
semirigid	O
diacylglycerol	O
(	O
DAG	O
)	O
analogues	O
embedded	O
into	O
five	O
-	O
membered	O
ring	O
lactones	O
as	O
templates	O
III	O
and	O
IV	O
are	O
investigated	O
.	O

The	O
first	O
two	O
templates	O
studied	O
in	O
previous	O
investigations	O
corresponded	O
to	O
2	I-IUPAC
-	I-IUPAC
deoxyribonolactone	I-IUPAC
(	O
template	O
I	O
)	O
and	O
4,4	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
gamma	I-IUPAC
-	I-IUPAC
butyrolactone	I-IUPAC
(	O
template	O
II	O
)	O
,	O
with	O
the	O
latter	O
producing	O
potent	O
protein	O
kinase	O
C	O
(	O
PK	O
-	O
C	O
)	O
ligands	O
with	O
low	O
nanomolar	O
binding	O
affinities	O
.	O

The	O
templates	O
reported	O
in	O
this	O
work	O
correspond	O
to	O
2,3	I-PARTIUPAC
-	I-PARTIUPAC
dideoxy	I-PARTIUPAC
-	I-PARTIUPAC
L	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	I-PARTIUPAC
threo	I-PARTIUPAC
-	I-PARTIUPAC
hexono	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
lactone	I-PARTIUPAC
(	O
template	O
III	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
deoxyapiolactone	I-IUPAC
(	O
template	O
IV	O
)	O
.	O

Compounds	O
constructed	O
with	O
the	O
dideoxy	I-PARTIUPAC
-	I-PARTIUPAC
L	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	I-PARTIUPAC
threo	I-PARTIUPAC
-	I-PARTIUPAC
hexono	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
lactone	I-PARTIUPAC
template	O
were	O
synthesized	O
stereospecifically	O
from	O
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glucal	I-IUPAC
and	O
L	I-IUPAC
-	I-IUPAC
galactono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
,	O
respectively	O
.	O

Compounds	O
constructed	O
with	O
the	O
2	I-IUPAC
-	I-IUPAC
deoxyapiolactone	I-IUPAC
template	O
were	O
synthesized	O
stereoselectively	O
from	O
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
isopropylidene	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
apiose	I-IUPAC
.	O

Inhibition	O
of	O
the	O
binding	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
phorbol	I-IUPAC
-	I-IUPAC
12,13	I-IUPAC
-	I-IUPAC
dibutyrate	I-IUPAC
to	O
PK	O
-	O
C	O
alpha	O
showed	O
that	O
only	O
the	O
threo	O
-	O
isomer	O
,	O
5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetradecanoyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
hexono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
(	O
2	O
)	O
was	O
a	O
good	O
PK	O
-	O
C	O
ligand	O
(	O
Ki	O
=	O
1	O
microM	O
)	O
.	O

The	O
rest	O
of	O
the	O
ligands	O
had	O
poorer	O
affinities	O
with	O
Ki	O
values	O
between	O
10	O
and	O
28	O
microM	O
.	O

With	O
these	O
results	O
,	O
the	O
order	O
of	O
importance	O
of	O
five	O
-	O
membered	O
ring	O
lactones	O
as	O
competent	O
templates	O
for	O
the	O
construction	O
of	O
semirigid	O
DAG	O
surrogates	O
with	O
effective	O
PK	O
-	O
C	O
binding	O
affinity	O
can	O
be	O
established	O
as	O
II	O
&	O
gt	O
;	O
&	O
gt	O
;	O
I	O
approximately	O
III	O
&	O
gt	O
;	O
IV	O
.	O

Structure	O
-	O
activity	O
relationships	O
have	O
been	O
investigated	O
for	O
inhibition	O
of	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
ATM	O
kinase	O
by	O
a	O
series	O
of	O
pyran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
thiopyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
and	O
pyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O

A	O
wide	O
range	O
of	O
IC50	O
values	O
were	O
observed	O
for	O
pyranones	O
and	O
thiopyranones	O
substituted	O
at	O
the	O
6	O
-	O
position	O
,	O
with	O
the	O
3	O
-	O
and	O
5	O
-	O
positions	O
proving	O
intolerant	O
to	O
substitution	O
.	O

Related	O
pyran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
and	O
thiopyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
showed	O
similar	O
IC50	O
values	O
against	O
DNA	O
-	O
PK	O
,	O
whereas	O
the	O
pyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
system	I-MODIFIER
proved	O
,	O
in	O
general	O
,	O
ineffective	O
at	O
inhibiting	O
DNA	O
-	O
PK	O
.	O

Extended	O
libraries	O
exploring	O
the	O
6	O
-	O
position	O
of	O
2	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
thiopyrano	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
identified	O
the	O
first	O
highly	O
potent	O
and	O
selective	O
ATM	O
inhibitor	O
2	I-IUPAC
-	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
thianthren	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
151C	O
;	O
ATM	O
;	O
IC50	O
=	O
13	O
nM	O
)	O
and	O
revealed	O
constrained	O
SARs	O
for	O
ATM	O
inhibition	O
compared	O
with	O
DNA	O
-	O
PK	O
.	O

One	O
of	O
the	O
most	O
potent	O
DNA	O
-	O
PK	O
inhibitors	O
identified	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
16	O
;	O
DNA	O
-	O
PK	O
;	O
IC50	O
=	O
220	O
nM	O
)	O
effectively	O
sensitized	O
HeLa	O
cells	O
to	O
the	O
topoisomerase	O
II	O
inhibitor	O
etoposide	O
in	O
vitro	O
.	O

Radiolabeled	O
m	I-IUPAC
-	I-IUPAC
iodobenzylguanidine	I-IUPAC
(	O
MIBG	O
)	O
is	O
a	O
tumor	O
-	O
seeking	O
radioactive	O
drug	O
used	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
pheochromocytomas	O
and	O
neuroblastomas	O
.	O

It	O
is	O
transported	O
into	O
the	O
tumor	O
cells	O
by	O
the	O
neuronal	O
norepinephrine	O
(	O
NE	O
)	O
transporter	O
(	O
NET	O
)	O
which	O
is	O
expressed	O
in	O
almost	O
all	O
neuroblastoma	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
synthesis	O
and	O
some	O
pharmacological	O
properties	O
of	O
a	O
series	O
of	O
fluorescent	O
compounds	O
structurally	O
related	O
to	O
the	O
NET	O
substrate	O
,	O
MIBG	O
,	O
or	O
to	O
the	O
NET	O
inhibitors	O
,	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2R	I-IUPAC
,	I-IUPAC
3S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cocaine	I-IUPAC
and	O
nisoxetine	O
.	O

Three	O
of	O
10	O
synthesized	O
fluorescent	O
compounds	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthylmethyl	I-IUPAC
)	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
(	O
1	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
(	O
2	O
)	O
,	O
and	O
(	I-IUPAC
2R	I-IUPAC
,	I-IUPAC
3S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
tropanyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
naphthalene	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sulfonate	I-IUPAC
(	O
6	O
)	O
,	O
exhibited	O
high	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
about	O
50	O
nM	O
)	O
for	O
the	O
NET	O
.	O

The	O
nisoxetine	O
derivatives	O
8	O
(	O
rac	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthale	I-IUPAC
nesulfonamide	I-IUPAC
)	O
and	O
9	O
(	O
rac	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2,1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoxadiazole	I-IUPAC
)	O
and	O
especially	O
the	O
guanidine	O
derivative	O
4	O
(	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
butadienyl	I-IUPAC
)	I-IUPAC
benzyl	I-IUPAC
]	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
)	O
which	O
are	O
characterized	O
by	O
intermediate	O
affinity	O
for	O
the	O
NET	O
(	O
IC	O
(	O
50	O
)	O
370-850	O
nM	O
)	O
caused	O
significant	O
and	O
nisoxetine	O
-	O
sensitive	O
cell	O
fluorescence	O
.	O

At	O
least	O
the	O
guanidine	O
derivative	O
4	O
might	O
represent	O
a	O
potentially	O
useful	O
agent	O
for	O
imaging	O
of	O
neuroblastoma	O
cells	O
.	O

Selective	O
protection	O
of	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxoerythromycin	I-IUPAC
A	I-IUPAC
allowed	O
for	O
elimination	O
of	O
the	O
12	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyl	I-PARTIUPAC
group	I-MODIFIER
to	O
afford	O
a	O
versatile	O
12,21	O
-	O
olefin	O
intermediate	O
.	O

Further	O
modifications	O
of	O
the	O
intermediate	O
led	O
to	O
the	O
syntheses	O
of	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
12,21	I-IUPAC
-	I-IUPAC
epoxyerythromycin	I-IUPAC
B	I-IUPAC
,	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
21	I-IUPAC
-	I-IUPAC
hydroxyerythromycin	I-IUPAC
A	I-IUPAC
,	O
and	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
21	I-IUPAC
-	I-IUPAC
hydroxyerythromycin	I-IUPAC
B	I-IUPAC
.	O

All	O
three	O
compounds	O
retained	O
antibacterial	O
activity	O
against	O
several	O
organisms	O
normally	O
susceptible	O
to	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxo	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
erythromycin	I-IUPAC
A	I-IUPAC
.	O

However	O
,	O
the	O
21	O
-	O
hydroxylated	O
erythromycin	O
A	O
analogue	O
was	O
weaker	O
in	O
potency	O
than	O
the	O
corresponding	O
erythromycin	O
B	O
congener	O
and	O
much	O
weaker	O
than	O
the	O
epoxy	O
derivative	O
.	O

This	O
suggests	O
that	O
while	O
substitution	O
of	O
a	O
polar	O
functionality	O
at	O
C	O
-	O
21	O
does	O
not	O
abolish	O
antibacterial	O
activity	O
,	O
introduction	O
of	O
vicinal	O
polar	O
groups	O
at	O
both	O
C	O
-	O
12	O
and	O
C	O
-	O
21	O
may	O
lead	O
to	O
reduction	O
in	O
potency	O
.	O

Nevertheless	O
,	O
these	O
21	O
-	O
functionalized	O
derivatives	O
of	O
(	I-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
erythromycylamine	I-IUPAC
provide	O
an	O
entry	O
into	O
novel	O
analogues	O
of	O
the	O
important	O
macrolide	O
antibiotic	O
erythromycin	O
.	O

The	O
syntheses	O
of	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
,	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
5SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
20	O
)	O
,	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetamidopiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
10	O
)	O
,	O
and	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
5SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
acetamidopiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
18	O
)	O
,	O
related	O
to	O
the	O
specific	O
gamma	I-IUPAC
-	I-IUPAC
aminobutyric	I-IUPAC
acid	I-IUPAC
(	O
GABA	O
)	O
uptake	O
inhibitors	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
nipecotic	O
acid	O
)	O
and	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
21	O
)	O
,	O
are	O
described	O
.	O

Furthermore	O
,	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
14	O
)	O
,	O
related	O
to	O
the	O
specific	O
GABA	O
agonist	O
piperidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
isonipecotic	O
acid	O
)	O
,	O
has	O
been	O
synthesized	O
.	O

The	O
structures	O
of	O
4	O
,	O
10	O
,	O
14	O
,	O
18	O
,	O
and	O
20	O
have	O
been	O
established	O
by	O
270	O
-	O
MHz	O
1H	O
NMR	O
spectroscopic	O
analyses	O
.	O

The	O
affinity	O
of	O
the	O
compounds	O
for	O
the	O
GABA	O
receptors	O
and	O
for	O
the	O
neuronal	O
(	O
synaptosomal	O
)	O
GABA	O
uptake	O
system	O
in	O
vitro	O
has	O
been	O
measured	O
.	O

Compound	O
14	O
interacts	O
selectively	O
with	O
the	O
GABA	O
receptors	O
but	O
less	O
effectively	O
than	O
isonipecotic	O
acid	O
and	O
the	O
cis	O
-	O
isomer	O
22	O
.	O

Compounds	O
4	O
,	O
18	O
,	O
and	O
20	O
are	O
inhibitors	O
of	O
the	O
GABA	O
uptake	O
system	O
,	O
although	O
much	O
weaker	O
than	O
nipecotic	O
acid	O
and	O
(	I-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
21	O
)	O
.	O

Compound	O
10	O
is	O
inactive	O
in	O
both	O
test	O
systems	O
.	O

This	O
study	O
emphasizes	O
the	O
importance	O
of	O
the	O
metabolic	O
conversion	O
of	O
the	O
enantiomers	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylpiperidine	I-IUPAC
(	O
3	O
-	O
PPP	O
)	O
into	O
their	O
catechol	O
analogues	O
,	O
the	O
enantiomers	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylpiperidine	I-IUPAC
.	O

These	O
isomers	O
are	O
both	O
shown	O
to	O
be	O
excellent	O
substrates	O
for	O
COMT	O
,	O
with	O
a	O
slight	O
preference	O
for	O
the	O
S	O
-	O
(	O
-	O
)	O
enantiomer	O
.	O

Assessment	O
of	O
the	O
dopaminergic	O
activity	O
of	O
these	O
catechols	O
and	O
the	O
results	O
from	O
the	O
determination	O
of	O
brain	O
levels	O
of	O
the	O
enantiomers	O
of	O
3	O
-	O
PPP	O
and	O
their	O
metabolites	O
indicate	O
that	O
the	O
metabolites	O
probably	O
do	O
not	O
alter	O
the	O
pharmacological	O
profiles	O
established	O
for	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-	O
and	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
.	O

The	O
conversion	O
of	O
the	O
monophenols	O
into	O
catecholic	O
metabolites	O
is	O
only	O
1-5%	O
,	O
and	O
the	O
further	O
conversion	O
of	O
these	O
catecholic	O
metabolites	O
into	O
methoxylated	O
analogues	O
is	O
very	O
rapid	O
.	O

However	O
,	O
the	O
very	O
interesting	O
observation	O
was	O
made	O
that	O
,	O
when	O
inhibiting	O
COMT	O
by	O
means	O
of	O
tropolone	O
and	O
subsequently	O
treating	O
the	O
rats	O
with	O
high	O
doses	O
of	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
(	O
ip	O
)	O
,	O
postsynaptic	O
dopaminergic	O
activity	O
was	O
elicited	O
.	O

This	O
has	O
never	O
been	O
seen	O
for	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
without	O
tropolone	O
pretreatment	O
and	O
might	O
indicate	O
that	O
,	O
in	O
this	O
special	O
case	O
,	O
the	O
catecholic	O
metabolite	O
affects	O
the	O
in	O
vivo	O
pharmacological	O
profile	O
of	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
.	O

The	O
synthesis	O
of	O
a	O
range	O
of	O
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinones	I-IUPAC
with	O
potential	O
for	O
the	O
chelation	O
of	O
iron	O
(	O
III	O
)	O
is	O
described	O
.	O

The	O
pKa	O
values	O
of	O
respective	O
ligands	O
and	O
the	O
stability	O
constants	O
of	O
their	O
iron	O
(	O
III	O
)	O
complexes	O
are	O
presented	O
.	O

The	O
distribution	O
coefficient	O
values	O
of	O
a	O
range	O
of	O
48	O
hydroxypyridinones	O
and	O
their	O
corresponding	O
iron	O
(	O
III	O
)	O
complexes	O
between	O
1	O
-	O
octanol	O
and	O
MOPS	O
buffer	O
(	O
pH	O
7.4	O
)	O
are	O
reported	O
.	O

The	O
range	O
of	O
log	O
Dcomplex	O
values	O
covers	O
7	O
orders	O
of	O
magnitude	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
biphasic	O
relationship	O
between	O
the	O
distribution	O
coefficient	O
values	O
of	O
the	O
chelator	O
and	O
the	O
corresponding	O
iron	O
(	O
III	O
)	O
complexes	O
.	O

For	O
ligands	O
with	O
a	O
log	O
Dligand	O
=	O
-	O
1	O
,	O
a	O
linear	O
relationship	O
exists	O
with	O
a	O
value	O
of	O
the	O
slope	O
2.53	O
,	O
whereas	O
with	O
ligands	O
with	O
a	O
log	O
Dligand	O
&	O
lt	O
;	O
-	O
1	O
,	O
a	O
linear	O
relationship	O
exists	O
with	O
a	O
slope	O
of	O
0.49	O
.	O

The	O
reduced	O
slope	O
for	O
the	O
more	O
hydrophilic	O
molecules	O
of	O
the	O
series	O
offers	O
some	O
advantage	O
for	O
this	O
type	O
of	O
hydroxypyridinone	O
as	O
the	O
distribution	O
coefficients	O
for	O
such	O
complexes	O
do	O
not	O
change	O
so	O
rapidly	O
with	O
increasing	O
ligand	O
hydrophilicity	O
.	O

The	O
ability	O
of	O
selected	O
3	I-IUPAC
-	I-IUPAC
hydroxypyridinones	I-IUPAC
to	O
facilitate	O
the	O
excretion	O
of	O
iron	O
in	O
bile	O
was	O
investigated	O
in	O
non	O
-	O
iron	O
-	O
overloaded	O
,	O
bile	O
duct	O
-	O
cannulated	O
rats	O
and	O
in	O
a	O
[	O
59Fe	O
]	O
ferritin	O
-	O
loaded	O
rat	O
model	O
.	O

Both	O
systems	O
compare	O
the	O
ability	O
of	O
chelators	O
to	O
remove	O
iron	O
from	O
the	O
liver	O
,	O
the	O
prime	O
target	O
organ	O
in	O
thalassemia	O
.	O

The	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
are	O
demonstrated	O
to	O
be	O
orally	O
active	O
under	O
the	O
in	O
vivo	O
conditions	O
adopted	O
.	O

Thus	O
both	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
hydroxyalkyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
pyridinones	I-IUPAC
are	O
able	O
to	O
remove	O
iron	O
from	O
the	O
liver	O
.	O

Although	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
are	O
active	O
,	O
they	O
do	O
not	O
demonstrate	O
any	O
clear	O
advantage	O
over	O
Deferiprone	O
(	O
1,2	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
)	O
.	O

Indeed	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
which	O
are	O
known	O
to	O
be	O
rapidly	O
converted	O
to	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
are	O
also	O
marginally	O
superior	O
to	O
Deferiprone	O
.	O

In	O
contrast	O
,	O
2	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
which	O
is	O
not	O
metabolized	O
to	O
the	O
corresponding	O
(	O
carboxyalkyl	O
)	O
hydroxypyridinone	O
,	O
was	O
found	O
to	O
be	O
superior	O
to	O
Deferiprone	O
and	O
therefore	O
deserves	O
further	O
consideration	O
as	O
an	O
orally	O
active	O
iron	O
chelator	O
with	O
potential	O
for	O
the	O
treatment	O
of	O
iron	O
overload	O
associated	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	O
.	O

Degarelix	O
(	O
FE200486	O
,	O
Ac	O
-	O
d	O
-	O
2Nal	O
(	O
1	O
)	O
-	O
d	O
-	O
4Cpa	O
(	O
2	O
)	O
-	O
d	O
-	O
3Pal	O
(	O
3	O
)	O
-	O
Ser	O
(	O
4	O
)	O
-	O
4Aph	O
(	O
l	O
-	O
Hor	O
)	O
(	O
5	O
)	O
-	O
d	O
-	O
4Aph	O
(	O
Cbm	O
)	O
(	O
6	O
)	O
-	O
Leu	O
(	O
7	O
)	O
-	O
ILys	O
(	O
8	O
)	O
-	O
Pro	O
(	O
9	O
)	O
-	O
d	O
-	O
Ala	O
(	O
10	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
is	O
a	O
potent	O
and	O
very	O
long	O
acting	O
antagonist	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
(	O
GnRH	O
)	O
after	O
subcutaneous	O
administration	O
in	O
mammals	O
including	O
humans	O
.	O

Analogues	O
of	O
degarelix	O
were	O
synthesized	O
,	O
characterized	O
,	O
and	O
screened	O
for	O
the	O
antagonism	O
of	O
GnRH	O
-	O
induced	O
response	O
in	O
a	O
reporter	O
gene	O
assay	O
in	O
HEK	O
-	O
293	O
cells	O
expressing	O
the	O
human	O
GnRH	O
receptor	O
.	O

The	O
duration	O
of	O
action	O
was	O
also	O
determined	O
in	O
the	O
castrated	O
male	O
rat	O
assay	O
to	O
measure	O
the	O
extent	O
(	O
efficacy	O
and	O
duration	O
of	O
action	O
)	O
of	O
inhibition	O
of	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
release	O
.	O

Structurally	O
,	O
this	O
series	O
of	O
analogues	O
has	O
novel	O
substitutions	O
at	O
positions	O
3	O
,	O
7	O
,	O
and	O
8	O
and	O
N	O
(	O
alpha	O
)	O
-	O
methylation	O
at	O
positions	O
6	O
,	O
7	O
,	O
and	O
8	O
in	O
the	O
structure	O
of	O
degarelix	O
.	O

These	O
substitutions	O
were	O
designed	O
to	O
probe	O
the	O
spatial	O
limitations	O
of	O
the	O
receptor	O
's	O
cavity	O
and	O
to	O
map	O
the	O
steric	O
and	O
ionic	O
boundaries	O
.	O

Some	O
functional	O
groups	O
were	O
introduced	O
that	O
were	O
hypothesized	O
to	O
influence	O
the	O
phamacokinetic	O
properties	O
of	O
the	O
analogues	O
such	O
as	O
bioavailability	O
,	O
solubility	O
,	O
intra	O
-	O
or	O
intermolecular	O
hydrogen	O
bond	O
forming	O
capacity	O
,	O
and	O
ability	O
to	O
bind	O
carrier	O
proteins	O
.	O

Substitutions	O
at	O
positions	O
3	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
d	I-IUPAC
-	I-IUPAC
Dap	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
2.71	O
nM	O
)	O
(	O
5	O
)	O
,	O
7	O
(	O
[	I-IUPAC
Pra	I-IUPAC
(	I-IUPAC
7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
2.11	O
nM	O
)	O
(	O
16	O
)	O
,	O
and	O
8	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
delta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IGly	I-IUPAC
)	I-IUPAC
Orn	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.38	O
nM	O
)	O
(	O
20	O
)	O
and	O
N	O
-	O
methylation	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
alpha	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
Leu	I-IUPAC
(	I-IUPAC
7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.47	O
nM	O
)	O
(	O
32	O
)	O
yielded	O
analogues	O
that	O
were	O
equipotent	O
to	O
degarelix	O
(	O
2	O
)	O
in	O
vitro	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.64	O
nM	O
)	O
but	O
shorter	O
acting	O
in	O
vivo	O
.	O

Out	O
of	O
the	O
33	O
novel	O
analogues	O
tested	O
for	O
the	O
duration	O
of	O
action	O
in	O
this	O
series	O
,	O
two	O
analogues	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
epsilon	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
Lys	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.50	O
nM	O
)	O
(	O
23	O
)	O
and	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IbetaAla	I-IUPAC
)	I-IUPAC
Dap	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.98	O
nM	O
)	O
(	O
26	O
)	O
had	O
antagonist	O
potencies	O
and	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
azaline	O
B	O
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
80%	O
)	O
release	O
for	O
&	O
gt	O
;	O
72	O
h	O
after	O
sc	O
injection	O
to	O
castrated	O
male	O
rats	O
at	O
a	O
standard	O
dose	O
of	O
50	O
mug	O
/	O
rat	O
in	O
5%	O
mannitol	O
}	O
.	O

Under	O
similar	O
conditions	O
analogues	O
(	O
[	I-IUPAC
N	I-IUPAC
(	I-IUPAC
gamma	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
IGly	I-IUPAC
)	I-IUPAC
Dab	I-IUPAC
(	I-IUPAC
8	I-IUPAC
)	I-IUPAC
]	I-IUPAC
degarelix	I-IUPAC
,	O
IC	O
(	O
50	O
)	O
=	O
1.56	O
nM	O
)	O
(	O
21	O
)	O
and	O
(	O
[	O
IOrn	O
(	O
8	O
)	O
]	O
degarelix	O
,	O
IC	O
(	O
50	O
)	O
=	O
1.72	O
nM	O
)	O
(	O
18	O
)	O
had	O
a	O
longer	O
duration	O
of	O
action	O
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
96	O
h	O
)	O
release	O
}	O
than	O
azaline	O
B	O
;	O
however	O
they	O
were	O
shorter	O
acting	O
than	O
degarelix	O
.	O

Hydrophilicity	O
of	O
these	O
analogues	O
,	O
a	O
potential	O
measure	O
of	O
their	O
ability	O
to	O
be	O
formulated	O
for	O
sustained	O
release	O
,	O
was	O
determined	O
using	O
RP	O
-	O
HPLC	O
at	O
neutral	O
pH	O
yielding	O
analogues	O
with	O
shorter	O
as	O
well	O
as	O
longer	O
retention	O
times	O
.	O

No	O
correlation	O
was	O
found	O
between	O
retention	O
times	O
and	O
antagonist	O
potency	O
or	O
duration	O
of	O
action	O
.	O

At	O
physiological	O
pH	O
,	O
the	O
spatial	O
arrangement	O
of	O
the	O
three	O
charges	O
of	O
DL	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
(	O
5	O
)	O
could	O
be	O
viewed	O
as	O
similar	O
to	O
those	O
found	O
in	O
certain	O
conformations	O
of	O
the	O
two	O
excitatory	O
amino	O
acids	O
(	O
EAAs	O
)	O
-	O
-	O
aspartic	O
and	O
glutamic	O
acids	O
.	O

Given	O
significant	O
binding	O
to	O
one	O
or	O
more	O
EAA	O
receptors	O
,	O
5	O
would	O
offer	O
unique	O
modeling	O
and	O
perhaps	O
biological	O
opportunities	O
.	O

We	O
have	O
previously	O
shown	O
it	O
to	O
be	O
the	O
most	O
potent	O
NMDA	O
agonist	O
known	O
,	O
with	O
a	O
unique	O
and	O
marked	O
in	O
vitro	O
neutrotoxicity	O
at	O
depolarizing	O
concentrations	O
.	O

Now	O
we	O
report	O
the	O
details	O
required	O
for	O
its	O
synthesis	O
,	O
together	O
with	O
its	O
potency	O
and	O
efficacy	O
in	O
two	O
assays	O
of	O
functional	O
activation	O
of	O
the	O
NMDA	O
receptor	O
,	O
namely	O
agonist	O
-	O
influenced	O
[	O
3H	O
]	O
MK801	O
binding	O
and	O
agonist	O
-	O
induced	O
release	O
of	O
the	O
neurotransmitter	O
[	O
3H	O
]	O
-	O
norepinephrine	O
from	O
brain	O
slices	O
.	O

In	O
both	O
these	O
assays	O
DL	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
proved	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
than	O
NMDA	O
and	O
cis	O
-	O
methanoglutamate	O
.	O

It	O
was	O
more	O
potent	O
than	O
,	O
and	O
equally	O
efficacious	O
to	O
,	O
L	O
-	O
glutamate	O
in	O
[	O
3H	O
]	O
MK801	O
binding	O
.	O

The	O
structural	O
features	O
of	O
5	O
may	O
well	O
reflect	O
optimal	O
agonist	O
interaction	O
at	O
the	O
NMDA	O
receptor	O
site	O
.	O

(	O
We	O
considered	O
the	O
possibility	O
that	O
some	O
decarboxylation	O
of	O
DL	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
may	O
have	O
occurred	O
during	O
testing	O
.	O

This	O
would	O
give	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
tetrazole	I-IUPAC
(	O
13	O
)	O
,	O
the	O
tetrazole	O
acid	O
analog	O
of	O
glycine	O
;	O
and	O
glycine	O
is	O
involved	O
in	O
NMDA	O
receptor	O
activation	O
.	O

Compound	O
13	O
does	O
not	O
affect	O
[	O
3H	O
]	O
glycine	O
binding	O
at	O
the	O
strychnine	O
-	O
insensitive	O
glycine	O
binding	O
site	O
,	O
and	O
[	O
3H	O
]	O
MK801	O
binding	O
studies	O
showed	O
that	O
the	O
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrazole	I-IUPAC
,	O
even	O
if	O
is	O
formed	O
,	O
would	O
probably	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylglycine	I-IUPAC
at	O
the	O
NMDA	O
receptor	O
.	O

The	O
thermal	O
Fischer	O
indolization	O
of	O
hydrazones	O
resulting	O
from	O
4	I-IUPAC
-	I-IUPAC
hydrazino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
various	O
beta	I-PARTIUPAC
-	I-PARTIUPAC
and	O
alpha	I-IUPAC
-	I-IUPAC
tetralones	I-IUPAC
led	O
to	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
,	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
e	I-IUPAC
]	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
,	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
g	I-IUPAC
]	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
respectively	O
.	O

After	O
aromatization	O
,	O
these	O
compounds	O
were	O
transformed	O
by	O
phosphorus	O
oxychloride	O
,	O
giving	O
1	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
5H	I-PARTIUPAC
-	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
4,3	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
e	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
g	I-PARTIUPAC
]	I-PARTIUPAC
indoles	I-PARTIUPAC
which	O
were	O
substituted	O
by	O
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
amines	I-IUPAC
.	O

The	O
resulting	O
1	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
dialkylamino	I-PARTIUPAC
)	I-PARTIUPAC
alkyl	I-PARTIUPAC
]	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
5H	I-PARTIUPAC
-	I-PARTIUPAC
pyrido	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
4,3	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
e	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
g	I-PARTIUPAC
]	I-PARTIUPAC
indoles	I-PARTIUPAC
,	O
as	O
well	O
as	O
hydroxy	O
derivatives	O
obtained	O
by	O
demethylation	O
of	O
methoxylated	O
compounds	O
with	O
hydrobromic	O
acid	O
,	O
were	O
tested	O
for	O
antitumor	O
activity	O
in	O
vitro	O
(	O
leukemic	O
and	O
solid	O
tumor	O
cells	O
)	O
and	O
in	O
vivo	O
on	O
various	O
experimental	O
tumor	O
models	O
using	O
the	O
standard	O
NCI	O
protocols	O
.	O

1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Dialkylamino	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
e	I-IUPAC
]	I-IUPAC
indoles	I-IUPAC
appeared	O
as	O
a	O
promising	O
new	O
class	O
of	O
antineoplastic	O
agents	O
.	O

The	O
determination	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
sigma	O
receptor	O
subtypes	O
and	O
their	O
physiological	O
role	O
(	O
s	O
)	O
has	O
been	O
impeded	O
by	O
the	O
unavailability	O
of	O
selective	O
ligands	O
.	O

We	O
have	O
developed	O
a	O
new	O
class	O
of	O
sigma	O
subtype	O
selective	O
receptor	O
ligands	O
that	O
are	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
derivatives	I-MODIFIER
of	O
the	O
synthetic	O
opioid	O
(	I-PARTIUPAC
+	I-PARTIUPAC
/	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
morphan	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
1	O
)	O
.	O

The	O
derivatives	O
can	O
be	O
prepared	O
by	O
reaction	O
of	O
1	O
,	O
(	O
+	O
)	O
-	O
1	O
,	O
and	O
(	O
-	O
)	O
-	O
1	O
with	O
the	O
appropriate	O
benzaldehyde	O
under	O
Claisen	O
-	O
Schmidt	O
conditions	O
.	O

Incorporation	O
of	O
substituted	I-MODIFIER
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
moieties	I-MODIFIER
onto	O
the	O
7	O
-	O
keto	O
precursor	O
of	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
morphan	I-IUPAC
,	O
(	O
+	O
)	O
-	O
1	O
,	O
produces	O
compounds	O
(	O
-	O
)	O
-	O
2	O
through	O
(	O
-	O
)	O
-	O
7	O
(	O
5.8-32.0	O
nM	O
,	O
sigma	O
1	O
)	O
,	O
which	O
have	O
between	O
a	O
25	O
-	O
and	O
131	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
sigma	O
1	O
receptor	O
subtype	O
relative	O
to	O
the	O
keto	O
precursor	O
(	O
+	O
)	O
-	O
1	O
(	O
Ki	O
=	O
762	O
nM	O
,	O
sigma	O
1	O
)	O
.	O

Compound	O
(	O
-	O
)	O
-	O
2	O
is	O
the	O
most	O
selective	O
of	O
this	O
group	O
(	O
16	O
-	O
fold	O
)	O
for	O
the	O
sigma	O
1	O
subtype	O
versus	O
sigma	O
2	O
.	O

Substitution	O
of	O
an	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
moiety	I-MODIFIER
onto	O
the	O
7	I-MODIFIER
-	I-MODIFIER
keto	I-MODIFIER
precursor	I-MODIFIER
of	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
morphan	I-IUPAC
,	O
(	O
-	O
)	O
-	O
1	O
,	O
produces	O
compounds	O
(	O
+	O
)	O
-	O
2	O
-	O
(	O
+	O
)	O
-	O
9	O
(	O
6.4-52.6	O
nM	O
,	O
sigma	O
2	O
)	O
,	O
which	O
have	O
at	O
least	O
a	O
475-3906	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
sigma	O
2	O
receptor	O
subtype	O
relative	O
to	O
the	O
keto	O
precursor	O
(	O
-	O
)	O
-	O
1	O
(	O
Ki	O
=	O
25	O
x	O
10	O
(	O
3	O
)	O
nM	O
)	O
.	O

This	O
enhancement	O
of	O
sigma	O
2	O
receptor	O
affinity	O
is	O
accompanied	O
by	O
substantial	O
selectivity	O
of	O
all	O
of	O
these	O
dextrorotatory	O
products	O
for	O
the	O
sigma	O
2	O
relative	O
to	O
the	O
sigma	O
1	O
subtype	O
(	O
32-238	O
-	O
fold	O
)	O
,	O
and	O
thus	O
,	O
they	O
are	O
among	O
the	O
most	O
sigma	O
2	O
selective	O
compounds	O
currently	O
known	O
.	O

Furthermore	O
,	O
the	O
sigma	O
1	O
subtype	O
is	O
highly	O
enantioselective	O
for	O
the	O
levorotatory	O
isomers	O
,	O
(	O
-	O
)	O
-	O
2	O
-	O
(	O
-	O
)	O
-	O
7	O
(	O
41-1034	O
-	O
fold	O
)	O
,	O
whereas	O
the	O
sigma	O
2	O
subtype	O
is	O
only	O
somewhat	O
enantioselective	O
for	O
the	O
dextrorotatory	O
isomers	O
,	O
(	O
+	O
)	O
-	O
2	O
-	O
(	O
+	O
)	O
-	O
7	O
(	O
2.6-9.3	O
-	O
fold	O
)	O
.	O

All	O
of	O
these	O
derivatives	O
retain	O
substantial	O
affinity	O
for	O
the	O
mu	O
opioid	O
receptor	O
.	O

Despite	O
the	O
high	O
affinity	O
of	O
the	O
dextrorotatory	O
derivatives	O
for	O
the	O
mu	O
opioid	O
receptor	O
,	O
the	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
over	O
sigma	O
1	O
sites	O
will	O
surely	O
prove	O
beneficial	O
as	O
tools	O
for	O
the	O
delineation	O
of	O
the	O
function	O
and	O
physiological	O
role	O
of	O
sigma	O
2	O
receptors	O
.	O

Some	O
novel	O
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	O
substituted	I-MODIFIER
-	O
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
have	O
been	O
prepared	O
.	O

At	O
the	O
N	O
-	O
1	O
position	O
"	O
standard	O
"	O
substitution	O
was	O
employed	O
with	O
the	O
ethyl	I-IUPAC
,	O
cyclopropyl	I-IUPAC
,	O
and	O
p	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
groups	I-MODIFIER
being	O
used	O
.	O

At	O
C	O
-	O
7	O
the	O
introduction	O
of	O
some	O
novel	O
piperazines	O
was	O
made	O
.	O

Most	O
notably	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
10	O
)	O
and	O
hexahydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diazepine	I-IUPAC
(	O
16	O
,	O
fluorohomopiperazine	O
)	O
at	O
the	O
quinolone	O
C	O
-	O
7	O
position	O
produced	O
products	O
with	O
similar	O
in	O
vitro	O
antibacterial	O
activity	O
as	O
the	O
ciprofloxacin	O
reference	O
.	O

The	O
in	O
vivo	O
efficacy	O
of	O
1	I-IUPAC
-	I-IUPAC
cyclopropyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
piperazinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
20	O
)	O
was	O
excellent	O
with	O
better	O
oral	O
absorption	O
than	O
ciprofloxacin	O
(	O
2	O
)	O
.	O

In	O
a	O
continuing	O
effort	O
to	O
design	O
small	O
-	O
molecule	O
inhibitors	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
that	O
combine	O
the	O
enzyme	O
-	O
binding	O
selectivity	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
)	I-IUPAC
pyrimidine	I-IUPAC
(	O
trimethoprim	O
,	O
TMP	O
)	O
with	O
the	O
potency	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
)	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
piritrexim	O
,	O
PTX	O
)	O
,	O
seven	O
previously	O
undescribed	O
2,4	I-PARTIUPAC
-	I-PARTIUPAC
diamino	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
2'	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
5'	I-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	I-MODIFIER
benzyl	B-PARTIUPAC
)	O
]	I-PARTIUPAC
pyrimidines	I-PARTIUPAC
were	O
synthesized	O
in	O
which	O
the	O
substituent	O
at	O
the	O
5'	O
-	O
position	O
was	O
a	O
carboxyphenyl	I-IUPAC
group	B-MODIFIER
linked	O
to	O
the	O
benzyl	I-IUPAC
moiety	B-MODIFIER
by	O
a	O
bridge	O
of	O
two	O
or	O
four	O
atoms	O
in	O
length	O
.	O

The	O
new	O
analogues	O
were	O
all	O
obtained	O
from	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
pyrimidine	I-IUPAC
via	O
a	O
Sonogashira	O
reaction	O
,	O
followed	O
,	O
where	O
appropriate	O
,	O
by	O
catalytic	O
hydrogenation	O
.	O

The	O
new	O
analogues	O
were	O
tested	O
as	O
inhibitors	O
of	O
DHFR	O
from	O
Pneumocystis	O
carinii	O
(	O
Pc	O
)	O
,	O
Toxoplasma	O
gondii	O
(	O
Tg	O
)	O
,	O
and	O
Mycobacterium	O
avium	O
(	O
Ma	O
)	O
,	O
three	O
life	O
-	O
threatening	O
pathogens	O
often	O
found	O
in	O
AIDS	O
patients	O
and	O
individuals	O
whose	O
immune	O
system	O
is	O
impaired	O
as	O
a	O
result	O
of	O
treatment	O
with	O
immunosuppressive	O
chemotherapy	O
or	O
radiation	O
.	O

The	O
selectivity	O
index	O
(	O
SI	O
)	O
of	O
each	O
compound	O
was	O
obtained	O
by	O
dividing	O
its	O
50%	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
)	O
)	O
against	O
Pc	O
,	O
Tg	O
,	O
or	O
Ma	O
DHFR	O
by	O
its	O
IC	O
(	O
50	O
)	O
against	O
rat	O
DHFR	O
.	O

2,4	I-IUPAC
-	I-IUPAC
Diamino	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxyphenyl	I-IUPAC
)	I-IUPAC
ethynylbenzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
28	O
)	O
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
23	O
nM	O
and	O
an	O
SI	O
of	O
28	O
in	O
the	O
Pc	O
DHFR	O
assay	O
,	O
had	O
about	O
the	O
same	O
potency	O
as	O
PTX	O
and	O
was	O
520	O
times	O
more	O
potent	O
than	O
TMP	O
.	O

As	O
an	O
inhibitor	O
of	O
Tg	O
DHFR	O
,	O
28	O
had	O
an	O
IC	O
(	O
50	O
)	O
of	O
5.5	O
nM	O
(	O
510	O
-	O
fold	O
lower	O
than	O
that	O
of	O
TMP	O
and	O
similar	O
to	O
that	O
of	O
PTX	O
)	O
and	O
an	O
SI	O
value	O
of	O
120	O
(	O
2	O
-	O
fold	O
better	O
than	O
TMP	O
and	O
vastly	O
superior	O
to	O
PTX	O
)	O
.	O

Against	O
Ma	O
DHFR	O
,	O
28	O
had	O
IC	O
(	O
50	O
)	O
and	O
SI	O
values	O
of	O
1.5	O
nM	O
and	O
430	O
,	O
respectively	O
,	O
compared	O
with	O
300	O
nM	O
and	O
610	O
for	O
TMP	O
.	O

Although	O
it	O
had	O
2.5	O
-	O
fold	O
lower	O
potency	O
than	O
28	O
against	O
Ma	O
DHFR	O
(	O
IC	O
(	O
50	O
)	O
=	O
3.7	O
nM	O
)	O
and	O
was	O
substantially	O
weaker	O
against	O
Pc	O
and	O
Tg	O
DHFR	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxyphenyl	I-IUPAC
)	I-IUPAC
ethynylbenzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
29	O
)	O
,	O
with	O
the	O
carboxy	I-IUPAC
group	B-MODIFIER
at	O
the	O
para	O
rather	O
than	O
the	O
meta	O
position	O
,	O
displayed	O
2200	O
-	O
fold	O
selectivity	O
against	O
the	O
Ma	O
enzyme	O
and	O
was	O
the	O
most	O
selective	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	O
5'	I-MODIFIER
-	O
substituted	I-MODIFIER
benzyl	I-PARTIUPAC
)	O
pyrimidine	I-PARTIUPAC
inhibitor	O
of	O
this	O
enzyme	O
we	O
have	O
encountered	O
to	O
date	O
.	O

Additional	O
bioassay	O
data	O
for	O
these	O
compounds	O
are	O
also	O
reported	O
.	O

A	O
series	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
thieno1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
	I-IUPAC
	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
was	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
inhibitory	O
activity	O
toward	O
human	O
leukocyte	O
elastase	O
(	O
HLE	O
)	O
.	O

The	O
Gewald	O
thiophene	O
synthesis	O
was	O
utilized	O
to	O
obtain	O
several	O
ethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminothiophene	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylates	I-IUPAC
.	O

These	O
precursors	O
were	O
subjected	O
to	O
a	O
five	O
-	O
step	O
route	O
to	O
obtain	O
thieno2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
	I-IUPAC
	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
bearing	O
various	O
substituents	O
at	O
positions	O
5	O
and	O
6	O
.	O

Both	O
thieno2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
and	O
thieno3	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
d	I-IUPAC
fused	O
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
possess	O
extraordinary	O
chemical	O
stability	O
,	O
which	O
was	O
expressed	O
as	O
rate	O
constants	O
of	O
the	O
alkaline	O
hydrolysis	O
.	O

The	O
kinetic	O
parameters	O
of	O
the	O
HLE	O
inhibition	O
were	O
determined	O
.	O

The	O
most	O
potent	O
compound	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1benzothieno2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
	I-IUPAC
	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
exhibited	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
5.8	O
nM	O
.	O

2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Diethylamino	I-IUPAC
)	I-IUPAC
thieno1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
	I-IUPAC
	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
act	O
as	O
acyl	O
-	O
enzyme	O
inhibitors	O
of	O
HLE	O
,	O
similar	O
to	O
the	O
inhibition	O
of	O
serine	O
proteases	O
by	O
4H	I-IUPAC
-	I-IUPAC
3,1	I-IUPAC
-	I-IUPAC
benzoxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O

The	O
isosteric	O
benzene	O
-	O
thiophene	O
replacement	O
accounts	O
for	O
an	O
enhanced	O
stability	O
of	O
the	O
acyl	O
-	O
enzyme	O
intermediates	O
.	O

In	O
order	O
to	O
develop	O
tracers	O
with	O
higher	O
specific	O
activity	O
to	O
supplant	O
the	O
currently	O
used	O
[	O
3H	O
]	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
[	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
tetralin	I-IUPAC
]	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
5	O
-	O
HT1A	O
receptors	O
,	O
a	O
new	O
radioiodinated	O
ligand	O
was	O
prepared	O
.	O

(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
tetralin	I-IUPAC
(	O
trans	O
-	O
8	O
-	O
OH	O
-	O
PIPAT	O
)	O
,	O
8	O
,	O
was	O
synthesized	O
by	O
a	O
10	O
-	O
step	O
reaction	O
.	O

Binding	O
studies	O
with	O
rat	O
hippocampal	O
membrane	O
homogenates	O
showed	O
that	O
8	O
exhibited	O
a	O
Ki	O
value	O
of	O
0.92	O
nM	O
against	O
(	O
R	O
,	O
S	O
)	O
-	O
[	O
3H	O
]	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
.	O

Radiolabeled	O
[	O
125I	O
]	O
-	O
8	O
was	O
prepared	O
from	O
the	O
corresponding	O
tri	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyltin	I-IUPAC
precursor	O
via	O
an	O
oxidative	O
iododestannylation	O
reaction	O
with	O
sodium	O
[	O
125I	O
]	O
iodide	O
.	O

Binding	O
studies	O
in	O
the	O
hippocampal	O
homogenates	O
revealed	O
that	O
[	O
125I	O
]	O
-	O
8	O
bound	O
to	O
a	O
single	O
high	O
-	O
affinity	O
site	O
(	O
Kd	O
=	O
0.38	O
+	O
/	O
-	O
0.03	O
nM	O
,	O
Bmax	O
=	O
310	O
+	O
/	O
-	O
20	O
fmol	O
/	O
mg	O
of	O
protein	O
)	O
.	O

Competition	O
binding	O
experiments	O
clearly	O
indicated	O
that	O
the	O
new	O
ligand	O
displayed	O
the	O
expected	O
5	O
-	O
HT1A	O
receptor	O
binding	O
profile	O
.	O

The	O
rank	O
order	O
of	O
potency	O
was	O
(	O
R	O
,	O
S	O
)	O
-	O
trans	O
-	O
8	O
-	O
OH	O
-	O
PIPAT	O
&	O
gt	O
;	O
(	O
R	O
,	O
S	O
)	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
&	O
gt	O
;	O
WB4101	O
&	O
gt	O
;	O
5	O
-	O
HT	O
&	O
gt	O
;	O
(	O
R	O
,	O
S	O
)	O
-	O
trans	O
-	O
7	O
-	O
OH	O
-	O
PIPAT	O
&	O
gt	O
;	O
(	O
R	O
,	O
S	O
)	O
-	O
7	O
-	O
OH	O
-	O
DPAT	O
&	O
gt	O
;	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
propranolol	I-IUPAC
&	O
gt	O
;	O
spiperone	O
&	O
gt	O
;	O
&	O
gt	O
;	O
ketanserin	O
&	O
gt	O
;	O
&	O
gt	O
;	O
dopamine	O
&	O
gt	O
;	O
atropine	O
.	O

This	O
new	O
ligand	O
offers	O
several	O
unique	O
advantages	O
,	O
including	O
high	O
specific	O
activity	O
,	O
high	O
binding	O
affinity	O
,	O
and	O
low	O
nonspecific	O
binding	O
,	O
all	O
of	O
which	O
make	O
it	O
an	O
excellent	O
probe	O
for	O
the	O
investigation	O
and	O
characterization	O
of	O
5	O
-	O
HT1A	O
receptors	O
.	O

Two	O
2,3	I-IUPAC
-	I-IUPAC
dihydrobenzofuran	I-IUPAC
analogues	I-MODIFIER
of	O
hallucinogenic	O
amphetamines	O
were	O
prepared	O
and	O
evaluated	O
for	O
activity	O
in	O
the	O
two	O
-	O
lever	O
drug	O
-	O
discrimination	O
paradigm	O
in	O
rats	O
trained	O
to	O
discriminate	O
saline	O
from	O
LSD	O
tartrate	O
(	O
0.08	O
mg	O
/	O
kg	O
)	O
and	O
for	O
the	O
ability	O
to	O
displace	O
[	O
125I	O
]	O
-	O
(	O
R	O
)	O
-	O
DOI	O
[	I-IUPAC
(	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
)	I-IUPAC
from	O
rat	O
cortical	O
homogenate	O
5	O
-	O
HT2	O
receptors	O
.	O

The	O
compounds	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydrobenzofuran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
6a	O
)	O
and	O
its	O
7	O
-	O
brominated	O
analogue	O
6b	O
,	O
possessed	O
activity	O
comparable	O
to	O
their	O
conformationally	O
flexible	O
counterparts	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dimethoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
3	O
)	O
and	O
its	O
4	O
-	O
bromo	O
derivative	O
DOB	O
(	O
5	O
)	O
,	O
respectively	O
.	O

The	O
results	O
suggest	O
that	O
the	O
dihydrofuran	O
ring	O
in	O
6a	O
and	O
6b	O
models	O
the	O
active	O
conformation	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
groups	I-MODIFIER
in	O
3	O
and	O
5	O
.	O

Free	O
energy	O
of	O
binding	O
,	O
derived	O
from	O
radioligand	O
displacement	O
KA	O
values	O
,	O
indicated	O
that	O
addition	O
of	O
the	O
bromine	O
in	O
either	O
series	O
contributes	O
2.4-3.2	O
kcal	O
/	O
mol	O
of	O
binding	O
energy	O
.	O

On	O
the	O
basis	O
of	O
surface	O
area	O
of	O
the	O
bromine	O
atom	O
,	O
this	O
value	O
is	O
2-3	O
times	O
higher	O
than	O
would	O
be	O
expected	O
on	O
the	O
basis	O
of	O
hydrophobic	O
binding	O
.	O

Thus	O
,	O
hydrophobicity	O
of	O
the	O
para	O
substituent	O
alone	O
cannot	O
account	O
for	O
the	O
dramatic	O
enhancement	O
of	O
hallucinogenic	O
activity	O
.	O

Although	O
this	O
substituent	O
may	O
play	O
a	O
minor	O
role	O
in	O
orienting	O
the	O
conformation	O
of	O
the	O
5	O
-	O
methoxy	O
group	O
in	O
derivatives	O
such	O
as	O
4	O
and	O
5	O
,	O
there	O
appears	O
to	O
be	O
some	O
other	O
,	O
as	O
yet	O
unknown	O
,	O
critical	O
receptor	O
interaction	O
.	O

N	O
,	O
O	O
-	O
Dicarbethoxy	O
-	O
4	O
-	O
chlorobenzenesulfohydroxamate	O
(	O
1c	O
)	O
and	O
O	I-IUPAC
-	I-IUPAC
carbethoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxysaccharin	I-IUPAC
(	O
6	O
)	O
,	O
both	O
potential	O
carbethoxylating	O
agents	O
,	O
inhibited	O
yeast	O
aldehyde	O
dehydrogenase	O
(	O
AlDH	O
)	O
with	O
IC50	O
's	O
of	O
24	O
and	O
56	O
microM	O
,	O
respectively	O
.	O

The	O
esterase	O
activity	O
of	O
the	O
enzyme	O
was	O
commensurably	O
inhibited	O
.	O

AlDH	O
activity	O
was	O
only	O
partially	O
restored	O
on	O
incubation	O
with	O
mercaptoethanol	O
(	O
20	O
mM	O
)	O
for	O
1	O
h	O
.	O

On	O
incubation	O
with	O
rat	O
plasma	O
,	O
1c	O
liberated	O
nitroxyl	I-IUPAC
,	O
a	O
potent	O
inhibitor	O
of	O
AlDH	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
nitroxyl	I-IUPAC
generation	O
from	O
6	O
was	O
minimal	O
,	O
a	O
result	O
compatible	O
with	O
a	O
previous	O
observation	O
that	O
nitroxyl	O
generation	O
from	O
N	I-IUPAC
-	I-IUPAC
hydroxysaccharin	I-IUPAC
(	O
7	O
)	O
,	O
the	O
product	O
of	O
the	O
hydrolysis	O
of	O
the	O
carbethoxy	I-IUPAC
group	B-MODIFIER
of	O
6	O
,	O
was	O
minimal	O
at	O
physiological	O
pH	O
.	O

Since	O
chemical	O
carbethoxylating	O
agents	O
represented	O
by	O
the	O
O	I-MODIFIER
-	I-MODIFIER
carbethoxylated	I-MODIFIER
N	I-IUPAC
-	I-IUPAC
hydroxyphthalimide	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
hydroxybenzotriazole	I-IUPAC
,	O
and	O
N	I-IUPAC
-	I-IUPAC
hydroxysuccinimide	I-IUPAC
(	O
8	O
,	O
9	O
,	O
and	O
10	O
,	O
respectively	O
)	O
likewise	O
inhibited	O
yeast	O
AlDH	O
,	O
albeit	O
with	O
IC50	O
's	O
1	O
order	O
of	O
magnitude	O
higher	O
,	O
we	O
postulate	O
that	O
1c	O
and	O
6	O
act	O
as	O
irreversible	O
inhibitors	O
of	O
AlDH	O
by	O
carbethoxylating	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

The	O
synthesis	O
of	O
aminoaceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidides	I-IUPAC
substituted	I-MODIFIER
on	O
the	O
amide	O
nitrogen	O
with	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
ethoxyethyl	I-IUPAC
groups	I-MODIFIER
is	O
described	O
.	O

The	O
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
derivatives	I-MODIFIER
were	O
prepared	O
by	O
treatment	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phthalimidoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidine	I-IUPAC
with	O
chloroacetyl	O
chloride	O
,	O
followed	O
by	O
treatment	O
with	O
either	O
potassium	O
phthalmide	O
or	O
diethylamine	O
.	O

Hydrazinolysis	O
of	O
the	O
phthalimides	O
liberated	O
the	O
free	O
amines	O
.	O

The	O
remaining	O
target	O
compounds	O
were	O
produced	O
by	O
alkylation	O
of	O
lidocaine	O
or	O
of	O
2	I-IUPAC
-	I-IUPAC
phthalimidoaceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidide	I-IUPAC
with	O
the	O
appropriate	O
halide	O
and	O
sodium	O
hydride	O
,	O
followed	O
by	O
hydrazinolysis	O
where	O
necessary	O
.	O

All	O
target	O
compounds	O
were	O
evaluated	O
for	O
antiarrhythmic	O
efficacy	O
against	O
chloroform	O
-	O
induced	O
ventricular	O
tachycardia	O
,	O
as	O
well	O
as	O
for	O
acute	O
CNS	O
toxicity	O
in	O
mice	O
.	O

Most	O
of	O
the	O
target	O
compounds	O
were	O
more	O
potent	O
than	O
the	O
corresponding	O
secondary	O
amides	O
and	O
had	O
improved	O
therapeutic	O
margins	O
toward	O
CNS	O
toxicity	O
.	O

The	O
diamines	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoaceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidide	I-IUPAC
(	O
13	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
aceto	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidide	I-IUPAC
(	O
29	O
)	O
are	O
especially	O
promising	O
in	O
this	O
respect	O
.	O

Several	O
compounds	O
were	O
tested	O
as	O
spinal	O
anesthetics	O
.	O

A	O
series	O
of	O
analogues	O
of	O
the	O
analgesic	O
dipeptide	O
derivative	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
has	O
been	O
designed	O
to	O
determine	O
the	O
influence	O
of	O
the	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
(	O
NPS	O
)	O
moiety	I-MODIFIER
on	O
the	O
activity	O
.	O

The	O
syntheses	O
and	O
antinociceptive	O
effects	O
of	O
these	O
analogues	O
of	O
general	O
formula	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
R	O
)	O
-	O
OMe	O
[	O
R	O
=	O
phenylsulfenyl	I-IUPAC
(	O
PS	O
)	O
(	O
9	O
)	O
;	O
R	O
=	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbomethyoxyphenyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
(	O
CmPS	O
)	O
(	O
10	O
)	O
;	O
R	O
=	O
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
(	O
pNPS	O
)	O
(	O
11	O
)	O
;	O
R	O
=	O
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dinitrophenyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
(	O
DNPS	O
)	O
(	O
12	O
)	O
;	O
R	O
=	O
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbomethoxyethyl	I-IUPAC
]	I-IUPAC
sulfenyl	I-IUPAC
(	O
AacCmES	O
)	O
(	O
13	O
)	O
;	O
R	O
=	O
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
sulfenyl	I-IUPAC
(	O
AacPS	O
)	O
(	O
17	O
)	O
;	O
R	O
=	O
tert	I-IUPAC
-	I-IUPAC
butylsulfenyl	I-IUPAC
(	O
t	O
-	O
BuS	O
)	O
(	O
23	O
)	O
;	O
R	O
=	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbomethoxyethyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
(	O
CmES	O
)	O
(	O
24	O
)	O
]	O
are	O
described	O
.	O

Reaction	O
of	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
-	O
OMe	O
(	O
3	O
)	O
with	O
PS	O
-	O
,	O
CmPS	O
-	O
,	O
pNPS	O
-	O
,	O
DNPS	O
-	O
,	O
and	O
AacCmES	O
-	O
Cl	O
afforded	O
the	O
corresponding	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
sulfenyl	I-IUPAC
)	I-IUPAC
tryptophan	I-IUPAC
derivatives	I-MODIFIER
,	O
which	O
on	O
treatment	O
with	O
boron	I-IUPAC
-	I-IUPAC
tris	I-IUPAC
(	I-IUPAC
trifluoroacetate	I-IUPAC
)	I-IUPAC
/	O
trifluoroacetic	O
acid	O
or	O
trimethylsilyl	O
iodide	O
in	O
acetonitrile	O
(	O
Me3SiI	O
/	O
CH3CN	O
)	O
provided	O
9-13	O
,	O
respectively	O
.	O

Sulfenylation	O
of	O
3	O
with	O
NPS	O
-	O
Cl	O
gave	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
,	O
which	O
,	O
on	O
catalytic	O
hydrogenation	O
of	O
the	O
nitro	O
group	O
using	O
10%	O
Pd	O
/	O
C	O
followed	O
by	O
acetylation	O
of	O
the	O
resulting	O
amino	O
function	O
and	O
removal	O
of	O
the	O
protecting	O
Z	O
groups	O
,	O
gave	O
17	O
.	O

Condensation	O
of	O
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
tert	I-PARTIUPAC
-	I-PARTIUPAC
butylsulfenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbomethoxyethyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
]	I-IUPAC
tryptophan	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
,	O
obtained	O
by	O
reaction	O
of	O
methyl	I-IUPAC
3a	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,3	I-IUPAC
a	I-IUPAC
,	I-IUPAC
8,8	I-IUPAC
a	I-IUPAC
-	I-IUPAC
hexahydropyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxyla	I-IUPAC
te	I-IUPAC
with	O
the	O
corresponding	O
thiol	O
,	O
with	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
OSu	O
afforded	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
t	O
-	O
BuS	O
)	O
-	O
OMe	O
and	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
CmES	O
)	O
-	O
OMe	O
,	O
which	O
on	O
treatment	O
with	O
Me3SiI	O
/	O
CH3CN	O
provided	O
23	O
and	O
24	O
,	O
respectively	O
.	O

Intracerebroventricular	O
administration	O
of	O
10	O
elicited	O
a	O
naloxone	O
-	O
reversible	O
antinociceptive	O
effect	O
in	O
mice	O
similar	O
to	O
that	O
of	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
.	O

No	O
analgesia	O
was	O
however	O
found	O
with	O
the	O
phenylsulfenyl	O
or	O
acyclic	O
sulfenyl	O
substituted	O
dipeptides	O
9	O
,	O
11	O
,	O
and	O
17	O
or	O
13	O
,	O
23	O
,	O
and	O
24	O
.	O

The	O
Trp	O
(	O
DNPS	O
)	O
-	O
containing	O
analogue	O
was	O
neurotoxic	O
.	O

Structure	O
-	O
activity	O
studies	O
indicate	O
that	O
the	O
role	O
of	O
the	O
NPS	O
and	O
CmPS	O
moieties	O
could	O
be	O
related	O
to	O
the	O
adoption	O
of	O
a	O
preferential	O
active	O
conformation	O
.	O

Adenosine	O
5'	O
-	O
triphosphate	O
(	O
ATP	O
)	O
derivatives	I-MODIFIER
of	O
the	O
types	O
N6	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
(	O
CH2	O
)	O
nNHCOCH2I	O
,	O
(	O
CH2	O
)	O
nNHCO	O
-	O
(	O
CH2	O
)	O
mNHCOCH2I	O
,	O
or	O
(	O
CH2	O
)	O
nCON	O
(	O
Me	O
)	O
(	O
CH2	O
)	O
mN	O
(	O
Me	O
)	O
CO	O
(	O
CH2	O
)	O
nNHCOCH2I	O
]	O
,	O
N6	O
-	O
Me	O
-	O
N6	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
(	O
CH2	O
)	O
nN	O
-	O
(	O
Me	O
)	O
CO	O
(	O
CH2	O
)	O
mNHCOCH2I	O
]	O
,	O
and	O
8	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
NM	O
(	O
CH2	O
)	O
nNHCOCH2I	O
]	O
with	O
5	O
-	O
-	O
19	O
spacer	O
atoms	O
between	O
N6	O
or	O
C	O
-	O
8	O
and	O
iodine	O
have	O
been	O
evaluated	O
as	O
potential	O
exo	O
-	O
ATP	O
-	O
site	O
-	O
directed	O
reagents	O
for	O
phosphokinases	O
.	O

Substrate	O
and	O
inhibitor	O
properties	O
indicated	O
that	O
the	O
compounds	O
possessed	O
affinity	O
for	O
the	O
ATP	O
sites	O
of	O
the	O
muscle	O
(	O
M	O
)	O
,	O
kidney	O
(	O
K	O
)	O
,	O
and	O
liver	O
(	O
L	O
)	O
isozymes	O
of	O
rat	O
pyruvate	O
kinase	O
(	O
PK	O
)	O
,	O
of	O
E	O
.	O

coli	O
thymidine	O
kinase	O
(	O
TK	O
)	O
,	O
and	O
of	O
yeast	O
hexokinase	O
(	O
HK	O
)	O
and	O
rat	O
KH	O
I	O
,	O
II	O
,	O
and	O
III	O
isozymes	O
.	O

Tests	O
for	O
time	O
-	O
dependent	O
loss	O
of	O
enzyme	O
activity	O
(	O
inactivation	O
)	O
were	O
performed	O
under	O
conditions	O
in	O
which	O
a	O
large	O
proportion	O
of	O
each	O
phosphokinase	O
was	O
present	O
as	O
an	O
enzyme	O
-	O
inhibitor	O
complex	O
.	O

No	O
ATP	O
-	O
site	O
-	O
directed	O
inactivations	O
resulted	O
when	O
the	O
M	O
,	O
L	O
,	O
or	O
K	O
isozymes	O
of	O
PK	O
were	O
exposed	O
for	O
8	O
h	O
,	O
22	O
degrees	O
C	O
,	O
to	O
5	O
mM	O
levels	O
of	O
18	O
ATP	O
derivatives	O
or	O
6	O
analogous	O
ADP	O
derivatives	O
or	O
when	O
yeast	O
HK	O
or	O
rat	O
KH	O
I	O
,	O
II	O
,	O
or	O
III	O
was	O
exposed	O
for	O
6	O
h	O
,	O
22	O
degrees	O
C	O
,	O
to	O
5	O
mM	O
levels	O
of	O
28	O
ATP	O
derivatives	O
.	O

Escherichia	O
coli	O
TK	O
was	O
inactivated	O
by	O
6	O
of	O
25	O
ATP	O
derivatives	O
tested	O
at	O
10	O
mM	O
,	O
6	O
h	O
,	O
0	O
degrees	O
C	O
;	O
inactivation	O
was	O
slowed	O
by	O
MgATP	O
in	O
the	O
case	O
of	O
N6	O
-	O
CH3	O
-	O
N6	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
(	O
CH2	O
)	O
4N	O
(	O
CH3	O
)	O
CO	O
(	O
CH2	O
)	O
5NHCOCH2I	O
]	O
.	O

Only	O
1%	O
of	O
298	O
enzyme	O
-	O
inhibitor	O
combinations	O
exhibited	O
ATP	O
-	O
site	O
-	O
directed	O
inactivation	O
,	O
signifying	O
that	O
few	O
suitably	O
positioned	O
and	O
sufficiently	O
reactive	O
nucleophilic	O
groups	O
were	O
present	O
near	O
the	O
enzymic	O
ATP	O
sites	O
.	O

Studies	O
have	O
now	O
shown	O
that	O
exo	O
-	O
active	O
-	O
site	O
-	O
directed	O
reagents	O
can	O
act	O
as	O
isozyme	O
-	O
or	O
species	O
-	O
selective	O
enzyme	O
inhibitors	O
.	O

The	O
present	O
survey	O
indicates	O
that	O
in	O
many	O
cases	O
such	O
reagents	O
may	O
be	O
difficult	O
of	O
access	O
when	O
data	O
are	O
not	O
available	O
regarding	O
structural	O
or	O
physicochemical	O
features	O
of	O
the	O
target	O
enzyme	O
adjacent	O
to	O
its	O
catalytic	O
site	O
.	O

The	O
synthesis	O
of	O
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
and	O
its	O
2	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxymethyl	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
analogues	I-MODIFIER
is	O
described	O
.	O

In	O
general	O
the	O
synthetic	O
route	O
involved	O
the	O
coupling	O
of	O
diethyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
prop	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ynylamino	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
with	O
the	O
appropriate	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
quinazoline	I-IUPAC
followed	O
by	O
deprotection	O
with	O
mild	O
alkali	O
.	O

These	O
four	O
compounds	O
together	O
with	O
the	O
2	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	I-MODIFIER
were	O
tested	O
for	O
their	O
activity	O
against	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O

They	O
were	O
also	O
examined	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
the	O
L1210	O
cell	O
line	O
and	O
of	O
two	O
mutant	O
L1210	O
cell	O
lines	O
,	O
the	O
L1210	O
:	O
R7A	O
that	O
overproduces	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
the	O
L1210	O
:	O
1565	O
that	O
has	O
impaired	O
uptake	O
of	O
reduced	O
folates	O
.	O

Compared	O
with	O
their	O
non	O
-	O
fluorinated	O
parent	O
compounds	O
,	O
the	O
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
analogues	I-MODIFIER
were	O
all	O
approximately	O
2	O
-	O
fold	O
more	O
potent	O
as	O
TS	O
inhibitors	O
.	O

Similarly	O
,	O
they	O
also	O
showed	O
improved	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
(	O
1.5-5	O
-	O
fold	O
)	O
,	O
and	O
this	O
activity	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
thymidine	O
.	O

All	O
had	O
retained	O
or	O
improved	O
activity	O
against	O
both	O
the	O
L1210	O
:	O
R7A	O
and	O
L1210	O
:	O
1565	O
cell	O
lines	O
.	O

A	O
series	O
of	O
8	O
-	O
(	O
trifluoromethyl	O
)	O
-	O
substituted	O
quinolones	O
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
,	O
and	O
phototolerance	O
in	O
a	O
mouse	O
phototolerance	O
assay	O
.	O

These	O
analogues	O
were	O
compared	O
to	O
the	O
corresponding	O
series	O
of	O
6,8	I-PARTIUPAC
-	I-PARTIUPAC
difluoro	I-PARTIUPAC
-	I-PARTIUPAC
and	O
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
8H	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
(	O
ciprofloxacin	O
type	O
)	O
.	O

Although	O
their	O
in	O
vitro	O
antibacterial	O
activities	O
are	O
less	O
than	O
the	O
6,8	I-IUPAC
-	I-IUPAC
difluoro	I-IUPAC
analogues	I-MODIFIER
,	O
the	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
quinolones	I-IUPAC
are	O
generally	O
equivalent	O
to	O
their	O
8H	O
analogues	O
.	O

In	O
vivo	O
,	O
they	O
are	O
comparable	O
to	O
the	O
6,8	I-IUPAC
-	I-IUPAC
difluoro	I-IUPAC
series	I-MODIFIER
and	O
show	O
up	O
to	O
10	O
-	O
fold	O
improvement	O
in	O
efficacy	O
when	O
compared	O
to	O
their	O
ciprofloxacin	O
counterparts	O
vs	O
Streptococcus	O
pyogenes	O
and	O
Streptococcus	O
pneumonia	O
.	O

In	O
the	O
phototolerance	O
model	O
,	O
the	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
quinolones	I-IUPAC
are	O
comparable	O
to	O
the	O
8H	I-IUPAC
-	I-IUPAC
quinolones	I-IUPAC
.	O

Both	O
of	O
these	O
series	O
display	O
much	O
higher	O
no	O
effect	O
doses	O
(	O
greater	O
tolerance	O
)	O
than	O
the	O
corresponding	O
6,8	I-IUPAC
-	I-IUPAC
difluoroquinolones	I-IUPAC
.	O

The	O
syntheses	O
and	O
anthelmintic	O
activities	O
of	O
31	O
3	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazoles	I-IUPAC
are	O
reported	O
.	O

In	O
the	O
primary	O
anthelmintic	O
screen	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
39	O
)	O
showed	O
100%	O
nematocidal	O
activity	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
63	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
64	O
)	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isothiocyanatophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
(	O
66	O
)	O
showed	O
100%	O
taeniacidal	O
activity	O
when	O
administered	O
orally	O
to	O
mice	O
.	O

The	O
two	O
most	O
active	O
members	O
of	O
this	O
series	O
,	O
39	O
and	O
63	O
,	O
were	O
active	O
against	O
the	O
gastrointestinal	O
nematodes	O
of	O
sheep	O
at	O
100	O
mg	O
/	O
kg	O
.	O

In	O
addition	O
,	O
39	O
was	O
also	O
found	O
to	O
be	O
active	O
against	O
hookworms	O
in	O
dogs	O
at	O
a	O
single	O
,	O
oral	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
.	O

A	O
novel	O
class	O
of	O
5	O
-	O
substituted	O
acyclic	O
pyrimidine	O
nucleosides	O
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
9a	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
9b	O
)	O
,	O
and	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
9c	O
)	O
,	O
were	O
synthesized	O
by	O
regiospecific	O
addition	O
of	O
bromine	O
azide	O
to	O
the	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
substituent	I-MODIFIER
of	O
the	O
respective	O
5	I-IUPAC
-	I-IUPAC
vinyluracils	I-IUPAC
(	O
2a	O
-	O
c	O
)	O
followed	O
by	O
treatment	O
of	O
the	O
obtained	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromoethyl	I-IUPAC
)	I-IUPAC
compounds	I-MODIFIER
(	O
3a	O
-	O
c	O
)	O
with	O
t	O
-	O
BuOK	O
,	O
to	O
affect	O
the	O
base	O
-	O
catalyzed	O
elimination	O
of	O
HBr	O
.	O

Thermal	O
decomposition	O
of	O
9b	O
and	O
9c	O
at	O
110	O
degrees	O
C	O
in	O
dioxane	O
yielded	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azirinyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
uracil	I-IUPAC
analogues	I-MODIFIER
(	O
10b	O
,	O
c	O
)	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azidovinyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
derivatives	I-MODIFIER
9a	O
-	O
c	O
were	O
found	O
to	O
exhibit	O
potent	O
and	O
selective	O
in	O
vitro	O
anti	O
-	O
HBV	O
activity	O
against	O
duck	O
hepatitis	O
B	O
virus	O
(	O
DHBV	O
)	O
infected	O
primary	O
duck	O
hepatocytes	O
at	O
low	O
concentrations	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.01-0.1	O
microg	O
/	O
mL	O
range	O
)	O
.	O

The	O
most	O
active	O
anti	O
-	O
DHBV	O
agent	O
(	O
9c	O
)	O
,	O
possessing	O
a	O
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
substituent	I-MODIFIER
at	O
N	O
-	O
1	O
,	O
exhibited	O
an	O
activity	O
(	O
EC	O
(	O
50	O
)	O
of	O
0.01-0.05	O
microg	O
/	O
mL	O
)	O
comparable	O
to	O
that	O
of	O
reference	O
compound	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
thiacytidine	I-IUPAC
(	O
3	O
-	O
TC	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.01-0.05	O
microg	O
/	O
mL	O
)	O
.	O

In	O
contrast	O
,	O
related	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azirinyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
uracil	I-IUPAC
analogues	I-MODIFIER
(	O
10b	O
,	O
c	O
)	O
were	O
devoid	O
of	O
anti	O
-	O
DHBV	O
activity	O
,	O
indicating	O
that	O
an	O
acyclic	O
side	O
chain	O
at	O
C	O
-	O
5	O
position	O
of	O
the	O
pyrimidine	O
ring	O
is	O
essential	O
for	O
anti	O
-	O
HBV	O
activity	O
.	O

The	O
pyrimidine	O
nucleosides	O
(	O
9a	O
-	O
c	O
,	O
10b	O
,	O
c	O
)	O
exhibited	O
no	O
cytotoxic	O
activity	O
against	O
a	O
panel	O
of	O
60	O
human	O
cancer	O
cell	O
lines	O
.	O

All	O
of	O
the	O
compounds	O
investigated	O
did	O
not	O
show	O
any	O
detectable	O
toxicity	O
to	O
several	O
stationary	O
and	O
proliferating	O
host	O
cell	O
lines	O
or	O
to	O
mitogen	O
stimulated	O
proliferating	O
human	O
T	O
lymphocytes	O
,	O
up	O
to	O
the	O
highest	O
concentration	O
tested	O
.	O

The	O
isomeric	O
4	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
,	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivative	I-MODIFIER
of	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
isomer	I-MODIFIER
,	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
.	O

The	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
and	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
isomer	I-MODIFIER
possessed	O
similar	O
potencies	O
as	O
D	O
-	O
1	O
antagonists	O
.	O

Introduction	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
enhanced	O
potency	O
about	O
twofold	O
.	O

The	O
"	O
pharmacophore	O
"	O
for	O
selective	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
appears	O
to	O
be	O
a	O
tertiary	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethylamine	I-IUPAC
.	O

Spiro	O
[	O
isobenzofuran	O
-	O
1	O
(	O
3H	O
)	O
,	O
4'	O
-	O
piperidines	O
]	O
and	O
the	O
corresponding	O
benzofuran	O
and	O
benzopyran	O
derivatives	O
have	O
been	O
synthesized	O
and	O
evaluated	O
as	O
sigma	O
ligands	O
.	O

The	O
compounds	O
are	O
related	O
to	O
Lu	O
28-179	O
(	O
1'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
)	O
that	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
selective	O
sigma	O
2	O
ligand	O
with	O
affinity	O
in	O
the	O
subnanomolar	O
range	O
.	O

The	O
object	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
structural	O
factors	O
governing	O
sigma	O
1	O
/	O
sigma	O
2	O
affinity	O
and	O
selectivity	O
within	O
this	O
class	O
of	O
compounds	O
.	O

The	O
N	O
-	O
substituent	O
in	O
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
is	O
highly	O
important	O
,	O
both	O
for	O
affinity	O
and	O
selectivity	O
.	O

Spiropiperidines	O
with	O
no	O
or	O
small	O
N	O
-	O
substituents	O
(	O
H	O
,	O
Me	O
,	O
Et	O
)	O
exert	O
very	O
low	O
affinity	O
for	O
both	O
sigma	O
1	O
and	O
sigma	O
2	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
,	O
sigma	O
2	O
)	O
&	O
gt	O
;	O
100	O
nM	O
)	O
,	O
whereas	O
medium	O
-	O
sized	O
substituents	O
(	O
e.g.	O
,	O
Pr	O
,	O
Bu	O
,	O
Ph	O
(	O
CH2	O
)	O
2	O
)	O
result	O
in	O
potent	O
,	O
but	O
unselective	O
compounds	O
(	O
IC50	O
(	O
sigma	O
1	O
,	O
sigma	O
2	O
)	O
=	O
2-5	O
nM	O
)	O
.	O

Increasing	O
the	O
chain	O
length	O
and	O
the	O
lipophilicity	O
of	O
the	O
N	O
-	O
substituent	O
result	O
in	O
compounds	O
in	O
which	O
high	O
affinity	O
for	O
sigma	O
2	O
binding	O
sites	O
is	O
retained	O
and	O
with	O
selectivity	O
for	O
sigma	O
2	O
vs	O
sigma	O
1	O
binding	O
sites	O
(	O
e.g.	O
,	O
4	I-IUPAC
-	I-IUPAC
cyclohexyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
:	O
IC50	O
-	O
(	O
sigma	O
1	O
)	O
=	O
1.5	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.07	O
nM	O
)	O
.	O

Introduction	O
of	O
substituents	O
in	O
the	O
benzene	O
ring	O
of	O
the	O
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
ring	O
system	O
of	O
Lu	O
28-179	O
mainly	O
affects	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
.	O

Compounds	O
with	O
substituents	O
(	O
F	O
,	O
CF3	O
)	O
in	O
the	O
4	O
-	O
or	O
7	O
-	O
position	O
of	O
the	O
isobenzofuran	O
display	O
high	O
affinity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.5-2	O
nM	O
)	O
and	O
very	O
low	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
)	O
&	O
gt	O
;	O
100	O
nM	O
)	O
.	O

Compounds	O
with	O
substituents	O
(	O
F	O
,	O
CF3	O
,	O
Me	O
)	O
in	O
the	O
5	O
-	O
or	O
6	O
-	O
position	O
of	O
the	O
isobenzofuran	O
exert	O
increased	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
5-30	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.3-7	O
nM	O
)	O
,	O
thus	O
rendering	O
unselective	O
compounds	O
.	O

Exchanging	O
the	O
isobenzofuran	O
moiety	O
of	O
Lu	O
28-179	O
with	O
thioisobenzofuran	O
,	O
benzofuran	O
,	O
or	O
benzopyran	O
also	O
has	O
a	O
pronounced	O
effect	O
on	O
both	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
binding	O
sites	O
.	O

The	O
position	O
of	O
the	O
oxygen	O
atom	O
and	O
the	O
position	O
of	O
the	O
spiroconnection	O
with	O
the	O
4	O
-	O
position	O
of	O
the	O
piperidine	O
ring	O
were	O
varied	O
,	O
and	O
only	O
compounds	O
in	O
which	O
both	O
the	O
benzene	O
ring	O
and	O
the	O
heteroatom	O
are	O
attached	O
directly	O
to	O
the	O
piperidine	O
ring	O
retain	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
e.g.	O
,	O
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
53	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.9	O
nM	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

A	O
series	O
of	O
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
derivatives	I-MODIFIER
with	O
a	O
modified	O
side	O
chain	O
terminus	O
was	O
prepared	O
.	O

These	O
agents	O
were	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
their	O
ability	O
to	O
suppress	O
HMG	O
CoA	O
reductase	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
cholesterol	O
biosynthesis	O
.	O

In	O
tissue	O
culture	O
assays	O
,	O
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
as	O
well	O
as	O
the	O
side	O
chain	O
modified	O
analogues	O
were	O
potent	O
inhibitors	O
of	O
HMG	O
CoA	O
reductase	O
.	O

However	O
,	O
only	O
those	O
sterols	O
with	O
a	O
modified	O
side	O
chain	O
terminus	O
were	O
effective	O
suppressors	O
of	O
liver	O
reductase	O
when	O
administered	O
ig	O
to	O
rats	O
.	O

22	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
25	I-IUPAC
-	I-IUPAC
methylcholesterol	I-IUPAC
(	O
4a	O
)	O
and	O
25	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
(	O
15a	O
)	O
significantly	O
lowered	O
serum	O
cholesterol	O
levels	O
when	O
administered	O
ig	O
to	O
primates	O
;	O
25	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
22	I-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
(	O
15b	O
)	O
and	O
the	O
analogue	O
with	O
a	O
cyclopropyl	I-IUPAC
terminus	B-MODIFIER
,	O
20b	O
,	O
were	O
ineffective	O
.	O

The	O
cholesterol	O
-	O
lowering	O
sterols	O
did	O
not	O
significantly	O
alter	O
lipoprotein	O
levels	O
;	O
however	O
,	O
the	O
two	O
compounds	O
have	O
been	O
shown	O
to	O
inhibit	O
acyl	O
-	O
coenzyme	O
A	O
:	O
cholesterol	O
acyl	O
-	O
transferase	O
(	O
ACAT	O
)	O
in	O
tissue	O
culture	O
studies	O
.	O

Hypoxic	O
cells	O
are	O
an	O
important	O
target	O
for	O
antitumor	O
therapy	O
because	O
tumors	O
are	O
typically	O
characterized	O
by	O
such	O
cells	O
.	O

Virtually	O
all	O
tumors	O
which	O
are	O
present	O
as	O
solid	O
masses	O
contain	O
hypoxic	O
cells	O
,	O
while	O
normal	O
cells	O
generally	O
have	O
an	O
adequate	O
supply	O
of	O
oxygen	O
.	O

Accordingly	O
,	O
antitumor	O
agents	O
can	O
be	O
made	O
selective	O
for	O
tumors	O
by	O
virtue	O
of	O
high	O
activity	O
under	O
hypoxic	O
conditions	O
.	O

The	O
initial	O
purpose	O
of	O
this	O
work	O
was	O
to	O
determine	O
the	O
influence	O
of	O
different	O
groups	O
in	O
position	O
3	O
.	O

Thus	O
,	O
the	O
synthesis	O
of	O
some	O
3	O
-	O
NH	O
-	O
substituted	O
derivatives	O
(	O
2a	O
,	O
3a	O
,	O
4a	O
)	O
starting	O
from	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
1a	O
)	O
is	O
described	O
.	O

Reductive	O
deamination	O
of	O
compounds	O
1a	O
-	O
k	O
provides	O
the	O
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitriles	I-IUPAC
5a	O
-	O
k	O
,	O
which	O
are	O
more	O
potent	O
,	O
while	O
selectivity	O
is	O
maintained	O
or	O
increased	O
in	O
some	O
derivatives	O
.	O

The	O
compound	O
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
5k	O
)	O
is	O
150	O
-	O
fold	O
more	O
potent	O
than	O
tirapazamine	O
(	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzotriazine	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
)	O
,	O
which	O
has	O
been	O
used	O
as	O
a	O
standard	O
.	O

Three	O
derivatives	O
(	O
5g	O
,	O
i	O
,	O
k	O
)	O
show	O
a	O
hypoxic	O
cytotoxicity	O
ratio	O
(	O
HCR	O
)	O
&	O
gt	O
;	O
or	O
=	O
200	O
,	O
better	O
than	O
that	O
of	O
tirapazamine	O
(	O
HCR	O
=	O
75	O
)	O
in	O
V79	O
cells	O
.	O

Replacement	O
of	O
the	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
by	O
chlorine	O
affords	O
the	O
potent	O
but	O
nonselective	O
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivatives	I-MODIFIER
6a	O
-	O
k	O
showing	O
similar	O
toxicities	O
under	O
both	O
aerobic	O
and	O
hypoxic	O
conditions	O
.	O

These	O
compounds	O
were	O
used	O
as	O
intermediates	O
for	O
the	O
synthesis	O
of	O
a	O
new	O
series	O
of	O
water	O
-	O
soluble	O
compounds	O
derived	O
from	O
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
[	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
10a	O
-	O
i	O
and	O
11a	O
-	O
i	O
.	O

The	O
7	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
and	O
the	O
7	I-IUPAC
-	I-IUPAC
trifluoromethyl	I-IUPAC
derivatives	I-MODIFIER
10b	O
,	O
f	O
have	O
demonstrated	O
high	O
potency	O
(	O
0.4	O
and	O
0.3	O
microM	O
)	O
and	O
excellent	O
selectivity	O
(	O
HCR	O
=	O
250	O
and	O
340	O
)	O
.	O

Several	O
7	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
analogues	I-MODIFIER
,	O
12b	O
,	O
13b	O
.1	O
,	O
b	O
.2	O
,	O
and	O
14b	O
,	O
and	O
the	O
dimer	O
16b	O
have	O
been	O
prepared	O
and	O
evaluated	O
in	O
order	O
to	O
determine	O
the	O
optimum	O
lateral	O
chain	O
in	O
position	O
3	O
,	O
which	O
appears	O
to	O
be	O
the	O
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
moiety	I-MODIFIER
.	O

Condensation	O
of	O
14	I-IUPAC
-	I-IUPAC
bromodaunorubicin	I-IUPAC
with	O
thiols	O
in	O
methanol	O
,	O
in	O
the	O
presence	O
of	O
potassium	O
carbonate	O
,	O
resulted	O
in	O
the	O
formation	O
of	O
14	O
-	O
thia	O
analogues	O
of	O
the	O
antitumor	O
antibiotic	O
adriamycin	O
.	O

However	O
,	O
similar	O
condensation	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
iododaunorubicin	I-IUPAC
with	O
thiols	O
invariably	O
led	O
to	O
a	O
redox	O
reaction	O
,	O
with	O
the	O
formation	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
daunorubicin	I-IUPAC
and	O
disulfides	O
.	O

Accordingly	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
bromodaunorubicin	I-IUPAC
was	O
used	O
for	O
reaction	O
with	O
thiols	O
to	O
yield	O
thia	O
analogues	O
of	O
the	O
clinically	O
active	O
but	O
non	O
-	O
DNA	O
-	O
binding	O
adriamycin	O
analogue	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
adriamycin	I-IUPAC
14	I-IUPAC
-	I-IUPAC
valerate	I-IUPAC
(	O
AD	O
32	O
)	O
.	O

Reaction	O
of	O
14	I-IUPAC
-	I-IUPAC
bromoadunorubicin	I-IUPAC
with	O
alpha	O
,	O
omega	O
-	O
alkanedithiols	O
gave	O
bis	O
(	O
thiaadriamycin	O
)	O
analogues	O
as	O
potential	O
difunctional	O
intercalating	O
agents	O
.	O

The	O
aforementioned	O
products	O
,	O
plus	O
two	O
related	O
phenylselena	O
derivatives	O
,	O
were	O
examined	O
for	O
in	O
vitro	O
growth	O
inhibition	O
,	O
in	O
vivo	O
antitumor	O
activity	O
,	O
and	O
,	O
where	O
appropriate	O
,	O
DNA	O
binding	O
.	O

A	O
number	O
of	O
agents	O
,	O
most	O
notably	O
14	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
thiaadriamycin	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
14	I-IUPAC
-	I-IUPAC
selenaadriamycin	I-IUPAC
,	O
were	O
active	O
against	O
murine	O
L1210	O
leukemia	O
in	O
vivo	O
.	O

Several	O
of	O
the	O
amino	O
glycoside	O
unsubstituted	O
14	I-IUPAC
-	I-IUPAC
thiaadriamycin	I-IUPAC
analogues	I-MODIFIER
exhibited	O
DNA	O
-	O
binding	O
properties	O
equivalent	O
to	O
those	O
of	O
adriamycin	O
.	O

Three	O
electrophilic	O
amide	O
analogues	O
of	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diaminopropionic	I-IUPAC
acid	I-IUPAC
(	O
1	O
,	O
DAP	O
)	O
have	O
been	O
prepared	O
as	O
potential	O
inhibitors	O
of	O
L	O
-	O
asparagine	O
synthetase	O
(	O
ASase	O
,	O
from	O
Novikoff	O
hepatoma	O
,	O
EC	O
6.3.5.4	O
)	O
.	O

DAP	O
was	O
selectively	O
blocked	O
by	O
the	O
carbobenzoxy	O
(	O
Cbz	O
)	O
group	O
to	O
give	O
3	O
-	O
N	O
-	O
Cbz	O
-	O
DAP	O
(	O
2a	O
)	O
.	O

Esterification	O
of	O
2a	O
with	O
isobutylene	O
afforded	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
carbobenzoxy	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diaminopropionate	I-IUPAC
(	O
3a	O
)	O
,	O
which	O
was	O
then	O
blocked	O
at	O
the	O
2	O
position	O
with	O
the	O
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
(	O
Boc	O
)	O
group	I-MODIFIER
to	O
give	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
carbobenzoxy	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
propionate	I-IUPAC
(	O
4	O
)	O
.	O

Selective	O
cleavage	O
of	O
the	O
Cbz	O
group	O
by	O
H2	O
/	O
Pd	O
gave	O
the	O
key	O
intermediate	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diaminopropionate	I-IUPAC
(	O
5	O
)	O
,	O
which	O
was	O
acylated	O
,	O
via	O
the	O
N	I-IUPAC
-	I-IUPAC
hydroxysuccinimide	I-IUPAC
esters	I-IUPAC
,	O
with	O
bromoacetic	I-IUPAC
acid	I-IUPAC
,	O
dichloroacetic	O
acid	O
,	O
and	O
fumaric	I-IUPAC
acid	I-IUPAC
monoethyl	I-IUPAC
ester	I-IUPAC
to	O
give	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromoacetamido	I-IUPAC
)	I-IUPAC
propionate	I-IUPAC
(	O
6a	O
)	O
,	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dichloroacetamido	I-IUPAC
)	I-IUPAC
propionate	I-IUPAC
(	O
6b	O
)	O
,	O
and	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxycarbonyl	I-IUPAC
)	I-IUPAC
acrylamido	I-IUPAC
]	I-IUPAC
-	I-IUPAC
propionate	I-IUPAC
(	O
6c	O
)	O
,	O
respectively	O
.	O

Deblocking	O
of	O
6a	O
-	O
c	O
gave	O
the	O
corresponding	O
amino	I-IUPAC
acids	I-IUPAC
(	B-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromoacetamido	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
hydrobromide	I-IUPAC
(	O
7a	O
)	O
,	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dichloroacetamido	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
7b	O
)	O
,	O
and	O
ethyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxyethyl	I-IUPAC
]	I-IUPAC
fumarate	I-IUPAC
(	O
7c	O
)	O
.	O

By	O
a	O
slightly	O
different	O
procedure	O
,	O
5	O
was	O
converted	O
in	O
two	O
steps	O
to	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
acetamidopropionic	I-IUPAC
acid	I-IUPAC
hydrobromide	I-IUPAC
(	O
7d	O
)	O
.	O

The	O
inhibition	O
of	O
ASase	O
by	O
7a	O
-	O
c	O
at	O
1	O
mM	O
was	O
93	O
,	O
19	O
,	O
and	O
37%	O
,	O
respectively	O
,	O
while	O
7d	O
was	O
without	O
inhibition	O
at	O
2	O
mM	O
.	O

Compounds	O
7a	O
-	O
c	O
failed	O
to	O
increase	O
the	O
life	O
span	O
of	O
mice	O
infected	O
with	O
B16	O
melanoma	O
.	O

4	O
-	O
(	O
Dimethylamino	O
)	O
-	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,1	I-IUPAC
'	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isobenzofuran	I-IUPAC
]	I-IUPAC
derivatives	I-MODIFIER
were	O
prepared	O
as	O
analogues	O
of	O
previously	O
reported	O
3	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
.	O

Metalation	O
of	O
benzanilide	O
with	O
n	I-IUPAC
-	I-IUPAC
butyllithium	I-IUPAC
,	O
addition	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
cyclohexanone	I-IUPAC
,	O
and	O
acidification	O
afforded	O
a	O
mixture	O
of	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,1	I-IUPAC
'	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isobenzofuran	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
1a	O
,	O
b	O
)	O
,	O
which	O
were	O
separated	O
by	O
fractional	O
crystallization	O
.	O

Addition	O
of	O
aryllithium	O
or	O
aryl	O
Grignard	O
reagents	O
to	O
1a	O
,	O
b	O
and	O
formic	O
acid	O
reduction	O
afforded	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,1	I-IUPAC
'	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isobenzofurans	I-IUPAC
]	I-IUPAC
3a	O
-	O
f	O
,	O
which	O
were	O
converted	O
to	O
secondary	O
amine	O
analogues	O
5a	O
-	O
e	O
.	O

Tentative	O
stereochemical	O
assignments	O
are	O
based	O
on	O
chemical	O
arguments	O
and	O
are	O
supported	O
by	O
13C	O
NMR	O
chemical	O
shift	O
data	O
.	O

Marked	O
inhibition	O
of	O
tetrabenazine	O
-	O
induced	O
ptosis	O
is	O
a	O
property	O
of	O
most	O
antidepressants	O
,	O
and	O
significant	O
antitetrabenazine	O
activity	O
is	O
observed	O
for	O
several	O
of	O
these	O
compounds	O
.	O

Optimal	O
antitetrabenazine	O
activity	O
is	O
associated	O
with	O
the	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
phenyl	I-PARTIUPAC
series	I-MODIFIER
,	O
and	O
the	O
cis	O
secondary	O
amine	O
5a	O
is	O
approximately	O
twice	O
as	O
potent	O
as	O
the	O
cis	O
tertiary	O
amine	O
3a	O
.	O

The	O
various	O
compounds	O
are	O
relatively	O
weak	O
with	O
respect	O
to	O
potentiation	O
of	O
L	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxytryptophan	I-IUPAC
-	O
induced	O
seizures	O
.	O

Several	O
series	O
of	O
N6	O
-	O
or	O
8	O
-	O
substituted	O
derivatives	O
of	O
adenosine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
triphosphate	I-IUPAC
(	O
ATP	O
)	O
were	O
synthesized	O
.	O

N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
Aminoalkyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
of	O
adenosine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
monophosphate	I-IUPAC
(	O
AMP	O
)	O
were	O
converted	O
into	O
their	O
omega	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
carbobenzyloxy	I-IUPAC
derivatives	I-MODIFIER
,	O
and	O
these	O
were	O
converted	O
,	O
via	O
the	O
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
derivatives	I-MODIFIER
of	O
their	O
5'	I-IUPAC
-	I-IUPAC
phosphorimidazolidates	I-IUPAC
,	O
into	O
the	O
corresponding	O
ATP	O
derivatives	O
.	O

Hydrogenolytic	O
removal	O
of	O
the	O
carbobenzyloxy	O
groups	O
,	O
followed	O
by	O
iodoacetylation	O
of	O
the	O
omega	O
-	O
amino	O
groups	O
with	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodoacetoxy	I-IUPAC
)	I-IUPAC
succinimide	I-IUPAC
,	O
gave	O
N6	O
-	O
R	O
-	O
ATP	O
,	O
where	O
R	O
=	O
(	O
CH2	O
)	O
nNHCOCH2I	O
(	O
n	O
=	O
2	O
-	O
-	O
8	O
)	O
or	O
(	O
CH2	O
)	O
nCON	O
)	O
CH3	O
)	O
(	O
CH2	O
)	O
mN	O
(	O
CH3	O
)	O
CO	O
(	O
CH2	O
)	O
nNHCOCH2I	O
(	O
n	O
=	O
m	O
=	O
3	O
;	O
n	O
=	O
3	O
,	O
m	O
=	O
4	O
;	O
n	O
=	O
4	O
,	O
m	O
=	O
3	O
;	O
n	O
=	O
m	O
=	O
4	O
)	O
.	O

Condensation	O
of	O
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
of	O
AMP	O
with	O
N	I-IUPAC
-	I-IUPAC
hydroxysuccinimide	I-IUPAC
esters	I-IUPAC
of	O
omega	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbobenzyloxy	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
gave	O
N6	O
-	O
(	O
CH2	O
)	O
nNHCO	O
(	O
CH2	O
)	O
mNH	O
-	O
Cbz	O
derivatives	O
of	O
AMP	O
which	O
,	O
upon	O
conversion	O
to	O
the	O
corresponding	O
derivatives	O
of	O
ATP	O
,	O
followed	O
by	O
removal	O
of	O
the	O
carbobenzyloxy	I-IUPAC
group	B-MODIFIER
and	O
iodoacetylation	O
,	O
as	O
described	O
above	O
,	O
gave	O
N6	O
-	O
(	O
CH2	O
)	O
nNHCO	O
(	O
CH2	O
)	O
mNHCOCH2I	O
-	O
ATP	O
derivatives	O
(	O
n	O
=	O
3	O
,	O
m	O
=	O
5	O
or	O
6	O
;	O
n	O
=	O
4	O
,	O
m	O
=	O
5	O
;	O
n	O
=	O
6	O
,	O
m	O
=	O
1	O
-	O
-	O
6	O
)	O
.	O

The	O
same	O
sequence	O
of	O
reactions	O
starting	O
with	O
N6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
derivatives	I-MODIFIER
of	O
N6	O
-	O
CH3	O
-	O
AMP	O
gave	O
N6	O
-	O
CH3	O
,	O
N6	O
-	O
(	O
CH2	O
)	O
nH	O
(	O
CH3	O
)	O
CO	O
(	O
CH2	O
)	O
mNHCOCH2I	O
derivatives	O
of	O
ATP	O
(	O
n	O
=	O
4	O
,	O
m	O
=	O
3	O
,	O
5	O
or	O
6	O
;	O
n	O
=	O
6	O
,	O
m	O
=	O
5	O
or	O
6	O
)	O
.	O

Reaction	O
of	O
alpha	O
,	O
omega	O
-	O
diaminoalkanes	O
with	O
8	O
-	O
Br	O
-	O
ATP	O
gave	O
8	O
-	O
NH	O
(	O
CH2	O
)	O
nNH2	O
derivatives	O
of	O
ATP	O
,	O
which	O
upon	O
iodoacetylation	O
gave	O
8	O
-	O
NH	O
(	O
CH2	O
)	O
nNHCOCH2I	O
derivatives	O
of	O
ATP	O
(	O
n	O
=	O
2	O
,	O
4	O
,	O
6	O
,	O
or	O
8	O
)	O
.	O

Substrate	O
and	O
inhibitor	O
properties	O
indicated	O
that	O
the	O
ATP	O
derivatives	O
are	O
potential	O
exco	O
-	O
ATP	O
-	O
site	O
-	O
directed	O
inactivators	O
of	O
hexokinases	O
,	O
adenylate	O
kinases	O
,	O
and	O
pyruvate	O
kinases	O
.	O

Several	O
7	I-IUPAC
-	I-IUPAC
hydroxypyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
1-21	O
)	O
,	O
7	I-IUPAC
-	I-IUPAC
mercaptopyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
37-49	O
)	O
,	O
and	O
4	I-IUPAC
-	I-IUPAC
alkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
50-55	O
)	O
and	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
alkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
thiones	I-IUPAC
(	O
56-60	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
antischistosomal	O
activity	O
against	O
Schistosoma	O
mansoni	O
.	O

Of	O
the	O
compounds	O
examined	O
,	O
the	O
greatest	O
degree	O
of	O
activity	O
in	O
vitro	O
was	O
found	O
with	O
the	O
7	I-IUPAC
-	I-IUPAC
mercaptopyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O

In	O
particular	O
,	O
compounds	O
37	O
and	O
47	O
proved	O
lethal	O
at	O
100	O
micrograms	O
/	O
mL	O
after	O
an	O
exposure	O
of	O
only	O
1	O
h	O
.	O

The	O
7	I-IUPAC
-	I-IUPAC
hydroxypyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
-	I-IUPAC
pyrimidines	I-IUPAC
were	O
not	O
as	O
active	O
.	O

None	O
of	O
the	O
compounds	O
exhibiting	O
in	O
vitro	O
activity	O
were	O
active	O
against	O
S	O
.	O

mansoni	O
in	O
vivo	O
.	O

The	O
metabolic	O
fate	O
of	O
tolazamide	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hexahydroazepin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
tolylsulfonylurea	I-IUPAC
(	O
1	O
)	O
,	O
was	O
studied	O
in	O
man	O
and	O
in	O
the	O
rat	O
using	O
tritium	O
-	O
labeled	O
1	O
.	O

The	O
metabolites	O
were	O
isolated	O
in	O
crystalline	O
form	O
from	O
urine	O
for	O
structure	O
determination	O
.	O

The	O
crystal	O
structure	O
and	O
final	O
molecular	O
structure	O
of	O
one	O
of	O
these	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyhexahydroazepin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
tolylsulfonylurea	I-IUPAC
(	O
5	O
)	O
,	O
were	O
determined	O
using	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
techniques	O
.	O

Following	O
oral	O
administration	O
of	O
tritiated	O
tolazamide	O
to	O
male	O
humans	O
,	O
85%	O
of	O
the	O
radioactivity	O
was	O
excreted	O
in	O
urine	O
during	O
a	O
5	O
-	O
day	O
period	O
.	O

In	O
addition	O
to	O
being	O
excreted	O
in	O
urine	O
unchanged	O
,	O
tolazamide	O
was	O
metabolized	O
to	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hexahydroazepin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyphenyl	I-IUPAC
)	I-IUPAC
sulfonylurea	I-IUPAC
(	O
2	O
)	O
,	O
p	I-IUPAC
-	I-IUPAC
toluenesulfonamide	I-IUPAC
(	O
3	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hexahydroazepin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethylphenyl	I-IUPAC
)	I-IUPAC
sulfonylurea	I-IUPAC
(	O
4	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyhexahydroazepin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
tolylsulfonylurea	I-IUPAC
(	O
5	O
)	O
and	O
a	O
labile	O
,	O
unidentified	O
metabolite	O
6	O
by	O
man	O
.	O

The	O
relative	O
amounts	O
of	O
these	O
materials	O
excreted	O
in	O
0-24	O
-	O
h	O
urine	O
collections	O
from	O
eight	O
subjects	O
averaged	O
7	O
,	O
17	O
,	O
26	O
,	O
10	O
,	O
25	O
,	O
and	O
15%	O
for	O
1-6	O
,	O
respectively	O
.	O

In	O
the	O
female	O
rat	O
,	O
79%	O
of	O
an	O
orally	O
administered	O
dose	O
of	O
tritiated	O
tolazamide	O
was	O
excreted	O
in	O
urine	O
during	O
a	O
5	O
-	O
day	O
period	O
as	O
1-4	O
.	O

The	O
relative	O
amounts	O
of	O
these	O
materials	O
excreted	O
during	O
the	O
24	O
-	O
h	O
period	O
following	O
administration	O
of	O
tolazamide	O
were	O
10	O
,	O
5	O
,	O
5	O
,	O
and	O
80%	O
for	O
1-4	O
,	O
respectively	O
.	O

Incubation	O
of	O
5	I-IUPAC
-	I-IUPAC
hydroxytryptamine	I-IUPAC
(	O
1	O
)	O
with	O
L	O
-	O
cysteine	O
and	O
pig	O
or	O
bovine	O
brain	O
microsomes	O
and	O
an	O
NADPH	O
-	O
generating	O
system	O
or	O
with	O
synaptosomes	O
results	O
in	O
the	O
rapid	O
formation	O
of	O
the	O
(	I-MODIFIER
2R	I-MODIFIER
,	I-MODIFIER
4R	I-MODIFIER
)	I-MODIFIER
-	I-MODIFIER
and	O
(	I-MODIFIER
2S	I-MODIFIER
,	I-MODIFIER
4R	I-MODIFIER
)	I-MODIFIER
-	I-MODIFIER
epimers	I-MODIFIER
of	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
thiazolidine	I-IUPAC
.	O

Incubation	O
of	O
1	O
and	O
glutathione	O
under	O
the	O
same	O
experimental	O
conditions	O
yields	O
the	O
(	I-MODIFIER
2R	I-MODIFIER
,	I-MODIFIER
4R	I-MODIFIER
)	I-MODIFIER
-	I-MODIFIER
and	O
(	I-MODIFIER
2S	I-MODIFIER
,	I-MODIFIER
4R	I-MODIFIER
)	I-MODIFIER
-	I-MODIFIER
epimers	I-MODIFIER
of	O
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
carboxymethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
thiazolidinepentanoic	I-IUPAC
acid	I-IUPAC
.	O

These	O
various	O
thiazolidine	O
derivatives	O
are	O
formed	O
by	O
nucleophilic	O
addition	O
of	O
the	O
thiol	O
residues	O
of	O
cysteine	O
or	O
glutathione	O
to	O
the	O
aldehyde	I-IUPAC
group	B-MODIFIER
of	O
5	I-IUPAC
-	I-IUPAC
hydroxyindole	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
acetaldehyde	I-IUPAC
(	O
2	O
)	O
,	O
the	O
primary	O
product	O
of	O
the	O
monoamine	O
oxidase	O
-	O
mediated	O
oxidative	O
deamination	O
of	O
1	O
.	O

The	O
facile	O
reaction	O
of	O
cysteine	O
and	O
glutathione	O
with	O
2	O
might	O
represent	O
a	O
mechanism	O
designed	O
to	O
scavenge	O
the	O
biogenic	O
aldehyde	O
and	O
therefore	O
to	O
prevent	O
its	O
alkylation	O
of	O
key	O
intraneuronal	O
protein	O
nucleophiles	O
.	O

We	O
have	O
found	O
that	O
alpha	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	O
substituted	I-MODIFIER
halo	B-IUPAC
enol	I-IUPAC
lactones	I-IUPAC
(	O
I	O
and	O
II	O
)	O
are	O
effective	O
mechanism	O
-	O
based	O
inactivators	O
for	O
chymotrypsin	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
,	O
for	O
comparative	O
purposes	O
,	O
halo	I-IUPAC
enol	I-IUPAC
lactones	I-IUPAC
with	O
aryl	O
functions	O
situated	O
beta	O
and	O
gamma	O
to	O
the	O
lactone	O
carbonyl	O
group	O
.	O

We	O
synthesized	O
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
(	O
1	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
(	O
2	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyranone	I-IUPAC
(	O
3	O
)	O
,	O
and	O
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyranone	I-IUPAC
(	O
4	O
)	O
,	O
using	O
a	O
halolactonization	O
reaction	O
to	O
convert	O
the	O
appropriate	O
phenyl	O
-	O
substituted	O
acetylenic	O
acid	O
precursor	O
into	O
the	O
corresponding	O
5	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
halomethylidene	I-IUPAC
)	I-IUPAC
furanone	I-IUPAC
and	O
6	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
halomethylidene	I-IUPAC
)	I-IUPAC
pyranone	I-IUPAC
system	I-MODIFIER
.	O

The	O
4	I-IUPAC
-	I-IUPAC
phenylfuranone	I-IUPAC
(	O
1	O
and	O
2	O
)	O
and	O
the	O
5	I-IUPAC
-	I-IUPAC
phenylpyranone	I-IUPAC
(	O
4	O
)	O
proved	O
to	O
be	O
only	O
reversible	O
,	O
competitive	O
inhibitors	O
.	O

By	O
contrast	O
,	O
the	O
4	I-IUPAC
-	I-IUPAC
phenyltetrahydropyranone	I-IUPAC
(	O
3	O
)	O
inactivated	O
alpha	O
-	O
chymotrypsin	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

This	O
inactivation	O
was	O
very	O
rapid	O
but	O
reversible	O
,	O
with	O
regeneration	O
of	O
enzyme	O
activity	O
being	O
spontaneous	O
and	O
hydrazine	O
-	O
accelerated	O
,	O
suggestive	O
of	O
the	O
intermediacy	O
of	O
a	O
stable	O
acyl	O
enzyme	O
.	O

Kinetic	O
comparison	O
of	O
the	O
iodomethylene	O
lactone	O
3	O
with	O
the	O
corresponding	O
protio	O
lactone	O
25	O
indicates	O
that	O
the	O
iodine	O
accelerates	O
the	O
rate	O
of	O
chymotrypsin	O
acylation	O
but	O
produces	O
an	O
acyl	O
enzyme	O
that	O
is	O
more	O
hydrolytically	O
labile	O
than	O
that	O
formed	O
from	O
lactone	O
25	O
.	O

From	O
the	O
results	O
of	O
this	O
study	O
,	O
we	O
conclude	O
that	O
a	O
phenyl	O
group	O
situated	O
at	O
C	O
-	O
3	O
(	O
alpha	O
to	O
the	O
lactone	O
carbonyl	O
group	O
)	O
in	O
both	O
the	O
5	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
(	O
I	O
)	O
and	O
6	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyranone	I-IUPAC
(	O
II	O
)	O
series	O
is	O
essential	O
for	O
their	O
activity	O
as	O
mechanism	O
-	O
based	O
irreversible	O
inactivators	O
of	O
chymotrypsin	O
.	O

The	O
corresponding	O
beta	O
-	O
aryl	O
-	O
substituted	O
lactones	O
,	O
by	O
contrast	O
,	O
are	O
potent	O
acylating	O
agents	O
that	O
lead	O
to	O
acyl	O
enzymes	O
of	O
high	O
stability	O
.	O

A	O
series	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
naphthalenylsulfonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
thiazolidinediones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
antihyperglycemic	O
activity	O
in	O
an	O
insulin	O
-	O
resistant	O
,	O
genetically	O
diabetic	O
db	O
/	O
db	O
mouse	O
model	O
of	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
)	O
.	O

The	O
sulfones	O
could	O
be	O
synthesized	O
by	O
a	O
novel	O
,	O
selective	O
C	O
-	O
5	O
sulfonylation	O
of	O
dilithio	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
thiazolidinedione	I-IUPAC
with	O
appropriate	O
sulfonyl	O
chlorides	O
.	O

Within	O
this	O
series	O
,	O
naphthalene	O
was	O
found	O
to	O
be	O
superior	O
to	O
other	O
groups	O
for	O
eliciting	O
antihyperglycemic	O
activity	O
,	O
including	O
the	O
p	I-IUPAC
-	I-IUPAC
alkoxyphenyl	I-IUPAC
group	I-MODIFIER
found	O
in	O
ciglitazone	O
,	O
a	O
prototypical	O
agent	O
for	O
this	O
activity	O
.	O

Attachment	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
sulfonyl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
thiazolidinedione	I-IUPAC
moiety	I-MODIFIER
to	O
the	O
2	O
-	O
naphthalene	O
position	O
led	O
to	O
optimum	O
activity	O
.	O

Other	O
linkers	O
between	O
the	O
naphthalene	O
and	O
2,4	I-IUPAC
-	I-IUPAC
thiazolidinedione	I-IUPAC
rings	I-MODIFIER
,	O
such	O
as	O
thio	O
,	O
methylene	O
,	O
oxy	O
,	O
and	O
sulfinyl	O
led	O
to	O
decreased	O
antihyperglycemic	O
activity	O
.	O

The	O
best	O
analogue	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthalenylsulfonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
thiazolidinedione	I-IUPAC
(	O
AY	O
-	O
31,637	O
)	O
was	O
equipotent	O
to	O
ciglitazone	O
in	O
two	O
animal	O
models	O
of	O
NIDDM	O
.	O

The	O
reduction	O
of	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
the	O
brain	O
has	O
been	O
measured	O
in	O
dementia	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
and	O
dementia	O
with	O
Lewy	O
bodies	O
using	O
(	O
11	O
)	O
C	O
-	O
labeled	O
acetylcholine	O
analogues	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
]	I-IUPAC
methylpiperidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
acetate	I-IUPAC
and	O
propionate	O
,	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

Our	O
aim	O
was	O
to	O
develop	O
an	O
(	O
18	O
)	O
F	O
-	O
labeled	O
acetylcholine	O
analogue	O
useful	O
for	O
brain	O
AChE	O
mapping	O
with	O
PET	O
,	O
since	O
(	O
18	O
)	O
F	O
,	O
with	O
a	O
longer	O
half	O
-	O
life	O
,	O
has	O
advantages	O
over	O
(	O
11	O
)	O
C	O
.	O

In	O
a	O
preliminary	O
study	O
,	O
a	O
series	O
of	O
N	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
14	I-PARTIUPAC
)	I-PARTIUPAC
C	I-PARTIUPAC
]	I-PARTIUPAC
ethylpiperidin	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
or	O
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
ylmethanol	I-PARTIUPAC
esters	I-PARTIUPAC
(	O
acetyl	O
and	O
propionyl	O
esters	O
)	O
were	O
newly	O
designed	O
and	O
evaluated	O
in	O
vitro	O
regarding	O
the	O
reactivity	O
with	O
and	O
specificity	O
to	O
AChE	O
using	O
purified	O
human	O
enzymes	O
,	O
leading	O
to	O
a	O
novel	O
(	O
18	O
)	O
F	O
-	O
labeled	O
acetylcholine	O
analogue	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
18	I-IUPAC
)	I-IUPAC
F	I-IUPAC
]	I-IUPAC
fluoroethylpiperidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
acetate	I-IUPAC
.	O

In	O
rat	O
experiments	O
,	O
the	O
(	O
18	O
)	O
F	O
-	O
labeled	O
candidate	O
showed	O
desirable	O
properties	O
for	O
PET	O
AChE	O
measurement	O
:	O
high	O
brain	O
uptake	O
of	O
the	O
authentic	O
ester	O
,	O
high	O
AChE	O
specificity	O
,	O
a	O
moderate	O
hydrolysis	O
rate	O
,	O
and	O
low	O
membrane	O
permeability	O
(	O
metabolic	O
trapping	O
)	O
of	O
the	O
metabolite	O
.	O

A	O
potent	O
and	O
orally	O
active	O
NK1	O
antagonist	O
,	O
trans	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
benzyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1,7	I-IUPAC
-	I-IUPAC
naphthyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
1t	O
)	O
,	O
was	O
shown	O
to	O
exist	O
as	O
a	O
mixture	O
of	O
separable	O
and	O
stable	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-	O
atropisomers	O
(	O
1t	O
-	O
A	O
and	O
1t	O
-	O
B	O
)	O
originating	O
from	O
the	O
restricted	O
rotation	O
around	O
the	O
-	O
C	O
(	O
6	O
)	O
-	O
C	O
(	O
=	O
O	O
)	O
-	O
bond	O
;	O
the	O
antagonistic	O
activities	O
of	O
1t	O
-	O
A	O
were	O
ca.	O
6-13	O
-	O
fold	O
higher	O
than	O
those	O
of	O
1t	O
-	O
B	O
.	O

Analogues	O
of	O
1t	O
(	O
3	O
)	O
,	O
which	O
have	O
(	I-PARTIUPAC
S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
groups	I-MODIFIER
at	O
the	O
benzylic	O
methylene	O
portion	O
of	O
1t	O
,	O
were	O
prepared	O
and	O
separated	O
into	O
the	O
diastereomeric	O
atropisomers	O
,	O
3a	O
-	O
A	O
,	O
3a	O
-	O
B	O
and	O
3b	O
-	O
A	O
,	O
3b	O
-	O
B	O
,	O
in	O
enantiomerically	O
pure	O
forms	O
.	O

Among	O
the	O
four	O
isomers	O
of	O
3	O
,	O
the	O
(	O
aR	O
,	O
S	O
)	O
-	O
enantiomer	O
(	O
3a	O
-	O
A	O
)	O
exhibited	O
the	O
most	O
potent	O
antagonistic	O
activities	O
with	O
an	O
IC50	O
value	O
of	O
0.80	O
nM	O
(	O
in	O
vitro	O
inhibition	O
of	O
[	O
125I	O
]	O
BH	O
-	O
SP	O
binding	O
in	O
human	O
IM	O
-	O
9	O
cells	O
)	O
and	O
ED50	O
values	O
of	O
9.3	O
micrograms	O
/	O
kg	O
(	O
iv	O
)	O
and	O
67.7	O
micrograms	O
/	O
kg	O
(	O
po	O
)	O
(	O
in	O
vivo	O
inhibition	O
of	O
capsaicin	O
-	O
induced	O
plasma	O
extravasation	O
in	O
guinea	O
pig	O
trachea	O
)	O
,	O
while	O
the	O
activity	O
of	O
the	O
(	O
aS	O
,	O
R	O
)	O
-	O
enantiomer	O
(	O
3b	O
-	O
B	O
)	O
was	O
the	O
weakest	O
with	O
an	O
IC50	O
value	O
of	O
620	O
nM	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
in	O
this	O
series	O
of	O
antagonists	O
indicate	O
that	O
the	O
(	O
R	O
)	O
-	O
configuration	O
at	O
the	O
axial	O
bond	O
and	O
the	O
stacking	O
(	O
or	O
stacking	O
-	O
like	O
)	O
conformation	O
between	O
the	O
two	O
phenyl	I-IUPAC
rings	B-MODIFIER
as	O
shown	O
in	O
1t	O
-	O
A	O
and	O
3a	O
-	O
A	O
are	O
essential	O
for	O
high	O
-	O
affinity	O
binding	O
and	O
suggest	O
that	O
the	O
amide	I-IUPAC
moiety	B-MODIFIER
functions	O
as	O
a	O
hydrogen	O
bond	O
acceptor	O
in	O
the	O
interaction	O
with	O
the	O
receptor	O
.	O

Nonclassical	O
antifolates	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
3-12	O
with	O
bridge	O
region	O
variations	O
of	O
C8	O
-	O
S9	O
,	O
C8	O
-	O
N9	O
,	O
and	O
C8	O
-	O
O9	O
and	O
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
phenoxyphenyl	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
phenoxyphenyl	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
biphenyl	I-IUPAC
side	I-MODIFIER
chains	I-MODIFIER
were	O
synthesized	O
as	O
phenyl	O
ring	O
appended	O
analogues	O
of	O
previously	O
reported	O
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
anilinomethyl	I-IUPAC
)	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O

The	O
phenyl	O
ring	O
appended	O
analogues	O
were	O
designed	O
to	O
specifically	O
interact	O
with	O
Phe69	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
from	O
Pneumocystis	O
carinii	O
(	O
pc	O
)	O
to	O
afford	O
selective	O
inhibitors	O
of	O
pcDHFR	O
.	O

Additional	O
substituted	O
phenyl	O
side	O
chains	O
which	O
include	O
2,5	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
,	O
3,4	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
,	O
3,4,5	I-IUPAC
-	I-IUPAC
trichloro	I-IUPAC
,	O
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
,	O
and	O
2,5	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
analogues	I-MODIFIER
13-17	O
were	O
also	O
synthesized	O
.	O

The	O
compounds	O
were	O
prepared	O
by	O
nucleophilic	O
displacement	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
2	O
)	O
with	O
the	O
appropriate	O
thiol	O
,	O
amine	O
,	O
or	O
naphthol	O
.	O

Compound	O
2	O
was	O
obtained	O
from	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxypyrimidine	I-IUPAC
and	O
1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
dichloroacetone	I-IUPAC
.	O

The	O
compounds	O
were	O
evaluated	O
as	O
inhibitors	O
against	O
DHFR	O
from	O
P	O
.	O

carinii	O
,	O
Toxoplasma	O
gondii	O
,	O
and	O
rat	O
liver	O
.	O

Two	O
analogues	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
naphthylthio	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
5	O
)	O
and	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
phenylanilino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
11	O
)	O
showed	O
significant	O
selectivity	O
and	O
potency	O
for	O
pcDHFR	O
compared	O
to	O
trimethoprim	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
5	O
with	O
pcDHFR	O
was	O
also	O
carried	O
out	O
,	O
which	O
corroborated	O
the	O
design	O
rationale	O
and	O
indicated	O
a	O
hydrophobic	O
interaction	O
of	O
the	O
naphthalene	O
ring	O
of	O
5	O
and	O
Phe69	O
of	O
pcDHFR	O
which	O
is	O
responsible	O
,	O
in	O
part	O
,	O
for	O
the	O
more	O
than	O
18	O
-	O
fold	O
selectivity	O
of	O
5	O
for	O
pcDHFR	O
as	O
compared	O
with	O
rat	O
liver	O
DHFR	O
.	O

New	O
compounds	O
of	O
the	O
nitroimidazole	O
series	O
have	O
been	O
synthesized	O
as	O
radiosensitizers	O
which	O
selectively	O
sensitize	O
hypoxic	O
cells	O
to	O
the	O
lethal	O
effect	O
of	O
radiation	O
.	O

The	O
reaction	O
of	O
2,4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dinitroimidazole	I-IUPAC
(	O
2	O
)	O
with	O
chloroethanol	O
or	O
hydrochloric	O
acid	O
yielded	O
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
chloroimidazole	I-IUPAC
(	O
3	O
)	O
,	O
which	O
upon	O
reaction	O
with	O
ethylene	O
oxide	O
yielded	O
the	O
4	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloroimidazole	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethanol	I-IUPAC
(	O
6	O
)	O
.	O

Reaction	O
of	O
2	O
with	O
ethylene	O
oxide	O
resulted	O
in	O
a	O
mixture	O
of	O
two	O
compounds	O
,	O
the	O
2,4	I-IUPAC
-	I-IUPAC
dinitroimidazole	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethanol	I-IUPAC
(	O
4	O
)	O
and	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitroimidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
oxazole	I-IUPAC
(	O
5	O
)	O
.	O

The	O
structure	O
of	O
the	O
new	O
heterocyclic	O
compound	O
5	O
was	O
confirmed	O
by	O
1H	O
NMR	O
,	O
mass	O
spectrum	O
,	O
and	O
X	O
-	O
ray	O
crystallography	O
.	O

These	O
agents	O
were	O
tested	O
for	O
their	O
ability	O
to	O
sensitize	O
hypoxic	O
Escherichia	O
coli	O
cells	O
to	O
killing	O
by	O
ionizing	O
radiation	O
.	O

Compound	O
4	O
was	O
found	O
to	O
be	O
the	O
most	O
active	O
agent	O
of	O
this	O
series	O
of	O
compounds	O
.	O

The	O
synthesis	O
of	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thienylvinyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiazoles	I-IUPAC
and	O
6	I-IUPAC
-	I-IUPAC
thienylimidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiazoles	I-IUPAC
is	O
reported	O
.	O

These	O
compounds	O
were	O
tested	O
as	O
specific	O
inhibitors	O
of	O
the	O
NADH	O
:	O
ubiquinone	O
(	O
UBQ	O
)	O
reductase	O
activity	O
of	O
NADH	O
dehydrogenase	O
in	O
mitochondrial	O
membranes	O
.	O

The	O
6	I-IUPAC
-	I-IUPAC
thienylimidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiazoles	I-IUPAC
were	O
more	O
potent	O
in	O
mammalian	O
than	O
in	O
nematode	O
mitochondria	O
and	O
had	O
an	O
average	O
titer	O
of	O
0.11	O
mM	O
for	O
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiazole	I-IUPAC
(	O
10	O
)	O
.	O

This	O
compound	O
is	O
noncompetitive	O
with	O
the	O
ubiquinone	O
substrate	O
and	O
interacts	O
with	O
a	O
site	O
which	O
is	O
mutually	O
exclusive	O
with	O
that	O
of	O
rotenone	O
but	O
nonexclusive	O
with	O
that	O
of	O
piericidin	O
and	O
several	O
other	O
inhibitors	O
of	O
NADH	O
dehydrogenase	O
.	O

In	O
the	O
series	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thienylvinyl	I-IUPAC
)	I-IUPAC
imidazothiazoles	I-IUPAC
,	O
the	O
hydrobromide	I-MODIFIER
of	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienylvinyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiazole	I-IUPAC
(	O
E	O
-	O
5	O
.	O

HBr	O
)	O
was	O
found	O
to	O
be	O
more	O
potent	O
as	O
an	O
inhibitor	O
of	O
the	O
NADH	O
:	O
UBQ	O
activity	O
(	O
IC50	O
=	O
15-17	O
microM	O
)	O
than	O
the	O
6	I-IUPAC
-	I-IUPAC
thienylimidazoles	I-IUPAC
such	O
as	O
10	O
.	O

The	O
inhibitory	O
action	O
of	O
E	O
-	O
5	O
.	O

HBr	O
and	O
its	O
analogs	O
is	O
different	O
from	O
that	O
of	O
compound	O
10	O
as	O
indicated	O
by	O
the	O
mutual	O
exclusivity	O
with	O
other	O
inhibitors	O
and	O
the	O
relative	O
inhibition	O
of	O
the	O
activity	O
with	O
various	O
electron	O
acceptors	O
.	O

The	O
transformation	O
of	O
milrinone	O
to	O
1,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
13a	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
thiazolo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
51	O
)	O
,	O
and	O
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
22	O
)	O
resulted	O
in	O
very	O
potent	O
cAMP	O
PDE	O
III	O
inhibitors	O
with	O
in	O
vitro	O
activity	O
in	O
the	O
nanomolar	O
range	O
.	O

1,3	I-IUPAC
-	I-IUPAC
Dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
13	O
were	O
prepared	O
from	O
2	I-IUPAC
-	I-IUPAC
aminopyridine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
(	O
7	O
,	O
10	O
)	O
via	O
Curtius	O
rearrangement	O
.	O

1,8	I-IUPAC
-	I-IUPAC
Naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
22	O
and	O
the	O
corresponding	O
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
derivative	I-MODIFIER
28	O
were	O
prepared	O
from	O
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bipyridin	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
21	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
bipyridin	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
24	O
)	O
,	O
respectively	O
,	O
via	O
Heck	O
reaction	O
.	O

Thiazolo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
35	O
were	O
prepared	O
from	O
6	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bipyridin	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
30	O
and	O
32	O
via	O
a	O
four	O
-	O
step	O
sequence	O
.	O

Treatment	O
of	O
6	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bipyridine	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thiol	I-IUPAC
(	O
59	O
)	O
with	O
ethyl	I-IUPAC
bromoacetate	B-IUPAC
and	O
ethyl	I-IUPAC
bromodifluoroacetate	B-IUPAC
gave	O
pyridothiazinones	O
60	O
and	O
61	O
,	O
respectively	O
.	O

Several	O
3beta	I-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	I-MODIFIER
phenyl	B-PARTIUPAC
)	O
-	I-PARTIUPAC
2beta	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
isoxazol	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
)	I-PARTIUPAC
tropanes	I-PARTIUPAC
(	O
3a	O
-	O
t	O
)	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
radioligand	O
binding	O
at	O
the	O
DAT	O
,	O
5	O
-	O
HTT	O
,	O
and	O
NET	O
as	O
well	O
as	O
in	O
gross	O
observation	O
and	O
locomotor	O
activity	O
in	O
mice	O
and	O
in	O
rats	O
trained	O
to	O
discriminate	O
cocaine	O
.	O

All	O
compounds	O
showed	O
high	O
affinity	O
for	O
the	O
DAT	O
.	O

The	O
IC	O
(	O
50	O
)	O
values	O
ranged	O
from	O
0.5	O
to	O
26	O
nM	O
.	O

With	O
the	O
exception	O
of	O
3e	O
and	O
3f	O
,	O
which	O
have	O
no	O
substituent	O
on	O
the	O
2beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
isoxazole	I-IUPAC
)	I-IUPAC
ring	I-MODIFIER
,	O
all	O
compounds	O
were	O
selective	O
for	O
the	O
DAT	O
relative	O
to	O
the	O
5	O
-	O
HTT	O
and	O
NET	O
.	O

No	O
compound	O
showed	O
death	O
when	O
dosed	O
at	O
100	O
mg	O
/	O
kg	O
;	O
however	O
,	O
most	O
compounds	O
did	O
show	O
signs	O
typical	O
of	O
dopamine	O
activity	O
.	O

The	O
ED	O
(	O
50	O
)	O
values	O
for	O
2beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
isoxazoles	I-IUPAC
)	I-IUPAC
that	O
caused	O
locomotor	O
stimulation	O
ranged	O
from	O
0.2	O
to	O
12.8	O
mg	O
/	O
kg	O
.	O

Most	O
compounds	O
showed	O
slower	O
on	O
-	O
set	O
and	O
longer	O
duration	O
of	O
action	O
relative	O
to	O
cocaine	O
.	O

Surprisingly	O
,	O
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
tropane	I-IUPAC
(	O
3p	O
)	O
and	O
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
tropane	I-IUPAC
(	O
3r	O
)	O
did	O
not	O
produce	O
significant	O
increases	O
in	O
locomotor	O
activity	O
.	O

In	O
the	O
cocaine	O
discrimination	O
test	O
,	O
all	O
analogues	O
showed	O
full	O
or	O
at	O
least	O
50%	O
generalization	O
with	O
the	O
exception	O
of	O
3p	O
,	O
which	O
did	O
not	O
show	O
generalization	O
.	O

Importantly	O
,	O
both	O
the	O
locomotor	O
activity	O
and	O
the	O
cocaine	O
discrimination	O
ED	O
(	O
50	O
)	O
values	O
were	O
correlated	O
with	O
the	O
DAT	O
binding	O
but	O
not	O
5	O
-	O
HTT	O
and	O
NET	O
binding	O
.	O

This	O
provides	O
further	O
support	O
for	O
the	O
dopamine	O
hypothesis	O
of	O
cocaine	O
abuse	O
.	O

High	O
DAT	O
affinity	O
and	O
selectivity	O
,	O
increased	O
locomotor	O
activity	O
with	O
slow	O
onset	O
and	O
long	O
duration	O
of	O
action	O
,	O
and	O
generalization	O
to	O
cocaine	O
shown	O
by	O
the	O
3beta	I-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	I-MODIFIER
phenyl	B-PARTIUPAC
)	O
-	I-PARTIUPAC
2beta	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
isoxazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
tropanes	I-IUPAC
are	O
properties	O
thought	O
necessary	O
for	O
a	O
pharmacotherapy	O
for	O
treating	O
cocaine	O
abuse	O
.	O

Tomaymycin	O
is	O
a	O
member	O
of	O
the	O
pyrrolo	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepine	I-IUPAC
antitumor	O
-	O
antibiotic	O
group	O
that	O
binds	O
covalently	O
to	O
the	O
exocyclic	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
of	O
guanine	O
in	O
DNA	O
.	O

Previous	O
correlation	O
of	O
fluorescence	O
and	O
NMR	O
data	O
suggested	O
that	O
the	O
11R	O
,	O
11aS	O
and	O
the	O
11S	O
,	O
11aS	O
diastereomers	O
of	O
tomaymycin	O
could	O
bind	O
to	O
DNA	O
in	O
two	O
orientations	O
relative	O
to	O
the	O
covalently	O
modified	O
guanine	O
(	O
Barkley	O
,	O
M	O
.	O

D	O
.	O

;	O
Cheatham	O
,	O
S	O
.	O

;	O
Thurston	O
,	O
D	O
.	O

E	O
.	O

;	O
Hurley	O
,	O
L	O
.	O

H	O
.	O

Biochemistry	O
1986	O
,	O
25	O
,	O
3021-3031	O
)	O
.	O

We	O
now	O
report	O
on	O
fluorescence	O
,	O
one	O
-	O
and	O
two	O
-	O
dimensional	O
proton	O
NMR	O
,	O
and	O
molecular	O
modeling	O
studies	O
of	O
the	O
tomaymycin	O
-	O
d	O
(	O
ATGCAT	O
)	O
2	O
adduct	O
,	O
which	O
corroborate	O
these	O
earlier	O
observations	O
.	O

Fluorescence	O
measurements	O
show	O
that	O
there	O
are	O
two	O
species	O
of	O
tomaymycin	O
bound	O
to	O
d	O
(	O
ATGCAT	O
)	O
2	O
,	O
which	O
are	O
tentatively	O
identified	O
as	O
the	O
11R	O
,	O
11aS	O
and	O
11S	O
,	O
11aS	O
diastereomers	O
.	O

Two	O
distinct	O
sets	O
of	O
signals	O
for	O
the	O
tomaymycin	O
molecule	O
are	O
present	O
in	O
the	O
proton	O
NMR	O
spectrum	O
of	O
the	O
tomaymycin	O
-	O
d	O
(	O
ATGCAT	O
)	O
2	O
duplex	O
adduct	O
.	O

Two	O
-	O
dimensional	O
correlation	O
spectroscopy	O
(	O
2D	O
-	O
COSY	O
)	O
studies	O
also	O
show	O
connectivities	O
for	O
four	O
cytosine	O
H5	O
-	O
H6	O
and	O
eight	O
thymine	O
methyl	O
-	O
H6	O
protons	O
and	O
thus	O
clearly	O
establish	O
the	O
presence	O
of	O
two	O
distinct	O
species	O
of	O
tomaymycin	O
-	O
d	O
(	O
ATGCAT	O
)	O
2	O
adducts	O
in	O
solution	O
.	O

A	O
single	O
scalar	O
11-11	O
a	O
1H	O
NMR	O
coupling	O
in	O
the	O
2D	O
-	O
COSY	O
spectrum	O
is	O
indicative	O
of	O
an	O
adduct	O
species	O
that	O
has	O
an	O
S	O
configuration	O
at	O
the	O
C	O
-	O
11	O
position	O
.	O

Two	O
-	O
dimensional	O
nuclear	O
Overhauser	O
effect	O
(	O
NOESY	O
)	O
spectra	O
of	O
the	O
tomaymycin	O
-	O
d	O
(	O
ATGCAT	O
)	O
2	O
duplex	O
adduct	O
show	O
that	O
the	O
adducts	O
are	O
relatively	O
nondistortive	O
.	O

In	O
a	O
NOESY	O
experiment	O
,	O
cross	O
-	O
peaks	O
were	O
identified	O
between	O
both	O
the	O
aromatic	O
H9	O
proton	O
and	O
the	O
ethylidine	O
methyl	O
protons	O
of	O
tomaymycin	O
and	O
two	O
different	O
adenine	O
H2	O
protons	O
of	O
d	O
(	O
ATGCAT	O
)	O
2	O
.	O

Molecular	O
mechanics	O
calculations	O
with	O
AMBER	O
show	O
that	O
the	O
two	O
species	O
with	O
the	O
thermodynamically	O
most	O
favorable	O
binding	O
energies	O
are	O
the	O
11R	O
,	O
11aS	O
and	O
11S	O
,	O
11aS	O
isomers	O
with	O
their	O
aromatic	O
rings	O
to	O
the	O
5'	O
and	O
3'	O
sides	O
of	O
the	O
covalently	O
bound	O
guanine	O
,	O
respectively	O
.	O

The	O
NOEs	O
observed	O
between	O
tomaymycin	O
protons	O
and	O
adenine	O
H2	O
protons	O
are	O
in	O
accord	O
with	O
molecular	O
modeling	O
studies	O
.	O

Taken	O
together	O
,	O
these	O
results	O
strongly	O
suggest	O
that	O
the	O
two	O
forms	O
of	O
tomaymycin	O
bound	O
to	O
d	O
(	O
ATGCAT	O
)	O
2	O
are	O
the	O
11S	O
,	O
11aS	O
and	O
11R	O
,	O
11aS	O
species	O
,	O
oriented	O
with	O
their	O
aromatic	O
rings	O
to	O
the	O
3'	O
and	O
5'	O
sides	O
,	O
respectively	O
,	O
of	O
the	O
covalently	O
modified	O
guanines	O
.	O

A	O
series	O
of	O
28	O
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
and	O
4,5	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
pyridylimidazoles	I-IUPAC
was	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
inhibition	O
of	O
xanthine	O
oxidase	O
.	O

Included	O
within	O
this	O
group	O
are	O
examples	O
of	O
2	I-IUPAC
-	I-IUPAC
pyridylimidazopyridines	I-IUPAC
and	O
halo	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
pyridylbenzimidazoles	I-IUPAC
.	O

Five	O
compounds	O
exhibited	O
inhibitory	O
activity	O
in	O
the	O
same	O
range	O
as	O
the	O
standards	O
,	O
4	I-IUPAC
-	I-IUPAC
hydroxypyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
trifluoromethylimidazole	I-IUPAC
(	O
22	O
)	O
.	O

Two	O
examples	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dicyanoimidazole	I-IUPAC
(	O
16	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
(	O
3	O
)	O
,	O
were	O
at	O
least	O
an	O
order	O
of	O
magnitude	O
more	O
active	O
than	O
the	O
standards	O
and	O
therefore	O
rank	O
among	O
the	O
most	O
potent	O
known	O
inhibitors	O
of	O
the	O
enzyme	O
.	O

A	O
series	O
of	O
N2	I-PARTIUPAC
(	O
and	O
N4	I-PARTIUPAC
)	O
-	I-PARTIUPAC
aryl	B-PARTIUPAC
-	B-PARTIUPAC
N4	B-PARTIUPAC
(	O
and	O
N2	I-PARTIUPAC
)	O
-	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
dialkylamino	I-PARTIUPAC
)	I-PARTIUPAC
alkyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
2,4	I-PARTIUPAC
-	I-PARTIUPAC
quinazolinediamines	I-PARTIUPAC
has	O
been	O
synthesized	O
for	O
antimalarial	O
evaluation	O
.	O

Condensation	O
of	O
the	O
appropriate	O
2,4	I-IUPAC
-	I-IUPAC
dichloroquinazoline	I-IUPAC
(	O
IV	O
)	O
with	O
the	O
requisite	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkylalkylenediamine	I-IUPAC
afforded	O
a	O
series	O
of	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
quinazolinamines	I-IUPAC
(	O
V	O
)	O
which	O
were	O
condensed	O
with	O
the	O
appropriate	O
arylamine	O
to	O
provide	O
the	O
corresponding	O
N2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
N4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
quinazolinediamines	I-IUPAC
(	O
VI	O
)	O
.	O

Hydrolysis	O
of	O
2,4	I-IUPAC
-	I-IUPAC
dichloroquinazoline	I-IUPAC
to	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
quinazolinol	I-IUPAC
was	O
followed	O
by	O
condensation	O
with	O
the	O
appropriate	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkylalkylenediamine	I-IUPAC
to	O
give	O
an	O
array	O
of	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
quinazolinols	I-IUPAC
(	O
IXa	O
)	O
.	O

Chlorination	O
with	O
phosphorus	O
oxychloride	O
and	O
condensation	O
with	O
a	O
requisite	O
arylamine	O
provided	O
the	O
N2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
quinazolinediamines	I-IUPAC
(	O
X	O
)	O
.	O

Antimalarial	O
activity	O
was	O
general	O
among	O
the	O
N2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
N4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
quinazolinediamines	I-IUPAC
(	O
VI	O
)	O
,	O
while	O
the	O
reverse	O
isomers	O
were	O
of	O
lower	O
activity	O
.	O

Phototoxic	O
liability	O
precluded	O
clinical	O
evaluation	O
of	O
a	O
member	O
of	O
the	O
series	O
.	O

Careful	O
analysis	O
of	O
the	O
NMR	O
structures	O
of	O
cyclo	O
(	O
4-10	O
)	O
[	O
Ac	O
-	O
Delta	O
(	O
3	O
)	O
Pro	O
(	O
1	O
)	O
,	O
DFpa	O
(	O
2	O
)	O
,	O
DTrp	O
(	O
3	O
)	O
,	O
Asp	O
(	O
4	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
Dpr	O
(	O
10	O
)	O
]	O
GnRH	O
,	O
dicyclo	O
(	O
4-10/5-8	O
)	O
[	O
Ac	O
-	O
DNal	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DTrp	O
(	O
3	O
)	O
,	O
Asp	O
(	O
4	O
)	O
,	O
Glu	O
(	O
5	O
)	O
,	O
DArg	O
(	O
6	O
)	O
,	O
Lys	O
(	O
8	O
)	O
,	O
Dpr	O
(	O
10	O
)	O
]	O
GnRH	O
,	O
and	O
dicyclo	O
(	O
4-10/5	O
,	O
5'	O
-	O
8	O
)	O
[	O
Ac	O
-	O
DNal	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DPal	O
(	O
3	O
)	O
,	O
Asp	O
(	O
4	O
)	O
,	O
Glu	O
(	O
5	O
)	O
(	O
Gly	O
)	O
,	O
DArg	O
(	O
6	O
)	O
,	O
Dbu	O
(	O
8	O
)	O
,	O
Dpr	O
(	O
10	O
)	O
]	O
GnRH	O
showed	O
that	O
,	O
in	O
the	O
N	O
-	O
terminal	O
tripeptide	O
,	O
a	O
type	O
II	O
beta	O
-	O
turn	O
around	O
residues	O
1	O
and	O
2	O
was	O
probable	O
along	O
with	O
a	O
gamma	O
-	O
turn	O
around	O
DTrp	O
(	O
3	O
)	O
/	O
DPal	O
(	O
3	O
)	O
.	O

This	O
suggested	O
the	O
possibility	O
of	O
constraining	O
the	O
N	O
-	O
terminus	O
by	O
the	O
introduction	O
of	O
a	O
cyclo	O
(	O
1-3	O
)	O
scaffold	O
.	O

Optimization	O
of	O
ring	O
size	O
and	O
composition	O
led	O
to	O
the	O
discovery	O
of	O
cyclo	O
(	O
1-3	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
5	O
,	O
K	O
(	O
i	O
)	O
=	O
0.82	O
nM	O
)	O
,	O
cyclo	O
(	O
1,1	O
'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
13	O
,	O
K	O
(	O
i	O
)	O
=	O
0.34	O
nM	O
)	O
,	O
cyclo	O
(	O
1	O
,	O
1'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DA	O
la	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
20	O
,	O
K	O
(	O
i	O
)	O
=	O
0.14	O
nM	O
)	O
,	O
and	O
cyclo	O
(	O
1,1	O
'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
21	O
,	O
K	O
(	O
i	O
)	O
=	O
0.17	O
nM	O
)	O
,	O
which	O
inhibited	O
ovulation	O
significantly	O
at	O
doses	O
equal	O
to	O
or	O
lower	O
than	O
25	O
microgram	O
/	O
rat	O
.	O

These	O
results	O
were	O
particularly	O
unexpected	O
in	O
view	O
of	O
the	O
critical	O
role	O
(	O
s	O
)	O
originally	O
ascribed	O
to	O
the	O
side	O
chains	O
of	O
residues	O
1	O
and	O
3	O
.	O

(	O
1	O
)	O
Other	O
closely	O
related	O
analogues	O
,	O
such	O
as	O
those	O
where	O
the	O
[	O
DAsp	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
]	O
cycle	O
of	O
21	O
was	O
changed	O
to	O
[	O
DOrn	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DAsp	O
(	O
3	O
)	O
]	O
of	O
cyclo	O
(	O
1,1	O
'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DOrn	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DAsp	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
22	O
,	O
K	O
(	O
i	O
)	O
=	O
2.2	O
nM	O
)	O
or	O
where	O
the	O
size	O
of	O
the	O
cycle	O
was	O
conserved	O
and	O
[	O
DAsp	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
]	O
was	O
replaced	O
by	O
[	O
DGlu	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
]	O
as	O
in	O
cyclo	O
(	O
1	O
,	O
1'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DGlu	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DOrn	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DA	O
la	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
23	O
,	O
K	O
(	O
i	O
)	O
=	O
4.2	O
nM	O
)	O
,	O
were	O
approximately	O
100	O
and	O
25	O
times	O
less	O
potent	O
in	O
vivo	O
,	O
respectively	O
.	O

Analogues	O
with	O
ring	O
sizes	O
of	O
18	O
	O
	O
cyclo	O
(	O
1	O
,	O
1'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DGlu	O
(	O
1	O
)	O
(	O
Gly	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DA	O
la	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
24	O
)	O
	O
	O
and	O
19	O
	O
	O
cyclo	O
(	O
1,1	O
'	O
-	O
3	O
)	O
[	O
Ac	O
-	O
DGlu	O
(	O
1	O
)	O
(	O
betaAla	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
25	O
)	O
	O
	O
atoms	O
were	O
also	O
less	O
potent	O
than	O
21	O
with	O
slightly	O
higher	O
K	O
(	O
i	O
)	O
values	O
(	O
1.5	O
and	O
2.2	O
nM	O
,	O
respectively	O
)	O
.	O

These	O
results	O
suggested	O
that	O
the	O
N	O
-	O
terminal	O
tripeptide	O
was	O
likely	O
to	O
assume	O
a	O
folded	O
conformation	O
favoring	O
the	O
close	O
proximity	O
of	O
the	O
side	O
chains	O
of	O
residues	O
1	O
and	O
3	O
.	O

The	O
dicyclic	O
analogue	O
dicyclo	O
(	O
1-3/4-10	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
Asp	O
(	O
4	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
Dpr	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
26	O
)	O
was	O
fully	O
active	O
at	O
500	O
microgram	O
,	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
1	O
nM	O
.	O

The	O
in	O
vivo	O
potency	O
of	O
26	O
was	O
at	O
least	O
10	O
-	O
fold	O
less	O
than	O
that	O
of	O
monocyclic	O
cyclo	O
(	O
1-3	O
)	O
[	O
Ac	O
-	O
DAsp	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
DAla	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
5	O
)	O
;	O
this	O
suggested	O
the	O
existence	O
of	O
unfavorable	O
interactions	O
between	O
the	O
now	O
optimized	O
and	O
constrained	O
(	O
1-3	O
)	O
and	O
(	O
4-10	O
)	O
cyclic	O
moieties	O
that	O
must	O
interact	O
as	O
originally	O
hypothesized	O
.	O

Tricyclo	O
(	O
1-3/4-10/5-8	O
)	O
[	O
Ac	O
-	O
DGlu	O
(	O
1	O
)	O
,	O
DCpa	O
(	O
2	O
)	O
,	O
DLys	O
(	O
3	O
)	O
,	O
Asp	O
(	O
4	O
)	O
,	O
Glu	O
(	O
5	O
)	O
,	O
DNal	O
(	O
6	O
)	O
,	O
Lys	O
(	O
8	O
)	O
,	O
Dpr	O
(	O
10	O
)	O
]	O
GnRH	O
(	O
27	O
)	O
was	O
inactive	O
at	O
500	O
microgram	O
/	O
rat	O
with	O
a	O
corresponding	O
low	O
affinity	O
(	O
K	O
(	O
i	O
)	O
=	O
4.6	O
nM	O
)	O
when	O
compared	O
to	O
those	O
of	O
the	O
most	O
potent	O
analogues	O
(	O
K	O
(	O
i	O
)	O
&	O
lt	O
;	O
0.5	O
nM	O
)	O
.	O

Molecular	O
interactions	O
between	O
RGD	O
peptides	O
and	O
integrins	O
are	O
known	O
to	O
mediate	O
many	O
biological	O
and	O
pathological	O
processes	O
.	O

This	O
has	O
led	O
to	O
an	O
increased	O
interest	O
in	O
the	O
development	O
of	O
RGD	O
compounds	O
with	O
high	O
affinity	O
and	O
improved	O
selectivity	O
for	O
integrin	O
receptors	O
.	O

In	O
this	O
study	O
,	O
we	O
synthesized	O
and	O
evaluated	O
a	O
series	O
of	O
multimeric	O
RGD	O
compounds	O
constructed	O
on	O
a	O
dicarboxylic	O
acid	O
-	O
containing	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
fluorescent	O
dye	O
(	O
cypate	O
)	O
for	O
tumor	O
targeting	O
.	O

An	O
array	O
of	O
NIR	O
fluorescent	O
RGD	O
compounds	O
was	O
prepared	O
efficiently	O
,	O
including	O
one	O
RGD	O
monomer	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
2	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
,	O
two	O
RGD	O
dimers	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
2	O
)	O
-	O
NH	O
(	O
2	O
)	O
and	O
cypate	O
-	O
(	O
RGD	O
-	O
NH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
)	O
,	O
one	O
trimer	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
3	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
,	O
two	O
tetramers	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
4	O
)	O
-	O
NH	O
(	O
2	O
)	O
and	O
cypate	O
-	O
[	O
(	O
RGD	O
)	O
(	O
2	O
)	O
-	O
NH	O
(	O
2	O
)	O
]	O
(	O
2	O
)	O
)	O
,	O
one	O
hexamer	O
(	O
cypate	O
-	O
[	O
(	O
RGD	O
)	O
(	O
3	O
)	O
-	O
NH	O
(	O
2	O
)	O
]	O
(	O
2	O
)	O
)	O
,	O
and	O
one	O
octamer	O
(	O
cypate	O
-	O
[	O
(	O
RGD	O
)	O
(	O
4	O
)	O
-	O
NH	O
(	O
2	O
)	O
]	O
(	O
2	O
)	O
)	O
.	O

The	O
binding	O
affinity	O
of	O
the	O
multimeric	O
RGD	O
compounds	O
for	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
receptor	O
(	O
ABIR	O
)	O
showed	O
a	O
remarkable	O
increase	O
relative	O
to	O
the	O
monomer	O
cypate	O
-	O
RGD	O
-	O
NH	O
(	O
2	O
)	O
.	O

Generally	O
,	O
the	O
divalent	O
linear	O
arrays	O
of	O
the	O
multimeric	O
RGD	O
units	O
bound	O
the	O
ABIR	O
with	O
slightly	O
higher	O
affinity	O
than	O
their	O
monovalent	O
analogues	O
.	O

These	O
results	O
suggest	O
that	O
the	O
receptor	O
binding	O
affinity	O
was	O
not	O
only	O
dependent	O
on	O
the	O
number	O
of	O
RGD	O
moieties	O
but	O
also	O
on	O
the	O
spatial	O
alignments	O
of	O
the	O
pendant	O
peptides	O
.	O

Internalization	O
of	O
the	O
compounds	O
by	O
ABIR	O
-	O
positive	O
tumor	O
cells	O
(	O
A549	O
)	O
was	O
monitored	O
by	O
NIR	O
fluorescence	O
microscopy	O
.	O

The	O
data	O
showed	O
that	O
endocytosis	O
of	O
the	O
octameric	O
RGD	O
derivative	O
was	O
significantly	O
higher	O
by	O
comparison	O
to	O
other	O
compounds	O
in	O
this	O
study	O
.	O

In	O
vivo	O
noninvasive	O
optical	O
imaging	O
and	O
biodistribution	O
data	O
showed	O
that	O
the	O
compounds	O
were	O
retained	O
in	O
A549	O
tumor	O
tissue	O
.	O

These	O
results	O
clearly	O
demonstrated	O
that	O
an	O
array	O
of	O
simple	O
RGD	O
tripeptides	O
on	O
a	O
NIR	O
fluorescent	O
dye	O
core	O
can	O
be	O
recognized	O
by	O
ABIR	O
.	O

Optimization	O
of	O
the	O
spatial	O
alignment	O
of	O
the	O
RGD	O
moieties	O
through	O
careful	O
molecular	O
design	O
and	O
library	O
construction	O
could	O
induce	O
multivalent	O
ligand	O
-	O
receptor	O
interactions	O
useful	O
for	O
in	O
vivo	O
tumor	O
imaging	O
and	O
tumor	O
-	O
targeted	O
therapy	O
.	O

Syntheses	O
of	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxyapomorphine	I-IUPAC
(	O
R	O
-	O
8	O
)	O
,	O
its	O
antipode	O
S	O
-	O
8	O
,	O
and	O
its	O
(	I-PARTIUPAC
R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
n	I-PARTIUPAC
-	I-PARTIUPAC
propyl	I-PARTIUPAC
R	O
-	O
9	O
derivatives	I-MODIFIER
are	O
described	O
.	O

The	O
dopaminergic	O
receptor	O
affinities	O
of	O
these	O
compounds	O
and	O
their	O
2	I-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
counterparts	I-MODIFIER
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
apomorphine	I-IUPAC
(	O
R	O
(	O
-	O
)	O
-	O
APO	O
,	O
R	O
-	O
1	O
)	O
,	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
apomorphine	I-IUPAC
(	O
S	O
(	O
+	O
)	O
-	O
APO	O
,	O
S	O
-	O
1	O
)	O
,	O
and	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylnorapomorphine	I-IUPAC
(	O
R	O
(	O
-	O
)	O
-	O
NPA	O
,	O
R	O
-	O
2	O
)	O
,	O
as	O
well	O
as	O
those	O
of	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroapomorphine	I-IUPAC
(	O
R	O
(	O
-	O
)	O
-	O
2	O
-	O
Cl	O
-	O
APO	O
,	O
R	O
-	O
6	O
)	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromoapomorphine	I-IUPAC
(	O
R	O
(	O
-	O
)	O
-	O
2	O
-	O
Br	O
-	O
APO	O
,	O
R	O
-	O
6	O
)	O
,	O
were	O
determined	O
with	O
tissue	O
membrane	O
preparations	O
of	O
corpus	O
striatum	O
from	O
rat	O
brain	O
.	O

Contribution	O
of	O
both	O
an	O
N	I-PARTIUPAC
-	I-PARTIUPAC
n	I-PARTIUPAC
-	I-PARTIUPAC
propyl	I-PARTIUPAC
and	O
a	O
2	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
in	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylnorapomorphine	I-IUPAC
(	O
R	O
(	O
-	O
)	O
-	O
2	O
-	O
OH	O
-	O
NPA	O
,	O
R	O
-	O
7	O
)	O
or	O
a	O
methoxy	O
group	O
in	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylnorapomorphine	I-IUPAC
(	O
R	O
(	O
-	O
)	O
-	O
2	O
-	O
OCH3	O
-	O
NPA	O
,	O
R	O
-	O
9	O
)	O
produced	O
the	O
highest	O
D2	O
affinity	O
(	O
0.053	O
and	O
0.17	O
nM	O
)	O
and	O
D2	O
over	O
D1	O
selectivity	O
(	O
17,300	O
and	O
10,500	O
times	O
)	O
of	O
the	O
compounds	O
evaluated	O
.	O

The	O
structure	O
-	O
affinity	O
relationships	O
of	O
these	O
2	O
-	O
substituted	O
aporphines	O
suggest	O
that	O
secondary	O
binding	O
sites	O
of	O
D2	O
receptors	O
interact	O
with	O
2	O
-	O
substituents	O
on	O
the	O
A	O
ring	O
of	O
aporphines	O
through	O
H	O
-	O
bonding	O
.	O

On	O
the	O
basis	O
of	O
our	O
previous	O
observation	O
that	O
N1	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
substituted	I-MODIFIER
chlorpropamide	B-IUPAC
derivatives	B-MODIFIER
when	O
administered	O
to	O
rats	O
nonenzymatically	O
eliminated	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
isocyanate	I-IUPAC
,	O
a	O
known	O
inhibitor	O
of	O
aldehyde	O
dehydrogenase	O
(	O
AlDH	O
)	O
,	O
we	O
have	O
synthesized	O
other	O
latentiated	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
isocyanates	I-IUPAC
as	O
in	O
vivo	O
inhibitors	O
of	O
AlDH	O
.	O

N1	I-IUPAC
-	I-IUPAC
Allylchlorpropamide	I-IUPAC
3	O
was	O
,	O
as	O
expected	O
,	O
a	O
potent	O
inhibitor	O
of	O
hepatic	O
AlDH	O
in	O
rats	O
,	O
as	O
indicated	O
by	O
the	O
4	O
-	O
fold	O
increase	O
in	O
the	O
levels	O
of	O
ethanol	O
-	O
derived	O
blood	O
acetaldehyde	O
relative	O
to	O
that	O
elicited	O
by	O
chlorpropamide	O
itself	O
.	O

Closely	O
following	O
in	O
activity	O
in	O
decreasing	O
order	O
were	O
N3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcarbamoyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
7	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcarbamoyl	I-IUPAC
)	I-IUPAC
saccharin	I-IUPAC
(	O
6	O
)	O
,	O
and	O
the	O
S	I-IUPAC
-	I-IUPAC
(	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcarbamoyl	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
(	O
9	O
)	O
of	O
benzyl	I-IUPAC
mercaptan	I-IUPAC
.	O

However	O
,	O
two	O
hydantoin	O
derivatives	O
,	O
5	O
and	O
8	O
,	O
were	O
totally	O
inactive	O
in	O
inhibiting	O
AlDH	O
in	O
vivo	O
.	O

A	O
prodrug	O
of	O
N1	I-IUPAC
-	I-IUPAC
ethylchlorpropamide	I-IUPAC
,	O
viz	O
.	O

,	O
its	O
N3	I-IUPAC
-	I-IUPAC
trifluoroacetyl	I-IUPAC
derivative	I-MODIFIER
(	O
4b	O
)	O
,	O
was	O
a	O
good	O
in	O
vivo	O
inhibitor	O
of	O
AlDH	O
,	O
mimicking	O
the	O
activity	O
of	O
the	O
parent	O
N1	I-IUPAC
-	I-IUPAC
ethylchlorpropamide	I-IUPAC
.	O

These	O
results	O
suggest	O
that	O
latent	O
alkyl	I-IUPAC
isocyanates	I-IUPAC
are	O
inhibitors	O
of	O
AlDH	O
,	O
giving	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
inhibition	O
of	O
AlDH	O
in	O
vivo	O
by	O
the	O
hypoglycemic	O
agent	O
chlorpropamide	O
may	O
be	O
due	O
to	O
the	O
release	O
of	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
isocyanate	I-IUPAC
following	O
metabolic	O
bioactivation	O
.	O

A	O
series	O
of	O
polyamines	O
based	O
on	O
the	O
high	O
affinity	O
sigma	O
receptor	O
ligand	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
ethylamine	I-IUPAC
(	O
3	O
)	O
were	O
developed	O
and	O
evaluated	O
for	O
their	O
binding	O
characteristics	O
at	O
sigma	O
-	O
1	O
and	O
sigma	O
-	O
2	O
receptor	O
subtypes	O
.	O

The	O
data	O
indicated	O
that	O
a	O
considerable	O
degree	O
of	O
structural	O
variation	O
is	O
possible	O
while	O
still	O
retaining	O
nanomolar	O
affinity	O
at	O
sigma	O
receptors	O
.	O

As	O
the	O
structure	O
of	O
the	O
polyamines	O
was	O
varied	O
,	O
their	O
binding	O
at	O
sigma	O
-	O
1	O
and	O
sigma	O
-	O
2	O
subtypes	O
showed	O
quite	O
different	O
and	O
in	O
some	O
cases	O
opposite	O
trends	O
,	O
supporting	O
the	O
belief	O
that	O
these	O
are	O
pharmacologically	O
distinct	O
entities	O
.	O

Polyamines	O
containing	O
two	O
nitrogen	O
atoms	O
showed	O
optimal	O
binding	O
at	O
both	O
sigma	O
-	O
1	O
and	O
sigma	O
-	O
2	O
receptor	O
subtypes	O
.	O

Although	O
additional	O
nitrogen	O
atoms	O
resulted	O
in	O
decreased	O
affinity	O
at	O
sigma	O
-	O
1	O
and	O
sigma	O
-	O
2	O
subtypes	O
,	O
an	O
increase	O
in	O
selectivity	O
for	O
sigma	O
-	O
2	O
subtypes	O
was	O
evident	O
;	O
the	O
parent	O
3	O
showed	O
greater	O
selectivity	O
for	O
sigma	O
-	O
1	O
subtypes	O
.	O

Internitrogen	O
spacings	O
had	O
a	O
large	O
effect	O
on	O
binding	O
affinity	O
and	O
subtype	O
selectivity	O
.	O

For	O
example	O
,	O
the	O
difference	O
between	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
dimethylethylenediamine	I-IUPAC
(	O
8	O
)	O
[	O
K	O
(	O
i	O
)	O
=	O
29.9	O
nM	O
at	O
sigma	O
-	O
1	O
receptor	O
and	O
18.3	O
nM	O
at	O
sigma	O
-	O
2	O
receptor	O
]	O
to	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
dimethylethylenediamine	I-IUPAC
(	O
10	O
)	O
[	O
K	O
(	O
i	O
)	O
=	O
1.49	O
nM	O
at	O
sigma	O
-	O
1	O
receptor	O
and	O
12.1	O
nM	O
at	O
sigma	O
-	O
2	O
receptor	O
]	O
illustrates	O
the	O
importance	O
of	O
internitrogen	O
spacing	O
.	O

Triamines	O
11	O
and	O
13	O
[	O
Ki	O
(	O
sigma	O
-	O
2	O
)	O
/	O
K	O
(	O
i	O
)	O
(	O
sigma	O
-	O
1	O
)	O
=	O
0.19	O
and	O
0.10	O
,	O
respectively	O
]	O
containing	O
the	O
N	O
-	O
N	O
-	O
N	O
-	O
Ar	O
spacings	O
3-3-2	O
and	O
4-4-2	O
,	O
proved	O
to	O
be	O
the	O
most	O
sigma	O
-	O
2	O
subtype	O
selective	O
of	O
the	O
15	O
polyamines	O
examined	O
in	O
this	O
study	O
.	O

The	O
N	O
-	O
N	O
-	O
N	O
spacings	O
appear	O
to	O
be	O
an	O
important	O
factor	O
in	O
their	O
sigma	O
-	O
2	O
subtype	O
selectivity	O
.	O

These	O
compounds	O
will	O
serve	O
as	O
templates	O
in	O
the	O
design	O
of	O
still	O
further	O
sigma	O
-	O
2	O
subtype	O
selective	O
ligands	O
.	O

The	O
pyrrolidine	O
ring	O
(	O
present	O
in	O
most	O
of	O
the	O
polyamines	O
tested	O
in	O
this	O
series	O
)	O
proved	O
to	O
be	O
an	O
important	O
recognition	O
site	O
for	O
sigma	O
receptor	O
binding	O
activity	O
.	O

Furthermore	O
,	O
alkyl	O
substitution	O
also	O
appears	O
to	O
be	O
important	O
since	O
the	O
stripped	O
down	O
polyamines	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
ethylenediamine	I-IUPAC
(	O
15	O
)	O
and	O
N1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
diethylenetriamine	I-IUPAC
(	O
16	O
)	O
exhibited	O
relatively	O
low	O
binding	O
affinity	O
.	O

Substituted	O
indole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
and	O
indole	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
have	O
been	O
found	O
to	O
be	O
potent	O
and	O
selective	O
antagonists	O
of	O
the	O
peptidoleukotrienes	O
.	O

Initial	O
derivatives	O
of	O
these	O
series	O
(	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
cyclopentylmethyl	I-IUPAC
)	I-IUPAC
carbamoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
benzamide	I-IUPAC
(	O
5a	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
cyclopentylmethyl	I-IUPAC
)	I-IUPAC
carbamoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylindol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
benzamide	I-IUPAC
(	O
6a	O
)	O
,	O
respectively	O
)	O
,	O
when	O
compared	O
to	O
the	O
corresponding	O
indole	O
amides	O
(	O
e.g.	O
28	O
and	O
29	O
)	O
,	O
were	O
found	O
to	O
be	O
approximately	O
10	O
-	O
fold	O
less	O
potent	O
in	O
vitro	O
and	O
substantially	O
less	O
active	O
when	O
administered	O
orally	O
to	O
guinea	O
pigs	O
.	O

Efforts	O
to	O
improve	O
the	O
potency	O
of	O
the	O
title	O
series	O
by	O
variation	O
of	O
the	O
amide	O
,	O
indole	O
,	O
or	O
sulfonamide	O
substituents	O
led	O
to	O
compounds	O
of	O
comparable	O
in	O
vitro	O
potency	O
to	O
ICI	O
204,219	O
,	O
but	O
of	O
somewhat	O
lower	O
oral	O
activity	O
.	O

A	O
trend	O
which	O
suggested	O
that	O
more	O
lipophilic	O
transposed	O
amides	O
were	O
needed	O
to	O
increase	O
oral	O
activity	O
was	O
exploited	O
with	O
some	O
success	O
and	O
has	O
led	O
to	O
the	O
discovery	O
of	O
5q	O
(	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethylbutyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carbamoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethylindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
benzamide	I-IUPAC
)	O
,	O
a	O
transposed	O
amide	O
with	O
subnanomolar	O
affinity	O
for	O
the	O
leukotriene	O
receptor	O
and	O
an	O
oral	O
ED50	O
of	O
5	O
mg	O
/	O
kg	O
in	O
a	O
model	O
of	O
asthma	O
in	O
guinea	O
pigs	O
.	O

In	O
this	O
model	O
,	O
ICI	O
204,219	O
was	O
active	O
at	O
0.4	O
mg	O
/	O
kg	O
.	O

The	O
absolute	O
bioavailability	O
of	O
5q	O
has	O
been	O
found	O
to	O
be	O
28%	O
in	O
the	O
rat	O
,	O
as	O
compared	O
to	O
68%	O
for	O
ICI	O
204,219	O
,	O
with	O
significant	O
levels	O
of	O
5q	O
observed	O
in	O
the	O
blood	O
of	O
rats	O
up	O
to	O
24	O
h	O
postdose	O
.	O

Variable	O
-	O
temperature	O
proton	O
nuclear	O
magnetic	O
resonance	O
studies	O
have	O
shown	O
that	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propylidene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylpiperazino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cycloheptene	I-IUPAC
,	O
a	O
5,11	I-IUPAC
-	I-IUPAC
dicarbo	I-IUPAC
analogue	I-MODIFIER
of	O
the	O
atypical	O
neuroleptic	O
agent	O
clozapine	I-IUPAC
[	I-IUPAC
8	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylpiperazino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
diazepine	I-IUPAC
]	I-IUPAC
,	O
exists	O
as	O
thermally	O
stable	O
configurational	O
isomers	O
.	O

The	O
presence	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
propylidene	I-IUPAC
group	I-MODIFIER
at	O
C	O
-	O
5	O
on	O
the	O
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cycloheptene	I-IUPAC
moiety	I-MODIFIER
did	O
not	O
interfere	O
greatly	O
,	O
as	O
compared	O
to	O
clozapine	O
,	O
with	O
the	O
in	O
vitro	O
affinity	O
of	O
this	O
5,11	I-IUPAC
-	I-IUPAC
dicarbo	I-IUPAC
analogue	I-MODIFIER
of	O
clozapine	O
for	O
muscarinic	O
and	O
dopamine	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
binding	O
sites	O
in	O
rat	O
brain	O
.	O

Since	O
the	O
presence	O
and	O
position	O
of	O
a	O
chloro	O
substituent	O
on	O
the	O
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
diazepine	I-IUPAC
moiety	I-MODIFIER
have	O
a	O
marked	O
influence	O
on	O
the	O
respective	O
binding	O
affinities	O
of	O
1,4	I-IUPAC
-	I-IUPAC
diazepines	I-IUPAC
related	O
to	O
clozapine	O
,	O
chloro	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
5,11	I-IUPAC
-	I-IUPAC
dicarbo	I-IUPAC
analogues	I-MODIFIER
of	O
clozapine	O
were	O
prepared	O
in	O
order	O
to	O
further	O
examine	O
structure	O
-	O
activity	O
relationships	O
.	O

Evaluation	O
of	O
these	O
analogues	O
for	O
binding	O
to	O
muscarinic	O
and	O
dopamine	O
binding	O
sites	O
in	O
comparison	O
with	O
clozapine	O
and	O
other	O
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
e	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
diazepine	I-IUPAC
analogues	I-MODIFIER
of	O
clozapine	O
shows	O
that	O
the	O
dopamine	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
receptor	O
affinities	O
of	O
both	O
the	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propylidene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,11	I-IUPAC
-	I-IUPAC
dicarbo	I-IUPAC
analogue	I-MODIFIER
and	O
its	O
corresponding	O
distal	O
-	O
chloro	O
derivative	O
,	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propylidene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylpiperazino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cycloheptene	I-IUPAC
,	O
are	O
retained	O
.	O

Because	O
of	O
the	O
susceptibility	O
to	O
acid	O
-	O
catalyzed	O
hydrolysis	O
of	O
these	O
tertiary	O
enamines	O
,	O
however	O
,	O
these	O
compounds	O
serve	O
only	O
as	O
model	O
compounds	O
for	O
their	O
structure	O
-	O
activity	O
evaluation	O
.	O

Since	O
the	O
proximal	O
nitrogen	O
atom	O
of	O
the	O
piperazine	O
ring	O
is	O
redundant	O
for	O
biological	O
activity	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propylidene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cycloh	I-IUPAC
eptene	I-IUPAC
and	O
its	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivative	I-MODIFIER
are	O
excellent	O
candidates	O
for	O
resolution	O
into	O
enantiomers	O
as	O
a	O
means	O
to	O
separate	O
antimuscarinic	O
and	O
antidopaminergic	O
activity	O
,	O
respectively	O
,	O
associated	O
with	O
only	O
a	O
single	O
stereoisomer	O
.	O

The	O
9	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
analogue	I-MODIFIER
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
demethoxydaunomycin	I-IUPAC
has	O
been	O
synthesized	O
from	O
2,5	I-IUPAC
-	I-IUPAC
dimethoxybenzaldehyde	I-IUPAC
.	O

Pomeranz	O
-	O
Fritsch	O
condensation	O
followed	O
by	O
borohydride	O
reduction	O
and	O
acid	O
-	O
catalyzed	O
cyclization	O
led	O
smoothly	O
to	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
.	O

Selective	O
N	O
-	O
acetylation	O
and	O
subsequent	O
Friedel	O
-	O
Crafts	O
acylation	O
with	O
phthalic	O
anhydride	O
produced	O
2	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
5,12	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azanaphthacene	I-IUPAC
-	I-IUPAC
6,11	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
,	O
which	O
was	O
protected	O
as	O
its	O
dimethyl	O
ether	O
and	O
epoxidized	O
to	O
an	O
acylated	O
aza	O
Brigl	O
's	O
anhydride	O
.	O

This	O
was	O
converted	O
to	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5,12	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azanaphthacene	I-IUPAC
-	I-IUPAC
6,11	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
by	O
dehydration	O
to	O
the	O
4	I-IUPAC
-	I-IUPAC
keto	I-IUPAC
analogue	I-MODIFIER
followed	O
by	O
cyanoborohydride	O
reduction	O
either	O
stepwise	O
or	O
in	O
situ	O
.	O

The	O
protecting	O
groups	O
were	O
removed	O
with	O
boron	O
trichloride	O
and	O
the	O
resulting	O
aglycone	O
glycosidated	O
with	O
optically	O
active	O
N	I-IUPAC
,	I-IUPAC
O	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
daunosamine	I-IUPAC
bromide	I-IUPAC
and	O
silver	O
trifluoromethanesulfonate	O
.	O

The	O
resulting	O
diastereoisomers	O
were	O
separated	O
by	O
column	O
chromatography	O
and	O
their	O
structures	O
established	O
by	O
CD	O
and	O
NMR	O
spectroscopy	O
.	O

Unexpectedly	O
it	O
was	O
not	O
possible	O
to	O
remove	O
the	O
N	I-IUPAC
-	I-IUPAC
trifluoroacetyl	I-IUPAC
blocking	I-MODIFIER
group	I-MODIFIER
without	O
aromatization	O
to	O
the	O
azanaphthaquinone	O
.	O

Both	O
(	I-PARTIUPAC
R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
daunosaminyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5,12	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azanaphthacene	I-IUPAC
-	I-IUPAC
6,11	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
were	O
inactive	O
ip	O
in	O
mice	O
carrying	O
the	O
P388	O
tumor	O
.	O

Drugs	O
were	O
given	O
at	O
various	O
concentrations	O
on	O
days	O
0	O
,	O
5	O
,	O
and	O
9	O
.	O

Novel	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
amide	I-IUPAC
derivatives	I-MODIFIER
1	O
were	O
synthesized	O
and	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
rabbit	O
small	O
intestinal	O
ACAT	O
(	O
acyl	O
-	O
CoA	O
:	O
cholesterol	O
acyltransferase	O
)	O
in	O
vitro	O
and	O
to	O
lower	O
serum	O
total	O
cholesterol	O
in	O
cholesterol	O
-	O
fed	O
rats	O
in	O
vivo	O
.	O

Among	O
the	O
synthesized	O
compounds	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
7	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
amide	I-IUPAC
derivatives	I-MODIFIER
showed	O
potent	O
ACAT	O
inhibitory	O
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
of	O
these	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
amides	I-IUPAC
and	O
related	O
compounds	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
these	O
two	O
assays	O
.	O

The	O
carbonyl	I-IUPAC
group	B-MODIFIER
at	O
position	O
4	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
chromanone	I-IUPAC
was	O
essential	O
for	O
potent	O
ACAT	O
inhibitory	O
activity	O
.	O

N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Chromon	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
were	O
less	O
potent	O
than	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
.	O

An	O
alkoxy	O
group	O
at	O
position	O
7	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
chromanone	I-IUPAC
moiety	I-MODIFIER
was	O
important	O
for	O
potent	O
ACAT	O
inhibitory	O
activity	O
.	O

In	O
the	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
7	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
amide	I-IUPAC
derivatives	I-MODIFIER
,	O
another	O
necessary	O
factor	O
to	O
elicit	O
the	O
potent	O
ACAT	O
inhibitory	O
activity	O
was	O
lipophilicity	O
of	O
the	O
molecules	O
.	O

The	O
highly	O
lipophilic	O
acid	O
amides	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dimethyldodecanamide	I-IUPAC
(	O
35	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenoxy	I-IUPAC
)	I-IUPAC
hexyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
benzamide	I-IUPAC
(	O
63	O
)	O
showed	O
potent	O
activity	O
.	O

Introduction	O
of	O
a	O
highly	O
lipophilic	O
alkoxy	O
group	O
at	O
position	O
7	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
chromanone	I-IUPAC
moiety	I-MODIFIER
instead	O
of	O
methoxy	O
group	O
also	O
resulted	O
in	O
potent	O
activity	O
.	O

In	O
this	O
case	O
,	O
highest	O
inhibitory	O
activity	O
was	O
obtained	O
by	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
decyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dimethylpropanamid	I-IUPAC
e	I-IUPAC
(	O
65	O
)	O
.	O

The	O
most	O
potent	O
compound	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxochroman	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dimethyldodecanamide	I-IUPAC
(	O
35	O
,	O
TEI	O
-	O
6522	O
)	O
,	O
showed	O
significant	O
ACAT	O
inhibitory	O
activity	O
(	O
rabbit	O
small	O
intestine	O
IC50	O
=	O
13	O
nM	O
,	O
rabbit	O
liver	O
IC50	O
=	O
16	O
nM	O
)	O
,	O
foam	O
cell	O
formation	O
inhibitory	O
activity	O
(	O
rat	O
peritoneal	O
macrophage	O
IC50	O
=	O
160	O
nM	O
)	O
,	O
and	O
extremely	O
potent	O
serum	O
cholesterol	O
-	O
lowering	O
activity	O
in	O
cholesterol	O
-	O
fed	O
rats	O
(	O
61%	O
at	O
a	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
/	O
day	O
po	O
)	O
.	O

An	O
enantiospecific	O
method	O
was	O
developed	O
for	O
the	O
synthesis	O
of	O
3	I-PARTIUPAC
-	I-PARTIUPAC
fluoromethyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	O
substituted	I-MODIFIER
-	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
(	O
THIQs	O
)	O
from	O
phenylalanine	O
.	O

Biochemical	O
evaluation	O
of	O
the	O
enantiomers	O
of	O
these	O
compounds	O
at	O
both	O
PNMT	O
and	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
indicates	O
that	O
both	O
sites	O
display	O
similar	O
stereoselectivity	O
.	O

Overall	O
the	O
R	O
-	O
enantiomer	O
was	O
usually	O
the	O
more	O
potent	O
enantiomer	O
at	O
both	O
PNMT	O
and	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
for	O
these	O
3	I-PARTIUPAC
-	I-PARTIUPAC
fluoromethyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
THIQs	I-IUPAC
.	O

The	O
one	O
exception	O
is	O
3	I-IUPAC
-	I-IUPAC
hydroxymethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
9	O
)	O
,	O
which	O
was	O
found	O
to	O
display	O
the	O
opposite	O
stereoselectivity	O
at	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
.	O

A	O
comparison	O
of	O
the	O
PNMT	O
inhibitory	O
potency	O
of	O
the	O
enantiomers	O
of	O
these	O
3	I-PARTIUPAC
-	I-PARTIUPAC
fluoromethyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
THIQs	I-IUPAC
indicates	O
that	O
all	O
of	O
the	O
3	O
-	O
substituted	O
-	O
THIQs	O
displayed	O
similar	O
inhibitory	O
potency	O
for	O
PNMT	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
3	O
-	O
substituent	O
was	O
found	O
to	O
have	O
a	O
major	O
effect	O
on	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
affinity	O
of	O
these	O
compounds	O
with	O
the	O
3	I-PARTIUPAC
-	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
3	I-IUPAC
-	I-IUPAC
fluoromethyl	I-IUPAC
-	I-IUPAC
THIQs	I-IUPAC
having	O
the	O
highest	O
affinity	O
and	O
THIQs	O
containing	O
the	O
3	I-PARTIUPAC
-	I-PARTIUPAC
chloromethyl	I-PARTIUPAC
moiety	I-MODIFIER
the	O
least	O
.	O

Compounds	O
R	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluoromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
R	O
-	O
12	O
)	O
and	O
R	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluoromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
aminosulfonyl	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
R	O
-	O
13	O
)	O
and	O
both	O
enantiomers	O
of	O
3	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
R	O
-	O
and	O
S	O
-	O
30	O
)	O
are	O
the	O
most	O
selective	O
inhibitors	O
in	O
this	O
study	O
and	O
display	O
selectivities	O
(	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
K	O
(	O
i	O
)	O
/	O
PNMT	O
K	O
(	O
i	O
)	O
)	O
greater	O
than	O
200	O
.	O

These	O
compounds	O
give	O
important	O
insight	O
into	O
the	O
steric	O
and	O
stereochemical	O
preferences	O
of	O
both	O
PNMT	O
and	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
,	O
which	O
should	O
assist	O
in	O
the	O
development	O
of	O
new	O
PNMT	O
inhibitors	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
receptor	O
agonist	O
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
ACPA	O
,	O
2	O
)	O
,	O
binds	O
to	O
AMPA	O
receptors	O
in	O
a	O
manner	O
different	O
from	O
that	O
of	O
AMPA	O
(	O
1	O
)	O
itself	O
and	O
that	O
2	O
,	O
in	O
contrast	O
to	O
1	O
,	O
also	O
binds	O
to	O
kainic	O
acid	O
receptor	O
sites	O
.	O

To	O
elucidate	O
the	O
structural	O
requirements	O
for	O
selective	O
activation	O
of	O
the	O
site	O
/	O
conformation	O
of	O
AMPA	O
receptors	O
recognized	O
by	O
2	O
,	O
a	O
number	O
of	O
isosteric	O
analogues	O
of	O
2	O
have	O
now	O
been	O
synthesized	O
and	O
pharmacologically	O
characterized	O
.	O

The	O
compound	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
3a	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.11	O
microM	O
;	O
EC	O
(	O
50	O
)	O
=	O
1.2	O
microM	O
)	O
,	O
which	O
is	O
a	O
regioisostere	O
of	O
2	O
with	O
a	O
methoxy	O
group	O
substituted	O
for	O
the	O
methyl	I-IUPAC
group	B-MODIFIER
,	O
was	O
approximately	O
equipotent	O
with	O
2	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.020	O
microM	O
;	O
EC	O
(	O
50	O
)	O
=	O
1.0	O
microM	O
)	O
as	O
an	O
inhibitor	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
AMPA	O
binding	O
and	O
as	O
an	O
AMPA	O
agonist	O
,	O
respectively	O
,	O
whereas	O
the	O
corresponding	O
3	O
-	O
ethoxy	O
analogue	O
3b	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.0	O
microM	O
;	O
EC	O
(	O
50	O
)	O
=	O
4.8	O
microM	O
)	O
was	O
slightly	O
weaker	O
.	O

The	O
analogues	O
3c	O
-	O
e	O
,	O
containing	O
C3	O
alkoxy	O
groups	O
,	O
were	O
an	O
order	O
of	O
magnitude	O
weaker	O
than	O
3b	O
,	O
whereas	O
the	O
additional	O
steric	O
bulk	O
of	O
the	O
alkoxy	O
groups	O
of	O
3f	O
-	O
i	O
or	O
the	O
presence	O
of	O
an	O
acidic	O
hydroxyl	O
group	O
at	O
the	O
3	O
-	O
position	O
of	O
the	O
isoxazole	O
ring	O
of	O
3j	O
prevented	O
interaction	O
with	O
AMPA	O
receptor	O
sites	O
.	O

The	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acids	I-IUPAC
4a	O
,	O
b	O
,	O
i	O
,	O
which	O
are	O
regioisosteric	O
analogues	O
of	O
3a	O
,	O
b	O
,	O
i	O
,	O
showed	O
negligible	O
interaction	O
with	O
AMPA	O
recognition	O
sites	O
.	O

Similarly	O
,	O
replacement	O
of	O
the	O
carboxyl	I-IUPAC
group	B-MODIFIER
of	O
3b	O
by	O
isosteric	O
tetrazolyl	I-IUPAC
or	O
1,2,4	I-IUPAC
-	I-IUPAC
triazolyl	I-IUPAC
groups	I-MODIFIER
to	O
give	O
5	O
and	O
6	O
,	O
respectively	O
,	O
or	O
conversion	O
of	O
3b	O
into	O
analogue	O
7	O
,	O
in	O
which	O
the	O
diaminosquaric	O
acid	O
group	O
has	O
been	O
bioisosterically	O
substituted	O
for	O
the	O
alpha	I-IUPAC
-	I-IUPAC
aminocarboxylic	I-IUPAC
acid	I-IUPAC
unit	O
,	O
provided	O
compounds	O
completely	O
devoid	O
of	O
effect	O
at	O
AMPA	O
receptors	O
.	O

In	O
contrast	O
to	O
the	O
parent	O
compound	O
ACPA	O
(	O
2	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
6.3	O
microM	O
)	O
,	O
none	O
of	O
the	O
analogues	O
described	O
showed	O
detectable	O
inhibitory	O
effect	O
on	O
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
H	I-IUPAC
]	I-IUPAC
kainic	I-IUPAC
acid	I-IUPAC
receptor	O
binding	O
.	O

A	O
series	O
of	O
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	O
substituted	I-MODIFIER
-	O
imidazoles	I-IUPAC
has	O
been	O
synthesized	O
and	O
tested	O
for	O
their	O
ability	O
to	O
selectively	O
radiosensitize	O
hypoxic	O
Chinese	O
hamster	O
cells	O
(	O
V	O
-	O
79	O
)	O
to	O
the	O
lethal	O
effect	O
of	O
radiation	O
.	O

The	O
reaction	O
of	O
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
with	O
1,2	I-IUPAC
-	I-IUPAC
epoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxypropane	I-IUPAC
and	O
ethyl	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
chloroacetate	I-IUPAC
produced	O
two	O
isomeric	O
products	O
in	O
each	O
case	O
,	O
which	O
were	O
identified	O
by	O
their	O
NMR	O
spectra	O
.	O

The	O
ethyl	O
esters	O
were	O
further	O
reacted	O
with	O
3	I-IUPAC
-	I-IUPAC
picolylamine	I-IUPAC
to	O
produce	O
corresponding	O
amides	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
picolyl	I-IUPAC
)	I-IUPAC
acetamide	I-IUPAC
on	O
further	O
reaction	O
with	O
m	I-IUPAC
-	I-IUPAC
chloroperbenzoic	I-IUPAC
acid	I-IUPAC
produced	O
the	O
corresponding	O
N	O
-	O
oxide	O
.	O

These	O
compounds	O
were	O
generally	O
more	O
toxic	O
to	O
V	O
-	O
79	O
cells	O
than	O
the	O
2	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
derivatives	I-MODIFIER
and	O
were	O
found	O
to	O
be	O
more	O
effective	O
radiosensitizers	O
in	O
vitro	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
derivatives	I-MODIFIER
were	O
more	O
efficient	O
as	O
sensitizers	O
than	O
the	O
4	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
derivatives	I-MODIFIER
,	O
and	O
the	O
sensitizing	O
efficiency	O
of	O
this	O
class	O
of	O
agents	O
was	O
found	O
to	O
have	O
significant	O
correlation	O
with	O
their	O
partition	O
coefficients	O
.	O

A	O
series	O
of	O
PGE2	O
,	O
16,16	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
PGE2	I-IUPAC
,	O
and	O
PGF2	O
alpha	O
analogues	O
modified	O
at	O
the	O
carboxyl	O
terminus	O
with	O
tetrazole	O
,	O
amide	O
,	O
acylurea	O
,	O
imide	O
,	O
and	O
sulfonimide	O
functionalities	O
was	O
evaluated	O
for	O
uterine	O
stimulant	O
,	O
bronchodilator	O
,	O
hypotensive	O
,	O
gastric	O
antisecretory	O
,	O
and	O
diarrheal	O
activity	O
.	O

These	O
compounds	O
were	O
prepared	O
by	O
modification	O
of	O
the	O
Corey	O
prostaglandin	O
synthesis	O
utilizing	O
as	O
a	O
key	O
step	O
condensation	O
of	O
known	O
hemiacetals	O
with	O
the	O
ylide	O
derived	O
from	O
the	O
requisite	O
substituted	O
phosphonium	O
salts	O
.	O

Structure	O
-	O
-	O
activity	O
relationships	O
suggest	O
that	O
a	O
proton	O
at	O
the	O
C	O
-	O
1	O
position	O
appears	O
necessary	O
for	O
agonist	O
activity	O
and	O
the	O
acidity	O
of	O
this	O
proton	O
has	O
a	O
relatively	O
greater	O
influence	O
on	O
activity	O
than	O
pendant	O
steric	O
bulk	O
.	O

Noteworthy	O
are	O
the	O
tissue	O
-	O
selective	O
bronchodilator	O
activity	O
of	O
N	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
PGE2	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
and	O
the	O
selectivity	O
for	O
uterine	O
tissue	O
of	O
N	I-IUPAC
-	I-IUPAC
methanesulfonyl	I-IUPAC
-	I-IUPAC
PGE2	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
decarboxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
16,16	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
PGE2	I-IUPAC
,	O
N	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
16,16	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
PGE2	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
,	O
and	O
N	I-IUPAC
-	I-IUPAC
methanesulfonyl	I-IUPAC
-	I-IUPAC
16,16	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
PGE2	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
.	O

The	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
transduce	O
retinoid	O
dependant	O
gene	O
regulation	O
,	O
and	O
many	O
biological	O
effects	O
of	O
retinoids	O
are	O
mediated	O
through	O
binding	O
and	O
activation	O
of	O
three	O
closely	O
related	O
receptor	O
subtypes	O
(	O
RAR	O
alpha	O
,	O
RAR	O
beta	O
,	O
and	O
RAR	O
gamma	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
receptor	O
subtypes	O
,	O
we	O
have	O
carried	O
out	O
a	O
chemical	O
synthesis	O
program	O
to	O
seek	O
selective	O
retinoids	O
for	O
these	O
receptors	O
.	O

We	O
measured	O
receptor	O
binding	O
affinity	O
using	O
recombinant	O
RAR	O
alpha	O
,	O
-	O
beta	O
,	O
and	O
-	O
gamma	O
proteins	O
and	O
assessed	O
cellular	O
differentiating	O
activity	O
in	O
F9	O
murine	O
teratocarcinoma	O
cells	O
(	O
F9	O
cells	O
)	O
.	O

This	O
research	O
has	O
identified	O
the	O
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
moiety	I-MODIFIER
as	O
a	O
new	O
pharmacophore	O
which	O
can	O
replace	O
the	O
beta	I-IUPAC
-	I-IUPAC
cyclogeranylidene	I-IUPAC
ring	I-MODIFIER
of	O
the	O
naturally	O
occurring	O
all	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
.	O

Two	O
chemical	O
series	O
derived	O
from	O
the	O
general	O
structures	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
tertioalkylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
series	O
I	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
tertioalkylphenyl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
series	O
II	O
)	O
were	O
developed	O
.	O

In	O
particular	O
,	O
we	O
have	O
obtained	O
the	O
RAR	O
gamma	O
selective	O
derivatives	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
7	O
)	O
[	O
Ki	O
(	O
RAR	O
alpha	O
)	O
=	O
6500	O
nM	O
,	O
Ki	O
(	O
RAR	O
beta	O
)	O
=	O
2480	O
nM	O
,	O
Ki	O
(	O
RAR	O
gamma	O
)	O
=	O
77	O
nM	O
]	O
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
]	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
19	O
)	O
[	O
Ki	O
(	O
RAR	O
alpha	O
)	O
=	O
1,144	O
nM	O
,	O
Ki	O
(	O
RAR	O
beta	O
)	O
=	O
1245	O
nM	O
,	O
Ki	O
(	O
RAR	O
gamma	O
)	O
=	O
53	O
nM	O
]	O
.	O

In	O
series	O
I	O
,	O
the	O
presence	O
of	O
a	O
phenol	I-PARTIUPAC
group	B-MODIFIER
,	O
irrespective	O
of	O
the	O
nature	O
of	O
tertioalkyl	I-PARTIUPAC
group	B-MODIFIER
,	O
imparted	O
at	O
least	O
partial	O
RAR	O
gamma	O
selectivity	O
,	O
whereas	O
in	O
series	O
II	O
,	O
the	O
presence	O
of	O
both	O
adamantyl	I-PARTIUPAC
and	O
phenol	I-PARTIUPAC
groups	B-MODIFIER
is	O
needed	O
to	O
confer	O
RAR	O
gamma	O
selectivity	O
.	O

The	O
RAR	O
gamma	O
selective	O
ligands	O
induce	O
differentiation	O
in	O
F9	O
cells	O
(	O
7	O
,	O
AC50	O
=	O
33	O
nM	O
;	O
19	O
,	O
AC50	O
=	O
66	O
nM	O
)	O
.	O

From	O
series	O
I	O
,	O
a	O
mixed	O
RAR	O
beta	O
-	O
gamma	O
agonist	O
with	O
potent	O
cellular	O
differentiating	O
activity	O
was	O
selected	O
for	O
development	O
as	O
a	O
topical	O
antiacne	O
agent	O
,	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
adamantyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
5	O
,	O
CD	O
271	O
)	O
[	O
Ki	O
(	O
RAR	O
alpha	O
)	O
=	O
1100	O
nM	O
,	O
Ki	O
-	O
(	O
RAR	O
beta	O
)	O
=	O
34	O
nM	O
,	O
Ki	O
(	O
RAR	O
gamma	O
)	O
=	O
130	O
nM	O
,	O
AC50	O
(	O
F9	O
)	O
=	O
37	O
nM	O
]	O
.	O

Finally	O
,	O
from	O
series	O
II	O
,	O
we	O
have	O
obtained	O
a	O
weak	O
antagonist	O
in	O
the	O
F9	O
cellular	O
differentiation	O
assay	O
,	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
15	O
,	O
IC50	O
=	O
700	O
nM	O
)	O
.	O

In	O
an	O
attempt	O
to	O
determine	O
some	O
of	O
the	O
structural	O
features	O
in	O
position	O
1	O
that	O
account	O
for	O
antivasopressor	O
activity	O
,	O
eight	O
new	O
1	O
-	O
(	O
beta	O
,	O
beta	O
-	O
dialkyl	O
-	O
substituted	O
)	O
analogues	O
of	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropanoic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropanoic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
have	O
been	O
designed	O
and	O
synthesized	O
.	O

The	O
protected	O
precursors	O
required	O
for	O
these	O
peptides	O
were	O
obtained	O
by	O
a	O
combination	O
of	O
solid	O
-	O
phase	O
and	O
solutions	O
methods	O
.	O

Some	O
of	O
the	O
reported	O
analogues	O
,	O
namely	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylcyclohexaneacetic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylcyclohexaneacetic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltryosine	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mercaptocyclohexaneacetic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylcyclohexaneacetic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylcyclohexaneacetic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
arginine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
,	O
are	O
among	O
the	O
most	O
potent	O
and	O
selective	O
antagonists	O
of	O
the	O
vasopressor	O
response	O
to	O
arginine	O
-	O
vasopressin	O
reported	O
to	O
date	O
.	O

Glycosylated	O
antitumor	O
ether	O
lipids	O
(	O
GAELs	O
)	O
,	O
analogs	O
of	O
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
octadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phosphocholine	I-IUPAC
(	O
1	O
,	O
ET	O
-	O
18	O
-	O
OCH3	O
,	O
edelfosine	O
)	O
,	O
were	O
synthesized	O
in	O
good	O
overall	O
yields	O
by	O
glycosylation	O
of	O
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycerol	I-IUPAC
and	O
tested	O
for	O
in	O
vitro	O
antineoplastic	O
activity	O
against	O
a	O
variety	O
of	O
murine	O
and	O
human	O
tumor	O
cell	O
lines	O
.	O

Stereospecific	O
glycosylation	O
was	O
achieved	O
by	O
the	O
use	O
of	O
2	I-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
acetyl	I-PARTIUPAC
-	I-PARTIUPAC
3,4,6	I-PARTIUPAC
-	I-PARTIUPAC
tri	I-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
benzylglucopyranosyl	I-PARTIUPAC
and	O
-	I-PARTIUPAC
mannopyranosyl	I-PARTIUPAC
trichloroacetimidates	I-PARTIUPAC
as	O
donors	O
,	O
with	O
trimethylsilyl	I-IUPAC
trifluoromethanesulfonate	I-IUPAC
as	O
catalyst	O
in	O
the	O
presence	O
of	O
molecular	O
sieves	O
at	O
-	O
78	O
degrees	O
C	O
.	O

The	O
GAELs	O
differ	O
from	O
1	O
in	O
having	O
the	O
sn	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phosphocholine	I-IUPAC
residue	O
replaced	O
by	O
one	O
of	O
the	O
following	O
monosaccharide	O
residues	O
:	O
beta	I-PARTIUPAC
-	I-PARTIUPAC
and	O
alpha	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabino	I-IUPAC
-	I-IUPAC
hexopyranosyl	I-IUPAC
,	O
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
mannopyranosyl	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
glucopyranosyl	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
mannopyranosyl	I-IUPAC
.	O

1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
Hexadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabino	I-IUPAC
-	I-IUPAC
hexopyranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycerol	I-IUPAC
(	O
2	O
)	O
was	O
more	O
effective	O
than	O
1	O
in	O
inhibiting	O
the	O
growth	O
of	O
MCF	O
-	O
7	O
(	O
human	O
breast	O
cancer	O
)	O
and	O
its	O
adriamycin	O
-	O
resistant	O
form	O
MCF	O
-	O
7	O
/	O
adriamycin	O
,	O
and	O
murine	O
Lewis	O
lung	O
cancer	O
cells	O
.	O

2	I-IUPAC
-	I-IUPAC
Deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabino	I-IUPAC
-	I-IUPAC
hexopyranoside	I-IUPAC
2	O
was	O
also	O
an	O
effective	O
growth	O
inhibitor	O
of	O
two	O
drug	O
-	O
resistant	O
leukemic	O
cell	O
lines	O
,	O
P388	O
/	O
Adr	O
and	O
L1210	O
/	O
vmdr	O
.	O

A	O
series	O
of	O
sulfonyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
derivatives	I-MODIFIER
was	O
designed	O
and	O
synthesized	O
for	O
cytotoxic	O
evaluation	O
as	O
potential	O
anticancer	O
agents	O
on	O
the	O
basis	O
of	O
the	O
lead	O
compound	O
LY	O
-	O
181984	O
.	O

Replacement	O
of	O
the	O
ureido	O
moiety	O
of	O
the	O
lead	O
compound	O
with	O
hydroxyguanidine	O
provided	O
a	O
stable	O
cytotoxic	O
agent	O
.	O

The	O
conformation	O
of	O
sulfonyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
derivatives	I-MODIFIER
,	O
such	O
as	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
2,1,3	I-IUPAC
]	I-IUPAC
thiadiazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
"	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
(	O
4g	O
)	O
,	O
investigated	O
utilizing	O
HMBC	O
NMR	O
,	O
theoretical	O
calculations	O
,	O
and	O
X	O
-	O
ray	O
crystallography	O
,	O
indicated	O
stacking	O
of	O
the	O
two	O
aromatic	O
rings	O
.	O

The	O
derivatives	O
were	O
evaluated	O
for	O
in	O
vitro	O
cytoxicity	O
against	O
five	O
human	O
tumor	O
cell	O
lines	O
,	O
including	O
HepG2	O
,	O
TSGH	O
8302	O
,	O
COLO	O
205	O
,	O
KB	O
,	O
and	O
MOLT	O
-	O
4	O
.	O

The	O
cytotoxic	O
activities	O
of	O
the	O
derived	O
compounds	O
against	O
the	O
human	O
tumor	O
cell	O
lines	O
were	O
equal	O
to	O
or	O
greater	O
than	O
that	O
of	O
the	O
lead	O
compound	O
.	O

N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
Chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenoxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
"	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
(	O
4n	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenoxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
"	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
(	O
4o	O
)	O
exhibited	O
the	O
greatest	O
growth	O
inhibition	O
of	O
solid	O
tumor	O
cell	O
lines	O
.	O

Compound	O
4o	O
was	O
found	O
to	O
possess	O
antitumor	O
activity	O
against	O
murine	O
K1735	O
/	O
M2	O
melanoma	O
xenografts	O
.	O

A	O
study	O
of	O
ring	O
-	O
expanded	O
analogues	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
propananilido	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
analgesics	O
has	O
been	O
undertaken	O
in	O
order	O
to	O
evaluate	O
the	O
influence	O
of	O
this	O
structural	O
modification	O
on	O
both	O
analgesic	O
activity	O
and	O
physical	O
-	O
dependence	O
capacity	O
.	O

Thus	O
,	O
a	O
series	O
of	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
propananilido	I-IUPAC
)	I-IUPAC
perhydroazepine	I-IUPAC
derivatives	I-MODIFIER
was	O
synthesized	O
and	O
pharmacologically	O
evaluated	O
in	O
mice	O
for	O
analgesic	O
activity	O
and	O
physical	O
-	O
dependence	O
capacity	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
ring	O
-	O
expanded	O
analogues	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
propananilido	I-IUPAC
)	I-IUPAC
piperidines	I-IUPAC
retain	O
a	O
relatively	O
high	O
degree	O
of	O
analgesic	O
potency	O
,	O
except	O
in	O
the	O
case	O
of	O
the	O
1	I-IUPAC
-	I-IUPAC
phenylethylated	I-IUPAC
analogue	I-MODIFIER
which	O
is	O
approximately	O
150	O
-	O
fold	O
less	O
potent	O
than	O
the	O
correspondingly	O
1	O
-	O
substituted	O
piperidine	O
analgesic	O
.	O

Evaluation	O
of	O
physical	O
-	O
dependence	O
capacity	O
of	O
the	O
most	O
potent	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
propananilido	I-IUPAC
)	I-IUPAC
perhydroazepines	I-IUPAC
reveals	O
no	O
significant	O
difference	O
for	O
these	O
compounds	O
as	O
compared	O
with	O
morphine	O
.	O

The	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
propananilido	I-IUPAC
)	I-IUPAC
perhydroazepines	I-IUPAC
having	O
1	O
-	O
substitutents	O
in	O
common	O
with	O
known	O
opiate	O
antagonists	O
failed	O
to	O
exhibit	O
antagonism	O
of	O
morphine	O
analgesia	O
.	O

A	O
series	O
of	O
compounds	O
related	O
to	O
ethyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
benzyloxybenzoate	I-IUPAC
was	O
synthesized	O
and	O
evaluated	O
for	O
potential	O
hypolipidemic	O
activity	O
in	O
rats	O
.	O

Structure	O
-	O
-	O
activity	O
relationships	O
are	O
discussed	O
in	O
terms	O
of	O
cholesterol	O
-	O
lowering	O
activity	O
together	O
with	O
effects	O
on	O
weight	O
gain	O
and	O
liver	O
lipids	O
.	O

A	O
number	O
of	O
the	O
compounds	O
inhibited	O
cholesterol	O
and	O
free	O
fatty	O
acid	O
biosynthesis	O
from	O
[	O
1-14	O
C	O
]	O
acetate	O
in	O
rat	O
liver	O
slices	O
in	O
vitro	O
.	O

Ethyl	O
4	I-IUPAC
-	I-IUPAC
benzyloxybenzoate	I-IUPAC
,	O
ethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
benzyloxybenzoic	I-IUPAC
acid	I-IUPAC
,	O
ethyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
bromobenzyloxybenzoates	I-IUPAC
,	O
and	O
4	I-IUPAC
-	I-IUPAC
o	I-IUPAC
-	I-IUPAC
methoxybenzyloxyphenyl	I-IUPAC
acetate	I-IUPAC
exhibited	O
the	O
most	O
favorable	O
spectrum	O
of	O
activity	O
.	O

In	O
this	O
paper	O
we	O
describe	O
the	O
synthesis	O
of	O
a	O
series	O
of	O
novel	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
alkylsemicarbazono	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
methylenedioxyphenylacetic	I-IUPAC
acid	I-IUPAC
alkyl	I-IUPAC
esters	I-IUPAC
(	O
10-19	O
)	O
carrying	O
an	O
alkylsemicarbazono	O
moiety	O
at	O
a	O
benzylic	O
site	O
.	O

The	O
influence	O
of	O
this	O
group	O
on	O
the	O
biological	O
activity	O
was	O
evaluated	O
by	O
testing	O
the	O
corresponding	O
derivatives	O
20-22	O
in	O
which	O
the	O
4	I-PARTIUPAC
-	I-PARTIUPAC
alkylsemicarbazono	I-PARTIUPAC
moiety	I-MODIFIER
was	O
removed	O
(	O
compound	O
20	O
)	O
or	O
its	O
alkylureido	O
portion	O
shifted	O
at	O
position	O
1	O
(	O
compounds	O
21-22	O
)	O
.	O

Furthermore	O
,	O
the	O
involvement	O
of	O
the	O
4	I-PARTIUPAC
-	I-PARTIUPAC
aminobenzyl	I-PARTIUPAC
moiety	I-MODIFIER
in	O
the	O
anticonvulsant	O
activity	O
was	O
evaluated	O
by	O
testing	O
derivative	O
23	O
.	O

The	O
anticonvulsant	O
activity	O
of	O
all	O
compounds	O
was	O
assayed	O
against	O
audiogenic	O
seizures	O
induced	O
in	O
DBA	O
/	O
2	O
mice	O
.	O

Within	O
this	O
series	O
of	O
derivatives	O
,	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylsemicarbazono	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
methylenedioxyphenylacetic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
10	O
)	O
proved	O
to	O
be	O
the	O
most	O
active	O
compound	O
.	O

It	O
displayed	O
a	O
potency	O
5	O
-	O
fold	O
higher	O
than	O
that	O
shown	O
by	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
methylenedioxy	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
benzodiazepine	I-IUPAC
(	O
1	O
,	O
GYKI	O
52466	O
)	O
,	O
a	O
well	O
-	O
known	O
noncompetitive	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
receptor	O
antagonist	O
.	O

Compound	O
10	O
was	O
also	O
effective	O
in	O
suppressing	O
seizures	O
induced	O
in	O
Swiss	O
mice	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
or	O
pentylenetetrazole	O
(	O
PTZ	O
)	O
.	O

Furthermore	O
,	O
it	O
antagonized	O
in	O
vivo	O
seizures	O
induced	O
by	O
icv	O
administration	O
of	O
AMPA	O
or	O
kainate	O
(	O
KA	O
)	O
.	O

Using	O
the	O
patch	O
-	O
clamp	O
technique	O
in	O
primary	O
cultures	O
of	O
granule	O
neurons	O
we	O
tested	O
compounds	O
10	O
and	O
21	O
for	O
their	O
ability	O
to	O
modulate	O
currents	O
evoked	O
by	O
KA	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
ATPA	O
)	O
.	O

These	O
two	O
derivatives	O
reduced	O
KA	O
and	O
ATPA	O
currents	O
to	O
a	O
larger	O
extent	O
than	O
that	O
shown	O
by	O
reference	O
compound	O
1	O
.	O

Compounds	O
10	O
and	O
21	O
were	O
also	O
able	O
to	O
reduce	O
neuronal	O
cell	O
death	O
induced	O
by	O
the	O
application	O
of	O
KA	O
(	O
100	O
microM	O
)	O
.	O

Novel	O
3	O
-	O
substituted	O
analogues	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
3	I-IUPAC
-	I-IUPAC
deazacytidine	I-IUPAC
,	O
3	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
3	I-IUPAC
-	I-IUPAC
deazauridine	I-IUPAC
,	O
4	O
)	O
have	O
been	O
synthesized	O
and	O
tested	O
for	O
antitumor	O
and	O
antiviral	O
activity	O
.	O

Thus	O
the	O
3	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
(	O
9a	O
)	O
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
(	O
9b	O
)	O
,	O
and	O
3	I-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
(	O
9c	O
)	O
analogues	I-MODIFIER
of	O
3	O
and	O
the	O
3	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
(	O
9d	O
)	O
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
(	O
9e	O
)	O
,	O
and	O
3	I-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
(	O
9f	O
)	O
analogues	I-MODIFIER
of	O
4	O
were	O
prepared	O
by	O
standard	O
glycosylating	O
procedures	O
.	O

Novel	O
requisite	O
heterocycles	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7a	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7b	O
)	O
were	O
prepared	O
by	O
halogenating	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
5	O
)	O
.	O

Requisite	O
heterocycles	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7c	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7d	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7e	O
)	O
,	O
and	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7f	O
)	O
were	O
synthesized	O
by	O
known	O
procedures	O
from	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
6	O
)	O
.	O

Structure	O
proof	O
of	O
target	O
nucleosides	O
was	O
provided	O
by	O
independent	O
synthesis	O
,	O
1H	O
NMR	O
,	O
and	O
UV	O
.	O

Compounds	O
9a	O
-	O
f	O
were	O
devoid	O
of	O
activity	O
against	O
intraperitoneally	O
implanted	O
L1210	O
leukemia	O
in	O
mice	O
.	O

Compound	O
9f	O
displayed	O
significant	O
activity	O
against	O
rhinovirus	O
type	O
34	O
grown	O
in	O
WISH	O
cells	O
.	O

4	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
1	O
)	O
displayed	O
good	O
activity	O
against	O
intraperitoneally	O
implanted	O
P388	O
leukemia	O
in	O
mice	O
,	O
but	O
it	O
was	O
devoid	O
of	O
activity	O
against	O
M5076	O
sarcoma	O
,	O
amelanotic	O
(	O
LOX	O
)	O
melanoma	O
xenograft	O
,	O
and	O
subrenal	O
capsule	O
human	O
mammary	O
carcinoma	O
MX	O
-	O
1	O
xenograft	O
in	O
mice	O
.	O

Compound	O
1	O
also	O
displayed	O
significant	O
activity	O
against	O
rhinovirus	O
type	O
34	O
.	O

The	O
in	O
vitro	O
screening	O
for	O
trypanocidal	O
activity	O
against	O
Trypanosoma	O
brucei	O
rhodesiense	O
of	O
an	O
in	O
-	O
house	O
library	O
of	O
62	O
compounds	O
[	O
i.e.	O
alkane	O
,	O
diphenyl	O
,	O
and	O
azaalkane	O
bisguanidines	O
and	O
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoimidazolines	I-IUPAC
)	I-IUPAC
]	O
,	O
which	O
were	O
chosen	O
for	O
their	O
structural	O
similarity	O
to	O
the	O
trypanocidal	O
agents	O
synthalin	O
(	O
1,10	I-IUPAC
-	I-IUPAC
decanediguanidine	I-IUPAC
)	O
and	O
4,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
diguanidinodiphenylmethane	I-IUPAC
and	O
the	O
polyamine	I-IUPAC
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
propane	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
respectively	O
,	O
is	O
reported	O
.	O

The	O
original	O
synthetic	O
procedure	O
for	O
the	O
preparation	O
of	O
21	O
of	O
these	O
compounds	O
is	O
also	O
reported	O
.	O

Most	O
compounds	O
displayed	O
low	O
micromolar	O
antitrypanosomal	O
activity	O
,	O
with	O
five	O
of	O
them	O
presenting	O
a	O
nanomolar	O
inhibitory	O
action	O
on	O
the	O
parasite	O
:	O
1,9	I-IUPAC
-	I-IUPAC
nonanediguanidine	I-IUPAC
(	O
1c	O
)	O
,	O
1,12	I-IUPAC
-	I-IUPAC
dodecanediguanidine	I-IUPAC
(	O
1d	O
)	O
,	O
4,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidinylimino	I-IUPAC
]	I-IUPAC
diphenylamine	I-IUPAC
(	O
28a	O
)	O
,	O
4,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolylamino	I-IUPAC
)	I-IUPAC
diphenylamine	I-IUPAC
(	O
28b	O
)	O
,	O
and	O
4,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
diguanidinodiphenylamine	I-IUPAC
(	O
32b	O
)	O
.	O

Those	O
molecules	O
that	O
showed	O
an	O
excellent	O
in	O
vitro	O
activity	O
as	O
well	O
as	O
high	O
selectivity	O
for	O
the	O
parasite	O
[	O
e.g.	O
1c	O
(	O
IC	O
(	O
50	O
)	O
=	O
49	O
nM	O
;	O
SI	O
&	O
gt	O
;	O
5294	O
)	O
,	O
28b	O
(	O
IC	O
(	O
50	O
)	O
=	O
69	O
nM	O
;	O
SI	O
=	O
3072	O
)	O
,	O
32b	O
(	O
IC	O
(	O
50	O
)	O
=	O
22	O
nM	O
;	O
SI	O
=	O
29.5	O
)	O
,	O
41b	O
(	O
IC	O
(	O
50	O
)	O
=	O
118	O
nM	O
;	O
SI	O
=	O
881	O
)	O
]	O
represent	O
new	O
antitrypanosomal	O
lead	O
compounds	O
.	O

In	O
earlier	O
reports	O
we	O
identified	O
specific	O
point	O
substitutions	O
(	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
)	O
,	O
cyclization	O
strategies	O
[	O
in	O
particular	O
,	O
introduction	O
of	O
lactam	O
rings	O
such	O
as	O
that	O
of	O
cyclo	O
(	O
Glu30	O
,	O
Lys33	O
)	O
]	O
,	O
and	O
deletions	O
(	O
residues	O
1-7	O
)	O
in	O
the	O
CRF	O
molecule	O
that	O
led	O
to	O
agonists	O
.	O

We	O
also	O
noted	O
that	O
further	O
deletions	O
(	O
residues	O
8-14	O
)	O
produced	O
antagonists	O
such	O
as	O
astressin	O
	O
	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
,	O
Glu30	O
,	O
Lys33	O
]	O
hCRF	O
(	O
12-41	O
)	O
	O
	O
(	O
1	O
)	O
.	O

We	O
hypothesized	O
that	O
the	O
lactam	O
ring	O
promoted	O
conformational	O
stability	O
to	O
yield	O
analogues	O
with	O
increased	O
potency	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
as	O
compared	O
to	O
that	O
of	O
their	O
linear	O
counterparts	O
.	O

Additionally	O
,	O
we	O
reported	O
that	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
,	O
Glu30	O
,	O
DHis32	O
,	O
Lys33	O
]	O
hCRF	O
(	O
12-41	O
)	O
(	O
3	O
)	O
and	O
dicyclo	O
(	O
26-36,30-33	O
)	O
[	O
Ac	O
-	O
Asp9	O
,	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
,	O
Cys26	O
,	O
Glu30	O
,	O
Lys33	O
,	O
Cys36	O
]	O
hCRF	O
(	O
9-41	O
)	O
were	O
ca.	O
twice	O
and	O
1/100	O
as	O
potent	O
as	O
astressin	O
,	O
respectively	O
,	O
suggesting	O
a	O
putative	O
turn	O
that	O
encompasses	O
residues	O
30-33	O
(	O
previous	O
paper	O
:	O
Koerber	O
et	O
al.	O
J	O
.	O

Med.	O
Chem.	O
1998	O
,	O
41	O
)	O
.	O

To	O
increase	O
the	O
potency	O
of	O
1	O
and	O
/	O
or	O
3	O
in	O
vivo	O
,	O
we	O
extended	O
their	O
chain	O
length	O
by	O
one	O
(	O
5-8	O
)	O
,	O
two	O
(	O
9	O
,	O
10	O
)	O
,	O
and	O
three	O
(	O
11	O
,	O
12	O
)	O
residues	O
at	O
the	O
N	O
-	O
terminus	O
and	O
acetylated	O
(	O
6	O
,	O
8	O
,	O
10	O
,	O
12	O
)	O
.	O

Of	O
the	O
compounds	O
tested	O
for	O
duration	O
of	O
action	O
(	O
1	O
,	O
3-6	O
,	O
8	O
)	O
,	O
we	O
found	O
6	O
and	O
8	O
to	O
be	O
slightly	O
longer	O
-	O
acting	O
than	O
astressin	O
or	O
[	O
DHis32	O
]	O
astressin	O
,	O
while	O
their	O
potencies	O
in	O
vitro	O
were	O
not	O
significantly	O
different	O
from	O
that	O
of	O
3	O
.	O

Additionally	O
,	O
we	O
introduced	O
CalphaMe	O
-	O
leucine	O
residues	O
in	O
lieu	O
of	O
leucine	O
at	O
positions	O
14	O
,	O
15	O
,	O
19	O
,	O
27	O
,	O
and	O
37	O
in	O
[	O
DHis32	O
]	O
astressin	O
.	O

The	O
analogue	O
[	O
CalphaMe	O
-	O
Leu27	O
,	O
DHis32	O
]	O
astressin	O
(	O
16	O
)	O
was	O
more	O
potent	O
(	O
although	O
not	O
statistically	O
in	O
all	O
cases	O
)	O
than	O
the	O
other	O
four	O
analogues	O
in	O
vitro	O
.	O

While	O
acetylation	O
of	O
the	O
N	O
-	O
terminus	O
of	O
16	O
(	O
i.e.	O
,	O
18	O
)	O
or	O
of	O
[	O
CalphaMe	O
-	O
Leu27	O
]	O
astressin	O
(	O
i.e.	O
,	O
19	O
)	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
in	O
vitro	O
potency	O
,	O
elongation	O
of	O
the	O
N	O
-	O
terminus	O
by	O
one	O
or	O
three	O
residues	O
in	O
addition	O
to	O
acetylation	O
resulted	O
in	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
CalphaMe	O
-	O
Leu27	O
,	O
Glu3	O
0	O
,	O
DHis32	O
,	O
Lys33	O
,	O
Nle38	O
]	O
Ac	O
-	O
hCRF	O
(	O
11-41	O
)	O
(	O
21	O
)	O
,	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
CalphaMe	O
-	O
Leu27	O
,	O
Glu30	O
,	O
Lys33	O
,	O
Nle38	O
]	O
Ac	O
-	O
hCRF	O
(	O
9-41	O
)	O
(	O
22	O
)	O
,	O
and	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
CalphaMe	O
-	O
Leu27	O
,	O
Glu30	O
,	O
DHis32	O
,	O
Lys33	O
,	O
Nle38	O
]	O
Ac	O
-	O
hCRF	O
(	O
9-41	O
)	O
(	O
23	O
)	O
that	O
were	O
longer	O
-	O
acting	O
than	O
6	O
and	O
8	O
(	O
ca.	O
2	O
h	O
inhibition	O
of	O
ACTH	O
secretion	O
at	O
25	O
micrograms	O
/	O
adrenalectomized	O
rat	O
)	O
.	O

Analogues	O
22	O
and	O
23	O
were	O
also	O
more	O
potent	O
than	O
astressin	O
at	O
reversing	O
intracisternal	O
CRF	O
-	O
and	O
abdominal	O
surgery	O
-	O
induced	O
delay	O
of	O
gastric	O
emptying	O
in	O
conscious	O
rats	O
.	O

A	O
new	O
means	O
of	O
accessing	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclopropylmethyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethylnorspermine	I-IUPAC
(	O
CPMENSPM	O
)	O
and	O
the	O
first	O
synthesis	O
of	O
(	I-IUPAC
2R	I-IUPAC
,	I-IUPAC
10S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclopropylmethyl	I-IUPAC
-	I-IUPAC
2,10	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethylnorspermine	I-IUPAC
[	O
(	O
2R	O
,	O
10S	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
CPMENSPM	O
]	O
are	O
described	O
.	O

Both	O
of	O
these	O
polyamine	O
analogues	O
are	O
shown	O
to	O
be	O
more	O
active	O
against	O
L1210	O
murine	O
leukemia	O
cell	O
growth	O
than	O
either	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
,	I-IUPAC
N	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
diethylnorspermine	I-IUPAC
(	O
DENSPM	O
)	O
or	O
(	I-IUPAC
2R	I-IUPAC
,	I-IUPAC
10R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
,	I-IUPAC
N	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
diethyl	I-IUPAC
-	I-IUPAC
2,10	I-IUPAC
-	I-IUPAC
dihydroxynorspermine	I-IUPAC
[	O
(	O
2R	O
,	O
10R	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
DENSPM	O
]	O
after	O
96	O
h	O
of	O
treatment	O
;	O
the	O
activity	O
was	O
comparable	O
to	O
that	O
of	O
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
10S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
,	I-IUPAC
N	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
diethyl	I-IUPAC
-	I-IUPAC
2,10	I-IUPAC
-	I-IUPAC
dihydroxynorspermine	I-IUPAC
[	O
(	O
2S	O
,	O
10S	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
DENSPM	O
]	O
at	O
96	O
h	O
.	O

Both	O
cyclopropyl	I-PARTIUPAC
compounds	B-MODIFIER
reduced	O
putrescine	O
and	O
spermidine	O
pools	O
,	O
but	O
less	O
effectively	O
than	O
did	O
DENSPM	O
and	O
its	O
derivatives	O
.	O

Only	O
CPMENSPM	O
,	O
and	O
not	O
(	O
2R	O
,	O
10S	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
CPMENSPM	O
,	O
lowered	O
spermine	O
pools	O
.	O

As	O
with	O
DENSPM	O
and	O
(	O
2R	O
,	O
10R	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
DENSPM	O
,	O
both	O
cyclopropyl	I-PARTIUPAC
analogues	B-MODIFIER
diminished	O
ornithine	O
decarboxylase	O
and	O
S	I-IUPAC
-	I-IUPAC
adenosylmethionine	I-IUPAC
decarboxylase	O
activity	O
.	O

Unlike	O
the	O
hydroxylated	O
DENSPM	O
compounds	O
,	O
both	O
cyclopropyl	O
norspermines	O
substantially	O
upregulated	O
spermidine	O
/	O
spermine	O
N	O
(	O
1	O
)	O
-	O
acetyltransferase	O
.	O

The	O
most	O
interesting	O
effect	O
of	O
hydroxylating	O
CPMENSPM	O
is	O
the	O
profound	O
reduction	O
in	O
toxicity	O
compared	O
with	O
that	O
of	O
the	O
parent	O
drug	O
.	O

The	O
same	O
phenomenon	O
had	O
been	O
observed	O
for	O
the	O
DENSPM	O
/	O
(	O
2R	O
,	O
10R	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
DENSPM	O
pair	O
.	O

Thus	O
,	O
hydroxylation	O
of	O
norspermine	O
analogues	O
appears	O
to	O
be	O
a	O
way	O
to	O
maintain	O
the	O
compounds	O
'	O
antiproliferative	O
activity	O
while	O
reducing	O
their	O
toxicity	O
.	O

Three	O
series	O
of	O
benzamides	O
of	O
N	I-MODIFIER
,	I-MODIFIER
N	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
ethylenediamines	I-IUPAC
(	O
linear	I-MODIFIER
alkane	B-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamines	I-IUPAC
)	O
,	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
pyrrolidines	I-IUPAC
,	O
and	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
3	I-IUPAC
-	I-IUPAC
aminopyrrolidines	I-IUPAC
(	O
cyclic	I-MODIFIER
alkane	B-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamines	I-IUPAC
)	O
were	O
designed	O
and	O
synthesized	O
as	O
potential	O
neuroleptics	O
.	O

All	O
target	O
compounds	O
were	O
evaluated	O
for	O
their	O
inhibitory	O
effects	O
on	O
apomorphine	O
-	O
induced	O
stereotyped	O
behavior	O
in	O
rats	O
,	O
and	O
a	O
good	O
correlation	O
between	O
structure	O
and	O
activity	O
was	O
found	O
throughout	O
the	O
series	O
.	O

In	O
the	O
linear	O
series	O
(	O
analogues	O
of	O
metoclopramide	O
)	O
,	O
introduction	O
of	O
a	O
benzyl	I-IUPAC
group	B-MODIFIER
on	O
the	O
terminal	O
nitrogen	O
,	O
rather	O
than	O
an	O
ethyl	I-IUPAC
group	B-MODIFIER
,	O
and	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
on	O
the	O
p	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
of	O
metoclopramide	O
both	O
enhanced	O
the	O
activity	O
.	O

The	O
resulting	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
benzamide	I-IUPAC
(	O
23	O
)	O
was	O
about	O
15	O
times	O
more	O
active	O
than	O
metoclopramide	O
.	O

In	O
the	O
cyclic	O
series	O
,	O
particularly	O
among	O
the	O
benzamides	O
of	O
1	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminopyrrolidine	I-IUPAC
,	O
most	O
of	O
the	O
compounds	O
tested	O
were	O
more	O
active	O
than	O
the	O
corresponding	O
linear	O
benzamides	O
.	O

cis	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
Benzyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylpyrrolidin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
benzamide	I-IUPAC
(	O
YM	O
-	O
09151-2	O
,	O
55	O
)	O
was	O
the	O
most	O
active	O
among	O
all	O
of	O
the	O
compounds	O
tested	O
,	O
being	O
13	O
and	O
408	O
times	O
more	O
potent	O
than	O
haloperidol	O
and	O
metoclopramide	O
,	O
respectively	O
.	O

Moreover	O
,	O
compound	O
55	O
exhibited	O
a	O
fairly	O
high	O
ratio	O
of	O
antistereotypic	O
activity	O
to	O
cataleptogenicity	O
compared	O
with	O
haloperidol	O
and	O
metoclopramide	O
.	O

It	O
is	O
expected	O
that	O
compound	O
55	O
may	O
be	O
used	O
as	O
a	O
potent	O
drug	O
with	O
few	O
side	O
effects	O
in	O
the	O
treatment	O
of	O
psychosis	O
.	O

A	O
series	O
of	O
monoamidic	I-MODIFIER
derivatives	I-MODIFIER
of	I-MODIFIER
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-PARTIUPAC
-	I-PARTIUPAC
1,2	I-PARTIUPAC
-	I-PARTIUPAC
cyclohexanedicarboxylic	I-PARTIUPAC
and	O
1,2	I-IUPAC
-	I-IUPAC
cyclopentanedicarboxylic	I-IUPAC
acids	I-IUPAC
bearing	O
either	O
a	O
carboxylic	O
,	O
sulfhydrylic	O
,	O
or	O
hydroxamic	O
group	O
in	O
the	O
side	O
chain	O
were	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
their	O
inhibitory	O
activity	O
against	O
angiotensin	O
converting	O
enzyme	O
.	O

The	O
compounds	O
were	O
designed	O
as	O
potential	O
ACE	O
inhibitors	O
of	O
novel	O
structure	O
,	O
assuming	O
that	O
a	O
monoamidic	O
residue	O
of	O
an	O
1,2	I-IUPAC
-	I-IUPAC
cyclomethylenedicarboxylic	I-IUPAC
acid	I-IUPAC
could	O
be	O
an	O
alternative	O
structure	O
to	O
the	O
acylproline	O
moiety	O
,	O
the	O
carboxyl	O
-	O
terminal	O
portion	O
common	O
to	O
various	O
ACE	O
inhibitors	O
.	O

The	O
most	O
active	O
compounds	O
were	O
found	O
in	O
the	O
hydroxamic	O
derivatives	O
of	O
cyclohexane	O
series	O
;	O
within	O
this	O
series	O
of	O
derivatives	O
a	O
marked	O
increase	O
of	O
potency	O
was	O
caused	O
by	O
alkylation	O
of	O
the	O
amidic	O
nitrogen	O
with	O
a	O
methyl	I-IUPAC
or	O
ethyl	I-IUPAC
group	B-MODIFIER
.	O

Therefore	O
enantiomers	O
of	O
the	O
selected	O
hydroxamic	O
derivatives	O
of	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
cyclohexanedicarboxylic	I-IUPAC
acid	I-IUPAC
were	O
prepared	O
by	O
two	O
different	O
chiral	O
synthetic	O
routes	O
and	O
evaluated	O
in	O
vitro	O
for	O
their	O
ACE	O
inhibitor	O
potencies	O
.	O

The	O
active	O
enantiomers	O
both	O
of	O
the	O
cis	O
series	O
(	O
21a	O
,	O
21c	O
)	O
and	O
trans	O
series	O
(	O
16b	O
,	O
16d	O
)	O
were	O
found	O
to	O
have	O
all	O
R	O
configuration	O
at	O
the	O
C	O
-	O
2	O
and	O
R	O
or	O
S	O
configuration	O
at	O
the	O
C	O
-	O
1	O
,	O
while	O
in	O
the	O
classical	O
ACE	O
inhibitors	O
S	O
configuration	O
at	O
the	O
terminal	O
carboxylate	O
(	O
corresponding	O
to	O
the	O
C	O
-	O
1	O
of	O
our	O
compounds	O
)	O
is	O
strictly	O
required	O
for	O
activity	O
.	O

The	O
most	O
potent	O
compound	O
of	O
the	O
series	O
was	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
cyclohexanecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
21a	O
)	O
with	O
an	O
IC50	O
value	O
of	O
7.0	O
nM	O
compared	O
with	O
the	O
value	O
of	O
3.0	O
nM	O
for	O
captopril	O
.	O

Further	O
21a	O
was	O
shown	O
to	O
be	O
highly	O
selective	O
and	O
competitive	O
ACE	O
inhibitor	O
.	O

These	O
results	O
indicate	O
that	O
this	O
non	O
-	O
amino	O
acid	O
structure	O
of	O
inhibitors	O
meets	O
the	O
ACE	O
active	O
site	O
requirements	O
for	O
the	O
binding	O
.	O

The	O
binding	O
compatibility	O
of	O
the	O
most	O
active	O
compounds	O
with	O
a	O
model	O
of	O
ACE	O
active	O
site	O
was	O
evaluated	O
by	O
molecular	O
modeling	O
techniques	O
.	O

The	O
nigrostriatal	O
toxin	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
(	O
MPTP	O
)	O
is	O
biotransformed	O
by	O
brain	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
to	O
an	O
unstable	O
dihydropyridinium	O
intermediate	O
that	O
reacts	O
with	O
cyanide	O
ion	O
to	O
form	O
an	O
alpha	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
adduct	O
and	O
,	O
in	O
the	O
absence	O
of	O
cyanide	O
ion	O
,	O
undergoes	O
disproportionation	O
to	O
the	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpyridinium	I-IUPAC
species	O
MPP+	O
and	O
MPTP	O
.	O

Comparison	O
of	O
the	O
HPLC	O
retention	O
times	O
,	O
diode	O
array	O
UV	O
,	O
and	O
chemical	O
ion	O
mass	O
spectral	O
characteristics	O
of	O
these	O
products	O
with	O
those	O
of	O
synthetic	O
standards	O
led	O
us	O
to	O
propose	O
the	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydropyridinium	I-IUPAC
species	O
2,3	O
-	O
MPDP+	O
and	O
6	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
as	O
tentative	O
structure	O
assignments	O
for	O
the	O
dihydropyridinium	O
metabolite	O
and	O
the	O
cyano	O
adduct	O
,	O
respectively	O
.	O

Results	O
presented	O
in	O
this	O
paper	O
confirm	O
the	O
first	O
assignment	O
and	O
establish	O
that	O
,	O
although	O
the	O
proposed	O
6	O
-	O
cyano	O
adduct	O
is	O
initially	O
formed	O
,	O
the	O
product	O
that	O
was	O
isolated	O
from	O
the	O
mitochondrial	O
incubation	O
mixtures	O
of	O
MPTP	O
and	O
sodium	O
cyanide	O
actually	O
is	O
the	O
isomeric	O
2	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
.	O

On	O
the	O
basis	O
of	O
the	O
selective	O
incorporation	O
of	O
deuterium	O
into	O
these	O
products	O
,	O
we	O
provide	O
rational	O
mechanistic	O
interpretations	O
of	O
the	O
disproportionation	O
reaction	O
and	O
the	O
rearrangement	O
of	O
the	O
cyano	O
adducts	O
.	O

These	O
results	O
establish	O
that	O
the	O
MAO	O
-	O
catalyzed	O
bioactivation	O
of	O
MPTP	O
leads	O
to	O
the	O
formation	O
of	O
a	O
variety	O
of	O
reactive	O
molecules	O
that	O
are	O
potentially	O
cytotoxic	O
to	O
nigrostriatal	O
cells	O
.	O

A	O
novel	O
class	O
of	O
tricyclic	O
tropane	O
analogues	O
has	O
been	O
synthesized	O
by	O
making	O
use	O
of	O
radical	O
cyclization	O
technology	O
in	O
combination	O
with	O
the	O
Stille	O
coupling	O
reaction	O
.	O

As	O
hybrids	O
between	O
tropanes	O
and	O
quinuclidines	O
,	O
these	O
tropaquinuclidines	O
represent	O
a	O
significant	O
structural	O
departure	O
from	O
many	O
of	O
the	O
other	O
classes	O
of	O
tropane	O
ligands	O
synthesized	O
to	O
date	O
.	O

This	O
structure	O
class	O
is	O
characterized	O
by	O
the	O
boat	O
conformation	O
of	O
the	O
tropane	O
ring	O
and	O
the	O
orientation	O
of	O
the	O
additional	O
bridge	O
(	O
and	O
therefore	O
of	O
the	O
nitrogen	O
lone	O
pair	O
)	O
together	O
with	O
the	O
unusual	O
placement	O
of	O
the	O
aromatic	O
moiety	O
.	O

All	O
compounds	O
were	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
monoamine	O
reuptake	O
under	O
identical	O
conditions	O
.	O

The	O
ability	O
to	O
inhibit	O
reuptake	O
of	O
dopamine	O
in	O
comparison	O
to	O
cocaine	O
is	O
generally	O
decreased	O
in	O
this	O
series	O
but	O
for	O
one	O
compound	O
.	O

(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thienylmethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
azatricyclo	I-IUPAC
[	I-IUPAC
4.3.1.0	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
decane	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
5h	O
)	O
exhibits	O
reasonable	O
activity	O
at	O
the	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
(	O
K	O
(	O
i	O
)	O
=	O
268	O
nM	O
)	O
and	O
good	O
activity	O
at	O
the	O
norepinephrine	O
transporter	O
(	O
NET	O
)	O
(	O
K	O
(	O
i	O
)	O
=	O
26	O
nM	O
)	O
.	O

The	O
potency	O
and	O
selectivity	O
shown	O
by	O
some	O
of	O
these	O
ligands	O
for	O
the	O
NET	O
,	O
serotonine	O
transporter	O
(	O
SERT	O
)	O
,	O
or	O
NET	O
/	O
SERT	O
is	O
striking	O
,	O
particularly	O
in	O
view	O
of	O
the	O
displacement	O
of	O
the	O
aromatic	O
ring	O
in	O
this	O
series	O
from	O
its	O
usual	O
position	O
at	O
C	O
-	O
3	O
in	O
the	O
WIN	O
analogues	O
.	O

Thus	O
,	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
biphenylylmethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
azatricyclo	I-IUPAC
[	I-IUPAC
4.3.1	I-IUPAC
.	I-IUPAC

0	I-IUPAC
(	I-IUPAC
3,7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
decane	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
5a	O
)	O
is	O
a	O
selective	O
inhibitor	O
of	O
norepinephrine	O
reuptake	O
(	O
K	O
(	O
i	O
)	O
=	O
12	O
nM	O
)	O
.	O

Its	O
p	O
-	O
methoxy	O
analogue	O
5c	O
is	O
a	O
mixed	O
inhibitor	O
of	O
norepinephrine	O
and	O
serotonin	O
reuptake	O
(	O
K	O
(	O
i	O
)	O
=	O
187	O
nM	O
at	O
the	O
NET	O
and	O
56	O
nM	O
at	O
the	O
SERT	O
)	O
.	O

The	O
most	O
active	O
and	O
selective	O
compound	O
we	O
found	O
in	O
the	O
present	O
series	O
is	O
compound	O
8b	O
[	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dichlorophenylmethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
azatricyclo	I-IUPAC
[	I-IUPAC
4.3.1.0	I-IUPAC
(	I-IUPAC
3,7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
decane	I-IUPAC
]	O
.	O

This	O
compound	O
is	O
a	O
potent	O
(	O
K	O
(	O
i	O
)	O
=	O
1.6	O
nM	O
)	O
and	O
selective	O
inhibitor	O
of	O
serotonin	O
reuptake	O
into	O
rat	O
midbrain	O
synaptosomes	O
.	O

Its	O
selectivity	O
is	O
about	O
400	O
-	O
fold	O
over	O
the	O
NET	O
and	O
about	O
1000	O
-	O
fold	O
over	O
the	O
DAT	O
.	O

The	O
results	O
of	O
this	O
study	O
further	O
demonstrate	O
the	O
possibility	O
of	O
tuning	O
the	O
selectivity	O
of	O
tropane	O
analogues	O
toward	O
the	O
SERT	O
or	O
NET	O
binding	O
site	O
.	O

The	O
ligands	O
disclosed	O
herein	O
provide	O
additional	O
pharmacological	O
tools	O
of	O
use	O
in	O
attempting	O
to	O
correlate	O
structure	O
and	O
transporter	O
selectivity	O
with	O
in	O
vivo	O
studies	O
of	O
behavioral	O
outcomes	O
.	O

Recently	O
,	O
we	O
reported	O
the	O
first	O
human	O
study	O
of	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
,	O
technetium	O
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
chlorophenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
azabicyclo	I-PARTIUPAC
[	O
3.2.1	O
]	O
oct	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
]	I-PARTIUPAC
methyl	I-PARTIUPAC
]	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
mercaptoethyl	I-PARTIUPAC
)	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
ethyl	I-PARTIUPAC
]	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
ethanethiolato	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
o	I-PARTIUPAC
xo	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
1R	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
exo	I-PARTIUPAC
-	I-PARTIUPAC
exo	I-PARTIUPAC
)	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
,	O
as	O
an	O
imaging	O
agent	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
dopamine	O
transporters	O
.	O

Due	O
to	O
the	O
existence	O
of	O
several	O
chiral	O
centers	O
on	O
this	O
molecule	O
,	O
upon	O
the	O
formation	O
of	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
complex	O
(	O
2	O
)	O
several	O
diastereomers	O
could	O
be	O
created	O
.	O

Two	O
major	O
diastereomers	O
of	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
(	O
2	O
)	O
,	O
designated	O
as	O
peak	O
A	O
(	O
2A	O
)	O
and	O
peak	O
B	O
(	O
2B	O
)	O
,	O
were	O
separated	O
by	O
HPLC	O
.	O

Biodistribution	O
of	O
the	O
purified	O
diastereomers	O
2A	O
,	O
B	O
was	O
evaluated	O
in	O
rats	O
.	O

It	O
appears	O
that	O
2A	O
displayed	O
a	O
higher	O
lipophilicity	O
than	O
2B	O
(	O
PC	O
=	O
305	O
and	O
229	O
,	O
respectively	O
)	O
,	O
and	O
a	O
similar	O
trend	O
was	O
observed	O
for	O
the	O
initial	O
brain	O
uptake	O
at	O
2	O
min	O
postinjection	O
(	O
0.50%	O
and	O
0.28%	O
dose	O
/	O
organ	O
for	O
2A	O
,	O
B	O
,	O
respectively	O
)	O
.	O

At	O
60	O
min	O
post	O
-	O
iv	O
-	O
injection	O
,	O
the	O
specific	O
uptakes	O
,	O
as	O
measured	O
by	O
[	O
striatum	O
-	O
cerebellum	O
]	O
/	O
cerebellum	O
(	O
[	O
ST	O
-	O
CB	O
]	O
/	O
CB	O
)	O
ratio	O
,	O
were	O
1.72	O
and	O
2.79	O
for	O
2A	O
,	O
B	O
,	O
respectively	O
.	O

The	O
higher	O
[	O
ST	O
-	O
CB	O
]	O
/	O
CB	O
ratio	O
observed	O
for	O
2B	O
was	O
corroborated	O
by	O
the	O
results	O
of	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

Higher	O
binding	O
affinity	O
for	O
dopamine	O
transporters	O
was	O
observed	O
for	O
3B	O
(	O
Ki	O
=	O
13.87	O
and	O
8.42	O
nM	O
for	O
the	O
analogous	O
rhenium	O
complexes	O
3A	O
,	O
B	O
,	O
respectively	O
)	O
.	O

The	O
structure	O
of	O
the	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
complexes	O
was	O
deduced	O
using	O
nonradioactive	O
rhenium	O
as	O
a	O
surrogate	O
for	O
radioactive	O
technetium	O
complex	O
.	O

Reacting	O
free	O
TRODAT	O
-	O
1	O
ligand	O
with	O
[	O
Bu4N	O
]	O
[	O
ReOCl4	O
]	O
yielded	O
two	O
major	O
complexes	O
:	O
Re	O
-	O
TRODAT	O
-	O
1A	O
(	O
3A	O
)	O
and	O
Re	O
-	O
TRODAT	O
-	O
1B	O
(	O
3B	O
)	O
(	O
corresponding	O
with	O
peaks	O
A	O
and	O
B	O
of	O
[	O
99mTc	O
]	O
TRODAT	O
-	O
1	O
,	O
respectively	O
)	O
,	O
whose	O
structures	O
were	O
determined	O
by	O
X	O
-	O
ray	O
analysis	O
.	O

The	O
X	O
-	O
ray	O
structures	O
show	O
that	O
both	O
complexes	O
have	O
a	O
pseudo	O
-	O
square	O
-	O
pyramidal	O
structure	O
of	O
[	O
RevO	O
]	O
3+	O
N2S2	O
core	O
with	O
oxygen	O
occupying	O
the	O
apical	O
position	O
and	O
the	O
N	O
-	O
alkyl	O
substitution	O
in	O
syn	O
-	O
configuration	O
to	O
the	O
oxo	O
-	O
rhenium	O
bond	O
.	O

In	O
conclusion	O
,	O
TRODAT	O
-	O
1	O
formed	O
at	O
least	O
two	O
diastereomers	O
after	O
complexing	O
with	O
a	O
metal	O
(	O
V	O
)	O
-	O
oxo	O
(	O
M	O
=	O
99mTc	O
,	O
Re	O
)	O
center	O
core	O
.	O

The	O
two	O
isomers	O
display	O
different	O
binding	O
affinities	O
toward	O
dopamine	O
transporters	O
and	O
distinct	O
properties	O
of	O
localization	O
in	O
the	O
striatum	O
area	O
of	O
the	O
brain	O
where	O
the	O
transporters	O
are	O
located	O
.	O

The	O
novel	O
calcium	O
antagonists	O
3	I-MODIFIER
-	I-MODIFIER
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
3,4	I-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
1	O
and	O
9	O
and	O
3	I-MODIFIER
-	I-MODIFIER
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
dihydro	I-IUPAC
-	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
8	O
were	O
regioselectively	O
synthesized	O
in	O
good	O
yields	O
.	O

Compounds	O
1	O
[	O
especially	O
1s	O
[	O
R1	O
=	O
(	I-PARTIUPAC
CH2	I-PARTIUPAC
)	I-PARTIUPAC
2N	I-PARTIUPAC
(	I-PARTIUPAC
benzyl	I-PARTIUPAC
)	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
naphthylmethyl	I-PARTIUPAC
)	O
,	O
R2	O
=	O
i	O
-	O
Pr	O
,	O
X	O
=	O
0	O
-	O
NO2	O
]	O
and	O
1t	O
[	O
R1	O
=	O
(	I-PARTIUPAC
CH2	I-PARTIUPAC
)	I-PARTIUPAC
2N	I-PARTIUPAC
(	I-PARTIUPAC
benzyl	I-PARTIUPAC
)	I-PARTIUPAC
(	I-PARTIUPAC
3,4	I-PARTIUPAC
-	I-PARTIUPAC
dichlorobenzyl	I-PARTIUPAC
)	O
,	O
R2	O
=	O
i	O
-	O
Pr	O
,	O
X	O
=	O
0	O
-	O
NO2	O
]	O
]	O
exhibited	O
not	O
only	O
more	O
potent	O
and	O
longer	O
lasting	O
vasodilative	O
action	O
but	O
also	O
a	O
hypotensive	O
activity	O
with	O
slow	O
onset	O
as	O
compared	O
with	O
dihydropyridines	O
.	O

Moreover	O
,	O
some	O
dihydropyrimidines	O
[	O
1q	O
[	O
R1	O
=	O
(	I-PARTIUPAC
CH2	I-PARTIUPAC
)	I-PARTIUPAC
2N	I-PARTIUPAC
(	I-PARTIUPAC
benzyl	I-PARTIUPAC
)	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
phenylpropyl	I-PARTIUPAC
)	O
,	O
R2	O
=	O
CH2	I-IUPAC
(	I-IUPAC
cyclopropyl	I-IUPAC
)	I-IUPAC
,	O
X	O
=	O
0	O
-	O
NO2	O
]	O
,	O
1s	O
,	O
and	O
1t	O
]	O
were	O
weaker	O
in	O
blocking	O
atrioventricular	O
conduction	O
in	O
anesthetized	O
open	O
-	O
chest	O
dogs	O
and	O
less	O
toxic	O
than	O
the	O
dihydropyridines	O
.	O

A	O
new	O
series	O
of	O
thyrotropin	O
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
analogues	O
,	O
obtained	O
by	O
further	O
modifications	O
of	O
our	O
most	O
potent	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
stimulating	O
neutral	O
tripeptides	O
at	O
both	O
termini	O
,	O
were	O
synthesized	O
by	O
the	O
pentafluorophenyl	O
ester	O
method	O
and	O
tested	O
for	O
CNS	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
releasing	O
activity	O
.	O

Replacement	O
of	O
pyroglutamic	O
acid	O
by	O
pyro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoadipic	I-IUPAC
acid	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
oxoimidazolidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
or	O
gamma	I-IUPAC
-	I-IUPAC
butyrolactone	I-IUPAC
-	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
and	O
that	O
of	O
proline	O
by	O
pipecolic	O
acid	O
,	O
thiazolidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
,	O
or	O
homoproline	O
in	O
[	O
Leu2	O
]	O
-	O
and	O
[	O
Nva2	O
]	O
TRH	O
led	O
to	O
tripeptides	O
structurally	O
widely	O
different	O
from	O
TRH	O
.	O

In	O
spite	O
of	O
this	O
fact	O
,	O
7	O
of	O
the	O
17	O
analogues	O
(	O
1	O
,	O
2	O
,	O
8-10	O
,	O
16	O
,	O
and	O
17	O
)	O
have	O
stronger	O
anticataleptic	O
effect	O
than	O
TRH	O
,	O
with	O
negligible	O
or	O
no	O
hormonal	O
potency	O
.	O

The	O
highest	O
CNS	O
activity	O
was	O
achieved	O
when	O
pyroglutamic	O
acid	O
was	O
replaced	O
by	O
pyro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoadipic	I-IUPAC
acid	I-IUPAC
at	O
the	O
N	O
-	O
terminus	O
[	O
pAad	O
-	O
Leu	O
-	O
Pro	O
-	O
NH2	O
,	O
1	O
(	O
RGH	O
2202	O
)	O
,	O
and	O
pAad	O
-	O
Nva	O
-	O
Pro	O
-	O
NH2	O
,	O
2	O
]	O
.	O

A	O
novel	O
synthesis	O
of	O
L	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoadipic	I-IUPAC
acid	I-IUPAC
suitable	O
for	O
large	O
-	O
scale	O
preparation	O
is	O
also	O
described	O
.	O

Novel	O
arylpiperazines	O
were	O
identified	O
as	O
alpha	O
1	O
-	O
adrenoceptor	O
(	O
AR	O
)	O
subtype	O
-	O
selective	O
antagonists	O
by	O
functional	O
in	O
vitro	O
screening	O
.	O

3	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
(	O
ortho	I-IUPAC
-	O
Substituted	I-MODIFIER
phenyl	B-IUPAC
)	O
piperazin	I-PARTIUPAC
-	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
]	I-PARTIUPAC
propylamines	I-PARTIUPAC
were	O
derivatized	O
with	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
anthranilamides	I-IUPAC
,	O
nicotinamides	O
,	O
as	O
well	O
as	O
carboxamides	O
of	O
quinoline	O
,	O
1,8	I-IUPAC
-	I-IUPAC
naphthyridine	I-IUPAC
,	O
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
isoxazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
and	O
pyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O

Strips	O
of	O
rabbit	O
bladder	O
neck	O
were	O
employed	O
as	O
a	O
predictive	O
assay	O
for	O
antagonism	O
in	O
the	O
human	O
lower	O
tract	O
.	O

Rings	O
of	O
rat	O
aorta	O
were	O
used	O
as	O
a	O
"	O
negative	O
screen	O
"	O
for	O
the	O
test	O
antagonists	O
.	O

Binding	O
to	O
alpha	O
1	O
-	O
ARs	O
was	O
relatively	O
sensitive	O
to	O
size	O
and	O
electronic	O
features	O
of	O
the	O
arylpiperazine	I-IUPAC
portion	O
of	O
the	O
antagonists	O
and	O
permissive	O
to	O
these	O
features	O
on	O
the	O
heteroaryl	O
carboxamide	O
side	O
.	O

These	O
structure	O
-	O
affinity	O
findings	O
were	O
exploited	O
to	O
produce	O
nicotinamides	O
(	O
e.g.	O
13ii	O
and	O
25x	O
)	O
and	O
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridines	I-IUPAC
(	O
e.g.	O
37f	O
and	O
37y	O
)	O
ligands	O
with	O
nanomolar	O
affinity	O
at	O
the	O
alpha	O
1	O
-	O
AR	O
subtype	O
prevalent	O
in	O
the	O
human	O
lower	O
urinary	O
tract	O
(	O
pA2	O
values	O
:	O
8.8	O
,	O
10.7	O
,	O
9.3	O
,	O
and	O
9.9	O
,	O
respectively	O
)	O
and	O
displaying	O
2-3	O
orders	O
of	O
magnitude	O
selectivity	O
over	O
the	O
alpha	O
1D	O
-	O
AR	O
.	O

A	O
series	O
of	O
N	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
pyridinyl	I-PARTIUPAC
)	I-PARTIUPAC
butyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
5,5	I-PARTIUPAC
-	O
disubstituted	I-MODIFIER
-	O
pentadienamides	I-PARTIUPAC
was	O
prepared	O
and	O
evaluated	O
for	O
PAF	O
-	O
antagonist	O
activity	O
.	O

Compounds	O
were	O
assayed	O
in	O
vitro	O
in	O
a	O
PAF	O
-	O
binding	O
assay	O
employing	O
washed	O
,	O
whole	O
dog	O
platelets	O
as	O
the	O
receptor	O
source	O
and	O
in	O
vivo	O
after	O
intravenous	O
or	O
oral	O
administration	O
for	O
their	O
ability	O
to	O
prevent	O
PAF	O
-	O
induced	O
bronchoconstriction	O
in	O
guinea	O
pigs	O
.	O

Criteria	O
required	O
for	O
good	O
oral	O
activity	O
in	O
the	O
latter	O
model	O
include	O
an	O
(	I-IUPAC
E	I-IUPAC
,	I-IUPAC
-	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pentadienamide	I-IUPAC
,	O
a	O
second	O
phenyl	I-PARTIUPAC
or	O
a	O
four	O
-	O
or	O
five	O
-	O
carbon	O
alkyl	I-PARTIUPAC
moiety	B-MODIFIER
in	O
the	O
5	O
-	O
position	O
of	O
the	O
diene	O
,	O
and	O
an	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
carboxamide	O
nitrogen	O
atom	O
.	O

The	O
alkyl	I-PARTIUPAC
substituent	B-MODIFIER
on	O
this	O
side	O
chain	O
can	O
be	O
methyl	I-PARTIUPAC
,	O
ethyl	I-PARTIUPAC
,	O
or	O
cyclopropyl	I-PARTIUPAC
.	O

Two	O
members	O
of	O
this	O
series	O
,	O
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pentadienamide	I-IUPAC
(	O
31	O
)	O
and	O
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
,	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
decadienamide	I-IUPAC
(	O
58	O
)	O
,	O
were	O
selected	O
for	O
further	O
pharmacological	O
evaluation	O
.	O

Both	O
were	O
found	O
to	O
be	O
substantially	O
longer	O
acting	O
after	O
oral	O
administration	O
than	O
the	O
corresponding	O
S	O
enantiomers	O
in	O
the	O
guinea	O
pig	O
bronchoconstriction	O
assay	O
.	O

A	O
second	O
in	O
vivo	O
model	O
used	O
to	O
evaluate	O
PAF	O
antagonists	O
determines	O
the	O
ability	O
of	O
test	O
compounds	O
to	O
decrease	O
the	O
area	O
of	O
skin	O
wheals	O
induced	O
by	O
an	O
intradermal	O
injection	O
of	O
PAF	O
.	O

In	O
this	O
model	O
,	O
using	O
both	O
rats	O
and	O
guinea	O
pigs	O
,	O
compounds	O
31	O
and	O
58	O
were	O
found	O
to	O
be	O
as	O
active	O
as	O
the	O
reference	O
PAF	O
antagonist	O
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
morpholinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propanone	I-IUPAC
(	O
45	O
)	O
.	O

Convenient	O
procedures	O
are	O
described	O
for	O
the	O
synthesis	O
of	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
N	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxycytidines	I-IUPAC
5a	O
,	O
b	O
,	O
d	O
-	O
h	O
via	O
transformation	O
of	O
the	O
respective	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
1a	O
-	O
c	O
,	O
e	O
-	O
h	O
.	O

These	O
procedures	O
involved	O
site	O
-	O
specific	O
triazolation	O
or	O
N	O
-	O
methylimidazolation	O
at	O
position	O
C	O
(	O
4	O
)	O
,	O
followed	O
by	O
hydroxylamination	O
and	O
deblocking	O
with	O
MeOH	O
-	O
NH	O
(	O
3	O
)	O
.	O

Nucleosides	O
5a	O
,	O
b	O
,	O
d	O
-	O
h	O
were	O
selectively	O
converted	O
to	O
the	O
corresponding	O
5'	O
-	O
monophosphates	O
6a	O
,	O
b	O
,	O
d	O
-	O
h	O
with	O
the	O
aid	O
of	O
the	O
wheat	O
shoot	O
phosphotransferase	O
system	O
.	O

Conformation	O
of	O
each	O
nucleoside	O
in	O
D	O
(	O
2	O
)	O
O	O
solution	O
,	O
deduced	O
from	O
(	O
1	O
)	O
H	O
NMR	O
spectra	O
and	O
confirmed	O
by	O
molecular	O
mechanics	O
calculations	O
,	O
showed	O
the	O
pentose	O
ring	O
to	O
exist	O
predominantly	O
in	O
the	O
conformation	O
S	O
(	O
C	O
-	O
2'	O
-	O
endo	O
)	O
and	O
the	O
N	O
(	O
4	O
)	O
-	O
OH	O
group	O
as	O
the	O
cis	O
rotamer	O
.	O

Cell	O
growth	O
inhibition	O
was	O
studied	O
with	O
two	O
L5178Y	O
murine	O
leukemia	O
cell	O
lines	O
,	O
parental	O
and	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
FdUrd	O
)	O
-	O
resistant	O
,	O
the	O
latter	O
70	O
-	O
fold	O
less	O
sensitive	O
toward	O
FdUrd	O
than	O
the	O
former	O
.	O

With	O
FdUrd	O
-	O
resistant	O
L5178Y	O
cells	O
,	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxycytidine	I-IUPAC
(	O
5e	O
)	O
caused	O
almost	O
3	O
-	O
fold	O
stronger	O
growth	O
inhibition	O
than	O
FdUrd	O
;	O
5e	O
was	O
only	O
some	O
3	O
-	O
fold	O
weaker	O
growth	O
inhibitor	O
of	O
the	O
resistant	O
cells	O
than	O
of	O
the	O
parental	O
cells	O
.	O

Thymidylate	O
synthase	O
inhibition	O
was	O
studied	O
with	O
two	O
forms	O
of	O
the	O
enzyme	O
differing	O
in	O
sensitivities	O
toward	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
monophosphate	I-IUPAC
(	O
FdUMP	O
)	O
,	O
isolated	O
from	O
parental	O
and	O
FdUrd	O
-	O
resistant	O
L1210	O
cell	O
lines	O
.	O

All	O
N	O
(	O
4	O
)	O
-	O
hydroxy	O
-	O
dCMP	O
(	O
6a	O
,	O
b	O
,	O
d	O
-	O
h	O
)	O
and	O
dUMP	O
analogues	O
studied	O
were	O
competitive	O
vs	O
dUMP	O
inhibitors	O
of	O
the	O
enzyme	O
.	O

Analogues	O
6b	O
,	O
d	O
-	O
h	O
and	O
5	O
-	O
hydroxymethyl	O
-	O
dUMP	O
,	O
similar	O
to	O
N	O
(	O
4	O
)	O
-	O
hydroxy	O
-	O
dCMP	O
(	O
6a	O
)	O
and	O
FdUMP	O
,	O
were	O
also	O
N	O
(	O
5	O
)	O
,	O
N	I-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenetetrahydrofolate	I-IUPAC
-	O
dependent	O
,	O
hence	O
mechanism	O
-	O
based	O
,	O
slow	O
-	O
binding	O
inhibitors	O
.	O

5	O
-	O
Chloro	O
-	O
dUMP	O
,	O
5	O
-	O
bromo	O
-	O
dUMP	O
,	O
and	O
5	O
-	O
iodo	O
-	O
dUMP	O
,	O
similar	O
to	O
dTMP	O
,	O
did	O
not	O
cause	O
a	O
time	O
-	O
dependent	O
inactivation	O
of	O
the	O
enzyme	O
.	O

Instead	O
,	O
they	O
behaved	O
as	O
classic	O
inhibitors	O
of	O
tritium	O
release	O
from	O
[	O
5	O
-	O
(	O
3	O
)	O
H	O
]	O
dUMP	O
.	O

5	O
-	O
Bromo	O
-	O
dUMP	O
and	O
5	O
-	O
iodo	O
-	O
dUMP	O
showed	O
substrate	O
activity	O
independent	O
of	O
N	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
,	I-IUPAC
N	I-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenetetrahydrofolate	I-IUPAC
in	O
the	O
thymidylate	O
synthase	O
-	O
catalyzed	O
dehalogenation	O
reaction	O
.	O

The	O
=	O
N	O
-	O
OH	O
substituent	O
of	O
the	O
pyrimidine	O
C	O
(	O
4	O
)	O
prevented	O
the	O
enzyme	O
-	O
catalyzed	O
release	O
from	O
the	O
C	O
(	O
5	O
)	O
of	O
Br	O
(	O
-	O
)	O
and	O
I	O
(	O
-	O
)	O
(	O
the	O
same	O
shown	O
previously	O
for	O
H	O
(	O
+	O
)	O
)	O
.	O

While	O
FdUMP	O
and	O
6a	O
showed	O
a	O
higher	O
affinity	O
and	O
greater	O
inactivation	O
power	O
with	O
the	O
parental	O
cell	O
than	O
FdUrd	O
-	O
resistant	O
cell	O
enzyme	O
,	O
an	O
opposite	O
relationship	O
could	O
be	O
seen	O
with	O
5	O
-	O
hydroxymethyl	O
-	O
dUMP	O
.	O

The	O
palladium	O
-	O
catalyzed	O
coupling	O
of	O
3	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trialkylstannyl	I-IUPAC
)	I-IUPAC
pyridines	I-IUPAC
with	O
7	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
or	O
7	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
quinolinecarboxylates	I-IUPAC
has	O
provided	O
access	O
to	O
the	O
corresponding	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
quinolinecarboxylic	I-IUPAC
acids	I-IUPAC
.	O

The	O
antibacterial	O
activity	O
of	O
these	O
derivatives	O
was	O
studied	O
with	O
the	O
finding	O
that	O
the	O
optimal	O
1	O
-	O
and	O
7	O
-	O
position	O
substituents	O
for	O
Gram	O
positive	O
activity	O
are	O
cyclopropyl	O
and	O
4	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2,6	I-PARTIUPAC
-	I-PARTIUPAC
dimethylpyridinyl	I-PARTIUPAC
)	I-PARTIUPAC
,	O
respectively	O
.	O

We	O
find	O
that	O
for	O
the	O
fluorine	O
-	O
substituted	O
derivatives	O
studied	O
,	O
the	O
position	O
of	O
the	O
fluorine	O
on	O
the	O
quinolone	O
nucleus	O
or	O
the	O
number	O
of	O
fluorine	O
atoms	O
does	O
not	O
seem	O
to	O
be	O
important	O
for	O
good	O
Gram	O
positive	O
activity	O
.	O

For	O
1	I-PARTIUPAC
-	I-PARTIUPAC
cyclopropyl	I-PARTIUPAC
7	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2,6	I-PARTIUPAC
-	I-PARTIUPAC
dimethyl	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
pyridinyl	I-PARTIUPAC
)	I-PARTIUPAC
derivatives	I-MODIFIER
,	O
the	O
6	I-PARTIUPAC
-	I-PARTIUPAC
fluoro	I-PARTIUPAC
4a	O
,	O
8	I-PARTIUPAC
-	I-PARTIUPAC
fluoro	I-PARTIUPAC
10d	O
,	O
6,8	I-PARTIUPAC
-	I-PARTIUPAC
difluoro	I-PARTIUPAC
10b	O
,	O
and	O
5,6,8	I-PARTIUPAC
-	I-PARTIUPAC
trifluoro	I-PARTIUPAC
8	O
,	O
all	O
provided	O
equal	O
antibacterial	O
activity	O
against	O
Staphylococcus	O
aureus	O
ATCC	O
29213	O
.	O

There	O
is	O
also	O
a	O
correlation	O
between	O
the	O
substitution	O
on	O
the	O
7	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
pyridinyl	I-PARTIUPAC
)	I-PARTIUPAC
group	I-MODIFIER
and	O
the	O
Gram	O
positive	O
activity	O
,	O
particularly	O
for	O
S	O
.	O

aureus	O
,	O
clearly	O
indicating	O
that	O
the	O
2,6	I-PARTIUPAC
-	I-PARTIUPAC
dimethylpyridinyl	I-PARTIUPAC
group	I-MODIFIER
is	O
optimal	O
.	O

The	O
MIC50	O
value	O
for	O
the	O
most	O
potent	O
agents	O
in	O
this	O
study	O
against	O
S	O
.	O

aureus	O
ATCC	O
29213	O
is	O
0.008	O
microgram	O
/	O
mL	O
.	O

By	O
comparison	O
,	O
ciprofloxacin	O
and	O
aminopyrrolidine	O
28	O
gave	O
values	O
of	O
0.25	O
and	O
0.015	O
microgram	O
/	O
mL	O
,	O
respectively	O
,	O
against	O
this	O
organism	O
.	O

In	O
an	O
effort	O
to	O
develop	O
selective	O
inhibitors	O
of	O
vesicular	O
acetylcholine	O
storage	O
,	O
we	O
have	O
synthesized	O
a	O
series	O
of	O
semirigid	O
vesamicol	O
receptor	O
ligands	O
based	O
on	O
the	O
structure	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpiperidino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexanol	I-IUPAC
(	O
vesamicol	O
,	O
AH5183	O
,	O
1	O
)	O
.	O

In	O
these	O
compounds	O
,	O
the	O
planes	O
of	O
the	O
phenyl	O
and	O
piperidyl	O
moieties	O
of	O
the	O
parent	O
ligand	O
1	O
are	O
held	O
at	O
right	O
angles	O
by	O
vinyl	O
,	O
ethylene	O
,	O
and	O
propylene	O
bridges	O
to	O
form	O
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
derivatives	B-MODIFIER
of	O
spiro	I-IUPAC
[	I-IUPAC
indene	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
2,3	I-IUPAC
-	I-IUPAC
dihydrospiro	I-IUPAC
[	I-IUPAC
indene	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
and	O
3,4	I-IUPAC
-	I-IUPAC
dihydrospiro	I-IUPAC
[	I-IUPAC
naphthalene	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
respectively	O
.	O

Preliminary	O
evaluation	O
of	O
these	O
compounds	O
in	O
electric	O
organ	O
synaptic	O
vesicles	O
revealed	O
several	O
potent	O
vesamicol	O
receptor	O
ligands	O
,	O
such	O
as	O
1'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphth	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indene	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
p	I-IUPAC
iperidine	I-IUPAC
(	O
11b	O
)	O
and	O
1'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphth	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
in	I-IUPAC
den	I-IUPAC
e	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
(	O
14	O
)	O
,	O
which	O
display	O
subnanomolar	O
affinity	O
for	O
this	O
receptor	O
.	O

In	O
general	O
,	O
the	O
vinyl	O
and	O
ethylene	O
bridges	O
yielded	O
the	O
most	O
potent	O
analogs	O
while	O
the	O
propylene	O
-	O
bridged	O
analogs	O
were	O
among	O
the	O
least	O
potent	O
compounds	O
.	O

The	O
increased	O
rigidity	O
of	O
these	O
spiro	O
-	O
fused	O
compounds	O
,	O
relative	O
to	O
the	O
corresponding	O
simple	O
4	I-IUPAC
-	I-IUPAC
phenylpiperidine	I-IUPAC
derivatives	I-MODIFIER
of	O
vesamicol	O
,	O
is	O
expected	O
to	O
confer	O
greater	O
selectivity	O
for	O
the	O
vesamicol	O
receptor	O
.	O

Analogues	O
of	O
methotrexate	O
(	O
MTX	O
)	O
and	O
aminopterin	O
(	O
AMT	O
)	O
modified	O
at	O
the	O
gamma	O
-	O
position	O
of	O
the	O
glutamate	O
side	O
chain	O
were	O
synthesized	O
and	O
evaluated	O
as	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
inhibitors	O
and	O
tumor	O
cell	O
growth	O
inhibitors	O
.	O

Condesations	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
methylpteroic	I-IUPAC
acid	I-IUPAC
(	O
mAPA	O
)	O
with	O
dimethyl	I-IUPAC
DL	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyleneglutamate	I-IUPAC
in	O
the	O
presence	O
of	O
diethyl	O
phosphorocyanidate	O
(	O
DEPC	O
)	O
followed	O
by	O
alkaline	O
hydrolysis	O
yielded	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
methylpteroyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
DL	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyleneglutamic	I-IUPAC
acid	I-IUPAC
(	O
gamma	O
-	O
methyleneMTX	O
)	O
.	O

Condensation	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
formylpteroic	I-IUPAC
acid	I-IUPAC
(	O
fAPA	O
)	O
with	O
dimethyl	I-IUPAC
-	I-IUPAC
DL	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyleneglutamate	I-IUPAC
by	O
the	O
mixed	O
carboxylic	O
-	O
carbonic	O
anhydride	O
method	O
yielded	O
N	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxypteroyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
DL	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyleneglutamic	I-IUPAC
acid	I-IUPAC
(	O
gamma	O
-	O
methyleneAMT	O
)	O
.	O

Also	O
prepared	O
via	O
DEPC	O
coupling	O
was	O
a	O
mixture	O
of	O
the	O
four	O
possible	O
diastereomers	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
methylpteroyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
cyanoglutamic	I-IUPAC
acid	I-IUPAC
(	O
gamma	O
-	O
cyanoMTX	O
)	O
.	O

The	O
requisite	O
intermediate	O
gamma	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
cyanoglutamate	I-IUPAC
,	O
as	O
a	O
DL	O
-	O
threo	O
/	O
DL	O
-	O
erythro	O
mixture	O
,	O
was	O
prepared	O
from	O
methyl	I-IUPAC
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
Boc	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
serinate	I-IUPAC
by	O
reaction	O
with	O
sodium	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
cyanoacetate	I-IUPAC
followed	O
by	O
mild	O
trifluoroacetic	O
treatment	O
to	O
selectively	O
remove	O
the	O
Boc	O
group	O
.	O

The	O
gamma	I-PARTIUPAC
-	I-PARTIUPAC
methylene	I-PARTIUPAC
derivatives	I-MODIFIER
of	O
MTX	O
and	O
AMT	O
are	O
attractive	O
because	O
of	O
their	O
potential	O
to	O
act	O
as	O
Michael	O
acceptors	O
within	O
the	O
DHFR	O
active	O
site	O
.	O

gamma	O
-	O
CyanoMTX	O
may	O
be	O
viewed	O
as	O
a	O
congener	O
of	O
the	O
nonpolyglutamated	O
MTX	O
analogue	O
gamma	O
-	O
fluoroMTX	O
.	O

In	O
vitro	O
bioassay	O
data	O
for	O
the	O
gamma	I-IUPAC
-	I-IUPAC
methylene	I-IUPAC
and	O
gamma	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
compounds	I-MODIFIER
support	O
the	O
idea	O
that	O
the	O
active	O
site	O
of	O
DHFR	O
,	O
already	O
known	O
for	O
its	O
ability	O
to	O
tolerate	O
modification	O
of	O
the	O
gamma	I-IUPAC
-	I-IUPAC
carboxyl	I-IUPAC
group	I-MODIFIER
of	O
MTX	O
and	O
AMT	O
,	O
can	O
likewise	O
accommodate	O
substitution	O
on	O
the	O
gamma	O
-	O
carbon	O
itself	O
.	O

Analogues	O
of	O
the	O
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosine	I-IUPAC
(	I-IUPAC
Dmt	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
Tic	O
)	O
pharmacophore	O
were	O
prepared	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
"	O
spacer	O
"	O
and	O
a	O
third	O
aromatic	O
center	O
in	O
opioid	O
peptides	O
are	O
required	O
to	O
convert	O
a	O
delta	O
-	O
antagonist	O
into	O
ligands	O
with	O
delta	O
-	O
agonist	O
or	O
with	O
mixed	O
delta	O
-	O
antagonist	O
/	O
mu	O
-	O
agonist	O
properties	O
.	O

Potent	O
delta	O
-	O
agonists	O
and	O
bifunctional	O
compounds	O
with	O
high	O
delta	O
-	O
and	O
mu	O
-	O
opioid	O
receptor	O
affinities	O
were	O
obtained	O
by	O
varying	O
the	O
spacer	O
length	O
[	O
none	O
,	O
NH	O
-	O
CH	O
(	O
2	O
)	O
,	O
NH	O
-	O
CH	O
(	O
2	O
)	O
-	O
CH	O
(	O
2	O
)	O
,	O
Gly	O
-	O
NH	O
-	O
CH	O
(	O
2	O
)	O
]	O
and	O
C	O
-	O
terminal	O
aromatic	O
nucleus	O
[	O
1H	I-PARTIUPAC
-	I-PARTIUPAC
benzimidazole	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
,	O
phenyl	I-PARTIUPAC
(	O
Ph	O
)	O
and	O
benzyl	I-IUPAC
groups	B-MODIFIER
]	O
.	O

C	O
-	O
terminal	O
modification	O
primarily	O
affected	O
mu	O
-	O
opioid	O
receptor	O
affinities	O
,	O
which	O
increased	O
maximally	O
1700	O
-	O
fold	O
relative	O
to	O
the	O
prototype	O
delta	O
-	O
antagonist	O
H	O
-	O
Dmt	O
-	O
Tic	O
-	O
NH	O
(	O
2	O
)	O
and	O
differentially	O
modified	O
bioactivity	O
.	O

In	O
the	O
absence	O
of	O
a	O
spacer	O
(	O
1	O
)	O
,	O
the	O
analogue	O
exhibited	O
dual	O
delta	O
-	O
agonism	O
(	O
pEC	O
(	O
50	O
)	O
,	O
7.28	O
)	O
and	O
delta	O
-	O
antagonism	O
(	O
pA	O
(	O
2	O
)	O
,	O
7.90	O
)	O
.	O

H	O
-	O
Dmt	O
-	O
Tic	O
-	O
NH	O
-	O
CH	O
(	O
2	O
)	O
-	O
1H	O
-	O
benzimidazole	O
-	O
2	O
-	O
yl	O
(	O
Bid	O
)	O
(	O
2	O
)	O
became	O
a	O
highly	O
potent	O
delta	O
-	O
agonist	O
(	O
pEC	O
(	O
50	O
)	O
,	O
9.90	O
)	O
,	O
slightly	O
greater	O
than	O
deltorphin	O
C	O
(	O
pEC	O
(	O
50	O
)	O
,	O
9.56	O
)	O
,	O
with	O
mu	O
-	O
agonism	O
(	O
pE	O
(	O
50	O
)	O
,	O
7.57	O
)	O
,	O
while	O
H	O
-	O
Dmt	O
-	O
Tic	O
-	O
Gly	O
-	O
NH	O
-	O
CH	O
(	O
2	O
)	O
-	O
Bid	O
(	O
4	O
)	O
retained	O
potent	O
delta	O
-	O
antagonism	O
(	O
pA	O
(	O
2	O
)	O
,	O
9.0	O
)	O
but	O
with	O
an	O
order	O
of	O
magnitude	O
less	O
mu	O
-	O
agonism	O
.	O

Similarly	O
,	O
H	O
-	O
Dmt	O
-	O
Tic	O
-	O
Gly	O
-	O
NH	O
-	O
Ph	O
(	O
5	O
)	O
had	O
nearly	O
equivalent	O
high	O
delta	O
-	O
agonism	O
(	O
pEC	O
(	O
50	O
)	O
,	O
8.52	O
)	O
and	O
mu	O
-	O
agonism	O
(	O
pEC	O
(	O
50	O
)	O
,	O
8.59	O
)	O
,	O
while	O
H	O
-	O
Dmt	O
-	O
Tic	O
-	O
Gly	O
-	O
NH	O
-	O
CH	O
(	O
2	O
)	O
-	O
Ph	O
(	O
6	O
)	O
whose	O
spacer	O
was	O
longer	O
by	O
a	O
single	O
methylene	O
group	O
exhibited	O
potent	O
delta	O
-	O
antagonism	O
(	O
pA	O
(	O
2	O
)	O
,	O
9.25	O
)	O
and	O
very	O
high	O
mu	O
-	O
agonism	O
(	O
pEC	O
(	O
50	O
)	O
,	O
8.57	O
)	O
.	O

These	O
data	O
confirm	O
that	O
the	O
distance	O
between	O
the	O
Dmt	O
-	O
Tic	O
pharmacophore	O
and	O
a	O
third	O
aromatic	O
nucleus	O
is	O
an	O
important	O
criterion	O
in	O
converting	O
Dmt	O
-	O
Tic	O
from	O
a	O
highly	O
potent	O
delta	O
-	O
antagonist	O
into	O
a	O
potent	O
delta	O
-	O
agonist	O
or	O
into	O
ligands	O
with	O
mixed	O
delta	O
-	O
and	O
mu	O
-	O
opioid	O
properties	O
.	O

Ring	O
closure	O
of	O
ethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminopyrazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
with	O
sulfamoyl	O
chloride	O
gave	O
1,7	I-IUPAC
-	I-IUPAC
dihydropyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,6	I-IUPAC
]	I-IUPAC
thiadiazine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
.	O

The	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
analogue	I-MODIFIER
of	O
this	O
new	O
heterocyclic	O
ring	O
system	O
was	O
similarly	O
prepared	O
from	O
3	I-IUPAC
-	I-IUPAC
aminopyrazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
.	O

Treatment	O
of	O
4,5,6	I-IUPAC
-	I-IUPAC
triamino	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,2,6	I-IUPAC
-	I-IUPAC
thiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
with	O
N	I-IUPAC
-	I-IUPAC
thionylaniline	I-IUPAC
gave	O
a	O
derivative	O
of	O
another	O
new	O
ring	O
system	O
,	O
7	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1,2,5	I-IUPAC
]	I-IUPAC
thiadiazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,6	I-IUPAC
]	I-IUPAC
thiadiazine	I-IUPAC
5,5	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
.	O

These	O
compounds	O
and	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	O
and	O
4	I-IUPAC
-	I-IUPAC
hydroxyimidazol	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,6	I-IUPAC
]	I-IUPAC
thiadiazine	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
were	O
examined	O
as	O
potential	O
transition	O
-	O
state	O
analogue	O
inhibitors	O
of	O
xanthine	O
oxidase	O
and	O
guanine	O
aminohydrolase	O
.	O

Two	O
of	O
the	O
compounds	O
possessed	O
Ki	O
values	O
of	O
about	O
2x	O
10	O
(	O
-	O
4	O
)	O
M	O
with	O
guanine	O
aminohydrolase	O
,	O
but	O
no	O
inhibition	O
of	O
xanthine	O
oxidase	O
was	O
observed	O
by	O
any	O
at	O
5	O
x	O
10	O
(	O
-	O
4	O
)	O
M	O
.	O

[	O
3	O
-	O
(	O
1,4	O
-	O
Cyclohexadienyl	O
)	O
-	O
L	O
-	O
alanine	O
,	O
8	O
-	O
lysine	O
]	O
vasopressin	O
,	O
otherwise	O
known	O
as	O
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dihydrophenylalanine	I-IUPAC
)	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
lysine	I-IUPAC
]	I-IUPAC
vasopressin	I-IUPAC
or	O
[	O
DiHPhe3	O
]	O
lysine	O
-	O
vasopressin	O
,	O
has	O
been	O
synthesized	O
in	O
an	O
attempt	O
to	O
utilize	O
2,5	I-IUPAC
-	I-IUPAC
dihydrophenylalanine	I-IUPAC
(	O
DiHPhe	O
)	O
to	O
evaluate	O
the	O
contribution	O
of	O
aromaticity	O
in	O
position	O
3	O
to	O
biological	O
activity	O
.	O

The	O
analogue	O
has	O
the	O
same	O
primary	O
structure	O
as	O
lysine	O
-	O
vasopressin	O
,	O
except	O
that	O
two	O
additional	O
hydrogen	O
atoms	O
are	O
present	O
on	O
the	O
ring	O
moiety	O
of	O
the	O
phenylalanine	O
residue	O
in	O
position	O
3	O
.	O

The	O
key	O
intermediate	O
was	O
the	O
protected	O
nonapeptide	O
N	I-IUPAC
-	I-IUPAC
carbobenzoxy	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
cysteinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosyldihydrophenyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutaminyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
asparaginyl	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
cysteinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
prolyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
epsilon	I-IUPAC
-	I-IUPAC
tosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
lysylglycinamide	I-IUPAC
that	O
was	O
synthesized	O
stepwise	O
by	O
the	O
solid	O
-	O
phase	O
technique	O
.	O

Deprotection	O
with	O
sodium	O
in	O
liquid	O
ammonia	O
was	O
followed	O
by	O
sulfhydryl	O
oxidation	O
with	O
I2	O
to	O
give	O
the	O
hormone	O
analogue	O
.	O

[	O
DiHPhe3	O
]	O
lysine	O
-	O
vasopressin	O
exhibited	O
125	O
-	O
-	O
130	O
units	O
/	O
mg	O
of	O
antidiuretic	O
,	O
129	O
-	O
-	O
132	O
units	O
/	O
mg	O
of	O
rat	O
pressor	O
,	O
and	O
6	O
units	O
/	O
mg	O
of	O
rat	O
uterus	O
contracting	O
activity	O
.	O

To	O
confirm	O
the	O
presence	O
of	O
DiHPhe	O
in	O
the	O
analogue	O
,	O
an	O
enzymatic	O
procedure	O
employing	O
Aspergillus	O
oryzae	O
was	O
developed	O
that	O
liberates	O
in	O
high	O
yield	O
the	O
amino	O
acid	O
residue	O
in	O
position	O
3	O
of	O
the	O
posterior	O
pituitary	O
hormone	O
structure	O
.	O

This	O
study	O
should	O
be	O
applicable	O
to	O
other	O
biologically	O
active	O
peptides	O
.	O

A	O
series	O
of	O
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
alkynyl	I-IUPAC
derivatives	I-MODIFIER
of	O
adenosine	O
(	O
Ado	O
)	O
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
their	O
affinity	O
at	O
human	O
A	O
(	O
1	O
)	O
,	O
A	O
(	O
2A	O
)	O
,	O
and	O
A	O
(	O
3	O
)	O
receptors	O
and	O
for	O
their	O
potency	O
at	O
A	O
(	O
2B	O
)	O
adenosine	O
receptor	O
subtypes	O
.	O

The	O
corresponding	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
alkynyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
of	O
5'	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
ethylcarboxamidoadenosine	I-IUPAC
(	O
NECA	O
)	O
and	O
Ado	O
are	O
used	O
as	O
reference	O
compounds	O
.	O

Binding	O
studies	O
demonstrated	O
that	O
the	O
activities	O
of	O
2	O
-	O
alkynylAdos	O
were	O
slightly	O
increased	O
for	O
the	O
adenosine	O
A	O
(	O
1	O
)	O
receptor	O
and	O
slightly	O
decreased	O
for	O
both	O
A	O
(	O
3	O
)	O
and	O
A	O
(	O
2B	O
)	O
subtypes	O
compared	O
to	O
those	O
of	O
their	O
corresponding	O
NECA	O
derivatives	O
,	O
whereas	O
the	O
A	O
(	O
2A	O
)	O
receptor	O
affinities	O
of	O
the	O
two	O
series	O
of	O
nucleosides	O
were	O
similar	O
.	O

The	O
presence	O
of	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
on	O
N	O
(	O
6	O
)	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
alkynyladenosines	I-IUPAC
,	O
inducing	O
an	O
increase	O
in	O
affinity	O
at	O
the	O
human	O
A	O
(	O
3	O
)	O
receptor	O
and	O
a	O
decrease	O
at	O
the	O
other	O
subtypes	O
,	O
resulted	O
in	O
an	O
increase	O
in	O
A	O
(	O
3	O
)	O
selectivity	O
.	O

In	O
particular	O
,	O
2	I-IUPAC
-	I-IUPAC
phenylethynyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
Ado	O
(	O
8b	O
)	O
showed	O
an	O
A	O
(	O
3	O
)	O
affinity	O
in	O
the	O
low	O
nanomolar	O
range	O
(	O
K	O
(	O
i	O
)	O
(	O
A	O
(	O
3	O
)	O
)	O
=	O
3.4	O
nM	O
)	O
,	O
with	O
a	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
3	O
)	O
and	O
A	O
(	O
2A	O
)	O
/	O
A	O
(	O
3	O
)	O
selectivity	O
of	O
about	O
500	O
and	O
2500	O
,	O
respectively	O
.	O

These	O
findings	O
motivated	O
us	O
to	O
search	O
for	O
the	O
preparation	O
of	O
new	O
selective	O
radioligands	O
for	O
the	O
A	O
(	O
3	O
)	O
subtype	O
;	O
hence	O
,	O
a	O
procedure	O
to	O
introduce	O
a	O
tritiated	O
alkylamino	O
group	O
in	O
these	O
molecules	O
was	O
carried	O
out	O
.	O

As	O
far	O
as	O
the	O
potency	O
at	O
the	O
A	O
(	O
2B	O
)	O
receptor	O
,	O
the	O
type	O
of	O
2	O
-	O
alkynyl	O
chain	O
and	O
the	O
presence	O
of	O
the	O
ethylcarboxamido	O
group	O
on	O
the	O
sugar	O
seem	O
to	O
be	O
very	O
important	O
;	O
in	O
fact	O
,	O
the	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylhydroxypropynyl	I-IUPAC
NECA	O
[	O
(	O
S	O
)	O
-	O
PHPNECA	O
,	O
1e	O
,	O
EC	O
(	O
50	O
)	O
(	O
A	O
(	O
2B	O
)	O
)	O
=	O
0.22	O
microM	O
]	O
proved	O
to	O
be	O
one	O
of	O
the	O
most	O
potent	O
A	O
(	O
2B	O
)	O
agonist	O
reported	O
so	O
far	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylhydroxypropynyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
Ado	O
(	O
9e	O
,	O
EC	O
(	O
50	O
)	O
(	O
A	O
(	O
2B	O
)	O
)	O
=	O
0.73	O
microM	O
)	O
showed	O
a	O
significantly	O
increase	O
of	O
potency	O
at	O
the	O
A	O
(	O
2B	O
)	O
subtype	O
in	O
comparison	O
with	O
the	O
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
,	O
and	O
the	O
unsubstituted	O
adenosine	O
derivatives	O
,	O
although	O
it	O
resulted	O
in	O
being	O
less	O
potent	O
than	O
(	O
S	O
)	O
-	O
PHPNECA	O
(	O
1e	O
,	O
EC	O
(	O
50	O
)	O
(	O
A	O
(	O
2B	O
)	O
)	O
=	O
0.22	O
microM	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
introduction	O
of	O
an	O
ethyl	O
group	O
in	O
the	O
N	O
(	O
6	O
)	O
-	O
position	O
and	O
an	O
ethylcarboxamido	O
substituent	O
in	O
the	O
4'	O
-	O
position	O
of	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylhydroxypropynyladenosine	I-IUPAC
could	O
lead	O
to	O
a	O
compound	O
endowed	O
with	O
high	O
potency	O
at	O
the	O
A	O
(	O
2B	O
)	O
receptor	O
.	O

Derivatives	O
of	O
the	O
nonselective	O
excitatory	O
amino	O
acid	O
antagonist	O
kynurenic	O
acid	O
(	O
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydroquinoline	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
,	O
1	O
)	O
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
antagonist	O
activity	O
at	O
the	O
excitatory	O
amino	O
acid	O
receptors	O
sensitive	O
to	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
(	O
NMDA	O
)	O
,	O
quisqualic	O
acid	O
(	O
QUIS	O
or	O
AMPA	O
)	O
,	O
and	O
kainic	O
acid	O
(	O
KA	O
)	O
.	O

Introduction	O
of	O
substituents	O
at	O
the	O
5	O
-	O
,	O
7	O
-	O
,	O
and	O
5,7	O
-	O
positions	O
resulted	O
in	O
analogues	O
having	O
selective	O
NMDA	O
antagonist	O
action	O
,	O
as	O
a	O
result	O
of	O
blockade	O
of	O
the	O
glycine	O
modulatory	O
(	O
or	O
coagonist	O
)	O
site	O
on	O
the	O
NMDA	O
receptor	O
.	O

Regression	O
analysis	O
suggested	O
a	O
requirement	O
for	O
optimally	O
sized	O
,	O
hydrophobic	O
5	O
-	O
and	O
7	O
-	O
substituents	O
,	O
with	O
bulk	O
tolerance	O
being	O
greater	O
at	O
the	O
5	O
-	O
position	O
.	O

Optimization	O
led	O
to	O
the	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivative	I-MODIFIER
(	O
53	O
)	O
,	O
which	O
is	O
the	O
most	O
potent	O
and	O
selective	O
glycine	O
/	O
NMDA	O
antagonist	O
to	O
date	O
(	O
IC50	O
vs	O
[	O
3H	O
]	O
glycine	O
binding	O
,	O
32	O
nM	O
;	O
IC50	O
's	O
for	O
other	O
excitatory	O
amino	O
acid	O
receptor	O
sites	O
,	O
greater	O
than	O
100	O
microM	O
)	O
.	O

Substitution	O
of	O
1	O
at	O
the	O
6	O
-	O
position	O
resulted	O
in	O
compounds	O
having	O
selective	O
non	O
-	O
NMDA	O
antagonism	O
and	O
8	O
-	O
substituted	O
compounds	O
were	O
inactive	O
at	O
all	O
receptors	O
.	O

The	O
retention	O
of	O
glycine	O
/	O
NMDA	O
antagonist	O
activity	O
in	O
heterocyclic	O
ring	O
modified	O
analogues	O
,	O
such	O
as	O
the	O
oxanilide	O
69	O
and	O
the	O
2	I-IUPAC
-	I-IUPAC
carboxybenzimidazole	I-IUPAC
70	O
,	O
suggests	O
that	O
the	O
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
tautomer	I-MODIFIER
of	O
1	O
and	O
its	O
derivatives	O
is	O
required	O
for	O
activity	O
.	O

Structurally	O
related	O
quinoxaline	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diones	I-IUPAC
are	O
also	O
glycine	O
/	O
NMDA	O
antagonists	O
,	O
but	O
are	O
not	O
selective	O
and	O
are	O
less	O
potent	O
than	O
the	O
1	O
derivatives	O
,	O
and	O
additionally	O
show	O
different	O
structure	O
-	O
activity	O
requirements	O
for	O
aromatic	O
ring	O
substitution	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
a	O
model	O
accounting	O
for	O
glycine	O
receptor	O
binding	O
of	O
the	O
1	O
derived	O
antagonists	O
is	O
proposed	O
,	O
comprising	O
(	O
a	O
)	O
size	O
-	O
limited	O
,	O
hydrophobic	O
binding	O
of	O
the	O
benzene	O
ring	O
,	O
(	O
b	O
)	O
hydrogen	O
-	O
bond	O
acceptance	O
by	O
the	O
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
group	I-MODIFIER
,	O
(	O
c	O
)	O
hydrogen	O
-	O
bond	O
donation	O
by	O
the	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
,	O
and	O
(	O
d	O
)	O
a	O
Coulombic	O
attraction	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
.	O

The	O
model	O
can	O
also	O
account	O
for	O
the	O
binding	O
of	O
quinoxaline	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
diones	I-IUPAC
,	O
quinoxalic	I-IUPAC
acids	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
carboxybenzimidazoles	I-IUPAC
.	O

To	O
enhance	O
the	O
intrinsic	O
potency	O
of	O
dihydropyrimidine	O
calcium	O
channel	O
blockers	O
,	O
we	O
have	O
modified	O
the	O
structure	O
of	O
previously	O
described	O
2	I-IUPAC
-	I-IUPAC
heteroalkyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
2	O
to	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1,4	I-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
3	O
.	O

Structure	O
-	O
activity	O
studies	O
using	O
potassium	O
-	O
depolarized	O
rabbit	O
aorta	O
show	O
that	O
ortho	I-IUPAC
,	O
meta	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
aryl	I-IUPAC
derivatives	B-MODIFIER
are	O
more	O
potent	O
than	O
either	O
ortho	O
-	O
or	O
meta	O
-	O
monosubstituted	O
compounds	O
.	O

While	O
vasorelaxant	O
activity	O
was	O
critically	O
dependent	O
on	O
the	O
size	O
of	O
the	O
C5	O
ester	I-IUPAC
group	B-MODIFIER
,	O
isopropyl	O
ester	O
being	O
the	O
best	O
,	O
a	O
variety	O
of	O
substituents	I-MODIFIER
(	O
carbamate	I-IUPAC
,	O
acyl	I-IUPAC
,	O
sulfonyl	I-IUPAC
,	O
alkyl	I-IUPAC
)	O
were	O
tolerated	O
at	O
N3	O
.	O

Our	O
results	O
show	O
dihydropyrimidines	I-IUPAC
3	O
are	O
significantly	O
more	O
potent	O
than	O
corresponding	O
2	I-IUPAC
-	I-IUPAC
heteroalkyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
2	O
and	O
only	O
slightly	O
less	O
potent	O
than	O
similarly	O
substituted	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
heteroalkyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyridines	I-IUPAC
4	O
and	O
5	O
.	O

Whereas	O
dihydropyridine	O
enantiomers	O
usually	O
show	O
10-15	O
-	O
fold	O
difference	O
in	O
activity	O
,	O
the	O
enantiomers	O
of	O
dihydropyrimidine	O
3j	O
show	O
more	O
than	O
a	O
1000	O
-	O
fold	O
difference	O
in	O
activity	O
.	O

These	O
results	O
strengthen	O
the	O
requirement	O
of	O
an	O
enamino	O
ester	O
for	O
binding	O
to	O
the	O
dihydropyridine	O
receptor	O
and	O
indicate	O
a	O
nonspecific	O
role	O
for	O
the	O
N3	O
-	O
substituent	O
.	O

A	O
number	O
of	O
N9	O
-	O
alkyl	O
-	O
substituted	O
purines	O
and	O
purine	O
ribonucleosides	O
have	O
been	O
synthesized	O
as	O
congeners	O
of	O
sulfinosine	O
and	O
evaluated	O
for	O
their	O
antileukemic	O
activity	O
in	O
mice	O
.	O

NaH	O
-	O
mediated	O
alkylation	O
of	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
4	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
5	O
)	O
with	O
certain	O
alkyl	O
bromides	O
gave	O
N7	O
-	O
and	O
N9	O
-	O
alkylated	O
derivatives	O
(	O
7a	O
-	O
d	O
and	O
6a	O
-	O
d	O
)	O
,	O
the	O
N9	O
-	O
isomer	O
being	O
the	O
major	O
product	O
.	O

Treatment	O
of	O
6a	O
-	O
d	O
and	O
7a	O
-	O
d	O
with	O
thiourea	O
furnished	O
the	O
corresponding	O
6	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
derivatives	I-MODIFIER
(	O
9a	O
-	O
d	O
and	O
8a	O
-	O
d	O
)	O
.	O

Amination	O
of	O
9a	O
-	O
e	O
with	O
aqueous	O
chloramine	O
solution	O
afforded	O
the	O
corresponding	O
purine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
sulfenamides	I-IUPAC
(	O
10	O
-	O
a	O
-	O
e	O
)	O
,	O
which	O
on	O
controlled	O
oxidation	O
with	O
3	I-IUPAC
-	I-IUPAC
chloroperoxbenzoic	I-IUPAC
acid	I-IUPAC
(	O
MCPBA	O
)	O
gave	O
the	O
respective	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
alkylpurine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
sulfinamides	I-IUPAC
(	O
11a	O
-	O
e	O
)	O
.	O

A	O
similar	O
oxidation	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methyl	I-IUPAC
/	I-IUPAC
benzylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpurine	I-IUPAC
(	O
12a	O
and	O
12b	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
purine	I-IUPAC
(	O
12c	O
)	O
with	O
MCPBA	O
gave	O
the	O
corresponding	O
sulfoxides	O
(	O
13a	O
-	O
c	O
)	O
,	O
which	O
on	O
further	O
oxidation	O
furnished	O
the	O
respective	O
sulfones	O
(	O
14a	O
-	O
c	O
)	O
.	O

Of	O
the	O
20	O
compounds	O
evaluated	O
,	O
six	O
exhibited	O
biologically	O
significant	O
anti	O
-	O
L1210	O
activity	O
in	O
BD2F1	O
mice	O
and	O
reduced	O
body	O
burdens	O
of	O
viable	O
L1210	O
cells	O
more	O
than	O
90-97%	O
by	O
single	O
treatment	O
.	O

Although	O
compounds	O
9b	O
and	O
9c	O
at	O
44	O
mg	O
and	O
40	O
mg	O
/	O
kg	O
per	O
day	O
x	O
1	O
showed	O
a	O
T	O
/	O
C	O
of	O
147	O
and	O
149	O
,	O
respectively	O
,	O
this	O
group	O
of	O
compounds	O
was	O
found	O
to	O
be	O
less	O
effective	O
than	O
some	O
of	O
the	O
sulfur	O
-	O
containing	O
drugs	O
that	O
we	O
previously	O
described	O
(	O
e.g.	O
sulfenosine	O
and	O
sulfinosine	O
)	O
.	O

A	O
series	O
of	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
anilinopyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
has	O
been	O
prepared	O
and	O
shown	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
tyrosine	O
kinase	O
activity	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O

These	O
compounds	O
are	O
structurally	O
related	O
to	O
the	O
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
3,2	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
pyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
-	I-IUPAC
pyrimidines	I-IUPAC
previously	O
shown	O
to	O
be	O
EGFR	O
inhibitors	O
.	O

Their	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
for	O
inhibition	O
of	O
the	O
isolated	O
enzyme	O
more	O
closely	O
resemble	O
those	O
of	O
the	O
[	O
3,2	O
-	O
d	O
]	O
than	O
the	O
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridopyrimidine	I-IUPAC
isomers	O
.	O

This	O
suggests	O
the	O
requirement	O
of	O
an	O
aza	O
atom	O
in	O
the	O
7	O
-	O
but	O
not	O
the	O
5	O
-	O
position	O
(	O
i.e.	O
,	O
a	O
carbon	O
atom	O
in	O
the	O
5	O
-	O
position	O
)	O
for	O
the	O
enhanced	O
potency	O
shown	O
by	O
6	O
-	O
N	O
-	O
methylated	O
derivatives	O
in	O
each	O
series	O
.	O

X	O
-	O
ray	O
crystal	O
structures	O
were	O
determined	O
for	O
the	O
three	O
NHMe	O
derivatives	O
2	O
,	O
3	O
,	O
and	O
5c	O
in	O
the	O
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
9,2	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
,	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
3,4	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
pyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
-	I-IUPAC
pyrimidine	I-IUPAC
series	I-MODIFIER
,	O
respectively	O
.	O

These	O
show	O
that	O
a	O
carbon	O
rather	O
than	O
a	O
nitrogen	O
atom	O
at	O
the	O
5	O
-	O
position	O
leads	O
to	O
significant	O
conformational	O
changes	O
in	O
the	O
molecule	O
(	O
a	O
longer	O
C5a	O
-	O
C4	O
bond	O
and	O
a	O
30	O
degrees	O
out	O
-	O
of	O
-	O
plane	O
rotation	O
of	O
the	O
phenyl	O
group	O
)	O
,	O
due	O
to	O
the	O
requirement	O
to	O
relieve	O
nonbonding	O
interactions	O
between	O
the	O
C5	O
and	O
N9	O
protons	O
.	O

Pyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
analogues	I-MODIFIER
bearing	O
bulky	O
,	O
weakly	O
basic	O
solubilizing	O
side	O
chains	O
linked	O
to	O
the	O
6	O
-	O
position	O
through	O
a	O
secondary	O
amine	O
generally	O
retained	O
potency	O
both	O
against	O
the	O
isolated	O
enzyme	O
and	O
for	O
inhibition	O
of	O
autophosphorylation	O
of	O
EGFR	O
in	O
intact	O
A431	O
cells	O
.	O

This	O
agrees	O
with	O
a	O
recent	O
binding	O
model	O
that	O
suggests	O
this	O
general	O
class	O
of	O
compounds	O
binds	O
to	O
EGFR	O
with	O
the	O
6	O
-	O
position	O
located	O
in	O
an	O
area	O
of	O
comparative	O
bulk	O
tolerance	O
at	O
the	O
entrance	O
to	O
the	O
ATP	O
-	O
binding	O
pocket	O
.	O

While	O
these	O
solubilized	O
pyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
analogues	I-MODIFIER
were	O
less	O
potent	O
than	O
the	O
NHMe	O
derivative	O
5c	O
in	O
the	O
isolated	O
enzyme	O
assay	O
,	O
some	O
were	O
considerably	O
superior	O
to	O
5c	O
(	O
and	O
among	O
the	O
most	O
potent	O
ever	O
reported	O
)	O
as	O
inhibitors	O
of	O
EGFR	O
autophosphorylation	O
in	O
cellular	O
assays	O
.	O

The	O
sodium	O
salt	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyanopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
1	O
)	O
was	O
condensed	O
with	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetoxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
bromide	I-IUPAC
(	O
2	O
)	O
to	O
provide	O
the	O
corresponding	O
protected	O
acyclic	O
nucleoside	O
,	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetoxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimid	I-IUPAC
ine	I-IUPAC
(	O
3	O
)	O
.	O

Treatment	O
of	O
3	O
with	O
sodium	O
methoxide	O
in	O
methanol	O
provided	O
a	O
good	O
yield	O
of	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
formimidate	I-IUPAC
(	O
4	O
)	O
.	O

Treatment	O
of	O
the	O
imidate	O
(	O
4	O
)	O
with	O
sodium	O
hydrogen	O
sulfide	O
gave	O
the	O
thiocarboxamide	I-IUPAC
derivative	B-MODIFIER
5	O
.	O

Aqueous	O
base	O
transformed	O
4	O
into	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
6	O
)	O
in	O
good	O
yield	O
.	O

Treatment	O
of	O
5	O
with	O
mercuric	O
chloride	O
furnished	O
the	O
toyocamycin	O
analogue	O
7	O
.	O

Evaluation	O
of	O
compounds	O
1	O
,	O
3-7	O
revealed	O
that	O
only	O
the	O
heterocycle	O
(	O
1	O
)	O
and	O
the	O
thiocarboxamide	O
acyclic	O
nucleoside	O
(	O
5	O
)	O
were	O
active	O
.	O

Compound	O
5	O
was	O
the	O
more	O
potent	O
with	O
activity	O
against	O
human	O
cytomegalovirus	O
and	O
herpes	O
simplex	O
virus	O
type	O
1	O
.	O

[	O
1	O
-	O
N	O
-	O
Methylisoasparagine	O
,	O
8	O
-	O
isoleucine	O
]	O
-	O
(	O
I	O
)	O
,	O
[	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
sarcosine	I-PARTIUPAC
,	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
methyltyrosine	I-PARTIUPAC
,	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
isoleucine	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
II	O
)	O
,	O
[	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
sarcosine	I-PARTIUPAC
,	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
methylisoleucine	I-PARTIUPAC
,	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
isoleucine	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
III	O
)	O
,	O
[	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
sarcosine	I-PARTIUPAC
,	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
methylisoleucine	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
IV	O
)	O
,	O
[	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
sarcosine8k	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
methylisoleucine	I-PARTIUPAC
,	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
methylisoleucine	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
V	O
)	O
,	O
[	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
sarcosine	I-PARTIUPAC
,	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
methylthreonine	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
VI	O
)	O
,	O
[	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
sarcosine	I-PARTIUPAC
,	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
methionine	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
VII	O
)	O
,	O
and	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
serine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
(	O
VIII	O
)	O
,	O
synthesized	O
by	O
Merrifield	O
's	O
solid	O
-	O
phase	O
procedure	O
,	O
possess	O
respectively	O
0.8	O
,	O
0.3	O
,	O
0.5	O
,	O
1.0	O
,	O
0.0	O
,	O
0.5	O
,	O
3.7	O
,	O
and	O
0.7%	O
pressor	O
activity	O
of	O
angiotensin	O
II	O
(	O
vagotomized	O
,	O
ganglion	O
-	O
blocked	O
rats	O
)	O
.	O

They	O
caused	O
an	O
initial	O
rise	O
in	O
blood	O
pressure	O
(	O
30	O
min	O
of	O
infusion	O
,	O
250	O
ng	O
/	O
kg	O
/	O
min	O
in	O
vagotomized	O
,	O
ganglion	O
-	O
blocked	O
rats	O
)	O
of	O
16.57	O
,	O
9.80	O
,	O
22.80	O
,	O
32.00	O
,	O
7.00	O
,	O
15.06	O
,	O
32.50	O
,	O
and	O
11.42	O
mmHg	O
and	O
showed	O
secretory	O
activity	O
(	O
isolated	O
cat	O
adrenal	O
medulla	O
)	O
of	O
1.0	O
,	O
0.1	O
,	O
0.01	O
,	O
0.1	O
,	O
less	O
than	O
0.01	O
,	O
0.1	O
,	O
less	O
than	O
0.01	O
,	O
and	O
0.05%	O
of	O
angiotensin	O
II	O
.	O

On	O
isolated	O
organs	O
pA2	O
values	O
(	O
rabbit	O
aortic	O
strips	O
)	O
of	O
8.74	O
,	O
7.44	O
,	O
7.64	O
,	O
7.85	O
,	O
7.89	O
,	O
8.76	O
,	O
8.63	O
,	O
and	O
8.08	O
,	O
and	O
pA2	O
values	O
(	O
cat	O
adrenal	O
medulla	O
of	O
8.16	O
,	O
9.16	O
,	O
9.31	O
,	O
8.00	O
,	O
8.00	O
,	O
7.00	O
,	O
9.16	O
,	O
and	O
9.33	O
were	O
obtained	O
.	O

Dose	O
ratios	O
(	O
ratio	O
of	O
ED20	O
of	O
angiotensin	O
II	O
during	O
infusion	O
of	O
the	O
antagonist	O
and	O
before	O
infusion	O
of	O
the	O
antagonist	O
)	O
in	O
vagotomized	O
,	O
ganglion	O
-	O
blocked	O
rats	O
,	O
infused	O
at	O
250	O
ng	O
/	O
kg	O
/	O
min	O
,	O
were	O
33.43	O
,	O
2.14	O
,	O
3.26	O
,	O
2.99	O
,	O
0.62	O
,	O
62.52	O
,	O
incalculable	O
,	O
and	O
11.15	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
suggest	O
that	O
(	O
a	O
)	O
analogs	O
I	O
and	O
VI	O
are	O
potent	O
antagonists	O
of	O
the	O
pressor	O
response	O
of	O
angiotensin	O
II	O
in	O
normal	O
rat	O
,	O
VI	O
being	O
the	O
most	O
potent	O
antagonist	O
thus	O
far	O
synthesized	O
;	O
(	O
b	O
)	O
replacement	O
of	O
position	O
4	O
(	O
Tyr	O
)	O
with	O
MeTyr	O
or	O
position	O
5	O
and	O
/	O
or	O
8	O
(	O
Ile	O
)	O
with	O
Melle	O
in	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
isoleucine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
reduced	O
the	O
antagonist	O
activity	O
of	O
this	O
peptide	O
(	O
rabbit	O
aortic	O
strips	O
and	O
rats	O
)	O
,	O
indicating	O
that	O
steric	O
hindrance	O
imposed	O
due	O
to	O
N	O
-	O
methylation	O
in	O
positions	O
4	O
,	O
5	O
,	O
or	O
8	O
was	O
not	O
favorable	O
in	O
eliminating	O
the	O
initial	O
pressor	O
activity	O
or	O
prolonging	O
the	O
duration	O
of	O
action	O
of	O
[	O
Sar1	O
,	O
Ile8	O
]	O
angiotensin	O
II	O
without	O
reducing	O
its	O
antagonistic	O
properties	O
;	O
(	O
c	O
)	O
except	O
II	O
,	O
none	O
of	O
the	O
analogs	O
showed	O
any	O
enhanced	O
duration	O
of	O
action	O
,	O
suggesting	O
that	O
N	O
-	O
methylation	O
in	O
positions	O
5	O
or	O
8	O
did	O
not	O
afford	O
protection	O
against	O
proteolytic	O
enzymes	O
;	O
and	O
(	O
d	O
)	O
perfusion	O
studies	O
in	O
cat	O
adrenals	O
indicated	O
that	O
all	O
of	O
these	O
analogs	O
are	O
only	O
very	O
weak	O
secretagogues	O
.	O

With	O
the	O
exception	O
of	O
[	O
Sar1	O
,	O
Thr	O
(	O
ObetaMe	O
)	O
8	O
]	O
angiotensin	O
II	O
,	O
which	O
gave	O
lower	O
antagonistic	O
properties	O
,	O
all	O
other	O
analogs	O
had	O
either	O
similar	O
antagonistic	O
properties	O
or	O
were	O
better	O
antagonists	O
in	O
adrenal	O
medulla	O
than	O
in	O
smooth	O
muscle	O
.	O

Treatment	O
of	O
7,12	I-IUPAC
-	I-IUPAC
benz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthraquinone	I-IUPAC
(	O
2	O
)	O
with	O
methylmagnesium	O
iodide	O
or	O
methyllithium	O
yields	O
mixtures	O
of	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
dimethylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracenes	I-IUPAC
(	O
3a	O
,	O
b	O
)	O
,	O
in	O
which	O
the	O
ratio	O
of	O
cis	O
to	O
trans	O
lies	O
in	O
the	O
3	O
-	O
-	O
4	O
:	O
1	O
region	O
.	O

Each	O
isomer	O
afforded	O
high	O
yields	O
of	O
7	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
5	O
)	O
on	O
treatment	O
with	O
hydrogen	O
chloride	O
in	O
ethyl	O
acetate	O
.	O

Similarly	O
,	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
benz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthraquinone	I-IUPAC
(	O
8	O
)	O
afforded	O
a	O
mixture	O
of	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
7,12	I-IUPAC
-	I-IUPAC
dimethylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracenes	I-IUPAC
(	O
9	O
)	O
which	O
yielded	O
7	I-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
10	O
)	O
on	O
treatment	O
with	O
HCl	O
.	O

The	O
chloromethyl	O
compounds	O
,	O
5	O
and	O
10	O
,	O
yielded	O
7	I-IUPAC
-	I-IUPAC
acetoxymethyl	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
6	O
)	O
and	O
7	I-IUPAC
-	I-IUPAC
acetoxymethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
11	O
)	O
on	O
treatment	O
with	O
acetate	O
ion	O
.	O

Hydrolysis	O
of	O
6	O
and	O
11	O
yielded	O
7	I-IUPAC
-	I-IUPAC
hydroxymethyl	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
7	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxymethyl	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
12	O
)	O
,	O
respectively	O
.	O

Since	O
neither	O
11	O
nor	O
12	O
is	O
appreciably	O
carcinogenic	O
,	O
the	O
carcinogenic	O
metabolism	O
of	O
7,12	I-IUPAC
-	I-IUPAC
dimethylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
DMBA	O
)	O
probably	O
does	O
not	O
involve	O
attack	O
at	O
the	O
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
.	O

The	O
synthesis	O
and	O
in	O
vitro	O
sigma	O
receptor	O
activity	O
of	O
the	O
two	O
diastereomers	O
of	O
U50	O
,	O
488	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
2	O
]	O
,	O
namely	O
,	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
benzeneacet	I-IUPAC
ami	I-IUPAC
de	I-IUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
1	I-PARTIUPAC
]	I-PARTIUPAC
and	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
benzeneacetamide	I-IUPAC
[	O
(	O
-	O
)	O
-	O
1	O
]	O
,	O
are	O
described	O
.	O

(	O
+	O
)	O
-	O
1	O
and	O
(	O
-	O
)	O
-	O
1	O
were	O
synthesized	O
from	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminocyclohexanol	I-IUPAC
[	O
(	O
+	O
/	O
-	O
)	O
-	O
3	O
]	O
.	O

Pyridinium	O
chlorochromate	O
(	O
PCC	O
)	O
oxidation	O
of	O
the	O
N	O
-	O
t	O
-	O
Boc	O
-	O
protected	O
derivative	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
3	O
afforded	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
cyclohexanone	I-IUPAC
[	O
(	O
+	O
/	O
-	O
)	O
-	O
5	O
]	O
.	O

The	O
sequence	O
of	O
enamine	O
formation	O
with	O
pyrrolidine	O
,	O
catalytic	O
reduction	O
,	O
N	O
-	O
deprotection	O
,	O
and	O
optical	O
resolution	O
afforded	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylcyclohexylamine	I-IUPAC
[	O
(	O
-	O
)	O
-	O
10	O
]	O
and	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylcyclohexylamine	I-IUPAC
[	O
(	O
+	O
)	O
-	O
10	O
]	O
.	O

The	O
optical	O
purity	O
(	O
greater	O
than	O
99.5%	O
)	O
of	O
(	O
-	O
)	O
-	O
10	O
and	O
(	O
+	O
)	O
-	O
10	O
was	O
determined	O
by	O
HPLC	O
analysis	O
of	O
the	O
diastereomeric	O
ureas	O
formed	O
by	O
reaction	O
with	O
optically	O
pure	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methylbenzyl	I-IUPAC
isocyanate	I-IUPAC
.	O

The	O
absolute	O
configuration	O
of	O
(	O
-	O
)	O
-	O
10	O
and	O
(	O
+	O
)	O
-	O
10	O
was	O
determined	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
diffractometry	O
of	O
the	O
bis	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
mandelate	I-IUPAC
salt	I-MODIFIER
.	O

Condensation	O
of	O
optically	O
pure	O
(	O
-	O
)	O
-	O
10	O
and	O
(	O
+	O
)	O
-	O
10	O
with	O
3,4	I-IUPAC
-	I-IUPAC
dichlorophenylacetic	I-IUPAC
acid	I-IUPAC
furnished	O
(	O
+	O
)	O
-	O
1	O
and	O
(	O
-	O
)	O
-	O
1	O
,	O
respectively	O
.	O

Compounds	O
(	O
+	O
)	O
-	O
1	O
,	O
(	O
-	O
)	O
-	O
1	O
,	O
(	O
-	O
)	O
-	O
2	O
,	O
and	O
(	O
+	O
)	O
-	O
2	O
were	O
compared	O
for	O
their	O
binding	O
affinities	O
at	O
kappa	O
opioid	O
,	O
sigma	O
,	O
D2	I-IUPAC
-	I-IUPAC
dopamine	I-IUPAC
,	O
and	O
phencyclidine	O
(	O
PCP	O
)	O
receptors	O
in	O
competitive	O
binding	O
assays	O
using	O
[	O
3H	O
]	O
bremazocine	O
(	O
[	O
3H	O
]	O
BREM	O
)	O
or	O
[	O
3H	O
]	O
U69	O
,	O
593	O
,	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
[	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
PPP	O
]	O
,	O
or	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
di	I-IUPAC
(	I-IUPAC
o	I-IUPAC
-	I-IUPAC
tolyl	I-IUPAC
)	I-IUPAC
guanidine	I-IUPAC
(	O
[	O
3H	O
]	O
DTG	O
)	O
,	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
sulpiride	I-IUPAC
[	O
[	O
3H	O
]	O
-	O
(	O
-	O
)	O
SULP	O
]	O
,	O
and	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
piperidine	I-IUPAC
(	O
[	O
3H	O
]	O
TCP	O
)	O
,	O
respectively	O
.	O

In	O
the	O
systems	O
examined	O
,	O
(	O
-	O
)	O
-	O
2	O
exhibited	O
the	O
highest	O
affinity	O
for	O
kappa	O
receptors	O
,	O
with	O
a	O
Ki	O
of	O
44	O
+	O
/	O
-	O
8	O
nM	O
.	O

However	O
,	O
(	O
-	O
)	O
-	O
2	O
also	O
showed	O
moderate	O
affinity	O
for	O
sigma	O
receptors	O
,	O
with	O
a	O
Ki	O
of	O
594	O
+	O
/	O
-	O
3	O
nM	O
[	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
PPP	O
]	O
.	O

The	O
(	O
1R	O
,	O
2R	O
)	O
-	O
(	O
+	O
)	O
-	O
enantiomer	O
,	O
(	O
+	O
)	O
-	O
2	O
,	O
had	O
low	O
affinity	O
for	O
both	O
kappa	O
and	O
sigma	O
receptors	O
,	O
exhibiting	O
Ki	O
values	O
of	O
1298	O
+	O
/	O
-	O
49	O
nM	O
at	O
kappa	O
(	O
[	O
3H	O
]	O
BREM	O
)	O
and	O
1270	O
+	O
/	O
-	O
168	O
nM	O
at	O
sigma	O
[	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
PPP	O
]	O
.	O

In	O
contrast	O
,	O
the	O
chiral	O
cis	O
compounds	O
(	O
+	O
)	O
-	O
1	O
and	O
(	O
-	O
)	O
-	O
1	O
showed	O
high	O
affinity	O
for	O
sigma	O
receptors	O
and	O
negligible	O
affinity	O
for	O
kappa	O
opioid	O
receptors	O
in	O
the	O
[	O
3H	O
]	O
BREM	O
assay	O
.	O

Compound	O
(	O
-	O
)	O
-	O
1	O
exhibited	O
a	O
Ki	O
of	O
81	O
+	O
/	O
-	O
13	O
nM	O
at	O
sigma	O
receptors	O
[	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
PPP	O
]	O
and	O
250	O
+	O
/	O
-	O
8	O
nM	O
(	O
[	O
3H	O
]	O
DTG	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Previously	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinuclidinyl	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
iodobenzilate	I-IUPAC
(	O
(	O
R	O
,	O
R	O
)	O
-	O
IQNB	O
)	O
,	O
a	O
muscarinic	O
receptor	O
antagonist	O
,	O
has	O
been	O
labeled	O
with	O
123I	O
and	O
125I	O
for	O
use	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
in	O
animals	O
and	O
humans	O
.	O

We	O
have	O
prepared	O
fluoroalkyl	O
analogs	O
of	O
QNB	O
,	O
which	O
are	O
amenable	O
to	O
labeling	O
with	O
18F	O
,	O
for	O
potential	O
imaging	O
applications	O
with	O
positron	O
emission	O
tomography	O
.	O

The	O
enantiomers	O
of	O
(	O
fluoroalkyl	O
)	O
benzilic	O
acids	O
were	O
prepared	O
via	O
an	O
enantioselective	O
Grignard	O
addition	O
reaction	O
.	O

Subsequent	O
coupling	O
of	O
the	O
enantiomeric	I-MODIFIER
(	B-IUPAC
fluoroalkyl	I-IUPAC
)	I-IUPAC
benzilic	I-IUPAC
acid	I-IUPAC
with	O
a	O
selected	O
enantiomer	O
of	O
quinuclidinol	O
provides	O
fluorinated	O
analogs	O
of	O
QNB	O
with	O
known	O
stereochemistry	O
at	O
each	O
of	O
the	O
stereogenic	O
centers	O
.	O

These	O
compounds	O
exhibit	O
different	O
affinities	O
for	O
the	O
muscarinic	O
receptor	O
tissue	O
subtypes	O
in	O
vitro	O
.	O

(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Fluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
QNB	I-IUPAC
,	O
and	O
(	O
R	O
,	O
R	O
)	O
-	O
IQNB	O
,	O
and	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoroethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
QNB	I-IUPAC
exhibit	O
selectivity	O
for	O
the	O
M1	O
subtype	O
,	O
and	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
QNB	I-IUPAC
exhibits	O
selectivity	O
for	O
the	O
M2	O
subtype	O
.	O

Hypoxic	O
cells	O
of	O
solid	O
tumors	O
are	O
an	O
obstacle	O
to	O
effective	O
cancer	O
therapy	O
.	O

Since	O
hypoxic	O
cells	O
remote	O
from	O
the	O
tumor	O
blood	O
supply	O
may	O
have	O
a	O
greater	O
capacity	O
for	O
reductive	O
reactions	O
than	O
well	O
-	O
oxygenated	O
cells	O
,	O
we	O
have	O
prepared	O
a	O
series	O
of	O
anthraquinone	O
prodrugs	O
which	O
may	O
be	O
capable	O
of	O
generating	O
a	O
reactive	O
quinonemethide	O
species	O
following	O
enzymatic	O
reduction	O
to	O
the	O
hydroquinone	O
and	O
loss	O
of	O
the	O
substituent	O
on	O
the	O
methylene	O
group	O
in	O
the	O
2	O
position	O
.	O

The	O
synthesized	O
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
anthraquinone	B-IUPAC
derivatives	B-MODIFIER
have	O
first	O
half	O
-	O
wave	O
reduction	O
potentials	O
of	O
-	O
0.52	O
to	O
-	O
0.56	O
V	O
at	O
pH	O
7.0	O
,	O
which	O
are	O
the	O
lowest	O
oxidation	O
-	O
reduction	O
potentials	O
of	O
quinone	O
bioreductive	O
alkylating	O
agents	O
synthesized	O
by	O
this	O
laboratory	O
to	O
date	O
.	O

Tests	O
of	O
the	O
cytotoxicity	O
of	O
these	O
agents	O
to	O
oxygenated	O
and	O
chronically	O
hypoxic	O
EMT6	O
tumor	O
cells	O
in	O
culture	O
demonstrated	O
that	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
anthraquinone	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylcarbamyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
anthraquinone	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluenesulfonyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
anthraquinone	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methoxymethyl	I-IUPAC
)	I-IUPAC
anthraquinone	I-IUPAC
were	O
significantly	O
more	O
toxic	O
to	O
hypoxic	O
cells	O
than	O
to	O
their	O
normally	O
aerated	O
counterparts	O
.	O

The	O
findings	O
demonstrate	O
differences	O
between	O
various	O
leaving	O
groups	O
in	O
the	O
2	O
position	O
for	O
the	O
expression	O
of	O
differential	O
cytotoxicity	O
.	O

Fourteen	O
125I	O
-	O
labeled	O
aralkylguanidines	O
were	O
synthesized	O
and	O
evaluated	O
as	O
potential	O
imaging	O
agents	O
for	O
the	O
adrenal	O
medullae	O
and	O
tumors	O
of	O
adrenomedullary	O
origin	O
.	O

These	O
guanidines	O
are	O
radiotracer	O
analogues	O
of	O
guanethidine	O
,	O
an	O
antihypertensive	O
agent	O
thought	O
to	O
mediate	O
neuron	O
blockade	O
by	O
uptake	O
into	O
adrenergic	O
nerves	O
.	O

Dog	O
adrenal	O
medullae	O
were	O
used	O
as	O
a	O
model	O
to	O
test	O
radiotracer	O
affinity	O
for	O
catecholamine	O
storage	O
tissue	O
.	O

Tissue	O
distribution	O
studies	O
revealed	O
that	O
a	O
number	O
of	O
radioiodinated	O
guanidines	O
showed	O
pronounced	O
localization	O
in	O
the	O
adrenal	O
medullae	O
following	O
intravenous	O
injection	O
,	O
in	O
certain	O
cases	O
exceeding	O
that	O
of	O
either	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
norepinephrine	I-IUPAC
or	O
[	I-IUPAC
14C	I-IUPAC
]	I-IUPAC
guanethidine	I-IUPAC
.	O

(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
Iodobenzyl	I-IUPAC
)	I-IUPAC
guanidine	I-IUPAC
(	O
m	O
-	O
IBG	O
,	O
2b	O
)	O
gave	O
the	O
best	O
combination	O
of	O
high	O
concentration	O
and	O
selectivity	O
.	O

The	O
low	O
adrenomedullary	O
affinity	O
observed	O
with	O
[	I-IUPAC
14C	I-IUPAC
]	I-IUPAC
guanidine	I-IUPAC
and	O
m	I-IUPAC
-	I-IUPAC
[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
iodobenzylamine	I-IUPAC
demonstrates	O
the	O
uniqueness	O
of	O
the	O
aralkylguanidine	O
structure	O
.	O

Preliminary	O
evidence	O
suggests	O
that	O
2b	O
is	O
a	O
storage	O
analogue	O
of	O
norepinephrine	O
.	O

[	O
125I	O
]	O
2a	O
is	O
now	O
being	O
used	O
clinically	O
in	O
imaging	O
and	O
radiotherapy	O
of	O
catecholamine	O
tumors	O
,	O
such	O
as	O
pheochromocytoma	O
.	O

The	O
1,2	I-IUPAC
-	I-IUPAC
dihydropyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyrazines	I-IUPAC
(	O
1	O
)	O
are	O
mitotic	O
inhibitors	O
with	O
significant	O
antitumor	O
activity	O
in	O
mice	O
.	O

Also	O
,	O
the	O
active	O
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
3	O
was	O
shown	O
to	O
cause	O
the	O
accumulation	O
of	O
cells	O
at	O
mitosis	O
.	O

Routes	O
were	O
developed	O
for	O
the	O
synthesis	O
of	O
congeners	O
of	O
3	O
by	O
cyclization	O
of	O
4	I-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	I-MODIFIER
amino	B-IUPAC
)	O
-	I-PARTIUPAC
5,6	I-PARTIUPAC
-	I-PARTIUPAC
diaminopyridines	I-PARTIUPAC
with	O
ethyl	O
orthoformate	O
.	O

Oxidative	O
cyclization	O
of	O
either	O
4,5	I-PARTIUPAC
-	I-PARTIUPAC
or	O
5,6	I-IUPAC
-	I-IUPAC
diaminopyridines	I-IUPAC
with	O
aryl	O
aldehydes	O
produced	O
the	O
[	O
4,5	O
-	O
c	O
]	O
and	O
[	O
4,5	O
-	O
b	O
]	O
imidazopyridine	O
ring	O
systems	O
,	O
respectively	O
.	O

The	O
latter	O
reaction	O
with	O
6	I-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	I-MODIFIER
amino	B-IUPAC
)	O
-	I-PARTIUPAC
4,5	I-PARTIUPAC
-	I-PARTIUPAC
diaminopyridines	I-PARTIUPAC
gave	O
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
ring	I-MODIFIER
analogues	I-MODIFIER
of	O
1	O
.	O

Biological	O
studies	O
indicated	O
that	O
the	O
target	O
compounds	O
were	O
less	O
active	O
than	O
1	O
and	O
3	O
.	O

The	O
design	O
,	O
synthesis	O
,	O
and	O
pharmacological	O
properties	O
of	O
a	O
novel	O
type	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,5,6	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiazolamine	I-IUPAC
with	O
dopaminergic	O
properties	O
are	O
described	O
.	O

In	O
particular	O
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,5,6	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiazolamine	I-IUPAC
(	O
4c	O
,	O
PD	O
118440	O
)	O
and	O
its	O
allyl	I-IUPAC
analogue	B-MODIFIER
(	O
4i	O
,	O
PD	O
120697	O
)	O
have	O
been	O
identified	O
as	O
orally	O
active	O
dopamine	O
(	O
DA	O
)	O
agonists	O
with	O
pronounced	O
central	O
nervous	O
system	O
effects	O
in	O
tests	O
that	O
include	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
haloperidol	I-IUPAC
and	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propylnorapomorphine	I-IUPAC
binding	O
,	O
inhibition	O
of	O
striatal	O
DA	O
synthesis	O
,	O
inhibition	O
of	O
DA	O
neuronal	O
firing	O
,	O
inhibition	O
of	O
spontaneous	O
locomotor	O
activity	O
,	O
and	O
reversal	O
of	O
reserpine	O
-	O
induced	O
depression	O
in	O
rats	O
.	O

The	O
DA	O
autoreceptor	O
selectivity	O
of	O
these	O
heterocyclic	O
analogues	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
)	I-IUPAC
phenol	I-IUPAC
(	O
3	O
-	O
PPP	O
)	O
was	O
also	O
evaluated	O
.	O

In	O
this	O
series	O
,	O
DA	O
agonist	O
activity	O
was	O
found	O
to	O
be	O
highly	O
dependent	O
on	O
the	O
size	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
substituent	I-MODIFIER
,	O
the	O
saturation	O
level	O
of	O
the	O
six	O
-	O
membered	O
ring	O
,	O
and	O
the	O
mode	O
of	O
attachment	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
aminothiazole	I-IUPAC
ring	I-MODIFIER
.	O

Diarylguanidines	O
,	O
acting	O
as	O
NMDA	O
receptor	O
ion	O
channel	O
site	O
ligands	O
,	O
represent	O
a	O
new	O
class	O
of	O
potential	O
neuroprotective	O
drugs	O
.	O

Several	O
diarylguanidines	O
structurally	O
related	O
to	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
o	I-IUPAC
-	I-IUPAC
tolylguanidine	I-IUPAC
(	O
DTG	O
)	O
,	O
a	O
known	O
selective	O
sigma	O
receptor	O
ligand	O
,	O
were	O
synthesized	O
and	O
evaluated	O
in	O
in	O
vitro	O
radioligand	O
displacement	O
assays	O
,	O
with	O
rat	O
or	O
guinea	O
pig	O
brain	O
membrane	O
homogenates	O
,	O
using	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
site	O
specific	O
radioligand	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
,	I-IUPAC
11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cyclohepten	I-IUPAC
-	I-IUPAC
5	I-IUPAC
,	I-IUPAC
10	I-IUPAC
-	I-IUPAC
imine	I-IUPAC
(	O
MK	O
-	O
801	O
,	O
3	O
)	O
,	O
and	O
the	O
sigma	O
receptor	O
-	O
specific	O
radioligand	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
o	I-IUPAC
-	I-IUPAC
tolylguanidine	I-IUPAC
(	O
DTG	O
,	O
5	O
)	O
.	O

This	O
paper	O
presents	O
the	O
structure	O
-	O
activity	O
relationships	O
leading	O
to	O
novel	O
tri	I-MODIFIER
-	I-MODIFIER
and	O
tetrasubstituted	I-MODIFIER
guanidines	B-IUPAC
,	O
which	O
exhibit	O
high	O
selectivity	O
for	O
NMDA	O
receptor	O
ion	O
channel	O
sites	O
and	O
weak	O
or	O
negligible	O
affinity	O
for	O
sigma	O
receptors	O
.	O

The	O
in	O
vitro	O
binding	O
results	O
from	O
symmetrically	O
substituted	O
diphenylguanidines	O
indicated	O
that	O
compounds	O
having	O
ortho	O
or	O
meta	O
substituents	O
(	O
with	O
respect	O
to	O
the	O
position	O
of	O
the	O
guanidine	O
nitrogen	O
)	O
on	O
the	O
phenyl	O
rings	O
showed	O
greater	O
affinity	O
for	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
site	O
compared	O
with	O
para	O
-	O
substituted	O
derivatives	O
.	O

Among	O
the	O
group	O
of	O
ring	O
substituents	O
studied	O
for	O
symmetrical	O
diarylguanidines	O
,	O
an	O
isopropyl	I-IUPAC
group	B-MODIFIER
was	O
preferred	O
at	O
the	O
ortho	O
position	O
and	O
an	O
ethyl	O
group	O
was	O
preferred	O
at	O
the	O
meta	O
position	O
.	O

Several	O
unsymmetrical	O
guanidines	O
containing	O
a	O
naphthalene	O
ring	O
on	O
one	O
nitrogen	O
atom	O
and	O
an	O
ortho	O
-	O
or	O
a	O
meta	O
-	O
substituted	O
phenyl	O
ring	O
on	O
the	O
second	O
nitrogen	O
atom	O
,	O
e.g.	O
,	O
N	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethylphenyl	I-IUPAC
)	I-IUPAC
guanidine	I-IUPAC
(	O
36	O
)	O
,	O
showed	O
a	O
3-5	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
site	O
and	O
no	O
change	O
in	O
sigma	O
receptor	O
affinity	O
compared	O
to	O
the	O
respective	O
symmetrical	O
counterparts	O
.	O

Additional	O
small	O
substituents	O
on	O
the	O
guanidine	O
nitrogen	O
atoms	O
bearing	O
the	O
aryl	O
rings	O
resulted	O
in	O
tri	O
-	O
and	O
tetrasubstituted	O
guanidine	O
derivatives	O
which	O
retained	O
affinity	O
for	O
NMDA	O
receptor	O
ion	O
channel	O
sites	O
but	O
exhibited	O
a	O
significant	O
reduction	O
in	O
their	O
affinities	O
for	O
sigma	O
receptors	O
.	O

For	O
example	O
,	O
N	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
methylguanidine	I-IUPAC
(	O
40	O
)	O
showed	O
high	O
affinity	O
for	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
site	O
(	O
IC50	O
=	O
36	O
nM	O
vs	O
[	O
3H	O
]	O
-	O
3	O
)	O
and	O
low	O
affinity	O
for	O
sigma	O
receptors	O
(	O
IC50	O
=	O
2540	O
nM	O
vs	O
[	O
3H	O
]	O
-	O
5	O
)	O
.	O

Selectivity	O
for	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
sites	O
over	O
sigma	O
receptors	O
appears	O
to	O
be	O
dependent	O
upon	O
the	O
structure	O
of	O
the	O
additional	O
substituents	O
on	O
the	O
guanidine	O
nitrogen	O
atoms	O
bearing	O
the	O
aryl	O
groups	O
.	O

Methyl	O
and	O
ethyl	O
substituents	O
are	O
most	O
preferred	O
in	O
the	O
tri	O
-	O
and	O
tetrasubstituted	O
diarylguanidines	O
.	O

The	O
trisubstituted	O
guanidine	O
,	O
N	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
methylguanidine	I-IUPAC
(	O
40	O
)	O
and	O
its	O
close	O
analogues	O
showed	O
good	O
in	O
vivo	O
neuroprotection	O
and	O
are	O
potential	O
neuroprotective	O
drug	O
candidates	O
for	O
the	O
treatment	O
of	O
stroke	O
and	O
other	O
neurodegenerative	O
disorders	O
.	O

Syntheses	O
of	O
several	O
carbamate	O
analogues	O
of	O
2	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amidinophenyl	I-IUPAC
)	I-IUPAC
furan	I-IUPAC
(	O
1	O
)	O
under	O
mild	O
conditions	O
and	O
their	O
evaluation	O
as	O
prodrugs	O
against	O
Pneumocystis	O
carinii	O
pneumonia	O
(	O
PCP	O
)	O
in	O
an	O
immunosuppressed	O
rat	O
model	O
are	O
described	O
.	O

Thus	O
,	O
nine	O
new	O
bis	O
-	O
carbamates	O
:	O
methoxycarbonyl	I-IUPAC
(	O
2	O
)	O
,	O
2,2,2	I-IUPAC
-	I-IUPAC
trichloroethoxycarbonyl	I-IUPAC
(	O
3	O
)	O
,	O
ethylthiocarbonyl	I-IUPAC
(	O
4	O
)	O
,	O
benzyloxycarbonyl	I-IUPAC
(	O
5	O
)	O
,	O
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
dioxol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methoxycarbonyl	I-IUPAC
(	O
6	O
)	O
,	O
phenoxycarbonyl	I-IUPAC
(	O
7	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
fluorophenoxycarbonyl	I-IUPAC
(	O
8	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
methoxyphenoxycarbonyl	I-IUPAC
(	O
9	O
)	O
,	O
and	O
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
)	I-IUPAC
ethoxycarbonyl	I-IUPAC
(	O
10	O
)	O
and	O
a	O
bis	I-IUPAC
-	I-IUPAC
carbonate	I-IUPAC
ethoxycarbonyloxy	I-IUPAC
(	O
11	O
)	O
of	O
the	O
bis	O
-	O
amidine	O
1	O
have	O
been	O
synthesized	O
and	O
evaluated	O
.	O

The	O
in	O
vivo	O
results	O
show	O
that	O
the	O
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
carbamate	I-IUPAC
8	O
and	O
the	O
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
carbamate	I-IUPAC
9	O
in	O
this	O
series	O
had	O
the	O
best	O
anti	O
-	O
PCP	O
activity	O
by	O
both	O
intravenous	O
and	O
oral	O
administration	O
at	O
a	O
dosage	O
level	O
of	O
22	O
mol	O
and	O
33	O
micromol	O
/	O
kg	O
/	O
day	O
,	O
respectively	O
.	O

Compounds	O
3-7	O
were	O
also	O
more	O
active	O
than	O
the	O
parent	O
drug	O
(	O
1	O
)	O
on	O
oral	O
administration	O
.	O

The	O
acute	O
toxicity	O
usually	O
exhibited	O
by	O
the	O
parent	O
amidine	O
1	O
at	O
a	O
dosage	O
level	O
of	O
22	O
micromol	O
/	O
kg	O
/	O
day	O
on	O
intravenous	O
administration	O
has	O
been	O
significantly	O
reduced	O
by	O
the	O
prodrug	O
modifications	O
,	O
with	O
the	O
exception	O
of	O
compound	O
10	O
which	O
exhibited	O
some	O
toxicity	O
.	O

This	O
report	O
also	O
describes	O
the	O
synthesis	O
of	O
several	O
aryl	O
-	O
alkyl	O
and	O
aryl	O
-	O
aryl	O
carbonates	O
(	O
12-14	O
,	O
16-23	O
)	O
as	O
efficient	O
reagents	O
for	O
the	O
preparation	O
of	O
carbamate	O
derivatives	O
from	O
bis	O
-	O
arylamidines	O
.	O

A	O
series	O
of	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalenes	I-IUPAC
(	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminotetralins	I-IUPAC
,	O
PATs	O
)	O
previously	O
was	O
found	O
to	O
modulate	O
tyrosine	O
hydroxylase	O
activity	O
and	O
dopamine	O
synthesis	O
in	O
rodent	O
forebrain	O
through	O
interaction	O
with	O
a	O
binding	O
site	O
labeled	O
by	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
(	O
-	O
)	O
-	O
(	O
1R	O
,	O
3S	O
)	O
-	O
trans	O
-	O
H	O
(	O
2	O
)	O
-	O
PAT	O
.	O

Recently	O
,	O
we	O
have	O
discovered	O
that	O
PATs	O
also	O
bind	O
with	O
high	O
affinity	O
to	O
the	O
[	O
(	O
3	O
)	O
H	O
]	O
mepyramine	O
-	O
labeled	O
H	O
(	O
1	O
)	O
receptor	O
in	O
rat	O
and	O
guinea	O
pig	O
brain	O
.	O

Here	O
,	O
we	O
report	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
additional	O
PAT	O
analogues	O
in	O
order	O
to	O
identify	O
differences	O
in	O
binding	O
at	O
these	O
two	O
sites	O
.	O

Further	O
molecular	O
modifications	O
involve	O
the	O
pendant	O
phenyl	O
ring	O
as	O
well	O
as	O
quaternary	O
amine	O
compounds	O
.	O

Comparison	O
of	O
about	O
38	O
PAT	O
analogues	O
,	O
10	O
structurally	O
diverse	O
H	O
(	O
1	O
)	O
ligands	O
,	O
and	O
several	O
other	O
CNS	O
-	O
active	O
compounds	O
revealed	O
no	O
significant	O
differences	O
in	O
affinity	O
at	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
(	O
-	O
)	O
-	O
trans	O
-	O
H	O
(	O
2	O
)	O
-	O
PAT	O
sites	O
versus	O
[	O
(	O
3	O
)	O
H	O
]	O
mepyramine	O
-	O
labeled	O
H	O
(	O
1	O
)	O
receptors	O
.	O

These	O
results	O
,	O
together	O
with	O
previous	O
autoradiographic	O
brain	O
receptor	O
-	O
mapping	O
studies	O
that	O
indicate	O
similar	O
distribution	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
(	O
-	O
)	O
-	O
trans	O
-	O
H	O
(	O
2	O
)	O
-	O
PAT	O
sites	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
mepyramine	O
-	O
labeled	O
H	O
(	O
1	O
)	O
receptors	O
,	O
suggest	O
that	O
both	O
radioligands	O
label	O
the	O
same	O
histamine	O
H	O
(	O
1	O
)	O
receptors	O
in	O
rodent	O
brain	O
.	O

We	O
also	O
report	O
a	O
revision	O
of	O
our	O
previous	O
comparative	O
molecular	O
field	O
analysis	O
(	O
CoMFA	O
)	O
study	O
of	O
the	O
PAT	O
ligands	O
that	O
yields	O
a	O
highly	O
predictive	O
model	O
for	O
66	O
compounds	O
with	O
a	O
cross	O
-	O
validated	O
R	O
(	O
2	O
)	O
(	O
q	O
(	O
2	O
)	O
)	O
value	O
of	O
0.67	O
.	O

This	O
model	O
will	O
be	O
useful	O
for	O
the	O
prediction	O
of	O
high	O
-	O
affinity	O
ligands	O
at	O
radiolabeled	O
H	O
(	O
1	O
)	O
receptors	O
in	O
mammalian	O
brain	O
.	O

A	O
new	O
class	O
of	O
histamine	O
analogues	O
characterized	O
by	O
a	O
3	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
diphenylpropyl	I-IUPAC
substituent	I-MODIFIER
at	O
the	O
2	O
-	O
position	O
of	O
the	O
imidazole	O
nucleus	O
has	O
been	O
prepared	O
outgoing	O
from	O
4,4	I-IUPAC
-	I-IUPAC
diphenylbutyronitrile	I-IUPAC
(	O
4b	O
)	O
via	O
cyclization	O
of	O
the	O
corresponding	O
methyl	O
imidate	O
5b	O
with	O
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phthalimido	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
acetate	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
butandiol	I-IUPAC
in	O
liquid	O
ammonia	O
,	O
followed	O
by	O
standard	O
reactions	O
.	O

The	O
title	O
compounds	O
displayed	O
partial	O
agonism	O
on	O
contractile	O
H	O
(	O
1	O
)	O
receptors	O
of	O
the	O
guinea	O
-	O
pig	O
ileum	O
and	O
endothelium	O
-	O
denuded	O
aorta	O
,	O
respectively	O
,	O
except	O
10	O
(	O
histaprodifen	O
;	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
diphenylpropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ethanamine	I-IUPAC
)	O
which	O
was	O
a	O
full	O
agonist	O
in	O
the	O
ileum	O
assay	O
.	O

While	O
10	O
was	O
equipotent	O
with	O
histamine	O
(	O
1	O
)	O
,	O
methylhistaprodifen	O
(	O
13	O
)	O
and	O
dimethylhistaprodifen	O
(	O
14	O
)	O
exceeded	O
the	O
functional	O
potency	O
of	O
1	O
by	O
a	O
factor	O
of	O
3-5	O
(	O
13	O
)	O
and	O
2-3	O
(	O
14	O
)	O
.	O

Compounds	O
10	O
and	O
13-17	O
relaxed	O
precontracted	O
rat	O
aortic	O
rings	O
(	O
intact	O
endothelium	O
)	O
with	O
relative	O
potencies	O
of	O
3.3	O
-	O
up	O
to	O
28	O
-	O
fold	O
(	O
compared	O
with	O
1	O
)	O
,	O
displaying	O
partial	O
agonism	O
as	O
well	O
.	O

Agonist	O
effects	O
were	O
sensitive	O
to	O
blockade	O
by	O
the	O
selective	O
H	O
(	O
1	O
)	O
-	O
receptor	O
antagonist	O
mepyramine	O
(	O
pA	O
(	O
2	O
)	O
approximately	O
9	O
(	O
guinea	O
-	O
pig	O
)	O
and	O
pA	O
(	O
2	O
)	O
approximately	O
8	O
(	O
rat	O
aorta	O
)	O
)	O
.	O

The	O
affinity	O
of	O
10	O
and	O
13-17	O
for	O
guinea	O
-	O
pig	O
H	O
(	O
1	O
)	O
receptors	O
increased	O
20	O
-	O
to	O
100	O
-	O
fold	O
compared	O
with	O
1	O
.	O

Two	O
lower	O
homologues	O
of	O
10	O
were	O
weak	O
partial	O
H	O
(	O
1	O
)	O
-	O
receptor	O
agonists	O
while	O
two	O
higher	O
homologues	O
of	O
10	O
were	O
silent	O
antagonists	O
endowed	O
with	O
micromolar	O
affinity	O
for	O
rat	O
and	O
guinea	O
-	O
pig	O
H	O
(	O
1	O
)	O
receptors	O
.	O

In	O
functional	O
selectivity	O
experiments	O
,	O
10	O
,	O
13	O
,	O
and	O
14	O
did	O
not	O
stimulate	O
H	O
(	O
2	O
)	O
,	O
H	O
(	O
3	O
)	O
,	O
and	O
several	O
other	O
neurotransmitter	O
receptors	O
.	O

They	O
displayed	O
only	O
low	O
to	O
moderate	O
affinity	O
for	O
these	O
sites	O
(	O
pA	O
(	O
2	O
)	O
&	O
lt	O
;	O
6	O
)	O
.	O

For	O
a	O
better	O
understanding	O
of	O
structure	O
-	O
activity	O
relationships	O
,	O
the	O
interaction	O
of	O
1	O
and	O
10	O
,	O
13	O
and	O
14	O
within	O
the	O
transmembrane	O
(	O
TM	O
)	O
domains	O
of	O
the	O
human	O
histamine	O
H	O
(	O
1	O
)	O
receptor	O
were	O
studied	O
using	O
molecular	O
dynamics	O
simulations	O
.	O

Remarkable	O
differences	O
were	O
found	O
between	O
the	O
binding	O
modes	O
of	O
10	O
,	O
13	O
,	O
and	O
14	O
and	O
that	O
of	O
1	O
.	O

The	O
imidazole	O
ring	O
of	O
10	O
,	O
13	O
,	O
and	O
14	O
was	O
placed	O
'	O
upside	O
down	O
'	O
compared	O
with	O
1	O
,	O
making	O
the	O
interaction	O
of	O
the	O
N	O
(	O
pi	O
)	O
-	O
atom	O
with	O
Tyr431	O
possible	O
.	O

This	O
new	O
orientation	O
was	O
mainly	O
caused	O
by	O
the	O
space	O
filling	O
substitution	O
at	O
the	O
2	O
-	O
position	O
of	O
the	O
imidazole	O
ring	O
and	O
influenced	O
the	O
location	O
of	O
the	O
protonated	O
N	O
(	O
alpha	O
)	O
-	O
atom	O
which	O
was	O
positioned	O
more	O
between	O
TM	O
III	O
and	O
TM	O
VI	O
.	O

This	O
orientation	O
can	O
explain	O
both	O
the	O
increased	O
relative	O
potency	O
and	O
the	O
maximum	O
effect	O
of	O
10	O
,	O
13	O
,	O
and	O
14	O
compared	O
with	O
1	O
.	O

Compound	O
13	O
(	O
methylhistaprodifen	O
;	O
N	I-IUPAC
(	I-IUPAC
alpha	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
diphenylpropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ethanamine	I-IUPAC
)	O
is	O
the	O
most	O
potent	O
histamine	O
H	O
(	O
1	O
)	O
-	O
receptor	O
agonist	O
reported	O
so	O
far	O
in	O
the	O
literature	O
and	O
may	O
become	O
a	O
valuable	O
tool	O
for	O
the	O
study	O
of	O
physiological	O
and	O
pathophysiological	O
H	O
(	O
1	O
)	O
-	O
receptor	O
-	O
mediated	O
effects	O
.	O

The	O
ability	O
of	O
conjugates	O
of	O
peptides	O
and	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
or	O
5	I-IUPAC
-	I-IUPAC
fluoroorotic	I-IUPAC
acid	I-IUPAC
to	O
enter	O
Candida	O
albicans	O
was	O
investigated	O
.	O

A	O
number	O
of	O
conjugates	O
of	O
5	I-IUPAC
-	I-IUPAC
fluoroorotic	I-IUPAC
acid	I-IUPAC
and	O
peptides	O
were	O
synthesized	O
using	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydroquinoline	I-IUPAC
as	O
the	O
coupling	O
agent	O
.	O

Orotyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucine	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
succinamoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucine	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyrimidinone	I-IUPAC
[	O
a	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
derivative	I-MODIFIER
]	O
,	O
and	O
5	I-IUPAC
-	I-IUPAC
fluoroorotyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucine	I-IUPAC
all	O
inhibited	O
the	O
uptake	O
of	O
trimethionine	O
into	O
C	O
.	O

albicans	O
WD	O
18-4	O
.	O

Inhibition	O
by	O
5	I-IUPAC
-	I-IUPAC
fluoroorotyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
leucine	I-IUPAC
was	O
competitive	O
as	O
judged	O
using	O
double	O
-	O
reciprocal	O
plots	O
.	O

Evaluation	O
of	O
minimum	O
inhibitory	O
concentrations	O
of	O
peptide	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
conjugates	I-MODIFIER
suggest	O
that	O
these	O
conjugates	O
enter	O
C	O
.	O

albicans	O
in	O
the	O
intact	O
form	O
.	O

These	O
results	O
provide	O
the	O
first	O
experimental	O
evidence	O
that	O
peptides	O
can	O
carry	O
pyrimidines	O
into	O
a	O
eukaryote	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
described	O
affinity	O
labeling	O
of	O
the	O
lamb	O
uterine	O
estrogen	O
receptor	O
by	O
17	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
bromoacetoxy	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
alkynyl	I-IUPAC
]	I-IUPAC
estradiols	I-IUPAC
.	O

However	O
,	O
the	O
intrinsic	O
receptor	O
-	O
alkylating	O
activities	O
of	O
these	O
compounds	O
were	O
probably	O
very	O
hampered	O
by	O
their	O
poor	O
hydrolytic	O
stability	O
in	O
estrogen	O
receptor	O
-	O
containing	O
tissue	O
extracts	O
.	O

Therefore	O
,	O
(	O
i	O
)	O
to	O
develop	O
affinity	O
labels	O
of	O
the	O
receptor	O
not	O
susceptible	O
to	O
hydrolysis	O
and	O
(	O
ii	O
)	O
to	O
specify	O
the	O
structural	O
requirements	O
for	O
17	O
alpha	O
-	O
electrophilic	O
estradiol	O
derivatives	O
to	O
be	O
potent	O
affinity	O
labels	O
of	O
the	O
receptor	O
,	O
we	O
prepared	O
four	O
17	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
haloacetamido	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
estradiols	I-IUPAC
.	O

Three	O
were	O
bromoacetamides	O
differing	O
at	O
the	O
alkyl	O
substituent	O
(	O
methyl	O
,	O
ethyl	O
,	O
or	O
propyl	O
)	O
,	O
and	O
the	O
last	O
was	O
an	O
[	I-IUPAC
(	I-IUPAC
iodoacetamido	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
prepared	O
under	O
both	O
nonradioactive	O
and	O
3H	O
-	O
labeled	O
forms	O
.	O

Although	O
their	O
affinities	O
for	O
the	O
estrogen	O
receptor	O
were	O
very	O
low	O
(	O
from	O
0.008%	O
to	O
0.02%	O
that	O
of	O
estradiol	O
)	O
,	O
they	O
appeared	O
to	O
be	O
efficient	O
affinity	O
labels	O
of	O
the	O
receptor	O
due	O
to	O
their	O
irreversible	O
inhibition	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
specific	O
binding	O
in	O
lamb	O
uterine	O
cytosol	O
.	O

The	O
effect	O
of	O
the	O
compounds	O
was	O
time	O
-	O
,	O
pH	O
-	O
,	O
and	O
concentration	O
-	O
dependent	O
,	O
with	O
&	O
gt	O
;	O
50%	O
and	O
&	O
gt	O
;	O
80%	O
estrogen	O
-	O
binding	O
sites	O
inactivated	O
at	O
0	O
degrees	O
C	O
and	O
pH	O
8.5	O
,	O
for	O
the	O
less	O
active	O
and	O
more	O
active	O
compounds	O
,	O
respectively	O
;	O
the	O
corresponding	O
IC50	O
values	O
varied	O
from	O
approximately	O
20	O
nM	O
to	O
approximately	O
10	O
microM	O
.	O

The	O
order	O
of	O
efficiency	O
was	O
[	I-IUPAC
(	I-IUPAC
bromoacetamido	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
&	O
lt	O
;	O
[	I-IUPAC
(	I-IUPAC
bromoacetamido	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
&	O
lt	O
;	O
&	O
lt	O
;	O
[	I-IUPAC
(	I-IUPAC
bromoacetamido	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
&	O
lt	O
;	O
[	I-IUPAC
(	I-IUPAC
iodoacetamido	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
.	O

Affinity	O
labeling	O
was	O
directly	O
demonstrated	O
by	O
ethanol	O
-	O
resistant	O
binding	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
[	I-IUPAC
(	I-IUPAC
iodoacetamido	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
to	O
the	O
receptor	O
.	O

The	O
irreversible	O
inactivation	O
of	O
the	O
hormone	O
-	O
binding	O
site	O
by	O
the	O
four	O
haloacetamides	O
was	O
prevented	O
by	O
treatment	O
of	O
the	O
cytosol	O
with	O
the	O
thiol	O
-	O
specific	O
reagent	O
methyl	O
methanethiosulfonate	O
,	O
suggesting	O
that	O
the	O
target	O
of	O
these	O
compounds	O
was	O
probably	O
the	O
-	O
SH	O
of	O
cysteines	O
.	O

Negative	O
results	O
obtained	O
with	O
other	O
17	O
alpha	O
-	O
electrophilic	O
estradiol	O
derivatives	O
suggested	O
that	O
affinity	O
labeling	O
of	O
the	O
receptor	O
by	O
such	O
derivatives	O
required	O
a	O
minimal	O
distance	O
,	O
including	O
at	O
least	O
four	O
C	O
-	O
C	O
or	O
C	O
-	O
N	O
bonds	O
,	O
between	O
the	O
steroid	O
and	O
the	O
electrophilic	O
carbon	O
.	O

We	O
therefore	O
concluded	O
that	O
target	O
cysteines	O
in	O
the	O
hormone	O
-	O
binding	O
site	O
were	O
not	O
in	O
direct	O
contact	O
with	O
the	O
steroid	O
but	O
probably	O
in	O
the	O
immediate	O
neighborhood	O
of	O
the	O
D	O
ring	O
of	O
the	O
bound	O
steroid	O
.	O

Ten	O
heretofore	O
undescribed	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloroquinazoline	I-IUPAC
analogues	I-MODIFIER
of	O
trimetrexate	O
(	O
TMQ	O
)	O
and	O
piritrexim	O
(	O
PTX	O
)	O
were	O
synthesized	O
and	O
tested	O
as	O
inhibitors	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
from	O
rat	O
liver	O
,	O
Pneumocystis	O
carinii	O
,	O
and	O
Toxoplasma	O
gondii	O
.	O

The	O
most	O
active	O
quinazolines	O
against	O
both	O
the	O
P	O
.	O

carinii	O
and	O
the	O
T	O
.	O

gondii	O
enzyme	O
were	O
those	O
with	O
an	O
ArCH2	O
-	O
NH	O
or	O
ArNHCH2	O
side	O
chain	O
.	O

Among	O
ArNH	O
(	O
CH2	O
)	O
n	O
compounds	O
with	O
n	O
=	O
1-3	O
and	O
either	O
2'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dimethoxyphenyl	I-IUPAC
or	O
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxyphenyl	I-IUPAC
as	O
the	O
Ar	O
moiety	O
,	O
activity	O
decreased	O
in	O
the	O
order	O
n	O
=	O
1	O
&	O
gt	O
;	O
n	O
=	O
2	O
&	O
gt	O
;	O
n	O
=	O
3	O
.	O

The	O
best	O
inhibitor	O
of	O
P	O
.	O

carinii	O
DHFR	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxyanilino	I-IUPAC
)	I-IUPAC
methy	I-IUPAC
l	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
10	O
)	O
had	O
an	O
IC50	O
of	O
0.012	O
microM	O
and	O
was	O
slightly	O
more	O
potent	O
than	O
TMQ	O
and	O
PTX	O
.	O

Compound	O
10	O
was	O
also	O
the	O
best	O
inhibitor	O
of	O
T	O
.	O

gondii	O
DHFR	O
,	O
with	O
an	O
IC50	O
of	O
0.0064	O
microM	O
corresponding	O
again	O
to	O
a	O
minor	O
increase	O
in	O
activity	O
over	O
TMQ	O
and	O
PTX	O
.	O

However	O
,	O
as	O
with	O
these	O
standard	O
agents	O
,	O
10	O
showed	O
no	O
appreciable	O
selectivity	O
for	O
either	O
the	O
P	O
.	O

carinii	O
or	O
T	O
.	O

gondii	O
enzyme	O
relative	O
to	O
the	O
rat	O
liver	O
enzyme	O
.	O

The	O
highest	O
selectivity	O
achieved	O
in	O
this	O
limited	O
series	O
was	O
with	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
17	O
)	O
against	O
T	O
.	O

gondii	O
DHFR	O
.	O

While	O
17	O
(	O
IC50	O
=	O
0.016	O
microM	O
)	O
was	O
somewhat	O
less	O
potent	O
than	O
10	O
,	O
its	O
selectivity	O
,	O
as	O
defined	O
by	O
the	O
ratio	O
IC50	O
(	O
rat	O
liver	O
)	O
/	O
IC50	O
(	O
T	O
.	O

gondii	O
)	O
was	O
ca.	O
30	O
-	O
fold	O
higher	O
than	O
that	O
of	O
TMQ	O
or	O
PTX	O
.	O

Two	O
compounds	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxyanilino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
9	O
)	O
and	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
15	O
)	O
,	O
were	O
also	O
tested	O
against	O
human	O
DHFR	O
and	O
were	O
found	O
to	O
have	O
an	O
IC50	O
/	O
[	O
E	O
]	O
of	O
0.5	O
,	O
indicating	O
that	O
their	O
binding	O
was	O
near	O
-	O
stoichiometric	O
.	O

A	O
number	O
of	O
5	I-IUPAC
-	I-IUPAC
heteroaromatic	I-IUPAC
-	O
substituted	I-MODIFIER
2'	B-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
were	O
synthesized	O
from	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
using	O
tetraorganotin	O
reagents	O
and	O
palladium	O
complexes	O
as	O
catalyst	O
.	O

The	O
palladium	O
-	O
catalyzed	O
cross	O
-	O
coupling	O
reaction	O
between	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
and	O
stannylated	O
heteroaromatics	O
was	O
optimized	O
for	O
the	O
synthesis	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
and	O
5	I-IUPAC
-	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
.	O

5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Iodothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
was	O
used	O
as	O
starting	O
material	O
for	O
the	O
synthesis	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylthien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
vinylthien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ethynylthien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
.	O

5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Nitrothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
was	O
synthesized	O
using	O
ceric	O
ammonium	O
nitrate	O
as	O
reagent	O
.	O

5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Isoxazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
was	O
synthesized	O
from	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxopropyn	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
.	O

Finally	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chlorothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyluracil	I-IUPAC
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bromothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyluracil	I-IUPAC
were	O
obtained	O
by	O
halogenation	O
of	O
5	I-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyluracil	I-IUPAC
.	O

Introduction	O
of	O
an	O
alkyl	O
substituent	O
in	O
the	O
5	O
-	O
position	O
of	O
the	O
thienyl	O
group	O
of	O
5	I-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
or	O
substitution	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
deoxyribofuranose	I-IUPAC
ring	I-MODIFIER
by	O
an	O
arabinofuranose	O
moiety	O
gave	O
decreased	O
activity	O
against	O
HSV	O
-	O
1	O
and	O
VZV	O
replication	O
when	O
compared	O
with	O
the	O
5	I-IUPAC
"	I-IUPAC
-	I-IUPAC
halogenated	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
.	O

5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Bromothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
caused	O
prompt	O
healing	O
of	O
HSV	O
-	O
1	O
keratitis	O
when	O
administered	O
as	O
eye	O
drops	O
(	O
0.2%	O
)	O
to	O
rabbits	O
.	O

(	O
3S	O
,	O
4R	O
)	O
-	O
4	O
-	O
(	O
4	O
-	O
Fluorophenyl	O
)	O
-	O
3	O
-	O
[	O
[	O
3,4	O
-	O
(	O
methylenedioxy	O
)	O
phenoxy	O
]	O
methyl	O
]	O
piperidine	O
[	O
(	O
3S	O
,	O
9R	O
)	O
-	O
3	O
,	O
paroxetine	O
]	O
is	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
used	O
as	O
an	O
antidepressant	O
in	O
humans	O
.	O

In	O
previous	O
studies	O
,	O
we	O
reported	O
that	O
certain	O
(	I-PARTIUPAC
1R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
(	O
substituted	I-MODIFIER
phenyl	B-IUPAC
)	O
nortropane	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
carboxylic	I-PARTIUPAC
acid	I-PARTIUPAC
methyl	I-PARTIUPAC
esters	I-PARTIUPAC
(	O
2a	O
)	O
exhibited	O
high	O
affinity	O
and	O
reasonable	O
selectivity	O
for	O
the	O
serotonin	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
.	O

The	O
major	O
structural	O
differences	O
between	O
2a	O
and	O
(	O
3S	O
,	O
4R	O
)	O
-	O
3	O
are	O
that	O
2a	O
possesses	O
a	O
different	O
absolute	O
stereochemistry	O
and	O
has	O
an	O
ethylene	O
bridge	O
not	O
present	O
in	O
3	O
.	O

In	O
addition	O
,	O
2a	O
possesses	O
a	O
carbomethoxy	O
substituent	O
adjacent	O
to	O
the	O
aryl	O
ring	O
,	O
whereas	O
(	O
3S	O
,	O
4R	O
)	O
-	O
3	O
contains	O
a	O
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylenedioxy	I-IUPAC
)	I-IUPAC
phenoxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
synthesis	O
and	O
biological	O
evaluations	O
of	O
six	O
of	O
the	O
possible	O
eight	O
isomers	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylenedioxy	I-IUPAC
)	I-IUPAC
phenoxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
nortropane	I-IUPAC
+	O
+	O
+	O
(	O
4	O
)	O
.	O

The	O
data	O
for	O
inhibition	O
of	O
[	O
3H	O
]	O
paroxetine	O
binding	O
show	O
that	O
(	O
1R	O
)	O
-	O
2	O
beta	O
,	O
3	O
alpha	O
-	O
4c	O
,	O
which	O
has	O
the	O
same	O
stereochemistry	O
as	O
paroxetine	O
,	O
has	O
the	O
highest	O
affinity	O
at	O
the	O
5	O
-	O
HTT	O
.	O

Strikingly	O
,	O
the	O
most	O
potent	O
compounds	O
for	O
inhibition	O
of	O
[	O
3H	O
]	O
WIN	O
-	O
35,428	O
binding	O
were	O
not	O
the	O
(	O
1R	O
)	O
-	O
2	O
beta	O
,	O
3	O
beta	O
-	O
isomers	O
but	O
rather	O
(	O
1R	O
)	O
-	O
2	O
beta	O
,	O
3	O
alpha	O
-	O
4c	O
and	O
(	O
1S	O
)	O
-	O
2	O
beta	O
,	O
3	O
alpha	O
-	O
4f	O
.	O

Conformational	O
analyses	O
show	O
that	O
these	O
isomers	O
exist	O
in	O
a	O
flattened	O
boat	O
conformation	O
with	O
pseudoequatorial	O
substituents	O
.	O

Thus	O
,	O
the	O
binding	O
data	O
show	O
that	O
this	O
conformation	O
is	O
recognized	O
by	O
the	O
DAT	O
-	O
associated	O
binding	O
site	O
and	O
also	O
suggest	O
that	O
this	O
conformation	O
of	O
paroxetine	O
is	O
recognized	O
by	O
the	O
5	O
-	O
HTT	O
-	O
associated	O
binding	O
site	O
.	O

A	O
series	O
of	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aryloxy	I-IUPAC
)	I-IUPAC
propan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ols	I-IUPAC
was	O
synthesized	O
together	O
with	O
several	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dimethoxyphenethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aryloxy	I-IUPAC
)	I-IUPAC
propan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ols	I-IUPAC
.	O

Their	O
affinity	O
to	O
beta	O
1	O
-	O
and	O
beta	O
-	O
2	O
-	O
adrenoceptors	O
was	O
determined	O
and	O
compared	O
with	O
the	O
affinity	O
of	O
known	O
beta	O
-	O
blockers	O
.	O

We	O
were	O
able	O
to	O
confirm	O
the	O
substantial	O
cardioselectivity	O
of	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3,4	I-PARTIUPAC
-	I-PARTIUPAC
dimethoxyphenethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
aryl	I-IUPAC
)	B-PARTIUPAC
oxy	I-PARTIUPAC
]	I-PARTIUPAC
propan	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
ols	I-PARTIUPAC
when	O
compared	O
to	O
those	O
with	O
a	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenethyl	I-IUPAC
)	I-IUPAC
group	I-MODIFIER
.	O

An	O
increase	O
in	O
the	O
size	O
of	O
the	O
4	O
substitutent	O
of	O
the	O
3	O
-	O
(	O
aryloxy	O
)	O
moiety	O
to	O
caproamido	O
leads	O
to	O
a	O
substantially	O
higher	O
affinity	O
for	O
the	O
beta	O
1	O
-	O
-	O
adrenoceptor	O
of	O
rat	O
ventricular	O
muscle	O
in	O
the	O
presence	O
of	O
the	O
3,4	I-IUPAC
-	I-IUPAC
dimethoxyphenethyl	I-IUPAC
than	O
in	O
the	O
presence	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
hydroxyphenethyl	I-IUPAC
or	O
isopropyl	O
group	O
;	O
this	O
combination	O
also	O
gave	O
the	O
highest	O
cardioselectivity	O
.	O

A	O
number	O
of	O
1	I-IUPAC
-	I-IUPAC
hydroxyazole	I-IUPAC
derivatives	I-MODIFIER
were	O
synthesized	O
as	O
bioisosteres	O
of	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
Glu	O
)	O
and	O
as	O
analogues	O
of	O
the	O
AMPA	O
receptor	O
agonist	O
(	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
,	O
3b	O
)	O
.	O

All	O
compounds	O
were	O
subjected	O
to	O
in	O
vitro	O
pharmacological	O
studies	O
,	O
including	O
a	O
series	O
of	O
Glu	O
receptor	O
binding	O
assays	O
,	O
uptake	O
studies	O
on	O
native	O
as	O
well	O
as	O
cloned	O
Glu	O
uptake	O
systems	O
,	O
and	O
the	O
electrophysiological	O
rat	O
cortical	O
slice	O
model	O
.	O

Compounds	O
7a	O
,	O
b	O
,	O
analogues	O
of	O
AMPA	O
bearing	O
a	O
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
pyrazolyl	I-IUPAC
moiety	I-MODIFIER
as	O
the	O
distal	O
carboxylic	O
functionality	O
,	O
showed	O
only	O
moderate	O
affinity	O
for	O
[	O
3H	O
]	O
AMPA	O
receptor	O
binding	O
sites	O
(	O
IC	O
(	O
50	O
)	O
=	O
2.7	O
+	O
/	O
-	O
0.4	O
microM	O
and	O
IC	O
(	O
50	O
)	O
=	O
2.6	O
+	O
/	O
-	O
0.6	O
microM	O
,	O
respectively	O
)	O
,	O
correlating	O
with	O
electrophysiological	O
data	O
from	O
the	O
rat	O
cortical	O
wedge	O
model	O
(	O
EC	O
(	O
50	O
)	O
=	O
280	O
+	O
/	O
-	O
48	O
microM	O
and	O
EC	O
(	O
50	O
)	O
=	O
586	O
+	O
/	O
-	O
41	O
microM	O
,	O
respectively	O
)	O
.	O

1	I-IUPAC
-	I-IUPAC
Hydroxy	I-IUPAC
-	I-IUPAC
1,2,3	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
analogues	I-MODIFIER
of	O
AMPA	O
,	O
compounds	O
8a	O
,	O
b	O
,	O
showed	O
high	O
affinity	O
for	O
[	O
3H	O
]	O
AMPA	O
receptor	O
binding	O
sites	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.15	O
+	O
/	O
-	O
0.03	O
microM	O
and	O
IC	O
(	O
50	O
)	O
=	O
0.13	O
+	O
/	O
-	O
0.02	O
microM	O
,	O
respectively	O
)	O
.	O

Electrophysiological	O
data	O
showed	O
that	O
compound	O
8a	O
was	O
devoid	O
of	O
activity	O
in	O
the	O
rat	O
cortical	O
wedge	O
model	O
(	O
EC	O
(	O
50	O
)	O
&	O
gt	O
;	O
1000	O
microM	O
)	O
,	O
whereas	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	I-MODIFIER
8b	O
was	O
a	O
potent	O
AMPA	O
receptor	O
agonist	O
(	O
EC	O
(	O
50	O
)	O
=	O
15	O
+	O
/	O
-	O
2	O
microM	O
)	O
.	O

In	O
accordance	O
with	O
this	O
disparity	O
,	O
compound	O
8a	O
was	O
found	O
to	O
inhibit	O
synaptosomal	O
[	O
3H	O
]	O
D	O
-	O
aspartic	O
acid	O
uptake	O
(	O
IC	O
(	O
50	O
)	O
=	O
93	O
+	O
/	O
-	O
25	O
microM	O
)	O
,	O
as	O
well	O
as	O
excitatory	O
amino	O
acid	O
transporters	O
(	O
EAATs	O
)	O
EAAT1	O
(	O
IC	O
(	O
50	O
)	O
=	O
100	O
+	O
/	O
-	O
30	O
microM	O
)	O
and	O
EAAT2	O
(	O
IC	O
(	O
50	O
)	O
=	O
300	O
+	O
/	O
-	O
80	O
microM	O
)	O
.	O

By	O
contrast	O
,	O
compound	O
8b	O
showed	O
no	O
appreciable	O
affinity	O
for	O
Glu	O
uptake	O
sites	O
,	O
neither	O
synaptosomal	O
nor	O
cloned	O
.	O

Compounds	O
9a	O
-	O
c	O
and	O
10a	O
,	O
b	O
,	O
possessing	O
1	I-IUPAC
-	I-IUPAC
hydroxyimidazole	I-IUPAC
as	O
the	O
terminal	O
acidic	O
function	O
,	O
were	O
devoid	O
of	O
activity	O
in	O
all	O
of	O
the	O
systems	O
tested	O
.	O

Protolytic	O
properties	O
of	O
compounds	O
7a	O
,	O
b	O
,	O
8b	O
,	O
and	O
9b	O
were	O
determined	O
by	O
titration	O
,	O
and	O
a	O
correlation	O
between	O
the	O
pK	O
(	O
a	O
)	O
values	O
and	O
the	O
activity	O
at	O
AMPA	O
receptors	O
was	O
apparent	O
.	O

Optimized	O
structures	O
of	O
all	O
the	O
synthesized	O
ligands	O
were	O
fitted	O
to	O
the	O
known	O
crystal	O
structure	O
of	O
an	O
AMPA	O
-	O
GluR2	O
construct	O
.	O

Where	O
substantial	O
reduction	O
or	O
abolition	O
of	O
affinity	O
at	O
AMPA	O
receptors	O
was	O
observed	O
,	O
this	O
could	O
be	O
rationalized	O
on	O
the	O
basis	O
of	O
the	O
ability	O
of	O
the	O
ligand	O
to	O
fit	O
the	O
construct	O
.	O

The	O
results	O
presented	O
in	O
this	O
article	O
point	O
to	O
the	O
utility	O
of	O
1	I-IUPAC
-	I-IUPAC
hydroxypyrazole	I-IUPAC
and	O
1,2,3	I-IUPAC
-	I-IUPAC
hydroxytriazole	I-IUPAC
as	O
bioisosteres	O
of	O
carboxylic	O
acids	O
at	O
Glu	O
receptors	O
and	O
transporters	O
.	O

None	O
of	O
the	O
compounds	O
showed	O
significant	O
activity	O
at	O
metabotropic	O
Glu	O
receptors	O
.	O

Methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatomethyl	I-IUPAC
)	I-IUPAC
thiazole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
and	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatomethyl	I-IUPAC
)	I-IUPAC
selenazole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
have	O
been	O
prepared	O
via	O
chemical	O
transformations	O
involving	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
thiazole	I-IUPAC
(	O
1	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
selenazole	I-IUPAC
(	O
2	O
)	O
,	O
respectively	O
,	O
as	O
starting	O
materials	O
.	O

The	O
homoanalog	O
,	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
isothiocyanatoethyl	I-IUPAC
)	I-IUPAC
thiazole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
,	O
was	O
prepared	O
from	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminothiazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
.	O

All	O
compounds	O
prepared	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
leukemia	O
L1210	O
cell	O
proliferation	O
.	O

Methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatomethyl	I-IUPAC
)	I-IUPAC
thiazole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
(	O
7	O
)	O
was	O
the	O
most	O
active	O
compound	O
in	O
this	O
screen	O
,	O
inhibiting	O
the	O
growth	O
of	O
L1210	O
leukemic	O
cells	O
with	O
an	O
IC50	O
=	O
3.2	O
microM	O
.	O

Mitotic	O
blocking	O
appears	O
to	O
be	O
its	O
primary	O
mechanism	O
of	O
cytotoxic	O
activity	O
.	O

Compound	O
7	O
also	O
was	O
the	O
only	O
compound	O
which	O
demonstrated	O
significant	O
in	O
vivo	O
antifilarial	O
activity	O
against	O
the	O
adult	O
worms	O
of	O
Acanthocheilonema	O
viteae	O
in	O
experimentally	O
infected	O
jirds	O
.	O

This	O
compound	O
was	O
inactive	O
against	O
Brugia	O
pahangi	O
at	O
a	O
dosage	O
of	O
100	O
mg	O
/	O
kg	O
x	O
5	O
days	O
.	O

From	O
salicyclic	O
acid	O
,	O
the	O
two	O
enantiomers	O
of	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxybenzamide	I-IUPAC
(	O
6b	O
)	O
were	O
prepared	O
in	O
a	O
five	O
-	O
step	O
synthesis	O
.	O

With	O
use	O
of	O
Heindel	O
's	O
triazene	O
method	O
for	O
introduction	O
of	O
the	O
radionuclide	O
,	O
the	O
iodine	O
-	O
125	O
-	O
labeled	O
substituted	O
benzamide	O
was	O
obtained	O
with	O
a	O
calculated	O
specific	O
activity	O
of	O
136	O
Ci	O
/	O
mmol	O
and	O
14%	O
radiochemical	O
yield	O
.	O

For	O
the	O
preparation	O
of	O
the	O
iodine	O
-	O
125	O
-	O
labeled	O
benzamide	O
with	O
higher	O
specific	O
activity	O
,	O
this	O
method	O
was	O
unsuccessful	O
and	O
utilization	O
of	O
the	O
corresponding	O
tri	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyltin	I-IUPAC
derivative	I-MODIFIER
was	O
required	O
.	O

Treatment	O
of	O
the	O
latter	O
in	O
dilute	O
hydrochloric	O
acid	O
with	O
sodium	O
iodide	O
-	O
125	O
and	O
chloramine	O
-	O
T	O
gave	O
[	O
125I	O
]	O
(	O
S	O
)	O
-	O
6b	O
in	O
56%	O
radiochemical	O
yield	O
and	O
at	O
least	O
97%	O
radiochemical	O
purity	O
.	O

The	O
displacement	O
of	O
[	I-PARTIUPAC
125I	I-PARTIUPAC
]	I-PARTIUPAC
(	I-PARTIUPAC
S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
6b	O
and	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
sulpiride	I-IUPAC
from	O
their	O
respective	O
binding	O
sites	O
in	O
striatal	O
rat	O
brain	O
homogenates	O
using	O
various	O
neuroleptic	O
agents	O
showed	O
that	O
(	O
S	O
)	O
-	O
6b	O
has	O
the	O
same	O
binding	O
profile	O
but	O
more	O
potent	O
binding	O
for	O
dopamine	O
D	O
-	O
2	O
receptors	O
than	O
has	O
sulpiride	O
.	O

These	O
experiments	O
also	O
indicate	O
that	O
the	O
S	O
enantiomer	O
of	O
6b	O
is	O
a	O
specific	O
ligand	O
(	O
KD	O
=	O
1.2	O
nM	O
)	O
for	O
the	O
D	O
-	O
2	O
receptor	O
.	O

Further	O
,	O
the	O
octanol	O
-	O
water	O
partition	O
coefficient	O
of	O
(	O
S	O
)	O
-	O
6b	O
as	O
determined	O
by	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
was	O
found	O
to	O
be	O
40	O
times	O
greater	O
than	O
that	O
for	O
sulpiride	O
.	O

Thus	O
(	O
S	O
)	O
-	O
6b	O
has	O
a	O
lipophilicity	O
that	O
will	O
allow	O
a	O
relatively	O
higher	O
uptake	O
into	O
the	O
brain	O
compared	O
to	O
sulpiride	O
.	O

In	O
vivo	O
experiments	O
with	O
rats	O
show	O
that	O
[	O
125I	O
]	O
(	O
S	O
)	O
-	O
6b	O
penetrates	O
readily	O
into	O
the	O
brain	O
and	O
is	O
preferentially	O
localized	O
in	O
the	O
striatum	O
as	O
compared	O
to	O
the	O
cerebellum	O
,	O
the	O
ratio	O
of	O
uptake	O
being	O
7.2	O
to	O
1	O
,	O
60	O
min	O
after	O
injection	O
.	O

These	O
observations	O
of	O
good	O
brain	O
penetration	O
and	O
high	O
affinity	O
and	O
selectivity	O
for	O
D	O
-	O
2	O
receptors	O
indicate	O
that	O
the	O
corresponding	O
iodine	O
-	O
123	O
-	O
labeled	O
benzamide	O
may	O
be	O
a	O
useful	O
ligand	O
for	O
the	O
noninvasive	O
visualization	O
study	O
of	O
dopamine	O
D	O
-	O
2	O
receptor	O
sites	O
in	O
vivo	O
by	O
single	O
photon	O
emission	O
computed	O
tomography	O
.	O

The	O
inhibitions	O
of	O
cytochrome	O
P	O
-	O
450	O
dependent	O
monooxygenase	O
activity	O
in	O
microsomes	O
from	O
rat	O
liver	O
by	O
1	I-IUPAC
-	I-IUPAC
phenylpyrrole	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
isopropylphenyl	I-IUPAC
)	I-IUPAC
pyrrole	I-IUPAC
,	O
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phenylimidazole	I-IUPAC
,	O
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
isopropylphenyl	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
have	O
been	O
compared	O
.	O

The	O
results	O
establish	O
that	O
the	O
presence	O
of	O
an	O
imidazole	O
N	O
-	O
3	O
nitrogen	O
substituent	O
is	O
not	O
required	O
to	O
inhibit	O
the	O
monooxygenase	O
activity	O
measured	O
by	O
the	O
deethylation	O
of	O
7	I-IUPAC
-	I-IUPAC
ethoxycoumarin	I-IUPAC
.	O

The	O
presence	O
of	O
an	O
appropriately	O
situated	O
N	O
-	O
3	O
atom	O
,	O
however	O
,	O
as	O
in	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
isopropylphenyl	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
,	O
significantly	O
decreases	O
both	O
the	O
Ki	O
and	O
alphaKi	O
of	O
these	O
mixed	O
type	O
inhibitors	O
.	O

The	O
induction	O
of	O
7	I-IUPAC
-	I-IUPAC
ethoxycoumarin	I-IUPAC
deethylase	O
activity	O
in	O
the	O
microsomal	O
fraction	O
from	O
rat	O
liver	O
by	O
alpha	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
,	O
beta	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
methylcholanthrene	I-IUPAC
and	O
the	O
inhibition	O
of	O
these	O
activities	O
by	O
flavone	O
and	O
alpha	I-PARTIUPAC
-	I-PARTIUPAC
,	O
beta	I-PARTIUPAC
,	O
and	O
gamma	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
have	O
also	O
been	O
examined	O
.	O

The	O
results	O
establish	O
that	O
alpha	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
is	O
the	O
most	O
effective	O
in	O
vitro	O
inhibitor	O
.	O

The	O
results	O
also	O
indicate	O
that	O
the	O
microsomal	O
monooxygenase	O
activities	O
induced	O
in	O
rat	O
liver	O
by	O
alpha	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
,	O
beta	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
methylcholanthrene	I-IUPAC
are	O
not	O
equivalent	O
.	O

Based	O
upon	O
the	O
observed	O
results	O
,	O
it	O
is	O
concluded	O
that	O
differential	O
effects	O
of	O
alpha	I-PARTIUPAC
-	I-PARTIUPAC
and	O
beta	I-IUPAC
-	I-IUPAC
naphthoflavone	I-IUPAC
on	O
aryl	O
hydrocarbon	O
skin	O
tumorigenesis	O
may	O
be	O
the	O
result	O
of	O
differential	O
enzyme	O
induction	O
rather	O
than	O
the	O
result	O
of	O
differential	O
enzyme	O
inhibition	O
.	O

A	O
series	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	O
substituted	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
phenylpiperidines	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyridines	I-IUPAC
,	O
and	O
4	I-IUPAC
-	I-IUPAC
phenylpiperazines	I-IUPAC
was	O
synthesized	O
.	O

The	O
phenyl	I-IUPAC
group	B-MODIFIER
was	O
optionally	O
substituted	O
with	O
4	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
substituents	I-MODIFIER
.	O

High	O
affinity	O
for	O
both	O
sigma	O
1	O
and	O
sigma	O
2	O
binding	O
sites	O
was	O
achieved	O
with	O
these	O
compounds	O
.	O

Additionally	O
,	O
these	O
compounds	O
had	O
relatively	O
high	O
affinity	O
for	O
serotonin	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2A	O
,	O
dopamine	O
D2	O
,	O
and	O
adrenergic	O
alpha	O
1	O
receptors	O
.	O

Introduction	O
of	O
a	O
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
substituent	I-MODIFIER
at	O
the	O
indole	O
nitrogen	O
atom	O
rendered	O
very	O
selective	O
sigma	O
2	O
ligands	O
with	O
subnanomolar	O
affinity	O
for	O
the	O
sigma	O
2	O
binding	O
site	O
.	O

The	O
prototype	O
of	O
such	O
a	O
compound	O
was	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indole	I-IUPAC
,	O
11a	O
(	O
code	O
no	O
.	O

Lu	O
29-253	O
)	O
.	O

This	O
compound	O
had	O
the	O
following	O
binding	O
affinities	O
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
16	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.27	O
nM	O
,	O
IC50	O
(	O
5	O
-	O
HT1A	O
)	O
=	O
22,000	O
nM	O
,	O
IC50	O
(	O
5	O
-	O
HT2A	O
)	O
=	O
270	O
nM	O
,	O
IC50	O
(	O
D2	O
)	O
=	O
4200	O
nM	O
,	O
IC50	O
(	O
alpha	O
1	O
)	O
=	O
220	O
nM	O
.	O

Spiro	O
-	O
joining	O
of	O
the	O
phenyl	I-IUPAC
and	O
the	O
piperidine	I-IUPAC
rings	B-MODIFIER
into	O
a	O
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperdine	I-IUPAC
]	I-IUPAC
ring	I-MODIFIER
system	I-MODIFIER
resulted	O
in	O
even	O
more	O
selective	O
compounds	O
.	O

Variations	O
of	O
the	O
1	O
-	O
substituent	O
at	O
the	O
indole	O
and	O
of	O
the	O
chain	O
length	O
of	O
the	O
alkylene	O
spacer	O
group	O
were	O
studied	O
.	O

The	O
optimal	O
compound	O
was	O
the	O
spiro	O
analogue	O
of	O
compound	O
11a	O
.	O

This	O
compound	O
is	O
1'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
14f	O
(	O
code	O
no	O
.	O

Lu	O
28-179	O
)	O
,	O
with	O
the	O
binding	O
affinities	O
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
17	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.12	O
nM	O
,	O
IC50	O
(	O
5	O
-	O
HT1A	O
)	O
=	O
21,000	O
nM	O
,	O
IC50	O
(	O
5	O
-	O
HT2A	O
)	O
=	O
2000	O
nM	O
,	O
IC50	O
(	O
D2	O
)	O
=	O
800	O
nM	O
,	O
IC50	O
(	O
alpha	O
1	O
)	O
=	O
330	O
nM	O
.	O

However	O
,	O
the	O
most	O
selective	O
sigma	O
2	O
versus	O
sigma	O
1	O
ligand	O
was	O
the	O
tropane	O
derivative	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
azabicyclo	I-IUPAC
[	I-IUPAC
3.2.1	I-IUPAC
]	I-IUPAC
oct	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indole	I-IUPAC
,	O
15a	O
.	O

This	O
compound	O
had	O
the	O
following	O
binding	O
affinities	O
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
1200	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
2.5	O
nM	O
.	O

Potent	O
anxiolytic	O
activity	O
in	O
the	O
black	O
/	O
white	O
box	O
exploration	O
test	O
in	O
rats	O
was	O
found	O
with	O
the	O
two	O
most	O
prominent	O
sigma	O
2	O
ligands	O
Lu	O
29-253	O
and	O
Lu	O
28-179	O
.	O

Good	O
penetration	O
into	O
the	O
CNS	O
was	O
documented	O
both	O
after	O
subcutaneous	O
and	O
peroral	O
administration	O
of	O
Lu	O
28-179	O
by	O
ex	O
vivo	O
binding	O
studies	O
.	O

Long	O
duration	O
of	O
action	O
was	O
demonstrated	O
both	O
in	O
ex	O
vivo	O
binding	O
(	O
T1/2	O
approximately	O
20	O
h	O
)	O
and	O
in	O
the	O
black	O
/	O
white	O
box	O
exploration	O
test	O
.	O

2beta	I-IUPAC
-	I-IUPAC
Carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethenyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
nortropane	I-IUPAC
(	O
ZIENT	O
)	O
(	O
6	O
)	O
and	O
2beta	I-IUPAC
-	I-IUPAC
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethenyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
nortropane	I-IUPAC
(	O
EIENT	O
)	O
(	O
10	O
)	O
were	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
selectivity	O
and	O
specificity	O
.	O

High	O
specific	O
activity	O
[	O
(	O
123	O
)	O
I	O
]	O
ZIENT	O
and	O
[	O
(	O
123	O
)	O
I	O
]	O
EIENT	O
were	O
synthesized	O
in	O
45%	O
(	O
n	O
=	O
5	O
)	O
and	O
42%	O
(	O
n	O
=	O
4	O
)	O
radiochemical	O
yield	O
(	O
decay	O
-	O
corrected	O
to	O
end	O
of	O
bombardment	O
(	O
EOB	O
)	O
)	O
,	O
respectively	O
,	O
by	O
preparation	O
of	O
the	O
precursor	O
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
trimethylstannylethenyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
nortropane	I-IUPAC
(	O
7	O
)	O
and	O
2beta	I-IUPAC
-	I-IUPAC
carbomethoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
tributylstannylethenyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
)	I-IUPAC
nortropane	I-IUPAC
(	O
9	O
)	O
,	O
respectively	O
,	O
followed	O
by	O
treatment	O
with	O
no	O
carrier	O
-	O
added	O
sodium	O
[	O
(	O
123	O
)	O
I	O
]	O
iodide	O
and	O
hydrogen	O
peroxide	O
in	O
ethanolic	O
HCl	O
.	O

Competition	O
binding	O
in	O
cells	O
stably	O
expressing	O
the	O
transfected	O
human	O
SERT	O
,	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
,	O
and	O
norepinephrine	O
transporter	O
(	O
NET	O
)	O
using	O
[	O
(	O
3	O
)	O
H	O
]	O
citalopram	O
,	O
[	O
(	O
3	O
)	O
H	O
]	O
WIN	O
35,428	O
,	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
nisoxetine	O
,	O
respectively	O
,	O
demonstrated	O
the	O
following	O
order	O
of	O
SERT	O
affinity	O
(	O
K	O
(	O
i	O
)	O
in	O
nM	O
)	O
:	O
ZIENT	O
(	O
0.05	O
)	O
&	O
gt	O
;	O
nor	O
-	O
CIT	O
(	O
0.12	O
)	O
&	O
gt	O
;	O
&	O
gt	O
;	O
EIENT	O
(	O
1.15	O
)	O
&	O
gt	O
;	O
fluvoxamine	O
(	O
1.46	O
)	O
.	O

The	O
affinity	O
of	O
ZIENT	O
and	O
EIENT	O
for	O
DAT	O
was	O
69	O
and	O
1.6	O
-	O
fold	O
lower	O
,	O
respectively	O
,	O
than	O
for	O
SERT	O
.	O

In	O
vivo	O
biodistribution	O
and	O
blocking	O
studies	O
were	O
performed	O
in	O
male	O
rats	O
and	O
demonstrated	O
that	O
the	O
brain	O
uptake	O
of	O
[	O
(	O
123	O
)	O
I	O
]	O
ZIENT	O
was	O
selective	O
and	O
specific	O
for	O
SERT	O
-	O
rich	O
regions	O
(	O
hypothalamus	O
,	O
striatum	O
,	O
pons	O
,	O
and	O
prefrontal	O
cortex	O
)	O
.	O

SPECT	O
brain	O
imaging	O
studies	O
in	O
monkeys	O
demonstrated	O
high	O
[	O
(	O
123	O
)	O
I	O
]	O
ZIENT	O
uptake	O
in	O
the	O
diencephalon	O
,	O
which	O
resulted	O
in	O
diencephalon	O
-	O
to	O
-	O
cerebellum	O
ratios	O
of	O
2.12	O
at	O
190	O
min	O
.	O

[	O
(	O
123	O
)	O
I	O
]	O
ZIENT	O
uptake	O
in	O
the	O
diencephalon	O
achieved	O
transient	O
equilibrium	O
at	O
157	O
min	O
.	O

In	O
a	O
displacement	O
experiment	O
of	O
[	O
(	O
123	O
)	O
I	O
]	O
ZIENT	O
in	O
a	O
cynomolgus	O
monkey	O
,	O
radioactivity	O
was	O
reduced	O
by	O
39%	O
in	O
the	O
diencephalon	O
at	O
101	O
min	O
following	O
injection	O
of	O
citalopram	O
.	O

The	O
high	O
specific	O
activity	O
one	O
-	O
step	O
radiolabeling	O
preparation	O
and	O
high	O
selectivity	O
of	O
[	O
(	O
123	O
)	O
I	O
]	O
ZIENT	O
for	O
SERT	O
support	O
its	O
candidacy	O
as	O
a	O
radioligand	O
for	O
mapping	O
brain	O
SERT	O
sites	O
.	O

Several	O
series	O
of	O
2,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2,4,5	I-IUPAC
-	O
trisubstituted	I-MODIFIER
-	O
3H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
with	O
acidic	O
sulfonamide	O
replacements	O
of	O
tetrazole	O
at	O
the	O
2'	O
-	O
position	O
of	O
the	O
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
side	I-MODIFIER
chain	I-MODIFIER
at	O
N4	O
were	O
prepared	O
and	O
tested	O
as	O
angiotensin	O
II	O
(	O
AII	O
)	O
antagonists	O
.	O

Preferred	O
substituents	O
on	O
the	O
triazolinone	O
ring	O
were	O
n	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
at	O
C5	O
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
at	O
N2	O
.	O

Subnanomolar	O
IC50	O
values	O
at	O
the	O
AT1	O
receptor	O
subtype	O
were	O
observed	O
for	O
a	O
variety	O
of	O
acylsulfonamides	O
,	O
including	O
aroyl	O
,	O
heteroaroyl	O
,	O
and	O
cycloalkylcarbonyl	I-IUPAC
derivatives	B-MODIFIER
.	O

Certain	O
other	O
acidic	O
sulfonamides	O
,	O
such	O
as	O
sulfonylcarbamates	O
and	O
disulfimides	O
also	O
displayed	O
high	O
affinity	O
for	O
the	O
AT1	O
receptor	O
.	O

In	O
addition	O
,	O
AT2	O
binding	O
for	O
some	O
of	O
these	O
compounds	O
was	O
increased	O
by	O
as	O
much	O
as	O
1000	O
-	O
fold	O
over	O
the	O
corresponding	O
tetrazole	O
(	O
e.g.	O
,	O
AT2	O
IC50	O
17	O
nM	O
for	O
the	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
sulfonylcarbamate	I-IUPAC
92	O
)	O
.	O

When	O
evaluated	O
for	O
inhibition	O
of	O
the	O
AII	O
pressor	O
response	O
,	O
the	O
benchmark	O
benzoylsulfonamide	O
9	O
(	O
L	O
-	O
159,913	O
)	O
was	O
efficacious	O
in	O
several	O
species	O
and	O
was	O
superior	O
to	O
losartan	O
(	O
1a	O
)	O
in	O
conscious	O
rhesus	O
monkeys	O
.	O

Several	O
subsequent	O
analogues	O
,	O
including	O
the	O
2	I-IUPAC
-	I-IUPAC
chlorobenzoyl	I-IUPAC
(	O
18	O
)	O
,	O
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorothiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
(	O
51	O
)	O
,	O
(	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dimethylcyclopropyl	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
(	O
80	O
)	O
,	O
and	O
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
(	O
92	O
)	O
derivatives	I-MODIFIER
,	O
were	O
highly	O
effective	O
in	O
rats	O
,	O
surpassing	O
9	O
and	O
losartan	O
in	O
duration	O
of	O
action	O
and	O
/	O
or	O
potency	O
.	O

Compound	O
18	O
(	O
L	O
-	O
162,223	O
)	O
displayed	O
very	O
prolonged	O
AII	O
antagonism	O
in	O
the	O
rat	O
model	O
(	O
&	O
gt	O
;	O
24	O
h	O
at	O
1	O
mg	O
/	O
kg	O
iv	O
)	O
.	O

At	O
1	O
mg	O
/	O
kg	O
po	O
in	O
rats	O
,	O
18	O
and	O
92	O
(	O
L	O
-	O
162,234	O
)	O
produced	O
85-87%	O
peak	O
inhibition	O
of	O
the	O
AII	O
pressor	O
response	O
with	O
duration	O
exceeding	O
6	O
h	O
.	O

The	O
identification	O
of	O
triazolinone	O
-	O
based	O
sulfonamide	O
derivatives	O
combining	O
high	O
AT1	O
affinity	O
,	O
considerably	O
enhanced	O
AT2	O
potency	O
,	O
and	O
favorable	O
in	O
vivo	O
properties	O
provides	O
insights	O
relevant	O
to	O
the	O
design	O
of	O
dual	O
AT1	O
/	O
AT2	O
receptor	O
antagonists	O
.	O

A	O
series	I-MODIFIER
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indoles	I-IUPAC
substituted	I-MODIFIER
in	I-MODIFIER
the	I-MODIFIER
1	I-MODIFIER
-	I-MODIFIER
position	I-MODIFIER
with	O
4	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
,	O
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
,	O
and	O
4	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
was	O
synthesized	O
.	O

By	O
variation	O
of	O
the	O
substituents	O
in	O
the	O
benzene	O
part	O
of	O
the	O
indole	O
nucleus	O
in	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3-4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidinones	I-IUPAC
,	O
the	O
highest	O
5	O
-	O
HT2	O
receptor	O
affinity	O
and	O
selectivity	O
with	O
respect	O
to	O
dopamine	O
D2	O
receptors	O
and	O
alpha	O
1	O
adrenoceptors	O
were	O
obtained	O
by	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
substitution	I-MODIFIER
.	O

Different	O
substituents	O
were	O
introduced	O
in	O
the	O
1	O
-	O
position	O
of	O
the	O
piperidine	O
ring	O
in	O
the	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
derivative	I-MODIFIER
.	O

Thus	O
replacement	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidinon	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
side	I-MODIFIER
chain	I-MODIFIER
with	O
a	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ureido	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
or	O
methyl	I-IUPAC
substituent	B-MODIFIER
resulted	O
in	O
unchanged	O
affinity	O
and	O
selectivity	O
for	O
5	O
-	O
HT2	O
receptors	O
.	O

Replacement	O
with	O
a	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidinon	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
side	I-MODIFIER
chain	I-MODIFIER
reduced	O
binding	O
to	O
alpha	O
1	O
adrenoceptors	O
with	O
a	O
factor	O
of	O
four	O
,	O
while	O
affinities	O
for	O
5	O
-	O
HT2	O
and	O
D2	O
receptors	O
were	O
retained	O
,	O
compared	O
to	O
the	O
3	I-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
imidazolidinone	I-IUPAC
.	O

Indoles	O
substituted	I-MODIFIER
in	O
the	O
1	O
-	O
position	O
with	O
4	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
had	O
generally	O
weaker	O
affinity	O
for	O
both	O
5	O
-	O
HT2	O
and	O
D2	O
receptors	O
compared	O
to	O
corresponding	O
4	I-PARTIUPAC
-	I-PARTIUPAC
piperidinyl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
-	O
substituted	I-MODIFIER
indoles	B-IUPAC
.	O

Introduction	O
of	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
in	O
the	O
2	O
-	O
position	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
indole	O
resulted	O
in	O
further	O
increase	O
of	O
selectivity	O
for	O
the	O
5	O
-	O
HT2	O
receptor	O
.	O

Compounds	O
with	O
potent	O
receptor	O
binding	O
also	O
potently	O
inhibited	O
the	O
quipazine	O
-	O
induced	O
head	O
twitch	O
syndrome	O
in	O
rats	O
.	O

The	O
compounds	O
were	O
equally	O
active	O
after	O
oral	O
and	O
subcutaneous	O
administration	O
and	O
showed	O
a	O
long	O
duration	O
of	O
action	O
(	O
&	O
gt	O
;	O
24	O
h	O
)	O
.	O

In	O
general	O
,	O
the	O
derivatives	O
were	O
found	O
to	O
be	O
considerably	O
more	O
potent	O
at	O
24	O
h	O
than	O
at	O
2	O
h	O
after	O
the	O
administration	O
.	O

The	O
compounds	O
within	O
this	O
series	O
were	O
prepared	O
as	O
analogues	O
of	O
the	O
previously	O
described	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indoles	I-IUPAC
by	O
interchange	O
of	O
the	O
C	O
-	O
3	O
carbon	O
atom	O
and	O
the	O
nitrogen	O
atom	O
in	O
the	O
indole	O
nucleus	O
.	O

The	O
pharmacological	O
results	O
indicate	O
that	O
this	O
isosteric	O
replacement	O
results	O
in	O
higher	O
selectivity	O
for	O
5	O
-	O
HT2	O
receptors	O
compared	O
to	O
the	O
former	O
series	O
.	O

The	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidinone	I-IUPAC
has	O
high	O
affinity	O
for	O
5	O
-	O
HT2	O
receptors	O
(	O
IC50	O
=	O
3.4	O
nM	O
)	O
and	O
extremely	O
low	O
affinity	O
for	O
both	O
dopamine	O
D2	O
receptors	O
(	O
IC50	O
=	O
6900	O
nM	O
)	O
and	O
alpha	O
1	O
adrenoceptors	O
(	O
IC50	O
=	O
2300	O
nM	O
)	O
.	O

The	O
dopaminergic	O
receptor	O
profile	O
of	O
a	O
series	O
of	O
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylcyclopropyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
arylpiperazines	I-IUPAC
was	O
examined	O
.	O

Aromatic	O
substitution	O
patterns	O
were	O
varied	O
with	O
the	O
goal	O
of	O
identifying	O
a	O
compound	O
having	O
affinities	O
for	O
the	O
D	O
(	O
2	O
)	O
and	O
D	O
(	O
4	O
)	O
receptors	O
in	O
a	O
ratio	O
similar	O
to	O
that	O
observed	O
for	O
the	O
atypical	O
neuroleptic	O
clozapine	O
.	O

The	O
compounds	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylcyclopropyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
5m	O
)	O
and	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylcyclopropyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dimethylphenyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
5t	O
)	O
were	O
selected	O
for	O
functional	O
antagonists	O
at	O
D	O
(	O
2	O
)	O
and	O
D	O
(	O
4	O
)	O
receptors	O
and	O
had	O
a	O
D	O
(	O
2	O
)	O
/	O
D	O
(	O
4	O
)	O
ratio	O
approximating	O
that	O
of	O
clozapine	O
;	O
they	O
proved	O
inactive	O
in	O
behavioral	O
tests	O
of	O
antipsychotic	O
activity	O
.	O

A	O
series	O
of	O
eight	O
previously	O
undescribed	O
2,4	I-IUPAC
-	I-IUPAC
diaminothieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
analogues	I-MODIFIER
of	O
the	O
potent	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
inhibitors	O
trimetrexate	O
(	O
TMQ	O
)	O
and	O
piritrexim	O
(	O
PTX	O
)	O
were	O
synthesized	O
as	O
potential	O
drugs	O
against	O
Pneumocystis	O
carinii	O
and	O
Toxoplasma	O
gondii	O
,	O
which	O
are	O
major	O
causes	O
of	O
severe	O
opportunistic	O
infections	O
in	O
AIDS	O
patients	O
.	O

2,4	I-IUPAC
-	I-IUPAC
Diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aryl	I-IUPAC
/	I-IUPAC
aralkyl	I-IUPAC
)	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
with	O
3,4,5	I-IUPAC
-	I-IUPAC
trimethoxy	I-IUPAC
or	O
2,5	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
substitution	I-MODIFIER
in	O
the	O
aryl	O
/	O
aralkyl	O
moiety	O
and	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aryl	I-IUPAC
/	I-IUPAC
aralkyl	I-IUPAC
)	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
with	O
2,5	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
substitution	I-MODIFIER
in	O
the	O
aryl	O
/	O
aralkyl	O
moiety	O
were	O
obtained	O
by	O
reaction	O
of	O
the	O
corresponding	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyanothiophenes	I-IUPAC
with	O
chloroformamidine	O
hydrochloride	O
.	O

The	O
aryl	O
group	O
in	O
the	O
5,6	O
-	O
disubstituted	O
analogues	O
was	O
either	O
attached	O
directly	O
to	O
the	O
hetero	O
ring	O
or	O
was	O
separated	O
from	O
it	O
by	O
one	O
or	O
two	O
carbons	O
,	O
whereas	O
the	O
aryl	O
group	O
in	O
the	O
5	O
-	O
monosubstituted	O
analogues	O
was	O
separated	O
from	O
the	O
hetero	O
ring	O
by	O
two	O
or	O
three	O
carbons	O
.	O

2	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aryl	I-IUPAC
/	I-IUPAC
alkyl	I-IUPAC
)	I-IUPAC
thiophene	I-IUPAC
intermediates	O
for	O
the	O
preparation	O
of	O
the	O
5,6	O
-	O
disubstituted	O
analogues	O
were	O
prepared	O
from	O
omega	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
alkylidene	I-IUPAC
-	I-IUPAC
malononitriles	I-IUPAC
and	O
sulfur	O
in	O
the	O
presence	O
of	O
a	O
secondary	O
amine	O
,	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aryl	I-IUPAC
/	I-IUPAC
aralkyl	I-IUPAC
)	I-IUPAC
thiophene	I-IUPAC
intermediates	I-MODIFIER
for	O
the	O
preparation	O
of	O
the	O
5	O
-	O
monosubstituted	O
analogues	O
were	O
obtained	O
from	O
omega	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
alkylidenemalononitriles	I-IUPAC
and	O
sodium	O
hydrosulfide	O
.	O

Synthetic	O
routes	O
to	O
the	O
heretofore	O
unknown	O
ylidenemalononitriles	O
,	O
and	O
the	O
ketone	O
precursors	O
thereof	O
,	O
were	O
developed	O
.	O

The	O
final	O
products	O
were	O
tested	O
in	O
vitro	O
as	O
inhibitors	O
of	O
DHFR	O
from	O
Pneumocystis	O
carinii	O
,	O
Toxoplasma	O
gondii	O
,	O
rat	O
liver	O
,	O
beef	O
liver	O
,	O
and	O
Lactobacillus	O
casei	O
.	O

A	O
selected	O
number	O
of	O
previously	O
known	O
2,4	I-IUPAC
-	I-IUPAC
diaminothieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
lacking	O
the	O
3,4,5	I-IUPAC
-	I-IUPAC
trimethoxyphenyl	I-IUPAC
and	O
2,5	I-IUPAC
-	I-IUPAC
dimethoxyphenyl	I-IUPAC
substitution	I-MODIFIER
pattern	I-MODIFIER
of	O
TMQ	O
and	O
PTX	O
,	O
respectively	O
,	O
were	O
also	O
tested	O
for	O
comparison	O
.	O

None	O
of	O
the	O
compounds	O
was	O
as	O
potent	O
as	O
TMQ	O
or	O
PTX	O
,	O
and	O
while	O
some	O
of	O
them	O
showed	O
some	O
selectivity	O
in	O
their	O
binding	O
to	O
Pneumocystis	O
carinii	O
and	O
Toxoplasma	O
gondii	O
versus	O
rat	O
liver	O
DHFR	O
,	O
this	O
effect	O
was	O
not	O
deemed	O
large	O
enough	O
to	O
warrant	O
further	O
preclinical	O
evaluation	O
.	O

Extensive	O
evidence	O
gathered	O
from	O
structure	O
-	O
activity	O
relationship	O
analysis	O
has	O
identified	O
and	O
confirmed	O
specific	O
positions	O
in	O
the	O
glucagon	O
sequence	O
that	O
are	O
important	O
either	O
for	O
binding	O
to	O
its	O
receptor	O
or	O
for	O
signal	O
transduction	O
.	O

Fifteen	O
glucagon	O
analogues	O
have	O
been	O
designed	O
and	O
synthesized	O
by	O
incorporating	O
structural	O
changes	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
glucagon	O
,	O
in	O
particular	O
histidine	O
-	O
1	O
,	O
phenylalanine	O
-	O
6	O
,	O
and	O
aspartic	O
acid	O
-	O
9	O
.	O

This	O
investigation	O
was	O
conducted	O
to	O
study	O
the	O
role	O
of	O
phenylalanine	O
at	O
position	O
6	O
on	O
the	O
glucagon	O
mechanism	O
of	O
action	O
.	O

These	O
glucagon	O
analogues	O
have	O
been	O
made	O
by	O
either	O
deleting	O
or	O
substituting	O
hydrophobic	O
groups	O
,	O
hydrophilic	O
groups	O
,	O
aromatic	O
amino	O
acids	O
,	O
or	O
a	O
D	O
-	O
phenylalanine	O
residue	O
at	O
this	O
position	O
.	O

The	O
structures	O
of	O
the	O
new	O
analogues	O
are	O
as	O
follows	O
:	O
[	O
des	O
-	O
His1	O
,	O
des	O
-	O
Phe6	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
1	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
Ala6	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
2	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
Tyr6	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
3	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
Trp6	O
,	O
Glu9	O
]	O
-	O
glucagon	O
-	O
NH2	O
(	O
4	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
D	O
-	O
Phe6	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
5	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
Nle6	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
6	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
Asp6	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
7	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
des	O
-	O
Gly4	O
,	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
8	O
)	O
;	O
[	O
desPhe6	O
,	O
-	O
Glu9	O
]	O
glucagon	O
-	O
NH2	O
(	O
9	O
)	O
;	O
[	O
des	O
-	O
Phe6	O
]	O
glucagon	O
-	O
NH2	O
(	O
10	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
des	O
-	O
Phe6	O
]	O
glucagon	O
-	O
NH2	O
(	O
11	O
)	O
;	O
[	O
des	O
-	O
His1	O
,	O
des	O
-	O
Phe6	O
,	O
Glu9	O
]	O
glucagon	O
(	O
12	O
)	O
;	O
[	O
des	O
-	O
Phe6	O
,	O
Glu9	O
]	O
glucagon	O
(	O
13	O
)	O
;	O
[	O
des	O
-	O
Phe6	O
]	O
glucagon	O
(	O
14	O
)	O
;	O
and	O
[	O
des	O
-	O
His1	O
,	O
des	O
-	O
Phe6	O
]	O
glucagon	O
(	O
15	O
)	O
.	O

The	O
receptor	O
binding	O
potencies	O
IC50	O
values	O
are	O
48	O
(	O
1	O
)	O
,	O
126	O
(	O
2	O
)	O
,	O
40	O
(	O
3	O
)	O
,	O
19	O
(	O
4	O
)	O
,	O
100	O
(	O
5	O
)	O
,	O
48	O
(	O
6	O
)	O
,	O
2000	O
(	O
7	O
)	O
,	O
52	O
(	O
8	O
)	O
,	O
113	O
(	O
9	O
)	O
,	O
512	O
(	O
10	O
)	O
,	O
128	O
(	O
11	O
)	O
,	O
1000	O
(	O
12	O
)	O
,	O
2000	O
(	O
13	O
)	O
,	O
500	O
(	O
14	O
)	O
,	O
and	O
200	O
nM	O
(	O
15	O
)	O
.	O

All	O
analogues	O
were	O
found	O
to	O
be	O
antagonists	O
unable	O
to	O
activate	O
the	O
adenylate	O
cyclase	O
system	O
even	O
at	O
concentrations	O
as	O
high	O
as	O
10	O
(	O
-	O
5	O
)	O
M	O
except	O
for	O
analogues	O
6	O
and	O
8	O
,	O
which	O
were	O
found	O
to	O
be	O
weak	O
partial	O
agonists	O
/	O
partial	O
antagonists	O
with	O
maximum	O
stimulation	O
between	O
6-12%	O
.	O

In	O
competitive	O
inhibition	O
experiments	O
,	O
all	O
the	O
analogues	O
caused	O
a	O
right	O
shift	O
of	O
the	O
glucagon	O
-	O
stimulated	O
adenylate	O
cyclase	O
dose	O
-	O
response	O
curve	O
.	O

The	O
pA2	O
values	O
were	O
8.20	O
(	O
1	O
)	O
,	O
6.40	O
(	O
2	O
)	O
,	O
6.20	O
(	O
3	O
)	O
,	O
6.25	O
(	O
4	O
)	O
,	O
6.30	O
(	O
5	O
)	O
,	O
6.30	O
(	O
7	O
)	O
,	O
6.05	O
(	O
8	O
)	O
,	O
6.20	O
(	O
9	O
)	O
,	O
6.30	O
(	O
10	O
)	O
,	O
6.25	O
(	O
11	O
)	O
,	O
6.10	O
(	O
12	O
)	O
,	O
6.20	O
(	O
13	O
)	O
,	O
6.20	O
(	O
14	O
)	O
,	O
and	O
6.35	O
(	O
15	O
)	O
.	O

A	O
convenient	O
synthesis	O
of	O
8	O
-	O
azapurine	O
ribonucleosides	O
substituted	O
at	O
the	O
6	O
position	O
with	O
thio	I-IUPAC
,	O
alkylthio	I-IUPAC
,	O
alkoxy	I-IUPAC
,	O
amino	I-IUPAC
,	O
and	O
alkylamino	I-IUPAC
groups	B-MODIFIER
is	O
described	O
.	O

The	O
reaction	O
of	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
azapurine	I-IUPAC
(	O
1	O
)	O
with	O
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
chloride	I-IUPAC
in	O
the	O
presence	O
of	O
Linde	O
AW	O
-	O
500	O
molecular	O
sieve	O
gave	O
a	O
2	O
:	O
1	O
mixture	O
of	O
2	O
and	O
3	O
,	O
respectively	O
.	O

This	O
mixture	O
was	O
rearranged	O
by	O
heating	O
with	O
molecular	O
sieve	O
in	O
refluxing	O
toluene	O
to	O
give	O
a	O
6	O
:	O
1	O
mixture	O
of	O
2	O
and	O
3	O
.	O

Treatment	O
of	O
2	O
or	O
3	O
with	O
the	O
appropriate	O
nucleophiles	O
at	O
room	O
temperature	O
gave	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
8	I-IUPAC
-	I-IUPAC
azapurine	I-IUPAC
ribonucleosides	I-IUPAC
(	O
7	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	I-PARTIUPAC
-	I-PARTIUPAC
or	O
3	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
1,2,3	I-IUPAC
-	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
)	O
4-13	O
.	O

The	O
thione	O
11	O
rearranges	O
to	O
N	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
[	I-IUPAC
1,2,3	I-IUPAC
]	I-IUPAC
thiadiazolo	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
14	O
)	O
in	O
the	O
solid	O
state	O
or	O
in	O
solution	O
.	O

All	O
of	O
these	O
compounds	O
were	O
cytotoxic	O
to	O
H	O
.	O

Ep	O
.	O

No	O
.	O

2	O
cells	O
in	O
culture	O
except	O
the	O
parent	O
base	O
,	O
8	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
purine	I-IUPAC
(	O
1	O
)	O
and	O
the	O
8	O
-	O
isomers	O
(	O
3,12	O
,	O
and	O
13	O
)	O
.	O

Three	O
of	O
these	O
compounds	O
-	O
8azaadenosine	I-IUPAC
(	O
4	O
)	O
,	O
8	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
purine	I-IUPAC
ribonucleoside	I-IUPAC
(	O
5	O
)	O
,	O
and	O
8	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methoxy	I-IUPAC
)	I-IUPAC
purine	I-IUPAC
ribonucleoside	I-IUPAC
(	O
7	O
)	O
-	O
showed	O
borderline	O
activity	O
in	O
the	O
leukemia	O
L1210	O
system	O
.	O

The	O
thiadiazolopyrimidine	O
(	O
14	O
)	O
showed	O
activity	O
at	O
three	O
dose	O
levels	O
.	O

The	O
synthesis	O
and	O
pharmacological	O
properties	O
of	O
several	O
racemic	I-MODIFIER
6,7,8,9	B-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzazepine	I-IUPAC
-	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
diones	I-IUPAC
(	O
THHBADs	O
)	O
are	O
described	O
.	O

Synthesis	O
was	O
accomplished	O
via	O
a	O
Schmidt	O
reaction	O
with	O
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxynaphthalene	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diones	I-IUPAC
(	O
THMNDs	O
)	O
followed	O
by	O
demethylation	O
.	O

THMNDs	O
were	O
prepared	O
via	O
a	O
Diels	O
-	O
Alder	O
reaction	O
with	O
2	I-IUPAC
-	I-IUPAC
methoxybenzoquinone	I-IUPAC
(	O
5	O
)	O
or	O
2	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxybenzoquinone	I-IUPAC
(	O
14	O
)	O
and	O
substituted	I-MODIFIER
1,3	B-IUPAC
-	I-IUPAC
butadienes	I-IUPAC
.	O

The	O
pharmacology	O
of	O
THHBADs	O
was	O
characterized	O
by	O
electrical	O
recordings	O
in	O
Xenopus	O
oocytes	O
expressing	O
rat	O
brain	O
NMDA	O
and	O
AMPA	O
receptors	O
.	O

THHBADs	O
are	O
antagonists	O
of	O
NMDA	O
and	O
AMPA	O
receptors	O
with	O
functional	O
potency	O
being	O
dependent	O
upon	O
the	O
substitution	O
pattern	O
on	O
the	O
tetrahydrobenzene	O
moiety	O
.	O

The	O
7,8	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
(	O
18a	O
)	O
and	O
7,8	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
(	O
18b	O
)	O
analogs	I-MODIFIER
are	O
the	O
most	O
potent	O
THHBADs	O
prepared	O
and	O
have	O
apparent	O
antagonist	O
dissociation	O
constants	O
(	O
Kb	O
values	O
)	O
of	O
0.0041	O
and	O
0.0028	O
microM	O
,	O
respectively	O
,	O
for	O
NMDA	O
receptors	O
and	O
0.51	O
and	O
0.72	O
microM	O
,	O
respectively	O
,	O
for	O
AMPA	O
receptors	O
.	O

Several	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
arylalkylpolyamines	I-IUPAC
containing	O
various	O
aromatic	O
ring	O
systems	O
were	O
synthesized	O
as	O
their	O
respective	O
HCl	O
salts	O
.	O

The	O
N	O
(	O
1	O
)	O
-	O
substituents	O
evaluated	O
ranged	O
in	O
size	O
from	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
naphthalen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
naphthalen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
naphthalen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
anthracen	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
anthracen	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
,	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
anthracen	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
,	O
and	O
pyren	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
.	O

The	O
polyamine	O
architecture	O
was	O
also	O
altered	O
and	O
ranged	O
from	O
diamine	O
to	O
triamine	O
and	O
tetraamine	O
systems	O
.	O

Biological	O
activities	O
in	O
L1210	O
(	O
murine	O
leukemia	O
)	O
,	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
,	O
and	O
CHO	O
's	O
polyamine	O
transport	O
-	O
deficient	O
mutant	O
(	O
CHO	O
-	O
MG	O
)	O
cell	O
lines	O
were	O
investigated	O
via	O
IC	O
(	O
50	O
)	O
cytotoxicity	O
determinations	O
.	O

K	O
(	O
i	O
)	O
values	O
for	O
spermidine	O
uptake	O
were	O
also	O
determined	O
in	O
L1210	O
cells	O
.	O

The	O
size	O
of	O
the	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
arylalkyl	I-IUPAC
substituent	I-MODIFIER
as	O
well	O
as	O
the	O
polyamine	O
sequence	O
used	O
had	O
direct	O
bearing	O
on	O
the	O
observed	O
cytotoxicity	O
profiles	O
.	O

N	O
(	O
1	O
)	O
-	O
Tethers	O
longer	O
than	O
ethylene	O
showed	O
dramatic	O
loss	O
of	O
selectivity	O
for	O
the	O
polyamine	O
transporter	O
(	O
PAT	O
)	O
as	O
shown	O
in	O
a	O
CHO	O
/	O
CHO	O
-	O
MG	O
cytotoxicity	O
screen	O
.	O

In	O
summary	O
,	O
there	O
are	O
clear	O
limits	O
to	O
the	O
size	O
of	O
N	O
(	O
1	O
)	O
-	O
substituents	O
,	O
which	O
can	O
be	O
accommodated	O
by	O
the	O
polyamine	O
transporter	O
.	O

A	O
direct	O
correlation	O
was	O
observed	O
between	O
polyamine	O
-	O
conjugate	O
uptake	O
and	O
cytotoxicity	O
.	O

In	O
this	O
regard	O
,	O
a	O
cytotoxicity	O
model	O
was	O
proposed	O
,	O
which	O
describes	O
a	O
hydrophobic	O
pocket	O
of	O
set	O
dimensions	O
adjacent	O
to	O
the	O
putative	O
PAT	O
polyamine	O
-	O
binding	O
site	O
.	O

A	O
variety	O
of	O
amine	O
complexes	O
with	O
1	I-IUPAC
-	I-IUPAC
boraadamatane	I-IUPAC
were	O
synthesized	O
and	O
subsequently	O
evaluated	O
for	O
an	O
antiproliferative	O
effect	O
on	O
CD81	O
-	O
enriched	O
cell	O
lines	O
to	O
provide	O
evidence	O
for	O
binding	O
and	O
activation	O
of	O
CD81	O
.	O

CD81	O
is	O
a	O
member	O
of	O
the	O
tetraspanin	O
family	O
of	O
membrane	O
proteins	O
found	O
in	O
all	O
cell	O
lineages	O
in	O
the	O
liver	O
.	O

CD81	O
signals	O
for	O
antiproliferation	O
when	O
bound	O
by	O
antibodies	O
.	O

It	O
is	O
known	O
that	O
the	O
HCV	O
-	O
E2	O
envelope	O
glycoprotein	O
binds	O
to	O
the	O
CD81	O
protein	O
.	O

While	O
it	O
is	O
unclear	O
whether	O
virus	O
entry	O
into	O
host	O
cells	O
is	O
directly	O
linked	O
to	O
virus	O
attachment	O
via	O
CD81	O
for	O
HCV	O
,	O
this	O
step	O
in	O
the	O
viral	O
life	O
cycle	O
has	O
recently	O
proven	O
to	O
be	O
an	O
effective	O
point	O
of	O
attack	O
for	O
other	O
viruses	O
including	O
HIV	O
and	O
rhinoviruses	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
concerns	O
the	O
synthesis	O
of	O
amantidine	O
analogues	O
by	O
appending	O
primary	O
amines	O
to	O
1	I-IUPAC
-	I-IUPAC
boraadamantane	I-IUPAC
to	O
evaluate	O
such	O
compounds	O
for	O
CD81	O
-	O
dependent	O
antiproliferation	O
of	O
CD81	O
-	O
enriched	O
cell	O
lines	O
(	O
astrocyte	O
)	O
vs	O
CD81	O
-	O
deficient	O
cell	O
lines	O
(	O
C6	O
glioma	O
)	O
.	O

If	O
the	O
antiproliferative	O
effect	O
of	O
these	O
amantidine	O
analogues	O
proves	O
to	O
be	O
an	O
effect	O
of	O
binding	O
and	O
activating	O
CD81	O
,	O
then	O
these	O
compounds	O
may	O
have	O
the	O
potential	O
to	O
prevent	O
or	O
treat	O
HCV	O
infections	O
.	O

Each	O
compound	O
's	O
potential	O
for	O
preventive	O
and	O
therapeutic	O
activity	O
stems	O
from	O
the	O
compound	O
's	O
potential	O
to	O
block	O
viral	O
attachment	O
,	O
virus	O
-	O
cell	O
fusion	O
,	O
or	O
virus	O
entry	O
into	O
host	O
cells	O
or	O
to	O
counter	O
potential	O
mechanisms	O
of	O
HCV	O
immune	O
evasion	O
.	O

Out	O
of	O
a	O
library	O
of	O
over	O
500	O
compounds	O
,	O
including	O
randomly	O
selected	O
small	O
molecules	O
and	O
rationally	O
designed	O
small	O
molecules	O
,	O
only	O
the	O
1	I-IUPAC
-	I-IUPAC
boraadamantaneamine	I-IUPAC
compounds	I-MODIFIER
and	O
structurally	O
similar	O
analogues	O
display	O
a	O
significant	O
antiproliferative	O
effect	O
on	O
the	O
CD81	O
-	O
enriched	O
astrocytes	O
relative	O
to	O
the	O
CD81	O
-	O
deficient	O
cell	O
lines	O
.	O

In	O
fact	O
,	O
1	I-IUPAC
-	I-IUPAC
boraadamantane	I-IUPAC
.	I-IUPAC

l	I-IUPAC
-	I-IUPAC
phenylalanine	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
complex	I-MODIFIER
(	O
5	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
boraadamantane	I-IUPAC
.	I-IUPAC

ethanolamine	I-IUPAC
complex	I-MODIFIER
(	O
8	O
)	O
,	O
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
adamantane	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylpropionic	I-IUPAC
acid	I-IUPAC
(	O
15	O
)	O
show	O
a	O
dose	O
-	O
dependent	O
,	O
astrocyte	O
-	O
selective	O
antiproliferative	O
activity	O
in	O
the	O
concentration	O
range	O
0.1-10	O
microM	O
.	O

This	O
is	O
consistent	O
with	O
the	O
binding	O
and	O
activation	O
of	O
CD81	O
and	O
represents	O
a	O
2	O
-	O
fold	O
improvement	O
compared	O
to	O
the	O
clinically	O
prescribed	O
anti	O
-	O
HCV	O
agent	O
,	O
amantidine	O
,	O
in	O
the	O
same	O
concentration	O
range	O
.	O

Consequently	O
,	O
the	O
1	I-IUPAC
-	I-IUPAC
boraadamantaneamine	I-IUPAC
derivatives	I-MODIFIER
present	O
a	O
promising	O
lead	O
in	O
the	O
development	O
of	O
small	O
molecules	O
with	O
potential	O
to	O
bind	O
to	O
CD81	O
and	O
treat	O
HCV	O
infections	O
.	O

A	O
broad	O
structure	O
-	O
activity	O
program	O
was	O
undertaken	O
in	O
search	O
of	O
effective	O
surrogates	O
for	O
the	O
key	O
benzothiazole	O
side	O
chain	O
of	O
the	O
potent	O
aldose	O
reductase	O
inhibitor	O
,	O
zopolrestat	O
(	O
1	O
)	O
.	O

A	O
structure	O
-	O
driven	O
approach	O
was	O
pursued	O
,	O
which	O
spanned	O
exploration	O
of	O
three	O
areas	O
:	O
(	O
1	O
)	O
5/6	O
fused	O
heterocycles	O
such	O
as	O
benzoxazole	O
,	O
benzothiophene	O
,	O
benzofuran	O
,	O
and	O
imidazopyridine	O
;	O
(	O
2	O
)	O
5	O
-	O
membered	O
heterocycles	O
,	O
including	O
oxadiazole	O
,	O
oxazole	O
,	O
thiazole	O
,	O
and	O
thiadiazole	O
,	O
with	O
pendant	O
aryl	O
groups	O
,	O
and	O
(	O
3	O
)	O
thioanilide	O
as	O
a	O
formal	O
equivalent	O
of	O
benzothiazole	O
.	O

Several	O
benzoxazole	I-IUPAC
-	O
and	O
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
-	O
derived	O
analogues	I-MODIFIER
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
aldose	O
reductase	O
from	O
human	O
placenta	O
and	O
were	O
orally	O
active	O
in	O
preventing	O
sorbitol	O
accumulation	O
in	O
rat	O
sciatic	O
nerve	O
,	O
in	O
an	O
acute	O
test	O
of	O
diabetic	O
complications	O
.	O

3,4	I-IUPAC
-	I-IUPAC
Dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
difluoro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzoxazolyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phthalazineacetic	I-IUPAC
acid	I-IUPAC
(	O
124	O
)	O
was	O
the	O
best	O
of	O
the	O
benzoxazole	O
series	O
(	O
IC50	O
=	O
3.2	O
x	O
10	O
(	O
-	O
9	O
)	O
M	O
)	O
;	O
it	O
suppressed	O
accumulation	O
of	O
sorbitol	O
in	O
rat	O
sciatic	O
nerve	O
by	O
78%	O
at	O
an	O
oral	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
.	O

Compound	O
139	O
,	O
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phthalazineacetic	I-IUPAC
acid	I-IUPAC
,	O
with	O
IC50	O
less	O
than	O
1.0	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
caused	O
a	O
69%	O
reduction	O
in	O
sorbitol	O
accumulation	O
in	O
rat	O
sciatic	O
nerve	O
at	O
an	O
oral	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
.	O

The	O
thioanilide	O
side	O
chain	O
featured	O
in	O
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thioxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phthalazineacetic	I-IUPAC
acid	I-IUPAC
(	O
195	O
)	O
proved	O
to	O
be	O
an	O
effective	O
surrogate	O
for	O
benzothiazole	O
.	O

Compound	O
195	O
was	O
highly	O
potent	O
in	O
vitro	O
(	O
IC50	O
=	O
5.2	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
but	O
did	O
not	O
show	O
oral	O
activity	O
when	O
tested	O
at	O
100	O
mg	O
/	O
kg	O
.	O

Additional	O
structure	O
-	O
activity	O
relationships	O
encompassing	O
a	O
variety	O
of	O
heterocyclic	O
side	O
chains	O
are	O
discussed	O
.	O

9,11	O
-	O
Secoestradiol	O
(	O
9	O
)	O
and	O
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
9,11	I-IUPAC
-	I-IUPAC
secoestradiol	I-IUPAC
(	O
12	O
)	O
have	O
been	O
synthesized	O
starting	O
from	O
17	I-IUPAC
-	I-IUPAC
acetoxyestradiol	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
ether	I-IUPAC
(	O
1	O
)	O
and	O
found	O
to	O
possess	O
significant	O
antifertility	O
activity	O
in	O
rats	O
.	O

3	I-IUPAC
-	I-IUPAC
Methoxy	I-IUPAC
-	I-IUPAC
9,11	I-IUPAC
-	I-IUPAC
seco	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
17beta	I-IUPAC
-	I-IUPAC
acetoxyestra	I-IUPAC
-	I-IUPAC
1,3,5	I-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trien	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
oic	I-IUPAC
acid	I-IUPAC
(	O
2	O
)	O
,	O
prepared	O
by	O
CrO3	O
oxidation	O
of	O
1	O
,	O
on	O
hydrogenolysis	O
gave	O
methyl	I-IUPAC
17beta	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
9,11	I-IUPAC
-	I-IUPAC
secoestra	I-IUPAC
-	I-IUPAC
1,3,5	I-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
triene	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
3	O
)	O
.	O

The	O
17	O
-	O
O	O
-	O
THP	O
derivative	O
of	O
3	O
was	O
treated	O
with	O
LiAlH4	O
to	O
give	O
17beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tetrahydropyranyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
9,11	I-IUPAC
-	I-IUPAC
secoestra	I-IUPAC
-	I-IUPAC
1,3,5	I-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
triene	I-IUPAC
(	O
5	O
)	O
.	O

The	O
11	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
mesylate	I-IUPAC
of	O
5	O
on	O
LiAlH4	O
reduction	O
followed	O
by	O
mild	O
acid	O
treatment	O
and	O
demethylation	O
under	O
alkaline	O
conditions	O
gave	O
9	O
.	O

LiAlH4	O
reduction	O
of	O
3	O
gave	O
9,11	I-IUPAC
-	I-IUPAC
seco	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxyestradiol	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
ether	I-IUPAC
(	O
11	O
)	O
which	O
on	O
demethylation	O
gave	O
9,11	I-IUPAC
-	I-IUPAC
seco	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxyestradiol	I-IUPAC
(	O
12	O
)	O
.	O

Previously	O
we	O
have	O
reported	O
the	O
discovery	O
of	O
ABT	O
-	O
627	O
(	O
1	O
,	O
A	O
-	O
147627	O
,	O
active	O
enantiomer	O
of	O
A	O
-	O
127722	O
)	O
,	O
a	O
2,4	I-IUPAC
-	I-IUPAC
diaryl	I-IUPAC
substituted	I-MODIFIER
pyrrolidine	B-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
based	O
endothelin	O
receptor	O
-	O
A	O
antagonist	O
.	O

This	O
compound	O
binds	O
to	O
the	O
ETA	O
receptor	O
with	O
an	O
affinity	O
(	O
Ki	O
)	O
of	O
0	O
.	O

034	O
nM	O
and	O
with	O
a	O
2000	O
-	O
fold	O
selectivity	O
for	O
the	O
ETA	O
receptor	O
versus	O
the	O
ETB	O
receptor	O
.	O

We	O
have	O
expanded	O
our	O
structure	O
-	O
activity	O
studies	O
in	O
this	O
series	O
,	O
in	O
an	O
attempt	O
to	O
further	O
increase	O
the	O
ETA	O
selectivity	O
.	O

When	O
the	O
p	O
-	O
anisyl	O
group	O
of	O
1	O
was	O
replaced	O
by	O
an	O
n	O
-	O
pentyl	O
group	O
,	O
the	O
resultant	O
antagonist	O
3	O
exhibited	O
substantially	O
increased	O
ETB	O
/	O
ETA	O
activity	O
ratio	O
,	O
but	O
a	O
decreased	O
ETA	O
affinity	O
.	O

Structure	O
-	O
activity	O
studies	O
revealed	O
that	O
substitution	O
and	O
geometry	O
of	O
this	O
alkyl	O
group	O
,	O
and	O
substitution	O
on	O
the	O
benzodioxolyl	O
ring	O
,	O
are	O
important	O
in	O
optimizing	O
this	O
series	O
of	O
highly	O
ETA	O
selective	O
antagonists	O
.	O

In	O
particular	O
,	O
the	O
combination	O
of	O
a	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pentenyl	I-IUPAC
group	I-MODIFIER
and	O
a	O
7	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
benzodioxol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
group	I-MODIFIER
provided	O
hydrophobic	O
compound	O
10b	O
with	O
subnanomolar	O
affinity	O
for	O
human	O
ETA	O
receptor	O
subtype	O
and	O
with	O
an	O
ETB	O
/	O
ETA	O
activity	O
ratio	O
of	O
over	O
130000	O
.	O

Meanwhile	O
,	O
synthetic	O
efforts	O
en	O
route	O
to	O
olefinic	O
compounds	O
led	O
to	O
the	O
discovery	O
that	O
2	I-IUPAC
-	I-IUPAC
pyridylethyl	I-IUPAC
(	O
9o	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopyrrolidinyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
(	O
9u	O
)	O
replacement	I-MODIFIER
of	O
the	O
p	O
-	O
anisyl	O
group	O
of	O
1yielded	O
very	O
hydrophilic	O
ETA	O
antagonists	O
with	O
potency	O
and	O
selectivity	O
equal	O
to	O
those	O
of	O
10b	O
.	O

On	O
the	O
basis	O
of	O
overall	O
superior	O
affinity	O
,	O
high	O
selectivity	O
for	O
the	O
ETA	O
receptor	O
(	O
Ki	O
,	O
0.46	O
nM	O
for	O
ETA	O
and	O
13000	O
nM	O
for	O
ETB	O
)	O
,	O
and	O
good	O
oral	O
bioavailability	O
(	O
48%	O
in	O
rats	O
)	O
,	O
A	O
-	O
216546	O
(	O
10a	O
)	O
was	O
selected	O
as	O
a	O
potential	O
clinical	O
backup	O
for	O
1	O
.	O

The	O
stereochemical	O
diversity	O
-	O
oriented	O
conformational	O
restriction	O
strategy	O
can	O
be	O
an	O
efficient	O
method	O
for	O
developing	O
specific	O
ligands	O
for	O
drug	O
target	O
proteins	O
,	O
especially	O
in	O
cases	O
where	O
neither	O
the	O
bioactive	O
conformation	O
nor	O
the	O
pharmacophore	O
is	O
known	O
.	O

To	O
develop	O
potent	O
H3	O
and	O
H4	O
receptor	O
antagonists	O
,	O
a	O
series	O
of	O
conformationally	O
restricted	O
analogues	O
of	O
histamine	O
with	O
a	O
chiral	I-MODIFIER
cis	B-PARTIUPAC
-	I-PARTIUPAC
or	O
trans	I-IUPAC
-	I-IUPAC
cyclopropane	I-IUPAC
structure	I-MODIFIER
were	O
designed	O
on	O
the	O
basis	O
of	O
this	O
strategy	O
.	O

These	O
target	O
compounds	O
with	O
stereochemical	O
diversity	O
were	O
synthesized	O
from	O
the	O
versatile	O
chiral	O
cyclopropane	O
units	O
(	I-PARTIUPAC
1S	I-PARTIUPAC
,	I-PARTIUPAC
2R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyldiphenylsilyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
formylcyclopropane	I-IUPAC
(	O
6	O
and	O
7	O
,	O
respectively	O
)	O
or	O
their	O
enantiomers	O
ent	O
-	O
6	O
and	O
ent	O
-	O
7	O
.	O

Pharmacological	O
profiles	O
of	O
these	O
conformationally	O
restricted	O
analogues	O
were	O
shown	O
to	O
be	O
different	O
depending	O
on	O
the	O
cyclopropane	O
backbones	O
.	O

Among	O
the	O
analogues	I-MODIFIER
,	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorobenzylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
cyclopropane	I-IUPAC
(	O
11a	O
)	O
with	O
the	O
(	I-IUPAC
1R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
cyclopropane	I-IUPAC
structure	I-MODIFIER
has	O
remarkable	O
antagonistic	O
activity	O
to	O
both	O
the	O
H3	O
(	O
Ki	O
=	O
8.4	O
nM	O
)	O
and	O
H4	O
(	O
Ki	O
=	O
7.6	O
nM	O
)	O
receptors	O
.	O

The	O
enantiomer	O
of	O
11a	O
,	O
i.e.	O
,	O
ent	O
-	O
11a	O
,	O
with	O
the	O
(	I-IUPAC
1S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
cyclopropane	I-IUPAC
structure	I-MODIFIER
turned	O
out	O
to	O
be	O
a	O
highly	O
potent	O
and	O
selective	O
H3	O
receptor	O
antagonist	O
with	O
a	O
Ki	O
of	O
3.6	O
nM	O
.	O

Conversely	O
,	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorobenzylamino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
cyclopropane	I-IUPAC
(	O
10a	O
)	O
with	O
the	O
(	O
1R	O
)	O
-	O
trans	O
structure	O
was	O
selective	O
for	O
the	O
H4	O
receptor	O
(	O
Ki	O
=	O
118	O
nM	O
)	O
compared	O
to	O
the	O
H3	O
receptor	O
(	O
Ki	O
&	O
gt	O
;	O
10	O
(	O
3	O
)	O
nM	O
)	O
.	O

Thus	O
,	O
a	O
variety	O
of	O
compounds	O
with	O
different	O
pharmacological	O
profiles	O
have	O
been	O
developed	O
.	O

These	O
results	O
show	O
that	O
when	O
the	O
structure	O
of	O
the	O
target	O
protein	O
is	O
unknown	O
,	O
the	O
stereochemical	O
diversity	O
-	O
oriented	O
approach	O
can	O
be	O
a	O
powerful	O
strategy	O
in	O
medicinal	O
chemical	O
studies	O
.	O

A	O
series	O
of	O
dioxolane	O
analogues	I-MODIFIER
based	O
on	O
dexoxadrol	O
(	O
(	I-IUPAC
4S	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
diphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
)	O
and	O
etoxadrol	O
(	O
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
4S	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
)	O
were	O
prepared	O
and	O
tested	O
for	O
their	O
ability	O
to	O
displace	O
[	O
3H	O
]	O
TCP	O
(	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
piperidine	I-IUPAC
)	O
from	O
PCP	O
(	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylcyclohexyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
)	O
binding	O
sites	O
in	O
rat	O
brain	O
tissue	O
homogenates	O
.	O

Qualitative	O
structure	O
-	O
activity	O
relationships	O
within	O
this	O
series	O
were	O
explored	O
through	O
modifications	O
of	O
the	O
three	O
major	O
structural	O
units	O
of	O
dexoxadrol	O
,	O
the	O
piperidine	O
,	O
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
,	O
and	O
aromatic	O
rings	O
of	O
the	O
molecule	O
.	O

N	O
-	O
Alkyl	O
derivatives	O
of	O
dexoxadrol	O
were	O
found	O
to	O
be	O
inactive	O
,	O
as	O
were	O
those	O
analogues	O
where	O
the	O
dioxolane	O
ring	O
was	O
modified	O
.	O

Phenyl	O
-	O
substituted	O
etoxadrol	O
analogues	O
were	O
compared	O
to	O
similarly	O
substituted	O
PCP	O
analogues	O
and	O
distinct	O
differences	O
were	O
found	O
in	O
their	O
structure	O
-	O
activity	O
relationships	O
suggesting	O
that	O
the	O
aromatic	O
rings	O
in	O
these	O
two	O
drug	O
classes	O
interact	O
differently	O
with	O
the	O
PCP	O
binding	O
sites	O
.	O

The	O
replacement	O
of	O
the	O
phenyl	O
ring	O
in	O
etoxadrol	O
by	O
either	O
a	O
2	O
-	O
or	O
3	O
-	O
thienyl	O
ring	O
led	O
to	O
compounds	O
with	O
affinity	O
comparable	O
to	O
etoxadrol	O
,	O
and	O
the	O
replacement	O
of	O
the	O
ethyl	O
moiety	O
on	O
etoxadrol	O
's	O
dioxolane	O
ring	O
with	O
propyl	O
(	O
7	O
)	O
or	O
isopropyl	O
(	O
8	O
)	O
led	O
to	O
compounds	O
which	O
were	O
more	O
potent	O
than	O
etoxadrol	O
or	O
PCP	O
.	O

The	O
most	O
potent	O
compound	O
was	O
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
4S	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
(	O
11	O
)	O
,	O
where	O
a	O
chlorine	O
moiety	O
was	O
placed	O
in	O
the	O
ortho	O
position	O
in	O
the	O
aromatic	O
ring	O
of	O
etoxadrol	O
.	O

Its	O
potency	O
was	O
comparable	O
with	O
TCP	O
in	O
vitro	O
.	O

A	O
new	O
metabolic	O
pathway	O
of	O
terminal	O
hydroxylation	O
(	O
omega	O
-	O
hydroxylation	O
)	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
group	I-MODIFIER
of	O
propranolol	O
(	O
1	O
)	O
was	O
established	O
.	O

Selected	O
ion	O
-	O
monitoring	O
GC	O
-	O
MS	O
analysis	O
,	O
based	O
on	O
use	O
of	O
the	O
synthesized	O
mixture	O
of	O
diastereoisomers	O
of	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propanol	I-IUPAC
(	O
2	O
)	O
as	O
a	O
standard	O
,	O
established	O
formation	O
of	O
both	O
diastereoisomers	O
of	O
2	O
as	O
metabolites	O
of	O
1	O
.	O

These	O
diastereoisomers	O
were	O
formed	O
in	O
unequal	O
amounts	O
when	O
1	O
,	O
its	O
hexadeuterated	O
analogue	O
8	O
or	O
heptadeuterated	O
analogue	O
9	O
,	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
rat	O
liver	O
microsomal	O
fraction	O
.	O

Authentic	O
(	O
2R	O
,	O
2	O
"	O
S	O
)	O
-	O
2	O
,	O
obtained	O
from	O
the	O
amide	O
formed	O
from	O
(	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
2S	O
)	O
-	O
5	O
]	O
and	O
(	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alaninol	I-IUPAC
by	O
diborane	O
reduction	O
,	O
facilitated	O
examination	O
of	O
stereochemical	O
aspects	O
of	O
this	O
process	O
.	O

From	O
incubations	O
of	O
the	O
enantiomers	O
of	O
1	O
and	O
pseudoracemic	O
propranolol	O
[	O
equimolar	O
(	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
propranolol	I-IUPAC
-	I-IUPAC
3,3	I-IUPAC
-	I-IUPAC
d2	I-IUPAC
and	O
(	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
propranolol	I-IUPAC
-	I-IUPAC
d0	I-IUPAC
]	O
in	O
the	O
presence	O
of	O
the	O
rat	O
liver	O
microsomal	O
fraction	O
,	O
we	O
established	O
that	O
the	O
diastereomeric	O
products	O
were	O
formed	O
in	O
the	O
order	O
(	O
2S	O
,	O
2	O
"	O
S	O
)	O
-	O
2	O
approximately	O
equal	O
to	O
(	O
2S	O
,	O
2	O
"	O
R	O
)	O
-	O
2	O
greater	O
than	O
(	O
2R	O
,	O
2	O
"	O
R	O
)	O
-	O
2	O
greater	O
than	O
(	O
2R	O
,	O
2	O
"	O
S	O
)	O
-	O
2	O
.	O

(	O
2S	O
)	O
-	O
1	O
,	O
which	O
was	O
metabolized	O
to	O
2	O
to	O
a	O
greater	O
extent	O
than	O
(	O
2R	O
)	O
-	O
1	O
,	O
showed	O
no	O
stereoselectivity	O
,	O
affording	O
about	O
equal	O
amounts	O
of	O
(	O
2S	O
,	O
2	O
"	O
S	O
)	O
-	O
2	O
and	O
(	O
2S	O
,	O
2	O
"	O
R	O
)	O
-	O
2	O
.	O

(	O
2R	O
)	O
-	O
1	O
,	O
which	O
was	O
metabolized	O
to	O
2	O
to	O
a	O
lesser	O
extent	O
,	O
afforded	O
considerably	O
more	O
(	O
2R	O
,	O
2	O
"	O
R	O
)	O
-	O
2	O
than	O
(	O
2R	O
,	O
2	O
"	O
S	O
)	O
-	O
2	O
.	O

omega	O
-	O
Hydroxylation	O
was	O
a	O
minor	O
metabolic	O
pathway	O
in	O
the	O
microsomal	O
incubation	O
.	O

About	O
2000X	O
less	O
2	O
than	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propanol	I-IUPAC
(	O
3	O
)	O
,	O
the	O
product	O
of	O
N	O
-	O
dealkylation	O
of	O
1	O
,	O
was	O
formed	O
.	O

A	O
detailed	O
structure	O
-	O
activity	O
analysis	O
was	O
carried	O
out	O
using	O
eight	O
1	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
(	I-IUPAC
aralkyl	I-IUPAC
)	I-IUPAC
nipecotamides	I-IUPAC
(	O
type	O
5	O
)	O
,	O
33	O
bis	I-IUPAC
-	I-IUPAC
nipecotamidoalkanes	I-IUPAC
and	O
aralkanes	I-IUPAC
(	O
type	O
6	O
)	O
,	O
and	O
7	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
nipecotoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
piperazines	I-IUPAC
(	O
type	O
7	O
)	O
as	O
inhibitors	O
of	O
human	O
platelet	O
aggregation	O
.	O

Steric	O
factors	O
played	O
an	O
important	O
role	O
in	O
determining	O
the	O
activity	O
of	O
type	O
5	O
compounds	O
possessing	O
an	O
an	O
appropriate	O
degree	O
of	O
hydrophobic	O
character	O
.	O

Types	O
6	O
and	O
7	O
compounds	O
were	O
more	O
potent	O
than	O
the	O
corresponding	O
type	O
5	O
molecules	O
.	O

Hydrophobic	O
character	O
appeared	O
to	O
influence	O
the	O
activity	O
of	O
type	O
6	O
compounds	O
.	O

A	O
3	O
-	O
substituent	O
on	O
the	O
piperidine	O
ring	O
was	O
necessary	O
for	O
antiplatelet	O
activity	O
;	O
the	O
substituent	O
should	O
be	O
preferably	O
an	O
amide	O
with	O
its	O
C	O
attached	O
directly	O
to	O
the	O
ring	O
.	O

3,5	O
-	O
Disubstitution	O
and	O
2	O
-	O
substitution	O
led	O
to	O
a	O
decline	O
in	O
activity	O
.	O

Optimal	O
activity	O
was	O
attained	O
when	O
the	O
two	O
nipecotoyl	O
ring	O
N	O
atoms	O
were	O
connected	O
by	O
an	O
aralkyl	I-IUPAC
group	B-MODIFIER
,	O
and	O
separated	O
by	O
approximately	O
7	O
A	O
.	O

It	O
is	O
suggested	O
that	O
van	O
der	O
Waals	O
forces	O
and	O
pi	O
interactions	O
may	O
govern	O
the	O
inhibitor	O
-	O
platelet	O
interaction	O
.	O

The	O
most	O
potent	O
type	O
6	O
inhibitor	O
was	O
alpha	I-IUPAC
,	I-IUPAC
alpha	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
butylcarbamoyl	I-IUPAC
)	I-IUPAC
piperidino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
xylene	I-IUPAC
(	O
6i	O
)	O
.	O

The	O
most	O
potent	O
type	O
5	O
compound	O
was	O
1	I-IUPAC
-	I-IUPAC
decyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
diethylcarbamoyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
(	O
5a	O
)	O
.	O

Any	O
substitution	O
on	O
the	O
piperazine	O
ring	O
of	O
type	O
7	O
compounds	O
led	O
to	O
a	O
decline	O
in	O
activity	O
,	O
the	O
most	O
active	O
analog	I-MODIFIER
being	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
decylnipecotoyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
7a	O
)	O
.	O

It	O
is	O
suggested	O
that	O
nipecotamides	O
interact	O
with	O
anionic	O
platelet	O
sites	O
located	O
7	O
A	O
from	O
each	O
other	O
and	O
connected	O
by	O
a	O
hydrophobic	O
well	O
.	O

Synthesis	O
of	O
various	O
substituted	I-MODIFIER
5	B-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acids	I-IUPAC
and	O
their	O
derivatives	O
is	O
described	O
by	O
three	O
methods	O
,	O
i.e.	O
,	O
displacement	O
of	O
nitrite	O
from	O
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylate	I-IUPAC
(	O
10	O
)	O
by	O
a	O
thiol	O
anion	O
,	O
alkylation	O
of	O
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylate	I-IUPAC
derived	O
from	O
reaction	O
of	O
the	O
diazotized	I-MODIFIER
methyl	B-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylate	I-IUPAC
(	O
5	O
)	O
with	O
thiocyanate	O
followed	O
by	O
borohydride	O
reduction	O
of	O
the	O
product	O
,	O
and	O
alkylation	O
of	O
5	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarbonitrile	I-IUPAC
followed	O
by	O
hydrolysis	O
.	O

5	I-IUPAC
-	I-IUPAC
Thio	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarbonitrile	I-IUPAC
was	O
obtained	O
from	O
butyl	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
sulfoxide	I-IUPAC
(	O
2	O
)	O
by	O
nitrosation	O
and	O
dehydration	O
of	O
the	O
oxime	O
.	O

Many	O
of	O
these	O
5	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acid	I-IUPAC
derivatives	I-MODIFIER
were	O
orally	O
active	O
antihypertensive	O
agents	O
in	O
the	O
spontaneously	O
hypertensive	O
rat	O
.	O

Optimization	O
of	O
the	O
structural	O
parameters	O
for	O
this	O
activity	O
yiedled	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
m	I-IUPAC
-	I-IUPAC
trifluorobenzyl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
41	O
)	O
and	O
its	O
sulfoxide	O
,	O
42	O
.	O

Further	O
biological	O
studies	O
with	O
these	O
compounds	O
are	O
described	O
.	O

A	O
series	O
of	O
gallium	O
(	O
III	O
)	O
and	O
iron	O
(	O
III	O
)	O
complexes	O
with	O
five	O
different	O
4N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
alpha	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
heterocyclic	I-IUPAC
thiosemicarbazones	I-IUPAC
,	O
viz	O
.	O

,	O
2	I-IUPAC
-	I-IUPAC
acetylpyridine	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylthiosemicarbazone	I-IUPAC
(	O
1	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
acetylpyridine	I-IUPAC
N	I-IUPAC
-	I-IUPAC
pyrrolidinylthiosemicarbazone	I-IUPAC
(	O
2	O
)	O
,	O
acetylpyrazine	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylthiosemicarbazone	I-IUPAC
(	O
3	O
)	O
,	O
acetylpyrazine	I-IUPAC
N	I-IUPAC
-	I-IUPAC
pyrrolidinylthiosemicarbazone	I-IUPAC
(	O
4	O
)	O
,	O
and	O
acetylpyrazine	I-IUPAC
N	I-IUPAC
-	I-IUPAC
piperidinylthiosemicarbazone	I-IUPAC
(	O
5	O
)	O
,	O
with	O
the	O
general	O
formula	O
[	O
GaLCl2	O
]	O
(	O
HL	O
=	O
1	O
and	O
2	O
)	O
and	O
[	O
ML2	O
]	O
[	O
Y	O
]	O
(	O
M	O
=	O
Ga	O
,	O
HL	O
=	O
1-5	O
,	O
Y	O
=	O
PF6	O
;	O
M	O
=	O
Fe	O
,	O
HL	O
=	O
1-5	O
,	O
Y	O
=	O
FeCl4	O
and	O
PF6	O
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
elemental	O
analysis	O
,	O
a	O
number	O
of	O
spectroscopic	O
methods	O
(	O
NMR	O
,	O
IR	O
,	O
UV	O
-	O
vis	O
)	O
,	O
mass	O
spectrometry	O
,	O
and	O
X	O
-	O
ray	O
crystallography	O
.	O

The	O
in	O
vitro	O
antitumor	O
potency	O
was	O
studied	O
in	O
two	O
human	O
cancer	O
cell	O
lines	O
(	O
41M	O
and	O
SK	O
-	O
BR	O
-	O
3	O
)	O
.	O

The	O
central	O
metal	O
ions	O
exert	O
pronounced	O
effects	O
in	O
a	O
divergent	O
manner	O
:	O
gallium	O
(	O
III	O
)	O
enhances	O
,	O
whereas	O
iron	O
(	O
III	O
)	O
weakens	O
the	O
cytotoxicity	O
of	O
the	O
ligands	O
.	O

The	O
capacity	O
of	O
ligand	O
1	O
and	O
its	O
Ga	O
(	O
III	O
)	O
and	O
Fe	O
(	O
III	O
)	O
complexes	O
to	O
destroy	O
the	O
tyrosyl	O
radical	O
of	O
the	O
presumed	O
target	O
ribonucleotide	O
reductase	O
is	O
reported	O
.	O

The	O
synthesis	O
of	O
11	I-IUPAC
-	I-IUPAC
thiohomofolic	I-IUPAC
acid	I-IUPAC
(	O
2	O
)	O
has	O
been	O
accomplished	O
by	O
an	O
unambiguous	O
procedure	O
.	O

Reaction	O
of	O
1	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbomethoxy	I-IUPAC
)	I-IUPAC
thiophenoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butanone	I-IUPAC
(	O
10	O
)	O
with	O
hydroxylamine	O
under	O
carefully	O
controlled	O
conditions	O
gave	O
the	O
corresponding	O
oxime	O
33	O
.	O

Conversion	O
of	O
this	O
oxime	O
to	O
1	I-IUPAC
-	I-IUPAC
phthalimido	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbomethoxy	I-IUPAC
)	I-IUPAC
thiophenoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butanone	I-IUPAC
oxime	I-IUPAC
(	O
4	O
)	O
was	O
carried	O
out	O
by	O
its	O
reaction	O
with	O
potassium	O
phthalimide	O
using	O
crown	O
18	O
ether	O
as	O
a	O
catalyst	O
.	O

Hydrazinolysis	O
of	O
compound	O
4	O
gave	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbomethoxy	I-IUPAC
)	I-IUPAC
thiophenoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butanone	I-IUPAC
oxime	I-IUPAC
(	O
5	O
)	O
,	O
which	O
was	O
used	O
for	O
the	O
construction	O
of	O
the	O
title	O
compound	O
2	O
by	O
modification	O
of	O
the	O
Boon	O
and	O
Leigh	O
procedure	O
.	O

An	O
alternate	O
synthesis	O
utilizing	O
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbomethoxy	I-IUPAC
)	I-IUPAC
thiophenoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butanone	I-IUPAC
(	O
11	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2,5,6	I-IUPAC
-	I-IUPAC
triaminopyrimidine	I-IUPAC
has	O
also	O
been	O
carried	O
out	O
.	O

Compound	O
2	O
did	O
not	O
exhibit	O
any	O
antifolate	O
activity	O
against	O
Lactobacillus	O
casei	O
or	O
Streptococcus	O
faecium	O
.	O

The	O
dithionite	O
reduction	O
product	O
,	O
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
thiohomofolic	I-IUPAC
acid	I-IUPAC
,	O
was	O
able	O
to	O
function	O
as	O
a	O
substrate	O
of	O
L	O
.	O

casei	O
dihydrofolate	O
reductase	O
.	O

The	O
catalytic	O
reduction	O
product	O
of	O
2	O
,	O
consisting	O
of	O
a	O
mixture	O
of	O
diastereomers	O
,	O
exhibited	O
powerful	O
antifolate	O
activity	O
against	O
both	O
these	O
organisms	O
.	O

Preference	O
for	O
the	O
Northern	O
(	O
N	O
)	O
ring	O
conformation	O
of	O
the	O
ribose	O
moiety	O
of	O
nucleotide	O
5'	O
-	O
triphosphate	O
agonists	O
at	O
P2Y	O
(	O
1	O
)	O
,	O
P2Y	O
(	O
2	O
)	O
,	O
P2Y	O
(	O
4	O
)	O
,	O
and	O
P2Y	O
(	O
11	O
)	O
receptors	O
,	O
but	O
not	O
P2Y	O
(	O
6	O
)	O
receptors	O
,	O
was	O
established	O
using	O
a	O
ring	O
-	O
constrained	O
methanocarba	O
(	O
a	O
3.1.0	O
-	O
bicyclohexane	O
)	O
ring	O
as	O
a	O
ribose	O
substitute	O
(	O
Kim	O
et	O
al.	O
J	O
.	O

Med.	O
Chem.	O
2002	O
,	O
45	O
,	O
208-218	O
.	O

)	O
.	O

We	O
have	O
now	O
combined	O
the	O
ring	O
-	O
constrained	O
(	O
N	O
)	O
-	O
methanocarba	O
modification	O
of	O
adenine	O
nucleotides	O
with	O
other	O
functionalities	O
known	O
to	O
enhance	O
potency	O
at	O
P2	O
receptors	O
.	O

The	O
potency	O
of	O
the	O
newly	O
synthesized	O
analogues	O
was	O
determined	O
in	O
the	O
stimulation	O
of	O
phospholipase	O
C	O
through	O
activation	O
of	O
turkey	O
erythrocyte	O
P2Y	O
(	O
1	O
)	O
or	O
human	O
P2Y	O
(	O
1	O
)	O
and	O
P2Y	O
(	O
2	O
)	O
receptors	O
stably	O
expressed	O
in	O
astrocytoma	O
cells	O
.	O

An	O
(	I-IUPAC
N	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methanocarba	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylthio	I-IUPAC
-	I-IUPAC
ADP	I-IUPAC
analogue	I-MODIFIER
displayed	O
an	O
EC	O
(	O
50	O
)	O
at	O
the	O
hP2Y	O
(	O
1	O
)	O
receptor	O
of	O
0.40	O
nM	O
and	O
was	O
55	O
-	O
fold	O
more	O
potent	O
than	O
the	O
corresponding	O
triphosphate	O
and	O
16	O
-	O
fold	O
more	O
potent	O
than	O
the	O
riboside	O
5'	I-IUPAC
-	I-IUPAC
diphosphate	I-IUPAC
.	O

2	I-IUPAC
-	I-IUPAC
Cl	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methanocarba	I-IUPAC
-	I-IUPAC
ATP	I-IUPAC
and	O
its	O
N	O
(	O
6	O
)	O
-	O
Me	O
analogue	O
were	O
also	O
highly	O
selective	O
,	O
full	O
agonists	O
at	O
P2Y	O
(	O
1	O
)	O
receptors	O
.	O

The	O
(	I-IUPAC
N	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methanocarba	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylthio	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
chloromonophosphate	I-IUPAC
analogues	I-MODIFIER
were	O
full	O
agonists	O
exhibiting	O
micromolar	O
potency	O
at	O
P2Y	O
(	O
1	O
)	O
receptors	O
,	O
while	O
the	O
corresponding	O
ribosides	O
were	O
inactive	O
.	O

Although	O
beta	I-IUPAC
,	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
methylene	I-IUPAC
-	I-IUPAC
ATP	I-IUPAC
was	O
inactive	O
at	O
P2Y	O
receptors	O
,	O
beta	I-IUPAC
,	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
methylene	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methanocarba	I-IUPAC
-	I-IUPAC
ATP	I-IUPAC
was	O
a	O
potent	O
hP2Y	O
(	O
1	O
)	O
receptor	O
agonist	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
160	O
nM	O
and	O
was	O
selective	O
versus	O
hP2Y	O
(	O
2	O
)	O
and	O
hP2Y	O
(	O
4	O
)	O
receptors	O
.	O

The	O
rates	O
of	O
hydrolysis	O
of	O
Northern	O
(	O
N	O
)	O
and	O
Southern	O
(	O
S	O
)	O
methanocarba	O
analogues	O
of	O
AMP	O
by	O
rat	O
5'	O
-	O
ectonucleotidase	O
were	O
negligible	O
.	O

The	O
rates	O
of	O
hydrolysis	O
of	O
the	O
corresponding	O
triphosphates	O
by	O
recombinant	O
rat	O
NTPDase1	O
and	O
2	O
were	O
studied	O
.	O

Both	O
isomers	O
were	O
hydrolyzed	O
by	O
NTPDase	O
1	O
at	O
about	O
half	O
the	O
rate	O
of	O
ATP	O
hydrolysis	O
.	O

The	O
(	O
N	O
)	O
isomer	O
was	O
hardly	O
hydrolyzed	O
by	O
NTPDase	O
2	O
,	O
while	O
the	O
(	O
S	O
)	O
isomer	O
was	O
hydrolyzed	O
at	O
one	O
-	O
third	O
of	O
the	O
rate	O
of	O
ATP	O
hydrolysis	O
.	O

This	O
suggests	O
that	O
new	O
,	O
more	O
stable	O
and	O
selective	O
nucleotide	O
agonists	O
may	O
be	O
designed	O
on	O
the	O
basis	O
of	O
the	O
(	O
N	O
)	O
-	O
conformation	O
,	O
which	O
greatly	O
enhanced	O
potency	O
at	O
P2Y	O
(	O
1	O
)	O
receptors	O
.	O

The	O
conformationally	O
restricted	O
,	O
cyclic	O
disulfide	O
-	O
containing	O
delta	O
opioid	O
receptor	O
selective	O
enkephalin	O
analogue	O
[	O
D	O
-	O
Pen2	O
,	O
D	O
-	O
Pen5	O
]	O
enkephalin	O
(	O
1	O
,	O
DPDPE	O
)	O
was	O
systematically	O
modified	O
topographically	O
by	O
addition	O
of	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
at	O
either	O
the	O
pro	O
-	O
S	O
or	O
pro	O
-	O
R	O
position	O
of	O
the	O
beta	O
carbon	O
of	O
an	O
L	O
-	O
Phe4	O
or	O
D	O
-	O
Phe4	O
residue	O
to	O
give	O
[	O
(	O
2S	O
,	O
3S	O
)	O
-	O
beta	O
-	O
MePhe4	O
]	O
DPDPE	O
(	O
2	O
)	O
,	O
[	O
(	O
2R	O
,	O
3R	O
)	O
-	O
beta	O
-	O
MePhe4	O
]	O
DPDPE	O
(	O
3	O
)	O
,	O
[	O
(	O
2S	O
,	O
3R	O
)	O
-	O
beta	O
-	O
MePhe4	O
]	O
DPDPE	O
(	O
4	O
)	O
,	O
and	O
[	O
(	O
2R	O
,	O
3S	O
)	O
-	O
beta	O
-	O
MePhe4	O
]	O
DPDPE	O
(	O
5	O
)	O
.	O

The	O
four	O
corresponding	O
isomers	O
were	O
prepared	O
in	O
which	O
the	O
beta	I-IUPAC
-	I-IUPAC
methylphenylalanine	I-IUPAC
residue	I-MODIFIER
was	O
p	O
-	O
nitro	O
substituted	O
,	O
that	O
is	O
with	O
a	O
beta	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrophenylalanine	I-IUPAC
(	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe	O
)	O
residue	O
,	O
to	O
give	O
[	O
(	O
2S	O
,	O
3S	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
6	O
)	O
,	O
[	O
(	O
2R	O
,	O
3R	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
7	O
)	O
,	O
[	O
(	O
2S	O
,	O
3R	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
8	O
)	O
,	O
and	O
[	O
(	O
2R	O
,	O
3S	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
9	O
)	O
,	O
respectively	O
.	O

The	O
potency	O
and	O
selectivity	O
(	O
delta	O
vs	O
mu	O
opioid	O
receptor	O
)	O
were	O
evaluated	O
by	O
radioreceptor	O
binding	O
assays	O
in	O
the	O
rat	O
brain	O
using	O
[	O
3H	O
]	O
CTOP	O
(	O
mu	O
ligand	O
)	O
and	O
[	O
3H	O
]	O
DPDPE	O
(	O
delta	O
ligand	O
)	O
and	O
by	O
bioassay	O
with	O
mouse	O
vas	O
deferens	O
(	O
MVD	O
,	O
delta	O
receptor	O
assay	O
)	O
and	O
guinea	O
pig	O
ileum	O
(	O
GPI	O
,	O
mu	O
receptor	O
assay	O
)	O
.	O

The	O
eight	O
analogues	O
of	O
DPDPE	O
showed	O
highly	O
variable	O
binding	O
and	O
bioassay	O
activities	O
particularly	O
at	O
the	O
delta	O
opioid	O
receptor	O
(	O
4	O
orders	O
of	O
magnitude	O
)	O
,	O
but	O
also	O
at	O
the	O
mu	O
opioid	O
receptor	O
,	O
which	O
led	O
to	O
large	O
differences	O
(	O
3	O
orders	O
of	O
magnitude	O
)	O
in	O
receptor	O
selectivity	O
.	O

For	O
example	O
,	O
[	O
(	O
2S	O
,	O
3S	O
)	O
-	O
beta	O
-	O
MePhe4	O
]	O
DPDPE	O
(	O
2	O
)	O
is	O
1800	O
-	O
fold	O
selective	O
in	O
binding	O
to	O
the	O
delta	O
vs	O
mu	O
receptor	O
,	O
making	O
it	O
one	O
of	O
the	O
most	O
selective	O
delta	O
opioid	O
receptor	O
ligands	O
in	O
the	O
enkephalin	O
series	O
as	O
assessed	O
by	O
the	O
rat	O
brain	O
binding	O
assay	O
,	O
whereas	O
the	O
corresponding	O
(	O
2R	O
,	O
3R	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe	O
-	O
containing	O
analogue	O
9	O
is	O
only	O
4.5	O
-	O
fold	O
selective	O
(	O
nonselective	O
)	O
in	O
this	O
same	O
assay	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
bioassay	O
systems	O
,	O
[	O
(	O
2S	O
,	O
3S	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
5	O
)	O
is	O
more	O
potent	O
than	O
DPDPE	O
and	O
8800	O
-	O
fold	O
selective	O
for	O
the	O
MVD	O
(	O
delta	O
receptor	O
)	O
vs	O
the	O
GPI	O
(	O
mu	O
receptor	O
)	O
,	O
making	O
it	O
the	O
most	O
highly	O
selective	O
ligand	O
in	O
this	O
series	O
for	O
the	O
delta	O
opioid	O
receptor	O
on	O
the	O
basis	O
of	O
these	O
bioassays	O
.	O

In	O
these	O
assay	O
systems	O
,	O
the	O
(	O
2R	O
,	O
3S	O
)	O
-	O
beta	O
-	O
MePhe4	O
-	O
containing	O
analogue	O
5	O
had	O
very	O
weak	O
potency	O
and	O
virtually	O
no	O
receptor	O
selectivity	O
(	O
4.4	O
-	O
fold	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
topographical	O
modification	O
alone	O
in	O
a	O
conformationally	O
restricted	O
peptide	O
ligand	O
can	O
significantly	O
modulate	O
both	O
potency	O
and	O
receptor	O
selectivity	O
of	O
peptide	O
ligands	O
that	O
have	O
multiple	O
sites	O
of	O
biological	O
activity	O
and	O
suggest	O
that	O
this	O
approach	O
may	O
have	O
general	O
application	O
to	O
peptide	O
ligand	O
design	O
.	O

A	O
series	O
of	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
was	O
prepared	O
from	O
the	O
key	O
intermediate	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
6a	O
-	O
c	O
)	O
in	O
order	O
to	O
clarify	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
various	O
analogues	O
of	O
2	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
ben	I-IUPAC
zimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
CV	O
-	O
11194	O
)	O
,	O
a	O
potent	O
and	O
long	O
acting	O
angiotensin	O
II	O
(	O
AII	O
)	O
receptor	O
antagonist	O
.	O

The	O
AII	O
antagonistic	O
activity	O
of	O
the	O
benzimidazoles	O
was	O
investigated	O
by	O
in	O
vitro	O
assays	O
,	O
which	O
included	O
an	O
AII	O
receptor	O
binding	O
assay	O
and	O
AII	O
-	O
induced	O
vasocontraction	O
assay	O
,	O
as	O
well	O
as	O
by	O
in	O
vivo	O
assays	O
such	O
as	O
an	O
AII	O
-	O
induced	O
pressor	O
response	O
in	O
rats	O
.	O

Most	O
of	O
the	O
benzimidazoles	O
showed	O
high	O
affinity	O
for	O
the	O
AII	O
receptor	O
(	O
IC50	O
value	O
,	O
10	O
(	O
-	O
6	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
and	O
inhibited	O
the	O
AII	O
-	O
induced	O
pressor	O
response	O
at	O
1	O
or	O
3	O
mg	O
/	O
kg	O
po	O
,	O
and	O
the	O
effects	O
were	O
more	O
potent	O
than	O
those	O
of	O
CV	O
-	O
11194	O
and	O
DuP	O
753	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
studies	O
on	O
the	O
binding	O
affinity	O
and	O
the	O
inhibition	O
of	O
AII	O
-	O
induced	O
pressor	O
response	O
suggested	O
that	O
straight	O
chains	O
of	O
a	O
certain	O
length	O
(	O
e.g.	O
,	O
ethoxy	O
groups	O
,	O
ethyl	O
groups	O
)	O
were	O
the	O
best	O
as	O
substituents	O
at	O
the	O
2	O
-	O
position	O
and	O
that	O
their	O
steric	O
factors	O
,	O
lipophilicity	O
,	O
and	O
electronic	O
effects	O
affected	O
the	O
potency	O
of	O
the	O
AII	O
antagonistic	O
action	O
.	O

Both	O
a	O
carboxyl	O
group	O
at	O
the	O
7	O
-	O
position	O
and	O
a	O
tetrazole	O
ring	O
at	O
the	O
2'	O
-	O
position	O
were	O
particularly	O
important	O
for	O
potent	O
and	O
orally	O
active	O
AII	O
antagonistic	O
activity	O
and	O
a	O
long	O
-	O
acting	O
hypotensive	O
effect	O
.	O

The	O
representative	O
compound	O
,	O
2	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
26b	O
,	O
CV	O
-	O
11974	O
)	O
,	O
inhibited	O
the	O
specific	O
binding	O
of	O
[	O
125I	O
]	O
AII	O
to	O
bovine	O
adrenal	O
cortical	O
membrane	O
with	O
an	O
IC50	O
value	O
of	O
1.1	O
x	O
10	O
(	O
-	O
7	O
)	O
M	O
.	O

The	O
AII	O
-	O
induced	O
contraction	O
of	O
rabbit	O
aortic	O
strips	O
was	O
antagonized	O
by	O
CV	O
-	O
11974	O
(	O
IC50	O
value	O
,	O
3.0	O
x	O
10	O
(	O
-	O
10	O
)	O
M	O
)	O
.	O

Oral	O
administration	O
of	O
CV	O
-	O
11974	O
to	O
conscious	O
normotensive	O
rats	O
at	O
1	O
mg	O
/	O
kg	O
resulted	O
in	O
long	O
-	O
lasting	O
inhibition	O
of	O
the	O
AII	O
-	O
induced	O
pressor	O
response	O
.	O

CV	O
-	O
11974	O
at	O
0.1-1	O
mg	O
/	O
kg	O
iv	O
reduced	O
blood	O
pressure	O
dose	O
-	O
dependently	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O

3	O
-	O
Deoxy	O
-	O
2,5	O
-	O
di	O
-	O
O	O
-	O
p	O
-	O
nitrobenzoyl	O
-	O
alpha	O
-	O
D	O
-	O
threo	O
-	O
entofuranosyl	O
bromide	O
(	O
1	O
)	O
reacted	O
with	O
mercuric	O
cyanide	O
to	O
give	O
2,5	I-IUPAC
-	I-IUPAC
anhydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
lyxo	I-IUPAC
-	I-IUPAC
hexononitrile	I-IUPAC
(	O
2	O
)	O
which	O
upon	O
acid	O
hydrolysis	O
of	O
the	O
CN	O
group	O
gave	O
acid	O
3	O
.	O

Saponification	O
of	O
the	O
protecting	O
groups	O
gave	O
2,5	I-IUPAC
-	I-IUPAC
anhydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
lyxo	I-IUPAC
-	I-IUPAC
hexonic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
which	O
reacted	O
with	O
4,5,6	I-IUPAC
-	I-IUPAC
triaminopyrimidine	I-IUPAC
forming	O
an	O
amide	O
(	O
5	O
)	O
that	O
was	O
pyrolized	O
to	O
give	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
6	O
)	O
.	O

Reaction	O
of	O
bromide	O
1	O
with	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzamido	I-IUPAC
)	I-IUPAC
chloromercuriopurine	I-IUPAC
followed	O
by	O
saponification	O
yielded	O
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
8	O
)	O
.	O

8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
Ribofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
and	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
as	O
well	O
as	O
compound	O
6	O
,	O
showed	O
no	O
antimalarial	O
activity	O
.	O

The	O
effect	O
of	O
substitution	O
in	O
the	O
acyclic	O
structure	O
of	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
thymine	I-IUPAC
(	O
HEPT	O
)	O
on	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
was	O
investigated	O
by	O
synthesizing	O
a	O
series	O
of	O
deoxy	I-IUPAC
analogs	B-MODIFIER
and	O
related	O
compounds	O
.	O

Preparation	O
of	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
alkyloxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
2-4	O
)	O
derivatives	I-MODIFIER
was	O
carried	O
out	O
based	O
on	O
alkylation	O
of	O
HEPT	O
with	O
primary	O
alkyl	O
halides	O
.	O

Preparation	O
of	O
the	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
26-31	O
)	O
and	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiouracil	I-IUPAC
(	O
32-45	O
)	O
derivatives	I-MODIFIER
was	O
carried	O
out	O
on	O
the	O
basis	O
of	O
LDA	O
lithiation	O
of	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
thymine	I-IUPAC
(	O
9-14	O
)	O
and	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiouracil	I-IUPAC
(	O
15-25	O
)	O
followed	O
by	O
reaction	O
with	O
diaryl	O
disulfides	O
.	O

The	O
oxidative	O
hydrolysis	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
thiouracil	I-IUPAC
derivatives	I-MODIFIER
gave	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylthio	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
derivatives	I-MODIFIER
(	O
46-57	O
)	O
.	O

1	I-IUPAC
-	I-IUPAC
Alkyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
59-61	O
)	O
derivatives	I-MODIFIER
were	O
prepared	O
on	O
the	O
basis	O
of	O
alkylation	O
of	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
58	O
)	O
.	O

Methylation	O
of	O
the	O
hydroxyl	I-IUPAC
group	B-MODIFIER
of	O
HEPT	O
did	O
not	O
affect	O
the	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
of	O
HEPT	O
.	O

Substitution	O
of	O
the	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
by	O
ethyl	I-IUPAC
,	O
butyl	I-IUPAC
,	O
methoxymethyl	I-IUPAC
,	O
(	I-IUPAC
propyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
,	O
and	O
(	I-IUPAC
butyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
groups	I-MODIFIER
somewhat	O
improved	O
the	O
original	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
of	O
HEPT	O
.	O

Substitution	O
with	O
ethoxymethyl	I-IUPAC
and	O
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
groups	I-MODIFIER
further	O
potentiated	O
the	O
activity	O
[	O
EC50	O
:	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
27	O
)	O
,	O
0.33	O
microM	O
;	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
31	O
)	O
,	O
0.088	O
microM	O
]	O
.	O

When	O
the	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
of	O
27	O
and	O
31	O
was	O
replaced	O
by	O
an	O
ethyl	I-IUPAC
or	O
an	O
isopropyl	I-IUPAC
group	B-MODIFIER
,	O
the	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
was	O
improved	O
remarkably	O
[	O
EC50	O
:	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
uracil	I-IUPAC
(	O
46	O
)	O
,	O
0.019	O
microM	O
;	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
52	O
)	O
,	O
0.0059	O
microM	O
;	O
5	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
55	O
)	O
,	O
0.012	O
microM	O
;	O
5	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
56	O
)	O
,	O
0.0027	O
microM	O
]	O
.	O

Introduction	O
of	O
two	O
m	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
groups	I-MODIFIER
into	O
the	O
phenylthio	I-IUPAC
ring	B-MODIFIER
also	O
potentiated	O
the	O
activity	O
.	O

alpha	O
-	O
Fluoromethyl	O
amino	O
acids	O
are	O
enzyme	O
-	O
activated	O
irreversible	O
inhibitors	O
of	O
amino	O
acid	O
decarboxylases	O
.	O

Aromatic	O
L	O
-	O
amino	O
acid	O
decarboxylase	O
(	O
AADC	O
)	O
is	O
the	O
enzyme	O
responsible	O
for	O
the	O
final	O
step	O
in	O
the	O
biosynthesis	O
of	O
both	O
dopamine	O
and	O
serotonin	O
via	O
decarboxylation	O
of	O
L	I-IUPAC
-	I-IUPAC
dopa	I-IUPAC
and	O
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tryptophan	I-IUPAC
,	O
respectively	O
.	O

Our	O
goal	O
is	O
to	O
utilize	O
antagonists	O
of	O
the	O
serotonin	O
-	O
producing	O
enzymes	O
(	O
tryptophan	O
hydroxylase	O
and	O
AADC	O
)	O
as	O
the	O
basis	O
for	O
a	O
chemotherapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
carcinoid	O
tumors	O
,	O
a	O
rare	O
tumor	O
type	O
characterized	O
by	O
the	O
overproduction	O
of	O
serotonin	O
.	O

We	O
report	O
here	O
an	O
enantiospecific	O
synthesis	O
of	O
alpha	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
tryptophan	I-IUPAC
[	O
(	O
S	O
)	O
-	O
11a	O
]	O
and	O
alpha	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxytryptophan	I-IUPAC
[	O
(	O
S	O
)	O
-	O
11b	O
]	O
,	O
as	O
well	O
as	O
the	O
(	O
R	O
)	O
-	O
enantiomers	O
,	O
based	O
upon	O
recent	O
methodology	O
involving	O
the	O
face	O
-	O
selective	O
alkylation	O
of	O
cyclic	O
tryptophan	O
tautomers	O
.	O

Our	O
synthetic	O
route	O
provided	O
both	O
enantiomers	O
of	O
11a	O
and	O
11b	O
with	O
greater	O
than	O
97%	O
enantiomeric	O
purity	O
based	O
upon	O
evaluation	O
of	O
the	O
NMR	O
spectra	O
of	O
their	O
Mosher	O
's	O
acid	O
derivatives	O
.	O

(	O
S	O
)	O
-	O
11a	O
was	O
evaluated	O
as	O
a	O
substrate	O
for	O
P815	O
tryptophan	O
hydroxylase	O
and	O
determined	O
to	O
have	O
an	O
apparent	O
Km	O
of	O
4.31	O
+	O
/	O
-	O
1.07	O
mM	O
,	O
essentially	O
half	O
the	O
value	O
previously	O
reported	O
for	O
the	O
racemic	O
mixture	O
of	O
11a	O
with	O
rat	O
brain	O
stem	O
tryptophan	O
hydroxylase	O
.	O

(	O
R	O
)	O
-	O
11a	O
was	O
not	O
a	O
substrate	O
for	O
P815	O
tryptophan	O
hydroxylase	O
.	O

(	O
S	O
)	O
-	O
11b	O
was	O
evaluated	O
as	O
an	O
enzyme	O
-	O
activated	O
irreversible	O
inhibitor	O
of	O
murine	O
liver	O
AADC	O
and	O
determined	O
to	O
have	O
a	O
KI	O
of	O
24.3	O
+	O
/	O
-	O
3.01	O
microM	O
and	O
a	O
k2	O
of	O
2.26	O
+	O
/	O
-	O
0.44	O
min	O
-	O
1	O
.	O

(	O
R	O
)	O
-	O
11b	O
was	O
not	O
an	O
inhibitor	O
of	O
murine	O
liver	O
AADC	O
.	O

Dextromethorphan	O
(	O
1	O
,	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
methylmorphinan	I-IUPAC
)	O
demonstrates	O
anticonvulsant	O
activity	O
in	O
a	O
variety	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
of	O
convulsive	O
action	O
.	O

It	O
is	O
well	O
known	O
that	O
1	O
is	O
metabolized	O
to	O
its	O
phenolic	O
derivative	O
dextrorphan	O
(	O
2	O
)	O
and	O
this	O
metabolite	O
is	O
also	O
a	O
potent	O
anticonvulsant	O
.	O

A	O
series	O
of	O
(	I-MODIFIER
+	I-MODIFIER
)	I-MODIFIER
-	I-MODIFIER
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
17	I-IUPAC
-	I-IUPAC
methylmorphinans	I-IUPAC
,	O
which	O
are	O
structurally	O
similar	O
to	O
1	O
but	O
are	O
either	O
not	O
expected	O
to	O
be	O
metabolized	O
to	O
2	O
or	O
might	O
do	O
so	O
at	O
a	O
reduced	O
rate	O
,	O
as	O
compared	O
to	O
1	O
,	O
were	O
prepared	O
.	O

Three	O
analogs	O
,	O
5	O
(	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
methylmorphinan	I-IUPAC
)	O
,	O
14	O
(	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
methylmorphinan	I-IUPAC
)	O
,	O
and	O
15	O
(	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
methylmorphinan	I-IUPAC
)	O
were	O
found	O
to	O
possess	O
potent	O
anticonvulsant	O
activity	O
with	O
full	O
efficacy	O
(	O
ED50	O
25	O
,	O
5.6	O
,	O
and	O
3.9	O
mg	O
/	O
kg	O
,	O
sc	O
,	O
respectively	O
)	O
in	O
the	O
rat	O
supramaximal	O
electroshock	O
(	O
MES	O
)	O
test	O
.	O

Binding	O
potencies	O
of	O
these	O
compounds	O
to	O
receptor	O
sites	O
labeled	O
with	O
[	O
3H	O
]	O
dextromethorphan	O
(	O
[	O
3H	O
]	O
1	O
)	O
,	O
in	O
rat	O
brain	O
and	O
guinea	O
pig	O
brain	O
subcellular	O
fractions	O
,	O
and	O
[	O
3H	O
]	O
thienylcyclohexylpiperidine	O
(	O
TCP	O
)	O
and	O
[	O
3H	O
]	O
glycine	O
in	O
rat	O
brain	O
,	O
were	O
determined	O
.	O

Most	O
of	O
the	O
analogs	O
displaced	O
[	O
3H	O
]	O
1	O
from	O
its	O
binding	O
sites	O
,	O
with	O
compounds	O
14	O
(	O
IC50	O
0.42	O
microM	O
)	O
and	O
15	O
(	O
IC50	O
0.88	O
microM	O
)	O
having	O
equivalent	O
potencies	O
to	O
1	O
(	O
IC50	O
0.59	O
microM	O
)	O
,	O
in	O
rat	O
brain	O
,	O
and	O
no	O
appreciable	O
activity	O
at	O
the	O
[	O
3H	O
]	O
TCP	O
or	O
[	O
3H	O
]	O
glycine	O
-	O
labeled	O
sites	O
.	O

Compound	O
5	O
did	O
not	O
bind	O
with	O
appreciable	O
activity	O
to	O
the	O
[	O
3H	O
]	O
1	O
site	O
,	O
in	O
rat	O
brain	O
,	O
but	O
did	O
bind	O
to	O
the	O
[	O
3H	O
]	O
TCP	O
site	O
with	O
lower	O
potency	O
than	O
the	O
parent	O
1	O
(	O
IC50	O
7.8	O
and	O
2.0	O
microM	O
,	O
respectively	O
)	O
.	O

The	O
mechanism	O
of	O
anticonvulsant	O
action	O
of	O
these	O
agents	O
is	O
not	O
clear	O
although	O
it	O
appears	O
that	O
interaction	O
at	O
the	O
[	O
3H	O
]	O
1	O
sites	O
may	O
be	O
involved	O
.	O

Clinical	O
studies	O
concerning	O
the	O
role	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
in	O
the	O
repair	O
of	O
drug	O
-	O
and	O
radiation	O
-	O
induced	O
DNA	O
damage	O
have	O
been	O
impeded	O
by	O
the	O
poor	O
solubility	O
,	O
lack	O
of	O
potency	O
,	O
and	O
limited	O
specificity	O
of	O
currently	O
available	O
inhibitors	O
.	O

A	O
series	O
of	O
2	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	O
and	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	O
substituted	I-MODIFIER
8	B-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
8	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
8	I-IUPAC
-	I-IUPAC
methylquinazolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
has	O
been	O
synthesized	O
and	O
evaluated	O
for	O
PARP	O
inhibitory	O
activity	O
in	O
permeabilized	O
L1210	O
murine	O
leukemia	O
cells	O
.	O

8	I-PARTIUPAC
-	I-PARTIUPAC
Methoxy	I-PARTIUPAC
-	I-PARTIUPAC
and	O
8	I-IUPAC
-	I-IUPAC
methylquinazolinones	I-IUPAC
(	O
14-34	O
)	O
were	O
readily	O
prepared	O
by	O
acylation	O
of	O
3	O
-	O
substituted	O
anthranilamides	O
with	O
the	O
appropriate	O
acid	O
chloride	O
,	O
followed	O
by	O
base	O
-	O
catalyzed	O
cyclization	O
.	O

The	O
requisite	O
8	I-IUPAC
-	I-IUPAC
hydroxyquinazolinones	I-IUPAC
(	O
6	O
,	O
35-39	O
)	O
were	O
synthesized	O
by	O
demethylation	O
of	O
the	O
corresponding	O
8	I-IUPAC
-	I-IUPAC
methoxyquinazolinones	I-IUPAC
with	O
BBr3	O
.	O

N	O
-	O
Methylation	O
of	O
8	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylquinazolinone	I-IUPAC
(	O
15	O
)	O
with	O
MeI	O
,	O
followed	O
by	O
O	O
-	O
demethylation	O
by	O
BBr3	O
,	O
afforded	O
the	O
control	O
N3	I-IUPAC
-	I-IUPAC
methylquinazolinones	I-IUPAC
42	O
and	O
43	O
,	O
respectively	O
.	O

In	O
general	O
,	O
an	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
or	O
8	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
substituent	I-MODIFIER
enhanced	O
inhibitory	O
activity	O
in	O
comparison	O
with	O
an	O
8	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
group	I-MODIFIER
.	O

2	I-IUPAC
-	I-IUPAC
Phenylquinazolinones	I-IUPAC
were	O
marginally	O
less	O
potent	O
than	O
the	O
corresponding	O
2	I-IUPAC
-	I-IUPAC
methylquinazolinones	I-IUPAC
,	O
but	O
the	O
introduction	O
of	O
an	O
electron	O
-	O
withdrawing	O
or	O
electron	O
-	O
donating	O
4'	O
-	O
substituent	O
on	O
the	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
ring	I-MODIFIER
invariably	O
increased	O
potency	O
.	O

This	O
was	O
particularly	O
evident	O
in	O
the	O
8	I-IUPAC
-	I-IUPAC
methylquinazolinone	I-IUPAC
series	I-MODIFIER
(	O
IC50	O
values	O
0.13-0.27	O
microM	O
)	O
,	O
which	O
are	O
among	O
the	O
most	O
potent	O
PARP	O
inhibitors	O
reported	O
to	O
date	O
.	O

N3	I-IUPAC
-	I-IUPAC
Methylquinazolinones	I-IUPAC
42	O
and	O
43	O
were	O
essentially	O
devoid	O
of	O
activity	O
(	O
IC50	O
values	O
&	O
gt	O
;	O
100	O
microM	O
)	O
.	O

In	O
studies	O
with	O
L1210	O
cells	O
in	O
vitro	O
,	O
a	O
concentration	O
of	O
200	O
microM	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylquinazolinone	I-IUPAC
(	O
6	O
,	O
NU1025	O
)	O
(	O
IC50	O
value	O
0.40	O
microM	O
)	O
potentiated	O
the	O
cytotoxicity	O
of	O
the	O
monomethylating	O
agent	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyltriazen	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
and	O
gamma	O
-	O
radiation	O
3.5	O
-	O
and	O
1.4	O
-	O
fold	O
,	O
respectively	O
,	O
at	O
the	O
10%	O
survival	O
level	O
.	O

A	O
number	O
of	O
nucleoside	O
and	O
nucleotide	O
derivatives	O
of	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
pyrazofurin	O
,	O
1	O
)	O
were	O
prepared	O
and	O
tested	O
for	O
their	O
antiviral	O
and	O
cytostatic	O
activity	O
in	O
cell	O
culture	O
.	O

Treatment	O
of	O
1	O
with	O
benzyl	I-IUPAC
bromide	I-IUPAC
gave	O
4	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzylpyrazofurin	I-IUPAC
(	O
4	O
)	O
.	O

Methylation	O
of	O
4	O
with	O
CH2N2	O
and	O
subsequent	O
removal	O
of	O
the	O
benzyl	I-IUPAC
group	B-MODIFIER
by	O
catalytic	O
hydrogenation	O
provided	O
1	I-IUPAC
-	I-IUPAC
methylpyrazofurin	I-IUPAC
(	O
8	O
)	O
.	O

Direct	O
methylation	O
of	O
1	O
with	O
CH3I	O
furnished	O
4	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methylpyrazofurin	I-IUPAC
(	O
6	O
)	O
.	O

Dehydration	O
of	O
the	O
pentaacetylpyrazofurin	O
(	O
9	O
)	O
with	O
phosgene	O
furnished	O
4	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetylpyrazol	I-IUPAC
e	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
(	O
10	O
)	O
.	O

A	O
similar	O
dehydration	O
of	O
the	O
precursor	O
tetraacetyl	I-IUPAC
derivative	B-MODIFIER
of	O
4	O
gave	O
the	O
corresponding	O
carbonitrile	O
,	O
which	O
on	O
deprotection	O
and	O
subsequent	O
treatment	O
with	O
hydroxylamine	O
furnished	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamidoxime	I-IUPAC
(	O
13	O
)	O
.	O

Treatment	O
of	O
the	O
tetraacetyl	I-IUPAC
derivative	B-MODIFIER
of	O
4	O
with	O
Lawesson	O
's	O
reagent	O
and	O
subsequent	O
deacetylation	O
furnished	O
a	O
mixture	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thiocarboxamide	I-IUPAC
(	O
15	O
)	O
and	O
the	O
corresponding	O
nitrile	I-IUPAC
derivative	B-MODIFIER
(	O
16	O
)	O
.	O

Phosphorylation	O
of	O
unprotected	O
4	O
with	O
POCl3	O
and	O
subsequent	O
debenzylation	O
of	O
the	O
intermediate	O
17	O
gave	O
pyrazofurin	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
phosphate	I-IUPAC
(	O
18	O
)	O
,	O
which	O
provided	O
the	O
first	O
chemical	O
synthesis	O
of	O
18	O
.	O

Similar	O
phosphorylation	O
of	O
4	O
with	O
POCl3	O
and	O
quenching	O
the	O
reaction	O
mixture	O
with	O
either	O
EtOH	O
or	O
MeOH	O
,	O
followed	O
by	O
debenzylation	O
,	O
furnished	O
the	O
5'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethyl	I-IUPAC
phosphate	I-IUPAC
)	I-IUPAC
(	O
19b	O
)	O
and	O
5'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethyl	I-IUPAC
phosphate	I-IUPAC
)	I-IUPAC
(	O
20b	O
)	O
derivatives	O
of	O
pyrazofurin	O
.	O

DCC	O
-	O
mediated	O
cyclization	O
of	O
17	O
,	O
followed	O
by	O
debenzylation	O
,	O
gave	O
pyrazofurin	O
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
cyclic	I-IUPAC
)	I-IUPAC
phosphate	I-IUPAC
(	O
21b	O
)	O
.	O

The	O
NAD	O
analogue	O
23b	O
was	O
also	O
prepared	O
by	O
the	O
treatment	O
of	O
17	O
with	O
an	O
activated	O
form	O
of	O
AMP	O
in	O
the	O
presence	O
of	O
AgNO3	O
.	O

The	O
structural	O
assignment	O
of	O
7,8	O
,	O
and	O
20a	O
were	O
made	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
,	O
and	O
along	O
with	O
pyrazofurin	O
,	O
their	O
intramolecular	O
hydrogen	O
bond	O
characteristics	O
have	O
been	O
studied	O
.	O

All	O
of	O
these	O
compounds	O
were	O
tested	O
in	O
Vero	O
cell	O
cultures	O
against	O
a	O
spectrum	O
of	O
viruses	O
.	O

Compounds	O
18	O
and	O
23b	O
were	O
active	O
at	O
concentrations	O
very	O
similar	O
to	O
pyrazofurin	O
but	O
are	O
less	O
toxic	O
to	O
the	O
cells	O
than	O
pyrazofurin	O
.	O

Compounds	O
19b	O
,	O
20b	O
,	O
and	O
the	O
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
cyclic	I-IUPAC
)	I-IUPAC
phosphate	I-IUPAC
21b	O
are	O
less	O
active	O
than	O
1	O
.	O

Compounds	O
18	O
,	O
19b	O
,	O
20b	O
,	O
and	O
23b	O
also	O
exhibited	O
significant	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
L1210	O
and	O
P388	O
leukemias	O
and	O
Lewis	O
lung	O
carcinoma	O
cells	O
in	O
vitro	O
,	O
whereas	O
B16	O
melanoma	O
cells	O
were	O
less	O
sensitive	O
to	O
growth	O
inhibition	O
by	O
these	O
compounds	O
.	O

Pyrazofurin	O
derivatives	O
modified	O
at	O
the	O
1	O
-	O
,	O
4	O
-	O
,	O
or	O
5	O
-	O
position	O
showed	O
neither	O
antiviral	O
nor	O
cytostatic	O
activity	O
in	O
cell	O
culture	O
.	O

A	O
series	O
of	O
7	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2,3	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
-	O
1	I-IUPAC
-	I-IUPAC
azetidinyl	I-IUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
fluoro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
oxoquinoline	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
1,8	I-PARTIUPAC
-	I-PARTIUPAC
naphthyridine	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
carboxylic	I-PARTIUPAC
acids	I-PARTIUPAC
,	O
with	O
varied	O
substituents	O
at	O
the	O
1	O
-	O
,	O
5	O
-	O
,	O
and	O
8	O
-	O
positions	O
,	O
was	O
prepared	O
to	O
study	O
the	O
effects	O
on	O
potency	O
and	O
physicochemical	O
properties	O
of	O
the	O
substituent	O
at	O
position	O
2	O
of	O
the	O
azetidine	O
moiety	O
.	O

The	O
activity	O
of	O
the	O
title	O
compounds	O
was	O
determined	O
in	O
vitro	O
against	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
and	O
the	O
in	O
vivo	O
efficacy	O
of	O
selected	O
derivatives	O
was	O
determined	O
using	O
a	O
mouse	O
infection	O
model	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
6b	O
,	O
6c	O
,	O
and	O
6d	O
were	O
found	O
to	O
be	O
in	O
reasonable	O
agreement	O
with	O
the	O
corresponding	O
AM1	O
calculated	O
geometries	O
.	O

Correlations	O
between	O
antibacterial	O
potency	O
of	O
all	O
the	O
synthesized	O
7	I-IUPAC
-	I-IUPAC
azetidinylquinolones	I-IUPAC
and	O
naphthyridines	O
and	O
their	O
calculated	O
electronic	O
properties	O
and	O
experimental	O
capacity	O
factors	O
were	O
established	O
.	O

Antibacterial	O
efficacy	O
and	O
pharmacokinetic	O
and	O
physicochemical	O
properties	O
of	O
selected	O
derivatives	O
were	O
compared	O
to	O
the	O
relevant	O
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azetidinyl	I-IUPAC
)	I-IUPAC
and	O
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azetidinyl	I-IUPAC
)	I-IUPAC
analogues	I-MODIFIER
(	O
for	O
Part	O
1	O
,	O
see	O
:	O
J	O
.	O

Med.	O
Chem.	O
1993	O
,	O
36	O
,	O
801-810	O
)	O
.	O

A	O
combination	O
of	O
a	O
cyclopropyl	O
or	O
a	O
substituted	O
phenyl	I-IUPAC
group	B-MODIFIER
at	O
N	O
-	O
1	O
and	O
a	O
trans	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azetidinyl	I-IUPAC
group	I-MODIFIER
at	O
C	O
-	O
7	O
conferred	O
the	O
best	O
overall	O
antibacterial	O
,	O
pharmacokinetic	O
,	O
and	O
physicochemical	O
properties	O
to	O
the	O
azetidinylquinolones	O
studied	O
.	O

Synthetic	O
procedures	O
for	O
the	O
preparation	O
of	O
various	O
3	I-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
xanthines	I-IUPAC
,	O
including	O
paraxanthine	O
analogs	O
(	O
1,7	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	I-IUPAC
)	O
and	O
1,8	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	I-IUPAC
,	O
were	O
developed	O
.	O

Silylation	O
of	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
xanthines	I-IUPAC
followed	O
by	O
alkylation	O
at	O
the	O
7	O
-	O
position	O
provides	O
a	O
facile	O
route	O
to	O
paraxanthine	O
analogs	O
.	O

Regioselective	O
alkylation	O
of	O
tris	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
aminouracil	I-IUPAC
provides	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
6	I-IUPAC
-	I-IUPAC
aminouracils	I-IUPAC
,	O
which	O
are	O
converted	O
to	O
1,8	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	I-IUPAC
by	O
standard	O
procedures	O
.	O

The	O
ring	O
closure	O
of	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
5	I-PARTIUPAC
-	I-PARTIUPAC
cyclopentanecarboxamido	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzoylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
aminouracils	I-IUPAC
requires	O
drastic	O
reaction	O
conditions	O
.	O

Affinity	O
for	O
brain	O
A1	O
and	O
A2	O
adenosine	O
receptors	O
was	O
determined	O
in	O
binding	O
assays	O
for	O
these	O
and	O
other	O
xanthines	O
with	O
substituents	O
in	O
1	O
-	O
,	O
3	O
-	O
,	O
7	O
-	O
,	O
8	O
-	O
,	O
and	O
9	O
-	O
positions	O
.	O

Substitution	O
at	O
the	O
1	O
-	O
position	O
was	O
necessary	O
for	O
high	O
affinity	O
at	O
adenosine	O
receptors	O
.	O

1,3	I-MODIFIER
-	I-MODIFIER
Disubstituted	I-MODIFIER
xanthines	I-IUPAC
generally	O
had	O
higher	O
affinity	O
than	O
1,7	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	I-IUPAC
.	O

1,8	I-MODIFIER
-	I-MODIFIER
Disubstituted	I-MODIFIER
xanthines	I-IUPAC
had	O
high	O
affinity	O
for	O
adenosine	O
receptors	O
;	O
some	O
were	O
highly	O
selective	O
for	O
A1	O
receptors	O
.	O

[	O
1	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylisoleucine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
]	O
-	O
(	O
I	O
)	O
,	O
[	O
1	I-IUPAC
-	I-IUPAC
dimethylglycine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
]	O
-	O
(	O
II	O
)	O
,	O
[	O
1	I-IUPAC
-	I-IUPAC
guanidineacetic	I-IUPAC
acid	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
]	O
-	O
(	O
III	O
)	O
,	O
des	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
-	I-IUPAC
[	I-IUPAC
8	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
]	I-IUPAC
-	O
(	O
IV	O
)	O
,	O
and	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methylserine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
(	O
V	O
)	O
were	O
synthesized	O
by	O
Merrifield	O
's	O
solid	O
-	O
phase	O
procedure	O
to	O
study	O
the	O
effect	O
of	O
(	O
a	O
)	O
substituents	O
in	O
position	O
1	O
on	O
the	O
antagonistic	O
activity	O
of	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
,	O
and	O
(	O
b	O
)	O
a	O
change	O
in	O
size	O
and	O
branching	O
in	O
position	O
8	O
of	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methylthreonine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
.	O

The	O
analogues	O
I	O
-	O
V	O
caused	O
an	O
initial	O
rise	O
in	O
blood	O
pressure	O
(	O
30	O
min	O
of	O
infusion	O
,	O
250	O
ng	O
/	O
kg	O
/	O
min	O
in	O
vagotomized	O
ganglion	O
-	O
blocked	O
rats	O
)	O
of	O
8.05	O
,	O
11.7	O
,	O
3.50	O
,	O
4.5	O
,	O
and	O
11.16	O
mmHg	O
.	O

The	O
pA2	O
values	O
(	O
rabbit	O
aortic	O
strips	O
)	O
obtained	O
were	O
7.68	O
,	O
7.53	O
,	O
7.23	O
,	O
7.53	O
,	O
and	O
9.66	O
,	O
and	O
the	O
dose	O
ratios	O
(	O
in	O
vagotomized	O
ganglion	O
-	O
blocked	O
rats	O
infused	O
at	O
250	O
ng	O
/	O
kg	O
/	O
min	O
)	O
obtained	O
were	O
2.37	O
,	O
4.49	O
,	O
1.02	O
,	O
1.47	O
,	O
and	O
24.04	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
indicate	O
that	O
(	O
a	O
)	O
the	O
nature	O
of	O
the	O
substituent	O
in	O
position	O
1	O
has	O
an	O
important	O
influence	O
on	O
the	O
biological	O
activity	O
of	O
these	O
peptides	O
,	O
and	O
(	O
b	O
)	O
the	O
potency	O
of	O
antagonists	O
I	O
-	O
IV	O
(	O
all	O
less	O
potent	O
antagonists	O
than	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
)	O
is	O
very	O
much	O
influenced	O
by	O
the	O
length	O
and	O
branching	O
of	O
the	O
side	O
chain	O
in	O
position	O
8	O
.	O

The	O
in	O
vivo	O
antagonistic	O
activity	O
of	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sarcosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methylthreonine	I-IUPAC
]	I-IUPAC
angiotensin	I-IUPAC
II	I-IUPAC
is	O
reduced	O
considerably	O
by	O
shortening	O
the	O
chain	O
length	O
by	O
one	O
carbon	O
atom	O
as	O
is	O
in	O
V	O
.	O

In	O
furtherance	O
of	O
our	O
SAR	O
study	O
on	O
the	O
chemistry	O
and	O
antitumor	O
activity	O
of	O
fused	O
nitrogen	O
heteroaromatic	O
compounds	O
,	O
a	O
series	O
of	O
linear	O
,	O
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
derivatives	B-MODIFIER
of	O
5H	I-PARTIUPAC
-	I-PARTIUPAC
and	O
6H	I-IUPAC
-	I-IUPAC
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
were	O
synthesized	O
according	O
to	O
the	O
modified	O
Graebe	O
-	O
Ullmann	O
reaction	O
.	O

To	O
establish	O
the	O
relationship	O
between	O
the	O
physicochemical	O
and	O
biological	O
activities	O
of	O
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
,	O
their	O
lipophilic	O
properties	O
,	O
cytotoxic	O
and	O
antimicrobial	O
activity	O
,	O
and	O
ability	O
to	O
induce	O
topoisomerase	O
II	O
dependent	O
pSP65	O
DNA	O
cleavage	O
in	O
vitro	O
were	O
investigated	O
.	O

We	O
found	O
that	O
the	O
antimicrobial	O
and	O
cytotoxic	O
activity	O
of	O
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
was	O
strongly	O
influenced	O
by	O
the	O
position	O
,	O
and	O
the	O
number	O
of	O
methyl	I-IUPAC
substituents	B-MODIFIER
and	O
the	O
presence	O
of	O
methyl	I-IUPAC
group	B-MODIFIER
at	O
pyridine	O
nitrogen	O
was	O
essential	O
for	O
the	O
cytotoxicity	O
of	O
these	O
compounds	O
.	O

All	O
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
belonging	O
to	O
the	O
5H	O
series	O
,	O
i.e.	O
,	O
bearing	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
on	O
the	O
pyridine	O
nitrogen	O
,	O
showed	O
significant	O
activity	O
against	O
procaryotic	O
and	O
eucaryotic	O
organisms	O
.	O

They	O
inhibited	O
the	O
growth	O
of	O
Gram	O
-	O
positive	O
bacteria	O
and	O
pathogenic	O
fungi	O
at	O
MIC	O
range	O
3	O
x	O
10	O
(	O
-	O
2	O
)	O
to	O
2.5	O
x	O
10	O
(	O
-	O
1	O
)	O
mumol	O
/	O
mL	O
,	O
displayed	O
cytotoxicity	O
against	O
KB	O
cells	O
ID50	O
in	O
the	O
range	O
2	O
x	O
10	O
(	O
-	O
3	O
)	O
to	O
9	O
x	O
10	O
(	O
-	O
3	O
)	O
mumol	O
/	O
mL	O
,	O
and	O
stimulated	O
the	O
formation	O
of	O
calf	O
thymus	O
topoisomerase	O
II	O
mediated	O
DNA	O
cleavage	O
at	O
concentration	O
between	O
0.4	O
and	O
10	O
microM	O
.	O

None	O
of	O
the	O
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
belonging	O
to	O
the	O
6H	O
series	O
,	O
i.e.	O
,	O
lacking	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
on	O
the	O
pyridine	O
nitrogen	O
,	O
was	O
active	O
in	O
analogous	O
tests	O
.	O

Of	O
the	O
investigated	O
compounds	O
,	O
the	O
most	O
active	O
was	O
2,5,9,11	I-IUPAC
-	I-IUPAC
tetramethyl	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
,	O
a	O
compound	O
bearing	O
the	O
highest	O
number	O
of	O
symmetrically	O
distributed	O
methyl	I-IUPAC
groups	B-MODIFIER
.	O

The	O
interaction	O
of	O
indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
with	O
DNA	O
was	O
studied	O
by	O
measuring	O
the	O
increase	O
of	O
calf	O
thymus	O
DNA	O
denaturating	O
temperature	O
(	O
Tm	O
)	O
.	O

The	O
delta	O
Tm	O
values	O
for	O
the	O
5H	O
series	O
were	O
found	O
to	O
be	O
about	O
10	O
times	O
as	O
high	O
as	O
those	O
for	O
the	O
6H	O
compounds	O
.	O

Indolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinolines	I-IUPAC
with	O
the	O
highest	O
number	O
of	O
methyl	I-IUPAC
groups	B-MODIFIER
had	O
the	O
greatest	O
contribution	O
to	O
the	O
increase	O
in	O
the	O
Tm	O
of	O
calf	O
thymus	O
DNA	O
.	O

The	O
values	O
of	O
delta	O
Tm	O
reached	O
19	O
degrees	O
C	O
and	O
1.6	O
degrees	O
C	O
for	O
the	O
most	O
substituted	O
compounds	O
of	O
both	O
series	O
.	O

The	O
dedifferentiation	O
agent	O
"	O
reversine	O
"	O
[	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
morpholinoanilino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyladenine	I-IUPAC
2	I-IUPAC
]	O
was	O
found	O
to	O
be	O
a	O
moderately	O
potent	O
antagonist	O
for	O
the	O
human	O
A	O
(	O
3	O
)	O
adenosine	O
receptor	O
(	O
AR	O
)	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
0.66	O
microM	O
.	O

This	O
result	O
prompted	O
an	O
exploration	O
of	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
related	O
derivatives	O
,	O
synthesized	O
via	O
sequential	O
substitution	O
of	O
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluoropurine	I-IUPAC
with	O
selected	O
nucleophiles	O
.	O

Optimization	O
of	O
substituents	O
at	O
these	O
two	O
positions	O
identified	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyladenine	I-IUPAC
(	O
12	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cycloheptyladenine	I-IUPAC
(	O
19	O
)	O
,	O
and	O
2	I-IUPAC
-	I-IUPAC
phenylamino	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
endo	I-IUPAC
-	I-IUPAC
norbornyladenine	I-IUPAC
(	O
21	O
)	O
as	O
potent	O
A	O
(	O
3	O
)	O
AR	O
ligands	O
with	O
K	O
(	O
i	O
)	O
values	O
of	O
51	O
,	O
42	O
,	O
and	O
37	O
nM	O
,	O
respectively	O
,	O
with	O
30-200	O
-	O
fold	O
selectivity	O
in	O
comparison	O
to	O
A	O
(	O
1	O
)	O
and	O
A	O
(	O
2A	O
)	O
ARs	O
.	O

The	O
most	O
selective	O
A	O
(	O
3	O
)	O
AR	O
antagonist	O
(	O
&	O
gt	O
;	O
200	O
-	O
fold	O
)	O
was	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyladenine	I-IUPAC
(	O
22	O
)	O
.	O

9	O
-	O
Methylation	O
of	O
12	O
,	O
but	O
not	O
19	O
,	O
was	O
well	O
-	O
tolerated	O
in	O
A	O
(	O
3	O
)	O
AR	O
binding	O
.	O

Extension	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
phenylamino	I-IUPAC
group	I-MODIFIER
to	O
2	I-PARTIUPAC
-	I-PARTIUPAC
benzyl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethylamino	I-IUPAC
)	I-IUPAC
reduced	O
affinity	O
.	O

In	O
the	O
series	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenyloxy	I-IUPAC
)	I-IUPAC
,	O
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
substitutions	I-MODIFIER
,	O
the	O
order	O
of	O
affinity	O
at	O
the	O
A	O
(	O
3	O
)	O
AR	O
was	O
oxy	O
&	O
gt	O
;	O
or	O
=	O
amino	O
&	O
gt	O
;	O
thio	O
.	O

Selected	O
derivatives	O
,	O
including	O
reversine	O
(	O
K	O
(	O
B	O
)	O
value	O
of	O
466	O
nM	O
via	O
Schild	O
analysis	O
)	O
,	O
competitively	O
antagonized	O
the	O
functional	O
effects	O
of	O
a	O
selective	O
A	O
(	O
3	O
)	O
AR	O
agonist	O
,	O
i.e.	O
,	O
inhibition	O
of	O
forskolin	O
-	O
stimulated	O
cAMP	O
production	O
in	O
stably	O
transfected	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

These	O
results	O
are	O
in	O
agreement	O
with	O
other	O
studies	O
suggesting	O
the	O
presence	O
of	O
a	O
lipophilic	O
pocket	O
in	O
the	O
AR	O
binding	O
site	O
that	O
is	O
filled	O
by	O
moderately	O
sized	O
cycloalkyl	O
rings	O
at	O
the	O
N	O
(	O
6	O
)	O
position	O
of	O
both	O
adenine	O
and	O
adenosine	O
derivatives	O
.	O

Thus	O
,	O
the	O
compound	O
series	O
reported	O
herein	O
comprise	O
an	O
important	O
new	O
series	O
of	O
selective	O
A	O
(	O
3	O
)	O
AR	O
antagonists	O
.	O

We	O
were	O
unable	O
to	O
reproduce	O
the	O
dedifferentiation	O
effect	O
of	O
reversine	O
,	O
previously	O
reported	O
,	O
or	O
to	O
demonstrate	O
any	O
connection	O
between	O
A	O
(	O
3	O
)	O
AR	O
antagonist	O
effects	O
and	O
dedifferentiation	O
.	O

In	O
order	O
to	O
investigate	O
the	O
structural	O
requirements	O
for	O
gastroprotective	O
activity	O
in	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
,	I-IUPAC
5	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ammoniohexanoate	I-IUPAC
[	O
AI	O
-	O
77	O
-	O
B	O
,	O
1	O
]	O
,	O
a	O
product	O
of	O
Bacillus	O
pumilus	O
AI	O
-	O
77	O
,	O
nine	O
derivatives	O
were	O
prepared	O
and	O
then	O
tested	O
for	O
protective	O
activity	O
against	O
stress	O
-	O
induced	O
ulcers	O
in	O
rats	O
.	O

Neither	O
the	O
chromophore	O
,	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
ammonium	I-IUPAC
chloride	I-IUPAC
(	O
2	O
)	O
,	O
nor	O
the	O
side	O
-	O
chain	O
moiety	O
,	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydroxyhexanedioic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
,	O
as	O
separate	O
fragments	O
alone	O
showed	O
any	O
significant	O
activity	O
.	O

Hydrolysis	O
of	O
the	O
lactone	O
ring	O
of	O
the	O
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
one	I-IUPAC
skeleton	I-MODIFIER
,	O
to	O
give	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylhex	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ammoniohexanoate	I-IUPAC
(	O
5	O
)	O
,	O
led	O
to	O
a	O
considerable	O
decrease	O
in	O
activity	O
.	O

The	O
formation	O
of	O
a	O
gamma	O
-	O
lactone	O
ring	O
in	O
the	O
side	O
chain	O
,	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olid	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ammonium	I-IUPAC
chloride	I-IUPAC
(	O
6	O
)	O
,	O
resulted	O
in	O
a	O
small	O
decrease	O
in	O
activity	O
.	O

Selective	O
acetylation	O
at	O
the	O
primary	O
amine	O
position	O
of	O
6	O
,	O
to	O
give	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olide	I-IUPAC
(	O
7	O
)	O
,	O
led	O
to	O
a	O
considerable	O
decrease	O
in	O
activity	O
.	O

Both	O
di	O
-	O
and	O
triacetylated	O
derivatives	O
of	O
6	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olide	I-IUPAC
(	O
8	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olide	I-IUPAC
(	O
9	O
)	O
,	O
were	O
inactive	O
.	O

Selective	O
methylation	O
of	O
the	O
phenolic	I-MODIFIER
hydroxyl	B-IUPAC
group	B-MODIFIER
of	O
to	O
give	O
1	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ammoniohexanoate	I-IUPAC
(	O
15	O
)	O
,	O
resulted	O
in	O
a	O
small	O
decrease	O
in	O
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
conversion	O
of	O
the	O
carboxyl	I-IUPAC
group	B-MODIFIER
of	O
the	O
side	O
chain	O
to	O
an	O
amide	O
,	O
to	O
give	O
[	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hexanamido	I-IUPAC
]	I-IUPAC
ammonium	I-IUPAC
chloride	I-IUPAC
(	O
10	O
)	O
,	O
caused	O
a	O
considerable	O
increase	O
in	O
both	O
activity	O
and	O
toxicity	O
.	O

The	O
findings	O
showed	O
that	O
modifications	O
at	O
the	O
position	O
of	O
the	O
amino	O
acid	O
moiety	O
of	O
1	O
significantly	O
influenced	O
the	O
activity	O
and	O
that	O
the	O
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
one	I-IUPAC
skeleton	I-MODIFIER
was	O
also	O
required	O
for	O
activity	O
to	O
occur	O
.	O

The	O
binding	O
of	O
selective	O
muscarinic	O
receptor	O
antagonists	O
to	O
regions	O
of	O
rat	O
brain	O
was	O
examined	O
through	O
quantitative	O
autoradiographic	O
techniques	O
.	O

5,11	I-IUPAC
-	I-IUPAC
Dihydro	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
)	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
one	I-IUPAC
[	O
pirenzepine	O
(	O
compound	O
I	O
)	O
]	O
and	O
11	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5,11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
one	I-IUPAC
[	O
AF	O
-	O
DX	O
116	O
(	O
compound	O
II	O
)	O
]	O
were	O
chosen	O
on	O
the	O
basis	O
of	O
their	O
selectivity	O
for	O
M1	O
and	O
M2	O
muscarinic	O
receptors	O
,	O
respectively	O
,	O
and	O
similarities	O
in	O
chemical	O
structure	O
.	O

Pirenzepine	O
displayed	O
a	O
higher	O
potency	O
than	O
II	O
for	O
inhibition	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
l	I-IUPAC
-	I-IUPAC
quinuclidinyl	I-IUPAC
benzilate	I-IUPAC
(	O
[	O
3H	O
]	O
-	O
l	O
-	O
QNB	O
)	O
binding	O
to	O
rat	O
brain	O
sections	O
.	O

Scatchard	O
analyses	O
of	O
binding	O
to	O
brain	O
sections	O
revealed	O
heterogeneous	O
binding	O
profiles	O
for	O
both	O
antagonists	O
,	O
suggesting	O
the	O
presence	O
of	O
multiple	O
receptor	O
binding	O
sites	O
.	O

Quantitative	O
autoradiographic	O
techniques	O
were	O
utilized	O
in	O
regional	O
analyses	O
of	O
antagonist	O
binding	O
.	O

Pirenzepine	O
displayed	O
the	O
highest	O
affinity	O
for	O
hippocampal	O
,	O
striatal	O
,	O
and	O
amygdaloid	O
muscarinic	O
receptors	O
(	O
IC50	O
values	O
less	O
than	O
0.4	O
microM	O
)	O
,	O
with	O
a	O
slightly	O
lower	O
affinity	O
for	O
cortical	O
receptors	O
(	O
IC50	O
values	O
between	O
0.4	O
and	O
0.8	O
microM	O
)	O
.	O

Pirenzepine	O
displayed	O
the	O
lowest	O
affinity	O
for	O
thalamic	O
and	O
brainstem	O
regions	O
with	O
IC50	O
values	O
generally	O
greater	O
than	O
1.0	O
microM	O
.	O

In	O
contrast	O
,	O
II	O
bound	O
with	O
higher	O
affinity	O
to	O
muscarinic	O
receptors	O
in	O
brainstem	O
,	O
cerebellar	O
,	O
and	O
hypothalamic	O
nuclei	O
(	O
IC50	O
values	O
less	O
than	O
0.5	O
microM	O
)	O
than	O
to	O
receptors	O
in	O
thalamic	O
nuclei	O
(	O
IC50	O
values	O
between	O
0.5	O
and	O
2.0	O
microM	O
)	O
.	O

Binding	O
sites	O
with	O
the	O
lowest	O
affinity	O
for	O
II	O
were	O
found	O
in	O
cortical	O
,	O
striatal	O
,	O
and	O
hippocampal	O
regions	O
(	O
IC50	O
values	O
greater	O
than	O
2.0	O
microM	O
)	O
.	O

The	O
binding	O
profiles	O
of	O
the	O
two	O
selective	O
muscarinic	O
antagonists	O
reveal	O
the	O
complexity	O
and	O
diversity	O
of	O
muscarinic	O
receptor	O
subtypes	O
throughout	O
the	O
brain	O
.	O

The	O
data	O
provide	O
a	O
basis	O
for	O
identifying	O
muscarinic	O
receptor	O
subtypes	O
(	O
as	O
defined	O
through	O
cloning	O
procedures	O
)	O
with	O
selective	O
ligands	O
.	O

Minimum	O
-	O
energy	O
conformations	O
of	O
pirenzepine	O
and	O
II	O
were	O
calculated	O
by	O
using	O
the	O
program	O
MacroModel	O
(	O
version	O
2.0	O
)	O
.	O

Pirenzepine	O
displayed	O
three	O
energy	O
minima	O
,	O
differing	O
in	O
the	O
relative	O
position	O
of	O
the	O
piperazine	O
ring	O
with	O
respect	O
to	O
the	O
tricyclic	O
system	O
.	O

In	O
contrast	O
,	O
the	O
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
piperidine	O
ring	O
conferred	O
a	O
much	O
larger	O
set	O
of	O
minimum	O
-	O
energy	O
conformations	O
on	O
II	O
.	O

It	O
is	O
suggested	O
that	O
the	O
greater	O
conformational	O
flexibility	O
of	O
the	O
side	O
chain	O
allows	O
II	O
to	O
achieve	O
a	O
conformation	O
inaccessible	O
to	O
pirenzepine	O
,	O
which	O
allows	O
it	O
to	O
bind	O
preferentially	O
to	O
M2	O
receptors	O
.	O

2	O
-	O
[	O
5	O
-	O
(	O
4	O
-	O
Amidinophenyl	O
)	O
-	O
furan	O
-	O
2	O
-	O
yl	O
]	O
-	O
5,6,7,8	O
-	O
tetrahydro	O
-	O
imidazo	O
[	O
1,2	O
-	O
a	O
]	O
pyridine	O
-	O
6	O
-	O
carboxamidine	O
acetate	O
salt	O
(	O
7	O
)	O
was	O
synthesized	O
from	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
cyanophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
(	O
4a	O
)	O
,	O
through	O
the	O
bis	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetoxyamidoxime	I-IUPAC
followed	O
by	O
hydrogenation	O
in	O
glacial	O
acetic	O
acid	O
.	O

Compound	O
4a	O
was	O
obtained	O
in	O
four	O
steps	O
starting	O
with	O
two	O
successive	O
brominations	O
of	O
2	I-IUPAC
-	I-IUPAC
acetylfuran	I-IUPAC
first	O
with	O
N	I-IUPAC
-	I-IUPAC
bromosuccinimide	I-IUPAC
,	O
and	O
second	O
with	O
bromine	O
to	O
form	O
alpha	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bromofuran	I-IUPAC
(	O
2	O
)	O
in	O
a	O
moderate	O
yield	O
.	O

The	O
product	O
(	O
3a	O
)	O
,	O
of	O
the	O
condensation	O
reaction	O
between	O
6	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
nicotinonitrile	I-IUPAC
and	O
2	O
,	O
undergoes	O
Suzuki	O
coupling	O
with	O
4	I-IUPAC
-	I-IUPAC
cyanophenylboronic	I-IUPAC
acid	I-IUPAC
to	O
furnish	O
4a	O
in	O
good	O
yield	O
.	O

Acetate	O
salt	O
of	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amidinophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamidine	I-IUPAC
(	O
8a	O
)	O
was	O
obtained	O
from	O
4a	O
,	O
through	O
the	O
bis	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetoxyamidoxime	I-IUPAC
followed	O
by	O
hydrogenation	O
in	O
a	O
mixture	O
of	O
ethanol	O
/	O
ethyl	O
acetate	O
.	O

N	I-IUPAC
-	I-IUPAC
Methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methoxyamidino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamidine	I-IUPAC
(	O
6	O
)	O
was	O
prepared	O
via	O
methylation	O
of	O
the	O
respective	O
diamidoxime	O
5a	O
with	O
dimethyl	O
sulfate	O
.	O

By	O
these	O
approaches	O
eight	O
new	O
diamidines	O
and	O
four	O
potential	O
prodrugs	O
were	O
prepared	O
.	O

All	O
of	O
the	O
diamidines	O
showed	O
strong	O
DNA	O
affinities	O
as	O
judged	O
by	O
high	O
DeltaT	O
(	O
m	O
)	O
values	O
.	O

Six	O
of	O
the	O
eight	O
diamidines	O
gave	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
values	O
of	O
63	O
nM	O
or	O
less	O
vs	O
T	O
.	O

b	O
.	O

rhodesiense	O
with	O
two	O
exhibiting	O
values	O
of	O
6	O
nM	O
and	O
1	O
nM	O
.	O

Also	O
,	O
six	O
of	O
the	O
eight	O
diamidines	O
gave	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
values	O
of	O
88	O
nM	O
or	O
less	O
vs	O
P	O
.	O

falciparum	O
with	O
two	O
exhibiting	O
values	O
of	O
14	O
nM	O
.	O

Excellent	O
in	O
vivo	O
activity	O
in	O
the	O
trypanosomal	O
STIB900	O
mouse	O
model	O
was	O
found	O
for	O
five	O
of	O
the	O
diamidines	O
on	O
ip	O
dosage	O
;	O
these	O
compounds	O
gave	O
4/4	O
cures	O
in	O
this	O
model	O
.	O

The	O
oral	O
activity	O
of	O
the	O
prodrugs	O
was	O
modest	O
with	O
only	O
one	O
showing	O
2/4	O
cures	O
in	O
the	O
same	O
mouse	O
model	O
.	O

Condensation	O
of	O
cyanothioacetamide	O
(	O
4	O
)	O
with	O
ethyl	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethylene	I-IUPAC
)	I-IUPAC
acetoacetate	I-IUPAC
(	O
5b	O
)	O
,	O
ethyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxobutanoate	I-IUPAC
(	O
5c	O
)	O
,	O
ethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethylene	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpropanoate	I-IUPAC
(	O
5d	O
)	O
afforded	O
exclusively	O
the	O
corresponding	O
6	O
-	O
substituted	O
pyridines	O
(	O
6b	O
-	O
d	O
)	O
.	O

Cyclization	O
of	O
4	O
with	O
3	I-IUPAC
-	I-IUPAC
carbethoxybutane	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
5e	O
)	O
gave	O
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4,6	I-IUPAC
-	I-IUPAC
dimethylpyridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
thione	I-IUPAC
(	O
6e	O
)	O
,	O
whereas	O
reaction	O
of	O
4	O
with	O
3	I-IUPAC
-	I-IUPAC
carbethoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylpropane	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
5f	O
)	O
yielded	O
two	O
products	O
,	O
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
phenylpyridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
thione	I-IUPAC
(	O
6f	O
)	O
and	O
the	O
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
isomer	I-MODIFIER
6g	O
.	O

The	O
structural	O
assignments	O
for	O
6f	O
and	O
6g	O
are	O
made	O
on	O
the	O
basis	O
of	O
1H	O
and	O
13C	O
NMR	O
spectral	O
analyses	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
nicotinates	I-IUPAC
(	O
7f	O
,	O
g	O
)	O
prepared	O
from	O
6f	O
and	O
6g	O
by	O
treatment	O
with	O
MeI	O
/	O
K2CO3	O
.	O

Nicotinates	O
7b	O
,	O
d	O
-	O
g	O
were	O
converted	O
into	O
their	O
corresponding	O
2,4	I-IUPAC
-	I-IUPAC
diaminopyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
12b	O
,	O
d	O
-	O
g	O
in	O
five	O
steps	O
,	O
via	O
reduction	O
,	O
protection	O
,	O
oxidation	O
,	O
condensation	O
with	O
guanidine	O
,	O
and	O
deprotection	O
.	O

The	O
7	I-MODIFIER
-	I-MODIFIER
mono	I-MODIFIER
-	I-MODIFIER
and	O
5,7	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
-	O
5	I-IUPAC
-	I-IUPAC
deazaaminopterins	I-IUPAC
(	O
1b	O
,	O
d	O
-	O
g	O
)	O
were	O
prepared	O
from	O
the	O
respective	O
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
12b	O
,	O
d	O
-	O
g	O
.	O

Preliminary	O
biological	O
studies	O
showed	O
that	O
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
and	O
5,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
analogues	I-MODIFIER
(	O
1b	O
and	O
1e	O
)	O
were	O
less	O
active	O
than	O
methotrexate	O
against	O
human	O
leukemic	O
HL	O
-	O
60	O
and	O
murine	O
L	O
-	O
1210	O
cells	O
in	O
tissue	O
culture	O
.	O

Compound	O
1e	O
produced	O
an	O
ILS	O
of	O
71%	O
at	O
100	O
mg	O
/	O
kg	O
per	O
day	O
X	O
5	O
(	O
ip	O
)	O
in	O
BDF	O
mice	O
inoculated	O
ip	O
with	O
10	O
(	O
6	O
)	O
L	O
-	O
1210	O
cells	O
.	O

In	O
a	O
sequence	O
of	O
reactions	O
,	O
methyl	O
mesopyropheophorbide	O
a	O
,	O
mesochlorin	I-IUPAC
e	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
trimethyl	I-IUPAC
ester	I-IUPAC
,	O
mesochlorin	I-IUPAC
p	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
trimethyl	I-IUPAC
ester	I-IUPAC
,	O
mesopurpurin	I-IUPAC
-	I-IUPAC
18	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hexylimide	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
,	O
and	O
mesopurpurin	I-IUPAC
-	I-IUPAC
18	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
benzylimide	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
were	O
synthesized	O
from	O
chlorophyll	O
-	O
a	O
.	O

These	O
chlorins	O
on	O
reacting	O
with	O
osmium	O
tetraoxide	O
produced	O
the	O
corresponding	O
vic	O
-	O
dihydroxybacteriochlorins	O
.	O

The	O
8	I-IUPAC
-	I-IUPAC
vinylchlorins	I-IUPAC
obtained	O
by	O
refluxing	O
the	O
related	O
vic	O
-	O
dihydroxybacteriochlorins	O
in	O
o	I-IUPAC
-	I-IUPAC
dichlorobenzene	I-IUPAC
were	O
individually	O
treated	O
with	O
dimethylacetylenedicarboxylate	I-IUPAC
(	O
DMAD	O
)	O
under	O
Diels	O
-	O
Alder	O
reaction	O
conditions	O
.	O

The	O
intermediate	O
adducts	O
on	O
1,8	I-IUPAC
-	I-IUPAC
diazabicyclo	I-IUPAC
[	I-IUPAC
5.4.0	I-IUPAC
]	I-IUPAC
undec	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
(	O
DBU	O
)	O
treatment	O
rearranged	O
to	O
the	O
corresponding	O
stable	O
benzobacteriochlorins	O
,	O
exhibiting	O
the	O
longest	O
wavelength	O
absorption	O
in	O
the	O
range	O
of	O
737	O
to	O
805	O
nm	O
.	O

In	O
preliminary	O
in	O
vitro	O
(	O
RIF	O
tumor	O
cells	O
)	O
and	O
in	O
vivo	O
screening	O
(	O
C3H	O
/	O
HeJ	O
mice	O
bearing	O
RIF	O
tumors	O
)	O
,	O
some	O
of	O
these	O
compounds	O
were	O
found	O
to	O
be	O
quite	O
effective	O
.	O

Under	O
similar	O
treatment	O
conditions	O
(	O
drug	O
dose	O
:	O
5.0	O
micromol	O
/	O
kg	O
;	O
light	O
dose	O
:	O
135	O
J	O
/	O
cm	O
(	O
2	O
)	O
,	O
tumors	O
were	O
exposed	O
to	O
light	O
for	O
30	O
min	O
at	O
24	O
h	O
postinjection	O
)	O
,	O
the	O
benzobacteriochlorins	O
containing	O
N	O
-	O
substituted	O
-	O
imide	O
ring	O
system	O
produced	O
enhanced	O
photosensitizing	O
efficacy	O
with	O
limited	O
skin	O
phototoxicity	O
.	O

These	O
compounds	O
were	O
also	O
found	O
to	O
bind	O
to	O
site	O
II	O
of	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
.	O

However	O
,	O
no	O
correlation	O
between	O
the	O
binding	O
constant	O
values	O
and	O
photosensitizing	O
efficacy	O
was	O
observed	O
.	O

A	O
competitive	O
intracellular	O
localization	O
study	O
of	O
these	O
novel	O
structures	O
with	O
Rhodamine	O
-	O
123	O
(	O
a	O
mitochondrial	O
probe	O
)	O
indicated	O
their	O
preferential	O
localization	O
in	O
mitochondria	O
,	O
without	O
producing	O
any	O
specific	O
displacement	O
of	O
(	O
3	O
)	O
H	O
-	O
PK11195	O
(	O
PBR	O
probe	O
,	O
(	I-MODIFIER
3	I-MODIFIER
)	I-MODIFIER
H	I-MODIFIER
-	I-MODIFIER
labeled	I-MODIFIER
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylpropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isoquinoline	I-IUPAC
carboxamide	I-IUPAC
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
mitochondrial	O
peripheral	O
benzodiazepine	O
receptor	O
(	O
PBR	O
)	O
is	O
not	O
the	O
cellular	O
binding	O
site	O
for	O
this	O
class	O
of	O
compounds	O
.	O

7	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,6	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
are	O
potent	O
inhibitors	O
of	O
protein	O
tyrosine	O
kinases	O
,	O
with	O
some	O
selectivity	O
for	O
c	O
-	O
Src	O
.	O

The	O
compounds	O
were	O
prepared	O
by	O
condensing	O
4	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
diaminonicotinaldehyde	I-IUPAC
with	O
2,6	I-IUPAC
-	I-IUPAC
dichlorophenylacetonitrile	I-IUPAC
and	O
selectively	O
converting	O
the	O
2	O
-	O
and	O
7	O
-	O
amino	O
groups	O
of	O
the	O
product	O
to	O
hydroxy	O
and	O
fluoro	O
groups	O
,	O
respectively	O
,	O
by	O
prolonged	O
diazotization	O
in	O
50%	O
aqueous	O
fluoboric	O
acid	O
.	O

N	O
-	O
Methylation	O
,	O
followed	O
by	O
treatment	O
with	O
aliphatic	O
diamines	O
,	O
aromatic	O
amines	O
,	O
or	O
their	O
derived	O
lithium	O
anions	O
,	O
gave	O
the	O
desired	O
compounds	O
.	O

Selected	O
isomeric	O
1	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
also	O
prepared	O
in	O
order	O
to	O
evaluate	O
the	O
relative	O
contributions	O
of	O
both	O
ring	O
A	O
aza	O
atoms	O
of	O
the	O
related	O
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
8H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
to	O
the	O
inhibitory	O
activity	O
.	O

The	O
compounds	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
prevent	O
phosphorylation	O
of	O
a	O
model	O
substrate	O
by	O
c	O
-	O
Src	O
,	O
FGF	O
-	O
1	O
receptor	O
,	O
and	O
PDGF	O
-	O
beta	O
receptor	O
enzymes	O
.	O

Overall	O
,	O
there	O
was	O
a	O
high	O
degree	O
of	O
correlation	O
of	O
the	O
activities	O
against	O
the	O
different	O
kinases	O
,	O
with	O
c	O
-	O
Src	O
being	O
generally	O
the	O
most	O
sensitive	O
to	O
structural	O
changes	O
.	O

1	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
Naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
analogues	I-MODIFIER
bearing	O
basic	O
aliphatic	O
side	O
chains	O
[	O
7	O
-	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
n	O
)	O
(	O
)	O
NRR	O
,	O
7	O
-	O
NHPhO	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
n	O
)	O
(	O
)	O
NRR	O
,	O
or	O
7	O
-	O
NHPhN	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
4	O
)	O
NMe	O
]	O
were	O
the	O
most	O
potent	O
against	O
c	O
-	O
Src	O
(	O
IC	O
(	O
50	O
)	O
s	O
of	O
10-80	O
nM	O
)	O
,	O
showing	O
good	O
selectivity	O
with	O
respect	O
to	O
PDGFR	O
(	O
10-300	O
-	O
fold	O
)	O
but	O
less	O
with	O
respect	O
to	O
FGFR	O
.	O

The	O
1	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
showed	O
broadly	O
similar	O
activity	O
to	O
the	O
analogous	I-MODIFIER
pyrido	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
8H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
whereas	O
the	O
1	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
at	O
least	O
10	O
(	O
3	O
)	O
-	O
fold	O
less	O
potent	O
.	O

These	O
results	O
,	O
indicating	O
that	O
the	O
3	O
-	O
aza	O
atom	O
in	O
the	O
pyrido	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
8H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
is	O
mandatory	O
,	O
whereas	O
the	O
1	O
-	O
aza	O
atom	O
is	O
not	O
,	O
support	O
the	O
published	O
binding	O
model	O
for	O
these	O
compounds	O
to	O
c	O
-	O
Src	O
(	O
J	O
.	O

Med.	O
Chem.	O
1998	O
,	O
41	O
,	O
1752	O
)	O
,	O
where	O
the	O
3	O
-	O
aza	O
and	O
2	O
-	O
NH	O
atoms	O
form	O
a	O
bidentate	O
H	O
-	O
bond	O
donor	O
-	O
acceptor	O
motif	O
that	O
interacts	O
with	O
Met341	O
and	O
the	O
1	O
-	O
aza	O
atom	O
is	O
not	O
involved	O
in	O
specific	O
binding	O
interactions	O
.	O

beta	O
-	O
(	O
1	O
-	O
Chloro	O
-	O
2	O
-	O
naphthyl	O
)	O
alanine	O
and	O
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
were	O
synthesized	O
by	O
ammonolysis	O
of	O
the	O
corresponding	O
alpha	I-IUPAC
,	I-IUPAC
1	I-IUPAC
-	I-IUPAC
dihalo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthalenepropanoic	I-IUPAC
acids	I-IUPAC
derived	O
from	O
1	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthylamine	I-IUPAC
by	O
diazotization	O
and	O
condensation	O
with	O
acrylic	O
acid	O
in	O
the	O
presence	O
of	O
cuprous	O
halides	O
.	O

The	O
two	O
analogs	O
as	O
well	O
as	O
the	O
previously	O
reported	O
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
and	O
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
were	O
studied	O
as	O
growth	O
inhibitors	O
of	O
Escherichia	O
coli	O
9723	O
,	O
Leuconostoc	O
dextranicum	O
8086	O
,	O
and	O
Lactobacillus	O
plantarum	O
8014	O
.	O

In	O
general	O
,	O
the	O
chloro	O
and	O
bromo	O
analogs	O
were	O
more	O
effective	O
than	O
the	O
unsubstituted	O
naphthylalanines	O
as	O
growth	O
inhibitors	O
of	O
the	O
three	O
microorganisms	O
studied	O
.	O

Several	O
6	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
analogs	I-MODIFIER
of	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
(	O
1	O
;	O
HEPT	O
)	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
.	O

LDA	O
(	O
lithium	O
diisopropylamide	O
)	O
lithiation	O
of	O
5	I-IUPAC
-	I-IUPAC
ethyluracil	I-IUPAC
derivatives	I-MODIFIER
7	O
and	O
8	O
and	O
subsequent	O
reaction	O
with	O
an	O
aryl	O
aldehyde	O
gave	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylhydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ethyluracil	I-IUPAC
derivatives	I-MODIFIER
9-12	O
.	O

6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Arylhydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isopropyluracil	I-IUPAC
derivatives	I-MODIFIER
15-18	O
were	O
prepared	O
from	O
the	O
5	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiouracil	I-IUPAC
derivatives	I-MODIFIER
13	O
and	O
14	O
by	O
the	O
above	O
procedure	O
following	O
oxidative	O
hydrolysis	O
of	O
the	O
thione	O
.	O

Preparation	O
of	O
the	O
target	O
5	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
benzyluracil	I-IUPAC
derivatives	I-MODIFIER
27-34	O
was	O
carried	O
out	O
by	O
acetylation	O
of	O
9-14	O
followed	O
by	O
Pd	O
-	O
catalyzed	O
hydrogenolysis	O
.	O

The	O
1	I-PARTIUPAC
-	I-PARTIUPAC
butyl	I-PARTIUPAC
-	I-PARTIUPAC
(	O
37	O
and	O
39	O
)	O
and	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
methoxyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	O
38	O
and	O
40	O
)	O
5	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
benzyluracils	I-IUPAC
were	O
synthesized	O
by	O
1	O
-	O
alkylation	O
of	O
the	O
3	I-IUPAC
-	I-IUPAC
phenacyl	I-IUPAC
derivatives	I-MODIFIER
35	O
and	O
36	O
with	O
alkyl	O
halides	O
followed	O
by	O
deprotection	O
of	O
the	O
3	I-IUPAC
-	I-IUPAC
phenacyl	I-IUPAC
group	I-MODIFIER
.	O

Compounds	O
synthesized	O
in	O
this	O
study	O
inhibited	O
HIV	O
-	O
1	O
replication	O
in	O
MT	O
-	O
4	O
cells	O
in	O
the	O
submicromolar	O
to	O
namomolar	O
concentration	O
range	O
.	O

From	O
this	O
series	O
of	O
compounds	O
,	O
6	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isopropyluracil	I-IUPAC
(	O
33	O
)	O
was	O
selected	O
for	O
clinical	O
evaluation	O
.	O

The	O
novel	O
semirigid	O
derivatives	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexyl	I-IUPAC
]	I-IUPAC
piperidine	I-IUPAC
[	O
(	O
+	O
)	O
-	O
8	O
]	O
,	O
its	O
enantiomer	O
(	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
,	O
and	O
(	I-IUPAC
+	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexyl	I-IUPAC
]	I-IUPAC
piperidine	I-IUPAC
[	O
(	O
+	O
/	O
-	O
)	O
-	O
9	O
]	O
were	O
synthesized	O
as	O
probes	O
to	O
investigate	O
the	O
mode	O
of	O
interaction	O
of	O
phencyclidine	O
(	O
PCP	O
)	O
with	O
its	O
binding	O
site	O
on	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartate	I-IUPAC
receptor	O
complex	O
.	O

Each	O
target	O
compound	O
was	O
obtained	O
in	O
five	O
steps	O
starting	O
from	O
cyclopent	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enone	I-IUPAC
.	O

(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
8	O
were	O
obtained	O
in	O
greater	O
than	O
98%	O
optical	O
purity	O
through	O
three	O
recrystallizations	O
from	O
ethanol	O
of	O
the	O
(	I-PARTIUPAC
S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
mandelate	I-IUPAC
salts	I-IUPAC
of	O
intermediate	O
(	I-IUPAC
+	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexylamine	I-IUPAC
(	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
16	O
]	O
.	O

Crystallization	O
of	O
the	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
mandelate	I-IUPAC
salt	I-IUPAC
afforded	O
(	O
1R	O
,	O
2R	O
,	O
5S	O
)	O
-	O
(	O
-	O
)	O
-	O
16	O
,	O
whereas	O
the	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
mandelate	I-IUPAC
salt	I-IUPAC
afforded	O
(	O
1S	O
,	O
2S	O
,	O
5R	O
)	O
-	O
(	O
+	O
)	O
-	O
16	O
;	O
the	O
absolute	O
configuration	O
was	O
determined	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
of	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
16	I-IUPAC
.	I-IUPAC

(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
mandelate	I-IUPAC
.	O

Single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
of	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
picrate	I-IUPAC
confirmed	O
its	O
trans	O
configuration	O
and	O
provided	O
conformational	O
data	O
.	O

(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
8	O
and	O
(	O
+	O
/	O
-	O
)	O
-	O
9	O
were	O
examined	O
for	O
their	O
ability	O
to	O
interact	O
with	O
PCP	O
and	O
sigma	O
binding	O
sites	O
in	O
vitro	O
using	O
[	O
3H	O
]	O
TCP	O
and	O
[	O
3H	O
]	O
pentazocine	O
as	O
radioligands	O
.	O

The	O
binding	O
was	O
compared	O
with	O
that	O
of	O
PCP	O
and	O
contrasted	O
with	O
the	O
rigid	O
symmetrical	O
phencyclidine	O
derivatives	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexyl	I-IUPAC
]	I-IUPAC
piperidines	I-IUPAC
(	O
6	O
and	O
7	O
)	O
.	O

The	O
results	O
of	O
the	O
study	O
indicated	O
that	O
the	O
conformations	O
of	O
PCP	O
represented	O
by	O
6-9	O
are	O
not	O
optimal	O
for	O
potent	O
interaction	O
at	O
either	O
of	O
these	O
sites	O
.	O

Affinities	O
ranged	O
from	O
582	O
nM	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
9	O
]	O
to	O
29,000	O
nM	O
[	O
(	O
+	O
)	O
-	O
8	O
]	O
at	O
PCP	O
binding	O
sites	O
and	O
from	O
1130	O
nM	O
[	O
(	O
-	O
)	O
-	O
8	O
]	O
to	O
16,300	O
nM	O
(	O
7	O
)	O
at	O
sigma	O
sites	O
.	O

In	O
this	O
assay	O
,	O
PCP	O
exhibited	O
affinities	O
of	O
64.5	O
nM	O
at	O
PCP	O
and	O
1090	O
nM	O
at	O
sigma	O
sites	O
.	O

Qualitative	O
correlation	O
between	O
the	O
sigma	O
and	O
PCP	O
binding	O
data	O
suggests	O
some	O
similarities	O
between	O
these	O
binding	O
sites	O
.	O

An	O
axial	O
phenyl	I-MODIFIER
and	O
equatorial	I-MODIFIER
piperidine	B-IUPAC
ring	B-MODIFIER
with	O
the	O
nitrogen	O
lone	O
pair	O
of	O
electrons	O
antiperiplanar	O
to	O
the	O
phenyl	I-IUPAC
ring	B-MODIFIER
has	O
been	O
postulated	O
as	O
the	O
receptor	O
-	O
active	O
conformation	O
of	O
PCP	O
-	O
like	O
ligands	O
at	O
the	O
PCP	O
binding	O
site	O
.	O

Comparison	O
of	O
the	O
binding	O
data	O
of	O
7-9	O
with	O
that	O
of	O
the	O
previously	O
described	O
methylcyclohexyl	O
-	O
PCP	O
derivatives	O
allowed	O
its	O
rationalization	O
in	O
terms	O
of	O
this	O
model	O
.	O

It	O
is	O
likely	O
that	O
the	O
lowered	O
affinity	O
in	O
this	O
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexane	I-IUPAC
series	I-MODIFIER
is	O
a	O
consequence	O
of	O
nonoptimal	O
geometry	O
(	O
pseudoequatorial	O
phenyl	O
or	O
pseudoboat	O
)	O
for	O
binding	O
as	O
opposed	O
to	O
the	O
presence	O
of	O
steric	O
bulk	O
which	O
proved	O
deleterious	O
in	O
the	O
methylcyclohexyl	O
-	O
PCP	O
derivatives	O
.	O

N10	I-IUPAC
-	I-IUPAC
Propargylfolic	I-IUPAC
acid	I-IUPAC
(	O
2	O
)	O
,	O
which	O
is	O
the	O
closest	O
pteridine	O
analogue	O
of	O
the	O
thymidylate	O
synthase	O
inhibitor	O
N10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
(	O
PDDF	O
)	O
,	O
was	O
synthesized	O
starting	O
from	O
diethyl	I-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propargylamino	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
(	O
5	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopropyl	I-IUPAC
)	I-IUPAC
phthalimide	I-IUPAC
(	O
8	O
)	O
.	O

The	O
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
derivative	I-MODIFIER
of	O
propargylfolic	O
acid	O
served	O
as	O
a	O
synthetic	O
substrate	O
of	O
Lactobacillus	O
casei	O
dihydrofolate	O
reductase	O
.	O

Propargylfolic	O
acid	O
and	O
its	O
reduced	O
derivatives	O
were	O
weak	O
inhibitors	O
of	O
L	O
.	O

casei	O
thymidylate	O
synthase	O
compared	O
to	O
PDDF	O
.	O

All	O
derivatives	O
of	O
propargylfolate	O
were	O
active	O
against	O
the	O
growth	O
of	O
Streptococcus	O
faecium	O
,	O
but	O
with	O
the	O
exception	O
of	O
7,8	I-IUPAC
-	I-IUPAC
dihydropropargylfolic	I-IUPAC
acid	I-IUPAC
,	O
all	O
were	O
inactive	O
against	O
L	O
.	O

casei	O
.	O

Although	O
less	O
potent	O
than	O
PDDF	O
,	O
marked	O
inhibition	O
of	O
thymidylate	O
synthase	O
by	O
2	O
was	O
observed	O
in	O
permeabilized	O
L1210	O
cells	O
.	O

Xanthine	O
derivatives	O
with	O
several	O
functional	O
groups	O
at	O
the	O
1	O
-	O
or	O
7	O
-	O
position	O
were	O
synthesized	O
,	O
and	O
their	O
pharmacological	O
activities	O
in	O
guinea	O
pigs	O
were	O
studied	O
.	O

In	O
general	O
,	O
the	O
in	O
vitro	O
tracheal	O
relaxant	O
action	O
and	O
positive	O
chronotropic	O
action	O
of	O
3	I-IUPAC
-	I-IUPAC
propylxanthines	I-IUPAC
were	O
increased	O
by	O
substitutions	O
with	O
nonpolar	O
functional	O
groups	O
at	O
the	O
1	O
-	O
position	O
,	O
but	O
decreased	O
by	O
any	O
substitution	O
at	O
the	O
7	O
-	O
position	O
.	O

On	O
the	O
other	O
hand	O
,	O
because	O
positive	O
chronotropic	O
actions	O
of	O
substituents	I-MODIFIER
with	O
allyl	I-IUPAC
,	O
aminoalkyl	I-IUPAC
,	O
alkoxyalkyl	I-IUPAC
,	O
and	O
normal	O
alkyl	I-IUPAC
groups	B-MODIFIER
were	O
much	O
less	O
than	O
tracheal	O
muscle	O
became	O
very	O
high	O
with	O
substitutions	I-MODIFIER
of	O
3'	I-IUPAC
-	I-IUPAC
butenyl	I-IUPAC
,	O
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
,	O
2'	I-IUPAC
-	I-IUPAC
ethoxyethyl	I-IUPAC
,	O
3'	I-IUPAC
-	I-IUPAC
methoxypropyl	I-IUPAC
,	O
and	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
groups	I-MODIFIER
at	O
the	O
1	O
-	O
position	O
and	O
of	O
2'	I-IUPAC
-	I-IUPAC
ethoxyethyl	I-IUPAC
,	O
2'	I-IUPAC
-	I-IUPAC
oxopropyl	I-IUPAC
,	O
and	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
groups	I-MODIFIER
at	O
the	O
7	O
-	O
position	O
,	O
compared	O
with	O
theophylline	O
and	O
the	O
corresponding	O
unsubstituted	O
xanthines	O
,	O
3	I-IUPAC
-	I-IUPAC
propylxanthine	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
propylxanthine	I-IUPAC
.	O

When	O
compounds	O
were	O
intraduodenally	O
administered	O
to	O
the	O
guinea	O
pig	O
,	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2'	I-PARTIUPAC
-	I-PARTIUPAC
ethoxyethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
methoxypropyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
1	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3'	I-PARTIUPAC
-	I-PARTIUPAC
butenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
propylxanthines	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
oxopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
propylxanthine	I-IUPAC
,	O
and	O
denbufylline	O
(	O
1,3	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
oxopropyl	I-IUPAC
)	I-IUPAC
xanthine	I-IUPAC
)	O
effectively	O
inhibited	O
the	O
acetylcholine	O
-	O
induced	O
bronchospasm	O
without	O
heart	O
stimulation	O
or	O
central	O
nervous	O
system	O
-	O
stimulation	O
at	O
the	O
effective	O
dosage	O
range	O
.	O

Particularly	O
,	O
the	O
bronchodilatory	O
effect	O
of	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
ethoxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
propylxanthine	I-IUPAC
was	O
much	O
stronger	O
and	O
more	O
continuous	O
than	O
those	O
of	O
theophylline	O
and	O
pentoxifylline	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
were	O
certain	O
relationships	O
among	O
the	O
in	O
vitro	O
tracheal	O
relaxant	O
activities	O
of	O
these	O
compounds	O
,	O
their	O
affinities	O
for	O
adenosine	O
(	O
A1	O
)	O
receptors	O
in	O
the	O
brain	O
membrane	O
,	O
and	O
their	O
inhibition	O
of	O
cyclic	O
AMP	O
-	O
phosphodiesterase	O
(	O
PDE	O
)	O
in	O
the	O
tracheal	O
muscle	O
.	O

The	O
affinity	O
for	O
A2	O
receptors	O
of	O
these	O
compounds	O
was	O
very	O
low	O
or	O
negligible	O
.	O

This	O
suggests	O
that	O
both	O
the	O
action	O
on	O
A1	O
receptors	O
or	O
interaction	O
with	O
adenosine	O
and	O
the	O
cyclic	O
AMP	O
-	O
PDE	O
inhibitory	O
activity	O
contribute	O
to	O
the	O
bronchodilator	O
action	O
of	O
1	O
-	O
and	O
7	O
-	O
substituted	O
xanthines	O
.	O

This	O
study	O
indicates	O
that	O
the	O
substitutions	O
with	O
none	O
or	O
low	O
polar	O
functional	O
groups	O
at	O
the	O
1	O
-	O
position	O
could	O
improve	O
the	O
selectivity	O
and	O
duration	O
of	O
the	O
bronchodilator	O
effects	O
of	O
xanthines	O
.	O

The	O
synthesis	O
of	O
5,11	I-IUPAC
-	I-IUPAC
methenyltetrahydrohomofolate	I-IUPAC
was	O
accomplished	O
by	O
treatment	O
of	O
tetrahydrohomofolate	O
(	O
H4homofolate	O
)	O
with	O
triethyl	O
orthoformate	O
in	O
glacial	O
acetic	O
acid	O
.	O

This	O
compound	O
is	O
a	O
homofolate	O
analogue	O
of	O
5,10	I-IUPAC
-	I-IUPAC
methenyltetrahydrofolate	I-IUPAC
which	O
serves	O
as	O
one	O
precursor	O
to	O
the	O
10	O
-	O
formyl	O
one	O
-	O
carbon	O
donor	O
for	O
the	O
first	O
transformylation	O
in	O
de	O
novo	O
purine	O
biosynthesis	O
,	O
namely	O
,	O
the	O
conversion	O
of	O
glycinamide	O
ribonucleotide	O
(	O
GAR	O
)	O
to	O
N	I-IUPAC
-	I-IUPAC
formylglycinamide	I-IUPAC
ribonucleotide	I-IUPAC
(	O
FGAR	O
)	O
,	O
catalyzed	O
by	O
the	O
enzyme	O
glycinamide	O
ribonucleotide	O
transformylase	O
(	O
EC	O
2.1.2.2	O
)	O
.	O

The	O
analogue	O
proved	O
to	O
retard	O
the	O
rate	O
of	O
formation	O
of	O
formylglycinamide	O
ribonucleotide	O
apparently	O
by	O
inhibiting	O
the	O
rate	O
of	O
synthesis	O
of	O
10	I-IUPAC
-	I-IUPAC
formyltetrahydrofolate	I-IUPAC
,	O
the	O
actual	O
cofactor	O
for	O
the	O
transformylase	O
enzyme	O
,	O
from	O
5,10	I-IUPAC
-	I-IUPAC
methenyltetrahydrofolate	I-IUPAC
.	O

Its	O
inhibition	O
of	O
the	O
enzyme	O
,	O
5,10	I-IUPAC
-	I-IUPAC
methenyltetrahydrofolate	I-IUPAC
cyclohydrolase	O
(	O
EC	O
3.5.4.9	O
)	O
,	O
was	O
competitive	O
against	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
methenyltetrahydrofolate	I-IUPAC
,	O
with	O
a	O
Ki	O
=	O
41	O
micro	O
M	O
.	O

This	O
derivative	O
of	O
homofolate	O
may	O
be	O
responsible	O
for	O
its	O
inhibition	O
of	O
purine	O
biosynthesis	O
in	O
Sarcoma	O
180	O
cells	O
.	O

The	O
anticonvulsant	O
activity	O
of	O
diphenylhydantoin	O
(	O
DPH	O
or	O
phenytoin	O
)	O
is	O
consistent	O
with	O
its	O
actions	O
on	O
the	O
neuronal	O
voltage	O
-	O
dependent	O
sodium	O
channel	O
.	O

To	O
further	O
elucidate	O
the	O
binding	O
requirements	O
for	O
this	O
site	O
,	O
we	O
synthesized	O
several	O
hydantoin	O
analogs	O
and	O
evaluated	O
these	O
in	O
in	O
vitro	O
sodium	O
channel	O
-	O
binding	O
and	O
/	O
or	O
in	O
vivo	O
whole	O
animal	O
anticonvulsant	O
assays	O
.	O

5	I-IUPAC
-	I-IUPAC
Pentyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
(	O
8	O
)	O
,	O
the	O
most	O
potent	O
binder	O
to	O
the	O
sodium	O
channel	O
in	O
this	O
study	O
,	O
had	O
the	O
same	O
affinity	O
as	O
DPH	O
(	O
IC50	O
=	O
40	O
microM	O
)	O
,	O
revealing	O
that	O
one	O
phenyl	O
ring	O
is	O
sufficient	O
for	O
good	O
interactions	O
.	O

Since	O
our	O
previous	O
studies	O
with	O
monophenyl	I-IUPAC
-	O
substituted	I-MODIFIER
bicyclic	B-MODIFIER
2,4	B-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
suggested	O
that	O
N3	O
-	O
alkylation	O
and	O
the	O
conformational	O
constraint	O
of	O
a	O
5	O
-	O
alkyl	O
substituent	O
over	O
one	O
face	O
of	O
the	O
oxazolidinedione	O
ring	O
improved	O
activity	O
,	O
we	O
synthesized	O
two	O
examples	O
of	O
analogous	O
bicyclic	O
hydantoins	O
.	O

However	O
,	O
the	O
bicyclic	O
hydantoins	O
were	O
much	O
less	O
potent	O
binders	O
to	O
the	O
neuronal	O
voltage	O
-	O
dependent	O
sodium	O
channel	O
than	O
their	O
monocyclic	O
counterparts	O
.	O

The	O
binding	O
activity	O
for	O
the	O
more	O
potent	O
bicyclic	O
hydantoin	O
,	O
1,8	I-IUPAC
-	I-IUPAC
diaza	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dioxo	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
phenylbicyclo	I-IUPAC
[	I-IUPAC
5.2.1	I-IUPAC
]	I-IUPAC
decane	I-IUPAC
(	O
4	O
)	O
(	O
IC50	O
=	O
427	O
microM	O
)	O
,	O
was	O
comparable	O
to	O
that	O
of	O
the	O
ring	O
-	O
opened	O
,	O
N3	O
-	O
methylated	O
monocyclic	O
hydantoin	O
model	O
,	O
5	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
(	O
9	O
)	O
(	O
IC50	O
=	O
285	O
microM	O
)	O
,	O
and	O
these	O
were	O
8-11	O
times	O
less	O
potent	O
than	O
the	O
monocyclic	O
model	O
8	O
,	O
which	O
contains	O
a	O
free	O
imide	O
NH	O
.	O

Furthermore	O
,	O
5	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
(	O
7	O
;	O
IC50	O
=	O
103	O
microM	O
)	O
was	O
less	O
potent	O
than	O
8	O
,	O
suggesting	O
that	O
increased	O
log	O
P	O
may	O
enhance	O
binding	O
.	O

Thus	O
,	O
unlike	O
2,4	I-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
,	O
N3	O
-	O
alkylation	O
of	O
hydantoins	O
dramatically	O
decreases	O
sodium	O
channel	O
-	O
binding	O
activity	O
.	O

Bicyclic	O
hydantoin	O
4	O
was	O
nevertheless	O
a	O
good	O
anti	O
-	O
MES	O
anticonvulsant	O
in	O
mice	O
(	O
ED50	O
=	O
86	O
mg	O
/	O
kg	O
)	O
,	O
although	O
this	O
activity	O
likely	O
results	O
from	O
mechanisms	O
other	O
than	O
interactions	O
at	O
the	O
neuronal	O
voltage	O
-	O
dependent	O
sodium	O
channel	O
.	O

Compound	O
4	O
was	O
also	O
relatively	O
neurotoxic	O
(	O
TD50	O
=	O
124	O
mg	O
/	O
kg	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
binding	O
of	O
hydantoins	O
to	O
the	O
sodium	O
channel	O
may	O
be	O
enhanced	O
by	O
(	O
a	O
)	O
a	O
free	O
imide	O
NH	O
group	O
and	O
(	O
b	O
)	O
an	O
increased	O
log	O
P	O
.	O

Furthermore	O
,	O
2,4	I-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
and	O
hydantoins	O
must	O
either	O
orient	O
differently	O
in	O
the	O
same	O
binding	O
site	O
or	O
interact	O
with	O
different	O
sites	O
on	O
the	O
neuronal	O
voltage	O
-	O
dependent	O
sodium	O
channel	O
.	O

Evidence	O
incicating	O
that	O
effective	O
in	O
vivo	O
inhibition	O
of	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
(	O
HGPRT	O
,	O
EC	O
2.4.2.8	O
)	O
should	O
produce	O
antiprotozoal	O
activity	O
without	O
significant	O
toxic	O
effects	O
on	O
mammalian	O
hosts	O
prompted	O
syntheses	O
of	O
1	O
-	O
substituted	O
hypoxanthines	O
bearing	O
functionalized	O
side	O
chains	O
whose	O
groupings	O
might	O
interact	O
with	O
appropriate	O
groupings	O
of	O
HGPRT	O
to	O
form	O
covalent	O
bonds	O
or	O
strong	O
hydrophobic	O
bonds	O
.	O

3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Fluorosulfonyl	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluorosulfonyl	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
chlorobenzoyl	I-IUPAC
,	O
and	O
bromacetyl	I-IUPAC
derivatives	B-MODIFIER
of	O
two	O
parent	O
amines	O
,	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
hypoxanthine	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobenzyl	I-IUPAC
)	I-IUPAC
hypoxanthine	I-IUPAC
,	O
were	O
synthesized	O
for	O
evaluation	O
in	O
this	O
connection	O
.	O

None	O
of	O
these	O
compounds	O
extended	O
the	O
life	O
span	O
of	O
Plasmodium	O
berghei	O
infected	O
mice	O
or	O
showed	O
significant	O
in	O
vitro	O
inhibition	O
of	O
HGPRT	O
from	O
H	O
.	O

Ep	O
.	O

-	O
2	O
cells	O
,	O
but	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromoacetamido	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
hypoxanthine	I-IUPAC
displayed	O
in	O
vivo	O
activity	O
against	O
Trypanosoma	O
rhodesiense	O
.	O

Glucuronic	O
acid	O
linked	O
prodrugs	O
of	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
and	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyguanosine	I-IUPAC
were	O
synthesized	O
.	O

The	O
prodrugs	O
were	O
found	O
to	O
be	O
quite	O
stable	O
at	O
physiological	O
pH	O
and	O
were	O
more	O
than	O
200	O
-	O
fold	O
less	O
active	O
as	O
inactivators	O
of	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alkylguanine	I-IUPAC
-	O
DNA	O
alkyltransferase	O
(	O
alkyltransferase	O
)	O
than	O
either	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
or	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyguanosine	I-IUPAC
.	O

Beta	O
-	O
glucuronidase	O
from	O
both	O
Escherichia	O
coli	O
and	O
bovine	O
liver	O
cleaved	O
the	O
prodrugs	O
efficiently	O
to	O
release	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
and	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyguanosine	I-IUPAC
,	O
respectively	O
.	O

In	O
combination	O
with	O
1,3	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
nitrosourea	I-IUPAC
(	O
BCNU	O
)	O
,	O
the	O
prodrugs	O
were	O
not	O
effective	O
adjuvants	O
for	O
HT29	O
cell	O
killing	O
.	O

However	O
,	O
as	O
expected	O
,	O
incubation	O
of	O
these	O
prodrugs	O
with	O
beta	O
-	O
glucuronidase	O
in	O
the	O
culture	O
medium	O
led	O
to	O
much	O
more	O
efficient	O
cell	O
killing	O
by	O
BCNU	O
as	O
a	O
result	O
of	O
the	O
liberation	O
of	O
the	O
more	O
potent	O
inactivators	O
,	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
and	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyguanosine	I-IUPAC
.	O

These	O
prodrugs	O
may	O
be	O
useful	O
for	O
prodrug	O
monotherapy	O
of	O
necrotic	O
tumors	O
that	O
liberate	O
beta	O
-	O
glucuronidase	O
or	O
for	O
antibody	O
-	O
directed	O
enzyme	O
prodrug	O
therapy	O
with	O
antibodies	O
that	O
can	O
deliver	O
beta	O
-	O
glucuronidase	O
to	O
target	O
tumor	O
cells	O
.	O

5,5	I-IUPAC
-	I-IUPAC
Bis	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
and	O
its	O
isomer	O
4,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
were	O
investigated	O
as	O
possible	O
templates	O
for	O
the	O
construction	O
of	O
conformationally	O
constrained	O
analogues	O
of	O
the	O
biologically	O
important	O
second	O
messenger	O
,	O
diacylglycerol	O
(	O
DAG	O
)	O
.	O

The	O
former	O
lactone	O
contains	O
embedded	O
within	O
its	O
structure	O
an	O
exact	O
glycerol	O
moiety	O
,	O
while	O
in	O
the	O
latter	O
the	O
ring	O
oxygen	O
has	O
been	O
transposed	O
to	O
the	O
other	O
side	O
of	O
the	O
carbonyl	O
group	O
.	O

All	O
target	O
compounds	O
were	O
synthesized	O
as	O
racemates	O
from	O
1,3	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propanone	I-IUPAC
.	O

The	O
5,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
proved	O
to	O
be	O
the	O
better	O
template	O
for	O
the	O
construction	O
of	O
DAG	O
surrogates	O
that	O
were	O
demonstrated	O
to	O
have	O
high	O
binding	O
affinities	O
for	O
the	O
biological	O
target	O
,	O
protein	O
kinase	O
C	O
(	O
PK	O
-	O
C	O
)	O
.	O

The	O
simplest	O
target	O
compounds	O
derived	O
from	O
this	O
template	O
(	O
3e	O
and	O
3f	O
)	O
have	O
one	O
of	O
the	O
hydroxyl	I-IUPAC
moieties	B-MODIFIER
functionalized	O
either	O
as	O
a	O
myristate	O
or	O
as	O
an	O
oleate	O
ester	O
.	O

The	O
simplest	O
target	O
compound	O
(	O
9c	O
)	O
derived	O
from	O
the	O
ineffective	O
4,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
template	O
was	O
investigated	O
only	O
with	O
a	O
myristoyl	O
acyl	O
chain	O
.	O

Reducing	O
the	O
long	O
acyl	O
chain	O
to	O
an	O
acetyl	O
moiety	O
and	O
attaching	O
a	O
compensating	O
lipophilic	O
chain	O
to	O
the	O
lactone	O
ring	O
as	O
an	O
alpha	I-IUPAC
-	I-IUPAC
alkylidene	I-IUPAC
moiety	I-MODIFIER
produced	O
compounds	O
10e	O
and	O
10f	O
(	O
Z	O
-	O
isomers	O
)	O
and	O
11e	O
and	O
11f	O
(	O
E	O
-	O
isomers	O
)	O
,	O
which	O
were	O
constructed	O
on	O
the	O
more	O
effective	O
5,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
template	O
.	O

Targets	O
14c	O
(	O
Z	O
-	O
isomer	O
)	O
and	O
15c	O
(	O
E	O
-	O
isomer	O
)	O
were	O
derived	O
,	O
in	O
turn	O
,	O
from	O
4,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
.	O

The	O
affinities	O
of	O
these	O
ligands	O
for	O
PK	O
-	O
C	O
were	O
assessed	O
in	O
terms	O
of	O
their	O
ability	O
to	O
displace	O
bound	O
[	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
20	I-IUPAC
]	I-IUPAC
phorbol	I-IUPAC
12,13	I-IUPAC
-	I-IUPAC
dibutyrate	I-IUPAC
(	O
PDBU	O
)	O
from	O
the	O
single	O
isozyme	O
PK	O
-	O
C	O
alpha	O
.	O

The	O
biological	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
increase	O
in	O
binding	O
affinity	O
for	O
PK	O
-	O
C	O
shown	O
by	O
some	O
of	O
these	O
constrained	O
DAG	O
mimetics	O
appears	O
to	O
be	O
entropic	O
in	O
nature	O
.	O

Two	O
of	O
the	O
designed	O
ligands	O
(	O
10e	O
and	O
10f	O
)	O
showed	O
the	O
highest	O
affinities	O
(	O
34	O
and	O
24	O
nM	O
,	O
respectively	O
)	O
reported	O
so	O
far	O
for	O
a	O
DAG	O
analogue	O
.	O

Assuming	O
that	O
the	O
interaction	O
between	O
these	O
racemic	O
compounds	O
and	O
PK	O
-	O
C	O
is	O
stereospecific	O
,	O
the	O
potency	O
of	O
the	O
active	O
enantiomer	O
is	O
anticipated	O
to	O
double	O
.	O

In	O
this	O
study	O
,	O
13	O
heteroarotinoids	O
were	O
synthesized	O
.	O

The	O
key	O
step	O
in	O
each	O
preparation	O
was	O
the	O
condensation	O
of	O
the	O
appropriate	O
chroman	I-IUPAC
-	O
,	O
thiochroman	I-IUPAC
-	I-IUPAC
,	O
or	O
benzothienyl	I-IUPAC
-	I-IUPAC
substituted	I-MODIFIER
phosphorus	B-IUPAC
ylide	I-IUPAC
,	O
obtained	O
from	O
the	O
independent	O
synthesis	O
of	O
the	O
corresponding	O
phosphonium	O
salts	O
,	O
with	O
selected	O
polyene	I-IUPAC
-	O
substituted	I-MODIFIER
aldehyde	B-IUPAC
esters	I-IUPAC
.	O

Nine	O
of	O
these	O
heterocycles	O
contained	O
a	O
thiochroman	O
group	O
,	O
two	O
had	O
a	O
chroman	O
group	O
,	O
and	O
two	O
others	O
had	O
a	O
benzothienyl	O
system	O
.	O

Screening	O
of	O
the	O
compounds	O
was	O
with	O
one	O
of	O
two	O
assays	O
.	O

One	O
assay	O
measured	O
the	O
ability	O
of	O
a	O
retinoid	O
to	O
inhibit	O
the	O
phorbol	O
ester	O
induced	O
increase	O
of	O
mouse	O
epidermal	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
activity	O
.	O

The	O
other	O
assay	O
measured	O
retinoid	O
-	O
induced	O
differentiation	O
of	O
the	O
human	O
myoloid	O
leukemia	O
cell	O
line	O
HL	O
-	O
60	O
.	O

In	O
the	O
ODC	O
assay	O
,	O
all	O
thirteen	O
compounds	O
were	O
screened	O
.	O

The	O
most	O
active	O
heteroarotinoids	O
were	O
ester	O
10	O
[	O
methyl	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,2,4,4	I-IUPAC
-	I-IUPAC
tetramethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
]	O
and	O
acid	O
11	O
[	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,2,4,4	I-IUPAC
-	I-IUPAC
tetramethyl	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzothiopyran	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
]	O
.	O

Both	O
of	O
these	O
retinoids	O
had	O
ID50	O
values	O
(	O
dose	O
required	O
for	O
half	O
-	O
maximal	O
inhibition	O
of	O
phorbol	O
ester	O
induced	O
ODC	O
activity	O
)	O
of	O
about	O
0.3	O
nmol	O
.	O

In	O
comparison	O
,	O
the	O
ID50	O
value	O
for	O
trans	O
-	O
retinoic	O
acid	O
(	O
1	O
)	O
was	O
0.12	O
nmol	O
while	O
the	O
ID50	O
values	O
for	O
acids	O
7	O
and	O
9	O
,	O
namely	O
(	I-IUPAC
2Z	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
,	I-IUPAC
6E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
thiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
heptatrienoic	I-IUPAC
acid	I-IUPAC
and	O
(	I-IUPAC
2E	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
,	I-IUPAC
6E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,2,4,4	I-IUPAC
-	I-IUPAC
tetramethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
heptatrienoic	I-IUPAC
acid	I-IUPAC
,	O
respectively	O
,	O
were	O
about	O
3.5	O
nmol	O
.	O

Heteroarotinoids	O
8	O
and	O
12-17	O
had	O
ID50	O
values	O
of	O
35	O
nmol	O
or	O
greater	O
.	O

With	O
a	O
thiochroman	O
unit	O
,	O
the	O
most	O
active	O
acids	O
in	O
decreasing	O
order	O
of	O
activity	O
in	O
the	O
ODC	O
assay	O
were	O
7	O
greater	O
than	O
9	O
greater	O
than	O
8	O
.	O

Thus	O
,	O
simple	O
replacement	O
of	O
the	O
terminal	O
propenyl	I-IUPAC
system	B-MODIFIER
[	O
C	O
(	O
16,17,18	O
)	O
]	O
in	O
7	O
with	O
a	O
cyclopropyl	I-IUPAC
group	B-MODIFIER
produced	O
acid	O
8	O
[	O
(	I-IUPAC
2E	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
,	I-IUPAC
6E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
dimethylthiochroman	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
methylene	I-IUPAC
-	I-IUPAC
4,6	I-IUPAC
-	I-IUPAC
heptadienoic	I-IUPAC
acid	I-IUPAC
with	O
markedly	O
reduced	O
activity	O
.	O

With	O
a	O
benzoic	O
acid	O
group	O
as	O
part	O
of	O
the	O
structure	O
attached	O
to	O
the	O
thiochroman	O
unit	O
,	O
the	O
ODC	O
activity	O
was	O
enhanced	O
as	O
shown	O
in	O
10	O
and	O
11	O
.	O

The	O
combination	O
of	O
the	O
2,2,4,4	I-IUPAC
-	I-IUPAC
tetramethylthiochroman	I-IUPAC
group	I-MODIFIER
and	O
the	O
benzoic	O
acid	O
(	O
or	O
ester	O
)	O
terminal	O
group	O
seemed	O
to	O
enhance	O
the	O
biological	O
action	O
which	O
resembles	O
that	O
found	O
with	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
5,5,8,8	I-IUPAC
-	I-IUPAC
tetramethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthalenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
TTNPB	O
,	O
6b	O
)	O
,	O
a	O
well	O
-	O
known	O
model	O
system	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

To	O
develop	O
a	O
novel	O
cerebroprotective	O
agent	O
with	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
stimulating	O
activity	O
,	O
a	O
series	I-MODIFIER
of	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxyindan	I-IUPAC
derivatives	I-MODIFIER
was	O
synthesized	O
,	O
and	O
their	O
effects	O
on	O
the	O
survival	O
time	O
of	O
mice	O
under	O
hypoxic	O
conditions	O
were	O
tested	O
.	O

CNS	O
-	O
stimulating	O
activity	O
was	O
also	O
evaluated	O
by	O
examining	O
the	O
promotional	O
effect	O
on	O
the	O
recovery	O
from	O
cerebral	O
concussion	O
induced	O
coma	O
in	O
mice	O
.	O

Several	O
compounds	O
prolonged	O
the	O
survival	O
time	O
of	O
mice	O
in	O
hypoxic	O
conditions	O
at	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
(	O
sc	O
or	O
ip	O
)	O
and	O
100	O
mg	O
/	O
kg	O
(	O
po	O
)	O
.	O

They	O
also	O
exhibited	O
the	O
promotional	O
effects	O
on	O
recovery	O
from	O
coma	O
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
po	O
.	O

The	O
three	O
most	O
potent	O
compounds	O
in	O
both	O
tests	O
,	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylpropyl	I-IUPAC
)	I-IUPAC
indan	I-IUPAC
,	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylindan	I-IUPAC
,	O
and	O
1	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2,2,4,6	I-IUPAC
-	I-IUPAC
tetramethylindan	I-IUPAC
were	O
selected	O
for	O
further	O
investigations	O
.	O

Structure	O
-	O
activity	O
relationships	O
were	O
also	O
discussed	O
.	O

Prazosin	O
-	O
related	O
quinazolines	O
4-20	O
were	O
synthesized	O
,	O
and	O
their	O
biological	O
profiles	O
at	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
were	O
assessed	O
by	O
functional	O
experiments	O
in	O
isolated	O
rat	O
vas	O
deferens	O
(	O
alpha1A	O
)	O
,	O
spleen	O
(	O
alpha1B	O
)	O
,	O
and	O
aorta	O
(	O
alpha1D	O
)	O
and	O
by	O
binding	O
assays	O
in	O
CHO	O
cells	O
expressing	O
human	O
cloned	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
.	O

The	O
replacement	O
of	O
piperazine	O
and	O
furan	O
units	O
of	O
prazosin	O
(	O
1	O
)	O
by	O
1	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hexanediamine	I-IUPAC
and	O
phenyl	I-IUPAC
moieties	B-MODIFIER
,	O
respectively	O
,	O
affording	O
3-20	O
,	O
markedly	O
affected	O
both	O
affinity	O
and	O
selectivity	O
for	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
in	O
functional	O
experiments	O
.	O

Cystazosin	O
(	O
3	O
)	O
,	O
bearing	O
a	O
cystamine	O
moiety	O
,	O
was	O
a	O
selective	O
alpha1D	O
-	O
adrenoreceptor	O
antagonist	O
being	O
1	O
order	O
of	O
magnitude	O
more	O
potent	O
at	O
alpha1D	O
-	O
adrenoreceptors	O
(	O
pA2	O
,	O
8.54	O
+	O
/	O
-	O
0.02	O
)	O
than	O
at	O
the	O
alpha1A	O
-	O
(	O
pA2	O
,	O
7.53	O
+	O
/	O
-	O
0.01	O
)	O
and	O
alpha1B	O
-	O
subtypes	O
(	O
pA2	O
,	O
7.49	O
+	O
/	O
-	O
0	O
.	O

01	O
)	O
.	O

The	O
insertion	O
of	O
substituents	O
on	O
the	O
furan	O
ring	O
of	O
3	O
,	O
as	O
in	O
compounds	O
4	O
and	O
5	O
,	O
did	O
not	O
improve	O
the	O
selectivity	O
profile	O
.	O

The	O
simultaneous	O
replacement	O
of	O
both	O
piperazine	O
and	O
furan	O
rings	O
of	O
1	O
gave	O
8	O
which	O
resulted	O
in	O
a	O
potent	O
,	O
selective	O
alpha1B	O
-	O
adrenoreceptor	O
antagonist	O
(	O
85	O
-	O
and	O
15	O
-	O
fold	O
more	O
potent	O
than	O
at	O
alpha1A	O
-	O
and	O
alpha1D	O
-	O
subtypes	O
,	O
respectively	O
)	O
.	O

The	O
insertion	O
of	O
substituents	O
on	O
the	O
benzene	O
ring	O
of	O
8	O
affected	O
,	O
according	O
to	O
the	O
type	O
and	O
the	O
position	O
of	O
the	O
substituent	O
,	O
affinity	O
and	O
selectivity	O
for	O
alpha1	O
-	O
adrenoreceptors	O
.	O

Consequently	O
,	O
the	O
insertion	O
of	O
appropriate	O
substituents	O
in	O
the	O
phenyl	O
ring	O
of	O
8	O
may	O
represent	O
the	O
basis	O
of	O
designing	O
new	O
selective	O
ligands	O
for	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
.	O

Interestingly	O
,	O
the	O
finding	O
that	O
polyamines	O
11	O
,	O
16	O
,	O
and	O
20	O
,	O
bearing	O
a	O
1,6	I-IUPAC
-	I-IUPAC
hexanediamine	I-IUPAC
moiety	I-MODIFIER
,	O
retained	O
high	O
affinity	O
for	O
alpha1	O
-	O
adrenoreceptor	O
subtypes	O
suggests	O
that	O
the	O
substituent	O
did	O
not	O
give	O
rise	O
to	O
negative	O
interactions	O
with	O
the	O
receptor	O
.	O

Finally	O
,	O
binding	O
assays	O
performed	O
with	O
selected	O
quinazolines	O
(	O
2	O
,	O
3	O
,	O
and	O
14	O
)	O
produced	O
affinity	O
results	O
,	O
which	O
were	O
not	O
in	O
agreement	O
with	O
the	O
selectivity	O
profiles	O
obtained	O
from	O
functional	O
experiments	O
.	O

This	O
rather	O
surprising	O
and	O
unexpected	O
finding	O
may	O
be	O
explained	O
by	O
considering	O
neutral	O
and	O
negative	O
antagonism	O
.	O

New	O
nucleoside	O
analogues	O
14-17	O
based	O
on	O
a	O
methylenecyclopropane	O
structure	O
were	O
synthesized	O
and	O
evaluated	O
for	O
antiviral	O
activity	O
.	O

Reaction	O
of	O
2,3	I-IUPAC
-	I-IUPAC
dibromopropene	I-IUPAC
(	O
19	O
)	O
with	O
adenine	O
(	O
18	O
)	O
led	O
to	O
bromoalkene	O
20	O
,	O
which	O
was	O
benzoylated	O
to	O
give	O
N6	I-IUPAC
,	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
dibenzoyl	I-IUPAC
derivative	I-MODIFIER
23	O
.	O

Attempts	O
to	O
convert	O
20	O
or	O
23	O
to	O
bromocyclopropanes	O
21	O
and	O
22	O
by	O
reaction	O
with	O
ethyl	O
diazoacetate	O
catalyzed	O
by	O
Rh2	O
(	O
OAc	O
)	O
4	O
were	O
futile	O
.	O

By	O
contrast	O
,	O
2,3	I-IUPAC
-	I-IUPAC
dibromopropene	I-IUPAC
(	O
19	O
)	O
afforded	O
smoothly	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
and	O
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dibromocyclopropane	I-IUPAC
carboxylic	I-IUPAC
esters	I-IUPAC
24	O
+	O
25	O
.	O

Alkylation	O
of	O
adenine	O
(	O
18	O
)	O
with	O
24	O
+	O
25	O
gave	O
(	O
E	O
)	O
-	O
and	O
(	O
Z	O
)	O
-	O
bromo	O
derivatives	O
21	O
+	O
22	O
.	O

Base	O
-	O
catalyzed	O
elimination	O
of	O
HBr	O
resulted	O
in	O
the	O
formation	O
of	O
(	I-PARTIUPAC
Z	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenecyclopropanecarboxylic	I-IUPAC
esters	I-IUPAC
26	O
+	O
27	O
.	O

More	O
convenient	O
one	O
-	O
pot	O
alkylation	O
-	O
elimination	O
of	O
adenine	O
(	O
18	O
)	O
or	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
30	O
)	O
with	O
24	O
+	O
25	O
afforded	O
(	I-PARTIUPAC
Z	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenecyclopropane	I-IUPAC
derivatives	I-MODIFIER
26	O
+	O
27	O
and	O
31	O
+	O
32	O
.	O

The	O
Z	O
-	O
isomers	O
were	O
always	O
predominant	O
in	O
these	O
mixtures	O
(	O
Z	O
/	O
E	O
approximately	O
2/1	O
)	O
.	O

Reduction	O
of	O
26	O
+	O
27	O
and	O
31	O
+	O
32	O
with	O
DIBALH	O
afforded	O
(	I-PARTIUPAC
Z	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenecyclopropane	I-IUPAC
alcohols	I-IUPAC
14	O
+	O
16	O
and	O
33	O
+	O
34	O
.	O

The	O
latter	O
were	O
resolved	O
directly	O
by	O
chromatography	O
.	O

Compounds	O
14	O
+	O
16	O
were	O
converted	O
to	O
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
derivatives	I-MODIFIER
28	O
and	O
29	O
which	O
were	O
separated	O
and	O
deprotected	O
to	O
give	O
14	O
and	O
16	O
.	O

Reaction	O
of	O
33	O
and	O
34	O
with	O
HCO2H	O
led	O
to	O
guanine	O
analogues	O
15	O
and	O
17	O
.	O

The	O
1H	O
NMR	O
spectra	O
of	O
the	O
Z	O
-	O
analogues	O
14	O
and	O
15	O
are	O
consistent	O
with	O
an	O
anti	O
-	O
like	O
conformation	O
of	O
the	O
nucleobases	O
.	O

By	O
contrast	O
,	O
1H	O
NMR	O
and	O
IR	O
spectra	O
of	O
bromo	O
ester	O
21	O
are	O
indicative	O
of	O
syn	O
-	O
conformation	O
of	O
adenine	O
.	O

Several	O
Z	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
methylenecyclopropanes	I-IUPAC
exhibited	O
in	O
vitro	O
antiviral	O
activity	O
in	O
micromolar	O
or	O
submicromolar	O
range	O
against	O
human	O
and	O
murine	O
cytomegalovirus	O
(	O
HCMV	O
and	O
MCMV	O
)	O
,	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
human	O
herpes	O
virus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
,	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
,	O
and	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
.	O

Analogues	O
14	O
,	O
15	O
,	O
and	O
33	O
were	O
the	O
most	O
effective	O
agents	O
against	O
HCMV	O
(	O
IC50	O
1-2.1	O
,	O
0.04-2.1	O
,	O
and	O
0.8-5.6	O
microM	O
)	O
,	O
MCMV	O
(	O
IC50	O
2.1	O
,	O
0.3	O
,	O
and	O
0.3	O
microM	O
)	O
and	O
EBV	O
in	O
H	O
-	O
1	O
(	O
IC50	O
0.2	O
,	O
0.3	O
,	O
and	O
0.7	O
microM	O
)	O
and	O
Daudi	O
cells	O
(	O
IC50	O
3.2	O
,	O
5.6	O
,	O
and	O
1.2	O
microM	O
)	O
.	O

Adenine	O
analogue	O
14	O
was	O
active	O
against	O
HBV	O
(	O
IC50	O
2	O
microM	O
)	O
,	O
VZV	O
(	O
IC50	O
2.5	O
microM	O
)	O
,	O
and	O
HHV	O
-	O
6	O
(	O
IC50	O
14	O
microM	O
)	O
.	O

Synadenol	O
(	O
14	O
)	O
and	O
the	O
E	O
-	O
isomer	O
(	O
16	O
)	O
were	O
substrates	O
of	O
moderate	O
efficiency	O
for	O
adenosine	O
deaminase	O
from	O
calf	O
intestine	O
.	O

The	O
E	O
-	O
isomer	O
16	O
was	O
more	O
reactive	O
than	O
Z	O
-	O
isomer	O
14	O
.	O

The	O
deamination	O
of	O
14	O
effectively	O
stopped	O
at	O
50%	O
conversion	O
.	O

Synadenol	O
(	O
14	O
)	O
was	O
also	O
deaminated	O
by	O
AMP	O
deaminase	O
from	O
aspergillus	O
sp	O
.	O

We	O
have	O
previously	O
reported	O
that	O
a	O
series	O
of	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
(	I-IUPAC
thio	I-IUPAC
)	I-IUPAC
carbamoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dimethoxyquinazoline	I-IUPAC
derivatives	I-MODIFIER
were	O
potent	O
and	O
selective	O
inhibitors	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFR	O
)	O
phosphorylation	O
and	O
demonstrated	O
several	O
biological	O
effects	O
such	O
as	O
suppression	O
of	O
neointima	O
formation	O
following	O
balloon	O
injury	O
in	O
rat	O
carotid	O
artery	O
by	O
oral	O
administration	O
.	O

Here	O
,	O
we	O
investigated	O
structure	O
-	O
activity	O
relationships	O
of	O
the	O
6,7	I-IUPAC
-	I-IUPAC
dimethoxyquinazolinyl	I-IUPAC
moiety	I-MODIFIER
.	O

In	O
regard	O
to	O
6,7	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
groups	I-MODIFIER
,	O
ethoxy	O
analogues	O
showed	O
potent	O
activity	O
(	O
IC	O
(	O
50	O
)	O
of	O
16b	O
is	O
0.04	O
microM	O
;	O
IC	O
(	O
50	O
)	O
of	O
17a	O
is	O
0.01	O
microM	O
)	O
and	O
further	O
extension	O
of	O
the	O
alkyl	O
group	O
reduced	O
activity	O
.	O

Interestingly	O
,	O
methoxyethoxy	O
(	O
IC	O
(	O
50	O
)	O
of	O
16j	O
is	O
0.02	O
microM	O
;	O
IC	O
(	O
50	O
)	O
of	O
17h	O
is	O
0.01	O
microM	O
)	O
and	O
ethoxyethoxy	O
(	O
IC	O
(	O
50	O
)	O
of	O
17j	O
is	O
0.02	O
micro	O
M	O
)	O
analogues	O
showed	O
the	O
most	O
potent	O
activity	O
,	O
suggesting	O
that	O
the	O
inserted	O
oxygen	O
atom	O
significantly	O
interacts	O
with	O
beta	O
-	O
PDGFR	O
.	O

Among	O
tricyclic	O
quinazoline	O
derivatives	O
,	O
the	O
2	I-IUPAC
-	I-IUPAC
oxoimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
derivative	I-MODIFIER
21a	O
showed	O
potent	O
activity	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.10	O
microM	O
)	O
.	O

Regarding	O
replacements	O
of	O
quinazoline	O
by	O
other	O
heterocyclic	O
rings	O
,	O
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
39a	O
,	O
IC	O
(	O
50	O
)	O
=	O
0.17	O
microM	O
)	O
and	O
quinoline	O
(	O
IC	O
(	O
50	O
)	O
of	O
40a	O
is	O
0.18	O
microM	O
;	O
IC	O
(	O
50	O
)	O
of	O
40b	O
is	O
0.09	O
microM	O
)	O
derivatives	O
showed	O
potent	O
activity	O
.	O

Isoquinoline	O
and	O
some	O
pyridopyrimidine	O
derivatives	O
were	O
completely	O
inactive	O
;	O
therefore	O
,	O
1	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
has	O
an	O
important	O
role	O
.	O

Also	O
7	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
and	O
8	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
substitution	I-MODIFIER
on	O
the	O
parent	O
quinazoline	O
ring	O
has	O
a	O
detrimental	O
effect	O
on	O
the	O
interaction	O
with	O
beta	O
-	O
PDGFR	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
substituents	O
on	O
the	O
quinazoline	O
ring	O
possess	O
major	O
consequences	O
for	O
metabolic	O
polymorphism	O
.	O

Although	O
there	O
existed	O
extensive	O
metabolizers	O
and	O
poor	O
metabolizers	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
administrated	O
6,7	I-IUPAC
-	I-IUPAC
dimethoxyquinazoline	I-IUPAC
derivatives	I-MODIFIER
(	O
1b	O
and	O
1c	O
)	O
,	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methoxyquinazoline	I-IUPAC
analogue	I-MODIFIER
16k	O
showed	O
no	O
metabolic	O
polymorphism	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
of	O
two	O
series	O
of	O
novel	O
retinoids	O
(	O
2	I-IUPAC
-	I-IUPAC
pyrazinylcarboxamidobenzoates	I-IUPAC
and	O
beta	I-IUPAC
-	I-IUPAC
ionylideneacetamidobenzoates	I-IUPAC
)	O
have	O
been	O
investigated	O
by	O
evaluating	O
their	O
ability	O
to	O
induce	O
differentiation	O
in	O
both	O
human	O
promyelocytic	O
leukemia	O
(	O
HL60	O
)	O
cells	O
and	O
mouse	O
embryonal	O
carcinoma	O
(	O
P19	O
)	O
cells	O
.	O

The	O
most	O
active	O
compound	O
(	O
ED50	O
=	O
8.3	O
x	O
10	O
(	O
-	O
9	O
)	O
M	O
)	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
pyrazinylcarboxamidobenzoates	I-IUPAC
is	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
5,5,8	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetramethylquinoxalyl	I-IUPAC
)	I-IUPAC
carboxamido	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
9u	O
)	O
,	O
while	O
the	O
most	O
active	O
analogue	O
of	O
the	O
beta	O
-	O
ionylideneacetamidobenzoates	O
is	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
trimethyl	I-IUPAC
-	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
cyclohexen	I-IUPAC
-	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2E	I-IUPAC
,	I-IUPAC
4E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentadienamido	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
10a	O
,	O
ED50	O
=	O
3.2	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
.	O

Our	O
studies	O
identify	O
an	O
absolute	O
requirement	O
for	O
the	O
carboxylic	O
acid	O
moiety	O
on	O
the	O
aromatic	O
ring	O
to	O
be	O
para	O
relative	O
to	O
the	O
amide	O
linkage	O
for	O
activity	O
.	O

Benzoate	O
substitutions	O
in	O
the	O
ortho	O
position	O
relative	O
to	O
the	O
terminal	O
carboxylate	O
(	O
9d	O
,	O
k	O
,	O
r	O
)	O
are	O
well	O
-	O
tolerated	O
;	O
however	O
,	O
a	O
methoxy	O
substituent	O
meta	O
relative	O
to	O
the	O
terminal	O
carboxylate	O
gives	O
rise	O
to	O
only	O
weakly	O
active	O
analogues	O
(	O
9x	O
)	O
.	O

Conformational	O
studies	O
(	O
NMR	O
,	O
X	O
-	O
ray	O
crystallography	O
)	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
pyrazinylcarboxamidobenzoates	I-IUPAC
indicate	O
that	O
the	O
preferred	O
conformation	O
exhibits	O
a	O
trans	O
-	O
amide	O
bond	O
and	O
an	O
internal	O
hydrogen	O
bond	O
between	O
the	O
quinoxaline	O
N1	O
and	O
HN	O
amide	O
which	O
locks	O
the	O
torsional	O
angle	O
between	O
C2	O
and	O
CO	O
in	O
the	O
s	O
-	O
trans	O
conformation	O
.	O

N	O
-	O
Methylation	O
(	O
9y	O
)	O
results	O
in	O
loss	O
of	O
activity	O
.	O

Studies	O
indicate	O
that	O
there	O
is	O
now	O
a	O
cis	O
-	O
amide	O
bond	O
present	O
which	O
redirects	O
the	O
carboxylate	O
toward	O
the	O
pharmacophoric	O
gem	O
-	O
dimethyl	O
groups	O
.	O

The	O
distance	O
between	O
the	O
gem	O
-	O
dimethyl	O
group	O
and	O
the	O
terminal	O
carboxylate	O
appears	O
to	O
be	O
too	O
short	O
to	O
activate	O
the	O
retinoid	O
receptor	O
.	O

N	O
-	O
Methylation	O
in	O
the	O
beta	I-IUPAC
-	I-IUPAC
ionylideneacetamidobenzoate	I-IUPAC
series	I-MODIFIER
(	O
10c	O
)	O
also	O
results	O
in	O
the	O
formation	O
of	O
a	O
cis	O
-	O
amide	O
bond	O
and	O
loss	O
of	O
activity	O
.	O

Examination	O
of	O
the	O
PTP1B	O
inhibitory	O
potency	O
of	O
an	O
extensive	O
series	O
of	O
phosphotyrosyl	I-IUPAC
(	O
pTyr	O
)	O
mimetics	I-MODIFIER
(	O
Xxx	O
)	O
expressed	O
in	O
the	O
EGFr	O
-	O
derived	O
hexapeptide	O
platform	O
Ac	O
-	O
Asp	O
-	O
Ala	O
-	O
Asp	O
-	O
Xxx	O
-	O
Leu	O
-	O
amide	O
previously	O
led	O
to	O
the	O
finding	O
of	O
high	O
inhibitory	O
potency	O
when	O
Xxx	O
=	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonodifluoromethyl	I-IUPAC
)	I-IUPAC
phenylalanyl	I-IUPAC
(	O
F2Pmp	O
)	O
(	O
K	O
(	O
i	O
)	O
=	O
0.2	O
microM	O
)	O
and	O
when	O
Xxx	O
=	O
3	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxymethyloxyphenylalanyl	I-IUPAC
(	O
K	O
(	O
i	O
)	O
=	O
3.6	O
microM	O
)	O
.	O

In	O
the	O
first	O
instance	O
,	O
further	O
work	O
led	O
from	O
the	O
F2Pmp	O
-	O
containing	O
peptide	O
to	O
monomeric	O
inhibitor	O
,	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonodifluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
K	O
(	O
i	O
)	O
=	O
22	O
microM	O
)	O
,	O
and	O
to	O
the	O
pseudo	O
-	O
dipeptide	O
mimetic	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonodifluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
K	O
(	O
i	O
)	O
=	O
12	O
microM	O
)	O
.	O

In	O
the	O
current	O
study	O
,	O
a	O
similar	O
approach	O
was	O
applied	O
to	O
the	O
3	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxymethyloxyphenylalanyl	I-IUPAC
-	O
containing	O
peptide	O
,	O
which	O
led	O
to	O
the	O
preparation	O
of	O
monomeric	O
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxymethyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
K	O
(	O
i	O
)	O
=	O
900	O
microM	O
)	O
.	O

However	O
,	O
contrary	O
to	O
expectations	O
based	O
on	O
the	O
aforementioned	O
F2Pmp	O
work	O
,	O
incorporation	O
of	O
this	O
putative	O
pTyr	O
mimetic	O
into	O
the	O
pseudo	O
-	O
dipeptide	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxymethyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
,	O
resulted	O
in	O
a	O
substantial	O
loss	O
of	O
binding	O
affinity	O
.	O

A	O
reevaluation	O
of	O
binding	O
orientation	O
for	O
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxymethyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
was	O
therefore	O
undertaken	O
,	O
which	O
indicated	O
a	O
180	O
degrees	O
reversal	O
of	O
the	O
binding	O
orientation	O
within	O
the	O
PTP1B	O
catalytic	O
site	O
.	O

In	O
the	O
new	O
orientation	O
,	O
the	O
naphthyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxyl	I-IUPAC
group	I-MODIFIER
,	O
and	O
not	O
the	O
o	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
carboxymethyloxy	I-IUPAC
groups	I-MODIFIER
,	O
mimics	O
a	O
phosphoryl	O
group	O
.	O

Indeed	O
,	O
when	O
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
itself	O
was	O
examined	O
at	O
neutral	O
pH	O
for	O
inhibitory	O
potency	O
,	O
it	O
was	O
found	O
to	O
have	O
K	O
(	O
i	O
)	O
=	O
31	O
+	O
/	O
-	O
7	O
microM	O
,	O
which	O
is	O
lower	O
than	O
parent	O
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxymethyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
.	O

In	O
this	O
fashion	O
,	O
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
or	O
more	O
appropriately	O
,	O
6	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
)	O
has	O
been	O
identified	O
as	O
a	O
novel	O
PTP1B	O
binding	O
motif	O
.	O

Novel	O
derivatives	O
of	O
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinolones	I-IUPAC
3a	O
-	O
j	O
were	O
synthesized	O
in	O
a	O
multistep	O
synthesis	O
starting	O
from	O
substituted	I-MODIFIER
benzo	B-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
chlorides	I-IUPAC
,	O
to	O
their	O
corresponding	O
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
,	O
which	O
were	O
photochemically	O
dehydrohalogenated	O
to	O
their	O
corresponding	O
substituted	O
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinolones	I-IUPAC
.	O

Compound	O
4	O
was	O
prepared	O
from	O
3i	O
by	O
alkylation	O
with	O
3	I-IUPAC
-	I-IUPAC
dimethylaminopropyl	I-IUPAC
chloride	I-IUPAC
in	O
the	O
presence	O
of	O
NaH	O
.	O

Compounds	O
7a	O
,	O
b	O
were	O
prepared	O
from	O
3g	O
in	O
the	O
multistep	O
synthesis	O
from	O
compounds	O
5	O
and	O
6	O
.	O

Compounds	O
3b	O
,	O
3c	O
-	O
f	O
,	O
3h	O
,	O
7a	O
,	O
and	O
7b	O
were	O
found	O
to	O
exert	O
cytostatic	O
activity	O
against	O
malignant	O
cell	O
lines	O
:	O
pancreatic	O
carcinoma	O
(	O
MiaPaCa2	O
)	O
,	O
breast	O
carcinoma	O
(	O
MCF7	O
)	O
,	O
cervical	O
carcinoma	O
(	O
HeLa	O
)	O
,	O
laryngeal	O
carcinoma	O
(	O
Hep2	O
)	O
,	O
colon	O
carcinoma	O
(	O
CaCo	O
-	O
2	O
)	O
,	O
melanoma	O
(	O
HBL	O
)	O
,	O
human	O
fibroblast	O
cell	O
lines	O
(	O
WI	O
-	O
38	O
)	O
.	O

The	O
compounds	O
that	O
bear	O
a	O
3	I-IUPAC
-	I-IUPAC
dimethylaminopropyl	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
quinolone	O
nitrogen	O
(	O
3b	O
,	O
3c	O
-	O
f	O
,	O
3h	O
)	O
showed	O
higher	O
antitumor	O
activity	O
than	O
compounds	O
bearing	O
the	O
same	O
substituent	O
on	O
the	O
amidic	O
nitrogen	O
(	O
7a	O
and	O
7b	O
)	O
.	O

The	O
compound	O
3h	O
,	O
which	O
has	O
a	O
3	I-IUPAC
-	I-IUPAC
dimethylaminopropyl	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
quinolone	O
nitrogen	O
and	O
a	O
methoxycarbonyl	I-IUPAC
substituent	B-MODIFIER
at	O
position	O
9	O
,	O
had	O
marked	O
antitumor	O
activity	O
.	O

Because	O
of	O
strong	O
cytotoxic	O
effect	O
of	O
compound	O
4	O
on	O
melanoma	O
cells	O
(	O
HBL	O
,	O
ME	O
67.3	O
,	O
and	O
ME	O
67.1	O
)	O
,	O
a	O
potential	O
mechanism	O
of	O
action	O
was	O
examined	O
.	O

Analysis	O
of	O
DNA	O
and	O
Annexin	O
-	O
V	O
-	O
FLUOS	O
staining	O
indicated	O
that	O
compound	O
4	O
causes	O
cell	O
death	O
by	O
apoptosis	O
.	O

A	O
series	O
of	O
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
as	O
inhibitors	O
of	O
poly	O
ADP	O
-	O
ribose	O
polymerase	O
-	O
1	O
(	O
PARP	O
-	O
1	O
)	O
.	O

Inhibitory	O
potency	O
of	O
the	O
unsubstituted	I-MODIFIER
aza	B-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
i.e.	O
,	O
benzonaphthyridones	O
)	O
was	O
dependent	O
on	O
the	O
position	O
of	O
the	O
nitrogen	O
atom	O
within	O
the	O
core	O
structure	O
.	O

The	O
A	O
ring	O
nitrogen	O
analogues	O
(	O
7	I-PARTIUPAC
-	I-PARTIUPAC
,	O
8	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
10	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
)	O
were	O
an	O
order	O
of	O
magnitude	O
less	O
potent	O
than	O
C	O
ring	O
nitrogen	O
analogues	O
(	O
1	I-PARTIUPAC
-	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
4	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
)	O
.	O

Preliminary	O
stroke	O
results	O
from	O
1	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
one	I-IUPAC
prompted	O
structure	O
-	O
activity	O
relationships	O
to	O
be	O
established	O
for	O
several	O
2	I-MODIFIER
-	I-MODIFIER
and	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O

The	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
designed	O
to	O
improve	O
the	O
solubility	O
and	O
pharmacokinetic	O
profiles	O
for	O
this	O
series	O
of	O
PARP	O
-	O
1	O
inhibitors	O
.	O

Most	O
importantly	O
,	O
three	O
compounds	O
from	O
this	O
series	O
demonstrated	O
statistically	O
significant	O
protective	O
effects	O
in	O
rat	O
models	O
of	O
stroke	O
and	O
heart	O
ischemia	O
.	O

Following	O
the	O
discovery	O
of	O
moderately	O
potent	O
antagonist	O
activity	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
in	O
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
(	O
2	O
)	O
(	O
IC50	O
=	O
840	O
nM	O
)	O
,	O
19	O
derivatives	O
(	O
3-21	O
)	O
were	O
prepared	O
which	O
incorporated	O
various	O
lipophilic	O
groups	O
attached	O
to	O
the	O
phenyl	O
4	O
-	O
position	O
.	O

Structure	O
-	O
activity	O
relationships	O
were	O
evaluated	O
where	O
PAF	O
antagonist	O
activity	O
was	O
measured	O
in	O
vitro	O
by	O
determining	O
the	O
concentration	O
of	O
compound	O
(	O
IC50	O
)	O
required	O
to	O
inhibit	O
the	O
PAF	O
-	O
induced	O
aggregation	O
of	O
rabbit	O
washed	O
platelets	O
and	O
in	O
vivo	O
by	O
determining	O
the	O
oral	O
dose	O
(	O
ED50	O
)	O
which	O
protected	O
mice	O
from	O
a	O
lethal	O
injection	O
of	O
PAF	O
.	O

[	I-IUPAC
1,5	I-IUPAC
]	I-IUPAC
Benzodiazepines	I-IUPAC
,	O
e.g.	O
,	O
14	O
(	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrid	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
)	O
(	O
IC50	O
=	O
4.9	O
nM	O
,	O
Ed50	O
=	O
0.03	O
mg	O
/	O
kg	O
po	O
)	O
,	O
were	O
found	O
to	O
possess	O
equivalent	O
or	O
superior	O
potency	O
to	O
the	O
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
PAF	O
antagonist	O
UK	O
-	O
74,505	O
(	O
1,4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrid	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
carbamoyl	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
potent	O
benzazepine	O
,	O
21	O
(	O
7,8	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrid	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,3,4,5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzazepin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
)	O
(	O
IC50	O
=	O
0.5	O
nM	O
,	O
ED50	O
=	O
0.03	O
mg	O
/	O
kg	O
po	O
)	O
,	O
was	O
discovered	O
.	O

These	O
investigations	O
prompted	O
the	O
synthesis	O
and	O
evaluation	O
of	O
additional	O
diazepine	O
derivatives	O
,	O
which	O
are	O
described	O
in	O
the	O
following	O
paper	O
.	O

The	O
relationship	O
between	O
the	O
key	O
PAF	O
antagonist	O
pharmacophores	O
of	O
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
a	O
triazolothienodiazepine	O
(	O
WEB2170	O
)	O
,	O
and	O
a	O
pyrrolothiazolidine	O
(	O
RP	O
-	O
52,770	O
)	O
is	O
discussed	O
.	O

Various	O
substituted	O
isoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
thiosemicarbazones	I-IUPAC
(	O
12	O
compounds	O
)	O
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
antineoplastic	O
activity	O
in	O
mice	O
bearing	O
the	O
L1210	O
leukemia	O
.	O

Condensation	O
of	O
4	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylisoquinoline	I-IUPAC
(	O
4	O
)	O
with	O
ammonium	O
hydroxide	O
,	O
methylamine	O
,	O
ethylamine	O
,	O
and	O
N	I-IUPAC
-	I-IUPAC
acetylethylenediamine	I-IUPAC
gave	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
ethylamino	I-IUPAC
,	O
and	O
4	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acetylethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
derivatives	I-MODIFIER
,	O
which	O
were	O
then	O
converted	O
to	O
amides	O
and	O
subsequently	O
oxidized	O
to	O
aldehydes	O
followed	O
by	O
condensation	O
with	O
thiosemicarbazide	O
to	O
yield	O
thiosemicarbazones	O
8a	O
-	O
c	O
,	O
9a	O
-	O
c	O
,	O
and	O
16	O
.	O

Nitration	O
of	O
4	O
,	O
followed	O
by	O
oxidation	O
with	O
selenium	O
dioxide	O
,	O
produced	O
aldehyde	O
18	O
,	O
which	O
was	O
then	O
converted	O
to	O
the	O
cyclic	O
ethylene	O
acetal	O
19	O
.	O

Condensation	O
of	O
19	O
with	O
morpholine	O
followed	O
by	O
catalytic	O
reduction	O
of	O
the	O
nitro	O
group	O
and	O
treatment	O
with	O
thiosemicarbazide	O
afforded	O
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
morpholinoisoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
thiosemicarbazone	I-IUPAC
(	O
22	O
)	O
.	O

N	O
-	O
Oxidation	O
of	O
1,5	I-IUPAC
-	I-IUPAC
dimethylisoquinoline	I-IUPAC
,	O
followed	O
by	O
rearrangement	O
with	O
acetic	O
anhydride	O
,	O
gave	O
,	O
after	O
acid	O
hydrolysis	O
,	O
1,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyisoquinoline	I-IUPAC
,	O
which	O
was	O
converted	O
to	O
its	O
acetate	O
and	O
then	O
oxidized	O
to	O
yield	O
4	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
(	O
32	O
)	O
.	O

Sulfonation	O
of	O
1,4	I-IUPAC
-	I-IUPAC
dimethylisoquinoline	I-IUPAC
,	O
followed	O
by	O
reaction	O
with	O
potassium	O
hydroxide	O
,	O
acetylation	O
,	O
and	O
oxidation	O
,	O
gave	O
5	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylisoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
(	O
40	O
)	O
.	O

Condensation	O
of	O
compounds	O
32	O
and	O
39	O
with	O
thiosemicarbazide	O
afforded	O
the	O
respective	O
4	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-PARTIUPAC
-	I-PARTIUPAC
acetoxy	I-PARTIUPAC
(	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
)	I-PARTIUPAC
thiosemicarbazones	I-PARTIUPAC
33	O
and	O
40	O
,	O
which	O
were	O
then	O
converted	O
to	O
their	O
respective	O
4	O
-	O
and	O
5	O
-	O
hydroxy	O
derivatives	O
34	O
and	O
41	O
by	O
acid	O
hydrolysis	O
.	O

The	O
most	O
active	O
compounds	O
synthesized	O
were	O
4	I-IUPAC
-	I-IUPAC
aminoisoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
thiosemicarbazone	I-IUPAC
(	O
9a	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
isoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
thiosemicarbazone	I-IUPAC
(	O
9b	O
)	O
,	O
which	O
both	O
produced	O
optimum	O
%	O
T	O
/	O
C	O
values	O
of	O
177	O
against	O
the	O
L1210	O
leukemia	O
in	O
mice	O
when	O
used	O
at	O
a	O
daily	O
dosage	O
of	O
40	O
mg	O
/	O
kg	O
for	O
6	O
consecutive	O
days	O
.	O

Furthermore	O
,	O
when	O
9a	O
was	O
given	O
twice	O
daily	O
at	O
a	O
dosage	O
of	O
40	O
mg	O
/	O
kg	O
for	O
6	O
consecutive	O
days	O
,	O
a	O
T	O
/	O
C	O
value	O
of	O
165	O
was	O
obtained	O
and	O
60%	O
of	O
the	O
mice	O
were	O
60	O
-	O
day	O
long	O
-	O
term	O
survivors	O
.	O

An	O
enzymatically	O
activated	O
liposome	O
-	O
based	O
drug	O
-	O
delivery	O
concept	O
involving	O
masked	O
antitumor	O
ether	O
lipids	O
(	O
AELs	O
)	O
has	O
been	O
investigated	O
.	O

This	O
concept	O
takes	O
advantage	O
of	O
the	O
cytotoxic	O
properties	O
of	O
AEL	O
drugs	O
as	O
well	O
as	O
the	O
membrane	O
permeability	O
enhancing	O
properties	O
of	O
these	O
molecules	O
,	O
which	O
can	O
lead	O
to	O
enhanced	O
drug	O
diffusion	O
into	O
cells	O
.	O

Three	O
prodrugs	O
of	O
AELs	O
(	O
proAELs	O
)	O
have	O
been	O
synthesized	O
and	O
four	O
liposome	O
systems	O
,	O
consisting	O
of	O
these	O
proAELs	O
,	O
were	O
investigated	O
for	O
enzymatic	O
degradation	O
by	O
secretory	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
sPLA	O
(	O
2	O
)	O
)	O
,	O
resulting	O
in	O
the	O
release	O
of	O
AELs	O
.	O

The	O
three	O
synthesized	O
proAELs	O
were	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
hexadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
palmitoyl	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phosphocholine	I-IUPAC
(	O
1	O
-	O
O	O
-	O
DPPC	O
)	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
hexadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
palmitoyl	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phosphoethanolamine	I-IUPAC
poly	I-IUPAC
(	I-IUPAC
ethylene	I-IUPAC
glycol	I-IUPAC
)	I-IUPAC
(	O
350	O
)	O
(	O
1	O
-	O
O	O
-	O
DPPE	O
-	O
PEG	O
(	O
350	O
)	O
)	O
,	O
and	O
1	O
-	O
O	O
-	O
DPPE	O
-	O
PEG	O
(	O
2000	O
)	O
of	O
which	O
1	O
-	O
O	O
-	O
DPPC	O
was	O
the	O
main	O
liposome	O
component	O
.	O

All	O
three	O
phospholipids	O
were	O
synthesized	O
from	O
the	O
versatile	O
starting	O
material	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
glycidol	I-IUPAC
.	O

A	O
phosphorylation	O
method	O
,	O
employing	O
methyl	O
dichlorophosphate	O
,	O
was	O
developed	O
and	O
applied	O
in	O
the	O
synthesis	O
of	O
two	O
analogues	O
of	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
hexadecyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
palmitoyl	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phosphoethanolamine	I-IUPAC
poly	I-IUPAC
(	I-IUPAC
ethylene	I-IUPAC
glycol	I-IUPAC
)	I-IUPAC
.	O

Differential	O
scanning	O
calorimetry	O
has	O
been	O
used	O
to	O
investigate	O
the	O
phase	O
behavior	O
of	O
the	O
lipid	O
bilayers	O
.	O

A	O
release	O
study	O
,	O
employing	O
calcein	O
encapsulated	O
in	O
non	O
-	O
hydrolyzable	O
1,2	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
octadecyl	I-IUPAC
-	I-IUPAC
sn	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phosphocholine	I-IUPAC
(	O
D	O
-	O
O	O
-	O
SPC	O
)	O
liposomes	O
,	O
showed	O
that	O
proAELs	O
,	O
activated	O
by	O
sPLA	O
(	O
2	O
)	O
,	O
perturb	O
membranes	O
because	O
of	O
the	O
detergent	O
-	O
like	O
properties	O
of	O
the	O
released	O
hydrolysis	O
products	O
.	O

A	O
hemolysis	O
investigation	O
was	O
conducted	O
on	O
human	O
red	O
blood	O
cells	O
,	O
and	O
the	O
results	O
demonstrate	O
that	O
proAEL	O
liposomes	O
display	O
a	O
very	O
low	O
hemotoxicity	O
,	O
which	O
has	O
been	O
a	O
major	O
obstacle	O
for	O
using	O
AELs	O
in	O
cancer	O
therapy	O
.	O

The	O
results	O
suggest	O
a	O
possible	O
way	O
of	O
combining	O
a	O
drug	O
-	O
delivery	O
and	O
prodrug	O
concept	O
in	O
a	O
single	O
liposome	O
system	O
.	O

Our	O
investigation	O
of	O
the	O
permeability	O
-	O
enhancing	O
properties	O
of	O
the	O
AEL	O
molecules	O
imply	O
that	O
by	O
encapsulating	O
conventional	O
chemotherapeutic	O
drugs	O
,	O
such	O
as	O
doxorubicin	O
,	O
in	O
liposomes	O
consisting	O
of	O
proAELs	O
,	O
an	O
increased	O
effect	O
of	O
the	O
encapsulated	O
drug	O
might	O
be	O
achievable	O
due	O
to	O
an	O
enhanced	O
transmembrane	O
drug	O
diffusion	O
.	O

As	O
a	O
continuation	O
of	O
our	O
earlier	O
study	O
(	O
J	O
.	O

Med.	O
Chem.	O
1992	O
,	O
35	O
,	O
4334-4343	O
)	O
we	O
conformationally	O
restricted	O
the	O
sigma	O
-	O
receptor	O
ligand	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylethylamine	I-IUPAC
(	O
1	O
)	O
by	O
incorporating	O
it	O
into	O
a	O
series	O
of	O
homologous	O
piperazines	O
3-9	O
and	O
homopiperazines	O
10	O
and	O
11	O
,	O
diazabicyclononanes	O
and	O
decanes	O
,	O
bridgehead	O
bicyclooctanes	O
and	O
nonanes	O
as	O
well	O
as	O
other	O
miscellaneous	O
compounds	O
.	O

sigma	O
-	O
Receptor	O
binding	O
affinities	O
were	O
obtained	O
using	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
in	O
guinea	O
pig	O
brain	O
membrane	O
sigma	O
1	O
sites	O
.	O

The	O
studies	O
suggest	O
that	O
the	O
nitrogen	O
lone	O
pair	O
orientation	O
found	O
in	O
the	O
piperazines	O
affords	O
the	O
strongest	O
binding	O
interaction	O
.	O

Other	O
nitrogen	O
lone	O
pair	O
orientations	O
or	O
compounds	O
representing	O
unlikely	O
staggered	O
conformations	O
of	O
1	O
[	O
as	O
in	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diazabicyclo	I-IUPAC
[	I-IUPAC
3.2.2	I-IUPAC
]	I-IUPAC
nonane	I-IUPAC
(	O
16	O
)	O
]	O
show	O
very	O
weak	O
sigma	O
interaction	O
.	O

Comparison	O
of	O
the	O
binding	O
data	O
of	O
different	O
N	O
-	O
substituted	O
homologues	O
of	O
1	O
with	O
those	O
of	O
the	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
alkylpiperazines	I-IUPAC
suggests	O
that	O
the	O
two	O
nitrogen	O
atoms	O
of	O
1	O
are	O
working	O
in	O
opposition	O
to	O
one	O
another	O
in	O
terms	O
of	O
their	O
sensitivity	O
to	O
steric	O
bulk	O
.	O

The	O
high	O
binding	O
affinity	O
of	O
the	O
1,4	I-IUPAC
-	I-IUPAC
diazabicyclo	I-IUPAC
[	O
4.3.0	O
]	O
nonanes	I-IUPAC
12	O
suggests	O
that	O
these	O
may	O
approximate	O
the	O
methyl	O
and	O
pyrrolidine	O
ring	O
conformations	O
found	O
in	O
1	O
when	O
it	O
is	O
bound	O
to	O
the	O
sigma	O
receptor	O
.	O

Compound	O
12	O
exhibited	O
a	O
4	O
-	O
fold	O
enantioselectivity	O
favoring	O
(	O
+	O
)	O
-	O
12	O
.	O

The	O
synthesis	O
of	O
6,7	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
tetralin	I-IUPAC
(	O
19	O
)	O
and	O
its	O
desmethyl	I-IUPAC
derivative	I-IUPAC
20	O
permitted	O
constraint	O
of	O
the	O
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
moieties	I-MODIFIER
of	O
1	O
into	O
a	O
gauche	O
orientation	O
.	O

The	O
binding	O
data	O
suggests	O
that	O
this	O
conformation	O
in	O
1	O
favors	O
strong	O
binding	O
interaction	O
at	O
sigma	O
-	O
receptors	O
.	O

sigma	O
-	O
Receptor	O
Ki	O
's	O
ranged	O
from	O
0.55	O
nM	O
for	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butylpiperazine	I-IUPAC
(	O
7	O
)	O
to	O
654	O
nM	O
for	O
16	O
.	O

Overall	O
comparison	O
of	O
the	O
results	O
indicate	O
that	O
1	O
is	O
subject	O
to	O
considerable	O
conformational	O
freedom	O
and	O
suggests	O
that	O
the	O
sigma	O
receptor	O
is	O
not	O
subject	O
to	O
rigid	O
stereochemical	O
restraints	O
with	O
1	O
.	O

These	O
results	O
add	O
to	O
our	O
earlier	O
study	O
where	O
we	O
restrained	O
1	O
using	O
simple	O
monocyclic	O
heterocycles	O
.	O

A	O
number	O
of	O
7	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
aminopyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
,	O
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
,	O
and	O
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thiocarboxamide	I-IUPAC
derivatives	I-MODIFIER
related	O
to	O
the	O
nucleoside	O
antibiotics	O
toyocamycin	O
and	O
sangivamycin	O
were	O
prepared	O
and	O
tested	O
for	O
their	O
activity	O
against	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
and	O
herpes	O
simplex	O
virus	O
type	O
-	O
1	O
(	O
HSV	O
-	O
1	O
)	O
.	O

Treatment	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dicyanopyrrole	I-IUPAC
(	O
1	O
)	O
with	O
triethyl	O
orthoformate	O
followed	O
by	O
alkylation	O
via	O
the	O
sodium	O
salt	O
method	O
with	O
a	O
variety	O
of	O
alkylating	O
agents	O
furnished	O
the	O
corresponding	O
1	O
-	O
substituted	O
pyrroles	O
2a	O
-	O
k	O
.	O

Ring	O
annulation	O
was	O
achieved	O
with	O
methanolic	O
ammonia	O
affording	O
the	O
7	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
bromopyrrolo+	I-IUPAC
+	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
derivatives	I-MODIFIER
3a	O
-	O
k	O
.	O

Debromination	O
of	O
3a	O
-	O
k	O
,	O
via	O
catalytic	O
hydrogenation	O
,	O
gave	O
the	O
corresponding	O
7	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
aminopyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
analogs	I-MODIFIER
4a	O
-	O
j	O
,	O
l	O
.	O

A	O
selective	O
reduction	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
allylpyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
-	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbon	I-IUPAC
ril	I-IUPAC
e	I-IUPAC
(	O
3k	O
)	O
in	O
zinc	O
and	O
acetic	O
acid	O
furnished	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
allylpyrrolo	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
(	O
4k	O
)	O
.	O

Conventional	O
functional	O
group	O
transformations	O
involving	O
the	O
5	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
group	I-MODIFIER
of	O
4	O
furnished	O
the	O
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
derivatives	I-MODIFIER
5a	O
-	O
1	O
and	O
the	O
5	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
amide	I-IUPAC
analogs	I-MODIFIER
6a	O
-	O
l	O
.	O

A	O
similar	O
transformation	O
of	O
the	O
aglycone	O
of	O
toyocamycin	O
(	O
4m	O
)	O
furnished	O
the	O
corresponding	O
aglycone	O
of	O
thiosangivamycin	O
(	O
6m	O
)	O
.	O

Several	O
of	O
the	O
new	O
compounds	O
(	O
4-6	O
a	O
-	O
ej	O
-	O
l	O
)	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
the	O
growth	O
of	O
L1210	O
murine	O
leukemic	O
cells	O
.	O

Whereas	O
a	O
number	O
of	O
the	O
carboxamide	O
(	O
5	O
)	O
and	O
thioamide	O
(	O
6	O
)	O
derivatives	O
had	O
modest	O
activity	O
,	O
the	O
corresponding	O
nitrile	I-IUPAC
analogs	B-MODIFIER
(	O
4	O
)	O
were	O
all	O
inactive	O
.	O

All	O
compounds	O
were	O
tested	O
for	O
activity	O
against	O
HCMV	O
and	O
HSV	O
-	O
1	O
.	O

The	O
non	O
-	O
nucleoside	O
nitrile	O
analogs	O
4a	O
-	O
m	O
and	O
carboxamide	I-IUPAC
derivatives	B-MODIFIER
5a	O
-	O
l	O
were	O
,	O
with	O
a	O
few	O
exceptions	O
,	O
essentially	O
inactive	O
against	O
HCMV	O
and	O
HSV	O
-	O
1	O
and	O
relatively	O
nontoxic	O
.	O

In	O
direct	O
contrast	O
,	O
nearly	O
all	O
of	O
the	O
thioamide	I-IUPAC
derivates	B-MODIFIER
6a	O
-	O
1	O
,	O
including	O
the	O
aglycone	O
of	O
thiosangivamycin	O
(	O
6m	O
)	O
,	O
were	O
good	O
inhibitors	O
of	O
HCMV	O
and	O
HSV	O
-	O
1	O
.	O

Most	O
were	O
noncytotoxic	O
in	O
their	O
antiviral	O
concentration	O
range	O
.	O

Cytotoxicity	O
which	O
was	O
observed	O
appeared	O
to	O
be	O
a	O
consequence	O
of	O
DNA	O
synthesis	O
inhibition	O
.	O

Several	O
of	O
these	O
compounds	O
,	O
such	O
as	O
6b	O
,	O
e	O
,	O
were	O
particularly	O
interesting	O
inhibitors	O
of	O
HCMV	O
with	O
IC	O
(	O
50	O
)	O
's	O
ranging	O
from	O
0.1	O
to	O
1.3	O
muM	O
.	O

The	O
antiviral	O
activity	O
of	O
both	O
compounds	O
was	O
well	O
separated	O
from	O
cytotoxicity	O
in	O
KB	O
,	O
HFF	O
,	O
and	O
L1210	O
cells	O
.	O

The	O
antitumor	O
activity	O
of	O
various	O
platinum	O
(	O
II	O
)	O
complexes	O
of	O
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
isomers	O
against	O
leukemia	O
P388	O
was	O
evaluated	O
by	O
means	O
of	O
the	O
platinum	O
analogue	O
study	O
protocol	O
recommended	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

For	O
the	O
former	O
complexes	O
,	O
trans	O
isomers	O
are	O
more	O
efficacious	O
than	O
the	O
corresponding	O
cis	O
isomers	O
.	O

For	O
the	O
latter	O
complexes	O
,	O
cis	O
isomers	O
seem	O
to	O
be	O
somewhat	O
more	O
active	O
than	O
trans	O
isomers	O
.	O

2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Aminomethyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
platinum	I-IUPAC
complexes	I-MODIFIER
exhibited	O
higher	O
activity	O
than	O
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
complexes	I-MODIFIER
in	O
this	O
tumor	O
system	O
.	O

These	O
findings	O
encouraged	O
us	O
to	O
determine	O
the	O
structural	O
differences	O
between	O
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
complexes	I-MODIFIER
.	O

Their	O
structures	O
of	O
platinum	O
complexes	O
were	O
elucidated	O
from	O
circular	O
dichroism	O
and	O
13C	O
NMR	O
spectral	O
analyses	O
,	O
and	O
it	O
has	O
been	O
concluded	O
that	O
the	O
cyclohexane	O
ring	O
of	O
cis	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
is	O
nearly	O
perpendicular	O
to	O
the	O
chelate	O
ring	O
,	O
while	O
both	O
rings	O
of	O
trans	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
complexes	I-MODIFIER
lie	O
in	O
a	O
common	O
plane	O
.	O

The	O
structure	O
of	O
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
complexes	I-MODIFIER
is	O
flexible	O
,	O
and	O
the	O
cyclohexane	O
ring	O
is	O
not	O
perpendicular	O
to	O
the	O
chelate	O
ring	O
.	O

The	O
coplanarity	O
of	O
trans	O
isomers	O
and	O
the	O
flexibility	O
of	O
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
complexes	I-MODIFIER
allow	O
them	O
easy	O
approach	O
to	O
the	O
target	O
DNA	O
.	O

However	O
,	O
the	O
perpendicular	O
ring	O
of	O
cis	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
complexes	I-MODIFIER
would	O
prevent	O
their	O
interactions	O
with	O
dna	O
molecules	O
due	O
to	O
the	O
steric	O
hindrance	O
.	O

Two	O
novel	O
classical	O
antifolates	O
N	I-IUPAC
-	I-IUPAC
{	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
3	O
and	O
N	I-IUPAC
-	I-IUPAC
{	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
4	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
as	O
antitumor	O
agents	O
.	O

Compounds	O
3	O
and	O
4	O
were	O
obtained	O
from	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylpyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
7	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylpyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
12	O
,	O
respectively	O
,	O
in	O
a	O
concise	O
three	O
-	O
step	O
sequence	O
.	O

Compound	O
3	O
is	O
the	O
first	O
example	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
a	O
2,4	O
-	O
diamino	O
classical	O
antifolate	O
that	O
has	O
potent	O
inhibitory	O
activity	O
against	O
both	O
human	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
human	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O

Compound	O
4	O
was	O
a	O
dual	O
DHFR	O
-	O
TS	O
inhibitor	O
against	O
the	O
bifunctional	O
enzyme	O
derived	O
from	O
Toxoplasma	O
gondii	O
(	O
tg	O
)	O
.	O

Further	O
evaluation	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
3	O
implicated	O
DHFR	O
as	O
its	O
primary	O
intracellular	O
target	O
.	O

Both	O
3	O
and	O
4	O
were	O
folylpolyglutamate	O
synthetase	O
(	O
FPGS	O
)	O
substrates	O
.	O

Compound	O
3	O
also	O
inhibited	O
the	O
growth	O
of	O
several	O
human	O
tumor	O
cell	O
lines	O
in	O
culture	O
with	O
GI50	O
&	O
lt	O
;	O
10	O
(	O
-	O
8	O
)	O
M	O
.	O

This	O
study	O
shows	O
that	O
the	O
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
scaffold	I-MODIFIER
is	O
conducive	O
to	O
dual	O
DHFR	O
-	O
TS	O
and	O
tumor	O
inhibitory	O
activity	O
,	O
and	O
the	O
potency	O
is	O
determined	O
by	O
the	O
4	O
-	O
position	O
substituent	O
.	O

A	O
diverse	O
range	O
of	O
chromen	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
chromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
pyrimidoisoquinolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
derivatives	I-MODIFIER
was	O
synthesized	O
and	O
evaluated	O
for	O
inhibitory	O
activity	O
against	O
the	O
DNA	O
repair	O
enzyme	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
,	O
with	O
a	O
view	O
to	O
elucidating	O
structure	O
-	O
activity	O
relationships	O
for	O
potency	O
and	O
kinase	O
selectivity	O
.	O

DNA	O
-	O
PK	O
inhibitory	O
activity	O
varied	O
widely	O
over	O
the	O
series	O
of	O
compounds	O
evaluated	O
(	O
IC	O
(	O
50	O
)	O
values	O
ranged	O
from	O
0.19	O
to	O
&	O
gt	O
;	O
10	O
microM	O
)	O
,	O
with	O
excellent	O
activity	O
being	O
observed	O
for	O
the	O
7,8	I-IUPAC
-	I-IUPAC
benzochromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
isoquinolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
templates	O
.	O

By	O
contrast	O
,	O
inhibitors	O
based	O
on	O
the	O
benzochromen	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
coumarin	O
)	O
or	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
benzochromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
flavone	O
)	O
scaffolds	I-MODIFIER
were	O
less	O
potent	O
.	O

Crucially	O
,	O
these	O
studies	O
revealed	O
a	O
very	O
constrained	O
structure	O
-	O
activity	O
relationship	O
at	O
the	O
2	O
-	O
position	O
of	O
the	O
benzopyranone	O
and	O
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
isoquinolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
pharmacophore	I-MODIFIER
,	O
with	O
only	O
a	O
2	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methylmorpholino	I-IUPAC
)	I-IUPAC
group	I-MODIFIER
being	O
tolerated	O
at	O
this	O
position	O
.	O

More	O
detailed	O
biological	O
studies	O
conducted	O
with	O
the	O
most	O
potent	O
inhibitor	O
NU7163	O
(	O
48	O
;	O
IC	O
(	O
50	O
)	O
=	O
0.19	O
microM	O
)	O
demonstrated	O
ATP	O
-	O
competitive	O
DNA	O
-	O
PK	O
inhibition	O
,	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
24	O
nM	O
,	O
and	O
48	O
exhibited	O
selectivity	O
for	O
DNA	O
-	O
PK	O
compared	O
with	O
the	O
related	O
enzymes	O
ATM	O
,	O
ATR	O
,	O
mTOR	O
,	O
and	O
PI	O
3	O
-	O
K	O
(	O
p110alpha	O
)	O
.	O

Compound	O
48	O
sensitized	O
the	O
HeLa	O
human	O
tumor	O
cell	O
line	O
to	O
the	O
cytotoxic	O
effects	O
of	O
ionizing	O
radiation	O
in	O
vitro	O
,	O
a	O
dose	O
modification	O
factor	O
of	O
2.3	O
at	O
10%	O
survival	O
being	O
observed	O
with	O
an	O
inhibitor	O
concentration	O
of	O
5	O
microM	O
.	O

This	O
study	O
identified	O
these	O
structural	O
classes	O
as	O
novel	O
DNA	O
-	O
PK	O
inhibitors	O
and	O
delineated	O
initial	O
structure	O
-	O
activity	O
relationships	O
against	O
DNA	O
-	O
PK	O
.	O

A	O
series	O
of	O
analogues	O
and	O
homologues	O
of	O
N1	I-IUPAC
,	I-IUPAC
N12	I-IUPAC
-	I-IUPAC
diethylspermine	I-IUPAC
(	O
DESPM	O
)	O
was	O
synthesized	O
,	O
and	O
their	O
biological	O
properties	O
were	O
evaluated	O
.	O

These	O
tetraamines	O
include	O
a	O
simple	O
linear	O
analogue	O
of	O
DESPM	O
,	O
N1	I-IUPAC
,	I-IUPAC
N12	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2,2,2	I-IUPAC
-	I-IUPAC
trifluoroethyl	I-IUPAC
)	I-IUPAC
spermine	I-IUPAC
(	O
FDESPM	O
)	O
,	O
the	O
cyclic	O
analogues	O
of	O
DESPM	O
,	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidinylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diaminobutane	I-IUPAC
[	O
PIP	O
(	O
4,4,4	O
)	O
]	O
and	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diaminobutane	I-IUPAC
[	O
PIP	O
(	O
5,4,5	O
)	O
]	O
,	O
and	O
their	O
aromatic	O
counterparts	O
,	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diaminobutane	I-IUPAC
[	O
PYR	O
(	O
4,4,4	O
)	O
]	O
and	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
diaminobutane	I-IUPAC
[	O
PYR	O
(	O
5,4,5	O
)	O
]	O
.	O

The	O
analogues	O
FDESPM	O
,	O
PIP	O
(	O
4,4,4	O
)	O
,	O
and	O
PYR	O
(	O
4,4,4	O
)	O
have	O
distances	O
between	O
their	O
nitrogen	O
atoms	O
almost	O
identical	O
to	O
those	O
of	O
DESPM	O
.	O

The	O
longer	O
analogues	O
PIP	O
(	O
5,4,5	O
)	O
and	O
PYR	O
(	O
5,4,5	O
)	O
are	O
very	O
similar	O
in	O
the	O
spacing	O
of	O
their	O
amino	O
groups	O
.	O

However	O
,	O
the	O
pKa	O
of	O
the	O
nitrogens	O
in	O
the	O
groups	O
differ	O
;	O
thus	O
,	O
the	O
extent	O
of	O
protonation	O
and	O
the	O
charge	O
characteristics	O
among	O
the	O
members	O
of	O
the	O
groups	O
differ	O
.	O

A	O
comparison	O
of	O
the	O
biological	O
properties	O
of	O
these	O
compounds	O
clearly	O
demonstrates	O
that	O
the	O
tetraamines	O
must	O
be	O
charged	O
to	O
be	O
"	O
recognized	O
"	O
by	O
the	O
cell	O
.	O

Analogues	O
with	O
low	O
nitrogen	O
pKa	O
's	O
such	O
that	O
the	O
nitrogens	O
are	O
poorly	O
protonated	O
at	O
physiological	O
pH	O
do	O
not	O
compete	O
well	O
with	O
spermidine	O
for	O
uptake	O
and	O
,	O
as	O
expected	O
,	O
have	O
high	O
96	O
h	O
IC50	O
values	O
and	O
have	O
little	O
effect	O
on	O
S	I-IUPAC
-	I-IUPAC
adenosylmethionine	I-IUPAC
decarboxylase	O
,	O
ornithine	O
decarboxylase	O
,	O
and	O
spermidine	O
/	O
spermine	O
N1	O
-	O
acetyltransferase	O
activities	O
and	O
on	O
intracellular	O
polyamine	O
pools	O
.	O

WB	O
4101	O
(	O
1	O
)	O
-	O
related	O
benzodioxanes	O
were	O
synthesized	O
by	O
replacing	O
the	O
ethylene	O
chain	O
separating	O
the	O
amine	O
and	O
the	O
phenoxy	O
units	O
of	O
1	O
with	O
a	O
cyclopentanol	I-IUPAC
moiety	I-IUPAC
,	O
a	O
feature	O
of	O
6	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenoxycyclopentyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
meth	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylbenzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
that	O
was	O
reported	O
to	O
display	O
an	O
intriguing	O
selectivity	O
profile	O
at	O
alpha	O
(	O
1	O
)	O
-	O
adrenoreceptors	O
.	O

This	O
synthesis	O
strategy	O
led	O
to	O
4	O
out	O
of	O
16	O
possible	O
stereoisomers	O
,	O
which	O
were	O
isolated	O
in	O
the	O
case	O
of	O
(	O
-	O
)	O
-	O
3	O
,	O
(	O
+	O
)	O
-	O
3	O
,	O
(	O
-	O
)	O
-	O
4	O
,	O
and	O
(	O
+	O
)	O
-	O
4	O
and	O
whose	O
absolute	O
configuration	O
was	O
assigned	O
using	O
a	O
chiral	O
building	O
block	O
for	O
the	O
synthesis	O
of	O
(	O
-	O
)	O
-	O
3	O
starting	O
from	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
benzodioxine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
(	O
+	O
)	O
-	O
9	O
)	O
and	O
(	I-IUPAC
1S	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
5S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenoxycyclopentan	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
(	O
+	O
)	O
-	O
10	O
)	O
.	O

The	O
aim	O
of	O
this	O
project	O
was	O
to	O
further	O
investigate	O
whether	O
it	O
is	O
possible	O
to	O
differentiate	O
between	O
these	O
compounds	O
with	O
respect	O
to	O
their	O
affinity	O
for	O
alpha	O
(	O
1	O
)	O
-	O
adrenoreceptor	O
subtypes	O
and	O
the	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
,	O
as	O
1	O
binds	O
with	O
high	O
affinity	O
at	O
both	O
receptor	O
systems	O
.	O

The	O
biological	O
profiles	O
of	O
reported	O
compounds	O
at	O
alpha	O
(	O
1	O
)	O
-	O
adrenoreceptor	O
subtypes	O
were	O
assessed	O
by	O
functional	O
experiments	O
in	O
isolated	O
rat	O
vas	O
deferens	O
(	O
alpha	O
(	O
1A	O
)	O
)	O
,	O
spleen	O
(	O
alpha	O
(	O
1B	O
)	O
)	O
,	O
and	O
aorta	O
(	O
alpha	O
(	O
1D	O
)	O
)	O
and	O
by	O
binding	O
assays	O
in	O
CHO	O
and	O
HeLa	O
cells	O
membranes	O
expressing	O
the	O
human	O
cloned	O
alpha	O
(	O
1	O
)	O
-	O
adrenoreceptor	O
subtypes	O
and	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
functional	O
activity	O
of	O
(	O
-	O
)	O
-	O
3	O
,	O
(	O
+	O
)	O
-	O
3	O
,	O
(	O
-	O
)	O
-	O
4	O
,	O
and	O
(	O
+	O
)	O
-	O
4	O
toward	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
was	O
evaluated	O
by	O
determining	O
the	O
induced	O
stimulation	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
GTPgammaS	O
binding	O
in	O
cell	O
membranes	O
from	O
HeLa	O
cells	O
transfected	O
with	O
human	O
cloned	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
.	O

The	O
configuration	O
of	O
the	O
cyclopentane	O
unit	O
determined	O
the	O
affinity	O
profile	O
:	O
a	O
1R	O
configuration	O
,	O
as	O
in	O
(	O
+	O
)	O
-	O
3	O
and	O
(	O
-	O
)	O
-	O
4	O
,	O
conferred	O
higher	O
affinity	O
at	O
alpha	O
(	O
1	O
)	O
-	O
adrenoreceptors	O
,	O
whereas	O
a	O
1S	O
configuration	O
,	O
as	O
in	O
(	O
-	O
)	O
-	O
3	O
and	O
(	O
+	O
)	O
-	O
4	O
,	O
produced	O
higher	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
.	O

For	O
the	O
enantiomers	O
(	O
+	O
)	O
-	O
4	O
and	O
(	O
-	O
)	O
-	O
4	O
also	O
a	O
remarkable	O
selectivity	O
was	O
achieved	O
.	O

Functionally	O
,	O
the	O
stereoisomers	O
displayed	O
a	O
similar	O
alpha	O
(	O
1	O
)	O
-	O
selectivity	O
profile	O
,	O
that	O
is	O
alpha	O
(	O
1D	O
)	O
&	O
gt	O
;	O
alpha	O
(	O
1B	O
)	O
&	O
gt	O
;	O
alpha	O
(	O
1A	O
)	O
,	O
which	O
is	O
different	O
from	O
that	O
exhibited	O
by	O
the	O
reference	O
compound	O
1	O
.	O

The	O
epimers	O
(	O
-	O
)	O
-	O
3	O
and	O
(	O
+	O
)	O
-	O
4	O
proved	O
to	O
be	O
agonists	O
at	O
the	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
,	O
with	O
a	O
potency	O
comparable	O
to	O
that	O
of	O
5	I-IUPAC
-	I-IUPAC
hydroxytryptamine	I-IUPAC
.	O

The	O
development	O
of	O
99mTc	O
-	O
labeled	O
fatty	O
acid	O
analogues	O
metabolized	O
by	O
beta	O
-	O
oxidation	O
in	O
the	O
myocardium	O
constitutes	O
an	O
unsolved	O
challenge	O
.	O

On	O
the	O
basis	O
of	O
our	O
recent	O
findings	O
that	O
[	I-IUPAC
188Re	I-IUPAC
]	I-IUPAC
tricarbonyl	I-IUPAC
(	I-IUPAC
cyclopentadienylcarbonate	I-IUPAC
)	I-IUPAC
rhenium	I-IUPAC
(	O
[	O
188Re	O
]	O
CpTR	O
-	O
COOH	O
)	O
was	O
recognized	O
as	O
an	O
aromatic	O
compound	O
and	O
was	O
metabolized	O
as	O
such	O
in	O
the	O
body	O
,	O
[	O
99mTc	O
]	O
cyclopentadienyltricarbonyltechnetium	O
(	O
[	O
99mTc	O
]	O
CpTT	O
)	O
was	O
conjugated	O
at	O
the	O
omega	O
-	O
position	O
of	O
pentadecanoic	O
acid	O
to	O
prepare	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
.	O

When	O
injected	O
into	O
rats	O
,	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
exhibited	O
the	O
maximum	O
myocardial	O
accumulation	O
and	O
heart	O
-	O
to	O
-	O
blood	O
ratio	O
of	O
3.85	O
%	O
ID	O
/	O
g	O
at	O
1	O
min	O
and	O
4.60	O
at	O
10	O
min	O
postinjection	O
,	O
respectively	O
.	O

The	O
metabolic	O
study	O
using	O
isolated	O
Langendorff	O
perfused	O
rat	O
hearts	O
demonstrated	O
that	O
approximately	O
67%	O
of	O
perfused	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
was	O
incorporated	O
and	O
[	O
99mTc	O
]	O
CpTT	O
-	O
propionic	O
acid	O
,	O
the	O
metabolite	O
after	O
six	O
cycles	O
of	O
beta	O
-	O
oxidation	O
of	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
,	O
was	O
detected	O
as	O
the	O
major	O
radiometabolite	O
in	O
the	O
perfusate	O
and	O
myocardium	O
.	O

These	O
findings	O
indicate	O
that	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
was	O
recognized	O
,	O
transported	O
,	O
and	O
metabolized	O
as	O
a	O
long	O
chain	O
fatty	O
acid	O
analogue	O
for	O
energy	O
production	O
in	O
the	O
myocardium	O
.	O

This	O
paper	O
outlines	O
the	O
synthesis	O
of	O
selected	O
acid	O
mimics	O
of	O
the	O
non	O
-	O
peptide	O
CCK	O
-	O
B	O
selective	O
antagonist	O
CI	O
-	O
988	O
,	O
1	O
.	O

CCK	O
-	O
B	O
and	O
CCK	O
-	O
A	O
binding	O
affinities	O
of	O
these	O
analogues	O
are	O
described	O
and	O
their	O
CCK	O
-	O
B	O
affinity	O
and	O
selectivity	O
rationalized	O
by	O
consideration	O
of	O
the	O
pK	O
(	O
a	O
)	O
values	O
,	O
charge	O
distribution	O
,	O
and	O
geometry	O
of	O
the	O
respective	O
acid	O
mimics	O
.	O

Several	O
of	O
the	O
compounds	O
have	O
CCK	O
-	O
B	O
binding	O
affinities	O
similar	O
to	O
the	O
parent	O
carboxylic	O
acid	O
1	O
(	O
CCK	O
-	O
B	O
,	O
IC50	O
=	O
1.7	O
nM	O
;	O
pK	O
(	O
a	O
)	O
=	O
5.6	O
)	O
and	O
span	O
a	O
pK	O
(	O
a	O
)	O
range	O
of	O
less	O
than	O
1	O
(	O
sulfonic	O
acid	O
27	O
)	O
to	O
greater	O
than	O
9.5	O
(	O
5	I-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
24	O
)	O
.	O

Among	O
the	O
more	O
active	O
compounds	O
synthesized	O
are	O
tricyclo	I-IUPAC
[	I-IUPAC
3.3.1.1	I-IUPAC
(	I-IUPAC
3,7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
dec	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolyl	I-IUPAC
)	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl+	I-IUPAC
+	I-IUPAC
+	I-IUPAC
]	I-IUPAC
carbamate	I-IUPAC
(	O
15	O
)	O
,	O
tricyclo	I-IUPAC
[	I-IUPAC
3.3.1.1	I-IUPAC
(	I-IUPAC
3,7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
dec	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
sulfopropyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
carbamate	I-IUPAC
,	O
monosodium	O
salt	O
(	O
27	O
)	O
,	O
and	O
tricyclo	I-IUPAC
[	I-IUPAC
3.3.1.1	I-IUPAC
(	I-IUPAC
3,7	I-IUPAC
)	I-IUPAC
]	I-IUPAC
dec	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylsulfinyl	I-IUPAC
)	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
a	I-IUPAC
mino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
carbamic	I-IUPAC
acid	I-IUPAC
(	O
34	O
)	O
which	O
have	O
CCK	O
-	O
B	O
binding	O
affinities	O
of	O
IC50	O
=	O
2.6	O
,	O
1.3	O
,	O
and	O
1.7	O
nM	O
,	O
CCK	O
-	O
A	O
/	O
-	O
B	O
ratios	O
of	O
650	O
,	O
780	O
,	O
and	O
550	O
and	O
pK	O
(	O
a	O
)	O
values	O
of	O
6.5	O
,	O
less	O
than	O
1	O
,	O
and	O
7.0	O
,	O
respectively	O
.	O

Synthesis	O
and	O
antitetrabenazine	O
activity	O
of	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
piperidines	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpiperidines	I-IUPAC
,	O
prepared	O
as	O
simplified	O
and	O
possibly	O
more	O
readily	O
synthesized	O
analogues	O
of	O
3	I-IUPAC
-	I-IUPAC
phenylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
,	O
are	O
reported	O
.	O

Several	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
piperidines	I-IUPAC
display	O
antitetrabenazine	O
activity	O
comparable	O
to	O
imipramine	O
or	O
amitriptyline	O
but	O
are	O
two	O
-	O
to	O
fourfold	O
less	O
active	O
than	O
analogous	O
3	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
.	O

Structure	O
-	O
-	O
activity	O
relationships	O
for	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2p	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
piperidines	I-IUPAC
are	O
generally	O
similar	O
to	O
the	O
profile	O
established	O
for	O
3	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
.	O

Significant	O
antitetrabenazine	O
activity	O
is	O
associated	O
only	O
with	O
derivatives	O
where	O
the	O
arylmethyl	O
group	O
is	O
ortho	O
to	O
the	O
piperidine	O
ring	O
.	O

4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenylpiperidines	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidinols	I-IUPAC
and	O
the	O
corresponding	O
methyl	O
ethers	O
and	O
esters	O
display	O
weak	O
to	O
modest	O
antitetrabenazine	O
activity	O
.	O

4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Arylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
derivatives	I-MODIFIER
,	O
at	O
best	O
,	O
exhibit	O
modest	O
antitetrabenazine	O
activity	O
,	O
with	O
the	O
exception	O
of	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyridine	I-IUPAC
which	O
is	O
approximately	O
equipotent	O
with	O
amitriptyline	O
.	O

The	O
results	O
of	O
these	O
investigations	O
allow	O
certain	O
speculations	O
to	O
be	O
made	O
with	O
respect	O
to	O
the	O
role	O
of	O
the	O
furan	O
ring	O
in	O
the	O
3	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
and	O
antitetrabenazine	O
activity	O
.	O

The	O
adenosine	O
antagonist	O
9	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinazolin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
CGS	O
15943	O
)	O
binds	O
nonselectively	O
to	O
human	O
A1	O
,	O
A2A	O
,	O
and	O
A3	O
receptors	O
with	O
high	O
affinity	O
.	O

Acylated	O
derivatives	O
and	O
one	O
alkyl	O
derivative	O
of	O
the	O
5	O
-	O
amino	O
group	O
and	O
other	O
modifications	O
were	O
prepared	O
in	O
an	O
effort	O
to	O
enhance	O
A2B	O
or	O
A3	O
subtype	O
potency	O
.	O

In	O
general	O
,	O
distal	O
modifications	O
of	O
the	O
N5	O
-	O
substituent	O
were	O
highly	O
modulatory	O
to	O
potency	O
and	O
selectivity	O
at	O
adenosine	O
receptors	O
,	O
as	O
determined	O
in	O
radioligand	O
binding	O
assays	O
at	O
rat	O
brain	O
A1	O
and	O
A2A	O
receptors	O
and	O
at	O
recombinant	O
human	O
A3	O
receptors	O
.	O

In	O
Chinese	O
hamster	O
ovary	O
cells	O
stably	O
transfected	O
with	O
human	O
A2B	O
receptor	O
cDNA	O
,	O
inhibition	O
of	O
agonist	O
-	O
induced	O
cyclic	O
AMP	O
production	O
was	O
measured	O
.	O

An	O
N5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
acetyl	I-IUPAC
derivative	I-MODIFIER
was	O
highly	O
selective	O
for	O
A2A	O
receptors	O
.	O

An	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N5	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
(	I-IUPAC
phenylacetyl	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
was	O
the	O
most	O
potent	O
derivative	O
at	O
A3	O
receptors	O
,	O
with	O
a	O
Ki	O
value	O
of	O
0.36	O
nM	O
.	O

A	O
bulky	O
N5	I-IUPAC
-	I-IUPAC
diphenylacetyl	I-IUPAC
derivative	I-MODIFIER
,	O
13	O
,	O
displayed	O
a	O
Ki	O
value	O
of	O
0	O
.	O

59	O
nM	O
at	O
human	O
A3	O
receptors	O
and	O
was	O
moderately	O
selective	O
for	O
that	O
subtype	O
.	O

Thus	O
,	O
a	O
large	O
,	O
nondiscriminating	O
hydrophobic	O
region	O
occurs	O
in	O
the	O
A3	O
receptor	O
in	O
proximity	O
to	O
the	O
N5	O
-	O
substituent	O
.	O

A	O
series	O
of	O
straight	O
-	O
chain	O
N5	I-IUPAC
-	I-IUPAC
aminoalkylacyl	I-IUPAC
derivatives	I-MODIFIER
demonstrated	O
that	O
for	O
A2B	O
receptors	O
the	O
optimal	O
chain	O
length	O
occurs	O
with	O
three	O
methylene	O
groups	O
,	O
i.e.	O
,	O
the	O
N5	I-IUPAC
-	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
aminobutyryl	I-IUPAC
derivative	I-MODIFIER
27	O
which	O
had	O
a	O
pA2	O
value	O
of	O
8.0	O
but	O
was	O
not	O
selective	O
for	O
A2B	O
receptors	O
.	O

At	O
A1	O
,	O
A2A	O
,	O
and	O
A3	O
receptors	O
however	O
the	O
optimum	O
occurs	O
with	O
four	O
methylene	O
groups	O
.	O

An	O
N5	I-IUPAC
-	I-IUPAC
pivaloyl	I-IUPAC
derivative	I-MODIFIER
,	O
which	O
was	O
less	O
potent	O
than	O
27	O
at	O
A1	O
,	O
A2A	O
,	O
and	O
A3	O
receptors	O
,	O
retained	O
moderate	O
potency	O
at	O
A2B	O
receptors	O
.	O

A	O
molecular	O
model	O
of	O
the	O
27	O
-	O
A2B	O
receptor	O
complex	O
based	O
on	O
the	O
structure	O
of	O
rhodopsin	O
utilizing	O
a	O
"	O
cross	O
-	O
docking	O
"	O
procedure	O
was	O
developed	O
in	O
order	O
to	O
visualize	O
the	O
environment	O
of	O
the	O
ligand	O
binding	O
site	O
.	O

By	O
the	O
use	O
of	O
space	O
-	O
filling	O
models	O
,	O
a	O
novel	O
compound	O
,	O
6	I-IUPAC
-	I-IUPAC
carbamylmethyl	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
isoquinolin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
was	O
devised	O
which	O
would	O
be	O
expected	O
to	O
hydrogen	O
bond	O
specifically	O
to	O
GC	O
pairs	O
in	O
the	O
major	O
groove	O
of	O
the	O
double	O
helix	O
such	O
that	O
(	O
i	O
)	O
the	O
amino	I-IUPAC
group	B-MODIFIER
of	O
the	O
cytosine	O
molecule	O
donates	O
a	O
hydrogen	O
bond	O
to	O
the	O
C	O
-	O
3	O
carbonyl	O
of	O
the	O
isoquinoline	O
moiety	O
and	O
(	O
ii	O
)	O
the	O
amide	O
proton	O
of	O
the	O
side	O
chain	O
donates	O
a	O
hydrogen	O
bond	O
to	O
the	O
N	O
-	O
7	O
of	O
guanine	O
.	O

3	I-IUPAC
-	I-IUPAC
Ethoxy	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
isoquinoline	I-IUPAC
(	O
4	O
)	O
which	O
constitutes	O
the	O
basic	O
ring	O
system	O
of	O
1	O
was	O
synthesized	O
in	O
a	O
multistep	O
procedure	O
starting	O
from	O
m	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
acetylbenzylamine	I-IUPAC
(	O
5	O
)	O
.	O

Friedel	O
-	O
Crafts	O
reaction	O
of	O
5	O
led	O
to	O
2,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
acetylbenzylamine	I-IUPAC
(	O
6	O
)	O
which	O
on	O
treatment	O
with	O
KCN	O
,	O
hydrolysis	O
of	O
the	O
resultant	O
nitrile	O
,	O
and	O
subsequent	O
esterification	O
afforded	O
6	I-IUPAC
-	I-IUPAC
carbethoxymethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
9	O
)	O
.	O

Treatment	O
of	O
9	O
with	O
triethyloxonium	O
fluoborate	O
followed	O
by	O
dehydrogenation	O
of	O
the	O
product	O
gave	O
6	I-IUPAC
-	I-IUPAC
carbethoxy	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methylisoquinoline	I-IUPAC
(	O
14	O
)	O
.	O

Chain	O
extension	O
of	O
14	O
followed	O
by	O
cyclization	O
led	O
to	O
3	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
7H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
isoquinolin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
19	O
)	O
which	O
on	O
reduction	O
and	O
subsequent	O
dehydration	O
yielded	O
3	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
isoquinoline	I-IUPAC
(	O
4	O
)	O
.	O

Reaction	O
of	O
hydroxyl	O
-	O
protected	O
derivatives	O
of	O
hydroxyalkoxyamines	O
(	O
3a	O
,	O
b	O
,	O
c	O
)	O
with	O
either	O
4,6	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
diformamidopyrimidine	I-IUPAC
(	O
5	O
)	O
or	O
4,6	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
formamidopyrimidine	I-IUPAC
(	O
31	O
)	O
and	O
subsequent	O
cyclization	O
of	O
the	O
resultant	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkoxyamino	I-IUPAC
)	I-IUPAC
pyrimidines	I-IUPAC
(	O
6	O
,	O
17	O
,	O
32	O
,	O
35	O
)	O
by	O
heating	O
with	O
diethoxymethyl	O
acetate	O
afforded	O
9	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurines	I-IUPAC
(	O
7	O
,	O
18	O
,	O
33	O
,	O
36	O
)	O
,	O
which	O
were	O
converted	O
subsequently	O
to	O
9	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
hydroxypropoxy	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
9	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
propoxy	I-IUPAC
]	I-IUPAC
derivatives	I-MODIFIER
of	O
guanine	O
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
alkoxypurines	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
aminopurine	I-IUPAC
,	O
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
,	O
adenine	O
,	O
hypoxanthine	O
,	O
and	O
6	I-IUPAC
-	I-IUPAC
methoxypurine	I-IUPAC
(	O
8	O
,	O
12	O
,	O
13	O
,	O
19-21	O
,	O
23-26	O
,	O
34	O
,	O
37-39	O
)	O
.	O

Carboxylic	O
acid	O
esters	O
(	O
9-11	O
,	O
14-16	O
,	O
27-29	O
)	O
and	O
a	O
cyclic	O
phosphate	O
derivative	O
(	O
22	O
)	O
of	O
the	O
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkoxy	I-IUPAC
)	I-IUPAC
guanines	I-IUPAC
(	O
8	O
,	O
21	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkoxy	I-IUPAC
)	I-IUPAC
purines	I-IUPAC
(	O
13	O
,	O
26	O
)	O
were	O
also	O
prepared	O
.	O

The	O
guanine	O
derivatives	O
(	O
8	O
,	O
21	O
)	O
showed	O
potent	O
and	O
selective	O
activity	O
against	O
herpes	O
simplex	O
virus	O
types	O
1	O
and	O
2	O
and	O
varicella	O
zoster	O
virus	O
in	O
cell	O
cultures	O
and	O
8	O
is	O
more	O
active	O
than	O
acyclovir	O
.	O

Although	O
without	O
significant	O
antiviral	O
activity	O
in	O
cell	O
cultures	O
,	O
the	O
2	I-IUPAC
-	I-IUPAC
aminopurines	I-IUPAC
(	O
13	O
,	O
14-16	O
,	O
26-29	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
alkoxypurines	I-IUPAC
(	O
12	O
,	O
23-25	O
)	O
are	O
well	O
absorbed	O
after	O
oral	O
administration	O
to	O
mice	O
and	O
are	O
converted	O
efficiently	O
to	O
the	O
antiviral	O
guanine	O
derivatives	O
(	O
8	O
,	O
21	O
)	O
in	O
vivo	O
.	O

Variation	O
of	O
the	O
bridge	O
linking	O
the	O
heterocyclic	O
ring	O
and	O
p	I-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
portions	I-MODIFIER
of	O
our	O
previously	O
described	O
classical	O
2,4	I-IUPAC
-	I-IUPAC
diaminofuro	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
1	O
and	O
2	O
are	O
reported	O
as	O
inhibitors	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
as	O
antitumor	O
agents	O
.	O

Specifically	O
-	O
CH2CH2	O
-	O
and	O
-	O
CH2NHCH2	O
-	O
bridged	O
analogues	O
,	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diaminofuro	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diaminofuro	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
,	O
respectively	O
,	O
were	O
synthesized	O
.	O

Compound	O
3	O
was	O
obtained	O
via	O
a	O
Wittig	O
reaction	O
of	O
the	O
tributylphosphonium	O
salt	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
5	O
)	O
and	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
formylbenzoate	I-IUPAC
(	O
6	O
)	O
followed	O
by	O
reduction	O
and	O
coupling	O
with	O
the	O
diethyl	O
ester	O
of	O
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
.	O

Compound	O
4	O
was	O
synthesized	O
by	O
the	O
nucleophilic	O
displacement	O
of	O
5	O
with	O
diethyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
(	O
15	O
)	O
and	O
saponification	O
.	O

Both	O
analogues	O
were	O
evaluated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
DHFRs	O
from	O
(	O
recombinant	O
)	O
human	O
,	O
human	O
CCRF	O
-	O
CEM	O
cells	O
,	O
and	O
Lactobacillus	O
casei	O
.	O

Compound	O
3	O
showed	O
moderate	O
activity	O
(	O
IC50	O
10	O
(	O
-	O
6	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
.	O

Compound	O
4	O
was	O
essentially	O
inactive	O
(	O
IC50	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
CCRF	O
-	O
CEM	O
)	O
.	O

The	O
compounds	O
were	O
also	O
evaluated	O
against	O
TS	O
from	O
(	O
recombinant	O
)	O
human	O
and	O
L	O
.	O

casei	O
and	O
were	O
of	O
low	O
activity	O
(	O
IC50	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
.	O

The	O
three	O
-	O
atom	O
-	O
bridged	O
analogue	O
4	O
was	O
somewhat	O
more	O
inhibitory	O
to	O
human	O
TS	O
than	O
methotrexate	O
(	O
MTX	O
)	O
.	O

Compound	O
3	O
inhibited	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
culture	O
(	O
IC50	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
while	O
4	O
showed	O
a	O
low	O
level	O
of	O
growth	O
inhibitory	O
activity	O
.	O

The	O
inhibition	O
of	O
the	O
growth	O
of	O
leukemia	O
CCRF	O
-	O
CEM	O
cells	O
by	O
both	O
compounds	O
parallels	O
their	O
inhibition	O
of	O
CCRF	O
-	O
CEM	O
DHFR	O
.	O

Analogue	O
3	O
was	O
a	O
good	O
substrate	O
for	O
human	O
folylpolyglutamate	O
synthetase	O
(	O
FPGS	O
)	O
derived	O
from	O
CCRF	O
-	O
CEM	O
cells	O
(	O
Km	O
8.5	O
microM	O
)	O
.	O

Further	O
evaluation	O
of	O
the	O
growth	O
inhibitory	O
activity	O
of	O
3	O
against	O
the	O
MTX	O
-	O
resistant	O
subline	O
of	O
CCRF	O
-	O
CEM	O
cells	O
(	O
R30dm	O
)	O
with	O
decreased	O
FPGS	O
indicated	O
that	O
poly	O
-	O
gamma	O
-	O
glutamylation	O
was	O
important	O
for	O
its	O
action	O
.	O

Protection	O
studies	O
with	O
3	O
in	O
the	O
FaDu	O
squamous	O
cell	O
carcinoma	O
cell	O
line	O
indicated	O
that	O
inhibition	O
was	O
completely	O
reversed	O
by	O
leucovorin	O
[	O
(	O
6R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
formyltetrahydrofolate	I-IUPAC
]	O
or	O
by	O
a	O
combination	O
of	O
thymidine	O
and	O
hypoxanthine	O
,	O
suggesting	O
an	O
antifolate	O
effect	O
directed	O
at	O
DHFR	O
.	O

Various	O
6	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
aryl	I-PARTIUPAC
and	O
aralkyl	I-PARTIUPAC
)	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
methyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
2,4	I-PARTIUPAC
-	I-PARTIUPAC
pteridinediamines	I-PARTIUPAC
and	O
their	O
8	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
have	O
been	O
synthesized	O
for	O
antimalarial	O
evaluation	O
.	O

Condensation	O
of	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrazinecarbonitrile	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
V	O
)	O
with	O
the	O
appropriately	O
substituted	O
amine	O
afforded	O
a	O
series	O
of	O
3	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
aryl	I-PARTIUPAC
and	O
aralkyl	I-PARTIUPAC
)	I-PARTIUPAC
amino	I-PARTIUPAC
]	I-PARTIUPAC
methyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
pyrazinecarbonitrile	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
oxides	I-PARTIUPAC
VI	O
.	O

Deoxygenation	O
gave	O
the	O
corresponding	O
pyrazines	O
VII	O
.	O

Cyclization	O
of	O
VI	O
and	O
VII	O
with	O
guanidine	O
then	O
produced	O
the	O
desired	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pteridinediamine	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
VIII	O
and	O
teridinediamines	O
IX	O
,	O
respectively	O
.	O

Formylation	O
of	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pteridinediamine	I-IUPAC
gave	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
pteridinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
formamide	I-IUPAC
.	O

The	O
N	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
VIII	O
did	O
not	O
exhibit	O
significant	O
activity	O
against	O
Plasmodium	O
berghei	O
infections	O
in	O
mice	O
.	O

Activity	O
among	O
the	O
2,4	I-IUPAC
-	I-IUPAC
pteridinediamines	I-IUPAC
IX	O
was	O
generally	O
poor	O
with	O
the	O
exception	O
of	O
the	O
3,4,5	I-IUPAC
-	I-IUPAC
trimethoxyphenyl	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
naphthalenyl	I-IUPAC
analogues	I-MODIFIER
which	O
showed	O
strong	O
suppressive	O
activity	O
at	O
doses	O
ranging	O
from	O
80	O
to	O
640	O
mg	O
/	O
kg	O
.	O

Furthermore	O
,	O
several	O
of	O
the	O
2,4	I-IUPAC
-	I-IUPAC
pteridinediamines	I-IUPAC
exhibited	O
potent	O
prophylactic	O
activity	O
against	O
Plasmodium	O
gallinaceum	O
infections	O
in	O
the	O
chick	O
and	O
also	O
showed	O
strong	O
antibacterial	O
action	O
against	O
Streptococcus	O
faecalis	O
and	O
Staphylococcus	O
aureus	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
improve	O
the	O
oral	O
bioavailability	O
of	O
a	O
recently	O
discovered	O
,	O
novel	O
structural	O
class	O
of	O
5	O
-	O
HT1A	O
receptor	O
agonists	O
:	O
aryl	I-IUPAC
-	I-IUPAC
{	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
R	I-IUPAC
-	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
piperidin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
metha	I-IUPAC
none	I-IUPAC
.	O

Incorporation	O
of	O
a	O
fluorine	O
atom	O
in	O
the	O
beta	O
-	O
position	O
to	O
the	O
amino	O
function	O
in	O
the	O
side	O
chain	O
led	O
to	O
analogues	O
that	O
exhibited	O
,	O
in	O
general	O
,	O
enhanced	O
and	O
long	O
-	O
lasting	O
5	O
-	O
HT1A	O
agonist	O
activity	O
in	O
rats	O
after	O
oral	O
administration	O
.	O

Location	O
of	O
the	O
fluorine	O
atom	O
at	O
the	O
C	O
-	O
4	O
position	O
of	O
the	O
piperidine	O
ring	O
was	O
the	O
most	O
favorable	O
,	O
and	O
among	O
the	O
various	O
substituents	O
tested	O
,	O
the	O
ability	O
of	O
the	O
fluorine	O
was	O
unique	O
in	O
improving	O
the	O
oral	O
activity	O
of	O
this	O
family	O
of	O
ligands	O
.	O

Thus	O
,	O
the	O
derivatives	O
39	O
,	O
46	O
,	O
and	O
61	O
bound	O
with	O
higher	O
affinity	O
and	O
selectivity	O
to	O
5	O
-	O
HT1A	O
receptors	O
(	O
versus	O
dopaminergic	O
D2	O
and	O
adrenergic	O
alpha1	O
receptors	O
)	O
and	O
displayed	O
more	O
potent	O
5	O
-	O
HT1A	O
agonist	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
than	O
their	O
C	O
-	O
4	O
desfluoro	O
analogues	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
the	O
conformation	O
of	O
the	O
pharmacophore	O
and	O
the	O
level	O
of	O
agonistic	O
activity	O
of	O
this	O
type	O
of	O
ligand	O
,	O
we	O
synthesized	O
a	O
series	O
of	O
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
{	I-IUPAC
[	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
H	I-IUPAC
or	I-IUPAC
CH3	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
R	I-IUPAC
-	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
piperidin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
+	I-IUPAC
+	I-IUPAC
+	I-IUPAC
methanone	I-IUPAC
derivatives	I-MODIFIER
and	O
found	O
that	O
the	O
combination	O
of	O
a	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
and	O
a	O
6	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
substituent	I-MODIFIER
on	O
the	O
pyridine	O
ring	O
synergistically	O
affected	O
their	O
5	O
-	O
HT1A	O
agonist	O
properties	O
.	O

Thus	O
,	O
the	O
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
{	I-IUPAC
[	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
-	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
piperidin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
methanone	I-IUPAC
40	O
behaved	O
as	O
a	O
more	O
potent	O
5	O
-	O
HT1A	O
receptor	O
agonist	O
in	O
vitro	O
and	O
in	O
vivo	O
than	O
its	O
5	O
-	O
unsubstituted	O
analogue	O
38	O
.	O

The	O
antidepressant	O
potential	O
of	O
the	O
lead	O
compounds	O
40	O
,	O
45	O
,	O
and	O
54	O
was	O
examined	O
by	O
means	O
of	O
the	O
forced	O
swimming	O
test	O
(	O
FST	O
)	O
in	O
rats	O
.	O

The	O
results	O
indicated	O
that	O
,	O
after	O
a	O
single	O
oral	O
administration	O
,	O
these	O
compounds	O
inhibited	O
immobility	O
in	O
the	O
FST	O
more	O
potently	O
and	O
more	O
extensively	O
than	O
the	O
clinically	O
used	O
antidepressant	O
imipramine	O
.	O

Thus	O
,	O
40	O
,	O
45	O
,	O
and	O
54	O
are	O
potent	O
,	O
orally	O
active	O
5	O
-	O
HT1A	O
receptor	O
agonists	O
with	O
marked	O
antidepressant	O
potential	O
.	O

A	O
series	O
of	O
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
thiosemicarbazones	I-IUPAC
has	O
been	O
synthesized	O
which	O
contain	O
a	O
tertiary	O
N	O
at	O
the	O
4	O
position	O
.	O

These	O
materials	O
were	O
obtained	O
by	O
reacting	O
4	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
picoline	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
,	O
either	O
directly	O
or	O
after	O
conversion	O
to	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivative	I-MODIFIER
,	O
with	O
a	O
variety	O
of	O
secondary	O
amines	O
.	O

Rearrangement	O
of	O
the	O
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
picoline	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxides	I-IUPAC
with	O
Ac2O	O
yielded	O
respective	O
methyl	O
acetates	O
,	O
which	O
upon	O
acid	O
hydrolysis	O
,	O
MnO2	O
oxidation	O
,	O
and	O
reaction	O
with	O
thiosemicarbazide	O
resulted	O
in	O
the	O
desired	O
compounds	O
.	O

An	O
alternate	O
procedure	O
which	O
consisted	O
of	O
reacting	O
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
ethylene	I-IUPAC
acetal	I-IUPAC
with	O
various	O
amines	O
,	O
followed	O
by	O
hydrolysis	O
and	O
reaction	O
with	O
thiosemicarbazide	O
,	O
was	O
also	O
employed	O
.	O

Introduction	O
of	O
an	O
alkyl	O
group	O
at	O
the	O
3	O
position	O
of	O
the	O
pyridine	O
ring	O
of	O
4	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
thiosemicarbazone	I-IUPAC
was	O
achieved	O
by	O
utilizing	O
2,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitropyridine	I-IUPAC
N	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
;	O
this	O
material	O
was	O
converted	O
to	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivative	I-MODIFIER
which	O
was	O
then	O
subjected	O
to	O
nucleophilic	O
substitution	O
.	O

4	I-IUPAC
-	I-IUPAC
Morpholino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
thiosemicarbazone	I-IUPAC
was	O
the	O
most	O
active	O
antineoplastic	O
agent	O
of	O
this	O
series	O
in	O
mice	O
bearing	O
Sarcoma	O
180	O
ascites	O
cells	O
and	O
was	O
significantly	O
superior	O
to	O
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
thiosemicarbazone	I-IUPAC
in	O
this	O
test	O
system	O
.	O

Syntheses	O
and	O
biological	O
activities	O
of	O
26	O
N4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
aminopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
as	O
analogs	O
of	O
naturally	O
occurring	O
modified	O
nucleic	O
acid	O
bases	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
purin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ylcarbamoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
and	O
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
delta2	I-IUPAC
-	I-IUPAC
isopentenyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
are	O
described	O
.	O

4	I-IUPAC
-	I-IUPAC
Aminopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
was	O
converted	O
into	O
the	O
desired	O
intermediate	O
,	O
ethyl	I-IUPAC
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
(	O
2	O
)	O
.	O

4	I-IUPAC
-	I-IUPAC
Ureidopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
6-26	O
)	O
were	O
prepared	O
by	O
displacement	O
of	O
the	O
ethoxy	O
group	O
of	O
the	O
carbamate	O
2	O
by	O
amino	O
acids	O
and	O
a	O
variety	O
of	O
amines	O
and	O
by	O
a	O
reaction	O
of	O
4	I-IUPAC
-	I-IUPAC
aminopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
1	O
)	O
with	O
isocyanates	O
.	O

N4	I-IUPAC
-	I-IUPAC
Alkylaminopyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
generally	O
prepared	O
by	O
displacement	O
of	O
the	O
chlorine	O
from	O
4	I-IUPAC
-	I-IUPAC
chloropyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
with	O
various	O
amines	O
.	O

Several	O
analogs	O
exhibited	O
moderate	O
to	O
very	O
good	O
growth	O
inhibitory	O
activities	O
against	O
cultured	O
L1210	O
leukemia	O
and	O
6410	O
human	O
leukemic	O
myeloblasts	O
.	O

In	O
pursuit	O
of	O
radiolabeled	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
with	O
rapid	O
urinary	O
excretion	O
of	O
radioactivity	O
from	O
nontarget	O
tissues	O
,	O
radioiodinated	O
mAbs	O
releasing	O
a	O
m	I-IUPAC
-	I-IUPAC
iodohippuric	I-IUPAC
acid	I-IUPAC
from	O
the	O
mAbs	O
in	O
nontarget	O
tissues	O
were	O
designed	O
.	O

A	O
novel	O
reagent	O
,	O
maleimidoethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butylstannyl	I-IUPAC
)	I-IUPAC
hippurate	I-IUPAC
(	O
MIH	O
)	O
,	O
was	O
synthesized	O
by	O
reacting	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
maleimide	I-IUPAC
with	O
N	I-IUPAC
-	I-IUPAC
Boc	I-IUPAC
-	I-IUPAC
glycine	I-IUPAC
before	O
coupling	O
with	O
N	I-IUPAC
-	I-IUPAC
succinimidyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butylstannyl	I-IUPAC
)	I-IUPAC
benzoate	I-IUPAC
(	O
ATE	O
)	O
.	O

MIH	O
possessed	O
a	O
maleimide	O
group	O
for	O
mAb	O
conjugation	O
and	O
a	O
butylstannyl	O
moiety	O
for	O
high	O
-	O
yield	O
and	O
site	O
-	O
specific	O
radioiodination	O
,	O
and	O
the	O
two	O
functional	O
groups	O
were	O
linked	O
via	O
an	O
ester	O
bond	O
to	O
release	O
m	I-IUPAC
-	I-IUPAC
iodohippuric	I-IUPAC
acid	I-IUPAC
.	O

To	O
investigate	O
the	O
fate	O
of	O
radiolabels	O
after	O
lysosomal	O
proteolysis	O
,	O
hepatic	O
parenchymal	O
cells	O
were	O
used	O
as	O
a	O
model	O
nontarget	O
tissue	O
and	O
131I	O
-	O
labeled	O
MIH	O
was	O
conjugated	O
with	O
galactosyl	O
-	O
neoglycoalbumin	O
(	O
NGA	O
)	O
.	O

Further	O
conjugation	O
of	O
[	O
131I	O
]	O
MIH	O
with	O
a	O
mAb	O
against	O
osteogenic	O
sarcoma	O
(	O
OST7	O
)	O
after	O
reduction	O
of	O
its	O
disulfide	O
bonds	O
was	O
followed	O
up	O
.	O

In	O
murine	O
biodistribution	O
studies	O
,	O
[	O
131I	O
]	O
MIH	O
-	O
NGA	O
exhibited	O
rapid	O
accumulation	O
in	O
the	O
liver	O
followed	O
by	O
radioactivity	O
elimination	O
from	O
the	O
liver	O
at	O
a	O
rate	O
that	O
was	O
identical	O
to	O
and	O
faster	O
than	O
those	O
of	O
131I	O
-	O
labeled	O
NGA	O
via	O
direct	O
iodination	O
(	O
[	O
131I	O
]	O
NGA	O
)	O
and	O
[	O
131I	O
]	O
ATE	O
-	O
labeled	O
NGA	O
,	O
respectively	O
.	O

While	O
[	O
131I	O
]	O
NGA	O
indicated	O
high	O
radioactivity	O
levels	O
in	O
the	O
murine	O
neck	O
,	O
stomach	O
,	O
and	O
blood	O
,	O
such	O
increases	O
in	O
the	O
radioactivity	O
count	O
were	O
not	O
detectable	O
by	O
the	O
administration	O
of	O
either	O
[	O
131I	O
]	O
MIH	O
-	O
NGA	O
or	O
[	O
131I	O
]	O
ATE	O
-	O
NGA	O
.	O

At	O
6	O
h	O
postinjection	O
of	O
[	O
131I	O
]	O
MIH	O
-	O
NGA	O
,	O
80%	O
of	O
the	O
injected	O
radioactivity	O
was	O
recovered	O
in	O
the	O
urine	O
.	O

Analyses	O
of	O
urine	O
samples	O
indicated	O
that	O
m	O
-	O
iodohippuric	O
acid	O
was	O
the	O
sole	O
radiolabeled	O
metabolite	O
.	O

In	O
biodistribution	O
studies	O
using	O
[	O
131I	O
]	O
-	O
MIH	O
-	O
OST7	O
and	O
[	O
131I	O
]	O
ATE	O
-	O
OST7	O
,	O
while	O
both	O
131I	O
-	O
labeled	O
OST7s	O
registered	O
almost	O
identical	O
radioactivity	O
levels	O
in	O
the	O
blood	O
up	O
to	O
6	O
h	O
postinjection	O
,	O
the	O
former	O
demonstrated	O
a	O
lower	O
radioactivity	O
level	O
than	O
[	O
131I	O
]	O
ATE	O
-	O
OST7	O
in	O
nontarget	O
tissues	O
throughout	O
the	O
experiment	O
.	O

Such	O
chemical	O
and	O
biological	O
characteristics	O
of	O
MIH	O
would	O
enable	O
high	O
target	O
/	O
nontarget	O
ratios	O
in	O
diagnostic	O
and	O
therapeutic	O
nuclear	O
medicine	O
using	O
mAbs	O
and	O
other	O
polypeptides	O
.	O

In	O
order	O
to	O
assess	O
steric	O
,	O
lipophilic	O
,	O
and	O
electronic	O
influences	O
on	O
opioid	O
binding	O
affinity	O
,	O
analogs	O
of	O
the	O
delta	O
receptor	O
selective	O
peptide	O
deltorphin	O
I	O
(	O
Tyr	O
-	O
D	O
-	O
Ala	O
-	O
Phe	O
-	O
Asp	O
-	O
Val	O
-	O
Val	O
-	O
GlyNH2	O
)	O
were	O
prepared	O
in	O
which	O
the	O
residue	O
3	O
phenylalanine	O
was	O
replaced	O
with	O
lipophilic	O
fluoro	I-IUPAC
-	O
and	O
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
phenylalanines	B-IUPAC
or	O
with	O
the	O
heterocyclic	O
aromatic	O
amino	O
acids	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
thiazolyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
,	O
histidine	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
thiazolyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
.	O

mu	O
binding	O
was	O
variable	O
,	O
with	O
KiS	O
in	O
excess	O
of	O
10,000	O
nM	O
for	O
most	O
analogs	O
,	O
and	O
all	O
of	O
the	O
analogs	O
bound	O
poorly	O
to	O
k	O
receptors	O
.	O

Among	O
the	O
phenyl	O
ring	O
-	O
substituted	O
analogs	O
,	O
those	O
containing	O
the	O
smaller	O
and	O
electron	O
-	O
withdrawing	O
halogens	O
were	O
favored	O
over	O
those	O
with	O
larger	O
,	O
electron	O
-	O
releasing	O
methyl	O
groups	O
,	O
although	O
delta	O
opioid	O
binding	O
affinity	O
was	O
reduced	O
in	O
all	O
cases	O
.	O

The	O
m	O
-	O
fluorophenylalanine	O
analog	O
demonstrated	O
the	O
best	O
delta	O
binding	O
of	O
the	O
group	O
,	O
with	O
a	O
Ki	O
of	O
4.79	O
nM	O
.	O

Within	O
the	O
group	O
of	O
heterocyclic	O
analogs	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
proved	O
to	O
be	O
the	O
best	O
modification	O
,	O
displaying	O
a	O
delta	O
receptor	O
Ki	O
of	O
1.38	O
nM	O
,	O
while	O
the	O
polar	O
histidine	O
analog	O
suffered	O
the	O
greatest	O
loss	O
in	O
delta	O
binding	O
(	O
Ki	O
=	O
317	O
)	O
.	O

Compounds	O
containing	O
pyridylalanine	O
and	O
thiazolylalanine	O
were	O
intermediate	O
in	O
binding	O
affinity	O
,	O
with	O
delta	O
KiS	O
ranging	O
from	O
39.5	O
to	O
62.4	O
nM	O
.	O

The	O
major	O
factor	O
influencing	O
the	O
opioid	O
binding	O
of	O
the	O
similar	O
-	O
sized	O
heterocyclic	O
compounds	O
was	O
relative	O
lipophilicity	O
,	O
which	O
outweighed	O
electronic	O
character	O
.	O

Six	O
new	O
B	O
-	O
ring	O
analogues	O
of	O
the	O
nonpolyglutamatable	O
antifolate	O
Nalpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxypteroyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
Ndelta	I-IUPAC
-	I-IUPAC
hemiphthaloy	I-IUPAC
l	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
(	O
PT523	O
,	O
3	O
)	O
were	O
synthesized	O
with	O
a	O
view	O
to	O
determining	O
the	O
effect	O
of	O
modifications	O
at	O
the	O
5	O
-	O
and	O
/	O
or	O
8	O
-	O
position	O
on	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
binding	O
and	O
tumor	O
cell	O
growth	O
inhibition	O
.	O

The	O
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
8	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogues	I-MODIFIER
were	O
prepared	O
from	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phthalimidopentanoate	I-IUPAC
and	O
4	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
deoxy	I-PARTIUPAC
-	I-PARTIUPAC
N10	I-PARTIUPAC
-	I-PARTIUPAC
formyl	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
deaza	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
deazapteroic	I-PARTIUPAC
acid	I-PARTIUPAC
,	O
respectively	O
.	O

The	O
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
analogues	I-MODIFIER
were	O
prepared	O
from	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phthalimidopentanoate	I-IUPAC
and	O
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diaminoquinazoline	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carbonitriles	I-IUPAC
.	O

The	O
Ki	O
for	O
inhibition	O
of	O
human	O
DHFR	O
by	O
the	O
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
and	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogues	I-MODIFIER
was	O
about	O
the	O
same	O
as	O
that	O
of	O
3	O
(	O
0.35	O
pM	O
)	O
,	O
11	O
-	O
fold	O
lower	O
than	O
that	O
of	O
aminopterin	O
(	O
AMT	O
,	O
1	O
)	O
,	O
and	O
15	O
-	O
fold	O
lower	O
than	O
that	O
of	O
methotrexate	O
(	O
MTX	O
,	O
2	O
)	O
.	O

However	O
the	O
Ki	O
of	O
the	O
8	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogue	I-MODIFIER
was	O
27	O
-	O
fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
and	O
that	O
of	O
the	O
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
,	O
and	O
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
analogues	I-MODIFIER
was	O
approximately	O
50	O
-	O
fold	O
lower	O
.	O

This	O
trend	O
was	O
consistent	O
with	O
the	O
published	O
literature	O
on	O
the	O
corresponding	O
DHFR	O
inhibitors	O
with	O
a	O
glutamate	O
side	O
chain	O
.	O

In	O
colony	O
formation	O
assays	O
against	O
the	O
human	O
head	O
and	O
neck	O
squamous	O
carcinoma	O
cell	O
line	O
SCC25	O
after	O
72	O
h	O
of	O
treatment	O
,	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
8	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogues	I-MODIFIER
were	O
approximately	O
as	O
potent	O
as	O
3	O
,	O
whereas	O
the	O
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
analogue	I-MODIFIER
was	O
3	O
times	O
more	O
potent	O
.	O

5	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
and	O
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
substitution	I-MODIFIER
was	O
also	O
favorable	O
,	O
with	O
the	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogue	I-MODIFIER
being	O
2	O
.	O

5	O
-	O
fold	O
more	O
potent	O
than	O
the	O
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogue	I-MODIFIER
.	O

However	O
the	O
effect	O
of	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
substitution	I-MODIFIER
was	O
less	O
pronounced	O
in	O
the	O
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
analogues	I-MODIFIER
than	O
in	O
the	O
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogues	I-MODIFIER
.	O

The	O
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
analogue	I-MODIFIER
of	O
3	O
was	O
the	O
most	O
active	O
member	O
of	O
the	O
series	O
,	O
with	O
an	O
IC50	O
=	O
0.33	O
nM	O
versus	O
1.8	O
nM	O
for	O
3	O
and	O
15	O
nM	O
for	O
MTX	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogue	I-MODIFIER
of	O
3	O
was	O
also	O
tested	O
at	O
the	O
National	O
Cancer	O
Institute	O
against	O
a	O
panel	O
of	O
50	O
human	O
tumor	O
cell	O
lines	O
in	O
culture	O
and	O
was	O
consistently	O
more	O
potent	O
than	O
3	O
,	O
with	O
IC50	O
values	O
in	O
the	O
low	O
-	O
nanomolar	O
to	O
subnanomolar	O
range	O
against	O
most	O
of	O
the	O
tumors	O
.	O

Leukemia	O
and	O
colorectal	O
carcinoma	O
cell	O
lines	O
were	O
generally	O
most	O
sensitive	O
,	O
though	O
good	O
activity	O
was	O
also	O
observed	O
against	O
CNS	O
tumors	O
and	O
carcinomas	O
of	O
the	O
breast	O
and	O
prostate	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
B	O
-	O
ring	O
analogues	O
of	O
3	O
inhibit	O
DHFR	O
activity	O
and	O
tumor	O
cell	O
colony	O
formation	O
as	O
well	O
as	O
,	O
or	O
better	O
than	O
,	O
the	O
parent	O
compound	O
.	O

In	O
view	O
of	O
the	O
fact	O
that	O
3	O
and	O
its	O
B	O
-	O
ring	O
analogues	O
cannot	O
form	O
polyglutamates	O
,	O
their	O
high	O
cytotoxicity	O
relative	O
to	O
the	O
corresponding	O
B	O
-	O
ring	O
analogues	O
of	O
AMT	O
is	O
noteworthy	O
.	O

[	O
1	O
-	O
Beta	O
-	O
mercapto	O
-	O
beta	O
,	O
beta	O
-	O
pentamethylenepropionic	O
acid	O
]	O
oxytocin	O
was	O
prepared	O
from	O
beta	O
-	O
Mpa	O
(	O
beta	O
-	O
(	O
CH2	O
)	O
5	O
)	O
(	O
Bzl	O
)	O
-	O
Tyr	O
(	O
Bzl	O
)	O
-	O
Ile	O
-	O
Gln	O
-	O
Asn	O
-	O
Cys	O
(	O
Bzl	O
)	O
-	O
Pro	O
-	O
Leu	O
-	O
Gly	O
-	O
NH2	O
by	O
removal	O
of	O
the	O
Bzl	O
-	O
protecting	O
groups	O
with	O
Na	O
-	O
NH3	O
followed	O
by	O
cyclization	O
of	O
the	O
resulting	O
disulfhydryl	O
compound	O
with	O
K3Fe	O
(	O
CN	O
)	O
6	O
.	O

The	O
analog	O
was	O
purified	O
by	O
desalting	O
on	O
Sephadex	O
G	O
-	O
15	O
in	O
50%	O
HOAc	O
and	O
gel	O
filtration	O
on	O
Sephadex	O
G	O
-	O
25	O
and	O
LH	O
-	O
20	O
.	O

The	O
protected	O
intermediate	O
above	O
was	O
synthesized	O
from	O
Z	O
-	O
Cys	O
(	O
Bzl	O
)	O
-	O
Pro	O
-	O
Leu	O
-	O
Gly	O
-	O
NH2	O
by	O
the	O
stepwose	O
p	O
-	O
nitrophenyl	O
ester	O
method	O
using	O
Nalpha	O
-	O
Boc	O
protection	O
at	O
the	O
penta	O
-	O
,	O
hexa	O
-	O
,	O
and	O
octapeptide	O
stages	O
.	O

The	O
analog	O
was	O
found	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
the	O
oxytocic	O
and	O
avian	O
vasodepressor	O
effects	O
of	O
oxytocin	O
(	O
pA2	O
values	O
of	O
7.43	O
and	O
8.30	O
,	O
respectively	O
)	O
but	O
was	O
only	O
a	O
weak	O
inhibitor	O
of	O
the	O
rat	O
pressor	O
effect	O
of	O
8	I-IUPAC
-	I-IUPAC
lysine	I-IUPAC
-	I-IUPAC
vasopressin	I-IUPAC
.	O

The	O
rat	O
antipressor	O
potency	O
of	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
deaminopenicillamine	I-IUPAC
]	I-IUPAC
oxytocin	I-IUPAC
was	O
also	O
determined	O
in	O
this	O
study	O
:	O
pA2	O
=	O
6.27	O
.	O

Of	O
the	O
alkyl	O
-	O
substituted	O
1	O
-	O
position	O
analogs	O
of	O
oxytocin	O
studied	O
so	O
far	O
,	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
pentamethylenepropionic	I-IUPAC
acid	I-IUPAC
]	I-IUPAC
oxytocin	I-IUPAC
is	O
the	O
most	O
potent	O
antioxytocic	O
agent	O
.	O

A	O
series	O
of	O
thieno	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
thieno	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
synthesized	O
and	O
investigated	O
as	O
inhibitors	O
of	O
the	O
alpha	O
/	O
beta	O
hydrolases	O
cholesterol	O
esterase	O
(	O
CEase	O
)	O
and	O
acetylcholinesterase	O
(	O
AChE	O
)	O
.	O

The	O
introduction	O
of	O
a	O
cycloaliphatic	O
five	O
-	O
or	O
six	O
-	O
membered	O
ring	O
fused	O
at	O
the	O
thiophene	O
was	O
favorable	O
for	O
CEase	O
inhibition	O
.	O

Such	O
compounds	O
were	O
analyzed	O
as	O
true	O
alternate	O
substrate	O
inhibitors	O
.	O

6,7	I-IUPAC
-	I-IUPAC
Dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
,	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
33	O
)	O
exhibited	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
630	O
nM	O
and	O
excelled	O
in	O
its	O
low	O
susceptibility	O
to	O
CEase	O
-	O
catalyzed	O
degradation	O
.	O

Compound	O
33	O
and	O
its	O
analogues	O
did	O
not	O
inhibit	O
AChE	O
.	O

The	O
introduction	O
of	O
a	O
tetrahydropyrido	O
ring	O
with	O
bulky	O
hydrophobic	O
substituents	O
at	O
the	O
basic	O
nitrogen	O
provided	O
inhibitors	O
of	O
AChE	O
which	O
were	O
completely	O
inactive	O
toward	O
CEase	O
.	O

7	I-IUPAC
-	I-IUPAC
Benzyl	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
:	I-IUPAC
4,5	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
21	O
)	O
had	O
the	O
IC	O
(	O
50	O
)	O
value	O
of	O
330	O
nM	O
for	O
AChE	O
inhibition	O
.	O

A	O
residual	O
enzymatic	O
activity	O
at	O
an	O
infinite	O
inhibitor	O
concentration	O
and	O
thus	O
a	O
catalytically	O
active	O
ternary	O
enzyme	O
-	O
substrate	O
-	O
inhibitor	O
complex	O
was	O
concluded	O
.	O

To	O
specify	O
kinetic	O
parameters	O
of	O
inhibition	O
,	O
a	O
new	O
method	O
was	O
derived	O
to	O
characterize	O
selected	O
thieno	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
as	O
hyperbolic	O
mixed	O
-	O
type	O
inhibitors	O
of	O
AChE	O
.	O

Series	O
of	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
9,10	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
3,4,6,7	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
6,1	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
isoquinoline	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diones	I-IUPAC
and	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
9,10	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
6,1	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
isoquinolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
synthesized	O
and	O
tested	O
for	O
blood	O
pressure	O
lowering	O
properties	O
in	O
anesthetized	O
normotensive	O
cats	O
and	O
conscious	O
spontaneously	O
hypertensive	O
rats	O
.	O

Several	O
compounds	O
in	O
the	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
6,1	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
isoquinolin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
series	I-MODIFIER
display	O
a	O
high	O
order	O
of	O
activity	O
.	O

The	O
most	O
active	O
compounds	O
are	O
the	O
alkyl	O
derivatives	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
mesitylamino	I-IUPAC
/	O
2	I-IUPAC
-	I-IUPAC
mesitylimino	I-IUPAC
tautomeric	I-MODIFIER
forms	I-MODIFIER
.	O

The	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
mesitylimino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	I-MODIFIER
trequinsin	O
is	O
a	O
potent	O
antihypertensive	O
agent	O
and	O
displays	O
a	O
hemodynamic	O
profile	O
characteristic	O
of	O
an	O
arteriolar	O
dilator	O
.	O

It	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
both	O
cAMP	O
phosphodiesterase	O
and	O
platelet	O
aggregation	O
.	O

Cyclic	O
depsipeptide	O
cyclo	O
-	O
[	O
D	O
-	O
Hmp	O
(	O
1	O
)	O
-	O
L	O
-	O
MeVal	O
(	O
2	O
)	O
-	O
L	O
-	O
Phe	O
(	O
3	O
)	O
-	O
L	O
-	O
MePhe	O
(	O
4	O
)	O
-	O
L	O
-	O
Pro	O
(	O
5	O
)	O
-	O
L	O
-	O
aIle+	O
+	O
+	O
(	O
6	O
)	O
-	O
L	O
-	O
MeVal	O
(	O
7	O
)	O
-	O
L	O
-	O
Leu	O
(	O
8	O
)	O
-	O
L	O
-	O
betaHOMeVal	O
(	O
9	O
)	O
]	O
,	O
the	O
antifungal	O
antibiotic	O
aureobasidin	O
A	O
(	O
AbA	O
)	O
,	O
was	O
reported	O
to	O
interfere	O
with	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
in	O
yeast	O
and	O
mammalian	O
cells	O
,	O
particularly	O
the	O
MDR1	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
)	O
,	O
a	O
transmembrane	O
phospholipid	O
flippase	O
or	O
"	O
hydrophobic	O
vacuum	O
cleaner	O
"	O
that	O
mediates	O
multidrug	O
resistance	O
(	O
MDR	O
)	O
of	O
cancer	O
cells	O
.	O

In	O
a	O
standardized	O
assay	O
that	O
measures	O
Pgp	O
function	O
by	O
the	O
Pgp	O
-	O
mediated	O
efflux	O
of	O
the	O
calcein	O
-	O
AM	O
Pgp	O
substrate	O
and	O
uses	O
human	O
lymphoblastoid	O
MDR	O
-	O
CEM	O
(	O
VBL	O
(	O
100	O
)	O
)	O
cells	O
as	O
highly	O
resistant	O
Pgp	O
-	O
expressing	O
cells	O
and	O
the	O
cyclic	O
undecapeptide	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
as	O
a	O
reference	O
MDR	O
-	O
reversing	O
agent	O
(	O
IC	O
(	O
50	O
)	O
of	O
3.4	O
microM	O
)	O
,	O
AbA	O
was	O
found	O
to	O
be	O
a	O
more	O
active	O
Pgp	O
inhibitor	O
(	O
IC	O
(	O
50	O
)	O
of	O
2.3	O
microM	O
)	O
.	O

Out	O
of	O
seven	O
natural	O
analogues	O
and	O
18	O
chemical	O
derivatives	O
of	O
AbA	O
,	O
several	O
were	O
shown	O
to	O
display	O
even	O
more	O
potent	O
Pgp	O
-	O
inhibitory	O
activity	O
.	O

The	O
Pgp	O
-	O
inhibitory	O
activity	O
was	O
increased	O
about	O
2	O
-	O
fold	O
by	O
some	O
minor	O
modifications	O
such	O
as	O
those	O
found	O
in	O
the	O
naturally	O
occurring	O
aureobasidins	O
AbB	O
(	O
[	O
D	O
-	O
Hiv	O
(	O
1	O
)	O
]	O
-	O
AbA	O
)	O
,	O
AbC	O
(	O
[	O
Val	O
(	O
6	O
)	O
]	O
-	O
AbA	O
)	O
,	O
and	O
AbD	O
[	O
gammaHOMeVal	O
(	O
9	O
)	O
]	O
-	O
AbA	O
)	O
.	O

The	O
replacement	O
of	O
the	O
[	O
Phe	O
(	O
3	O
)	O
-	O
MePhe	O
(	O
4	O
)	O
-	O
Pro	O
(	O
5	O
)	O
]	O
tripeptide	O
by	O
an	O
8	I-IUPAC
-	I-IUPAC
aminocaprylic	I-IUPAC
acid	I-IUPAC
or	O
the	O
N	O
(	O
7	O
)	O
(	O
)	O
-	O
desmethylation	O
of	O
MeVal	O
(	O
7	O
)	O
led	O
to	O
only	O
a	O
3.3	O
-	O
fold	O
decreased	O
capacity	O
to	O
inhibit	O
Pgp	O
function	O
,	O
suggesting	O
that	O
the	O
Pgp	O
inhibitory	O
potential	O
of	O
aureobasidins	O
,	O
though	O
favored	O
by	O
the	O
establishment	O
of	O
an	O
antiparallel	O
beta	O
-	O
sheet	O
between	O
the	O
[	O
D	O
-	O
Hmp	O
(	O
1	O
)	O
-	O
L	O
-	O
MeVal	O
(	O
2	O
)	O
-	O
L	O
-	O
Phe	O
(	O
3	O
)	O
]	O
and	O
[	O
L	O
-	O
aIle	O
(	O
6	O
)	O
-	O
L	O
-	O
MeVal	O
(	O
7	O
)	O
-	O
L	O
-	O
Leu	O
(	O
8	O
)	O
-	O
]	O
tripeptides	O
,	O
does	O
not	O
critically	O
depend	O
on	O
the	O
occurrence	O
of	O
the	O
[	O
L	O
-	O
Phe	O
(	O
3	O
)	O
-	O
L	O
-	O
MePhe	O
(	O
4	O
)	O
-	O
L	O
-	O
Pro	O
(	O
5	O
)	O
-	O
L	O
-	O
aIle	O
(	O
6	O
)	O
]	O
type	O
II	O
'	O
beta	O
-	O
turn	O
secondary	O
structure	O
.	O

In	O
contrast	O
,	O
the	O
most	O
potent	O
Pgp	O
inhibitors	O
were	O
found	O
among	O
AbA	O
analogues	O
with	O
[	O
betaHO	O
-	O
MeVal	O
(	O
9	O
)	O
]	O
residue	O
alterations	O
,	O
with	O
some	O
data	O
suggesting	O
a	O
negative	O
impact	O
of	O
the	O
[	O
L	O
-	O
Leu	O
(	O
8	O
)	O
-	O
L	O
-	O
betaHOMeVal	O
(	O
9	O
)	O
-	O
D	O
-	O
Hmp	O
(	O
1	O
)	O
]	O
gamma	O
-	O
turn	O
secondary	O
structure	O
on	O
Pgp	O
inhibitory	O
potential	O
.	O

The	O
[	O
2,3	O
-	O
dehydro	O
-	O
MeVal	O
(	O
9	O
)	O
]	O
-	O
AbA	O
was	O
the	O
most	O
potent	O
Pgp	O
inhibitory	O
aureobasidin	O
,	O
being	O
13	O
-	O
fold	O
more	O
potent	O
than	O
AbA	O
and	O
19	O
-	O
fold	O
more	O
potent	O
(	O
on	O
a	O
molar	O
basis	O
)	O
than	O
CsA	O
.	O

Finally	O
,	O
there	O
was	O
no	O
correlation	O
between	O
the	O
SAR	O
for	O
the	O
human	O
MDR1	O
Pgp	O
inhibition	O
and	O
the	O
SAR	O
for	O
Saccharomyces	O
cerevisiae	O
antifungal	O
activity	O
,	O
which	O
is	O
mediated	O
by	O
an	O
inositol	O
phosphoceramide	O
synthase	O
activity	O
.	O

5	O
-	O
(	O
4	O
-	O
Piperidyl	O
)	O
isoxazol	O
-	O
3	O
-	O
ol	O
(	O
4	O
-	O
PIOL	O
,	O
10	O
)	O
,	O
a	O
structural	O
analog	O
of	O
4	I-IUPAC
-	I-IUPAC
aminobutanoic	I-IUPAC
acid	I-IUPAC
(	O
GABA	O
,	O
1	O
)	O
and	O
the	O
GABAA	O
agonist	O
4,5,6,7	I-IUPAC
-	I-IUPAC
tetrahydroisoxazolo	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
THIP	O
,	O
5	O
)	O
,	O
is	O
a	O
low	O
-	O
efficacy	O
partial	O
GABAA	O
agonist	O
.	O

A	O
number	O
of	O
compounds	O
bioisosterically	O
derived	O
from	O
10	O
,	O
including	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
isothiazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
11	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
12	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyrid	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
13	O
)	O
,	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,3,6	I-IUPAC
-	I-IUPAC
tetrahydropyrid	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
isothiazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
14	O
)	O
,	O
were	O
synthesized	O
and	O
tested	O
as	O
GABAA	O
receptor	O
ligands	O
.	O

Whereas	O
none	O
of	O
these	O
compounds	O
significantly	O
affected	O
GABAB	O
receptor	O
binding	O
or	O
GABA	O
uptake	O
,	O
they	O
showed	O
affinities	O
for	O
GABAA	O
receptor	O
sites	O
in	O
the	O
low	O
-	O
micromolar	O
range	O
.	O

Using	O
cultured	O
cerebral	O
cortical	O
neurons	O
and	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
techniques	O
,	O
the	O
efficacies	O
of	O
these	O
compounds	O
relative	O
to	O
that	O
of	O
the	O
full	O
GABAA	O
agonist	O
,	O
isoguvacine	O
(	O
8	O
)	O
(	O
20	O
microM	O
)	O
,	O
were	O
determined	O
.	O

The	O
relative	O
efficacy	O
of	O
11	O
,	O
which	O
has	O
a	O
higher	O
receptor	O
affinity	O
(	O
IC50	O
=	O
1.3	O
+	O
/	O
-	O
0.3	O
microM	O
)	O
than	O
10	O
(	O
IC50	O
=	O
9.3	O
+	O
/	O
-	O
2.6	O
microM	O
)	O
,	O
was	O
comparable	O
with	O
that	O
of	O
10	O
(	O
30-35%	O
)	O
.	O

The	O
tetrahydropyridine	O
analog	O
of	O
10	O
,	O
compound	O
13	O
,	O
showed	O
a	O
markedly	O
lower	O
receptor	O
affinity	O
(	O
IC50	O
=	O
32	O
+	O
/	O
-	O
10	O
microM	O
)	O
and	O
apparently	O
a	O
lower	O
relative	O
efficacy	O
than	O
10	O
.	O

The	O
corresponding	O
unsaturated	O
analog	O
of	O
11	O
,	O
compound	O
14	O
,	O
showed	O
a	O
slightly	O
weaker	O
receptor	O
affinity	O
(	O
IC50	O
=	O
4.0	O
+	O
/	O
-	O
2.0	O
microM	O
)	O
but	O
a	O
significantly	O
higher	O
relative	O
efficacy	O
(	O
50-55%	O
)	O
than	O
11	O
.	O

The	O
5	O
-	O
isoxazolol	O
isomer	O
of	O
10	O
,	O
compound	O
12	O
,	O
showed	O
a	O
reduced	O
receptor	O
affinity	O
(	O
IC50	O
=	O
26	O
+	O
/	O
-	O
7	O
microM	O
)	O
and	O
a	O
very	O
low	O
relative	O
efficacy	O
.	O

Substitution	O
of	O
propanoic	O
or	O
propenoic	O
acid	O
moieties	O
for	O
the	O
acidic	O
heterocyclic	O
units	O
of	O
these	O
compounds	O
gave	O
the	O
monocyclic	O
amino	O
acids	O
15-18	O
,	O
which	O
have	O
very	O
little	O
or	O
no	O
affinity	O
for	O
GABAA	O
receptor	O
sites	O
.	O

Continuing	O
studies	O
on	O
the	O
chemical	O
modification	O
of	O
the	O
previously	O
reported	O
novel	O
tripeptide	O
SP	O
antagonist	O
,	O
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyloxycarbonyl	I-IUPAC
)	I-IUPAC
glutaminyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N1	I-IUPAC
-	I-IUPAC
formyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
tryptophyl	I-IUPAC
]	I-IUPAC
phenylalanine	I-IUPAC
benzyl	I-IUPAC
ester	I-IUPAC
[	O
Boc	O
-	O
Gln	O
-	O
D	O
-	O
Trp	O
-	O
(	O
CHO	O
)	O
-	O
Phe	O
-	O
OBzl	O
(	O
1	O
)	O
]	O
,	O
are	O
described	O
herein	O
.	O

We	O
initially	O
investigated	O
the	O
stability	O
of	O
1	O
in	O
guinea	O
pig	O
plasma	O
and	O
liver	O
homogenate	O
to	O
elucidate	O
the	O
most	O
labile	O
part	O
in	O
the	O
structure	O
.	O

It	O
was	O
consequently	O
revealed	O
that	O
the	O
benzyl	O
ester	O
part	O
was	O
easily	O
hydrolyzed	O
to	O
produce	O
the	O
inactive	O
acid	O
analog	O
.	O

Thus	O
we	O
searched	O
for	O
a	O
benzyl	O
ester	O
surrogate	O
that	O
would	O
be	O
more	O
resistant	O
to	O
hydrolytic	O
enzymes	O
.	O

This	O
approach	O
found	O
an	O
isosteric	O
amide	O
structure	O
,	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylmethyl	I-IUPAC
)	I-IUPAC
amide	I-IUPAC
,	O
suitable	O
in	O
terms	O
of	O
potency	O
and	O
stability	O
.	O

Subsequent	O
modification	O
of	O
the	O
amino	O
terminal	O
into	O
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
threonine	I-IUPAC
led	O
to	O
the	O
most	O
potent	O
compound	O
,	O
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
threonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N1	I-IUPAC
-	I-IUPAC
formyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
tryptophyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
phenylalaninamide	I-IUPAC
[	O
Ac	O
-	O
Thr	O
-	O
D	O
-	O
Trp	O
(	O
CHO	O
)	O
-	O
Phe	O
-	O
NMeBzl	O
(	O
5a	O
,	O
FR113680	O
)	O
]	O
.	O

This	O
compound	O
5a	O
potently	O
blocked	O
3H	O
-	O
SP	O
binding	O
to	O
guinea	O
pig	O
lung	O
membranes	O
with	O
IC50	O
of	O
(	O
5.8	O
+	O
/	O
-	O
0.78	O
)	O
x	O
10	O
(	O
-	O
9	O
)	O
M	O
.	O

In	O
vitro	O
,	O
5a	O
inhibited	O
SP	O
-	O
induced	O
contraction	O
of	O
isolated	O
guinea	O
pig	O
trachea	O
strips	O
with	O
IC50	O
of	O
2.3	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
and	O
caused	O
no	O
contraction	O
when	O
used	O
alone	O
in	O
this	O
preparation	O
up	O
to	O
3.2	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
.	O

In	O
addition	O
5a	O
exhibited	O
no	O
effect	O
on	O
the	O
contraction	O
induced	O
by	O
histamine	O
or	O
acetylcholine	O
.	O

Intriguingly	O
,	O
it	O
was	O
demonstrated	O
in	O
vivo	O
that	O
5a	O
suppressed	O
the	O
SP	O
-	O
induced	O
bronchoconstriction	O
and	O
airway	O
edema	O
in	O
guinea	O
pigs	O
with	O
ED50	O
of	O
0.42	O
mg	O
/	O
kg	O
and	O
0.66	O
mg	O
/	O
kg	O
,	O
respectively	O
,	O
when	O
administered	O
intravenously	O
.	O

Piperidine	O
and	O
cyclohexyl	O
ring	O
homologues	O
of	O
the	O
high	O
-	O
affinity	O
dopamine	O
(	O
DA	O
)	O
uptake	O
inhibitor	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
piperidine	I-IUPAC
(	O
BTCP	O
,	O
3	O
)	O
were	O
each	O
prepared	O
in	O
four	O
steps	O
from	O
the	O
appropriate	O
cycloalkanones	O
.	O

These	O
compounds	O
were	O
tested	O
for	O
their	O
ability	O
to	O
displace	O
[	O
3H	O
]	O
BTCP	O
and	O
[	O
3H	O
]	O
cocaine	O
and	O
to	O
inhibit	O
[	O
3H	O
]	O
DA	O
uptake	O
in	O
rat	O
striatal	O
homogenates	O
.	O

The	O
ratios	O
IC50	O
(	O
[	O
3H	O
]	O
cocaine	O
)	O
/	O
IC50	O
(	O
[	O
3H	O
]	O
BTCP	O
)	O
ranged	O
from	O
62	O
for	O
BTCP	O
to	O
1.5	O
for	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclopentylamine	I-IUPAC
(	O
17	O
)	O
;	O
cocaine	O
gave	O
a	O
ratio	O
of	O
0.6	O
.	O

This	O
indicates	O
that	O
BTCP	O
is	O
the	O
most	O
selective	O
of	O
all	O
the	O
compounds	O
tested	O
for	O
sites	O
labeled	O
by	O
[	O
3H	O
]	O
BTCP	O
whereas	O
cocaine	O
is	O
most	O
selective	O
for	O
sites	O
labeled	O
by	O
[	O
3H	O
]	O
cocaine	O
.	O

The	O
wide	O
differences	O
in	O
the	O
relative	O
abilities	O
of	O
these	O
compounds	O
to	O
displace	O
[	O
3H	O
]	O
BTCP	O
and	O
[	O
3H	O
]	O
cocaine	O
suggests	O
that	O
these	O
two	O
radioligands	O
are	O
labeling	O
different	O
sites	O
on	O
the	O
transporter	O
.	O

In	O
general	O
,	O
the	O
compounds	O
structurally	O
related	O
to	O
BTCP	O
exhibited	O
greater	O
selectivity	O
for	O
sites	O
labeled	O
by	O
[	O
3H	O
]	O
BTCP	O
.	O

However	O
,	O
several	O
of	O
the	O
BTCP	O
-	O
related	O
derivatives	O
showed	O
greater	O
(	O
compared	O
with	O
BTCP	O
and	O
cocaine	O
)	O
ability	O
to	O
displace	O
[	O
3H	O
]	O
cocaine	O
.	O

Most	O
notably	O
,	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
pyrrolidine	I-IUPAC
(	O
7	O
)	O
exhibited	O
a	O
3.4	O
-	O
fold	O
greater	O
affinity	O
for	O
these	O
sites	O
compared	O
with	O
BTCP	O
and	O
a	O
9	O
-	O
fold	O
greater	O
affinity	O
at	O
these	O
sites	O
than	O
cocaine	O
.	O

Most	O
of	O
the	O
BTCP	O
homologues	O
displayed	O
greater	O
ability	O
to	O
inhibit	O
[	O
3H	O
]	O
DA	O
uptake	O
in	O
rat	O
forebrain	O
synaptosomes	O
than	O
cocaine	O
.	O

BTCP	O
and	O
7	O
were	O
the	O
most	O
potent	O
of	O
all	O
the	O
compounds	O
tested	O
in	O
terms	O
of	O
their	O
ability	O
to	O
inhibit	O
uptake	O
of	O
[	O
3H	O
]	O
DA	O
.	O

IC50	O
ratios	O
for	O
[	O
3H	O
]	O
cocaine	O
binding	O
/	O
[	O
3H	O
]	O
DA	O
uptake	O
ranged	O
from	O
0.47	O
for	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclopentyl	I-IUPAC
]	I-IUPAC
homopiperidine	I-IUPAC
(	O
11	O
)	O
to	O
8.8	O
for	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
(	O
4	O
)	O
.	O

The	O
importance	O
of	O
this	O
ratio	O
remains	O
unclear	O
in	O
terms	O
of	O
identification	O
of	O
potential	O
cocaine	O
antagonists	O
.	O

As	O
for	O
BTCP	O
,	O
all	O
of	O
the	O
compounds	O
tested	O
showed	O
Ki	O
values	O
&	O
gt	O
;	O
10,000	O
nM	O
for	O
displacement	O
of	O
[	O
3H	O
]	O
TCP	O
from	O
rat	O
brain	O
homogenates	O
.	O

These	O
compounds	O
were	O
able	O
to	O
displace	O
the	O
highly	O
selective	O
sigma	O
receptor	O
probe	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
from	O
guinea	O
pig	O
brain	O
homogenates	O
with	O
Ki	O
values	O
ranging	O
from	O
125	O
to	O
9170	O
nM	O
.	O

The	O
significance	O
of	O
their	O
sigma	O
-	O
binding	O
activity	O
in	O
light	O
of	O
their	O
dopaminergic	O
properties	O
is	O
unclear	O
.	O

The	O
diverse	O
binding	O
properties	O
of	O
these	O
compounds	O
at	O
the	O
DA	O
-	O
uptake	O
site	O
and	O
their	O
spectrum	O
of	O
inhibitory	O
activities	O
for	O
[	O
3H	O
]	O
DA	O
uptake	O
identifies	O
them	O
as	O
a	O
useful	O
base	O
for	O
the	O
development	O
of	O
subtype	O
selective	O
probes	O
at	O
this	O
site	O
.	O

These	O
compounds	O
will	O
allow	O
further	O
study	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
"	O
cocaine	O
"	O
receptor	O
as	O
well	O
as	O
the	O
development	O
of	O
potential	O
cocaine	O
antagonists	O
.	O

A	O
series	O
of	O
new	O
enantiomerically	O
pure	O
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyrans	I-IUPAC
(	O
3	I-IUPAC
-	I-IUPAC
aminochromans	I-IUPAC
)	O
has	O
been	O
synthesized	O
from	O
(	I-PARTIUPAC
R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
.	O

The	O
absolute	O
configuration	O
of	O
the	O
respective	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-	O
enantiomers	O
was	O
deduced	O
from	O
X	O
-	O
ray	O
crystallography	O
of	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
isopropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
,	O
(	O
R	O
)	O
-	O
9a	O
.	O

Various	O
5	O
-	O
substituents	O
were	O
introduced	O
via	O
palladium	O
-	O
catalyzed	O
carbonylation	O
of	O
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
trifluoromethanesulfonyloxy	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
.	O

The	O
effect	O
of	O
N	O
-	O
and	O
5	O
-	O
substitution	O
on	O
affinity	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
was	O
evaluated	O
in	O
competition	O
experiments	O
using	O
rat	O
hippocampal	O
membranes	O
and	O
[	O
3H	O
]	O
8	O
-	O
OH	O
-	O
DPAT	O
as	O
radioligand	O
.	O

Selected	O
compounds	O
were	O
also	O
tested	O
for	O
their	O
affinity	O
to	O
the	O
D1	O
(	O
rat	O
striatum	O
)	O
,	O
D2	O
(	O
rat	O
striatum	O
)	O
,	O
D2A	O
(	O
human	O
cloned	O
)	O
,	O
and	O
5	O
-	O
HT2A	O
(	O
rat	O
cortex	O
)	O
receptors	O
.	O

The	O
intrinsic	O
activity	O
of	O
the	O
compounds	O
was	O
evaluated	O
by	O
measuring	O
their	O
effect	O
on	O
VIP	O
-	O
stimulated	O
cAMP	O
production	O
in	O
GH4ZD10	O
cells	O
stably	O
transfected	O
with	O
the	O
5	O
-	O
HT1A	O
receptor	O
.	O

High	O
-	O
affinity	O
compounds	O
with	O
high	O
selectivity	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
were	O
found	O
among	O
structures	O
substituted	O
with	O
carboxylate	O
esters	O
,	O
amides	O
,	O
and	O
ketones	O
in	O
the	O
5	O
-	O
position	O
.	O

Primary	O
and	O
secondary	O
amines	O
bound	O
with	O
lower	O
affinity	O
than	O
tertiary	O
amines	O
.	O

Larger	O
substituents	O
were	O
well	O
-	O
tolerated	O
by	O
the	O
receptor	O
,	O
but	O
the	O
smaller	O
N	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
bound	I-MODIFIER
with	O
lower	O
affinity	O
.	O

Generally	O
,	O
the	O
(	O
R	O
)	O
-	O
enantiomers	O
displayed	O
higher	O
affinity	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
than	O
the	O
corresponding	O
(	O
S	O
)	O
-	O
enantiomers	O
.	O

In	O
the	O
present	O
series	O
of	O
compounds	O
,	O
both	O
full	O
and	O
partial	O
agonists	O
were	O
found	O
.	O

3	I-IUPAC
-	I-IUPAC
Ethylaminomethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolone	I-IUPAC
(	O
1a	O
)	O
and	O
its	O
6	O
-	O
CH3	O
,	O
6	O
-	O
OCH3	O
,	O
and	O
7	O
-	O
Cl	O
derivatives	O
were	O
prepared	O
by	O
means	O
of	O
the	O
Mannich	O
reaction	O
.	O

Conversion	O
to	O
the	O
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivatives	I-MODIFIER
and	O
condensation	O
with	O
3	I-IUPAC
-	I-IUPAC
chloroaniline	I-IUPAC
gave	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloroanilino	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
.	O

Cyclization	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloroanilino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
aminomethylquinoline	I-IUPAC
(	O
3a	O
)	O
and	O
its	O
6	O
-	O
OCH3	O
derivative	O
with	O
paraformaldehyde	O
gave	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,9	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethyltetrahydropyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
(	O
4a	O
)	O
and	O
the	O
9	O
-	O
OCH3	O
derivative	O
4b	O
.	O

Treatment	O
of	O
4b	O
with	O
benzaldehyde	I-IUPAC
gave	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
styryltetrahydropyrimido	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
(	O
5	O
)	O
.	O

3	I-IUPAC
-	I-IUPAC
Benzylaminomethyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolone	I-IUPAC
(	O
1e	O
)	O
and	O
3,3	I-IUPAC
'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
benzyliminodimethylene	I-IUPAC
)	I-IUPAC
di	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolone	I-IUPAC
]	I-IUPAC
(	O
6b	O
)	O
were	O
also	O
synthesized	O
.	O

The	O
compounds	O
were	O
inactive	O
as	O
antimalarials	O
.	O

A	O
series	O
of	O
1,1	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2,2,3	I-IUPAC
-	I-IUPAC
triarylcyclopropanes	I-IUPAC
(	O
DTACs	O
)	O
was	O
synthesized	O
and	O
evaluated	O
as	O
pure	O
antiestrogens	O
.	O

Addition	O
of	O
4	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
or	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
Grignard	O
reagents	O
to	O
p	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
,	O
p	I-IUPAC
-	I-IUPAC
benzyloxy	I-IUPAC
,	O
or	O
unsubstituted	O
deoxybenzoins	O
,	O
followed	O
by	O
dehydration	O
of	O
the	O
resulting	O
carbinols	O
produced	O
a	O
mixture	O
of	O
E	O
and	O
Z	O
olefins	O
,	O
which	O
were	O
reacted	O
with	O
dichlorocarbene	O
to	O
give	O
O	O
-	O
protected	O
DTACs	O
.	O

The	O
E	O
and	O
Z	O
isomers	O
were	O
separated	O
by	O
fractional	O
crystallization	O
and	O
the	O
central	O
or	O
geminal	O
phenyl	O
ring	O
was	O
deprotected	O
to	O
provide	O
phenolic	O
DTACs	O
.	O

Alkylation	O
with	O
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
chloride	I-IUPAC
yielded	O
basic	O
cyclopropanes	O
.	O

Two	O
chlorodiarylindenes	O
were	O
isolated	O
as	O
thermolysis	O
products	O
of	O
the	O
DTACs	O
,	O
and	O
one	O
was	O
converted	O
to	O
a	O
phenol	O
by	O
hydrogenolysis	O
.	O

All	O
DTACs	O
and	O
indenes	O
were	O
competitive	O
inhibitors	O
of	O
[	O
3H	O
]	O
estradiol	O
binding	O
in	O
the	O
immature	O
rat	O
uterine	O
cytosol	O
receptor	O
assay	O
,	O
with	O
relative	O
binding	O
affinities	O
of	O
0.1-3.6%	O
of	O
estradiol	O
.	O

None	O
of	O
the	O
new	O
compounds	O
were	O
estrogenic	O
in	O
the	O
3	O
-	O
day	O
immature	O
mouse	O
uterotrophic	O
assay	O
at	O
doses	O
up	O
to	O
750	O
micrograms	O
.	O

In	O
the	O
3	O
-	O
day	O
immature	O
mouse	O
antiuterotrophic	O
assay	O
,	O
five	O
DTACs	O
with	O
either	O
a	O
methoxy	I-IUPAC
(	O
5a	O
)	O
,	O
benzyloxy	I-IUPAC
(	O
4d	O
,	O
5c	O
)	O
,	O
or	O
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
(	O
7a	O
,	O
7b	O
)	O
central	O
ring	O
side	O
chain	O
produced	O
significant	O
decreases	O
in	O
uterine	O
weight	O
at	O
doses	O
up	O
to	O
750	O
micrograms	O
.	O

One	O
compound	O
,	O
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylcyclopropane	I-IUPAC
(	O
7b	O
)	O
,	O
elicited	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
vivo	O
comparable	O
to	O
MER	O
25	O
.	O

These	O
same	O
five	O
compounds	O
,	O
as	O
well	O
as	O
the	O
lead	O
compound	O
Analog	O
II	O
,	O
were	O
active	O
in	O
vitro	O
against	O
the	O
estrogen	O
-	O
dependent	O
MCF	O
-	O
7	O
human	O
breast	O
tumor	O
cell	O
line	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

To	O
develop	O
potential	O
antitumor	O
agents	O
directed	O
toward	O
HER2	O
/	O
ErbB2	O
overexpression	O
in	O
cancer	O
,	O
we	O
have	O
designed	O
inhibitors	O
of	O
the	O
recognition	O
between	O
the	O
phosphotyrosine	O
of	O
the	O
receptor	O
and	O
the	O
SH2	O
domain	O
of	O
the	O
adaptor	O
protein	O
Grb2	O
.	O

In	O
the	O
first	O
part	O
of	O
the	O
paper	O
,	O
we	O
report	O
the	O
synthesis	O
of	O
mimetics	O
of	O
the	O
constrained	O
(	O
alpha	O
-	O
Me	O
)	O
phosphotyrosine	O
residue	O
such	O
as	O
(	I-MODIFIER
alpha	I-MODIFIER
-	I-MODIFIER
Me	I-MODIFIER
)	I-MODIFIER
-	O
4	I-IUPAC
-	I-IUPAC
phosphonomethylphenylalanine	I-IUPAC
(	O
-	O
CH2PO3H2	O
)	O
,	O
(	I-MODIFIER
alpha	I-MODIFIER
-	I-MODIFIER
Me	I-MODIFIER
)	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
phosphonodifluoromethylphenylalanine	I-IUPAC
(	O
-	O
CF2PO3H2	O
)	O
,	O
and	O
(	I-MODIFIER
alpha	I-MODIFIER
-	I-MODIFIER
Me	I-MODIFIER
)	I-MODIFIER
-	O
4	I-IUPAC
-	I-IUPAC
phosphonophenylalanine	I-IUPAC
(	O
-	O
PO3H2	O
)	O
.	O

The	O
incorporation	O
of	O
these	O
residues	O
in	O
the	O
mAZ	O
-	O
pTyr	O
-	O
Xaa	O
-	O
Asn	O
-	O
NH2	O
series	O
provided	O
compounds	O
with	O
very	O
high	O
affinity	O
for	O
the	O
Grb2	O
SH2	O
domain	O
,	O
in	O
the	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
9	O
)	O
range	O
of	O
Kd	O
values	O
.	O

These	O
compounds	O
behave	O
as	O
potent	O
antagonists	O
of	O
the	O
Grb2	O
-	O
Shc	O
interaction	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
the	O
doubly	O
negative	O
charge	O
borne	O
by	O
the	O
pY	O
+	O
1	O
amino	O
acid	O
in	O
accordance	O
with	O
the	O
interactions	O
observed	O
in	O
the	O
complex	O
crystallized	O
between	O
mAZ	O
-	O
pTyr	O
-	O
(	O
alphaMe	O
)	O
pTyr	O
-	O
Asn	O
-	O
NH2	O
and	O
the	O
Grb2	O
SH2	O
domain	O
.	O

mAZ	O
-	O
pTyr	O
-	O
(	O
alphaMe	O
)	O
pTyr	O
-	O
Asn	O
-	O
NH2	O
was	O
derivatized	O
as	O
the	O
S	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
thioester	I-IUPAC
(	O
SATE	O
)	O
of	O
the	O
phosphotyrosine	O
residues	O
,	O
and	O
its	O
surrogates	O
provided	O
prodrugs	O
with	O
very	O
potent	O
antiproliferative	O
activity	O
on	O
cells	O
overexpressing	O
HER2	O
/	O
ErbB2	O
,	O
with	O
ED50	O
values	O
amounting	O
to	O
0.1	O
microM	O
.	O

Finally	O
a	O
new	O
prodrug	O
is	O
put	O
forth	O
under	O
the	O
form	O
of	O
a	O
monobenzyl	O
ester	O
of	O
phosphate	O
group	O
that	O
is	O
as	O
active	O
as	O
and	O
much	O
easier	O
to	O
synthesize	O
than	O
SATE	O
prodrugs	O
.	O

These	O
compounds	O
show	O
promising	O
activity	O
for	O
further	O
testing	O
on	O
in	O
vivo	O
models	O
.	O

Analogs	O
of	O
CVFM	O
(	O
a	O
known	O
nonsubstrate	O
farnesyltransferase	O
(	O
FT	O
)	O
inhibitor	O
derived	O
from	O
a	O
CA1A2X	O
sequence	O
where	O
C	O
is	O
cysteine	O
,	O
A	O
is	O
an	O
aliphatic	O
residue	O
,	O
and	O
X	O
is	O
any	O
residue	O
)	O
were	O
prepared	O
where	O
phenylalanine	O
was	O
replaced	O
by	O
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dehydrophenylalanine	I-IUPAC
,	O
2	I-IUPAC
-	I-IUPAC
aminoindan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
,	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
Tic	O
)	O
,	O
and	O
indoline	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
.	O

The	O
greatest	O
improvement	O
in	O
FT	O
inhibitory	O
potency	O
was	O
observed	O
for	O
the	O
Tic	O
derivative	O
(	O
IC50	O
=	O
1	O
nM	O
)	O
;	O
however	O
,	O
this	O
compound	O
was	O
ineffective	O
in	O
blocking	O
oncogenic	O
Ras	O
-	O
induced	O
transformation	O
of	O
NIH	O
-	O
3T3	O
fibroblast	O
cells	O
.	O

A	O
compound	O
was	O
prepared	O
in	O
which	O
both	O
the	O
Cys	O
-	O
Val	O
methyleneamine	O
isostere	O
and	O
the	O
Tic	O
replacement	O
were	O
incorporated	O
.	O

This	O
derivative	O
inhibited	O
FT	O
with	O
an	O
IC50	O
of	O
0.6	O
nM	O
and	O
inhibited	O
anchorage	O
-	O
independent	O
growth	O
of	O
stably	O
transformed	O
NIH	O
-	O
3T3	O
fibroblast	O
cells	O
by	O
50%	O
at	O
5	O
microM	O
.	O

Replacing	O
the	O
A1	O
side	O
chain	O
of	O
this	O
derivative	O
with	O
a	O
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
group	I-MODIFIER
and	O
replacing	O
the	O
X	O
position	O
with	O
glutamine	O
led	O
to	O
a	O
derivative	O
with	O
an	O
IC50	O
of	O
2.8	O
nM	O
and	O
an	O
EC50	O
of	O
0.19	O
microM	O
,	O
a	O
26	O
-	O
fold	O
improvement	O
over	O
(	I-IUPAC
S	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
valyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isoquinolinyl	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
methionine	I-IUPAC
.	O

This	O
derivative	O
,	O
(	I-IUPAC
S	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
leucyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isoquinolinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamine	I-IUPAC
,	O
was	O
evaluated	O
in	O
vivo	O
along	O
with	O
(	I-IUPAC
S	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
leucyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isoquinolinyl	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
methionine	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
for	O
antitumor	O
activity	O
in	O
an	O
athymic	O
mouse	O
model	O
implanted	O
ip	O
with	O
H	O
-	O
ras	O
-	O
transformed	O
rat	O
-	O
1	O
tumor	O
cells	O
.	O

When	O
administered	O
by	O
injection	O
twice	O
a	O
day	O
at	O
45	O
mg	O
/	O
kg	O
for	O
11	O
consecutive	O
days	O
,	O
both	O
compounds	O
showed	O
prolonged	O
survival	O
time	O
(	O
T	O
/	O
C	O
=	O
142-145%	O
)	O
,	O
thus	O
demonstrating	O
efficacy	O
against	O
ras	O
oncogene	O
-	O
containing	O
tumors	O
in	O
vivo	O
.	O

Substituted	I-MODIFIER
9H	B-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indoles	I-IUPAC
(	O
beta	O
-	O
carbolines	O
)	O
,	O
identified	O
in	O
our	O
laboratory	O
as	O
potential	O
pharmacophores	O
for	O
designing	O
macrofilaricidal	O
agents	O
,	O
have	O
been	O
explored	O
further	O
for	O
identifying	O
the	O
pharmacophore	O
responsible	O
for	O
the	O
high	O
order	O
of	O
adulticidal	O
activity	O
.	O

This	O
has	O
led	O
to	O
syntheses	O
and	O
macrofilaricidal	O
evaluations	O
of	O
a	O
number	O
of	O
1	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
derivatives	I-MODIFIER
(	O
3-7	O
)	O
.	O

The	O
macrofilaricidal	O
activity	O
was	O
initially	O
evaluated	O
in	O
vivo	O
against	O
Acanthoeilonema	O
viteae	O
.	O

Among	O
all	O
the	O
synthesized	O
compounds	O
,	O
only	O
12	O
compounds	O
,	O
namely	O
3a	O
,	O
3c	O
,	O
3d	O
,	O
3f	O
,	O
4c	O
,	O
4d	O
,	O
4f	O
,	O
5a	O
,	O
6f	O
,	O
6h	O
,	O
6i	O
,	O
and	O
7h	O
,	O
have	O
exhibited	O
either	O
&	O
gt	O
;	O
90%	O
micro	O
-	O
or	O
macrofilaricidal	O
activity	O
or	O
sterlization	O
of	O
female	O
worms	O
.	O

These	O
compounds	O
have	O
also	O
been	O
screened	O
against	O
Litomosoides	O
carinii	O
,	O
and	O
of	O
these	O
only	O
3f	O
and	O
5a	O
have	O
also	O
been	O
found	O
to	O
be	O
active	O
.	O

Finally	O
these	O
two	O
compounds	O
have	O
been	O
evaluated	O
against	O
Brugia	O
malayi	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
associated	O
with	O
position	O
1	O
and	O
3	O
substituents	O
in	O
beta	O
-	O
carbolines	O
has	O
been	O
discussed	O
.	O

It	O
has	O
been	O
observed	O
that	O
the	O
presence	O
of	O
a	O
carbomethoxy	O
at	O
position	O
3	O
and	O
an	O
aryl	O
substituent	O
at	O
position	O
1	O
in	O
beta	O
-	O
carbolines	O
effectively	O
enhances	O
antifilarial	O
activity	O
particularly	O
against	O
A	O
.	O

viteae	O
.	O

Among	O
the	O
various	O
compounds	O
screened	O
,	O
methyl	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
4c	O
)	O
has	O
shown	O
the	O
highest	O
adulticidal	O
activity	O
and	O
methyl	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
3a	O
)	O
has	O
shown	O
the	O
highest	O
microfilaricidal	O
action	O
against	O
A	O
.	O

viteae	O
at	O
50	O
mg	O
/	O
kg	O
x	O
5	O
days	O
(	O
ip	O
)	O
.	O

Another	O
derivative	O
of	O
this	O
compound	O
,	O
namely	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
(	O
5a	O
)	O
,	O
exhibited	O
the	O
highest	O
activity	O
against	O
L	O
.	O

carinii	O
at	O
30	O
mg	O
/	O
kg	O
x	O
5	O
days	O
(	O
ip	O
)	O
and	O
against	O
B	O
.	O

malayiat	O
50	O
mg	O
/	O
kg	O
x	O
5	O
days	O
(	O
ip	O
)	O
or	O
at	O
200	O
mg	O
/	O
kg	O
x	O
5	O
days	O
(	O
po	O
)	O
.	O

Certain	O
novel	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalenes	I-IUPAC
(	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminotetralins	I-IUPAC
,	O
PATs	O
)	O
produced	O
stimulation	O
(	O
ca.	O
30%	O
above	O
basal	O
levels	O
)	O
of	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
activity	O
at	O
0.1	O
microM	O
concentrations	O
in	O
rodent	O
brain	O
tissue	O
.	O

This	O
effect	O
on	O
TH	O
was	O
blocked	O
by	O
the	O
putative	O
sigma	O
-	O
receptor	O
antagonist	O
BMY	O
-	O
14802	O
,	O
suggesting	O
involvement	O
of	O
a	O
novel	O
neuromodulatory	O
sigma	O
-	O
like	O
receptor	O
.	O

Within	O
the	O
new	O
phenylaminotetralin	O
series	O
,	O
a	O
correlation	O
was	O
found	O
between	O
the	O
ability	O
to	O
stimulate	O
TH	O
and	O
the	O
potency	O
to	O
compete	O
for	O
binding	O
sites	O
labeled	O
by	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalene	I-IUPAC
(	O
[	O
3H	O
]	O
(	O
+	O
/	O
-	O
)	O
-	O
4	O
)	O
.	O

trans	O
-	O
Catechol	O
analogs	O
had	O
low	O
affinity	O
for	O
[	O
3H	O
]	O
4	O
sites	O
,	O
and	O
although	O
they	O
inhibited	O
TH	O
activity	O
,	O
this	O
effect	O
was	O
not	O
blocked	O
by	O
known	O
sigma	O
or	O
dopamine	O
antagonists	O
.	O

Analogs	O
with	O
dihydroxy	I-IUPAC
substituents	B-MODIFIER
(	O
catechols	O
)	O
,	O
as	O
well	O
as	O
nitrogen	O
substituents	O
larger	O
than	O
methyl	O
,	O
had	O
little	O
affinity	O
for	O
[	O
3H	O
]	O
4	O
binding	O
sites	O
and	O
did	O
not	O
significantly	O
affect	O
TH	O
activity	O
.	O

The	O
pharmacology	O
of	O
the	O
[	O
3H	O
]	O
4	O
binding	O
site	O
is	O
unique	O
from	O
that	O
of	O
any	O
known	O
sigma	O
or	O
dopamine	O
receptor	O
,	O
thus	O
the	O
effects	O
appear	O
to	O
be	O
mediated	O
by	O
a	O
previously	O
uncharacterized	O
binding	O
site	O
/	O
receptor	O
.	O

The	O
site	O
has	O
stereoselectivity	O
for	O
the	O
(	O
1R	O
,	O
3S	O
)	O
-	O
(	O
-	O
)	O
-	O
isomer	O
of	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalene	I-IUPAC
;	O
this	O
isomer	O
is	O
also	O
more	O
active	O
at	O
stimulating	O
TH	O
.	O

Thus	O
,	O
certain	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalenes	I-IUPAC
appear	O
to	O
be	O
selective	O
probes	O
of	O
a	O
novel	O
receptor	O
type	O
that	O
mediates	O
sigma	O
-	O
like	O
neuromodulatory	O
activity	O
and	O
may	O
have	O
pharmacotherapeutic	O
utility	O
in	O
conditions	O
in	O
which	O
modulation	O
of	O
dopamine	O
function	O
is	O
important	O
.	O

Various	O
4	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
3	I-PARTIUPAC
-	I-PARTIUPAC
alkylamino	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
alkoxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
alkylthio	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
sulfamoylbenzoic	I-IUPAC
acids	I-IUPAC
related	O
to	O
known	O
aminobenzoic	O
acid	O
diuretics	O
were	O
synthesized	O
and	O
screened	O
for	O
their	O
diuretic	O
properties	O
in	O
dogs	O
.	O

The	O
tabulated	O
results	O
from	O
a	O
3	O
-	O
hr	O
test	O
period	O
revealed	O
that	O
generally	O
the	O
diuretic	O
profile	O
and	O
potency	O
could	O
be	O
retained	O
when	O
3	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
,	O
3	I-IUPAC
-	I-IUPAC
alkylthio	I-IUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
were	O
substituted	O
for	O
the	O
3	I-IUPAC
-	I-IUPAC
alkylamino	I-IUPAC
moiety	I-MODIFIER
.	O

The	O
high	O
potency	O
of	O
several	O
3	I-PARTIUPAC
-	I-PARTIUPAC
alkoxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
alkylthio	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
sulfamoylbenzoic	I-IUPAC
acids	I-IUPAC
confirmed	O
previous	O
suggestions	O
that	O
the	O
apparent	O
diuretic	O
effect	O
of	O
4	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
alkylamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazole	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
originates	O
from	O
the	O
corresponding	O
4	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
sulfamoylbenzoic	I-IUPAC
acid	I-IUPAC
derivatives	I-MODIFIER
due	O
to	O
an	O
existing	O
equilibrium	O
in	O
plasma	O
.	O

4	I-IUPAC
-	I-IUPAC
Benzoyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
sulfamoyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
thenyloxy	I-IUPAC
)	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
118	O
)	O
is	O
among	O
the	O
most	O
potent	O
benzoic	O
acid	O
diuretics	O
hitherto	O
synthesized	O
and	O
shows	O
significant	O
diuretic	O
activity	O
in	O
dogs	O
at	O
1	O
mug	O
/	O
kg	O
.	O

The	O
results	O
obtained	O
with	O
different	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
sulfamoylbenzoic	I-IUPAC
acids	I-IUPAC
supported	O
the	O
earlier	O
concept	O
regarding	O
the	O
steric	O
influence	O
of	O
the	O
4	O
-	O
substituent	O
on	O
the	O
diuretic	O
potency	O
of	O
sulfamoylbenzoic	O
acid	O
diuretics	O
.	O

A	O
series	O
of	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2,4	I-IUPAC
-	I-IUPAC
dinitroimidazole	I-IUPAC
analogues	I-MODIFIER
have	O
been	O
synthesized	O
and	O
tested	O
for	O
their	O
radiosensitizing	O
ability	O
for	O
selectively	O
sensitizing	O
hypoxic	O
mammalian	O
cells	O
to	O
the	O
lethal	O
effect	O
of	O
radiation	O
.	O

The	O
reaction	O
of	O
2,4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dinitroimidazole	I-IUPAC
(	O
1	O
)	O
with	O
a	O
variety	O
of	O
oxiranes	O
upon	O
heating	O
in	O
absolute	O
ethanol	O
yielded	O
the	O
expected	O
1	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2,4	I-IUPAC
-	I-IUPAC
dinitroimidazoles	I-IUPAC
(	O
2	O
)	O
and	O
also	O
resulted	O
in	O
the	O
formation	O
of	O
a	O
novel	O
class	O
of	O
isomeric	I-MODIFIER
nitroimidazo	B-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
oxazoles	I-IUPAC
3	O
and	O
4	O
)	O
by	O
intramolecular	O
cyclization	O
.	O

The	O
results	O
of	O
radiosensitizing	O
activity	O
of	O
these	O
agents	O
against	O
hypoxic	O
Chinese	O
hamster	O
cells	O
(	O
V	O
-	O
79	O
)	O
indicated	O
that	O
2,4	I-IUPAC
-	I-IUPAC
dinitroimidazoles	I-IUPAC
were	O
better	O
sensitizers	O
than	O
the	O
nitroimidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
oxazoles	I-IUPAC
,	O
suggesting	O
the	O
necessity	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
function	I-MODIFIER
in	O
the	O
molecule	O
.	O

The	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dinitroimidazole	I-IUPAC
(	O
2d	O
)	O
was	O
found	O
to	O
be	O
the	O
most	O
effective	O
radiosensitizer	O
of	O
this	O
series	O
.	O

Several	O
8	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
O6	I-IUPAC
-	I-IUPAC
benzylguanines	I-IUPAC
,	O
2	I-MODIFIER
-	I-MODIFIER
and	O
/	O
or	O
8	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
purines	I-IUPAC
,	O
substituted	I-MODIFIER
6	B-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
pyrimidines	I-IUPAC
,	O
and	O
a	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
s	I-IUPAC
-	I-IUPAC
triazine	I-IUPAC
were	O
tested	O
for	O
their	O
ability	O
to	O
inactivate	O
the	O
human	O
DNA	O
repair	O
protein	O
,	O
O6	I-IUPAC
-	I-IUPAC
alkylguanine	I-IUPAC
-	O
DNA	O
alkyltransferase	O
(	O
AGT	O
,	O
alkyltransferase	O
)	O
.	O

Two	O
types	O
of	O
compounds	O
were	O
identified	O
as	O
being	O
significantly	O
more	O
effective	O
than	O
O6	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
(	O
the	O
prototype	O
low	O
molecular	O
weight	O
inactivator	O
)	O
at	O
inactivating	O
AGT	O
in	O
human	O
HT29	O
colon	O
tumor	O
cell	O
extracts	O
.	O

These	O
were	O
8	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
O6	I-IUPAC
-	I-IUPAC
benzylguanines	I-IUPAC
bearing	O
electron	O
-	O
withdrawing	O
groups	O
at	O
the	O
8	O
-	O
position	O
(	O
e.g.	O
8	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
O6	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
and	O
O6	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
bromoguanine	I-IUPAC
)	O
and	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
pyrimidines	I-IUPAC
bearing	O
electron	O
-	O
withdrawing	O
groups	O
at	O
the	O
5	O
-	O
position	O
(	O
e.g.	O
2,4	I-PARTIUPAC
-	I-PARTIUPAC
diamino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
benzyloxy	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
nitroso	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitropyrimidine	I-IUPAC
)	O
.	O

The	O
latter	O
derivatives	O
were	O
also	O
more	O
effective	O
than	O
O6	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
at	O
inactivating	O
AGT	O
in	O
intact	O
HT29	O
colon	O
tumor	O
cells	O
.	O

Provided	O
these	O
types	O
of	O
purines	O
and	O
pyrimidines	O
do	O
not	O
exhibit	O
undesirable	O
toxicity	O
,	O
they	O
may	O
be	O
superior	O
to	O
O6	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
as	O
chemotherapeutic	O
adjuvants	O
for	O
enhancing	O
the	O
effectiveness	O
of	O
antitumor	O
drugs	O
for	O
which	O
the	O
mechanism	O
of	O
action	O
involves	O
modification	O
of	O
the	O
O6	O
-	O
position	O
of	O
DNA	O
guanine	O
residues	O
.	O

Structure	O
-	O
activity	O
relationships	O
for	O
inhibition	O
of	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
have	O
been	O
defined	O
for	O
substituted	I-MODIFIER
chromen	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O

For	O
the	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	O
substituted	I-MODIFIER
benzo	B-IUPAC
[	I-IUPAC
h	I-IUPAC
]	I-IUPAC
chromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
a	O
morpholine	O
substituent	O
at	O
this	O
position	O
was	O
essential	O
for	O
activity	O
.	O

Small	O
libraries	O
of	O
6	I-PARTIUPAC
-	I-PARTIUPAC
and	O
7	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	O
substituted	I-MODIFIER
chromen	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
showed	O
that	O
a	O
number	O
of	O
7	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	O
substituted	I-MODIFIER
chromenones	B-IUPAC
displayed	O
improved	O
activity	O
.	O

Focused	O
libraries	O
incorporating	O
6	I-PARTIUPAC
-	I-PARTIUPAC
,	O
7	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
8	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
and	O
heteroaryl	I-IUPAC
substituents	B-MODIFIER
were	O
prepared	O
.	O

In	O
these	O
cases	O
,	O
6	O
-	O
and	O
7	O
-	O
substitution	O
was	O
disfavored	O
,	O
whereas	O
8	O
-	O
substitution	O
was	O
largely	O
tolerated	O
.	O

Surprisingly	O
,	O
two	O
compounds	O
,	O
2	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
dibenzofuranyl	I-IUPAC
-	I-IUPAC
chromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
NU7427	O
,	O
32	O
{	O
38	O
}	O
)	O
and	O
the	O
2	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
dibenzothiophenyl	I-IUPAC
-	I-IUPAC
chromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
NU7441	O
,	O
32	O
{	O
26	O
}	O
)	O
were	O
excellent	O
inhibitors	O
(	O
IC50	O
vs	O
DNA	O
-	O
PK	O
=	O
40	O
and	O
13	O
nM	O
,	O
respectively	O
)	O
.	O

The	O
ring	I-MODIFIER
-	I-MODIFIER
saturated	I-MODIFIER
analogue	I-MODIFIER
2	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6'	I-IUPAC
,	I-IUPAC
7'	I-IUPAC
,	I-IUPAC
8'	I-IUPAC
,	I-IUPAC
9'	I-IUPAC
-	I-IUPAC
tetrahydrodibenzothiophene	I-IUPAC
)	I-IUPAC
chromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
36	O
,	O
retained	O
potent	O
activity	O
(	O
IC50	O
vs	O
DNA	O
-	O
PK	O
=	O
23	O
nM	O
)	O
.	O

The	O
dibenzothiophene	O
32	O
{	O
38	O
}	O
sensitized	O
HeLa	O
cells	O
to	O
ionizing	O
radiation	O
in	O
vitro	O
,	O
with	O
dose	O
modification	O
factors	O
of	O
2.5	O
at	O
10%	O
survival	O
being	O
observed	O
at	O
0.5	O
microM	O
.	O

The	O
cytotoxicity	O
of	O
the	O
topoisomerase	O
II	O
inhibitor	O
etoposide	O
was	O
also	O
potentiated	O
.	O

4,5,6,7	I-IUPAC
-	I-IUPAC
Tetrahydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5,1	I-IUPAC
-	I-IUPAC
jk	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
TIBO	O
)	O
,	O
1	O
,	O
have	O
been	O
shown	O
to	O
significantly	O
inhibit	O
HIV	O
-	O
1	O
replication	O
in	O
vitro	O
by	O
interfering	O
with	O
the	O
virus	O
's	O
reverse	O
transcriptase	O
enzyme	O
.	O

They	O
have	O
also	O
demonstrated	O
potential	O
clinical	O
efficacy	O
in	O
combating	O
HIV	O
-	O
1	O
,	O
on	O
the	O
basis	O
of	O
a	O
preliminary	O
study	O
.	O

Our	O
prior	O
publications	O
have	O
discussed	O
the	O
discovery	O
of	O
this	O
series	O
of	O
compounds	O
and	O
reported	O
some	O
preliminary	O
chemical	O
and	O
biological	O
studies	O
around	O
N	O
-	O
6	O
substitutions	O
and	O
5	O
-	O
membered	O
ring	O
variations	O
of	O
1	O
.	O

This	O
manuscript	O
describes	O
our	O
synthetic	O
endeavors	O
around	O
4	O
,	O
5	O
,	O
and	O
7	O
mono	O
-	O
and	O
disubstitutions	O
of	O
1	O
and	O
discusses	O
related	O
HIV	O
-	O
1	O
inhibitory	O
structure	O
-	O
activity	O
relationships	O
.	O

On	O
the	O
basis	O
of	O
inhibition	O
of	O
HIV	O
-	O
1'	O
s	O
cytopathic	O
effects	O
in	O
MT	O
-	O
4	O
cells	O
,	O
we	O
found	O
that	O
5	O
-	O
mono	O
-	O
Me	O
-	O
substituted	O
analogues	O
,	O
the	O
original	O
substitution	O
in	O
the	O
early	O
lead	O
compounds	O
,	O
and	O
7	O
-	O
mono	O
-	O
Me	O
-	O
substituted	O
analogues	O
of	O
1	O
were	O
comparable	O
as	O
being	O
consistently	O
the	O
most	O
active	O
compounds	O
.	O

Although	O
generally	O
less	O
active	O
,	O
the	O
4,5,7	O
-	O
unsubstituted	O
,	O
4	O
-	O
mono	O
-	O
substituted	O
,	O
cis	O
-	O
and	O
trans	O
-	O
5,7	O
-	O
di	O
-	O
Me	O
-	O
substituted	O
,	O
and	O
cis	O
-	O
4,5	O
-	O
di	O
-	O
Me	O
-	O
substituted	O
analogues	O
of	O
1	O
also	O
exhibited	O
some	O
significant	O
desired	O
activity	O
.	O

The	O
remaining	O
trans	O
-	O
4,5	O
-	O
di	O
-	O
Me	O
-	O
substituted	O
,	O
cis	O
-	O
and	O
trans	O
-	O
4,7	O
-	O
di	O
-	O
Me	O
-	O
substituted	O
,	O
and	O
all	O
4,5	O
-	O
,	O
5,6	O
-	O
,	O
6,7	O
-	O
,	O
and	O
7,8	O
-	O
fused	O
disubstituted	O
analogues	O
of	O
1	O
possessed	O
no	O
noticeable	O
desired	O
activity	O
.	O

From	O
the	O
reaction	O
of	O
silylated	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
triazeno	I-IUPAC
)	I-IUPAC
imidazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
DTIC	O
,	O
5	O
)	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
triazeno	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
DTPC	O
,	O
9	O
)	O
with	O
2	I-IUPAC
-	I-IUPAC
chlorotetrahydrofuran	I-IUPAC
,	O
we	O
have	O
isolated	O
in	O
both	O
cases	O
a	O
single	O
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
derivative	I-MODIFIER
.	O

However	O
,	O
when	O
silylated	O
DTPC	O
was	O
reacted	O
with	O
2	I-IUPAC
-	I-IUPAC
chlorotetrahydropyran	I-IUPAC
,	O
two	O
tetrahydropyran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
compounds	I-MODIFIER
were	O
obtained	O
,	O
and	O
these	O
were	O
shown	O
to	O
be	O
positional	O
isomers	O
on	O
the	O
basis	O
of	O
1H	O
NMR	O
and	O
UV	O
data	O
.	O

These	O
furanyl	I-IUPAC
and	O
pyranyl	I-IUPAC
derivatives	B-MODIFIER
were	O
tested	O
for	O
antileukemic	O
activity	O
(	O
L	O
-	O
1210	O
,	O
in	O
vivo	O
)	O
and	O
the	O
results	O
were	O
compared	O
with	O
the	O
results	O
obtained	O
for	O
the	O
corresponding	O
ribosyl	I-IUPAC
derivatives	B-MODIFIER
of	O
DTIC	O
and	O
DTPC	O
.	O

Syntheses	O
of	O
the	O
trans	I-IUPAC
-	I-IUPAC
dihydrodiol	I-IUPAC
derivatives	I-MODIFIER
implicated	O
as	O
the	O
proximate	O
carcinogenic	O
metabolites	O
of	O
the	O
polycyclic	O
hydrocarbons	O
cholanthrene	O
,	O
6	I-IUPAC
-	I-IUPAC
methylcholanthrene	I-IUPAC
,	O
benz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
,	O
and	O
7	I-PARTIUPAC
-	I-PARTIUPAC
and	O
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
are	O
described	O
.	O

These	O
compounds	O
are	O
useful	O
models	O
for	O
research	O
to	O
determine	O
the	O
molecular	O
basis	O
of	O
the	O
strong	O
enhancement	O
of	O
carcinogenicity	O
consequent	O
upon	O
methyl	I-IUPAC
substitution	B-MODIFIER
in	O
nonbenzo	O
bay	O
molecular	O
sites	O
and	O
meso	O
regions	O
of	O
polycyclic	O
hydrocarbons	O
.	O

Synthesis	O
of	O
the	O
bay	O
region	O
anti	O
-	O
diol	O
epoxide	O
derivative	O
of	O
cholanthrene	O
,	O
its	O
putative	O
ultimate	O
carcinogenic	O
metabolite	O
,	O
is	O
also	O
described	O
.	O

Tumorigenicity	O
assays	O
indicate	O
that	O
the	O
9,10	I-IUPAC
-	I-IUPAC
dihydrodiol	I-IUPAC
derivatives	I-MODIFIER
of	O
cholanthrene	O
and	O
its	O
3	I-PARTIUPAC
-	I-PARTIUPAC
and	O
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivatives	I-MODIFIER
are	O
all	O
potent	O
tumor	O
initiators	O
on	O
mouse	O
skin	O
.	O

The	O
most	O
active	O
member	O
of	O
the	O
series	O
is	O
the	O
dihydrodiol	I-IUPAC
derivative	B-MODIFIER
of	O
6	I-IUPAC
-	I-IUPAC
methylcholanthrene	I-IUPAC
,	O
which	O
contains	O
a	O
bay	O
region	O
methyl	I-IUPAC
group	B-MODIFIER
.	O

The	O
ability	O
of	O
the	O
dihydrodiols	O
3a	O
-	O
c	O
and	O
the	O
trans	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydrodiol	I-IUPAC
of	O
7,12	I-IUPAC
-	I-IUPAC
dimethylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
3d	O
)	O
to	O
induce	O
chromosomal	O
aberrations	O
in	O
rat	O
bone	O
marrow	O
cells	O
was	O
also	O
examined	O
.	O

The	O
observed	O
order	O
of	O
activity	O
was	O
3d	O
greater	O
than	O
3c	O
greater	O
than	O
3b	O
greater	O
than	O
3a	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
diol	O
epoxide	O
metabolites	O
of	O
these	O
dihydrodiols	O
are	O
the	O
active	O
carcinogenic	O
forms	O
of	O
the	O
parent	O
hydrocarbons	O
.	O

The	O
syntheses	O
of	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
9	O
,	O
ATPA	O
)	O
,	O
(	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
RS	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
8	O
)	O
,	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolebutyric	I-IUPAC
acid	I-IUPAC
(	O
15a	O
)	O
,	O
and	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolevaleric	I-IUPAC
acid	I-IUPAC
(	O
15b	O
)	O
are	O
described	O
.	O

The	O
compounds	O
were	O
tested	O
in	O
vitro	O
together	O
with	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
ABPA	O
)	O
as	O
inhibitors	O
of	O
the	O
binding	O
of	O
radioactive	O
-	O
labeled	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
to	O
rat	O
brain	O
synaptic	O
membranes	O
.	O

These	O
data	O
were	O
compared	O
with	O
the	O
earlier	O
reported	O
effects	O
of	O
the	O
compounds	O
on	O
single	O
neurons	O
in	O
the	O
feline	O
spinal	O
cord	O
obtained	O
by	O
microelectrophoretic	O
techniques	O
.	O

The	O
three	O
compounds	O
AMPA	O
,	O
ATPA	O
,	O
and	O
ABPA	O
are	O
agonists	O
at	O
the	O
class	O
of	O
receptors	O
assumed	O
to	O
represent	O
a	O
subtype	O
of	O
physiological	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
Glu	O
)	O
receptors	O
.	O

Inhibition	O
of	O
[	O
3H	O
]	O
AMPA	O
binding	O
by	O
ATPA	O
was	O
1	O
order	O
of	O
magnitude	O
weaker	O
than	O
that	O
of	O
AMPA	O
,	O
in	O
agreement	O
with	O
the	O
relative	O
potency	O
of	O
these	O
compounds	O
in	O
vivo	O
.	O

ABPA	O
proved	O
to	O
be	O
equipotent	O
with	O
AMPA	O
both	O
as	O
an	O
inhibitor	O
of	O
AMPA	O
binding	O
and	O
as	O
a	O
neuronal	O
excitant	O
.	O

The	O
compounds	O
8	O
,	O
15a	O
,	O
and	O
15b	O
have	O
no	O
effect	O
as	O
inhibitors	O
of	O
AMPA	O
binding	O
,	O
in	O
agreement	O
with	O
in	O
vivo	O
studies	O
that	O
have	O
shown	O
that	O
8	O
does	O
not	O
affect	O
the	O
firing	O
of	O
central	O
neurons	O
whereas	O
15a	O
and	O
15b	O
are	O
antagonists	O
at	O
NMDA	O
receptors	O
,	O
a	O
subpopulation	O
of	O
excitatory	O
receptors	O
not	O
affected	O
by	O
AMPA	O
.	O

Molecular	O
mechanical	O
calculations	O
on	O
AMPA	O
,	O
ATPA	O
,	O
and	O
ABPA	O
using	O
the	O
program	O
MM2	O
showed	O
that	O
conformations	O
of	O
AMPA	O
,	O
ABPA	O
,	O
and	O
especially	O
ATPA	O
by	O
rotation	O
of	O
the	O
amino	O
acid	O
side	O
chain	O
have	O
energy	O
barriers	O
.	O

A	O
possible	O
receptor	O
-	O
active	O
conformation	O
is	O
suggested	O
.	O

A	O
number	O
of	O
3	I-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
dialkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
synthesized	O
and	O
screened	O
as	O
in	O
vitro	O
cAMP	O
phosphodiesterase	O
inhibitors	O
.	O

The	O
condensation	O
of	O
3	I-IUPAC
-	I-IUPAC
aminopyrazole	I-IUPAC
with	O
symmetrical	O
beta	O
-	O
diketones	O
(	O
acetylacetone	O
,	O
heptane	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
,	O
etc	O
.	O

)	O
afforded	O
symmetrical	O
dialkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
5	O
)	O
.	O

The	O
reaction	O
of	O
3	I-IUPAC
-	I-IUPAC
aminopyrazole	I-IUPAC
with	O
unsymmetrical	O
beta	O
-	O
diketones	O
(	O
hexane	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
,	O
heptane	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
,	O
etc	O
.	O

)	O
gave	O
a	O
mixture	O
of	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
alkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
3	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
4	O
)	O
.	O

The	O
technique	O
for	O
the	O
separation	O
of	O
3	O
from	O
4	O
is	O
described	O
.	O

The	O
inhibition	O
constants	O
,	O
alpha	O
(	O
the	O
ratio	O
of	O
the	O
molar	O
I50	O
of	O
theophylline	O
to	O
the	O
molar	O
I50	O
of	O
the	O
test	O
compounds	O
)	O
,	O
were	O
subjected	O
to	O
a	O
Hansch	O
correlation	O
analysis	O
.	O

The	O
results	O
indicated	O
that	O
PDE	O
isolated	O
from	O
beef	O
heart	O
tissue	O
was	O
most	O
sensitive	O
to	O
changes	O
in	O
the	O
length	O
of	O
the	O
alkyl	O
group	O
in	O
the	O
5	O
position	O
of	O
the	O
pyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
ring	I-MODIFIER
,	O
whereas	O
the	O
PDE	O
isolated	O
from	O
rabbit	O
lung	O
tissue	O
was	O
more	O
sensitive	O
to	O
changes	O
in	O
the	O
length	O
of	O
the	O
7	O
-	O
alkyl	O
group	O
.	O

Experimentally	O
and	O
theoretically	O
,	O
the	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	I-MODIFIER
was	O
found	O
to	O
approximate	O
the	O
ideal	O
size	O
for	O
the	O
alkyl	O
group	O
in	O
both	O
the	O
5	O
and	O
7	O
positions	O
;	O
5,7	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxycarbonylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
5e	O
)	O
was	O
the	O
most	O
potent	O
inhibitor	O
of	O
both	O
lung	O
and	O
heart	O
PDE	O
.	O

In	O
order	O
to	O
improve	O
the	O
oral	O
bioavailability	O
(	O
BA	O
)	O
of	O
2	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimid	I-IUPAC
azole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
3	O
:	O
CV	O
-	O
11194	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
4	O
:	O
CV	O
-	O
11974	O
)	O
,	O
novel	O
angiotensin	O
II	O
(	O
AII	O
)	O
receptor	O
antagonists	O
,	O
chemical	O
modification	O
to	O
yield	O
prodrugs	O
has	O
been	O
examined	O
.	O

After	O
selective	O
tritylation	O
of	O
the	O
tetrazole	O
rings	O
in	O
3	O
and	O
4	O
,	O
treatment	O
of	O
N	I-MODIFIER
-	I-MODIFIER
tritylated	I-MODIFIER
benzimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
(	O
6	O
,	O
7	O
)	O
with	O
a	O
variety	O
of	O
alkyl	O
halides	O
,	O
followed	O
by	O
deprotection	O
with	O
hydrochloric	O
acid	O
,	O
afforded	O
esters	O
of	O
3	O
and	O
4	O
.	O

Mainly	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acyloxy	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
esters	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkoxycarbonyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
alkyl	I-IUPAC
esters	I-IUPAC
,	O
double	O
ester	O
derivatives	O
,	O
were	O
synthesized	O
.	O

Their	O
inhibitory	O
effect	O
on	O
AII	O
-	O
induced	O
pressor	O
response	O
in	O
rats	O
and	O
oral	O
BA	O
were	O
investigated	O
.	O

(	I-PARTIUPAC
Pivaloyloxy	I-PARTIUPAC
)	I-PARTIUPAC
methyl	I-PARTIUPAC
and	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
cyclohexyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
esters	I-IUPAC
of	O
3	O
and	O
4	O
showed	O
marked	O
increases	O
in	O
oral	O
bioavailability	O
which	O
significantly	O
potentiated	O
the	O
inhibitory	O
effect	O
of	O
the	O
parent	O
compounds	O
on	O
AII	O
-	O
induced	O
pressor	O
response	O
.	O

Among	O
them	O
,	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
cyclohexyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimida	I-IUPAC
zole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
10s	O
,	O
TCV	O
-	O
116	O
)	O
was	O
selected	O
as	O
a	O
candidate	O
for	O
clinical	O
evaluation	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
structure	O
-	O
activity	O
studies	O
of	O
the	O
bicyclic	O
oxytocin	O
antagonist	O
[	O
Mpa1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
.	O

The	O
monocylic	O
analogue	O
[	O
dPen1	O
,	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
was	O
a	O
weak	O
oxytocin	O
antagonist	O
with	O
a	O
pA2	O
value	O
of	O
5.8	O
in	O
the	O
uterotonic	O
assay	O
.	O

Bicyclization	O
of	O
this	O
analogue	O
yielded	O
[	O
dPen1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
,	O
a	O
potent	O
antagonist	O
of	O
oxytocin	O
in	O
the	O
uterotonic	O
assay	O
(	O
pA2	O
8.74	O
)	O
with	O
a	O
potency	O
3	O
times	O
greater	O
than	O
that	O
of	O
[	O
Mpa1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
.	O

[	O
dPen1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
also	O
was	O
a	O
weak	O
antagonist	O
in	O
the	O
pressor	O
assay	O
with	O
a	O
pA2	O
of	O
6.3	O
.	O

To	O
establish	O
if	O
the	O
potent	O
antagonistic	O
effects	O
of	O
these	O
bicyclic	O
compounds	O
was	O
because	O
of	O
the	O
lactam	O
ring	O
or	O
merely	O
the	O
result	O
of	O
obtaining	O
an	O
optimal	O
degree	O
of	O
lipophilicity	O
of	O
the	O
side	O
chains	O
in	O
positions	O
4	O
and	O
8	O
,	O
we	O
synthesized	O
a	O
series	O
of	O
analogues	O
containing	O
neutral	O
and	O
/	O
or	O
charged	O
groups	O
on	O
these	O
side	O
chains	O
.	O

Monocyclic	O
derivatives	O
of	O
[	O
Mpa1	O
,	O
Gln4	O
,	O
Lys	O
(	O
CHO	O
)	O
8	O
]	O
oxytocin	O
were	O
moderate	O
to	O
weak	O
agonists	O
of	O
oxytocin	O
all	O
following	O
classical	O
structure	O
-	O
activity	O
profiles	O
of	O
oxytocin	O
.	O

The	O
monocyclic	O
derivatives	O
of	O
[	O
dPen1	O
,	O
Gln4	O
,	O
Lys	O
(	O
CHO	O
)	O
8	O
]	O
oxytocin	O
were	O
antagonists	O
of	O
oxytocin	O
which	O
was	O
attributed	O
to	O
the	O
dPen1	O
substitution	O
.	O

However	O
,	O
the	O
potency	O
of	O
all	O
of	O
these	O
latter	O
derivatives	O
was	O
at	O
least	O
1	O
order	O
of	O
magnitude	O
less	O
than	O
[	O
dPen1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
.	O

These	O
results	O
suggest	O
that	O
the	O
potent	O
antagonistic	O
properties	O
of	O
the	O
bicyclic	O
analogues	O
[	O
Mpa1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
and	O
[	O
dPen1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
can	O
be	O
attributed	O
to	O
the	O
effect	O
of	O
the	O
lactam	O
bridge	O
on	O
the	O
conformational	O
flexibility	O
and	O
topographical	O
properties	O
of	O
the	O
analogues	O
,	O
rendering	O
them	O
more	O
favorable	O
for	O
binding	O
to	O
the	O
receptor	O
in	O
such	O
a	O
manner	O
as	O
to	O
prevent	O
transduction	O
of	O
a	O
biological	O
response	O
.	O

A	O
series	I-MODIFIER
of	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylthio	I-IUPAC
)	I-IUPAC
furoxans	I-IUPAC
were	O
synthesized	O
by	O
oxidation	O
of	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylglyoxymes	I-IUPAC
with	O
dinitrogen	O
tetroxide	O
.	O

Reduction	O
with	O
trimethyl	O
phosphite	O
of	O
the	O
furoxan	O
derivatives	O
afforded	O
the	O
corresponding	O
furazans	O
,	O
while	O
oxidation	O
with	O
an	O
equimolar	O
amount	O
of	O
30%	O
hydrogen	O
peroxide	O
in	O
acetic	O
acid	O
or	O
with	O
an	O
excess	O
of	O
81%	O
hydrogen	O
peroxide	O
in	O
trifluoroacetic	O
acid	O
afforded	O
the	O
corresponding	O
arylsulfinyl	I-IUPAC
and	O
arylsulfonyl	I-IUPAC
analogues	B-MODIFIER
,	O
respectively	O
.	O

All	O
the	O
furoxan	O
and	O
furazan	O
derivatives	O
showed	O
activity	O
as	O
inhibitors	O
of	O
platelet	O
aggregation	O
.	O

4	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylsulfonyl	I-IUPAC
)	I-IUPAC
furoxans	I-IUPAC
were	O
the	O
most	O
potent	O
derivatives	O
of	O
the	O
series	O
.	O

4	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylsulfonyl	I-IUPAC
)	I-IUPAC
furoxan	I-IUPAC
(	O
10a	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
derivatives	O
,	O
inhibits	O
the	O
AA	O
-	O
induced	O
increase	O
of	O
cytosolic	O
free	O
Ca2+	O
and	O
production	O
of	O
malondialdehyde	O
.	O

A	O
primary	O
action	O
of	O
the	O
compound	O
on	O
cyclooxygenase	O
is	O
excluded	O
,	O
as	O
a	O
stable	O
epoxymethano	O
analogue	O
of	O
prostaglandin	O
H2	O
does	O
not	O
reverse	O
the	O
inhibitory	O
effect	O
of	O
10a	O
.	O

This	O
compound	O
produces	O
a	O
significant	O
increase	O
in	O
cGMP	O
which	O
is	O
likely	O
to	O
cause	O
inhibition	O
at	O
an	O
early	O
stage	O
of	O
the	O
platelet	O
activation	O
pathway	O
.	O

A	O
series	O
of	O
aldehydo	O
sugars	O
was	O
subjected	O
to	O
condensation	O
reactions	O
with	O
active	O
methylene	O
compounds	O
.	O

Acetylacetone	O
was	O
condensed	O
with	O
2,4	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
dibenzoyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribose	I-IUPAC
(	O
1	O
)	O
,	O
2,4	I-IUPAC
:	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
dibenzylidene	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribose	I-IUPAC
(	O
6	O
)	O
,	O
2,3,4,5	I-IUPAC
-	I-IUPAC
tetraacetyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribose	I-IUPAC
(	O
7	O
)	O
,	O
and	O
2,3,4,5,6	I-IUPAC
-	I-IUPAC
pentaacetyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
glucose	I-IUPAC
(	O
9	O
)	O
to	O
yield	O
3	I-IUPAC
-	I-IUPAC
ylidene	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pentanedione	I-IUPAC
derivatives	I-MODIFIER
2	O
,	O
11	O
,	O
12	O
,	O
and	O
13	O
,	O
respectively	O
.	O

Sugar	O
derivatives	O
1	O
and	O
6	O
were	O
also	O
condensed	O
with	O
benzoylacetone	O
to	O
give	O
14	O
and	O
18	O
,	O
with	O
acetoacetanilide	O
to	O
give	O
16	O
and	O
19	O
,	O
with	O
malononitrile	O
to	O
give	O
17	O
and	O
20	O
,	O
and	O
with	O
alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
butyrolactonylidene	I-IUPAC
)	I-IUPAC
triphenylphosphorane	I-IUPAC
to	O
give	O
21	O
and	O
22	O
,	O
respectively	O
.	O

Condensation	O
of	O
1	O
with	O
dibenzoylmethane	I-IUPAC
gave	O
15	O
.	O

The	O
double	O
bond	O
in	O
compounds	O
2	O
and	O
11	O
was	O
saturated	O
by	O
hydrogenation	O
to	O
give	O
23	O
and	O
24	O
.	O

All	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
carbonyl	O
compounds	O
obtained	O
exhibited	O
antiviral	O
activity	O
and	O
cytotoxicity	O
.	O

Compound	O
11	O
was	O
found	O
to	O
have	O
the	O
most	O
significant	O
and	O
selective	O
antiviral	O
activity	O
against	O
herpes	O
simplex	O
virus	O
.	O

New	O
boron	O
-	O
containing	O
polyamine	O
have	O
been	O
synthesized	O
:	O
(	I-IUPAC
aminoalkylamine	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
azanonaborane	I-IUPAC
(	O
11	O
)	O
derivatives	I-MODIFIER
[	O
H	O
(	O
2	O
)	O
N	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
n	O
)	O
H	O
(	O
2	O
)	O
NB	O
(	O
8	O
)	O
H	O
(	O
11	O
)	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
n	O
)	O
NH	O
(	O
2	O
)	O
]	O
,	O
where	O
n	O
=	O
4-6	O
and	O
12	O
,	O
and	O
[	O
H	O
(	O
2	O
)	O
N	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
H	O
(	O
2	O
)	O
NB	O
(	O
8	O
)	O
H	O
(	O
11	O
)	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
4	O
)	O
NH	O
(	O
2	O
)	O
]	O
.	O

(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
Aminobutylamine	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobutyl	I-IUPAC
)	I-IUPAC
azanonaborane	I-IUPAC
and	O
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminopropylamine	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobutyl	I-IUPAC
)	I-IUPAC
azanonaborane	I-IUPAC
were	O
less	O
toxic	O
in	O
vitro	O
(	O
LD	O
(	O
50	O
)	O
of	O
approximately	O
700	O
and	O
approximately	O
1100	O
microM	O
,	O
respectively	O
)	O
than	O
spermine	O
,	O
while	O
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobutylamine	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
isopropylazanonaborane	I-IUPAC
with	O
its	O
hydrophobic	O
isopropyl	I-IUPAC
group	B-MODIFIER
and	O
those	O
with	O
n	O
=	O
5	O
,	O
6	O
,	O
and	O
12	O
were	O
already	O
toxic	O
under	O
similar	O
conditions	O
(	O
LD	O
(	O
50	O
)	O
&	O
lt	O
;	O
&	O
lt	O
;	O
500	O
microM	O
)	O
.	O

These	O
compounds	O
may	O
be	O
useful	O
as	O
delivery	O
agents	O
for	O
boron	O
neutron	O
capture	O
therapy	O
.	O

A	O
series	O
of	O
squalestatins	O
modified	O
at	O
the	O
C3	O
-	O
position	O
with	O
a	O
heterocyclic	O
functionality	O
was	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
squalene	O
synthase	O
(	O
SQS	O
)	O
.	O

Structure	O
-	O
activity	O
relationships	O
for	O
compounds	O
with	O
the	O
4,6	I-IUPAC
-	I-IUPAC
dimethyloctenoate	I-IUPAC
at	O
C6	O
(	O
S1	O
analogues	O
)	O
were	O
different	O
from	O
those	O
for	O
analogues	O
lacking	O
the	O
C6	O
ester	O
(	O
H1	O
analogues	O
)	O
,	O
with	O
a	O
greater	O
dependence	O
on	O
the	O
nature	O
of	O
the	O
C3	O
-	O
substituent	O
for	O
the	O
H1	O
series	O
.	O

Potent	O
SQS	O
inhibitory	O
activity	O
equivalent	O
to	O
that	O
of	O
H1	O
is	O
retained	O
by	O
a	O
C3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
analogue	I-MODIFIER
,	O
i.e.	O
,	O
a	O
carboxylic	O
acid	O
mimetic	O
.	O

The	O
C3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
derivative	I-MODIFIER
is	O
10	O
-	O
fold	O
less	O
active	O
than	O
H1	O
,	O
and	O
SQS	O
inhibitory	O
activity	O
similar	O
to	O
that	O
of	O
the	O
methyl	O
ester	O
was	O
retained	O
only	O
in	O
those	O
C3	O
-	O
heterocycle	O
-	O
substituted	O
H1	O
analogues	O
for	O
which	O
electrostatic	O
potential	O
maps	O
of	O
the	O
C3	O
-	O
substituent	O
were	O
closely	O
similar	O
to	O
that	O
of	O
a	O
methyl	O
ester	O
.	O

The	O
present	O
work	O
explored	O
3	I-IUPAC
-	I-IUPAC
alkylamino	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzothiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
diversely	O
substituted	O
in	O
the	O
7	O
-	O
position	O
.	O

Those	O
compounds	O
,	O
structurally	O
related	O
to	O
previously	O
described	O
potassium	O
channel	O
openers	O
such	O
as	O
the	O
benzothiadiazine	O
dioxide	O
BPDZ	O
73	O
,	O
were	O
tested	O
as	O
putative	O
K	O
(	O
ATP	O
)	O
channel	O
activators	O
on	O
the	O
pancreatic	O
endocrine	O
tissue	O
and	O
on	O
the	O
vascular	O
smooth	O
muscle	O
tissue	O
.	O

The	O
nature	O
of	O
the	O
substituent	O
introduced	O
in	O
the	O
7	O
-	O
position	O
as	O
well	O
as	O
the	O
nature	O
of	O
the	O
alkylamino	O
side	O
chain	O
in	O
the	O
3	O
-	O
position	O
strongly	O
affected	O
both	O
potency	O
and	O
tissue	O
selectivity	O
of	O
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzothiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
.	O

Thus	O
,	O
compounds	O
bearing	O
in	O
the	O
7	O
-	O
position	O
a	O
methyl	O
or	O
a	O
methoxy	O
group	O
or	O
devoid	O
of	O
a	O
substituent	O
in	O
this	O
position	O
,	O
and	O
bearing	O
an	O
ethyl	O
,	O
an	O
isopropyl	O
,	O
or	O
a	O
cyclobutylamino	O
group	O
in	O
the	O
3	O
-	O
position	O
were	O
found	O
to	O
be	O
potent	O
and	O
selective	O
inhibitors	O
of	O
insulin	O
release	O
from	O
rat	O
pancreatic	O
B	O
-	O
cells	O
(	O
i.e.	O
10a	O
,	O
10b	O
,	O
12b	O
,	O
12d	O
,	O
22c	O
)	O
.	O

In	O
contrast	O
,	O
3	I-PARTIUPAC
-	I-PARTIUPAC
alkylamino	I-PARTIUPAC
-	I-PARTIUPAC
7	I-PARTIUPAC
-	I-PARTIUPAC
trifluoromethyl	I-PARTIUPAC
-	I-PARTIUPAC
(	O
20a	O
-	O
c	O
)	O
and	O
3	I-IUPAC
-	I-IUPAC
alkylamino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
pentyl	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzothiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
(	O
11a	O
,	O
b	O
)	O
expressed	O
a	O
marked	O
myorelaxant	O
activity	O
on	O
rat	O
aorta	O
ring	O
.	O

Among	O
the	O
latter	O
compounds	O
,	O
the	O
3	I-IUPAC
-	I-IUPAC
alkylamino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
pentyl	I-IUPAC
derivative	I-MODIFIER
(	O
11a	O
)	O
showed	O
a	O
clear	O
selectivity	O
for	O
the	O
vascular	O
smooth	O
muscle	O
tissue	O
.	O

The	O
present	O
work	O
gives	O
new	O
insights	O
into	O
the	O
role	O
of	O
the	O
substituent	O
in	O
both	O
the	O
7	O
-	O
and	O
the	O
3	O
-	O
position	O
for	O
the	O
design	O
of	O
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzothiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
potassium	O
channel	O
openers	O
exhibiting	O
different	O
tissue	O
selectivity	O
profiles	O
.	O

In	O
order	O
to	O
study	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
L	I-IUPAC
-	I-IUPAC
oxathiolanyl	I-IUPAC
nucleosides	I-MODIFIER
as	O
potential	O
anti	O
-	O
HIV	O
agents	O
,	O
a	O
series	O
of	O
enantiomerically	O
pure	O
L	I-IUPAC
-	I-IUPAC
oxathiolanyl	I-IUPAC
pyrimidine	I-IUPAC
and	O
purine	O
nucleosides	O
were	O
synthesized	O
and	O
evaluated	O
for	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
(	O
PBM	O
)	O
cells	O
.	O

The	O
key	O
intermediate	O
8	O
was	O
synthesized	O
starting	O
from	O
L	O
-	O
gulose	O
via	O
1,6	I-IUPAC
-	I-IUPAC
thioanhydro	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
gulopyranose	I-IUPAC
.	O

The	O
acetate	O
8	O
was	O
condensed	O
with	O
thymine	O
,	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
uracils	I-IUPAC
and	O
cytosines	I-IUPAC
,	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
and	O
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluoropurine	I-IUPAC
to	O
give	O
pyrimidine	O
and	O
purine	O
nucleosides	O
.	O

Upon	O
evaluation	O
of	O
these	O
final	O
nucleosides	O
,	O
the	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
derivative	I-MODIFIER
51	O
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
compound	O
among	O
those	O
tested	O
.	O

In	O
the	O
case	O
of	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
cytosine	I-IUPAC
analogues	B-MODIFIER
,	O
the	O
antiviral	O
potency	O
was	O
found	O
to	O
be	O
in	O
the	O
following	O
decreasing	O
order	O
:	O
cytosine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
iodocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
methylcytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
methylcytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
bromocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
chlorocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
.	O

Among	O
the	O
thymine	O
,	O
uracil	O
,	O
and	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
uracil	I-IUPAC
derivatives	B-MODIFIER
,	O
thymine	O
(	O
alpha	O
-	O
isomer	O
)	O
and	O
uracil	O
(	O
beta	O
-	O
isomer	O
)	O
derivatives	O
exhibited	O
moderate	O
anti	O
-	O
HIV	O
activity	O
.	O

In	O
the	O
purine	O
series	O
,	O
the	O
antiviral	O
potency	O
is	O
found	O
to	O
be	O
in	O
the	O
following	O
decreasing	O
order	O
:	O
adenine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2	O
-	O
NH2	O
-	O
6	O
-	O
Cl	O
-	O
purine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
guanine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
N6	I-IUPAC
-	I-IUPAC
methyladenine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
N6	I-IUPAC
-	I-IUPAC
methyladenine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
.	O

The	O
cytotoxicity	O
was	O
also	O
determined	O
in	O
human	O
PBM	O
cells	O
as	O
well	O
as	O
Vero	O
cells	O
.	O

None	O
of	O
the	O
synthesized	O
nucleosides	O
was	O
toxic	O
up	O
to	O
100	O
microM	O
in	O
PBM	O
cells	O
.	O

The	O
3	I-IUPAC
-	I-IUPAC
isoxazolol	I-IUPAC
amino	I-IUPAC
acid	I-IUPAC
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
,	O
2	O
)	O
and	O
the	O
isomeric	O
compound	O
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
4	I-IUPAC
-	I-IUPAC
methylhomoibotenic	I-IUPAC
acid	I-IUPAC
,	O
4a	O
)	O
are	O
potent	O
agonists	O
at	O
the	O
AMPA	O
subtype	O
of	O
central	O
excitatory	O
amino	O
acid	O
receptors	O
.	O

Using	O
4a	O
as	O
a	O
lead	O
structure	O
,	O
the	O
amino	O
acids	O
4c	O
-	O
e	O
,	O
in	O
which	O
the	O
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
of	O
4a	O
is	O
replaced	O
by	O
substituents	O
of	O
different	O
size	O
and	O
polarity	O
,	O
were	O
synthesized	O
.	O

Attempts	O
to	O
synthesize	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
homoibotenic	I-IUPAC
acid	I-IUPAC
(	O
4f	O
)	O
,	O
a	O
potential	O
receptor	O
alkylating	O
agent	O
,	O
were	O
unsuccessful	O
.	O

4	I-IUPAC
-	I-IUPAC
Butylhomoibotenic	I-IUPAC
acid	I-IUPAC
(	O
4c	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
homoibotenic	I-IUPAC
acid	I-IUPAC
(	O
4e	O
)	O
were	O
equipotent	O
as	O
inhibitors	O
of	O
[	O
3H	O
]	O
AMPA	O
binding	O
(	O
IC50	O
=	O
2	O
microM	O
)	O
and	O
showed	O
similar	O
excitatory	O
activity	O
in	O
the	O
rat	O
cortical	O
slice	O
preparation	O
.	O

4d	O
did	O
not	O
show	O
significant	O
affinity	O
for	O
AMPA	O
receptor	O
sites	O
,	O
but	O
turned	O
out	O
to	O
be	O
a	O
weak	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
(	O
NMDA	O
)	O
receptor	O
antagonist	O
.	O

However	O
,	O
like	O
4c	O
,	O
e	O
,	O
4d	O
did	O
not	O
significantly	O
affect	O
the	O
binding	O
of	O
the	O
competitive	O
NMDA	O
antagonist	O
,	O
[	O
3H	O
]	O
CPP	O
,	O
or	O
the	O
noncompetitive	O
NMDA	O
antagonist	O
,	O
[	O
3H	O
]	O
MK	O
-	O
801	O
.	O

None	O
of	O
the	O
amino	O
acids	O
4c	O
-	O
e	O
showed	O
detectable	O
affinity	O
for	O
[	O
3H	O
]	O
kainic	O
acid	O
binding	O
sites	O
.	O

Like	O
the	O
parent	O
compound	O
4a	O
(	O
IC50	O
=	O
0.18	O
microM	O
)	O
,	O
4c	O
(	O
IC50	O
=	O
0.18	O
microM	O
)	O
,	O
4e	O
(	O
IC50	O
=	O
0.14	O
microM	O
)	O
,	O
and	O
in	O
particular	O
4d	O
(	O
IC50	O
=	O
0.02	O
microM	O
)	O
were	O
effective	O
inhibitors	O
of	O
calcium	O
chloride	O
-	O
dependent	O
[	O
3H	O
]	O
glutamic	O
acid	O
binding	O
,	O
whereas	O
AMPA	O
is	O
inactive	O
(	O
IC50	O
greater	O
than	O
100	O
microM	O
)	O
in	O
this	O
binding	O
assay	O
.	O

Thus	O
,	O
4d	O
is	O
an	O
effective	O
and	O
highly	O
selective	O
inhibitor	O
of	O
calcium	O
chloride	O
-	O
dependent	O
[	O
3H	O
]	O
glutamic	O
acid	O
binding	O
and	O
may	O
be	O
a	O
useful	O
tool	O
for	O
studies	O
of	O
the	O
physiological	O
relevance	O
and	O
pharmacological	O
importance	O
of	O
this	O
binding	O
affinity	O
.	O

New	O
water	O
-	O
soluble	O
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylazopyridine	I-IUPAC
)	I-IUPAC
ruthenium	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
,	O
all	O
derivatives	O
of	O
the	O
highly	O
cytotoxic	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
Cl	O
(	O
2	O
)	O
]	O
(	O
alpha	O
denoting	O
the	O
coordinating	O
pairs	O
Cl	O
,	O
N	O
(	O
py	O
)	O
,	O
and	O
N	O
(	O
azo	O
)	O
as	O
cis	O
,	O
trans	O
,	O
cis	O
,	O
respectively	O
)	O
have	O
been	O
developed	O
.	O

The	O
compounds	O
1,1	I-IUPAC
-	I-IUPAC
cyclobutanedicarboxylatobis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylazopyridine	I-IUPAC
)	I-IUPAC
ruthenium	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
,	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
cbdca	O
-	O
O	O
,	O
O'	O
)	O
]	O
(	O
1	O
)	O
,	O
oxalatobis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylazopyridine	I-IUPAC
)	I-IUPAC
ruthenium	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
,	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
ox	O
)	O
]	O
(	O
2	O
)	O
,	O
and	O
malonatobis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylazopyridine	I-IUPAC
)	I-IUPAC
ruthenium	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
,	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
mal	O
)	O
]	O
(	O
3	O
)	O
,	O
have	O
been	O
synthesized	O
and	O
fully	O
characterized	O
.	O

X	O
-	O
ray	O
analyses	O
of	O
1	O
and	O
2	O
are	O
reported	O
,	O
and	O
compound	O
1	O
is	O
the	O
first	O
example	O
in	O
which	O
the	O
cbdca	O
ligand	O
is	O
coordinated	O
to	O
a	O
ruthenium	O
center	O
.	O

The	O
cytotoxicity	O
of	O
this	O
series	O
of	O
water	O
-	O
soluble	O
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylazopyridine	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
has	O
been	O
determined	O
in	O
A2780	O
human	O
ovarian	O
carcinoma	O
and	O
A2780cisR	O
,	O
the	O
corresponding	O
cisplatin	O
-	O
resistant	O
cell	O
line	O
.	O

For	O
comparison	O
reasons	O
,	O
the	O
cytotoxicity	O
of	O
the	O
complexes	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
Cl	O
(	O
2	O
)	O
]	O
,	O
alpha	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
NO	O
(	O
3	O
)	O
)	O
(	O
2	O
)	O
]	O
,	O
beta	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
Cl	O
(	O
2	O
)	O
]	O
(	O
beta	O
indicating	O
the	O
coordinating	O
pairs	O
Cl	O
,	O
N	O
(	O
py	O
)	O
,	O
and	O
N	O
(	O
azo	O
)	O
as	O
cis	O
,	O
cis	O
,	O
cis	O
,	O
respectively	O
)	O
,	O
and	O
beta	O
-	O
[	O
Ru	O
(	O
azpy	O
)	O
(	O
2	O
)	O
(	O
NO	O
(	O
3	O
)	O
)	O
(	O
2	O
)	O
]	O
have	O
been	O
determined	O
in	O
this	O
cell	O
line	O
.	O

All	O
the	O
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylazopyridine	I-IUPAC
)	I-IUPAC
ruthenium	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
compounds	I-MODIFIER
display	O
a	O
promising	O
cytotoxicity	O
in	O
the	O
A2780	O
cell	O
line	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.9-10	O
microM	O
)	O
,	O
with	O
an	O
activity	O
comparable	O
to	O
that	O
of	O
cisplatin	O
and	O
even	O
higher	O
than	O
the	O
activity	O
of	O
carboplatin	O
.	O

Interestingly	O
,	O
the	O
IC	O
(	O
50	O
)	O
values	O
of	O
this	O
series	O
of	O
ruthenium	O
compounds	O
(	O
except	O
the	O
beta	O
isomeric	O
compounds	O
)	O
are	O
similar	O
in	O
the	O
cisplatin	O
-	O
resistant	O
A2780cisR	O
cell	O
line	O
compared	O
to	O
the	O
normal	O
cell	O
line	O
A2780	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
these	O
compounds	O
might	O
not	O
be	O
influenced	O
by	O
the	O
multifactorial	O
resistance	O
mechanism	O
that	O
affect	O
platinum	O
anticancer	O
agents	O
.	O

Water	O
-	O
soluble	O
prodrugs	O
of	O
potent	O
,	O
A	O
(	O
2A	O
)	O
-	O
selective	O
adenosine	O
receptor	O
(	O
AR	O
)	O
antagonists	O
were	O
prepared	O
.	O

8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
Bromostyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propargylxanthine	I-IUPAC
(	O
BS	O
-	O
DMPX	O
,	O
11	O
)	O
and	O
the	O
analogous	I-MODIFIER
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
methoxystyryl	I-IUPAC
)	I-IUPAC
xanthine	I-IUPAC
derivative	I-MODIFIER
(	O
MS	O
-	O
DMPX	O
,	O
5b	O
)	O
were	O
used	O
as	O
starting	O
points	O
.	O

It	O
was	O
found	O
that	O
polar	O
functional	O
groups	O
suitable	O
for	O
the	O
attachment	O
of	O
a	O
prodrug	O
moiety	O
were	O
tolerated	O
on	O
the	O
styryl	O
ring	O
and	O
even	O
better	O
on	O
the	O
3	O
-	O
substituent	O
.	O

8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
Hydroxystyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
DMPX	I-IUPAC
(	O
7	O
)	O
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
methoxystyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propargylxanthine	I-IUPAC
(	O
5e	O
,	O
MSX	O
-	O
2	O
)	O
were	O
the	O
most	O
potent	O
and	O
A	O
(	O
2A	O
)	O
-	O
selective	O
compounds	O
and	O
were	O
selected	O
for	O
prodrug	O
formation	O
.	O

For	O
the	O
preparation	O
of	O
5e	O
a	O
new	O
ring	O
-	O
closure	O
method	O
was	O
applied	O
.	O

Treatment	O
of	O
6	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
methoxycinnamoylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
propa	I-IUPAC
rgylur	I-IUPAC
acil	I-IUPAC
with	O
hexamethyldisilazane	O
at	O
high	O
temperature	O
resulted	O
in	O
higher	O
yields	O
of	O
the	O
target	O
xanthine	O
than	O
the	O
standard	O
ring	O
-	O
closure	O
procedure	O
using	O
sodium	O
hydroxide	O
.	O

Phosphate	O
prodrugs	O
were	O
prepared	O
by	O
classical	O
phosphorylation	O
using	O
phosphorus	O
oxychloride	O
and	O
alternatively	O
by	O
using	O
a	O
phosphoramidite	O
method	O
.	O

Phosphates	O
of	O
the	O
aliphatic	O
alcohol	O
5e	O
could	O
be	O
obtained	O
by	O
both	O
methods	O
in	O
similar	O
yields	O
.	O

The	O
phenolic	O
compound	O
7	O
,	O
however	O
,	O
could	O
be	O
phosphorylated	O
only	O
by	O
using	O
the	O
phosphoramidite	O
method	O
.	O

The	O
disodium	O
salts	O
of	O
the	O
phosphate	O
prodrugs	O
exhibited	O
high	O
water	O
solubility	O
(	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
methoxystyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
phosphatylpropyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propargylxan	I-IUPAC
thine	I-IUPAC
disodium	I-IUPAC
salt	I-IUPAC
,	O
9b	O
:	O
17	O
mM	O
,	O
9	O
mg	O
/	O
mL	O
)	O
.	O

Prodrug	O
9b	O
was	O
found	O
to	O
be	O
stable	O
in	O
aqueous	O
solution	O
(	O
pH	O
7	O
)	O
but	O
readily	O
cleaved	O
by	O
phosphatases	O
to	O
liberate	O
5e	O
(	O
MSX	O
-	O
2	O
)	O
.	O

Compound	O
5e	O
showed	O
high	O
affinity	O
for	O
rat	O
A	O
(	O
2A	O
)	O
AR	O
(	O
K	O
(	O
i	O
)	O
=	O
8	O
nM	O
)	O
,	O
human	O
recombinant	O
A	O
(	O
2A	O
)	O
AR	O
(	O
K	O
(	O
i	O
)	O
=	O
5	O
nM	O
)	O
,	O
and	O
human	O
native	O
A	O
(	O
2A	O
)	O
AR	O
(	O
K	O
(	O
i	O
)	O
=	O
15	O
nM	O
)	O
and	O
was	O
highly	O
selective	O
versus	O
rat	O
A	O
(	O
1	O
)	O
AR	O
(	O
110	O
-	O
fold	O
)	O
,	O
human	O
recombinant	O
A	O
(	O
2A	O
)	O
AR	O
(	O
500	O
-	O
fold	O
)	O
,	O
human	O
A	O
(	O
2B	O
)	O
AR	O
(	O
&	O
gt	O
;	O
2000	O
-	O
fold	O
)	O
,	O
and	O
human	O
A	O
(	O
3	O
)	O
AR	O
(	O
&	O
gt	O
;	O
2000	O
-	O
fold	O
)	O
.	O

The	O
adenosine	O
antagonist	O
9	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinazolin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
CGS15943	O
)	O
binds	O
to	O
human	O
A3	O
receptors	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
14	O
nM	O
)	O
,	O
while	O
it	O
lacks	O
affinity	O
at	O
rat	O
A3	O
receptors	O
.	O

Acylated	O
derivatives	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
and	O
other	O
modifications	O
were	O
prepared	O
in	O
an	O
effort	O
to	O
provide	O
A3	O
subtype	O
selectivity	O
.	O

Affinity	O
was	O
determined	O
in	O
radioligand	O
binding	O
assays	O
at	O
rat	O
brain	O
A1	O
and	O
A2A	O
receptors	O
using	O
[	O
3H	O
]	O
-	O
(	O
R	O
)	O
-	O
PIA	O
(	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylisopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
adenosine	I-IUPAC
)	O
and	O
[	O
3H	O
]	O
CGS	O
21680	O
(	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
ethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
ethylaminol	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
carbamoyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
)	O
,	O
respectively	O
.	O

Affinity	O
was	O
determined	O
at	O
cloned	O
human	O
A3	O
receptors	O
using	O
[	O
125I	O
]	O
AB	O
-	O
MECA	O
(	O
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylcarbamoyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
)	O
.	O

A	O
series	O
of	O
straight	O
chain	O
alkyl	O
amides	O
demonstrated	O
that	O
the	O
optimal	O
chain	O
length	O
occurs	O
with	O
the	O
5	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propionyl	I-IUPAC
derivative	I-MODIFIER
,	O
3	O
,	O
which	O
had	O
a	O
Ki	O
value	O
of	O
7.7	O
nM	O
at	O
human	O
A3	O
receptors	O
,	O
and	O
was	O
40	O
-	O
and	O
14	O
-	O
fold	O
selective	O
vs	O
rat	O
A1	O
and	O
A2A	O
receptors	O
,	O
respectively	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
derivative	I-MODIFIER
,	O
10	O
,	O
displayed	O
Ki	O
values	O
of	O
680	O
and	O
273	O
nM	O
at	O
rat	O
A1	O
and	O
A2A	O
receptors	O
,	O
respectively	O
,	O
and	O
3.0	O
nM	O
at	O
human	O
A3	O
receptors	O
.	O

A	O
5	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
phenylacetyl	I-IUPAC
derivative	I-MODIFIER
,	O
12	O
,	O
was	O
470	O
-	O
fold	O
selective	O
for	O
human	O
A3	O
vs	O
rat	O
A1	O
receptors	O
with	O
a	O
Ki	O
value	O
of	O
0.65	O
nM	O
.	O

A	O
conjugate	O
of	O
Boc	O
-	O
gamma	O
-	O
aminobutyric	O
acid	O
was	O
also	O
prepared	O
but	O
was	O
nonselective	O
.	O

Conversion	O
of	O
the	O
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
of	O
CGS15943	O
to	O
an	O
oxo	O
function	O
resulted	O
in	O
lower	O
affinity	O
but	O
15	O
-	O
fold	O
selectivity	O
for	O
human	O
A3	O
receptors	O
.	O

Treatment	O
of	O
the	O
5'	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
derived	O
by	O
Moffatt	O
oxidation	O
of	O
6	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
isopropylideneadenosine	I-IUPAC
(	O
1	O
)	O
with	O
the	O
"	O
(	I-IUPAC
bromofluoromethylene	I-IUPAC
)	I-IUPAC
triphenylphosphorane	I-IUPAC
"	O
reagent	O
and	O
deprotection	O
gave	O
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
ribo	I-IUPAC
-	I-IUPAC
hex	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
enofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
4	O
)	O
.	O

Parallel	O
treatment	O
with	O
a	O
"	O
dibromomethylene	O
Wittig	O
reagent	O
"	O
and	O
deprotection	O
gave	O
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
6,6	I-IUPAC
-	I-IUPAC
dibromo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
ribo	I-IUPAC
-	I-IUPAC
hex	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
enofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
7	O
)	O
,	O
which	O
also	O
was	O
prepared	O
by	O
successive	O
bromination	O
and	O
dehydrobromination	O
of	O
the	O
6'	I-IUPAC
-	I-IUPAC
bromohomovinyl	I-IUPAC
nucleoside	I-IUPAC
8	O
.	O

Bromination	O
-	O
dehydrobromination	O
of	O
the	O
5'	I-IUPAC
-	I-IUPAC
bromohomovinyl	I-IUPAC
analogue	I-MODIFIER
11	O
and	O
deprotection	O
gave	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dibromo	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
ribo	I-IUPAC
-	I-IUPAC
hex	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
enofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
15	O
)	O
.	O

Compounds	O
4	O
,	O
7	O
,	O
and	O
15	O
were	O
designed	O
as	O
putative	O
substrates	O
of	O
the	O
"	O
hydrolytic	O
activity	O
"	O
of	O
S	I-IUPAC
-	I-IUPAC
adenosyl	I-IUPAC
-	I-IUPAC
l	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
(	O
AdoHcy	O
)	O
hydrolase	O
.	O

Enzyme	O
-	O
mediated	O
addition	O
of	O
water	O
across	O
the	O
5,6	O
-	O
double	O
bond	O
could	O
generate	O
electrophilic	O
acyl	O
halide	O
or	O
alpha	I-IUPAC
-	I-IUPAC
halo	I-IUPAC
ketone	I-IUPAC
species	O
that	O
could	O
undergo	O
nucleophilic	O
attack	O
by	O
proximal	O
groups	O
on	O
the	O
enzyme	O
.	O

Such	O
type	O
II	O
(	O
covalent	O
)	O
mechanism	O
-	O
based	O
inactivation	O
is	O
supported	O
by	O
protein	O
labeling	O
with	O
8	O
-	O
[	O
3H	O
]	O
-	O
4	O
and	O
concomitant	O
release	O
of	O
bromide	O
and	O
fluoride	O
ions	O
.	O

Incubation	O
of	O
AdoHcy	O
hydrolase	O
with	O
7	O
or	O
15	O
resulted	O
in	O
irreversible	O
inactivation	O
and	O
release	O
of	O
bromide	O
ion	O
.	O

In	O
contrast	O
with	O
type	O
I	O
mechanism	O
-	O
based	O
inactivation	O
,	O
reduction	O
of	O
enzyme	O
-	O
bound	O
NAD+	O
to	O
NADH	O
was	O
not	O
observed	O
.	O

Compounds	O
4	O
,	O
7	O
,	O
and	O
15	O
were	O
not	O
inhibitory	O
to	O
a	O
variety	O
of	O
viruses	O
in	O
cell	O
culture	O
,	O
and	O
weak	O
cytotoxicity	O
was	O
observed	O
only	O
for	O
CEM	O
cells	O
.	O

New	O
1	I-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylurea	I-IUPAC
derivatives	I-MODIFIER
and	O
their	O
1	I-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylthiourea	I-IUPAC
isosteres	I-MODIFIER
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
human	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptor	O
affinity	O
.	O

These	O
compounds	O
proved	O
to	O
be	O
selective	O
CB1	O
cannabinoid	O
receptor	O
ligands	O
,	O
acting	O
as	O
inverse	O
agonists	O
in	O
a	O
[	O
35S	O
]	O
-	O
GTPgammaS	O
assay	O
.	O

The	O
affinity	O
of	O
3,5,5	I-IUPAC
'	I-IUPAC
-	I-IUPAC
triphenylimidazolidine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
and	O
3,5,5	I-IUPAC
'	I-IUPAC
-	I-IUPAC
triphenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thioxoimidazolidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
derivatives	I-MODIFIER
,	O
possessing	O
the	O
1	I-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylurea	I-IUPAC
and	O
1	I-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylthiourea	I-IUPAC
moiety	I-MODIFIER
,	O
respectively	O
,	O
was	O
also	O
evaluated	O
.	O

In	O
conclusion	O
,	O
the	O
1	I-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylurea	I-IUPAC
scaffold	I-MODIFIER
seems	O
to	O
be	O
a	O
new	O
interesting	O
template	O
of	O
CB1	O
cannabinoid	O
receptor	O
inverse	O
agonists	O
.	O

2	O
-	O
(	O
4	O
-	O
Chloro	O
-	O
3	O
-	O
hydroxyphenyl	O
)	O
ethylamine	O
(	O
4	O
)	O
and	O
some	O
derivatives	O
were	O
synthesized	O
as	O
dopamine	O
(	O
DA	O
)	O
receptor	O
ligands	O
.	O

Amine	O
4	O
retains	O
the	O
dopaminergic	O
pharmacophore	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethylamine	I-IUPAC
,	O
and	O
the	O
chlorine	O
atom	O
replaces	O
the	O
"	O
para	O
"	O
hydroxyl	I-IUPAC
group	B-MODIFIER
of	O
DA	O
.	O

The	O
derivatives	O
18a	O
-	O
e	O
were	O
obtained	O
by	O
introducing	O
on	O
the	O
nitrogen	O
of	O
amine	O
4	O
the	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
or	O
3	I-IUPAC
-	I-IUPAC
phenylpropyl	I-IUPAC
groups	I-MODIFIER
which	O
can	O
be	O
accommodated	O
by	O
the	O
D	O
-	O
2	O
receptor	O
lipophilic	O
sites	O
3C	O
and	O
pi	O
3	O
,	O
respectively	O
.	O

The	O
affinity	O
and	O
selectivity	O
of	O
these	O
compounds	O
for	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
subtypes	O
was	O
determined	O
in	O
radioligand	O
competition	O
assays	O
for	O
the	O
DA	O
receptors	O
of	O
rat	O
striatum	O
membranes	O
using	O
[	O
3H	O
]	O
SCH	O
23390	O
(	O
D	O
-	O
1	O
selective	O
)	O
and	O
[	O
3H	O
]	O
spiperone	O
(	O
D	O
-	O
2	O
selective	O
)	O
as	O
radioligands	O
.	O

The	O
amine	O
4	O
shows	O
about	O
7	O
-	O
fold	O
lower	O
affinity	O
than	O
DA	O
for	O
both	O
sites	O
and	O
is	O
not	O
able	O
to	O
discriminate	O
between	O
the	O
two	O
subtypes	O
of	O
DA	O
receptors	O
.	O

The	O
introduction	O
of	O
two	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
groups	I-MODIFIER
(	O
18a	O
)	O
on	O
the	O
nitrogen	O
atom	O
reduces	O
by	O
one	O
-	O
half	O
and	O
doubles	O
the	O
affinity	O
for	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
binding	O
sites	O
,	O
respectively	O
.	O

The	O
substitution	O
of	O
an	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	I-MODIFIER
with	O
different	O
alkylphenyl	O
groups	O
,	O
to	O
give	O
compounds	O
18b	O
-	O
e	O
,	O
increases	O
the	O
affinity	O
for	O
the	O
D	O
-	O
2	O
subtype	O
from	O
19	O
-	O
fold	O
to	O
36	O
-	O
fold	O
.	O

These	O
compounds	O
have	O
the	O
same	O
affinity	O
at	O
the	O
D	O
-	O
2	O
site	O
as	O
the	O
DA	O
agonist	O
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethylamine	I-IUPAC
(	O
2a	O
)	O
and	O
are	O
about	O
20	O
times	O
more	O
selective	O
than	O
DA	O
for	O
this	O
binding	O
site	O
.	O

In	O
the	O
assay	O
for	O
D	O
-	O
2	O
receptor	O
mediated	O
inhibition	O
of	O
adenylate	O
cyclase	O
activity	O
,	O
all	O
the	O
tested	O
compounds	O
behaved	O
as	O
D	O
-	O
2	O
agonists	O
;	O
N	I-PARTIUPAC
-	I-PARTIUPAC
n	I-PARTIUPAC
-	I-PARTIUPAC
propyl	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
2	I-PARTIUPAC
(	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
ethyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
(	O
18d	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
ethylamine	I-IUPAC
(	O
18b	O
)	O
were	O
more	O
effective	O
than	O
DA	O
or	O
2a	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
compounds	O
were	O
less	O
effective	O
than	O
DA	O
in	O
stimulation	O
of	O
adenylate	O
cyclase	O
activity	O
in	O
rat	O
striatal	O
homogenates	O
,	O
a	O
kind	O
of	O
effect	O
which	O
is	O
mediated	O
by	O
the	O
D	O
-	O
1	O
subtype	O
of	O
DA	O
receptors	O
.	O

These	O
results	O
suggest	O
that	O
the	O
nitrogen	O
substitution	O
enhances	O
the	O
affinity	O
and	O
selectivity	O
for	O
the	O
D	O
-	O
2	O
receptor	O
.	O

In	O
the	O
adenylate	O
cyclase	O
assay	O
,	O
the	O
compounds	O
behave	O
as	O
potent	O
D	O
-	O
2	O
agonists	O
.	O

The	O
nuclear	O
enzyme	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
facilitates	O
the	O
repair	O
of	O
DNA	O
strand	O
breaks	O
and	O
is	O
implicated	O
in	O
the	O
resistance	O
of	O
cancer	O
cells	O
to	O
certain	O
DNA	O
-	O
damaging	O
agents	O
.	O

Inhibitors	O
of	O
PARP	O
have	O
clinical	O
potential	O
as	O
resistance	O
-	O
modifying	O
agents	O
capable	O
of	O
potentiating	O
radiotherapy	O
and	O
the	O
cytotoxicity	O
of	O
some	O
forms	O
of	O
cancer	O
chemotherapy	O
.	O

The	O
preclinical	O
development	O
of	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
as	O
resistance	O
-	O
modifying	O
agents	O
in	O
cancer	O
chemotherapy	O
is	O
described	O
.	O

1H	I-IUPAC
-	I-IUPAC
Benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
,	O
particularly	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
derivatives	I-MODIFIER
,	O
are	O
identified	O
as	O
a	O
class	O
of	O
potent	O
PARP	O
inhibitors	O
.	O

Derivatives	O
of	O
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
23	O
,	O
K	O
(	O
i	O
)	O
=	O
15	O
nM	O
)	O
,	O
in	O
which	O
the	O
phenyl	O
ring	O
contains	O
substituents	O
,	O
have	O
been	O
synthesized	O
.	O

Many	O
of	O
these	O
derivatives	O
exhibit	O
K	O
(	O
i	O
)	O
values	O
for	O
PARP	O
inhibition	O
&	O
lt	O
;	O
10	O
nM	O
,	O
with	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxymethylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
78	O
,	O
K	O
(	O
i	O
)	O
=	O
1.6	O
nM	O
)	O
being	O
one	O
of	O
the	O
most	O
potent	O
.	O

Insight	O
into	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
for	O
2	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
has	O
been	O
enhanced	O
by	O
studying	O
the	O
complex	O
formed	O
between	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
44	O
,	O
K	O
(	O
i	O
)	O
=	O
6	O
nM	O
)	O
and	O
the	O
catalytic	O
domain	O
of	O
chicken	O
PARP	O
.	O

Important	O
hydrogen	O
-	O
bonding	O
and	O
hydrophobic	O
interactions	O
with	O
the	O
protein	O
have	O
been	O
identified	O
for	O
this	O
inhibitor	O
.	O

2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
Hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
45	O
,	O
K	O
(	O
i	O
)	O
=	O
6	O
nM	O
)	O
potentiates	O
the	O
cytotoxicity	O
of	O
both	O
temozolomide	O
and	O
topotecan	O
against	O
A2780	O
cells	O
in	O
vitro	O
(	O
by	O
2.8	O
-	O
and	O
2.9	O
-	O
fold	O
,	O
respectively	O
)	O
.	O

The	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
new	O
histamine	O
H3	O
receptor	O
antagonists	O
with	O
an	O
iodinated	O
aryl	O
partial	O
structure	O
are	O
described	O
as	O
part	O
of	O
an	O
extensive	O
research	O
program	O
to	O
find	O
model	O
compounds	O
for	O
the	O
development	O
of	O
a	O
new	O
radioligand	O
with	O
high	O
H3	O
receptor	O
affinity	O
and	O
specific	O
activity	O
.	O

All	O
compounds	O
were	O
tested	O
for	O
their	O
H3	O
receptor	O
antagonist	O
activity	O
in	O
a	O
[	O
3H	O
]	O
-	O
histamine	O
-	O
release	O
assay	O
with	O
synaptosomes	O
from	O
rat	O
cerebral	O
cortex	O
.	O

The	O
new	O
leads	O
with	O
potent	O
H3	O
receptor	O
antagonist	O
activity	O
belong	O
to	O
a	O
series	O
of	O
derivatives	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propanol	I-IUPAC
with	O
carbamate	O
(	O
4-7	O
)	O
,	O
ester	O
(	O
8-16	O
)	O
,	O
and	O
ether	O
(	O
17-22	O
)	O
as	O
functional	O
groups	O
.	O

Structure	O
-	O
activity	O
relationships	O
are	O
discussed	O
.	O

The	O
most	O
active	O
compound	O
in	O
the	O
functional	O
test	O
(	O
-	O
log	O
Ki	O
=	O
8.3	O
)	O
and	O
in	O
binding	O
studies	O
with	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methylhistamine	I-IUPAC
on	O
rat	O
cerebral	O
cortex	O
(	O
-	O
log	O
Ki	O
=	O
9.0	O
)	O
in	O
vitro	O
was	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
imidazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
ether	I-IUPAC
(	O
iodoproxyfan	O
,	O
19	O
)	O
exhibiting	O
no	O
central	O
H3	O
receptor	O
antagonist	O
activity	O
in	O
vivo	O
.	O

The	O
potency	O
of	O
iodoproxyfan	O
is	O
more	O
than	O
300	O
times	O
lower	O
at	O
H1	O
,	O
H2	O
,	O
alpha1	O
,	O
alpha2	O
,	O
beta1	O
,	O
5	O
-	O
HT2A	O
,	O
5	O
-	O
HT3	O
,	O
and	O
M3	O
receptors	O
than	O
at	O
histamine	O
H3	O
receptors	O
.	O

Because	O
of	O
the	O
high	O
potency	O
and	O
selectivity	O
of	O
19	O
,	O
this	O
compound	O
has	O
also	O
been	O
prepared	O
in	O
the	O
[	O
125I	O
]	O
-	O
iodinated	O
form	O
by	O
a	O
nucleophilic	O
halogen	O
exchange	O
reaction	O
using	O
the	O
corresponding	O
bromo	O
derivative	O
22	O
as	O
a	O
precursor	O
.	O

The	O
newly	O
prepared	O
[	O
125I	O
]	O
iodoproxyfan	O
(	O
23	O
)	O
possesses	O
advantageous	O
pharmacological	O
properties	O
and	O
fulfills	O
all	O
criteria	O
of	O
a	O
useful	O
radioligand	O
.	O

Thrombin	O
is	O
a	O
serine	O
protease	O
responsible	O
for	O
blood	O
coagulation	O
.	O

Since	O
thrombin	O
inhibitors	O
appear	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
thrombotic	O
and	O
embolic	O
disorders	O
,	O
considerable	O
attention	O
has	O
been	O
focused	O
on	O
the	O
structure	O
and	O
interactions	O
of	O
this	O
enzyme	O
.	O

In	O
this	O
work	O
,	O
to	O
evaluate	O
the	O
relative	O
free	O
energies	O
of	O
hydration	O
and	O
binding	O
to	O
thrombin	O
for	O
some	O
benzamidine	O
derivatives	O
,	O
we	O
used	O
the	O
finite	O
difference	O
thermodynamic	O
integration	O
(	O
FDTI	O
)	O
algorithm	O
within	O
the	O
Discover	O
program	O
of	O
MSI	O
.	O

By	O
this	O
method	O
,	O
two	O
possible	O
orders	O
of	O
hydration	O
for	O
the	O
candidates	O
were	O
obtained	O
:	O
p	I-IUPAC
-	I-IUPAC
amidinophenylpyruvate	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
benzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
methylbenzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
ethylbenzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
benzamidine	I-IUPAC
&	O
gt	O
;	O
benzamidine	I-IUPAC
and	O
p	I-IUPAC
-	I-IUPAC
amidinophenylpyruvate	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
benzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
methylbenzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
ethylbenzamidine	I-IUPAC
&	O
gt	O
;	O
benzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
benzamidine	I-IUPAC
.	O

We	O
also	O
obtained	O
the	O
following	O
order	O
for	O
thrombin	O
binding	O
:	O
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
benzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
ethylbenzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
benzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
methylbenzamidine	I-IUPAC
&	O
gt	O
;	O
benzamidine	I-IUPAC
&	O
gt	O
;	O
p	I-IUPAC
-	I-IUPAC
amidinophenylpyruvate	I-IUPAC
.	O

In	O
this	O
paper	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
a	O
series	O
of	O
novel	O
substituted	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
methylenedioxyphthalazin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O

The	O
anticonvulsant	O
activity	O
of	O
these	O
compounds	O
against	O
audiogenic	O
seizures	O
was	O
evaluated	O
in	O
DBA	O
/	O
2	O
mice	O
after	O
intraperitoneal	O
(	O
ip	O
)	O
injection	O
.	O

Most	O
of	O
these	O
derivatives	O
are	O
more	O
active	O
than	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
methylenedioxy	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
benzodiazepine	I-IUPAC
(	O
1	O
,	O
GYKI	O
52466	O
)	O
,	O
a	O
well	O
-	O
known	O
noncompetitive	O
AMPA	O
receptor	O
antagonist	O
.	O

As	O
deduced	O
by	O
the	O
rotarod	O
test	O
,	O
all	O
the	O
compounds	O
exhibit	O
a	O
toxicity	O
lower	O
than	O
that	O
of	O
1	O
.	O

Within	O
the	O
series	O
of	O
derivatives	O
submitted	O
to	O
investigation	O
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butylcarbamoyl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
methylenedioxyphthalazin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
21	O
)	O
proved	O
to	O
be	O
the	O
most	O
active	O
compound	O
and	O
is	O
11	O
-	O
fold	O
more	O
potent	O
than	O
1	O
(	O
i.e.	O
,	O
ED50	O
3.25	O
micromol	O
/	O
kg	O
for	O
21	O
versus	O
ED50	O
35.8	O
micromol	O
/	O
kg	O
for	O
1	O
)	O
.	O

When	O
compared	O
to	O
1	O
,	O
compound	O
21	O
as	O
well	O
as	O
its	O
analogue	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
methylenedioxyphthalazin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
16	O
)	O
show	O
a	O
longer	O
lasting	O
anticonvulsant	O
activity	O
.	O

Compound	O
21	O
also	O
effectively	O
suppresses	O
seizures	O
induced	O
in	O
Swiss	O
mice	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
and	O
pentylenetetrazole	O
(	O
PTZ	O
)	O
.	O

Furthermore	O
,	O
it	O
antagonizes	O
in	O
vivo	O
seizures	O
induced	O
by	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
isoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
ATPA	O
)	O
,	O
and	O
kainate	O
(	O
KA	O
)	O
,	O
and	O
its	O
anticonvulsant	O
activity	O
is	O
reversed	O
by	O
pretreatment	O
with	O
aniracetam	O
.	O

Using	O
the	O
patch	O
-	O
clamp	O
technique	O
,	O
the	O
capability	O
of	O
derivatives	O
16	O
and	O
21	O
to	O
antagonize	O
KA	O
-	O
evoked	O
currents	O
in	O
primary	O
cultures	O
of	O
granule	O
neurons	O
was	O
tested	O
.	O

They	O
behaved	O
as	O
antagonists	O
,	O
but	O
they	O
proved	O
to	O
be	O
less	O
effective	O
than	O
1	O
and	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylcarbamoyl	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
met	I-IUPAC
hylenedioxy	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
benzodiazepine	I-IUPAC
(	O
2	O
,	O
GYKI	O
53655	O
)	O
to	O
reduce	O
the	O
KA	O
-	O
evoked	O
currents	O
.	O

The	O
synthesis	O
of	O
ethyl	I-IUPAC
or	O
methyl	I-IUPAC
4	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
or	O
unsubstituted	I-MODIFIER
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
pyrimidinecarboxylates	I-IUPAC
10-20	O
,	O
which	O
is	O
mainly	O
carried	O
out	O
by	O
reaction	O
of	O
ethyl	I-IUPAC
or	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxoalkanoates	I-IUPAC
with	O
1,1	I-IUPAC
-	I-IUPAC
dimethylguanidine	I-IUPAC
,	O
is	O
described	O
.	O

The	O
above	O
esters	O
were	O
hydrolyzed	O
to	O
the	O
relative	O
carboxylic	O
acids	O
21-30	O
,	O
which	O
were	O
decarboxylated	O
to	O
the	O
corresponding	O
2,4	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
pyrimidines	I-IUPAC
31-40	O
.	O

All	O
the	O
new	O
synthesized	O
pyrimidines	O
were	O
evaluated	O
in	O
spontaneously	O
beating	O
and	O
electrically	O
driven	O
atria	O
from	O
reserpine	O
-	O
treated	O
guinea	O
pigs	O
.	O

Their	O
effects	O
were	O
compared	O
to	O
those	O
induced	O
by	O
milrinone	O
in	O
both	O
atria	O
preparations	O
.	O

Compound	O
28	O
(	O
4	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
pyrimidinecarboxylic	I-IUPAC
acid	I-IUPAC
)	O
was	O
the	O
most	O
effective	O
positive	O
inotropic	O
agent	O
,	O
while	O
the	O
corresponding	O
methyl	O
ester	O
17	O
reduced	O
both	O
the	O
contractile	O
force	O
and	O
the	O
frequency	O
of	O
guinea	O
pig	O
atria	O
.	O

An	O
antagonism	O
toward	O
the	O
negative	O
influence	O
exerted	O
by	O
endogenous	O
adenosine	O
on	O
the	O
heart	O
seems	O
to	O
be	O
involved	O
in	O
the	O
contractile	O
activity	O
of	O
compound	O
28	O
.	O

By	O
contrast	O
,	O
compound	O
17	O
might	O
be	O
partial	O
agonist	O
at	O
the	O
purinergic	O
inhibitory	O
(	O
A1	O
)	O
receptor	O
.	O

X	O
-	O
ray	O
analysis	O
carried	O
out	O
on	O
17	O
and	O
28	O
and	O
molecular	O
modeling	O
investigations	O
extended	O
also	O
to	O
related	O
derivatives	O
allowed	O
a	O
possible	O
rationalization	O
between	O
structure	O
and	O
inotropic	O
activity	O
for	O
this	O
series	O
of	O
compounds	O
.	O

A	O
series	O
of	O
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
indolones	I-IUPAC
and	O
related	O
compounds	O
was	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
as	O
peripheral	O
prejunctional	O
dopaminergic	O
agonists	O
in	O
the	O
field	O
-	O
stimulated	O
isolated	O
perfused	O
rabbit	O
ear	O
artery	O
.	O

4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
indolone	I-IUPAC
was	O
the	O
most	O
potent	O
compound	O
(	O
ED50	O
=	O
2	O
+	O
/	O
-	O
0.3	O
nM	O
)	O
tested	O
,	O
while	O
the	O
related	O
secondary	O
amine	O
24	O
and	O
the	O
des	O
-	O
OH	O
derivatives	O
28	O
and	O
34	O
were	O
only	O
slightly	O
less	O
potent	O
.	O

4	I-IUPAC
-	I-IUPAC
Methoxybenzeneethanamine	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nitrophenylacetic	I-IUPAC
acid	I-IUPAC
were	O
employed	O
as	O
starting	O
materials	O
for	O
for	O
the	O
synthesis	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
indolones	I-IUPAC
.	O

The	O
ring	O
-	O
opened	O
3	I-IUPAC
-	I-IUPAC
acylamino	I-IUPAC
analogues	I-MODIFIER
46	O
and	O
47	O
were	O
prepared	O
via	O
nitration	O
of	O
the	O
phenethylamine	O
43	O
derived	O
from	O
4	I-IUPAC
-	I-IUPAC
methoxyphenylacetic	I-IUPAC
acid	I-IUPAC
.	O

The	O
inactive	O
isomeric	O
indolones	O
38	O
,	O
39	O
,	O
and	O
41	O
were	O
derived	O
from	O
4	I-IUPAC
-	I-IUPAC
nitrobenzeneethanamine	I-IUPAC
and	O
from	O
indolone	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
.	O

Synthesis	O
of	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
benzoxazaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
2	O
)	O
,	O
which	O
is	O
a	O
benzo	O
annulated	O
analog	O
of	O
cyclophosphamide	O
[	O
2	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
aminotetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
1	O
)	O
]	O
,	O
was	O
carried	O
out	O
in	O
order	O
to	O
test	O
for	O
possible	O
increased	O
antitumor	O
activity	O
relative	O
to	O
1	O
due	O
to	O
the	O
presence	O
of	O
an	O
oxidatively	O
reactive	O
C	O
-	O
4	O
benzylic	O
site	O
in	O
2	O
.	O

A	O
structural	O
isomer	O
of	O
2	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
3,1,2	I-IUPAC
-	I-IUPAC
benzoxazaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
3	O
)	O
,	O
and	O
cognate	O
systems	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
benzodiazaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
4	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
benzodioxaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
5	O
)	O
were	O
also	O
prepared	O
for	O
comparative	O
purposes	O
.	O

In	O
vivo	O
antitumor	O
evaluation	O
in	O
mice	O
against	O
L1210	O
lymphoid	O
leukemia	O
indicated	O
no	O
significant	O
activity	O
for	O
compound	O
2	O
.	O

Compounds	O
3	O
and	O
4	O
were	O
likewise	O
found	O
to	O
be	O
inactive	O
and	O
only	O
marginal	O
activity	O
was	O
exhibited	O
by	O
5	O
.	O

Replacement	O
of	O
the	O
polar	O
head	O
of	O
our	O
previous	O
series	O
of	O
1	I-IUPAC
-	I-IUPAC
acyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyanomethyl	I-IUPAC
]	I-IUPAC
piperazines	I-IUPAC
with	O
a	O
2	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
group	I-MODIFIER
has	O
led	O
to	O
the	O
identification	O
of	O
a	O
new	O
series	O
of	O
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
acyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
derivatives	I-MODIFIER
as	O
potent	O
,	O
orally	O
active	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
antagonists	O
.	O

On	O
the	O
basis	O
of	O
the	O
general	O
structure	O
-	O
-	O
activity	O
relationship	O
trends	O
found	O
for	O
the	O
acyl	I-IUPAC
substituent	B-MODIFIER
in	O
our	O
earlier	O
series	O
,	O
five	O
groups	O
of	O
compounds	O
were	O
tested	O
,	O
diaryl	I-PARTIUPAC
-	I-PARTIUPAC
or	O
alkylarylpropanoyl	I-IUPAC
derivatives	B-MODIFIER
,	O
their	O
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	O
substituted	I-MODIFIER
analogues	I-MODIFIER
,	O
and	O
urea	O
,	O
carbamate	O
and	O
amino	O
acid	O
derivatives	O
.	O

The	O
optimal	O
compound	O
19	O
UR	O
-	O
12670	O
)	O
,	O
bearing	O
the	O
3,3	I-IUPAC
-	I-IUPAC
diphenylpropanoyl	I-IUPAC
moiety	I-MODIFIER
,	O
exhibited	O
very	O
high	O
in	O
vitro	O
and	O
in	O
vivo	O
potency	O
IC50	O
=	O
0.0076	O
microM	O
for	O
the	O
in	O
vitro	O
PAF	O
-	O
induced	O
platelet	O
aggregation	O
assay	O
,	O
ID50	O
=	O
0.0086	O
mg	O
/	O
kg	O
for	O
the	O
in	O
vivo	O
PAF	O
-	O
induced	O
hypotension	O
test	O
in	O
normotensive	O
rats	O
,	O
and	O
ID50	O
=	O
0.092	O
mg	O
/	O
kg	O
po	O
and	O
0.0008	O
mg	O
/	O
kg	O
i	O
.	O

v	O
.	O

for	O
the	O
PAF	O
-	O
induced	O
mortality	O
test	O
in	O
mice	O
)	O
.	O

Compound	O
19	O
also	O
showed	O
long	O
duration	O
of	O
activity	O
.	O

It	O
gave	O
100%	O
protection	O
against	O
PAF	O
-	O
induced	O
mortality	O
in	O
mice	O
7	O
h	O
after	O
i	O
.	O

v	O
.	O

administration	O
of	O
a	O
single	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
and	O
also	O
provided	O
100%	O
inhibition	O
of	O
PAF	O
-	O
induced	O
aggregation	O
in	O
dog	O
whole	O
blood	O
6	O
h	O
after	O
i	O
.	O

v	O
.	O

administration	O
of	O
the	O
same	O
dose	O
.	O

The	O
lead	O
structure	O
19	O
has	O
been	O
selected	O
for	O
in	O
-	O
depth	O
pharmacological	O
evaluation	O
.	O

On	O
the	O
basis	O
of	O
the	O
SAR	O
of	O
a	O
series	O
of	O
known	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
uptake	O
inhibitors	O
,	O
including	O
4	O
(	O
SKF	O
89976	O
)	O
,	O
new	O
tricyclic	O
analogues	O
have	O
been	O
prepared	O
.	O

These	O
novel	O
compounds	O
are	O
derivatives	O
of	O
nipecotic	O
acid	O
,	O
guvacine	O
,	O
and	O
homo	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
proline	I-IUPAC
,	O
substituted	O
at	O
the	O
nitrogen	O
of	O
these	O
amino	O
acids	O
by	O
various	O
lipophilic	O
moieties	O
such	O
as	O
(	I-IUPAC
10,11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
alkoxyalkyl	I-IUPAC
or	O
(	I-IUPAC
10,11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cyclohepten	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ylidene	I-IUPAC
)	I-IUPAC
alkoxyalkyl	I-IUPAC
.	O

The	O
in	O
vitro	O
values	O
for	O
inhibition	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
GABA	O
uptake	O
in	O
rat	O
synaptosomes	O
was	O
determined	O
for	O
each	O
compound	O
in	O
this	O
new	O
series	O
,	O
and	O
it	O
was	O
found	O
that	O
several	O
of	O
the	O
novel	O
compounds	O
showed	O
a	O
high	O
potency	O
comparable	O
with	O
that	O
of	O
the	O
reference	O
compounds	O
4	O
,	O
5	O
(	O
tiagabine	O
)	O
,	O
and	O
6	O
(	O
CI	O
-	O
966	O
)	O
.	O

Several	O
of	O
the	O
novel	O
compounds	O
were	O
also	O
evaluated	O
for	O
their	O
ability	O
in	O
vivo	O
to	O
inhibit	O
clonic	O
seizures	O
induced	O
by	O
a	O
15	O
mg	O
/	O
kg	O
(	O
ip	O
)	O
dose	O
of	O
methyl	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
carboline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
DMCM	O
)	O
.	O

One	O
compound	O
,	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
10,11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5H	I-IUPAC
-	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
piperidinecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
23	O
)	O
,	O
was	O
selected	O
for	O
further	O
biological	O
investigations	O
and	O
showed	O
a	O
protective	O
index	O
comparable	O
to	O
or	O
slightly	O
better	O
than	O
that	O
of	O
the	O
recently	O
launched	O
anticonvulsant	O
product	O
5	O
(	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
butenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
piperidinecarboxylic	I-IUPAC
acid	I-IUPAC
)	O
.	O

In	O
order	O
to	O
study	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
L	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2S	I-PARTIUPAC
,	I-PARTIUPAC
4S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
L	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
4R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dioxolanyl	I-IUPAC
nucleoside	I-IUPAC
as	O
potential	O
anti	O
-	O
HIV	O
agents	O
,	O
various	O
enantiomerically	O
pure	O
L	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2S	I-PARTIUPAC
,	I-PARTIUPAC
4S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
4R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dioxolanylpyrimidine	I-IUPAC
and	O
-	I-PARTIUPAC
purine	I-PARTIUPAC
nucleosides	I-PARTIUPAC
have	O
been	O
synthesized	O
and	O
evaluated	O
against	O
HIV	O
-	O
1	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
(	O
PBM	O
)	O
cells	O
.	O

The	O
enantiomerically	O
pure	O
key	O
intermediate	O
8	O
has	O
been	O
synthesized	O
in	O
six	O
steps	O
from	O
1,6	I-IUPAC
-	I-IUPAC
anhydro	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
gulose	I-IUPAC
(	O
2	O
)	O
,	O
and	O
compound	O
8	O
was	O
condensed	O
with	O
5	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
pyrimidines	I-IUPAC
,	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
and	O
2,6	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
purine	I-IUPAC
to	O
obtain	O
various	O
dioxolanylpyrimidine	I-IUPAC
and	O
-	I-PARTIUPAC
purine	I-PARTIUPAC
nucleosides	I-PARTIUPAC
,	O
respectively	O
.	O

Among	O
the	O
compound	O
synthesized	O
,	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
derivative	I-MODIFIER
29	O
was	O
found	O
to	O
exhibit	O
the	O
most	O
potent	O
anti	O
-	O
HIV	O
activity	O
(	O
EC50	O
=	O
0.0012	O
microM	O
)	O
although	O
it	O
was	O
toxic	O
(	O
IC50	O
=	O
10.0	O
microM	O
)	O
.	O

The	O
order	O
of	O
anti	O
-	O
HIV	O
potency	O
of	O
pyrimidine	O
analogues	O
was	O
as	O
follows	O
:	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
cytosine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
iodocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
cytosine	O
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
bromocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
thymine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
methylcytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
iodocytosine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
5	I-IUPAC
-	I-IUPAC
chlorocytosine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
.	O

The	O
anti	O
-	O
HIV	O
potency	O
of	O
purine	O
analogues	O
was	O
found	O
to	O
be	O
in	O
the	O
following	O
decreasing	O
order	O
:	O
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2	I-IUPAC
-	I-IUPAC
chloroadenine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2	I-IUPAC
-	I-IUPAC
fluoroadenine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
adenine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
guanine	O
(	O
beta	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2	I-IUPAC
-	I-IUPAC
fluoroadenine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
adenine	O
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
(	O
alpha	O
-	O
isomer	O
)	O
&	O
gt	O
;	O
N6	I-IUPAC
-	I-IUPAC
methyladenine	I-IUPAC
(	O
beta	O
-	O
isomer	O
)	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
alpha	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
analogue	I-MODIFIER
exhibited	O
an	O
excellent	O
anti	O
-	O
HIV	O
activity	O
(	O
EC50	O
=	O
0.063	O
microM	O
)	O
without	O
cytotoxicity	O
up	O
to	O
100	O
microM	O
in	O
PBM	O
cell	O
.	O

As	O
shown	O
by	O
structure	O
-	O
activity	O
relationship	O
studies	O
in	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
,	O
the	O
most	O
important	O
structural	O
requirement	O
for	O
a	O
marked	O
antidepressant	O
action	O
is	O
the	O
presence	O
of	O
an	O
ureido	I-IUPAC
,	O
(	I-IUPAC
alkoxycarbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
,	O
or	O
[	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
acyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
attached	O
to	O
the	O
isoquinoline	O
skeleton	O
in	O
position	O
8	O
.	O

In	O
one	O
of	O
the	O
biological	O
tests	O
a	O
significant	O
difference	O
was	O
found	O
between	O
8	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
(	O
nomifensine	O
)	O
and	O
the	O
new	O
compounds	O
synthesized	O
.	O

Nearly	O
all	O
compounds	O
substituted	O
in	O
the	O
amino	O
group	O
either	O
decrease	O
the	O
spontaneous	O
motility	O
in	O
mice	O
or	O
exert	O
no	O
effect	O
on	O
it	O
.	O

Two	O
syntheses	O
have	O
been	O
elaborated	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
represented	O
by	O
the	O
general	O
formulas	O
II	O
-	O
V	O
where	O
R1	O
=	O
hydrogen	O
,	O
halogen	O
,	O
or	O
methyl	I-IUPAC
;	O
Y	O
=	O
CONHR	O
,	O
OCOR	O
,	O
or	O
CO	O
(	O
CH2	O
)	O
nNHR	O
,	O
in	O
which	O
R	O
=	O
alkyl	O
or	O
aralkyl	O
or	O
NHR	O
=	O
cyclic	O
amine	O
and	O
n	O
=	O
1-2	O
.	O

The	O
syntheses	O
start	O
either	O
from	O
the	O
corresponding	O
8	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
or	O
from	O
the	O
corresponding	O
noncyclized	O
amino	O
alcohols	O
.	O

Of	O
the	O
compounds	O
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
was	O
found	O
to	O
possess	O
the	O
highest	O
activity	O
.	O

As	O
part	O
of	O
an	O
effort	O
to	O
develop	O
a	O
new	O
class	O
of	O
subtype	O
selective	O
nicotine	O
agonists	O
,	O
we	O
have	O
synthesized	O
and	O
tested	O
a	O
group	O
of	O
12	O
hydroxylated	O
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
piperidyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyrrolidyl	I-IUPAC
)	I-IUPAC
chromans	I-IUPAC
.	O

In	O
rat	O
brain	O
membranes	O
,	O
all	O
12	O
compounds	O
displayed	O
poor	O
affinity	O
for	O
[	O
(	O
125	O
)	O
I	O
]	O
-	O
alpha	O
-	O
bunagarotoxin	O
binding	O
sites	O
.	O

In	O
contrast	O
,	O
three	O
compounds	O
,	O
17c	O
,	O
24	O
,	O
and	O
26	O
,	O
displayed	O
moderate	O
to	O
high	O
affinity	O
for	O
[	O
(	O
3	O
)	O
H	O
]	O
cytisine	O
binding	O
sites	O
,	O
while	O
three	O
(	O
17b	O
,	O
18b	O
,	O
c	O
)	O
and	O
six	O
(	O
17a	O
,	O
d	O
,	O
e	O
and	O
18a	O
,	O
d	O
,	O
e	O
)	O
compounds	O
showed	O
weak	O
and	O
poor	O
affinity	O
,	O
respectively	O
,	O
for	O
these	O
same	O
sites	O
.	O

In	O
subsequent	O
studies	O
,	O
compounds	O
17a	O
and	O
17c	O
were	O
found	O
to	O
stimulate	O
the	O
efflux	O
of	O
(	O
86	O
)	O
Rb	O
(	O
+	O
)	O
from	O
rat	O
cortical	O
synaptosomes	O
,	O
an	O
indication	O
of	O
agonist	O
activity	O
.	O

Further	O
,	O
both	O
17c	O
and	O
26	O
displayed	O
high	O
intrinsic	O
activity	O
in	O
stimulating	O
the	O
release	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
dopamine	O
from	O
striatal	O
synaptosomes	O
;	O
however	O
,	O
only	O
17c	O
was	O
effective	O
at	O
stimulating	O
the	O
release	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
acetylcholine	O
from	O
cortical	O
synaptosomes	O
,	O
suggesting	O
differential	O
selectivity	O
.	O

In	O
cloned	O
human	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChR	O
)	O
expressed	O
in	O
Xenopus	O
oocytes	O
,	O
both	O
17c	O
and	O
26	O
activated	O
alpha7	O
and	O
alpha3beta2	O
receptor	O
subtypes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
but	O
26	O
was	O
clearly	O
the	O
more	O
potent	O
agonist	O
.	O

Last	O
,	O
neither	O
compound	O
displayed	O
dose	O
-	O
dependent	O
activation	O
of	O
alpha4beta2	O
nAChRs	O
.	O

We	O
conclude	O
that	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azacyclic	I-IUPAC
)	I-IUPAC
chromans	I-IUPAC
appear	O
to	O
be	O
a	O
promising	O
new	O
class	O
of	O
nicotine	O
agonists	O
.	O

In	O
this	O
paper	O
,	O
it	O
is	O
hypothesized	O
that	O
the	O
distinction	O
between	O
certain	O
active	O
and	O
inactive	O
cannabinoids	O
is	O
that	O
the	O
inactive	O
analogs	O
possess	O
extra	O
volume	O
associated	O
with	O
their	O
carbocyclic	O
rings	O
that	O
may	O
be	O
responsible	O
for	O
an	O
unfavorable	O
interaction	O
at	O
the	O
cannabinoid	O
receptor	O
.	O

Using	O
the	O
active	O
analog	O
approach	O
,	O
a	O
model	O
is	O
developed	O
of	O
a	O
region	O
of	O
steric	O
interference	O
at	O
this	O
receptor	O
using	O
the	O
active	O
cannabinoids	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
9	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
,	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
,	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
hexahydrocannabinol	I-IUPAC
,	O
and	O
a	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
dimethylheptyl	I-IUPAC
derivative	I-MODIFIER
and	O
the	O
inactive	O
cannabinoids	O
(	I-IUPAC
9S	I-IUPAC
,	I-IUPAC
6aR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
10,10	I-IUPAC
a	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
and	O
a	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
dimethylheptyl	I-IUPAC
derivative	I-MODIFIER
.	O

Each	O
of	O
these	O
molecules	O
satisfy	O
the	O
cannabinoid	O
pharmacophoric	O
requirements	O
,	O
i.e.	O
,	O
a	O
phenolic	O
oxygen	O
at	O
C1	O
and	O
a	O
side	O
chain	O
of	O
acceptable	O
length	O
at	O
C3	O
.	O

Accessible	O
conformers	O
of	O
each	O
molecule	O
were	O
identified	O
by	O
using	O
the	O
method	O
of	O
molecular	O
mechanics	O
as	O
encoded	O
in	O
the	O
MMP2	O
(	O
85	O
)	O
program	O
.	O

The	O
MAP	O
facility	O
within	O
the	O
Chem	O
-	O
X	O
molecular	O
modeling	O
program	O
was	O
then	O
used	O
to	O
calculate	O
the	O
region	O
of	O
steric	O
interference	O
(	O
termed	O
the	O
receptor	O
essential	O
volume	O
,	O
REV	O
)	O
from	O
these	O
accessible	O
conformers	O
.	O

The	O
calculations	O
revealed	O
an	O
REV	O
region	O
located	O
near	O
the	O
top	O
of	O
the	O
carbocyclic	O
ring	O
in	O
the	O
bottom	O
face	O
of	O
the	O
molecule	O
.	O

In	O
order	O
to	O
explore	O
the	O
use	O
of	O
this	O
REV	O
to	O
account	O
for	O
the	O
activities	O
of	O
other	O
cannabinoids	O
,	O
the	O
minimally	O
active	O
classical	O
cannabinoid	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
hexahydrocannabinol	I-IUPAC
,	O
an	O
active	O
benzofuran	O
cannabinoid	O
,	O
and	O
the	O
active	O
nonclassical	O
cannabinoid	O
CP	O
-	O
47,497	O
were	O
then	O
studied	O
.	O

In	O
each	O
case	O
,	O
the	O
activity	O
or	O
minimal	O
activity	O
of	O
each	O
compound	O
can	O
be	O
explained	O
on	O
the	O
basis	O
of	O
the	O
ability	O
of	O
one	O
or	O
more	O
accessible	O
conformer	O
of	O
each	O
molecule	O
to	O
clear	O
the	O
REV	O
calculated	O
here	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
an	O
explanation	O
at	O
the	O
molecular	O
level	O
for	O
observed	O
activity	O
differences	O
between	O
cannabinoids	O
that	O
exhibit	O
shape	O
differences	O
associated	O
with	O
their	O
carbocyclic	O
rings	O
.	O

A	O
series	O
of	O
functionalized	O
congeners	O
of	O
1,3	I-IUPAC
-	I-IUPAC
dialkylxanthines	I-IUPAC
has	O
been	O
prepared	O
as	O
adenosine	O
receptor	O
antagonists	O
.	O

On	O
the	O
basis	O
of	O
the	O
high	O
potency	O
of	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dialkylxanthines	I-IUPAC
,	O
the	O
parent	O
compounds	O
were	O
8	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
carboxymethyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
derivatives	I-MODIFIER
of	O
theophylline	O
and	O
1,3	I-IUPAC
-	I-IUPAC
dipropylxanthine	I-IUPAC
.	O

A	O
series	O
of	O
analogues	O
including	O
esters	O
of	O
ethanol	O
and	O
N	I-IUPAC
-	I-IUPAC
hydroxysuccinimide	I-IUPAC
,	O
amides	O
,	O
a	O
hydrazide	O
,	O
an	O
acylurea	O
,	O
and	O
anilides	O
were	O
prepared	O
.	O

The	O
potency	O
in	O
blocking	O
A1	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
binding	O
of	O
N6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
cyclohexyladenosine	I-IUPAC
to	O
brain	O
membranes	O
)	O
and	O
A2	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
2	I-IUPAC
-	I-IUPAC
chloroadenosine	I-IUPAC
-	O
elicited	O
accumulations	O
of	O
cyclic	O
AMP	O
in	O
brain	O
slices	O
)	O
was	O
markedly	O
affected	O
by	O
structural	O
changes	O
distal	O
to	O
the	O
primary	O
pharmacophore	O
(	O
8	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dialkylxanthine	I-IUPAC
)	O
.	O

Potencies	O
in	O
the	O
dipropyl	I-IUPAC
series	B-MODIFIER
at	O
the	O
A1	O
receptor	O
ranged	O
from	O
Ki	O
values	O
of	O
1.2	O
nM	O
for	O
a	O
congener	O
with	O
a	O
terminal	O
amidoethyleneamine	I-IUPAC
moiety	B-MODIFIER
to	O
a	O
Ki	O
value	O
of	O
58	O
nM	O
for	O
the	O
parent	O
carboxylic	O
acid	O
to	O
a	O
Ki	O
of	O
96	O
nM	O
for	O
the	O
bulky	O
ureido	O
congener	O
.	O

Certain	O
congeners	O
were	O
up	O
to	O
145	O
-	O
fold	O
more	O
active	O
at	O
A1	O
receptors	O
than	O
at	O
A2	O
receptors	O
.	O

Various	O
derivatives	O
of	O
the	O
congeners	O
should	O
be	O
useful	O
as	O
receptor	O
probes	O
and	O
for	O
radioiodination	O
,	O
avidin	O
binding	O
,	O
and	O
preparation	O
of	O
affinity	O
columns	O
.	O

In	O
general	O
,	O
3alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diphenylmethoxy	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
(	O
benztropine	O
)	O
-	O
based	O
dopamine	O
uptake	O
inhibitors	O
do	O
not	O
demonstrate	O
cocaine	O
-	O
like	O
pharmacological	O
activity	O
in	O
models	O
of	O
psychostimulant	O
abuse	O
and	O
have	O
been	O
proposed	O
as	O
potential	O
medications	O
for	O
the	O
treatment	O
of	O
cocaine	O
addiction	O
.	O

However	O
,	O
several	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboalkoxy	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
3alpha	I-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
methoxy	I-IUPAC
]	I-IUPAC
tropane	I-IUPAC
analogues	I-MODIFIER
were	O
discovered	O
to	O
stimulate	O
locomotor	O
activity	O
and	O
substitute	O
in	O
subjects	O
trained	O
to	O
discriminate	O
cocaine	O
,	O
suggesting	O
a	O
role	O
of	O
the	O
2	O
-	O
position	O
substituent	O
in	O
mediating	O
these	O
cocaine	O
-	O
like	O
actions	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
a	O
series	O
of	O
novel	O
N	I-MODIFIER
-	I-MODIFIER
and	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
3alpha	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
bis	I-PARTIUPAC
(	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
fluoro	I-PARTIUPAC
-	I-PARTIUPAC
or	O
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
methoxy	I-IUPAC
]	I-IUPAC
tropane	I-IUPAC
analogues	I-MODIFIER
.	O

Most	O
of	O
these	O
analogues	O
demonstrated	O
high	O
affinity	O
binding	O
to	O
the	O
dopamine	O
transporter	O
(	O
DAT	O
;	O
K	O
(	O
i	O
)	O
=	O
1.8-40	O
nM	O
)	O
,	O
and	O
selectivity	O
over	O
the	O
other	O
monoamine	O
transporters	O
and	O
muscarinic	O
M	O
(	O
1	O
)	O
receptors	O
.	O

When	O
the	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboalkoxy	I-IUPAC
substituent	I-MODIFIER
was	O
replaced	O
with	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethenyl	I-IUPAC
,	O
the	O
resulting	O
analogue	O
11	O
demonstrated	O
the	O
highest	O
DAT	O
binding	O
affinity	O
in	O
the	O
series	O
(	O
K	O
(	O
i	O
)	O
=	O
1.81	O
nM	O
)	O
with	O
DAT	O
selectivity	O
over	O
serotonin	O
transporters	O
(	O
SERT	O
;	O
989	O
-	O
fold	O
)	O
,	O
norepinephrine	O
transporters	O
(	O
NET	O
;	O
261	O
-	O
fold	O
)	O
and	O
muscarinic	O
receptors	O
(	O
90	O
-	O
fold	O
)	O
.	O

When	O
the	O
4'	O
-	O
F	O
groups	O
of	O
compounds	O
5	O
(	O
K	O
(	O
i	O
)	O
=	O
2.94	O
nM	O
)	O
and	O
8	O
(	O
K	O
(	O
i	O
)	O
=	O
6.87	O
nM	O
)	O
were	O
replaced	O
with	O
4'	O
-	O
Cl	O
in	O
the	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboalkoxy	I-IUPAC
series	I-MODIFIER
,	O
DAT	O
binding	O
affinities	O
were	O
slightly	O
reduced	O
(	O
K	O
(	O
i	O
)	O
=	O
12.6	O
and	O
14.6	O
nM	O
for	O
6	O
and	O
7	O
,	O
respectively	O
)	O
,	O
yet	O
inhibition	O
of	O
dopamine	O
uptake	O
potency	O
remained	O
comparably	O
high	O
(	O
IC	O
(	O
50	O
)	O
range	O
=	O
1.5-2.5	O
nM	O
)	O
.	O

Interestingly	O
,	O
the	O
4'	O
-	O
Cl	O
analogue	O
(	O
+	O
/	O
-	O
)	O
-	O
6	O
substituted	O
less	O
in	O
rats	O
trained	O
to	O
discriminate	O
cocaine	O
than	O
the	O
4'	O
-	O
F	O
analogue	O
(	O
+	O
/	O
-	O
)	O
-	O
5	O
.	O

These	O
studies	O
demonstrate	O
that	O
manipulation	O
of	O
the	O
2	I-MODIFIER
-	I-MODIFIER
,	O
N	I-MODIFIER
-	I-MODIFIER
,	O
and	O
3	I-MODIFIER
-	I-MODIFIER
position	I-MODIFIER
substituents	I-MODIFIER
in	O
the	O
3alpha	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diphenylmethoxy	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
class	I-MODIFIER
of	O
dopamine	O
uptake	O
inhibitors	O
can	O
result	O
in	O
ligands	O
with	O
high	O
affinity	O
and	O
selectivity	O
for	O
the	O
DAT	O
,	O
and	O
distinctive	O
in	O
vivo	O
pharmacological	O
profiles	O
that	O
cannot	O
be	O
predicted	O
by	O
their	O
effects	O
in	O
vitro	O
.	O

The	O
nonapeptide	O
[	O
des	O
-	O
Asp1	O
]	O
angiotensin	O
I	O
(	O
IV	O
)	O
,	O
synthesized	O
by	O
Merrifield	O
's	O
solid	O
-	O
phase	O
procedure	O
,	O
was	O
tested	O
as	O
a	O
possible	O
substrate	O
for	O
the	O
converting	O
enzymes	O
from	O
porcine	O
lung	O
and	O
plasma	O
.	O

IV	O
,	O
[	O
des	O
-	O
Asp1	O
]	O
angiotensin	O
II	O
(	O
III	O
)	O
,	O
[	O
des	O
-	O
(	O
Asp1	O
,	O
Arg2	O
)	O
]	O
angiotensin	O
II	O
(	O
V	O
)	O
,	O
[	O
des	O
-	O
(	O
Asp1	O
,	O
Arg2	O
,	O
Val3	O
)	O
]	O
angiotensin	O
II	O
(	O
VI	O
)	O
,	O
[	O
Sar1	O
,	O
Ile8	O
]	O
angiotensin	O
II	O
(	O
VII	O
)	O
,	O
and	O
[	O
des	O
-	O
Asp1	O
,	O
Ile8	O
]	O
angiotensin	O
II	O
(	O
VIII	O
)	O
possessed	O
0.5	O
,	O
20	O
,	O
2	O
,	O
0	O
less	O
than	O
0.1	O
,	O
and	O
less	O
than	O
0.01%	O
of	O
the	O
inotropic	O
activity	O
(	O
rabbit	O
atria	O
)	O
,	O
1	O
,	O
15	O
,	O
5	O
,	O
0	O
,	O
3	O
,	O
and	O
0%	O
secretory	O
activity	O
of	O
the	O
cat	O
adrenal	O
medulla	O
,	O
and	O
0.0	O
,	O
150	O
,	O
0.5	O
,	O
3	O
,	O
and	O
10%	O
of	O
the	O
adrenal	O
steroidogenic	O
activity	O
of	O
angiotensin	O
II	O
,	O
respectively	O
.	O

When	O
tested	O
for	O
their	O
antagonistic	O
activity	O
in	O
the	O
above	O
tissues	O
,	O
only	O
VII	O
and	O
VIII	O
were	O
found	O
to	O
inhibit	O
responses	O
to	O
angiotensin	O
II	O
.	O

The	O
pA2	O
values	O
for	O
VII	O
and	O
VIII	O
were	O
8.31	O
and	O
10.0	O
in	O
the	O
adrenal	O
cortex	O
and	O
9.31	O
and	O
9.16	O
in	O
the	O
adrenal	O
medulla	O
,	O
respectively	O
.	O

All	O
these	O
peptides	O
were	O
also	O
tested	O
as	O
product	O
inhibitors	O
for	O
the	O
plasma	O
and	O
lung	O
converting	O
enzymes	O
.	O

With	O
the	O
plasma	O
enzyme	O
,	O
the	O
ID50	O
values	O
were	O
II	O
,	O
1.6	O
X	O
10	O
(	O
-	O
4	O
)	O
M	O
;	O
III	O
,	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
;	O
V	O
,	O
1.2	O
X	O
10	O
(	O
-	O
4	O
)	O
M	O
;	O
VI	O
5	O
X	O
10	O
(	O
-	O
4	O
)	O
M	O
;	O
VII	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
;	O
VIII	O
,	O
5	O
X	O
10	O
(	O
-	O
4	O
)	O
M	O
.	O

Thus	O
,	O
IV	O
is	O
a	O
good	O
substrate	O
for	O
converting	O
enzymes	O
from	O
lung	O
and	O
plasma	O
while	O
all	O
other	O
compounds	O
were	O
inhibitors	O
of	O
these	O
enzymes	O
.	O

The	O
most	O
potent	O
inhibitors	O
of	O
converting	O
enzyme	O
were	O
III	O
followed	O
by	O
VII	O
and	O
VIII	O
.	O

With	O
the	O
exception	O
of	O
II	O
and	O
III	O
,	O
all	O
the	O
other	O
analogs	O
had	O
very	O
low	O
intrinsic	O
activities	O
,	O
per	O
se	O
.	O

These	O
results	O
suggest	O
(	O
a	O
)	O
an	O
alternate	O
pathway	O
for	O
the	O
formation	O
of	O
heptapeptide	O
III	O
,	O
viz	O
.	O

,	O
by	O
the	O
action	O
of	O
converting	O
enzyme	O
on	O
the	O
nonapeptide	O
IV	O
,	O
and	O
(	O
b	O
)	O
that	O
III	O
may	O
also	O
be	O
acting	O
as	O
inhibitor	O
of	O
the	O
converting	O
enzyme	O
by	O
the	O
feedback	O
mechanism	O
.	O

The	O
sugar	O
moiety	O
of	O
nucleosides	O
in	O
solution	O
is	O
known	O
to	O
exist	O
in	O
a	O
rapid	O
dynamic	O
equilibrium	O
between	O
extreme	O
Northern	O
and	O
Southern	O
conformations	O
as	O
defined	O
in	O
the	O
pseudorotational	O
cycle	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
describe	O
how	O
the	O
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexane	I-IUPAC
template	O
fixes	O
the	O
ring	O
pucker	O
of	O
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
methanocarba	I-IUPAC
-	I-IUPAC
nucleosides	I-IUPAC
1-5	O
and	O
12	O
to	O
values	O
corresponding	O
to	O
either	O
one	O
of	O
these	O
two	O
extreme	O
conformations	O
that	O
are	O
typical	O
of	O
nucleosides	O
.	O

The	O
syntheses	O
of	O
the	O
fixed	O
Northern	O
conformers	O
1-5	O
were	O
performed	O
by	O
Mitsunobu	O
coupling	O
of	O
the	O
heterocyclic	O
bases	O
with	O
the	O
chiral	O
carbocyclic	O
alcohol	O
6	O
[	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
,	I-IUPAC
4R	I-IUPAC
,	I-IUPAC
5S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydrox	I-IUPAC
ybicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexane	I-IUPAC
]	O
,	O
while	O
the	O
synthesis	O
of	O
the	O
Southern	O
conformer	O
,	O
(	O
S	O
)	O
-	O
methanocarba	O
-	O
T	O
(	O
12	O
)	O
,	O
was	O
reported	O
earlier	O
.	O

Carbocyclic	O
thymidine	O
(	O
carba	O
-	O
T	O
,	O
13	O
)	O
was	O
used	O
as	O
a	O
reference	O
,	O
flexible	O
carbocyclic	O
nucleoside	O
.	O

Antiviral	O
evaluation	O
of	O
these	O
compounds	O
revealed	O
a	O
very	O
potent	O
antiherpetic	O
activity	O
associated	O
with	O
the	O
Northern	O
thymidine	O
analogue	O
2	O
,	O
which	O
was	O
more	O
powerful	O
than	O
the	O
reference	O
standard	O
acyclovir	O
against	O
both	O
HSV	O
-	O
1	O
and	O
HSV	O
-	O
2	O
.	O

(	O
N	O
)	O
-	O
Methanocarba	O
-	O
T	O
(	O
2	O
)	O
was	O
further	O
evaluated	O
as	O
a	O
component	O
of	O
a	O
short	O
oligodeoxynucleotide	O
(	O
ODN	O
)	O
phosphorothioate	O
(	O
5'	O
-	O
CTTCATTTTTTCTTC	O
-	O
3'	O
)	O
where	O
all	O
thymidines	O
were	O
replaced	O
by	O
2	O
.	O

The	O
expected	O
thermodynamic	O
stability	O
resulting	O
from	O
the	O
preorganization	O
of	O
the	O
pseudosugar	O
rings	O
into	O
a	O
Northern	O
conformation	O
,	O
typical	O
of	O
A	O
-	O
DNA	O
,	O
was	O
evident	O
by	O
the	O
increase	O
in	O
Tm	O
of	O
the	O
corresponding	O
DNA	O
/	O
RNA	O
heteroduplex	O
.	O

However	O
,	O
the	O
rigid	O
A	O
-	O
tract	O
ODN	O
caused	O
loss	O
of	O
RNase	O
H	O
recruitment	O
.	O

A	O
detailed	O
conformational	O
analysis	O
of	O
(	O
N	O
)	O
-	O
methanocarba	O
-	O
T	O
(	O
2	O
)	O
and	O
(	O
S	O
)	O
-	O
methanocarba	O
-	O
T	O
(	O
12	O
)	O
,	O
as	O
representative	O
examples	O
of	O
conformationally	O
rigid	O
pseudorotational	O
antipodes	O
,	O
revealed	O
that	O
in	O
addition	O
to	O
their	O
different	O
forms	O
of	O
ring	O
pucker	O
,	O
(	O
S	O
)	O
-	O
methanocarba	O
-	O
T	O
appears	O
to	O
be	O
a	O
rather	O
stiff	O
molecule	O
with	O
fewer	O
low	O
-	O
energy	O
conformational	O
states	O
available	O
compared	O
to	O
(	O
N	O
)	O
-	O
methanocarba	O
-	O
T	O
.	O

The	O
syn	O
/	O
anti	O
-	O
energy	O
barrier	O
for	O
these	O
nucleoside	O
analogues	O
is	O
5-6	O
kcal	O
/	O
mol	O
higher	O
than	O
for	O
common	O
nucleosides	O
.	O

31P	O
NMR	O
spectroscopy	O
was	O
used	O
to	O
study	O
the	O
products	O
of	O
the	O
decomposition	O
of	O
the	O
antitumor	O
drug	O
ifosfamide	O
(	O
IF	O
,	O
1d	O
)	O
and	O
its	O
N	I-IUPAC
-	I-IUPAC
dechloroethylated	I-IUPAC
metabolites	I-MODIFIER
,	O
namely	O
,	O
2,3	I-IUPAC
-	I-IUPAC
didechloroethylIF	I-IUPAC
(	O
1a	O
)	O
and	O
2	I-PARTIUPAC
-	I-PARTIUPAC
(	O
1b	O
)	O
and	O
3	I-IUPAC
-	I-IUPAC
dechloroethylIF	I-IUPAC
(	O
1c	O
)	O
,	O
in	O
buffered	O
solutions	O
at	O
acidic	O
pH	O
.	O

The	O
first	O
stage	O
of	O
acid	O
hydrolysis	O
of	O
these	O
four	O
oxazaphosphorines	O
is	O
a	O
P	O
-	O
N	O
bond	O
cleavage	O
of	O
the	O
six	O
-	O
membered	O
ring	O
leading	O
to	O
the	O
phosphoramidic	O
acid	O
monoesters	O
(	O
2a	O
-	O
d	O
)	O
of	O
type	O
R'	O
HN	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
NHR	O
,	O
with	O
R	O
and	O
/	O
or	O
R'	O
=	O
H	O
or	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
Cl	O
.	O

The	O
electron	O
-	O
withdrawing	O
chloroethyl	I-IUPAC
group	B-MODIFIER
at	O
the	O
endocyclic	O
and	O
/	O
or	O
exocyclic	O
nitrogens	O
counteracts	O
the	O
endocyclic	O
P	O
-	O
N	O
bond	O
hydrolysis	O
.	O

This	O
effect	O
is	O
even	O
more	O
marked	O
when	O
the	O
N	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
group	I-MODIFIER
is	O
in	O
the	O
exocyclic	O
position	O
since	O
the	O
order	O
of	O
stability	O
is	O
1d	O
&	O
gt	O
;	O
1c	O
&	O
gt	O
;	O
1b	O
&	O
gt	O
;	O
1a	O
.	O

In	O
the	O
second	O
stage	O
of	O
hydrolysis	O
,	O
the	O
remaining	O
P	O
-	O
N	O
bond	O
is	O
cleaved	O
together	O
with	O
an	O
intramolecular	O
attack	O
at	O
the	O
phosphorus	O
atom	O
by	O
the	O
non	O
-	O
P	O
-	O
linked	O
nitrogen	O
of	O
the	O
compounds	O
2a	O
-	O
d	O
.	O

This	O
leads	O
to	O
the	O
formation	O
of	O
a	O
2	I-IUPAC
-	I-IUPAC
hydroxyoxazaphosphorine	I-IUPAC
ring	O
with	O
R	O
=	O
H	O
(	O
3a	O
coming	O
from	O
compounds	O
2a	O
,	O
c	O
)	O
or	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
Cl	O
(	O
3b	O
coming	O
from	O
compounds	O
2b	O
,	O
d	O
)	O
and	O
to	O
the	O
release	O
of	O
ammonia	O
or	O
chloroethylamine	O
.	O

The	O
third	O
step	O
is	O
the	O
P	O
-	O
N	O
ring	O
opening	O
of	O
the	O
oxazaphosphorines	O
3a	O
,	O
b	O
leading	O
to	O
the	O
phosphoric	O
acid	O
monoesters	O
,	O
H	O
(	O
2	O
)	O
N	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
(	O
2	O
)	O
(	O
4a	O
)	O
and	O
Cl	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
HN	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
(	O
2	O
)	O
(	O
4b	O
-	O
1	O
)	O
,	O
respectively	O
.	O

For	O
the	O
latter	O
compound	O
,	O
the	O
chloroethyl	O
group	O
is	O
partially	O
(	O
at	O
pH	O
5.5	O
)	O
or	O
totally	O
(	O
at	O
pH	O
7.0	O
)	O
cyclized	O
into	O
aziridine	O
(	O
4b	O
-	O
2	O
)	O
,	O
which	O
is	O
then	O
progressively	O
hydrolyzed	O
into	O
an	O
N	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
group	I-MODIFIER
(	O
4b	O
-	O
3	O
)	O
.	O

Compounds	O
3a	O
,	O
b	O
are	O
transient	O
intermediates	O
,	O
which	O
in	O
strongly	O
acidic	O
medium	O
are	O
not	O
observed	O
with	O
(	O
31	O
)	O
P	O
NMR	O
.	O

In	O
this	O
case	O
,	O
cleavage	O
of	O
the	O
P	O
-	O
N	O
bond	O
of	O
the	O
type	O
2	O
phosphoramidic	O
acid	O
monoesters	O
leads	O
directly	O
to	O
the	O
type	O
4	O
phosphoric	O
acid	O
monoesters	O
.	O

The	O
phosphate	O
anion	O
,	O
derived	O
from	O
P	O
-	O
O	O
bond	O
cleavage	O
of	O
these	O
latter	O
compounds	O
,	O
is	O
only	O
observed	O
at	O
low	O
levels	O
after	O
a	O
long	O
period	O
of	O
hydrolysis	O
.	O

Compounds	O
1a	O
-	O
c	O
and	O
some	O
of	O
their	O
hydrolytic	O
degradation	O
products	O
(	O
4b	O
-	O
1	O
,	O
4b	O
-	O
2	O
,	O
diphosphoric	O
diester	O
[	O
Cl	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
]	O
(	O
2	O
)	O
O	O
(	O
5	O
)	O
,	O
and	O
chloroethylamine	O
)	O
did	O
not	O
exhibit	O
,	O
as	O
expected	O
,	O
any	O
antitumor	O
efficacy	O
in	O
vivo	O
against	O
P388	O
leukemia	O
.	O

(	O
31	O
)	O
P	O
NMR	O
determination	O
of	O
the	O
N	O
-	O
dechloroethylated	O
metabolites	O
of	O
IF	O
or	O
its	O
structural	O
isomer	O
,	O
cyclophosphamide	O
(	O
CP	O
)	O
,	O
and	O
their	O
degradation	O
compounds	O
could	O
provide	O
an	O
indirect	O
and	O
accurate	O
estimation	O
of	O
chloroacetaldehyde	O
amounts	O
formed	O
from	O
CP	O
or	O
IF	O
.	O

The	O
high	O
antiradiation	O
activity	O
and	O
low	O
toxicity	O
of	O
sodium	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
hydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
1	O
)	O
suggested	O
the	O
introduction	O
of	O
hydroxyl	I-IUPAC
groups	B-MODIFIER
into	O
other	O
types	O
of	O
radioprotective	O
phosphorothioates	O
.	O

A	O
number	O
of	O
such	O
compounds	O
were	O
synthesized	O
,	O
including	O
S	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminopropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
11	O
,	O
n	O
equals	O
3	O
)	O
,	O
S	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
20	O
)	O
and	O
its	O
propyl	I-IUPAC
homolog	B-MODIFIER
26	O
,	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxytrimethylene	I-IUPAC
)	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
S	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
)	I-IUPAC
(	O
40	O
)	O
,	O
S	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethylamino	I-IUPAC
)	I-IUPAC
propylaminoi1ethyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
44	O
)	O
,	O
and	O
sodium	I-IUPAC
S	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
hydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
49	O
)	O
.	O

Compounds	O
11	O
(	O
n	O
equals	O
3	O
)	O
,	O
20	O
,	O
26	O
,	O
and	O
49	O
were	O
highly	O
protective	O
when	O
administered	O
intraperitoneally	O
but	O
were	O
generally	O
ineffective	O
when	O
given	O
perorally	O
,	O
as	O
were	O
the	O
other	O
hydroxylated	O
phosphorothioates	O
prepared	O
.	O

The	O
introduction	O
of	O
hydroxyl	I-IUPAC
groups	B-MODIFIER
significantly	O
enhanced	O
the	O
radioprotective	O
properties	O
of	O
nonhydroxylated	O
parent	O
compounds	O
,	O
however	O
,	O
only	O
in	O
the	O
case	O
of	O
intraperitoneally	O
administered	O
.	O

We	O
have	O
designed	O
and	O
synthesized	O
16	O
new	O
olean	I-PARTIUPAC
-	I-PARTIUPAC
and	O
urs	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
one	I-IUPAC
triterpenoids	I-IUPAC
with	O
various	O
modified	O
rings	O
C	O
as	O
potential	O
antiinflammatory	O
and	O
cancer	O
chemopreventive	O
agents	O
and	O
evaluated	O
their	O
inhibitory	O
activities	O
against	O
production	O
of	O
nitric	O
oxide	O
induced	O
by	O
interferon	O
-	O
gamma	O
in	O
mouse	O
macrophages	O
.	O

This	O
investigation	O
revealed	O
that	O
9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
12	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
one	I-IUPAC
functionalities	O
in	O
ring	O
C	O
increase	O
the	O
potency	O
by	O
about	O
2-10	O
times	O
compared	O
with	O
the	O
original	O
12	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
.	O

Subsequently	O
,	O
we	O
have	O
designed	O
and	O
synthesized	O
novel	O
olean	I-PARTIUPAC
-	I-PARTIUPAC
and	O
urs	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
one	I-IUPAC
derivatives	I-MODIFIER
with	O
nitrile	I-IUPAC
and	O
carboxyl	I-IUPAC
groups	B-MODIFIER
at	O
C	O
-	O
2	O
in	O
ring	O
A	O
and	O
with	O
9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
one	I-IUPAC
and	O
12	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
one	I-IUPAC
functionalities	I-MODIFIER
in	O
ring	O
C	O
.	O

Among	O
them	O
,	O
we	O
have	O
found	O
that	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
3	I-IUPAC
,	I-IUPAC
12	I-IUPAC
-	I-IUPAC
dioxooleana	I-IUPAC
-	I-IUPAC
1,9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oate	I-IUPAC
(	O
25	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
3,12	I-IUPAC
-	I-IUPAC
dioxooleana	I-IUPAC
-	I-IUPAC
1,9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oic	I-IUPAC
acid	I-IUPAC
(	O
CDDO	O
)	O
(	O
26	O
)	O
,	O
and	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
3,12	I-IUPAC
-	I-IUPAC
dioxooleana	I-IUPAC
-	I-IUPAC
1,9	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oate	I-IUPAC
(	O
29	O
)	O
have	O
extremely	O
high	O
potency	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.1	O
nM	O
level	O
)	O
.	O

Their	O
potency	O
is	O
similar	O
to	O
that	O
of	O
dexamethasone	O
although	O
they	O
do	O
not	O
act	O
through	O
the	O
glucocorticoid	O
receptor	O
.	O

Overall	O
,	O
the	O
combination	O
of	O
modified	O
rings	O
A	O
and	O
C	O
increases	O
the	O
potency	O
by	O
about	O
10	O
000	O
times	O
compared	O
with	O
the	O
lead	O
compound	O
,	O
3	I-IUPAC
-	I-IUPAC
oxooleana	I-IUPAC
-	I-IUPAC
1,12	I-IUPAC
-	I-IUPAC
dien	I-IUPAC
-	I-IUPAC
28	I-IUPAC
-	I-IUPAC
oic	I-IUPAC
acid	I-IUPAC
(	O
8	O
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
1	O
microM	O
level	O
)	O
.	O

The	O
selected	O
oleanane	O
triterpenoid	O
,	O
CDDO	O
(	O
26	O
)	O
,	O
was	O
found	O
to	O
be	O
a	O
potent	O
,	O
multifunctional	O
agent	O
in	O
various	O
in	O
vitro	O
assays	O
and	O
to	O
show	O
antiinflammatory	O
activity	O
against	O
thioglycollate	O
-	O
interferon	O
-	O
gamma	O
-	O
induced	O
mouse	O
peritonitis	O
.	O

A	O
series	O
of	O
new	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
alkylamides	I-IUPAC
44-84	O
has	O
been	O
prepared	O
in	O
the	O
search	O
of	O
novel	O
antiallergic	O
compounds	O
.	O

Synthesis	O
of	O
the	O
desired	O
ethyl	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
acetates	I-IUPAC
1-4	O
was	O
achieved	O
by	O
indolization	O
under	O
Fischer	O
conditions	O
;	O
Japp	O
-	O
Klingemann	O
method	O
followed	O
by	O
2	O
-	O
decarboxylation	O
afforded	O
the	O
ethyl	I-IUPAC
(	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
alkanoates	I-IUPAC
17-25	O
.	O

Amidification	O
was	O
successfully	O
carried	O
out	O
by	O
condensation	O
of	O
the	O
corresponding	O
acids	O
or	O
their	O
N	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
(	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
with	O
4	I-IUPAC
-	I-IUPAC
aminopyridine	I-IUPAC
promoted	O
by	O
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylpyridinium	I-IUPAC
iodide	I-IUPAC
.	O

Efforts	O
to	O
improve	O
the	O
antiallergic	O
potency	O
of	O
the	O
title	O
series	O
by	O
variation	O
of	O
the	O
indole	O
substituents	O
(	O
R1	O
,	O
R2	O
,	O
R	O
)	O
and	O
the	O
length	O
of	O
the	O
alkanoic	O
chain	O
(	O
n	O
=	O
1	O
,	O
2	O
,	O
3	O
)	O
led	O
to	O
the	O
selection	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorobenzyl	I-IUPAC
)	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
acetamide	I-IUPAC
45	O
,	O
out	O
of	O
41	O
compounds	O
.	O

This	O
amide	O
was	O
406	O
-	O
fold	O
more	O
potent	O
than	O
astemizole	O
in	O
the	O
ovalbumin	O
-	O
induced	O
histamine	O
release	O
assay	O
,	O
using	O
guinea	O
pig	O
peritoneal	O
mast	O
cells	O
,	O
with	O
an	O
IC50	O
=	O
0.016	O
microM	O
.	O

Its	O
inhibitory	O
activity	O
in	O
IL	O
-	O
4	O
production	O
test	O
from	O
Th	O
-	O
2	O
cells	O
was	O
identical	O
to	O
that	O
of	O
the	O
reference	O
histamine	O
antagonist	O
(	O
IC50	O
=	O
8.0	O
microM	O
)	O
and	O
twice	O
higher	O
in	O
IL	O
-	O
5	O
assay	O
:	O
IC50	O
=	O
1.5	O
and	O
3.3	O
microM	O
,	O
respectively	O
.	O

In	O
vivo	O
antiallergic	O
activity	O
evaluation	O
confirmed	O
efficiency	O
of	O
45	O
in	O
sensitized	O
guinea	O
pig	O
late	O
phase	O
eosinophilia	O
inhibition	O
,	O
after	O
parenteral	O
and	O
oral	O
administration	O
at	O
5	O
and	O
30	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Its	O
efficiency	O
in	O
inhibition	O
of	O
microvascular	O
permeability	O
was	O
assessed	O
in	O
two	O
rhinitis	O
models	O
;	O
ovalbumin	O
and	O
capsaicin	O
-	O
induced	O
rhinorrhea	O
could	O
be	O
prevented	O
after	O
topical	O
application	O
of	O
submicromolar	O
concentrations	O
of	O
45	O
(	O
IC50	O
=	O
0.25	O
and	O
0.30	O
microM	O
)	O
;	O
and	O
it	O
also	O
exerted	O
significant	O
inhibitory	O
effect	O
in	O
the	O
first	O
test	O
after	O
iv	O
and	O
oral	O
administration	O
,	O
with	O
ID50	O
=	O
0.005	O
and	O
0.46	O
mg	O
/	O
kg	O
.	O

5	O
-	O
Alkyl	O
-	O
and	O
5	I-IUPAC
-	I-IUPAC
arylalkyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylenedihydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
13a	O
-	O
e	O
,	O
3	I-IUPAC
-	I-IUPAC
alkylidenedihydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
18a	O
-	O
c	O
,	O
and	O
3	I-IUPAC
-	I-IUPAC
methylenepyrrolidin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
16a	O
-	O
e	O
were	O
synthesized	O
utilizing	O
ethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
diethoxyphosphoryl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitroalkanoates	I-IUPAC
9a	O
-	O
e	O
as	O
common	O
intermediates	O
.	O

All	O
obtained	O
compounds	O
were	O
tested	O
against	O
L	O
-	O
1210	O
,	O
HL	O
-	O
60	O
,	O
and	O
NALM	O
-	O
6	O
leukemia	O
cells	O
.	O

The	O
highest	O
cytotoxic	O
activity	O
was	O
observed	O
for	O
3	I-IUPAC
-	I-IUPAC
methylenefuranones	I-IUPAC
13d	O
,	O
e	O
bearing	O
benzyl	I-IUPAC
or	O
3,4	I-IUPAC
-	I-IUPAC
dimethoxyphenylmethyl	I-IUPAC
substituents	I-MODIFIER
at	O
position	O
5	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
5.4	O
and	O
6.0	O
microM	O
,	O
respectively	O
.	O

Contrary	O
to	O
the	O
literature	O
reports	O
,	O
no	O
enhancement	O
in	O
activity	O
due	O
to	O
the	O
presence	O
of	O
a	O
hydroxy	O
group	O
was	O
found	O
when	O
the	O
cytotoxicity	O
of	O
furanones	O
13a	O
,	O
b	O
,	O
d	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylenedihydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
6a	O
,	O
b	O
,	O
d	O
was	O
compared	O
.	O

The	O
anticancer	O
activity	O
of	O
pyrrolidinones	O
16a	O
-	O
e	O
and	O
3	I-IUPAC
-	I-IUPAC
alkylidenefuranones	I-IUPAC
18a	O
-	O
c	O
was	O
much	O
weaker	O
than	O
that	O
of	O
furanones	O
13a	O
-	O
e	O
.	O

Several	O
derivatives	O
of	O
4,5	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
imidazole	I-IUPAC
,	O
2,4,5	I-MODIFIER
-	I-MODIFIER
trisubstituted	I-MODIFIER
pyrimidine	I-IUPAC
,	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
purine	I-IUPAC
,	O
thiazolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazino	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
thiazolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
i	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazino	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
i	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
and	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
pyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
were	O
synthesized	O
and	O
tested	O
as	O
inhibitors	O
of	O
the	O
xanthine	O
oxidase	O
enzyme	O
.	O

Of	O
those	O
,	O
some	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
acylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbamoylimidazoles	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
thioalkyl	I-IUPAC
-	O
substituted	I-MODIFIER
purines	B-IUPAC
exhibited	O
very	O
good	O
inhibitory	O
activity	O
,	O
being	O
at	O
least	O
500	O
times	O
more	O
effective	O
than	O
allopurinol	O
.	O

The	O
ineffectiveness	O
of	O
6	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
alkylpyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
is	O
imputable	O
to	O
the	O
alkyl	O
chain	O
which	O
could	O
hinder	O
the	O
coordination	O
with	O
molybdenum	O
according	O
to	O
the	O
known	O
mechanism	O
for	O
the	O
binding	O
of	O
the	O
inhibitor	O
allopurinol	O
;	O
the	O
effectiveness	O
of	O
imidazole	O
derivatives	O
,	O
by	O
contrast	O
with	O
the	O
ineffectiveness	O
of	O
4,5	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
thioalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxypyrimidines	I-IUPAC
,	O
indicates	O
the	O
relative	O
importance	O
of	O
the	O
five	O
-	O
membered	O
ring	O
in	O
the	O
interaction	O
with	O
the	O
enzyme	O
.	O

Moreover	O
,	O
the	O
marked	O
effectiveness	O
of	O
the	O
angularly	O
-	O
cyclized	O
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazino	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
i	I-IUPAC
]	I-IUPAC
purinones	I-IUPAC
,	O
which	O
constitute	O
an	O
interesting	O
new	O
class	O
of	O
inhibitors	O
,	O
together	O
with	O
the	O
weak	O
activity	O
of	O
linearly	O
-	O
cyclized	O
derivatives	O
,	O
allowed	O
us	O
to	O
characterize	O
more	O
precisely	O
the	O
lipophilic	O
region	O
of	O
the	O
enzyme	O
facing	O
the	O
N	O
(	O
1	O
)	O
-	O
C	O
(	O
2	O
)	O
positions	O
of	O
the	O
substrate	O
hypoxanthine	O
.	O

A	O
synthesis	O
scheme	O
for	O
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxynucleosides	I-IUPAC
and	O
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methylidene	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
has	O
been	O
proposed	O
with	O
2	I-IUPAC
-	I-IUPAC
deoxyribose	I-IUPAC
as	O
the	O
starting	O
material	O
.	O

Methyl	O
5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxyribofuranose	I-IUPAC
was	O
oxidized	O
and	O
the	O
mixture	O
of	O
the	O
3'	I-IUPAC
-	I-IUPAC
keto	I-IUPAC
derivatives	I-MODIFIER
was	O
separated	O
into	O
the	O
alpha	O
-	O
and	O
beta	O
-	O
anomers	O
.	O

The	O
beta	O
-	O
keto	O
derivative	O
was	O
converted	O
by	O
reaction	O
with	O
MeMgBr	O
,	O
and	O
after	O
reaction	O
with	O
thymine	O
and	O
subsequent	O
deprotection	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
and	O
its	O
beta	O
-	O
anomer	O
were	O
obtained	O
.	O

The	O
same	O
reactions	O
with	O
the	O
alpha	O
-	O
keto	O
sugar	O
gave	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
and	O
its	O
beta	O
-	O
anomer	O
.	O

1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
Benzoyl	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
threo	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
was	O
converted	O
to	O
a	O
mixture	O
of	O
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methylidene	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
and	O
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
didehydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
,	O
which	O
were	O
separated	O
.	O

The	O
stereoselectivity	O
of	O
the	O
Grignard	O
reagent	O
's	O
attachment	O
to	O
2	I-IUPAC
-	I-IUPAC
deoxyfuranose	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ulosides	I-IUPAC
has	O
been	O
ruled	O
by	O
the	O
substitute	O
configuration	O
at	O
Cl	O
.	O

Also	O
,	O
the	O
effect	O
of	O
the	O
hydroxyl	I-IUPAC
or	O
OBz	O
group	O
configuration	O
at	O
C3	O
on	O
the	O
condensation	O
stereoselectivity	O
of	O
3	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxyfuranosides	I-IUPAC
with	O
silylated	O
thymine	O
has	O
been	O
studied	O
.	O

The	O
structure	O
of	O
the	O
obtained	O
compounds	O
was	O
proved	O
by	O
1H	O
NMR	O
UV	O
,	O
13C	O
NMR	O
,	O
and	O
CD	O
spectroscopy	O
,	O
as	O
well	O
as	O
elemental	O
(	O
C	O
,	O
H	O
,	O
N	O
)	O
analysis	O
.	O

The	O
C2	O
'	O
-	O
endo	O
-	O
C1	O
'	O
-	O
exo	O
conformation	O
,	O
the	O
anti	O
conformation	O
of	O
thymine	O
in	O
relation	O
to	O
the	O
glycosidic	O
bond	O
,	O
and	O
the	O
gauche+	O
conformation	O
in	O
relation	O
to	O
the	O
C4	O
'	O
-	O
C5	O
'	O
bond	O
are	O
characteristic	O
for	O
the	O
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxythymidine	I-IUPAC
structure	O
in	O
the	O
crystals	O
.	O

3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxythymidine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
triphosphate	I-IUPAC
was	O
synthesized	O
and	O
proved	O
to	O
be	O
a	O
competitive	O
inhibitor	O
,	O
with	O
respect	O
to	O
dTTP	O
,	O
of	O
a	O
number	O
of	O
DNA	O
polymerases	O
,	O
including	O
the	O
reverse	O
transcriptases	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
and	O
avian	O
myeloblastosis	O
virus	O
(	O
AMV	O
)	O
.	O

None	O
of	O
the	O
DNA	O
polymerases	O
examined	O
were	O
able	O
to	O
incorporate	O
this	O
compound	O
into	O
the	O
growing	O
DNA	O
chain	O
.	O

In	O
contrast	O
,	O
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methylidene	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
triphosphate	I-IUPAC
was	O
found	O
to	O
be	O
incorporated	O
at	O
the	O
3'	O
-	O
end	O
of	O
the	O
DNA	O
chain	O
by	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
,	O
albeit	O
with	O
very	O
low	O
efficiency	O
.	O

3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
did	O
not	O
suppress	O
HIV	O
-	O
1	O
replication	O
in	O
MT	O
-	O
4	O
cells	O
at	O
500	O
microM	O
while	O
its	O
5'	I-IUPAC
-	I-IUPAC
phosphite	I-IUPAC
derivative	I-MODIFIER
exhibited	O
modest	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
.	O

Treatment	O
of	O
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
2	O
)	O
with	O
p	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
phosphorodichloridate	I-IUPAC
and	O
1,2,4	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
gave	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
br	I-IUPAC
o	I-IUPAC
movinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
3	O
)	O
.	O

Reaction	O
of	O
3	O
with	O
ammonia	O
gave	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxycytidine	I-IUPAC
(	O
1	O
)	O
,	O
the	O
overall	O
yield	O
from	O
2	O
being	O
60%	O
.	O

A	O
similar	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
(	O
4	O
)	O
was	O
obtained	O
from	O
3'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
thymidine	I-IUPAC
by	O
the	O
use	O
of	O
phosphoryl	O
chloride	O
as	O
the	O
condensing	O
agent	O
.	O

Treatment	O
of	O
thymidine	O
with	O
trimethylsilyl	O
chloride	O
and	O
then	O
with	O
phosphoryl	O
chloride	O
and	O
1,2,4	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
gave	O
upon	O
workup	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
5	O
)	O
.	O

(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
Bromovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
BVDU	O
)	O
when	O
similarly	O
treated	O
gave	O
the	O
corresponding	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromovinyl	I-IUPAC
)	I-IUPAC
compound	I-MODIFIER
7	O
.	O

A	O
minor	O
product	O
formed	O
in	O
both	O
cases	O
was	O
a	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
in	O
which	O
the	O
nucleoside	O
5'	I-IUPAC
-	I-IUPAC
hydroxyl	I-IUPAC
group	I-MODIFIER
had	O
been	O
replaced	O
by	O
chlorine	O
(	O
6	O
and	O
8	O
)	O
.	O

Whereas	O
compounds	O
4-6	O
and	O
8	O
did	O
not	O
exhibit	O
a	O
selective	O
antiviral	O
effect	O
,	O
compounds	O
1-3	O
and	O
7	O
proved	O
almost	O
as	O
active	O
as	O
the	O
reference	O
compound	O
BVDU	O
.	O

In	O
particular	O
,	O
compound	O
7	O
,	O
the	O
4	I-IUPAC
-	I-IUPAC
triazolyl	I-IUPAC
derivative	I-MODIFIER
of	O
BVDU	O
,	O
would	O
seem	O
worth	O
pursuing	O
for	O
its	O
potential	O
as	O
an	O
inhibitor	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
and	O
varicella	O
-	O
zoster	O
virus	O
.	O

Certain	O
derivatives	O
containing	O
the	O
1,2	I-IUPAC
-	I-IUPAC
dihydropyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyrazine	I-IUPAC
(	O
1	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydropteridine	I-IUPAC
)	O
ring	I-MODIFIER
system	I-MODIFIER
are	O
active	O
against	O
experimental	O
neoplasms	O
in	O
mice	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
these	O
agents	O
has	O
been	O
attributed	O
to	O
the	O
accumulation	O
of	O
cells	O
at	O
mitosis	O
.	O

Identification	O
of	O
the	O
structural	O
features	O
that	O
are	O
necessary	O
for	O
activity	O
was	O
accomplished	O
by	O
evaluation	O
of	O
modified	O
1	I-IUPAC
-	I-IUPAC
deazapteridines	I-IUPAC
and	O
ring	O
and	O
ring	O
-	O
opened	O
analogues	O
.	O

Relative	O
to	O
ethyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylanilino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
pteridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
(	O
11	O
)	O
and	O
the	O
corresponding	O
6	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
compound	I-MODIFIER
(	O
12	O
)	O
,	O
no	O
antitumor	O
activity	O
was	O
observed	O
with	O
7,8	I-IUPAC
-	I-IUPAC
dihydropteridines	I-IUPAC
,	O
3	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydropteridines	I-IUPAC
,	O
and	O
the	O
corresponding	O
heteroaromatic	O
compounds	O
.	O

Also	O
,	O
activity	O
was	O
diminished	O
or	O
destroyed	O
when	O
1	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydropteridines	I-IUPAC
were	O
oxidized	O
to	O
1	I-IUPAC
-	I-IUPAC
deazapteridines	I-IUPAC
or	O
reduced	O
to	O
1	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydropteridines	I-IUPAC
.	O

In	O
addition	O
,	O
replacement	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	I-MODIFIER
with	O
other	O
substituents	O
destroyed	O
activity	O
.	O

The	O
presence	O
of	O
a	O
6	O
-	O
substituent	O
containing	O
an	O
aryl	O
group	O
appeared	O
to	O
be	O
necessary	O
for	O
activity	O
,	O
which	O
was	O
increased	O
when	O
a	O
methyl	I-IUPAC
group	I-IUPAC
was	O
substituted	I-MODIFIER
at	O
the	O
7	O
-	O
position	O
.	O

2	O
-	O
(	O
Aminomethyl	O
)	O
-	O
4	O
-	O
aminobutyric	O
acid	O
(	O
isoornithine	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
methylisoornithine	I-IUPAC
,	O
and	O
2,3	I-IUPAC
-	I-IUPAC
dimethylisoornithine	I-IUPAC
were	O
not	O
decarboxylated	O
by	O
liver	O
ornithine	O
decarboxylase	O
(	O
ODC	O
,	O
EC	O
4.1.1.17	O
)	O
of	O
thioacetamide	O
-	O
treated	O
rats	O
but	O
were	O
good	O
competitive	O
inhibitors	O
of	O
the	O
enzyme	O
(	O
Ki	O
ranged	O
from	O
0.72	O
to	O
1.79	O
mM	O
)	O
.	O

When	O
assayed	O
in	O
vivo	O
in	O
the	O
treated	O
rats	O
,	O
the	O
above	O
mentioned	O
isoornithines	O
were	O
also	O
found	O
to	O
inhibit	O
liver	O
ODC	O
when	O
administered	O
1	O
h	O
before	O
sacrifice	O
.	O

When	O
the	O
methylputrescines	O
formally	O
derived	O
from	O
the	O
decarboxylation	O
of	O
several	O
isoornithines	O
were	O
assayed	O
on	O
rat	O
liver	O
ODC	O
,	O
it	O
was	O
found	O
that	O
only	O
2,3	I-IUPAC
-	I-IUPAC
dimethylputrescine	I-IUPAC
decreased	O
the	O
enzymatic	O
activity	O
.	O

When	O
assayed	O
in	O
vivo	O
,	O
it	O
was	O
found	O
to	O
decrease	O
ODC	O
activity	O
by	O
60%	O
,	O
when	O
the	O
latter	O
was	O
measured	O
1	O
h	O
after	O
administration	O
.	O

The	O
effect	O
was	O
reverted	O
4	O
h	O
after	O
administration	O
of	O
the	O
drug	O
.	O

Isoornithines	O
were	O
not	O
taken	O
up	O
by	O
H	O
-	O
35	O
hepatoma	O
cells	O
;	O
hence	O
they	O
did	O
not	O
affect	O
their	O
ODC	O
activity	O
.	O

2,3	I-IUPAC
-	I-IUPAC
Dimethylputrescine	I-IUPAC
however	O
,	O
was	O
transported	O
into	O
the	O
cells	O
and	O
significantly	O
decreased	O
its	O
ODC	O
activity	O
.	O

Eleven	O
new	O
12	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6,7,10,11	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
,	I-IUPAC
11	I-IUPAC
-	I-IUPAC
methanocycloocta	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
derivatives	I-MODIFIER
[	O
tacrine	O
(	O
THA	O
)	O
-	O
huperzine	O
A	O
hybrids	O
,	O
rac	O
-	O
21-31	O
]	O
have	O
been	O
synthesized	O
as	O
racemic	O
mixtures	O
and	O
tested	O
as	O
acetylcholinesterase	O
(	O
AChE	O
)	O
inhibitors	O
.	O

For	O
derivatives	O
unsubstituted	O
at	O
the	O
benzene	O
ring	O
,	O
the	O
highest	O
activity	O
was	O
obtained	O
for	O
the	O
9	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
derivative	I-MODIFIER
rac	O
-	O
20	O
,	O
previously	O
prepared	O
by	O
our	O
group	O
.	O

More	O
bulky	O
substituents	O
at	O
position	O
9	O
led	O
to	O
less	O
active	O
compounds	O
,	O
although	O
some	O
of	O
them	O
[	O
9	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
(	O
rac	O
-	O
22	O
)	O
,	O
9	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
(	O
rac	O
-	O
23	O
)	O
,	O
and	O
9	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
(	O
rac	O
-	O
26	O
)	O
]	O
show	O
activities	O
similar	O
to	O
that	O
of	O
THA	O
.	O

Substitution	O
at	O
position	O
1	O
or	O
3	O
with	O
methyl	O
or	O
fluorine	O
atoms	O
always	O
led	O
to	O
more	O
active	O
compounds	O
.	O

Among	O
them	O
,	O
the	O
highest	O
activity	O
was	O
observed	O
for	O
the	O
3	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivative	I-MODIFIER
rac	O
-	O
28	O
[	O
about	O
15	O
-	O
fold	O
more	O
active	O
than	O
THA	O
and	O
about	O
9	O
-	O
fold	O
more	O
active	O
than	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
]	O
.	O

The	O
activity	O
of	O
some	O
THA	O
-	O
huperzine	O
A	O
hybrids	O
(	O
rac	O
-	O
19	O
,	O
rac	O
-	O
20	O
,	O
rac	O
-	O
28	O
,	O
and	O
rac	O
-	O
30	O
)	O
,	O
which	O
were	O
separated	O
into	O
their	O
enantiomers	O
by	O
chiral	O
medium	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
chiral	O
MPLC	O
)	O
,	O
using	O
microcrystalline	O
cellulose	O
triacetate	O
as	O
the	O
chiral	O
stationary	O
phase	O
,	O
showed	O
the	O
eutomer	O
to	O
be	O
always	O
the	O
levorotatory	O
enantiomer	O
,	O
their	O
activity	O
being	O
roughly	O
double	O
that	O
of	O
the	O
corresponding	O
racemic	O
mixture	O
,	O
the	O
distomer	O
being	O
much	O
less	O
active	O
.	O

Also	O
,	O
the	O
activity	O
of	O
some	O
of	O
these	O
compounds	O
inhibiting	O
butyrylcholinesterase	I-IUPAC
(	O
BChE	O
)	O
was	O
tested	O
.	O

Most	O
of	O
them	O
[	O
rac	O
-	O
27-31	O
,	O
(	O
-	O
)	O
-	O
28	O
,	O
and	O
(	O
-	O
)	O
-	O
30	O
]	O
,	O
which	O
are	O
more	O
active	O
than	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
as	O
AChE	O
inhibitors	O
,	O
turned	O
out	O
to	O
be	O
quite	O
selective	O
for	O
AChE	O
,	O
although	O
not	O
so	O
selective	O
as	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
.	O

Most	O
of	O
the	O
tested	O
compounds	O
19-31	O
proved	O
to	O
be	O
much	O
more	O
active	O
than	O
THA	O
in	O
reversing	O
the	O
neuromuscular	O
blockade	O
induced	O
by	O
d	O
-	O
tubocurarine	O
.	O

Molecular	O
modeling	O
of	O
the	O
interaction	O
of	O
these	O
compounds	O
with	O
AChE	O
from	O
Torpedo	O
californica	O
showed	O
them	O
to	O
interact	O
as	O
truly	O
THA	O
-	O
huperzine	O
A	O
hybrids	O
:	O
the	O
4	I-IUPAC
-	I-IUPAC
aminoquinoline	I-IUPAC
subunit	I-MODIFIER
of	O
(	O
-	O
)	O
-	O
19	O
occupies	O
the	O
same	O
position	O
of	O
the	O
corresponding	O
subunit	O
in	O
THA	O
,	O
while	O
its	O
bicyclo	O
[	O
3.3.1	O
]	O
nonadiene	O
substructure	O
roughly	O
occupies	O
the	O
same	O
position	O
of	O
the	O
corresponding	O
substructure	O
in	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
,	O
in	O
agreement	O
with	O
the	O
absolute	O
configurations	O
of	O
(	O
-	O
)	O
-	O
19	O
and	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
.	O

The	O
linear	O
octadentate	O
ligand	O
3,4,3	O
-	O
LIHOPO	O
,	O
which	O
contains	O
four	O
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
1,2	O
-	O
HOPO	O
)	O
groups	O
,	O
is	O
the	O
most	O
effective	O
agent	O
for	O
in	O
vivo	O
chelation	O
of	O
Pu	O
(	O
IV	O
)	O
yet	O
prepared	O
.	O

However	O
,	O
its	O
clinical	O
potential	O
is	O
limited	O
by	O
acute	O
toxicity	O
of	O
the	O
free	O
ligand	O
(	O
but	O
not	O
Fe3+	O
complex	O
)	O
at	O
high	O
dosage	O
.	O

The	O
high	O
acidity	O
of	O
HOPO	O
ligands	O
and	O
the	O
much	O
lower	O
acidity	O
of	O
catechol	O
(	O
CAM	O
)	O
ligands	O
suggested	O
that	O
mixed	O
octadentate	O
(	O
CAM	O
-	O
HOPO	O
)	O
ligands	O
containing	O
one	O
or	O
two	O
1,2	O
-	O
HOPO	O
and	O
three	O
(	O
or	O
two	O
)	O
catechol	O
(	O
CAM	O
)	O
groups	O
might	O
be	O
as	O
effective	O
for	O
Pu	O
removal	O
[	O
fully	O
eight	O
-	O
coordinated	O
Pu	O
(	O
IV	O
)	O
complexes	O
formed	O
at	O
pH	O
&	O
gt	O
;	O
or	O
=	O
6	O
]	O
and	O
less	O
toxic	O
than	O
3,4,3	O
-	O
LIHOPO	O
.	O

Treatment	O
of	O
spermine	O
with	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dimethoxybenzoyl	I-IUPAC
)	I-IUPAC
thiazol	I-IUPAC
-	I-IUPAC
idine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thione	I-IUPAC
(	O
1	O
)	O
(	O
molar	O
ratio	O
2	O
:	O
1	O
)	O
gave	O
1,14	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dimethoxybenzoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,5,10,14	I-IUPAC
-	I-IUPAC
tetraazatetradecane	I-IUPAC
(	O
2	O
,	O
DiCAM	O
-	O
spermine	O
)	O
in	O
80%	O
yield	O
.	O

Addition	O
of	O
2	O
to	O
a	O
2	O
-	O
fold	O
excess	O
of	O
the	O
reaction	O
product	O
of	O
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridone	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
HOPO	O
-	O
C	O
)	O
and	O
1,1	I-IUPAC
'	I-IUPAC
-	I-IUPAC
carbonyldiimidazole	I-IUPAC
(	O
CDI	O
)	O
in	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylformamide	I-IUPAC
(	O
DMF	O
)	O
and	O
deprotection	O
with	O
BBr3	O
gave	O
1,14	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydroxybenzoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridon	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,5,10,14	I-IUPAC
-	I-IUPAC
tetraaza	I-IUPAC
-	I-IUPAC
tetradecane	I-IUPAC
[	O
3	O
,	O
3,4,3	O
-	O
LI	O
(	O
diCAM	O
-	O
diHOPO	O
)	O
]	O
in	O
5%	O
yield	O
.	O

Addition	O
of	O
2	O
to	O
an	O
equimolar	O
amount	O
of	O
the	O
reaction	O
product	O
of	O
HOPO	O
-	O
C	O
and	O
CDI	O
in	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylacetamide	I-IUPAC
(	O
DMAA	O
)	O
,	O
purification	O
of	O
the	O
hexadentate	O
intermediate	O
,	O
subsequent	O
treatment	O
with	O
an	O
equimolar	O
amount	O
of	O
2,3	I-IUPAC
-	I-IUPAC
dimethoxybenzoyl	I-IUPAC
chloride	I-IUPAC
(	O
DMB	O
)	O
,	O
and	O
deprotection	O
with	O
BBr3	O
gave	O
1,5,14	I-IUPAC
-	I-IUPAC
tris	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydroxybenzoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridon	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
,	I-IUPAC
5,10,14	I-IUPAC
-	I-IUPAC
tetraazatetradecane	I-IUPAC
[	O
4	O
,	O
3,4,3	O
-	O
LI	O
(	O
triCAM	O
-	O
HOPO	O
)	O
]	O
in	O
5%	O
yield	O
.	O

Ligands	O
were	O
administered	O
to	O
mice	O
[	O
30	O
mumol	O
kg	O
-	O
1	O
ip	O
at	O
1	O
h	O
or	O
orally	O
at	O
3	O
min	O
after	O
iv	O
injection	O
of	O
plutonium	O
(	O
IV	O
)	O
-	O
238	O
citrate	O
,	O
kill	O
at	O
24	O
h	O
]	O
.	O

Plutonium	O
excretion	O
after	O
injection	O
of	O
either	O
CAM	O
-	O
HOPO	O
ligand	O
was	O
700%	O
of	O
that	O
for	O
24	O
-	O
h	O
Pu	O
-	O
injected	O
controls	O
,	O
140%	O
of	O
that	O
for	O
mice	O
given	O
the	O
tetracatecholate	O
analogue	O
3,4,3	O
-	O
LICAM	O
(	O
significantly	O
more	O
,	O
p	O
&	O
lt	O
;	O
0.01	O
)	O
,	O
but	O
only	O
80%	O
of	O
that	O
promoted	O
by	O
3,4,3	O
-	O
LIHOPO	O
(	O
significantly	O
less	O
)	O
.	O

Orally	O
administered	O
3,4,3	O
-	O
LI	O
-	O
(	O
diCAM	O
-	O
diHOPO	O
)	O
promoted	O
significantly	O
more	O
Pu	O
excretion	O
than	O
an	O
equimolar	O
amount	O
of	O
CaNa3DTPA	O
.	O

Potency	O
of	O
the	O
CAM	O
-	O
HOPO	O
ligands	O
for	O
in	O
vivo	O
chelation	O
of	O
Pu	O
(	O
IV	O
)	O
resembled	O
that	O
of	O
structurally	O
hexadentate	I-IUPAC
tris	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxypyridinonate	I-IUPAC
)	I-IUPAC
and	O
tris	I-IUPAC
(	I-IUPAC
sulfocatecholate	I-IUPAC
)	I-IUPAC
ligands	O
and	O
functionally	O
hexadentate	O
tetrakis	I-IUPAC
-	I-IUPAC
(	I-IUPAC
sulfocatecholate	I-IUPAC
)	I-IUPAC
and	O
tetrakis	I-IUPAC
(	I-IUPAC
carboxycatecholate	I-IUPAC
)	I-IUPAC
ligands	O
.	O

The	O
Pu	O
complexes	O
of	O
the	O
CAM	O
-	O
HOPO	O
ligands	O
are	O
to	O
some	O
degree	O
unstable	O
at	O
pH	O
&	O
lt	O
;	O
7.4	O
,	O
as	O
judged	O
by	O
Pu	O
residues	O
in	O
kidneys	O
in	O
excess	O
of	O
24	O
-	O
h	O
Pu	O
-	O
injected	O
controls	O
.	O

Synthetic	O
yields	O
were	O
insufficient	O
for	O
chemical	O
investigations	O
or	O
evaluation	O
of	O
acute	O
toxicity	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

A	O
series	O
of	O
2,6	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2,4	I-IUPAC
-	I-IUPAC
dihydroxyphenyl	I-IUPAC
alkyl	I-IUPAC
ketones	I-IUPAC
has	O
been	O
investigated	O
as	O
inhibitors	O
of	O
hepatic	O
microsomal	O
aniline	O
hydroxylase	O
and	O
aminopyrine	O
demethylase	O
activities	O
.	O

Structural	O
alterations	O
in	O
both	O
series	O
did	O
little	O
to	O
enhance	O
the	O
inhibitory	O
activity	O
of	O
the	O
parent	O
compounds	O
2,6	I-IUPAC
-	I-IUPAC
dihydroxyacetophenone	I-IUPAC
(	O
3	O
)	O
and	O
2,4	I-IUPAC
-	I-IUPAC
dihydroxyacetophenone	I-IUPAC
(	O
27	O
)	O
.	O

In	O
the	O
2,6	O
series	O
activity	O
against	O
both	O
microsomal	O
systems	O
varied	O
only	O
over	O
a	O
relatively	O
narrow	O
range	O
,	O
6	I-IUPAC
-	I-IUPAC
allyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyacetophenone	I-IUPAC
(	O
19	O
)	O
being	O
the	O
most	O
potent	O
inhibitor	O
.	O

In	O
the	O
2,4	O
series	O
,	O
activity	O
against	O
aniline	O
hydroxylase	O
was	O
poor	O
or	O
absent	O
in	O
most	O
cases	O
.	O

tthe	O
most	O
potent	O
inhibitor	O
was	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dihydroxyacetophenone	I-IUPAC
(	O
31	O
)	O
.	O

In	O
contrast	O
,	O
high	O
activity	O
against	O
aminopyrine	O
demethylase	O
was	O
frequently	O
displayed	O
in	O
this	O
series	O
,	O
3,5	I-IUPAC
-	I-IUPAC
dibromo	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dihydroxypropiophenone	I-IUPAC
(	O
36	O
)	O
showing	O
greatest	O
inhibitory	O
potency	O
.	O

The	O
effects	O
of	O
some	O
compounds	O
on	O
hexobarbital	O
sleeping	O
times	O
and	O
zoxazolamine	O
paralysis	O
times	O
in	O
mice	O
were	O
also	O
examined	O
.	O

A	O
series	O
of	O
aporphine	O
nitrogen	O
mustards	O
and	O
their	O
congeners	O
(	O
1b	O
-	O
g	O
)	O
has	O
been	O
prepared	O
.	O

N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
Bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,11	I-IUPAC
-	I-IUPAC
dihyroxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
methoxynoraporphine	I-IUPAC
(	O
1b	O
)	O
and	O
its	O
mono	O
-	O
and	O
diacetyl	O
ester	O
derivatives	O
(	O
1c	O
-	O
d	O
)	O
were	O
prepared	O
from	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,11	I-IUPAC
-	I-IUPAC
diacetoxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
methoxynoraporphine	I-IUPAC
(	O
2	O
)	O
.	O

Reaction	O
of	O
2	O
with	O
diethanolamine	O
under	O
various	O
conditions	O
and	O
different	O
solvents	O
resulted	O
in	O
the	O
corresponding	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
precursors	O
,	O
which	O
were	O
subsequently	O
treated	O
with	O
SOCl2	O
to	O
yield	O
the	O
target	O
compounds	O
.	O

N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
Choroethyl	I-IUPAC
)	I-IUPAC
norapocodeine	I-IUPAC
(	O
1e	O
)	O
was	O
obtained	O
from	O
the	O
chlorination	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
norapocodeine	I-IUPAC
(	O
9	O
)	O
with	O
SOCl2	O
.	O

Prolonging	O
such	O
treatment	O
was	O
found	O
to	O
result	O
in	O
the	O
formation	O
of	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloroethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
norapocodeine	I-IUPAC
(	O
1f	O
)	O
at	O
the	O
expense	O
of	O
1e	O
.	O

N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
Chloroethyl	I-IUPAC
)	I-IUPAC
carbamyl	I-IUPAC
]	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
norapocodeine	I-IUPAC
(	O
1g	O
)	O
and	O
its	O
11	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
carbamyl	I-IUPAC
derivative	I-MODIFIER
(	O
1h	O
)	O
were	O
also	O
prepared	O
.	O

All	O
the	O
double	O
-	O
armed	O
aporphine	O
amide	O
nitrogen	O
mustards	O
(	O
ab	O
-	O
d	O
)	O
were	O
found	O
to	O
have	O
antitumor	O
activity	O
.	O

The	O
single	O
-	O
armed	O
aporphine	O
nitrogen	O
mustard	O
(	O
1e	O
)	O
was	O
also	O
active	O
in	O
P388	O
but	O
the	O
activity	O
was	O
less	O
than	O
that	O
observed	O
with	O
1b	O
-	O
d	O
.	O

The	O
lead	O
compound	O
1a	O
was	O
inactive	O
in	O
the	O
LE1210	O
and	O
P388	O
systems	O
at	O
the	O
doses	O
tested	O
.	O

Similarly	O
,	O
the	O
two	O
aporphine	O
mustard	O
congeners	O
(	O
1f	O
,	O
g	O
)	O
were	O
also	O
inactive	O
in	O
the	O
P388	O
system	O
.	O

All	O
the	O
activity	O
was	O
observed	O
in	O
the	O
intraperitoneally	O
innoculated	O
tumor	O
systems	O
.	O

7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Aminosulfonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
(	O
SK	O
&	O
amp	O
;	O
F	O
29661	O
,	O
1	O
)	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
enzyme	O
phenylethanolamine	O
N	O
-	O
methyltransferase	O
(	O
PNMT	O
,	O
EC	O
2.1.1.28	O
)	O
.	O

In	O
contrast	O
to	O
other	O
inhibitors	O
of	O
PNMT	O
,	O
it	O
is	O
also	O
highly	O
selective	O
toward	O
PNMT	O
in	O
comparison	O
with	O
its	O
affinity	O
toward	O
the	O
alpha	O
2	O
-	O
adrenoceptor	O
(	O
PNMT	O
Ki	O
=	O
0.55	O
microM	O
,	O
alpha	O
2	O
Ki	O
=	O
100	O
microM	O
,	O
selectivity	O
[	O
alpha	O
2	O
Ki	O
/	O
PNMT	O
Ki	O
]	O
=	O
180	O
)	O
.	O

A	O
diverse	O
set	O
of	O
compounds	O
was	O
synthesized	O
and	O
evaluated	O
to	O
probe	O
the	O
role	O
of	O
the	O
acidic	O
hydrogen	O
of	O
the	O
aminosulfonyl	I-IUPAC
group	B-MODIFIER
of	O
1	O
in	O
imparting	O
this	O
selectivity	O
.	O

Compounds	O
were	O
designed	O
to	O
investigate	O
the	O
effect	O
on	O
selectivity	O
of	O
the	O
acidity	O
of	O
the	O
NH	O
group	O
[	O
the	O
7	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
(	O
compound	O
5	O
)	O
and	O
7	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
(	O
compound	O
4	O
)	O
derivatives	I-MODIFIER
of	O
1	O
]	O
,	O
the	O
relative	O
spatial	O
position	O
of	O
the	O
acidic	O
hydrogen	I-IUPAC
[	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylsulfonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
(	O
6	O
)	O
and	O
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylsulfonyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
(	O
8	O
)	O
]	O
,	O
or	O
the	O
effect	O
of	O
the	O
substitution	O
of	O
an	O
acidic	O
phenolic	O
group	O
for	O
the	O
aminosulfonyl	I-IUPAC
moiety	B-MODIFIER
[	B-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxynaphthalene	I-IUPAC
(	O
23	O
)	O
and	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydrobenz	I-IUPAC
[	I-IUPAC
h	I-IUPAC
]	I-IUPAC
isoquinoline	I-IUPAC
(	O
9	O
)	O
]	O
.	O

All	O
of	O
the	O
compounds	O
studied	O
displayed	O
lower	O
affinity	O
for	O
PNMT	O
than	O
1	O
,	O
and	O
nine	O
of	O
the	O
eleven	O
compounds	O
studied	O
showed	O
increased	O
,	O
rather	O
than	O
the	O
desired	O
decreased	O
,	O
affinity	O
for	O
the	O
alpha	O
2	O
-	O
adrenoceptor	O
.	O

Specifically	O
,	O
compound	O
4	O
,	O
in	O
which	O
the	O
aminosulfonyl	O
NH	O
group	O
is	O
more	O
acidic	O
than	O
that	O
in	O
1	O
,	O
showed	O
greatly	O
reduced	O
selectivity	O
on	O
account	O
of	O
increased	O
alpha	O
2	O
-	O
adrenoceptor	O
affinity	O
as	O
compared	O
to	O
1	O
(	O
PNMT	O
Ki	O
=	O
2.6	O
microM	O
,	O
alpha	O
2	O
Ki	O
=	O
6.3	O
microM	O
,	O
selectivity	O
=	O
2.4	O
)	O
.	O

Compound	O
8	O
,	O
in	O
which	O
the	O
acidic	O
NH	O
group	O
is	O
in	O
the	O
same	O
region	O
of	O
space	O
as	O
that	O
in	O
1	O
,	O
although	O
the	O
aminosulfonyl	I-IUPAC
group	B-MODIFIER
is	O
reversed	O
with	O
respect	O
to	O
the	O
aromatic	O
ring	O
,	O
showed	O
poor	O
PNMT	O
affinity	O
and	O
modest	O
alpha	O
2	O
-	O
adrenoceptor	O
affinity	O
(	O
PNMT	O
Ki	O
=	O
330	O
microM	O
,	O
alpha	O
2	O
Ki	O
=	O
18	O
microM	O
,	O
selectivity	O
=	O
0.055	O
)	O
.	O

Compound	O
9	O
,	O
in	O
which	O
a	O
phenolic	O
group	O
is	O
in	O
the	O
same	O
region	O
of	O
space	O
as	O
the	O
acidic	O
NH	O
of	O
1	O
,	O
exhibited	O
the	O
best	O
alpha	O
2	O
-	O
adrenoceptor	O
affinity	O
of	O
any	O
of	O
the	O
compounds	O
studied	O
(	O
PNMT	O
Ki	O
=	O
0.98	O
microM	O
,	O
alpha	O
2	O
Ki	O
=	O
0.078	O
microM	O
,	O
selectivity	O
=	O
0.080	O
)	O
.	O

Results	O
from	O
this	O
study	O
suggest	O
that	O
the	O
selectivity	O
of	O
1	O
is	O
not	O
solely	O
due	O
to	O
the	O
presence	O
of	O
an	O
acidic	O
hydrogen	O
on	O
the	O
7	I-IUPAC
-	I-IUPAC
aminosulfonyl	I-IUPAC
group	I-MODIFIER
of	O
1	O
but	O
is	O
likely	O
also	O
dependent	O
on	O
some	O
other	O
property	O
(	O
e.g.	O
electron	O
-	O
withdrawing	O
character	O
)	O
of	O
the	O
aminosulfonyl	I-IUPAC
group	B-MODIFIER
.	O

Synthetic	O
routes	O
to	O
a	O
series	O
of	O
mono	I-PARTIUPAC
-	I-PARTIUPAC
and	O
difluorinated	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	O
substituted	I-MODIFIER
-	O
phenyl	I-IUPAC
)	I-IUPAC
benzothiazoles	I-IUPAC
have	O
been	O
devised	O
.	O

Whereas	O
mixtures	O
of	O
regioisomeric	O
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
7	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
benzothiazoles	I-IUPAC
were	O
formed	O
from	O
the	O
established	O
Jacobsen	O
cyclization	O
of	O
precursor	O
3	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
thiobenzanilides	I-IUPAC
,	O
two	O
modifications	O
to	O
this	O
general	O
process	O
have	O
allowed	O
the	O
synthesis	O
of	O
pure	O
samples	O
of	O
these	O
target	O
compounds	O
.	O

Fluorinated	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
benzothiazoles	I-IUPAC
were	O
potently	O
cytotoxic	O
(	O
GI	O
(	O
50	O
)	O
&	O
lt	O
;	O
1	O
nM	O
)	O
in	O
vitro	O
in	O
sensitive	O
human	O
breast	O
MCF	O
-	O
7	O
(	O
ER+	O
)	O
and	O
MDA	O
468	O
(	O
ER	O
-	O
)	O
cell	O
lines	O
but	O
inactive	O
(	O
GI	O
(	O
50	O
)	O
&	O
gt	O
;	O
10	O
microM	O
)	O
against	O
PC	O
3	O
prostate	O
,	O
nonmalignant	O
HBL	O
100	O
breast	O
,	O
and	O
HCT	O
116	O
colon	O
cells	O
.	O

The	O
biphasic	O
dose	O
-	O
response	O
relationship	O
characteristically	O
shown	O
by	O
the	O
benzothiazole	O
series	O
against	O
sensitive	O
cell	O
lines	O
was	O
exhibited	O
by	O
the	O
4	I-PARTIUPAC
-	I-PARTIUPAC
and	O
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
benzothiazoles	I-IUPAC
(	O
10b	O
,	O
d	O
)	O
but	O
not	O
by	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
7	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
benzothiazoles	I-IUPAC
(	O
10h	O
,	O
i	O
)	O
.	O

The	O
most	O
potent	O
broad	O
spectrum	O
agent	O
in	O
the	O
NCI	O
cell	O
panel	O
was	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorobenzothiazole	I-IUPAC
(	O
10h	O
)	O
which	O
,	O
unlike	O
the	O
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
isomer	I-MODIFIER
(	O
10d	O
)	O
,	O
produces	O
no	O
exportable	O
metabolites	O
in	O
the	O
presence	O
of	O
sensitive	O
MCF	O
-	O
7	O
cells	O
.	O

Induction	O
of	O
cytochrome	O
P450	O
CYP1A1	O
,	O
a	O
crucial	O
event	O
in	O
determining	O
the	O
antitumor	O
specificity	O
of	O
this	O
series	O
of	O
benzothiazoles	O
,	O
was	O
not	O
compromised	O
.	O

10h	O
is	O
currently	O
the	O
focus	O
of	O
pharmaceutical	O
and	O
preclinical	O
development	O
.	O

With	O
a	O
novel	O
assay	O
using	O
isolated	O
ferret	O
detrusor	O
to	O
estimate	O
beta	O
(	O
3	O
)	O
-	O
adrenoceptor	O
agonistic	O
activity	O
,	O
we	O
found	O
that	O
a	O
series	O
of	O
glycine	O
derivatives	O
of	O
ritodrine	O
,	O
a	O
beta	O
(	O
2	O
)	O
-	O
adrenoceptor	O
agonist	O
,	O
are	O
potent	O
beta	O
(	O
3	O
)	O
-	O
adrenoceptor	O
agonists	O
,	O
with	O
excellent	O
selectivity	O
versus	O
beta	O
(	O
1	O
)	O
and	O
beta	O
(	O
2	O
)	O
subtypes	O
.	O

Substitution	O
of	O
halogens	O
in	O
the	O
phenyl	I-IUPAC
ring	B-MODIFIER
increased	O
potency	O
and	O
selectivity	O
for	O
the	O
beta	O
(	O
3	O
)	O
-	O
adrenoceptor	O
,	O
and	O
this	O
was	O
dependent	O
upon	O
the	O
position	O
of	O
the	O
halogens	O
.	O

The	O
chlorine	O
-	O
substituted	O
derivatives	O
3f	O
-	O
i	O
exhibited	O
potent	O
beta	O
(	O
3	O
)	O
-	O
adrenoceptor	O
-	O
mediated	O
relaxation	O
of	O
ferret	O
detrusor	O
(	O
EC	O
(	O
50	O
)	O
=	O
0.93	O
,	O
11	O
,	O
14	O
,	O
and	O
160	O
nM	O
)	O
and	O
higher	O
potency	O
at	O
beta	O
(	O
3	O
)	O
-	O
adrenoceptors	O
than	O
at	O
beta	O
(	O
1	O
)	O
or	O
beta	O
(	O
2	O
)	O
.	O

The	O
intravenous	O
administration	O
of	O
3h	O
significantly	O
reduced	O
the	O
urinary	O
bladder	O
pressure	O
in	O
anesthetized	O
male	O
rats	O
(	O
ED	O
(	O
50	O
)	O
=	O
48	O
microg	O
/	O
kg	O
)	O
without	O
cardiovascular	O
side	O
effects	O
.	O

This	O
article	O
is	O
the	O
first	O
report	O
of	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
concerning	O
beta	O
(	O
3	O
)	O
-	O
adrenoceptor	O
agonists	O
as	O
agents	O
for	O
the	O
treatment	O
of	O
urinary	O
frequency	O
and	O
incontinence	O
.	O

Sugar	O
-	O
modified	O
analogs	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
1	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
3	O
)	O
were	O
prepared	O
in	O
an	O
effort	O
to	O
obtain	O
selective	O
antiviral	O
agents	O
.	O

Treatment	O
of	O
ethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
pyrrole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
6	O
)	O
with	O
hydrazine	O
afforded	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
7	O
)	O
.	O

Treatment	O
of	O
7	O
with	O
bromine	O
afforded	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
hydrobromide	I-IUPAC
(	O
9	O
)	O
.	O

The	O
benzyl	I-IUPAC
ether	I-IUPAC
functions	I-MODIFIER
of	O
7	O
and	O
9	O
were	O
removed	O
with	O
boron	O
trichloride	O
to	O
afford	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
8	O
)	O
and	O
its	O
3	O
-	O
bromo	O
analog	O
10	O
.	O

4	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrida	I-IUPAC
zin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
13	O
)	O
was	O
prepared	O
by	O
the	O
sodium	O
salt	O
condensation	O
of	O
ethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyanopyrrole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
5	O
)	O
with	O
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
chloride	I-IUPAC
(	O
11	O
)	O
followed	O
by	O
ring	O
annulation	O
with	O
hydrazine	O
.	O

Deprotection	O
of	O
ethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
pyrr	I-IUPAC
ole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
12	O
)	O
using	O
sodium	O
ethoxide	O
furnished	O
ethyl	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyanopyrrole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
late	I-IUPAC
(	O
14	O
)	O
which	O
served	O
as	O
the	O
starting	O
material	O
for	O
the	O
preparation	O
of	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
20	O
)	O
.	O

Selective	O
protection	O
of	O
the	O
5'	I-IUPAC
-	I-IUPAC
hydroxyl	I-IUPAC
group	I-MODIFIER
of	O
14	O
with	O
tert	I-IUPAC
-	I-IUPAC
butyldimethylsilyl	I-IUPAC
chloride	I-IUPAC
followed	O
by	O
a	O
Barton	O
type	O
deoxygenation	O
sequence	O
of	O
the	O
3'	I-IUPAC
-	I-IUPAC
hydroxyl	I-IUPAC
groups	I-MODIFIER
afforded	O
ethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyldimethylsilyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
glycero	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
]	I-IUPAC
pyrrole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
18	O
)	O
.	O

Deprotection	O
of	O
18	O
with	O
tetra	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butylammonium	I-IUPAC
fluoride	I-IUPAC
and	O
ring	O
annulation	O
with	O
hydrazine	O
afforded	O
20	O
.	O

The	O
acyclic	I-MODIFIER
analog	I-MODIFIER
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
24	O
)	O
was	O
prepared	O
via	O
the	O
sodium	O
salt	O
glycosylation	O
of	O
5	O
with	O
(	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
bromide	I-IUPAC
(	O
22	O
)	O
followed	O
by	O
a	O
ring	O
annulation	O
with	O
hydrazine	O
.	O

N	I-IUPAC
-	I-IUPAC
Bromosuccinimide	I-IUPAC
treatment	O
of	O
13	O
,	O
20	O
,	O
and	O
25	O
afforded	O
the	O
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
derivatives	I-MODIFIER
15	O
,	O
21	O
,	O
and	O
25	O
.	O

Evaluation	O
of	O
these	O
compounds	O
in	O
L1210	O
,	O
HFF	O
,	O
and	O
KB	O
cells	O
showed	O
that	O
the	O
sugar	O
-	O
modified	O
analogs	O
all	O
were	O
less	O
cytotoxic	O
than	O
their	O
corresponding	O
ribonucleoside	O
analogs	O
.	O

The	O
compounds	O
also	O
were	O
less	O
active	O
against	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
and	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
.	O

The	O
3	O
-	O
bromo	O
derivatives	O
were	O
much	O
more	O
active	O
than	O
the	O
3	O
-	O
unsubstituted	O
analogs	O
in	O
both	O
the	O
cytotoxicity	O
,	O
and	O
antiviral	O
assays	O
.	O

However	O
,	O
there	O
was	O
only	O
modest	O
separation	O
between	O
activity	O
against	O
HCMV	O
and	O
cytotoxicity	O
and	O
there	O
was	O
virtually	O
no	O
selectivity	O
for	O
activity	O
against	O
HSV	O
-	O
1	O
.	O

The	O
conformationally	O
restricted	O
linear	O
tricyclic	O
analogs	O
of	O
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetralins	I-IUPAC
were	O
investigated	O
for	O
their	O
serotonergic	O
and	O
dopaminergic	O
properties	O
.	O

These	O
cis	O
and	O
trans	O
analogs	O
of	O
2,3,3	I-IUPAC
a	I-IUPAC
,	I-IUPAC
4,9,9	I-IUPAC
a	I-IUPAC
-	I-IUPAC
hexahydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benz	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
(	O
3	O
)	O
,	O
where	O
a	O
five	O
-	O
membered	O
ring	O
is	O
fused	O
between	O
the	O
nitrogen	O
and	O
C	O
-	O
3	O
carbon	O
of	O
2	I-IUPAC
-	I-IUPAC
aminotetralin	I-IUPAC
,	O
were	O
synthesized	O
from	O
5	I-PARTIUPAC
-	I-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
and	O
8	I-IUPAC
-	I-IUPAC
methoxytetralones	I-IUPAC
.	O

The	O
enantiomers	O
of	O
trans	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
and	O
-	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
allyl	I-PARTIUPAC
analogs	I-MODIFIER
were	O
obtained	O
via	O
fractional	O
recrystallization	O
of	O
their	O
di	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
(	O
or	O
D	I-PARTIUPAC
)	O
tartaric	I-IUPAC
acid	I-IUPAC
salts	I-IUPAC
.	O

All	O
analogs	O
were	O
evaluated	O
in	O
the	O
in	O
vitro	O
5	O
-	O
HT1A	O
and	O
D2	O
binding	O
assays	O
and	O
selected	O
analogs	O
were	O
investigated	O
further	O
in	O
biochemical	O
and	O
behavioral	O
tests	O
.	O

In	O
the	O
5	O
-	O
substituted	O
series	O
(	O
R1	O
in	O
3	O
)	O
,	O
the	O
trans	O
isomers	O
were	O
found	O
to	O
possess	O
higher	O
levels	O
of	O
pharmacological	O
activity	O
then	O
the	O
corresponding	O
cis	O
isomers	O
.	O

The	O
trans	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
analogs	I-MODIFIER
showed	O
selective	O
5	O
-	O
HT1A	O
receptor	O
activity	O
in	O
vitro	O
but	O
displayed	O
mixed	O
5	O
-	O
HT1A	O
and	O
D2	O
agonist	O
properties	O
in	O
vivo	O
.	O

The	O
corresponding	O
trans	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
analogs	I-MODIFIER
were	O
found	O
to	O
be	O
potent	O
D2	O
agonists	O
with	O
full	O
intrinsic	O
activity	O
.	O

An	O
examination	O
of	O
nitrogen	O
substitution	O
(	O
R2	O
in	O
3	O
)	O
revealed	O
that	O
analogs	O
with	O
either	O
an	O
allyl	O
or	O
an	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	I-MODIFIER
displayed	O
equipotent	O
activities	O
.	O

Substitution	O
with	O
a	O
cyclopropylmethyl	O
or	O
benzyl	O
group	O
resulted	O
in	O
reduced	O
activity	O
.	O

Among	O
the	O
resolved	O
analogs	O
tested	O
,	O
the	O
activity	O
was	O
found	O
to	O
reside	O
exclusively	O
in	O
the	O
(	O
3aS	O
)	O
-	O
(	O
-	O
)	O
-	O
enantiomers	O
.	O

In	O
the	O
8	O
-	O
substituted	O
series	O
(	O
R1	O
in	O
3	O
)	O
,	O
only	O
8	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
analogs	I-MODIFIER
were	O
synthesized	O
and	O
evaluated	O
.	O

In	O
this	O
case	O
,	O
both	O
cis	O
and	O
trans	O
isomers	O
showed	O
equally	O
weak	O
in	O
vitro	O
5	O
-	O
HT1A	O
receptor	O
agonist	O
activity	O
devoid	O
of	O
dopaminergic	O
effects	O
.	O

The	O
presence	O
of	O
an	O
additional	O
methyl	O
group	O
at	O
the	O
C	O
-	O
2	O
position	O
(	O
R3	O
in	O
3	O
)	O
of	O
the	O
cis	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
analog	I-MODIFIER
resulted	O
in	O
enhancement	O
of	O
in	O
vitro	O
5	O
-	O
HT1A	O
receptor	O
binding	O
affinity	O
,	O
with	O
the	O
(	O
2	O
beta	O
,	O
3a	O
alpha	O
,	O
9a	O
alpha	O
)	O
-	O
(	O
+	O
/	O
-	O
)	O
-	O
isomer	O
displaying	O
potency	O
35	O
times	O
greater	O
than	O
the	O
(	O
2	O
alpha	O
,	O
3a	O
alpha	O
,	O
9a	O
alpha	O
)	O
-	O
(	O
+	O
/	O
-	O
)	O
-	O
isomer	O
.	O

N	I-IUPAC
-	I-IUPAC
Acetyl	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
imine	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
imine	I-IUPAC
were	O
prepared	O
from	O
2,6	I-IUPAC
-	I-IUPAC
dimethylacetaminophen	I-IUPAC
and	O
3,5	I-IUPAC
-	I-IUPAC
dimethylacetaminophen	I-IUPAC
by	O
oxidation	O
with	O
lead	O
tetraacetate	O
.	O

Reaction	O
of	O
N	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
imine	I-IUPAC
with	O
hydrochloric	O
acid	O
gave	O
3'	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyacetanilide	I-IUPAC
,	O
whereas	O
ethanethiol	O
,	O
aniline	O
,	O
and	O
ethanol	O
gave	O
tetrahedral	O
adducts	O
resulting	O
from	O
addition	O
to	O
the	O
imine	O
carbon	O
.	O

Water	O
gave	O
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
.	O

With	O
N	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
imine	I-IUPAC
,	O
water	O
and	O
aniline	O
gave	O
substitution	O
on	O
the	O
imine	O
carbon	O
,	O
yielding	O
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
and	O
3,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
benzoquinone	I-IUPAC
imine	I-IUPAC
,	O
respectively	O
.	O

Ethanethiol	O
gave	O
3'	I-IUPAC
.5	I-IUPAC
'	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyacetanilide	I-IUPAC
.	O

The	O
toxicity	O
of	O
2,6	I-IUPAC
-	I-IUPAC
dimethylacetaminophen	I-IUPAC
and	O
3,5	I-IUPAC
-	I-IUPAC
dimethylacetaminophen	I-IUPAC
was	O
examined	O
histologically	O
in	O
mice	O
and	O
rats	O
.	O

3,5	I-IUPAC
-	I-IUPAC
Dimethylacetaminophen	I-IUPAC
was	O
slightly	O
more	O
nephrotoxic	O
but	O
showed	O
a	O
similar	O
hepatotoxicity	O
to	O
acetaminophen	O
.	O

2,6	I-IUPAC
-	I-IUPAC
Dimethylacetaminophen	I-IUPAC
,	O
like	O
N	I-IUPAC
-	I-IUPAC
methylacetaminophen	I-IUPAC
,	O
showed	O
very	O
little	O
tissue	O
damage	O
.	O

The	O
in	O
vitro	O
pharmacological	O
properties	O
and	O
conformational	O
features	O
of	O
analogs	O
of	O
the	O
delta	O
opioid	O
receptor	O
selective	O
tetrapeptide	O
Tyr	O
-	O
c	O
[	O
D	O
-	O
Cys	O
-	O
Phe	O
-	O
D	O
-	O
Pen	O
]	O
OH	O
(	O
JOM	O
-	O
13	O
)	O
in	O
which	O
the	O
Phe3	O
residue	O
was	O
replaced	O
by	O
each	O
of	O
the	O
four	O
stereoisomers	O
of	O
beta	I-IUPAC
-	I-IUPAC
methylphenylalanine	I-IUPAC
(	O
beta	O
-	O
MePhe	O
)	O
were	O
investigated	O
.	O

Both	O
analogs	O
in	O
which	O
the	O
alpha	O
carbon	O
of	O
the	O
Phe3	O
replacement	O
has	O
L	O
-	O
stereochemistry	O
display	O
high	O
affinity	O
for	O
delta	O
receptors	O
with	O
the	O
(	O
2S	O
,	O
3S	O
)	O
-	O
MePhe3	O
analog	O
exhibiting	O
approximately	O
8	O
-	O
fold	O
higher	O
affinity	O
than	O
the	O
(	O
2S	O
,	O
3R	O
)	O
-	O
MePhe3	O
diastereomer	O
.	O

Surprisingly	O
,	O
one	O
analog	O
with	O
D	O
-	O
stereochemistry	O
in	O
residue	O
3	O
,	O
the	O
(	O
2R	O
,	O
3R	O
)	O
-	O
MePhe3	O
analog	O
,	O
also	O
displays	O
high	O
affinity	O
for	O
the	O
delta	O
receptor	O
and	O
is	O
extraordinarily	O
selective	O
for	O
this	O
receptor	O
.	O

All	O
analogs	O
were	O
agonists	O
in	O
the	O
mouse	O
vas	O
deferens	O
(	O
MVD	O
)	O
and	O
guinea	O
pig	O
ileum	O
(	O
GPI	O
)	O
smooth	O
muscle	O
bioassays	O
,	O
displaying	O
MVD	O
and	O
GPI	O
potencies	O
consistent	O
with	O
their	O
delta	O
and	O
mu	O
opioid	O
receptor	O
affinities	O
,	O
respectively	O
.	O

The	O
use	O
of	O
beta	O
-	O
MePhe	O
as	O
a	O
replacement	O
for	O
Phe3	O
was	O
based	O
upon	O
the	O
desire	O
to	O
reduce	O
the	O
conformational	O
flexibility	O
of	O
the	O
Phe3	O
side	O
chain	O
by	O
imposing	O
a	O
steric	O
rotational	O
constraint	O
in	O
the	O
form	O
of	O
the	O
beta	O
-	O
methyl	O
substituent	O
and	O
to	O
thus	O
deduce	O
the	O
residue	O
3	O
side	O
chain	O
orientation	O
in	O
the	O
delta	O
receptor	O
-	O
bound	O
conformation	O
from	O
the	O
correlation	O
between	O
delta	O
receptor	O
binding	O
affinities	O
and	O
conformational	O
preferences	O
.	O

Molecular	O
mechanics	O
computations	O
revealed	O
,	O
however	O
,	O
that	O
the	O
conformational	O
constraints	O
imposed	O
by	O
the	O
beta	O
-	O
methyl	O
group	O
in	O
the	O
(	O
2S	O
,	O
3S	O
)	O
-	O
MePhe3	O
and	O
(	O
2S	O
,	O
3R	O
)	O
-	O
MePhe3	O
analogs	O
were	O
too	O
modest	O
to	O
allow	O
unequivocal	O
determination	O
of	O
delta	O
receptor	O
-	O
bound	O
residue	O
3	O
side	O
chain	O
conformation	O
.	O

However	O
,	O
analysis	O
of	O
the	O
high	O
-	O
affinity	O
(	O
2R	O
,	O
3R	O
)	O
-	O
MePhe3	O
analog	O
revealed	O
a	O
strong	O
preference	O
for	O
a	O
single	O
side	O
chain	O
conformer	O
(	O
chi	O
1	O
approximately	O
60	O
degrees	O
)	O
.	O

Low	O
-	O
energy	O
conformers	O
of	O
this	O
analog	O
could	O
only	O
be	O
effectively	O
superimposed	O
with	O
low	O
-	O
energy	O
conformers	O
of	O
the	O
parent	O
peptide	O
in	O
which	O
the	O
Phe3	O
side	O
chain	O
conformation	O
was	O
limited	O
to	O
chi	O
1	O
approximately	O
-	O
60	O
degrees	O
.	O

This	O
observation	O
eliminates	O
the	O
last	O
remaining	O
uncertainty	O
regarding	O
conformational	O
features	O
of	O
the	O
pharmacophore	O
elements	O
in	O
the	O
delta	O
receptor	O
-	O
bound	O
state	O
,	O
allowing	O
the	O
proposal	O
of	O
a	O
complete	O
model	O
.	O

Aromatic	O
carboxylic	O
esters	O
of	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidinol	I-IUPAC
were	O
prepared	O
and	O
evaluated	O
for	O
analgesic	O
activity	O
.	O

In	O
addition	O
,	O
aralkyl	I-IUPAC
,	O
alkyl	I-IUPAC
,	O
and	O
cycloalkyl	I-IUPAC
carboxylates	B-IUPAC
of	O
the	O
4	I-IUPAC
-	I-IUPAC
piperidinol	I-IUPAC
system	I-MODIFIER
and	O
3,4	I-IUPAC
-	I-IUPAC
dimethoxybenzoates	I-IUPAC
of	O
isomeric	O
piperidinols	O
(	O
24-26	O
)	O
were	O
synthesized	O
.	O

The	O
3,4	I-IUPAC
-	I-IUPAC
dimethoxybenzoate	I-IUPAC
23	O
was	O
nearly	O
twice	O
as	O
active	O
as	O
codeine	O
in	O
the	O
mouse	O
hot	O
-	O
plate	O
assay	O
.	O

In	O
monkeys	O
,	O
23	O
showed	O
no	O
morphine	O
-	O
like	O
physical	O
dependence	O
liability	O
,	O
cis	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidinol	I-IUPAC
esters	I-IUPAC
24	O
and	O
25	O
showed	O
no	O
binding	O
to	O
the	O
opiate	O
receptor	O
in	O
rat	O
brain	O
homogenates	O
.	O

The	O
3	O
-	O
and	O
4	O
-	O
monosubstituted	O
and	O
the	O
3,4	O
-	O
disubstituted	O
benzoate	O
esters	O
were	O
examined	O
for	O
qualitative	O
structure	O
-	O
activity	O
relationships	O
with	O
respect	O
to	O
parameters	O
Esc	O
and	O
pi	O
.	O

Various	O
structural	O
features	O
of	O
this	O
series	O
of	O
compounds	O
that	O
may	O
have	O
an	O
affinity	O
for	O
receptor	O
binding	O
sites	O
are	O
discussed	O
.	O

Convenient	O
and	O
efficient	O
methods	O
were	O
developed	O
for	O
preparing	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
(	O
Thf	O
-	O
FU	O
,	O
3	O
)	O
[	O
trade	O
name	O
,	O
Futraful	O
(	O
Ftorafur	O
)	O
or	O
FT	O
-	O
207	O
]	O
,	O
which	O
is	O
used	O
clinically	O
as	O
an	O
antitumor	O
agent	O
,	O
and	O
1,3	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
(	O
Thf2	O
-	O
FU	O
,	O
4	O
)	O
.	O

For	O
the	O
syntheses	O
,	O
2,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
trimethylsily	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
(	O
Me3Si	O
-	O
FU	O
,	O
1	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
acetoxytetrahydrofuran	I-IUPAC
(	O
Thf	O
-	O
OAc	O
,	O
2	O
)	O
were	O
condensed	O
in	O
the	O
presence	O
of	O
Friedel	O
-	O
Crafts	O
catalysts	O
,	O
such	O
as	O
SnCl4	O
and	O
BF3	O
-	O
Et2O	O
in	O
dichloromethane	O
,	O
or	O
in	O
the	O
presence	O
of	O
NaI	O
in	O
acetonitrile	O
to	O
give	O
Thf	O
-	O
Fu	O
or	O
Thf2	O
-	O
FU	O
depending	O
on	O
the	O
reaction	O
conditions	O
and	O
workup	O
procedure	O
.	O

A	O
trace	O
of	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
(	O
3	O
-	O
Thf	O
-	O
FU	O
,	O
5	O
)	O
was	O
formed	O
in	O
these	O
reactions	O
.	O

Thf2	O
-	O
FU	O
was	O
easily	O
hydrolyzed	O
to	O
Thf	O
-	O
FU	O
.	O

2	I-IUPAC
-	I-IUPAC
Methoxytetrahydrofuran	I-IUPAC
can	O
be	O
used	O
instead	O
of	O
Thf	O
-	O
OAc	O
for	O
preparation	O
of	O
Thf	O
-	O
FU	O
under	O
similar	O
conditions	O
.	O

The	O
optimal	O
ratios	O
of	O
Me3Si	O
-	O
FU	O
,	O
Thf	O
-	O
OAc	O
,	O
and	O
SnCl4	O
or	O
NaI	O
for	O
preparation	O
of	O
Thf	O
-	O
FU	O
and	O
Thf2	O
-	O
FU	O
were	O
determined	O
.	O

In	O
all	O
cases	O
,	O
2-2.5	O
equiv	O
of	O
Thf	O
-	O
OAc	O
with	O
respect	O
to	O
Me3Si	O
-	O
FU	O
gave	O
the	O
best	O
results	O
.	O

The	O
yields	O
of	O
Thf	O
-	O
FU	O
and	O
more	O
especially	O
of	O
Thf2	O
-	O
FU	O
were	O
greatly	O
dependent	O
on	O
the	O
relative	O
amount	O
of	O
SnCl4	O
,	O
and	O
0.01-0.1	O
equiv	O
of	O
the	O
catalyst	O
with	O
respect	O
to	O
Me3Si	O
-	O
FU	O
gave	O
the	O
best	O
results	O
.	O

Thf2	O
-	O
FU	O
was	O
found	O
to	O
be	O
effective	O
against	O
murine	O
solid	O
tumors	O
and	O
it	O
was	O
less	O
toxic	O
than	O
Thf	O
-	O
FU	O
when	O
given	O
orally	O
.	O

The	O
antitumor	O
activity	O
of	O
3	O
-	O
Thf	O
-	O
FU	O
is	O
also	O
reported	O
.	O

Previous	O
findings	O
suggesting	O
that	O
5,10	I-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
-	O
substituted	I-MODIFIER
derivatives	I-MODIFIER
of	O
5,10	I-IUPAC
-	I-IUPAC
dideazaaminopterin	I-IUPAC
warranted	O
study	O
as	O
potential	O
antifolates	O
prompted	O
synthesis	O
of	O
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
dideazaaminopterin	I-IUPAC
(	O
12a	O
)	O
.	O

The	O
key	O
step	O
in	O
the	O
synthetic	O
route	O
to	O
12a	O
was	O
Wittig	O
condensation	O
of	O
the	O
tributylphosphorane	O
derived	O
from	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylpyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
7a	O
)	O
with	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
propionylbenzoate	I-IUPAC
.	O

Reaction	O
conditions	O
for	O
the	O
Wittig	O
condensation	O
were	O
developed	O
using	O
the	O
tributylphosphorane	O
prepared	O
from	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
pteridinediamine	I-IUPAC
(	O
7b	O
)	O
as	O
a	O
model	O
.	O

Each	O
of	O
the	O
respective	O
Wittig	O
products	O
8a	O
and	O
8b	O
was	O
obtained	O
in	O
75-80%	O
yield	O
.	O

Hydrogenation	O
of	O
8a	O
and	O
8b	O
at	O
their	O
9,10	O
-	O
double	O
bond	O
afforded	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
9a	O
)	O
and	O
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
deazapteroic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
9b	O
)	O
.	O

This	O
route	O
to	O
9b	O
intersects	O
reported	O
synthetic	O
approaches	O
leading	O
to	O
10	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
(	O
10	O
-	O
EDAM	O
,	O
edatrexate	O
)	O
,	O
an	O
agent	O
now	O
in	O
advanced	O
clinical	O
trials	O
.	O

Thus	O
the	O
Wittig	O
approach	O
affords	O
an	O
alternative	O
synthetic	O
route	O
to	O
10	O
-	O
EDAM	O
.	O

Remaining	O
steps	O
were	O
ester	O
hydrolysis	O
of	O
9a	O
,	O
b	O
to	O
give	O
carboxylic	O
acids	O
10a	O
,	O
b	O
followed	O
by	O
standard	O
peptide	O
coupling	O
with	O
diethyl	O
L	O
-	O
glutamate	O
to	O
produce	O
diethyl	O
esters	O
11a	O
,	O
b	O
,	O
which	O
on	O
hydrolysis	O
gave	O
12a	O
and	O
10	O
-	O
EDAM	O
(	O
12b	O
)	O
,	O
respectively	O
.	O

The	O
relative	O
influx	O
of	O
12a	O
was	O
enhanced	O
about	O
3.2	O
-	O
fold	O
over	O
MTX	O
,	O
but	O
as	O
an	O
inhibitor	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
from	O
L1210	O
cells	O
and	O
in	O
the	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
in	O
vitro	O
,	O
this	O
compound	O
was	O
approximately	O
20	O
-	O
fold	O
less	O
effective	O
than	O
MTX	O
(	O
DHFR	O
inhibition	O
,	O
Ki	O
=	O
4.82	O
+	O
/	O
-	O
0.60	O
pM	O
for	O
MTX	O
,	O
100	O
pM	O
for	O
12a	O
;	O
cell	O
growth	O
,	O
IC50	O
=	O
3.4	O
+	O
/	O
-	O
1.0	O
nM	O
for	O
MTX	O
,	O
65	O
+	O
/	O
-	O
18	O
nM	O
for	O
12a	O
)	O
.	O

The	O
lead	O
compound	O
of	O
a	O
new	O
series	O
of	O
3	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
ethers	I-IUPAC
,	O
the	O
azetidine	O
derivative	O
A	O
-	O
85380	O
(	O
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azetidinylmethoxy	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
)	O
,	O
is	O
a	O
potent	O
and	O
selective	O
ligand	O
for	O
the	O
human	O
alpha4beta2	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
nAChR	O
)	O
subtype	O
.	O

In	O
vitro	O
,	O
the	O
fluoro	O
derivative	O
of	O
A	O
-	O
85380	O
(	O
2	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azetidinylmethoxy	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
or	O
F	O
-	O
A	O
-	O
85380	O
)	O
competitively	O
displaced	O
[	O
3H	O
]	O
cytisine	O
or	O
[	O
3H	O
]	O
epibatidine	O
with	O
Ki	O
values	O
of	O
48	O
and	O
46	O
pM	O
,	O
respectively	O
.	O

F	O
-	O
A	O
-	O
85380	O
has	O
been	O
labeled	O
with	O
the	O
positron	O
emitter	O
fluorine	O
-	O
18	O
(	O
t1/2	O
(	O
half	O
-	O
life	O
)	O
=	O
110	O
min	O
)	O
by	O
no	O
-	O
carrier	O
-	O
added	O
nucleophilic	O
aromatic	O
substitution	O
by	O
K	O
[	O
18F	O
]	O
F	O
-	O
K222	O
complex	O
with	O
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azetidinylmethoxy	I-IUPAC
]	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
tri	I-IUPAC
methylammonium	I-IUPAC
trifluoromethanesulfonate	I-IUPAC
as	O
a	O
highly	O
efficient	O
labeling	O
precursor	O
,	O
followed	O
by	O
TFA	O
removal	O
of	O
the	O
Boc	O
protective	O
group	O
.	O

The	O
total	O
synthesis	O
time	O
was	O
50-53	O
min	O
from	O
the	O
end	O
of	O
cyclotron	O
fluorine	O
-	O
18	O
production	O
(	O
EOB	O
)	O
.	O

Radiochemical	O
yields	O
,	O
with	O
respect	O
to	O
initial	O
[	O
18F	O
]	O
fluoride	O
ion	O
radioactivity	O
,	O
were	O
68-72%	O
(	O
decay	O
-	O
corrected	O
)	O
and	O
49-52%	O
(	O
non	O
-	O
decay	O
-	O
corrected	O
)	O
,	O
and	O
the	O
specific	O
radioactivities	O
at	O
EOB	O
were	O
4-7	O
Ci	O
/	O
micromol	O
(	O
148-259	O
GBq	O
/	O
micromol	O
)	O
.	O

In	O
vivo	O
characterization	O
of	O
[	O
18F	O
]	O
F	O
-	O
A	O
-	O
85380	O
showed	O
promising	O
properties	O
for	O
PET	O
imaging	O
of	O
central	O
nAChRs	O
.	O

This	O
compound	O
does	O
not	O
bind	O
in	O
vivo	O
to	O
alpha7	O
nicotinic	O
or	O
5HT3	O
receptors	O
.	O

Moreover	O
,	O
its	O
cerebral	O
uptake	O
can	O
be	O
modulated	O
by	O
the	O
synaptic	O
concentration	O
of	O
the	O
endogenous	O
ligand	O
acetylcholine	O
.	O

The	O
preliminary	O
PET	O
experiments	O
in	O
baboons	O
with	O
[	O
18F	O
]	O
F	O
-	O
A	O
-	O
85380	O
show	O
an	O
accumulation	O
of	O
the	O
radiotracer	O
in	O
the	O
brain	O
within	O
60	O
min	O
.	O

In	O
the	O
thalamus	O
,	O
a	O
nAChR	O
-	O
rich	O
area	O
,	O
uptake	O
of	O
radioactivity	O
reached	O
a	O
maximum	O
at	O
60	O
min	O
(	O
4%	O
I	O
.	O

D	O
.	O

/	O
100	O
mL	O
of	O
tissue	O
)	O
.	O

[	O
18F	O
]	O
F	O
-	O
A	O
-	O
85380	O
appears	O
to	O
be	O
a	O
suitable	O
radioligand	O
for	O
brain	O
imaging	O
nAChRs	O
with	O
PET	O
.	O

A	O
series	O
of	O
28	O
new	O
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
,	O
pyrimido	I-IUPAC
[	I-IUPAC
4	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
,	O
and	O
tetrahydropyrimido	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
was	O
synthesized	O
and	O
their	O
adenosine	O
receptor	O
affinity	O
determined	O
in	O
radioligand	O
binding	O
assays	O
at	O
rat	O
A	O
(	O
1	O
)	O
and	O
A	O
(	O
2A	O
)	O
adenosine	O
receptors	O
(	O
ARs	O
)	O
.	O

Selected	O
compounds	O
were	O
additionally	O
investigated	O
in	O
binding	O
assays	O
at	O
recombinant	O
A	O
(	O
3	O
)	O
ARs	O
.	O

The	O
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
residue	I-MODIFIER
in	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylbenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylpyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
ADPEP	O
,	O
1	O
)	O
and	O
in	O
the	O
corresponding	O
pyrimido	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
(	O
APEPI	O
,	O
3	O
)	O
could	O
be	O
bioisosterically	O
replaced	O
by	O
heterocyclic	O
rings	O
,	O
such	O
as	O
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
.	O

The	O
resulting	O
compounds	O
retained	O
high	O
affinity	O
and	O
selectivity	O
for	O
A	O
(	O
1	O
)	O
ARs	O
.	O

Judging	O
from	O
the	O
investigation	O
of	O
selected	O
compounds	O
,	O
it	O
appears	O
that	O
they	O
are	O
also	O
potent	O
at	O
human	O
A	O
(	O
1	O
)	O
ARs	O
and	O
selective	O
not	O
only	O
versus	O
A	O
(	O
2A	O
)	O
ARs	O
but	O
also	O
highly	O
selective	O
versus	O
A	O
(	O
2B	O
)	O
and	O
A	O
(	O
3	O
)	O
ARs	O
.	O

The	O
p	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
-	O
substituted	I-MODIFIER
derivatives	B-MODIFIER
11	O
and	O
27	O
(	O
APPPI	O
)	O
may	O
be	O
interesting	O
pharmacological	O
tools	O
due	O
to	O
their	O
fluorescent	O
properties	O
.	O

Pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
derivatives	I-MODIFIER
which	O
were	O
simultaneously	O
substituted	O
at	O
N7	O
and	O
N	O
(	O
4	O
)	O
,	O
combining	O
the	O
substitution	O
pattern	O
of	O
ADPEP	O
(	O
1	O
)	O
and	O
DPEAP	O
(	O
2	O
)	O
,	O
showed	O
very	O
low	O
affinity	O
for	O
A	O
(	O
1	O
)	O
ARs	O
.	O

This	O
finding	O
supports	O
our	O
previously	O
published	O
hypothesis	O
of	O
different	O
binding	O
modes	O
for	O
pyrrolopyrimidines	O
,	O
such	O
as	O
ADPEP	O
(	O
1	O
)	O
and	O
DPEAP	O
(	O
2	O
)	O
.	O

DPEAP	O
(	O
2	O
)	O
,	O
a	O
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
substituted	O
at	O
the	O
amino	O
group	O
(	O
N	O
(	O
4	O
)	O
)	O
,	O
was	O
found	O
to	O
exhibit	O
high	O
affinity	O
for	O
human	O
A	O
(	O
3	O
)	O
ARs	O
(	O
K	O
(	O
i	O
)	O
=	O
28	O
nM	O
)	O
,	O
whereas	O
N	O
(	O
4	O
)	O
-	O
unsubstituted	O
analogues	O
were	O
inactive	O
.	O

DPEAP	O
(	O
2	O
)	O
and	O
related	O
compounds	O
provide	O
new	O
leads	O
for	O
the	O
development	O
of	O
antagonists	O
for	O
the	O
human	O
A	O
(	O
3	O
)	O
AR	O
.	O

N	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
omega	I-PARTIUPAC
-	I-PARTIUPAC
Aminoalkyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
2,2,5,5	I-PARTIUPAC
-	I-PARTIUPAC
tetramethyl	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
pyrroline	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	I-PARTIUPAC
pyrrolidine	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
carboxamides	I-PARTIUPAC
were	O
acylated	O
on	O
the	O
primary	O
amino	O
group	O
of	O
the	O
side	O
chain	O
by	O
means	O
of	O
reactive	O
acid	O
derivatives	O
(	O
acid	O
chlorides	O
,	O
activated	O
esters	O
,	O
phthalic	O
anhydrides	O
,	O
phthalimide	O
,	O
2	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
3,1	I-IUPAC
-	I-IUPAC
benzoxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
)	O
or	O
they	O
were	O
alkylated	O
by	O
forming	O
the	O
Schiff	O
bases	O
and	O
subsequent	O
sodium	O
borohydride	O
reduction	O
.	O

Other	O
tetramethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyrrolinecarboxamide	I-IUPAC
compounds	I-MODIFIER
were	O
synthesized	O
by	O
acylating	O
the	O
aminoalkyl	I-IUPAC
compounds	B-MODIFIER
with	O
2,2,6,6	I-IUPAC
-	I-IUPAC
tetramethyl	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dibromo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
piperidinone	I-IUPAC
in	O
a	O
reaction	O
involving	O
Favorskii	O
rearrangement	O
.	O

Saturation	O
of	O
the	O
double	O
bond	O
of	O
some	O
pyrroline	I-IUPAC
derivatives	B-MODIFIER
furnished	O
the	O
pyrrolidinecarboxamides	O
.	O

The	O
new	O
compounds	O
of	O
each	O
type	O
were	O
active	O
against	O
aconitine	O
-	O
induced	O
arrhythmia	O
and	O
several	O
of	O
them	O
had	O
higher	O
activity	O
and	O
better	O
chemotherapeutic	O
index	O
than	O
quinidine	O
.	O

A	O
few	O
selected	O
examples	O
from	O
each	O
type	O
of	O
the	O
active	O
new	O
compounds	O
showed	O
strong	O
activity	O
against	O
ouabain	O
-	O
induced	O
arrhythmia	O
;	O
for	O
comparison	O
known	O
drugs	O
such	O
as	O
lidocaine	O
,	O
mexiletine	O
,	O
and	O
tocainide	O
were	O
selected	O
.	O

The	O
most	O
potent	O
compounds	O
were	O
oxidized	O
to	O
the	O
paramagnetic	O
nitroxides	O
and	O
the	O
latter	O
were	O
reduced	O
to	O
the	O
N	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
derivatives	I-MODIFIER
;	O
these	O
products	O
had	O
no	O
or	O
only	O
decreased	O
antiarrhythmic	O
effect	O
.	O

New	O
1H	I-IUPAC
,	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
derivatives	I-MODIFIER
of	O
arylpiperazine	O
(	O
11-22	O
)	O
were	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
for	O
their	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
,	O
5	O
-	O
HT	O
(	O
2A	O
)	O
,	O
alpha	O
(	O
1	O
)	O
,	O
and	O
D	O
(	O
2	O
)	O
receptors	O
.	O

The	O
tested	O
compounds	O
showed	O
high	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
and	O
alpha	O
(	O
1	O
)	O
receptors	O
(	O
K	O
(	O
i	O
)	O
=	O
1.1-87	O
and	O
10-62	O
nM	O
,	O
respectively	O
)	O
and	O
moderate	O
to	O
low	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
2A	O
)	O
(	O
K	O
(	O
i	O
)	O
=	O
56-881	O
nM	O
)	O
and	O
D	O
(	O
2	O
)	O
receptors	O
(	O
K	O
(	O
i	O
)	O
=	O
94-1245	O
nM	O
)	O
.	O

Compounds	O
14	O
,	O
15	O
,	O
18	O
,	O
19	O
,	O
and	O
21	O
,	O
mostly	O
3'	I-IUPAC
-	I-IUPAC
chlorophenylpiperazine	I-IUPAC
derivatives	I-MODIFIER
,	O
can	O
be	O
classified	O
as	O
mixed	O
5	O
-	O
HT	O
(	O
1A	O
)	O
/	O
5	O
-	O
HT	O
(	O
2A	O
)	O
/	O
alpha	O
(	O
1	O
)	O
ligands	O
.	O

Compound	O
13	O
,	O
which	O
showed	O
the	O
highest	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptor	O
affinity	O
(	O
K	O
(	O
i	O
)	O
=	O
1.1	O
nM	O
)	O
,	O
was	O
50	O
-	O
fold	O
selective	O
in	O
relation	O
to	O
alpha	O
(	O
1	O
)	O
adrenoceptors	O
and	O
at	O
least	O
250	O
-	O
fold	O
over	O
5	O
-	O
HT	O
(	O
2A	O
)	O
and	O
D	O
(	O
2	O
)	O
sites	O
.	O

On	O
the	O
basis	O
of	O
in	O
vivo	O
functional	O
tests	O
,	O
8	I-IUPAC
-	I-IUPAC
phenylpiperazinoethylamino	I-IUPAC
(	O
11	O
)	O
,	O
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxyphenylpiperazino	I-IUPAC
)	I-IUPAC
ethylamino	I-IUPAC
(	O
13	O
)	O
,	O
and	O
8	I-IUPAC
-	I-IUPAC
phenylpiperazinopropylamino	I-IUPAC
(	O
14	O
)	O
derivatives	I-MODIFIER
of	O
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
,	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
were	O
identified	O
as	O
potent	O
pre	O
-	O
and	O
postsynaptic	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptor	O
antagonists	O
.	O

1,3	I-IUPAC
-	I-IUPAC
Dimethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylpiperazinopropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
,	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
(	O
20	O
)	O
behaved	O
like	O
an	O
agonist	O
of	O
presynaptic	O
and	O
as	O
a	O
partial	O
agonist	O
of	O
postsynaptic	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
and	O
resembled	O
ipsapirone	O
in	O
terms	O
of	O
functional	O
intrinsic	O
activity	O
.	O

It	O
revealed	O
marked	O
anxiolytic	O
-	O
like	O
activity	O
in	O
the	O
Vogel	O
test	O
in	O
rats	O
,	O
comparable	O
to	O
that	O
of	O
the	O
reference	O
drug	O
diazepam	O
,	O
and	O
exhibited	O
antidepressant	O
-	O
like	O
activity	O
in	O
the	O
Porsolt	O
test	O
in	O
rats	O
.	O

The	O
sedative	O
effect	O
of	O
20	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
in	O
rats	O
,	O
appeared	O
at	O
doses	O
twice	O
as	O
high	O
as	O
those	O
inducing	O
a	O
minimal	O
anxiolytic	O
-	O
like	O
effect	O
and	O
was	O
similar	O
to	O
the	O
effects	O
of	O
diazepam	O
.	O

N	I-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
phenethylphenylacetamide	I-IUPAC
has	O
been	O
reported	O
to	O
be	O
a	O
key	O
binding	O
domain	O
to	O
LTB4	O
receptors	O
.	O

Here	O
we	O
describe	O
the	O
synthesis	O
and	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
studies	O
of	O
two	O
new	O
series	O
of	O
LTB4	O
receptor	O
antagonists	O
in	O
which	O
the	O
phenyl	O
ring	O
of	O
this	O
receptor	O
binding	O
domain	O
is	O
replaced	O
with	O
indole	O
and	O
naphthalene	O
,	O
respectively	O
.	O

Results	O
of	O
these	O
studies	O
indicate	O
that	O
,	O
in	O
addition	O
to	O
the	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
methyl	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
moiety	I-MODIFIER
,	O
the	O
presence	O
of	O
an	O
acid	O
group	O
and	O
a	O
lipophilic	O
side	O
chain	O
,	O
as	O
well	O
as	O
the	O
spatial	O
relationship	O
of	O
these	O
three	O
functions	O
,	O
is	O
crucial	O
for	O
high	O
binding	O
affinity	O
with	O
LTB4	O
receptors	O
.	O

Our	O
SAR	O
studies	O
also	O
reveal	O
that	O
an	O
arenecarboxylic	O
acid	O
,	O
or	O
an	O
enoic	O
acid	O
in	O
which	O
the	O
carboxyl	I-IUPAC
group	B-MODIFIER
is	O
conjugated	O
with	O
the	O
central	O
ring	O
,	O
is	O
the	O
preferred	O
polar	O
group	O
.	O

The	O
lipophilic	O
side	O
chain	O
of	O
the	O
naphthyl	I-IUPAC
series	B-MODIFIER
was	O
found	O
to	O
tolerate	O
minor	O
variations	O
,	O
ranging	O
from	O
a	O
phenylmethoxy	I-IUPAC
group	B-MODIFIER
to	O
phenyl	I-IUPAC
and	O
alkyloxy	I-IUPAC
groups	B-MODIFIER
.	O

The	O
most	O
active	O
compounds	O
are	O
2	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
methyl	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylmethoxy	I-IUPAC
)	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
propenoic+	I-IUPAC
+	I-IUPAC
+	I-IUPAC
acid	I-IUPAC
(	O
4g	O
)	O
of	O
the	O
indolyl	O
series	O
and	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
methyl	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylmethoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthalenecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
2a	O
)	O
or	O
the	O
naphthyl	I-IUPAC
series	B-MODIFIER
,	O
with	O
IC50	O
of	O
8	O
and	O
4.7	O
nM	O
respectively	O
,	O
in	O
the	O
receptor	O
binding	O
assay	O
using	O
intact	O
human	O
neutrophils	O
.	O

5	I-IUPAC
-	I-IUPAC
Deaza	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
propargylfolic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
,	O
an	O
analogue	O
of	O
the	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
inhibitor	O
10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
(	O
PDDF	O
,	O
1	O
)	O
,	O
was	O
prepared	O
via	O
alkylation	O
of	O
diethyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
propargylamino	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
(	O
7	O
)	O
by	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidinone	I-IUPAC
(	O
15	O
)	O
.	O

Bromomethyl	O
intermediate	O
15	O
was	O
prepared	O
from	O
the	O
corresponding	O
hydroxymethyl	I-IUPAC
precursor	B-MODIFIER
14	O
by	O
treatment	O
with	O
48%	O
HBr	O
.	O

Hydroxymethyl	O
compound	O
14	O
was	O
obtained	O
by	O
deamination	O
of	O
reported	O
2,4	I-IUPAC
-	I-IUPAC
diaminopyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methanol	I-IUPAC
(	O
12a	O
)	O
in	O
refluxing	O
1	O
N	O
NaOH	O
.	O

Both	O
12a	O
and	O
its	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
analogue	B-MODIFIER
12b	O
were	O
converted	O
to	O
versatile	O
6	I-IUPAC
-	I-IUPAC
bromomethyl	I-IUPAC
intermediates	I-MODIFIER
13a	O
and	O
13b	O
from	O
which	O
important	O
antifolates	O
may	O
be	O
readily	O
derived	O
.	O

Alkylation	O
of	O
7	O
by	O
13a	O
,	O
b	O
led	O
to	O
10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
(	O
5	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
(	O
6	O
)	O
.	O

As	O
an	O
inhibitor	O
of	O
TS	O
from	O
H35F	O
/	O
F	O
cells	O
,	O
4	O
gave	O
an	O
IC50	O
value	O
showing	O
it	O
to	O
be	O
approximately	O
6	O
-	O
fold	O
less	O
inhibitory	O
than	O
PDDF	O
(	O
90	O
nM	O
for	O
4	O
vs	O
14	O
nM	O
for	O
PDDF	O
)	O
.	O

In	O
in	O
vitro	O
studies	O
,	O
IC50	O
(	O
microM	O
)	O
values	O
obtained	O
for	O
4	O
vs	O
L1210	O
and	O
S180	O
of	O
1.50	O
and	O
2.35	O
,	O
respectively	O
,	O
were	O
similar	O
to	O
those	O
obtained	O
for	O
PDDF	O
(	O
2.61	O
and	O
1.97	O
)	O
.	O

Against	O
HL60	O
cells	O
,	O
4	O
was	O
about	O
7	O
-	O
fold	O
more	O
cytotoxic	O
than	O
PDDF	O
(	O
IC50	O
values	O
0.72	O
and	O
5.29	O
microM	O
)	O
.	O

Inclusion	O
of	O
thymidine	O
did	O
not	O
establish	O
TS	O
as	O
the	O
site	O
of	O
cytotoxic	O
action	O
for	O
either	O
4	O
or	O
PDDF	O
in	O
the	O
cell	O
lines	O
used	O
.	O

In	O
in	O
vivo	O
tests	O
against	O
L1210	O
in	O
mice	O
,	O
4	O
failed	O
to	O
show	O
therapeutic	O
effect	O
.	O

The	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
compounds	I-MODIFIER
5	O
and	O
6	O
were	O
as	O
potent	O
inhibitors	O
of	O
DHFR	O
from	O
L1210	O
cells	O
as	O
MTX	O
and	O
7	O
-	O
and	O
35	O
-	O
fold	O
,	O
respectively	O
,	O
more	O
inhibitory	O
than	O
MTX	O
toward	O
L1210	O
cell	O
growth	O
.	O

In	O
mediated	O
influx	O
into	O
L1210	O
cells	O
,	O
5	O
and	O
6	O
were	O
transported	O
2.7	O
-	O
and	O
8.5	O
-	O
fold	O
,	O
respectively	O
,	O
more	O
readily	O
than	O
MTX	O
.	O

Against	O
the	O
EO771	O
mammary	O
adenocarcinoma	O
in	O
mice	O
,	O
6	O
produced	O
greater	O
antitumor	O
effect	O
than	O
MTX	O
.	O

A	O
dose	O
of	O
36	O
mg	O
/	O
kg	O
per	O
day	O
for	O
5	O
days	O
caused	O
no	O
toxic	O
deaths	O
while	O
the	O
average	O
tumor	O
volume	O
among	O
10	O
mice	O
was	O
reduced	O
to	O
8-9%	O
of	O
that	O
of	O
the	O
control	O
,	O
and	O
20%	O
of	O
the	O
test	O
animals	O
were	O
rendered	O
tumor	O
free	O
.	O

1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
Chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidine	I-IUPAC
(	O
1	O
)	O
,	O
the	O
N	I-IUPAC
-	I-IUPAC
desnitro	I-IUPAC
metabolite	I-MODIFIER
of	O
the	O
major	O
insecticide	O
imidacloprid	O
,	O
is	O
known	O
to	O
have	O
similar	O
potency	O
to	O
that	O
of	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nicotine	I-IUPAC
as	O
an	O
inhibitor	O
of	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nicotine	I-IUPAC
binding	O
at	O
the	O
rat	O
recombinant	O
alpha4beta2	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
nAChR	O
)	O
;	O
IC50	O
values	O
in	O
the	O
present	O
study	O
are	O
3.8	O
nM	O
for	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nicotine	I-IUPAC
,	O
6.0	O
nM	O
for	O
1	O
,	O
and	O
155	O
nM	O
for	O
imidacloprid	O
.	O

Synthesis	O
of	O
new	O
analogues	O
of	O
1	O
,	O
modified	O
only	O
in	O
the	O
heterocyclic	O
moiety	O
(	O
five	O
-	O
,	O
six	O
-	O
,	O
or	O
seven	O
-	O
membered	O
rings	O
with	O
NH	O
,	O
S	O
,	O
O	O
,	O
and	O
CH2	O
substituents	O
)	O
,	O
gave	O
compounds	O
varying	O
from	O
4	O
-	O
fold	O
higher	O
potency	O
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iminothiazole	I-IUPAC
analogue	O
10	O
)	O
to	O
&	O
gt	O
;	O
6000	O
-	O
fold	O
less	O
active	O
than	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nicotine	I-IUPAC
.	O

Other	O
potent	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
compounds	I-MODIFIER
are	O
those	O
in	O
which	O
the	O
heterocyclic	O
imine	O
is	O
replaced	O
with	O
pyrrolidine	O
(	O
19	O
)	O
(	O
IC50	O
9	O
nM	O
)	O
or	O
trimethylammonium	O
(	O
22	O
)	O
(	O
IC50	O
18	O
nM	O
)	O
.	O

A	O
novel	O
conversion	O
of	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nicotine	I-IUPAC
to	O
its	O
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
analogue	I-MODIFIER
increased	O
the	O
potency	O
2	O
-	O
fold	O
.	O

These	O
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
compounds	I-MODIFIER
are	O
of	O
interest	O
as	O
novel	O
nAChR	O
probes	O
and	O
potential	O
metabolites	O
of	O
candidate	O
insecticides	O
.	O

Two	O
complete	O
and	O
two	O
partial	O
structure	O
-	O
activity	O
relationship	O
scans	O
of	O
the	O
active	O
fragment	O
of	O
human	O
growth	O
hormone	O
-	O
releasing	O
hormone	O
,	O
[	O
Nle27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
,	O
have	O
identified	O
potent	O
agonists	O
in	O
vitro	O
.	O

Single	O
-	O
point	O
replacement	O
of	O
each	O
amino	O
acid	O
by	O
alanine	O
led	O
to	O
the	O
identification	O
of	O
[	O
Ala8	O
]	O
-	O
,	O
[	O
Ala9	O
]	O
-	O
,	O
[	O
Ala15	O
]	O
-	O
(	O
Felix	O
et	O
al.	O
Peptides	O
1986	O
1986	O
,	O
481	O
)	O
,	O
[	O
Ala22	O
]	O
-	O
,	O
and	O
[	O
Ala28	O
,	O
Nle27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
as	O
being	O
2-6	O
times	O
more	O
potent	O
than	O
hGHRH	O
(	O
1-40	O
)	O
-	O
OH	O
(	O
standard	O
)	O
in	O
vitro	O
.	O

Nearly	O
complete	O
loss	O
of	O
potency	O
was	O
seen	O
for	O
[	O
Ala1	O
]	O
,	O
[	O
Ala3	O
]	O
,	O
[	O
Ala5	O
]	O
,	O
[	O
Ala6	O
]	O
,	O
[	O
Ala10	O
]	O
,	O
[	O
Ala11	O
]	O
,	O
[	O
Ala13	O
]	O
,	O
[	O
Ala14	O
]	O
,	O
and	O
[	O
Ala23	O
]	O
,	O
whereas	O
[	O
Ala16	O
]	O
,	O
[	O
Ala18	O
]	O
,	O
[	O
Ala24	O
]	O
,	O
[	O
Ala25	O
]	O
,	O
[	O
Ala26	O
]	O
,	O
and	O
[	O
Ala29	O
]	O
yielded	O
equipotent	O
analogues	O
and	O
[	O
Ala7	O
]	O
,	O
[	O
Ala12	O
]	O
,	O
[	O
Ala17	O
]	O
,	O
[	O
Ala20	O
]	O
,	O
[	O
Ala21	O
]	O
,	O
and	O
[	O
Ala27	O
]	O
gave	O
weak	O
agonists	O
with	O
potencies	O
15-40%	O
that	O
of	O
the	O
standard	O
.	O

The	O
multiple	O
-	O
alanine	O
-	O
substituted	O
peptides	O
[	O
MeTyr1	O
,	O
Ala15	O
,	O
22	O
,	O
Nle27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
(	O
29	O
)	O
and	O
[	O
MeTyr1	O
,	O
Ala8	O
,	O
9,15,22,28	O
,	O
Nle	O
27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
(	O
30	O
)	O
released	O
growth	O
hormone	O
26	O
and	O
11	O
times	O
,	O
respectively	O
,	O
more	O
effectively	O
than	O
the	O
standard	O
in	O
vitro	O
.	O

Individual	O
substitution	O
of	O
the	O
nine	O
most	O
potent	O
peptides	O
identified	O
from	O
the	O
Ala	O
series	O
with	O
the	O
helix	O
promoter	O
alpha	I-IUPAC
-	I-IUPAC
aminoisobutyric	I-IUPAC
acid	I-IUPAC
(	O
Aib	O
)	O
produced	O
similar	O
results	O
,	O
except	O
for	O
[	O
Aib8	O
]	O
(	O
doubling	O
vs	O
[	O
Ala8	O
]	O
)	O
,	O
[	O
Aib9	O
]	O
(	O
having	O
vs	O
[	O
Ala9	O
]	O
)	O
,	O
and	O
[	O
Aib15	O
]	O
(	O
10	O
-	O
fold	O
decrease	O
vs	O
[	O
Ala15	O
]	O
)	O
.	O

A	O
series	O
of	O
cyclic	O
analogues	O
was	O
synthesized	O
having	O
the	O
general	O
formula	O
cyclo	O
(	O
25-29	O
)	O
[	O
MeTyr1	O
,	O
-	O
Ala15	O
,	O
Xaa25	O
,	O
Nle27	O
,	O
Yaa29+	O
+	O
+	O
]	O
-	O
GHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
,	O
where	O
Xaa	O
and	O
Yaa	O
represent	O
the	O
bridgehead	O
residues	O
of	O
a	O
side	O
-	O
chain	O
cystine	O
or	O
[	O
i	O
-	O
(	O
i	O
+	O
4	O
)	O
]	O
lactam	O
ring	O
.	O

The	O
ring	O
size	O
,	O
bridgehead	O
amino	O
acid	O
chirality	O
,	O
and	O
side	O
-	O
chain	O
amide	O
bond	O
location	O
were	O
varied	O
in	O
this	O
partial	O
series	O
in	O
an	O
attempt	O
to	O
maximize	O
potency	O
.	O

Application	O
of	O
lactam	O
constraints	O
in	O
the	O
C	O
-	O
terminus	O
of	O
GHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
identified	O
cyclo	O
(	O
25-29	O
)	O
[	O
MeTyr1	O
,	O
Ala15	O
,	O
DAsp25	O
,	O
Nle27	O
,	O
Orn29+	O
+	O
+	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
(	O
46	O
)	O
as	O
containing	O
the	O
optimum	O
bridging	O
element	O
(	O
19	O
-	O
membered	O
ring	O
)	O
in	O
this	O
region	O
of	O
the	O
molecule	O
.	O

This	O
analogue	O
(	O
46	O
)	O
was	O
17	O
times	O
more	O
potent	O
than	O
the	O
standard	O
.	O

Equally	O
effective	O
was	O
an	O
[	O
i	O
-	O
(	O
i	O
+	O
3	O
)	O
]	O
constraint	O
yielding	O
the	O
18	O
-	O
membered	O
ring	O
cyclo	O
(	O
25-28	O
)	O
[	O
MeTyr1	O
,	O
Ala15	O
,	O
Glu25	O
,	O
Nle	O
,	O
27Lys28	O
]	O
-	O
hGHRH	O
-	O
(	O
1-29	O
)	O
-	O
NH2	O
(	O
51	O
)	O
which	O
was	O
14	O
times	O
more	O
potent	O
than	O
the	O
standard	O
.	O

A	O
complete	O
[	O
i	O
-	O
(	O
i	O
+	O
3	O
)	O
]	O
scan	O
of	O
cyclo	O
(	O
i	O
,	O
i	O
+	O
3	O
)	O
[	O
MeTyr1	O
,	O
Ala15	O
,	O
Glui	O
,	O
Lys	O
(	O
i	O
+	O
3	O
)	O
,	O
Nle27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
was	O
then	O
produced	O
in	O
order	O
to	O
test	O
the	O
effects	O
of	O
a	O
Glu	O
-	O
to	O
-	O
Lys	O
lactam	O
bridge	O
at	O
all	O
points	O
in	O
the	O
peptide	O
.	O

Of	O
the	O
26	O
analogues	O
in	O
the	O
series	O
,	O
11	O
had	O
diminished	O
potencies	O
of	O
less	O
than	O
10%	O
that	O
of	O
the	O
agonist	O
standard	O
,	O
4	O
were	O
weak	O
agonists	O
(	O
15-40%	O
relative	O
potency	O
)	O
,	O
and	O
4	O
analogues	O
were	O
equipotent	O
to	O
the	O
standard	O
.	O

The	O
7	O
most	O
potent	O
analogues	O
ranged	O
in	O
potency	O
from	O
3	O
to	O
14	O
times	O
greater	O
than	O
that	O
of	O
the	O
standard	O
and	O
contained	O
the	O
[	O
i	O
-	O
(	O
i	O
+	O
3	O
)	O
]	O
cycles	O
between	O
residues	O
4-7	O
,	O
5-8	O
,	O
9-12	O
,	O
16-19	O
,	O
21-24	O
,	O
22-25	O
,	O
and	O
25-28	O
.	O

The	O
combined	O
results	O
from	O
these	O
systematic	O
studies	O
allowed	O
for	O
an	O
analysis	O
of	O
structural	O
features	O
in	O
the	O
native	O
peptide	O
that	O
are	O
important	O
for	O
receptor	O
activation	O
.	O

Reinforcement	O
of	O
the	O
characteristics	O
of	O
amphiphilicity	O
,	O
helicity	O
,	O
and	O
peptide	O
dipolar	O
effects	O
,	O
using	O
recognized	O
medicinal	O
chemistry	O
approaches	O
including	O
introduction	O
of	O
conformational	O
constraints	O
,	O
has	O
resulted	O
in	O
several	O
potent	O
GHRH	O
analogues	O
.	O

A	O
series	O
of	O
unsaturated	O
analogues	O
of	O
nucleosides	O
were	O
prepared	O
and	O
their	O
cytotoxic	O
,	O
antitumor	O
,	O
and	O
antiviral	O
activities	O
were	O
investigated	O
.	O

Alkylation	O
of	O
cytosine	O
with	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butene	I-IUPAC
gave	O
chloro	O
derivative	O
2f	O
,	O
which	O
was	O
hydrolyzed	O
to	O
alcohol	O
2h	O
.	O

Cytosine	O
,	O
adenine	O
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
thymine	O
,	O
and	O
(	I-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butene	I-IUPAC
gave	O
compounds	O
4c	O
-	O
f	O
,	O
which	O
,	O
after	O
hydrolysis	O
,	O
afforded	O
alcohols	O
4a	O
,	O
4b	O
,	O
4g	O
,	O
and	O
4h	O
.	O

Alkenes	O
4d	O
and	O
4e	O
were	O
cyclized	O
to	O
heterocycles	O
12	O
and	O
13	O
.	O

Alkylation	O
of	O
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
with	O
1,4	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butyne	I-IUPAC
led	O
to	O
chloro	I-IUPAC
derivative	B-MODIFIER
6a	O
,	O
which	O
was	O
hydrolyzed	O
to	O
alcohol	O
6b	O
.	O

Allenic	O
isomerization	O
of	O
6b	O
gave	O
compound	O
5c	O
.	O

Chloro	I-IUPAC
derivatives	B-MODIFIER
2e	O
-	O
g	O
,	O
4c	O
-	O
f	O
,	O
5d	O
,	O
and	O
6c	O
-	O
e	O
as	O
well	O
as	O
pyrimidine	O
oxacyclopentenes	O
9c	O
and	O
9d	O
are	O
slow	O
-	O
acting	O
inhibitors	O
of	O
murine	O
leukemia	O
L1210	O
of	O
IC50	O
10-100	O
microM	O
.	O

The	O
most	O
active	O
were	O
analogues	O
4c	O
,	O
4d	O
,	O
4e	O
,	O
and	O
6e	O
(	O
IC50	O
10-20	O
microM	O
)	O
.	O

The	O
corresponding	O
hydroxy	I-IUPAC
derivatives	B-MODIFIER
were	O
less	O
active	O
of	O
inactive	O
.	O

Inhibition	O
of	O
macromolecular	O
synthesis	O
with	O
compounds	O
4c	O
,	O
4d	O
,	O
6e	O
,	O
9c	O
,	O
and	O
9d	O
follows	O
the	O
order	O
:	O
DNA	O
greater	O
than	O
RNA	O
greater	O
than	O
or	O
equal	O
to	O
protein	O
.	O

Cytotoxic	O
effects	O
of	O
4c	O
,	O
6e	O
,	O
and	O
9d	O
are	O
not	O
reversed	O
with	O
any	O
of	O
the	O
four	O
basic	O
ribonucleosides	O
or	O
2'	I-IUPAC
-	I-IUPAC
deoxyribonucleosides	I-IUPAC
.	O

Inhibitory	O
activity	O
of	O
cytosine	O
derivative	O
9c	O
is	O
reversed	O
with	O
uridine	O
and	O
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
but	O
not	O
with	O
the	O
corresponding	O
cytosine	O
nucleosides	O
.	O

Zone	O
assays	O
in	O
several	O
tumor	O
cell	O
lines	O
show	O
that	O
active	O
compounds	O
are	O
cytotoxic	O
agents	O
with	O
little	O
selectivity	O
for	O
tumor	O
cells	O
.	O

Analogue	O
6c	O
showed	O
16.7%	O
ILS	O
in	O
leukemia	O
P388	O
/	O
o	O
implanted	O
ip	O
in	O
mice	O
at	O
510	O
and	O
1020	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Cytallene	O
(	O
5b	O
)	O
and	O
6'	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
hydroxyaristeromycin	I-IUPAC
(	O
10	O
)	O
exhibited	O
significant	O
activity	O
against	O
Friend	O
and	O
Rauscher	O
murine	O
leukemia	O
viruses	O
.	O

The	O
rest	O
of	O
the	O
hydroxy	O
derivatives	O
,	O
with	O
the	O
exception	O
of	O
4a	O
,	O
were	O
moderately	O
effective	O
or	O
inactive	O
as	O
antiviral	O
agents	O
.	O

None	O
of	O
the	O
chloro	O
derivatives	O
or	O
oxacyclopentenes	O
exhibited	O
an	O
antiviral	O
effect	O
at	O
noncytotoxic	O
concentrations	O
.	O

Z	O
-	O
Olefin	O
4b	O
and	O
2	I-IUPAC
-	I-IUPAC
aminoadenallene	I-IUPAC
(	O
5c	O
)	O
are	O
substrates	O
for	O
adenosine	O
deaminase	O
.	O

A	O
series	O
of	O
bis	O
(	O
hydroxymethyl	O
)	O
-	O
substituted	O
heterocycles	O
were	O
synthesized	O
and	O
converted	O
to	O
the	O
corresponding	O
bis	I-IUPAC
(	I-IUPAC
methylcarbamate	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
.	O

The	O
heterocyclic	O
systems	O
studied	O
were	O
based	O
on	O
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylfuran	I-IUPAC
(	O
2-4	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
phenylpyrazole	I-IUPAC
(	O
5-7	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylpyrazole	I-IUPAC
(	O
9-11	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylthiophene	I-IUPAC
(	O
13	O
)	O
,	O
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,3	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
(	O
14	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
phenylisoxazole	I-IUPAC
(	O
15	O
)	O
,	O
3	I-IUPAC
-	I-IUPAC
phenylisothiazole	I-IUPAC
(	O
16	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
phenylthiazole	I-IUPAC
(	O
17	O
)	O
,	O
and	O
2	I-IUPAC
-	I-IUPAC
phenyloxazole	I-IUPAC
(	O
18	O
)	O
.	O

None	O
of	O
the	O
bis	O
(	O
carbamates	O
)	O
prepared	O
was	O
active	O
against	O
murine	O
P388	O
lymphocytic	O
leukemia	O
.	O

Pyrrole	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
carbamates	I-IUPAC
)	I-IUPAC
20	O
and	O
21	O
,	O
which	O
exhibited	O
antileukemic	O
activity	O
,	O
also	O
showed	O
reactivity	O
toward	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
while	O
the	O
inactive	O
bis	I-IUPAC
(	I-IUPAC
carbamates	I-IUPAC
)	I-IUPAC
were	O
unreactive	O
in	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
assay	O
.	O

Urokinase	O
-	O
type	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
,	O
a	O
trypsin	O
-	O
like	O
serine	O
protease	O
,	O
has	O
been	O
implicated	O
in	O
large	O
number	O
of	O
malignancies	O
,	O
tumor	O
cell	O
invasion	O
,	O
angiogenesis	O
and	O
metastasis	O
;	O
hence	O
,	O
the	O
potent	O
and	O
selective	O
inhibitors	O
of	O
uPA	O
may	O
therefore	O
be	O
therapeutically	O
useful	O
drugs	O
for	O
treatment	O
of	O
various	O
forms	O
of	O
cancer	O
.	O

A	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
QSAR	O
)	O
study	O
was	O
performed	O
on	O
five	O
different	O
chemical	O
series	O
reported	O
as	O
selective	O
uPA	O
inhibitors	O
employing	O
comparative	O
molecular	O
field	O
analysis	O
(	O
CoMFA	O
)	O
/	O
comparative	O
molecular	O
similarity	O
indices	O
analysis	O
(	O
CoMSIA	O
)	O
techniques	O
to	O
investigate	O
the	O
structural	O
requirements	O
for	O
substrates	O
and	O
derive	O
a	O
predictive	O
model	O
that	O
may	O
be	O
used	O
for	O
the	O
design	O
of	O
novel	O
uPA	O
inhibitors	O
.	O

ClogP	O
has	O
been	O
used	O
as	O
an	O
additional	O
descriptor	O
in	O
the	O
CoMFA	O
analysis	O
to	O
study	O
the	O
effects	O
of	O
lipophilic	O
parameters	O
on	O
activity	O
.	O

Inclusion	O
of	O
ClogP	O
did	O
not	O
improve	O
the	O
models	O
significantly	O
and	O
exhibited	O
comparable	O
correlation	O
coefficients	O
with	O
CoMFA	O
steric	O
and	O
electrostatic	O
models	O
.	O

3D	O
QSAR	O
models	O
were	O
derived	O
for	O
2	I-IUPAC
-	I-IUPAC
pyridinylguanidines	I-IUPAC
(	O
training	O
set	O
N	O
=	O
25	O
,	O
test	O
set	O
N	O
=	O
8	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
aminoarylguanidines	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
aminoarylbenzamidines	I-IUPAC
(	O
training	O
set	O
N	O
=	O
29	O
,	O
test	O
set	O
N	O
=	O
8	O
)	O
,	O
thiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxamindines	I-IUPAC
(	O
training	O
set	O
N	O
=	O
64	O
,	O
test	O
set	O
N	O
=	O
19	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
naphthamidines	I-IUPAC
(	O
training	O
set	O
N	O
=	O
32	O
,	O
test	O
set	O
N	O
=	O
8	O
)	O
,	O
and	O
1	I-IUPAC
-	I-IUPAC
isoquinolinylguanidines	I-IUPAC
(	O
training	O
set	O
N	O
=	O
29	O
,	O
test	O
set	O
N	O
=	O
7	O
)	O
.	O

The	O
CoMFA	O
models	O
with	O
steric	O
and	O
electrostatic	O
fields	O
exhibited	O
r	O
(	O
2	O
)	O
(	O
cv	O
)	O
0.452-0.722	O
,	O
r	O
(	O
2	O
)	O
(	O
ncv	O
)	O
0.812-0.986	O
,	O
r	O
(	O
2	O
)	O
(	O
pred	O
)	O
0.597-0.870	O
,	O
whereas	O
CoMFA	O
ClogP	O
models	O
showed	O
r	O
(	O
2	O
)	O
(	O
cv	O
)	O
0.420-0.707	O
,	O
r	O
(	O
2	O
)	O
(	O
ncv	O
)	O
0.849-0.957	O
,	O
r	O
(	O
2	O
)	O
(	O
pred	O
)	O
0.600-0.870	O
.	O

The	O
CoMSIA	O
models	O
displayed	O
r	O
(	O
2	O
)	O
(	O
cv	O
)	O
0.663-0.729	O
,	O
r	O
(	O
2	O
)	O
(	O
ncv	O
)	O
0.909-0.998	O
,	O
r	O
(	O
2	O
)	O
(	O
pred	O
)	O
0.554-0.855	O
.	O

3D	O
contour	O
maps	O
generated	O
from	O
these	O
models	O
were	O
analyzed	O
individually	O
,	O
which	O
provides	O
the	O
regions	O
in	O
space	O
where	O
interactive	O
fields	O
may	O
influence	O
the	O
activity	O
.	O

The	O
superimposition	O
of	O
contour	O
maps	O
on	O
the	O
active	O
site	O
of	O
serine	O
proteases	O
additionally	O
helps	O
in	O
understanding	O
the	O
structural	O
requirements	O
of	O
these	O
inhibitors	O
.	O

Further	O
,	O
the	O
predictive	O
ability	O
of	O
3D	O
QSAR	O
models	O
was	O
affirmed	O
by	O
predicting	O
the	O
activity	O
of	O
novel	O
2	I-IUPAC
-	I-IUPAC
naphthamidines	I-IUPAC
.	O

3D	O
QSAR	O
models	O
developed	O
may	O
be	O
used	O
in	O
designing	O
and	O
predicting	O
the	O
uPA	O
inhibitory	O
activity	O
of	O
novel	O
molecules	O
.	O

A	O
new	O
class	O
of	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
cyanamido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
haloethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
(	O
4-6	O
)	O
and	O
arabinouridines	O
(	O
7	O
,	O
8	O
)	O
were	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
halogenocyanamides	O
(	O
X	O
-	O
NHCN	O
)	O
to	O
the	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
substituent	I-MODIFIER
of	O
the	O
respective	O
5	I-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
2	O
)	O
and	O
2'	I-IUPAC
-	I-IUPAC
arabinouridine	I-IUPAC
(	O
3	O
)	O
.	O

Reaction	O
of	O
2	O
with	O
sodium	O
azide	O
,	O
ceric	O
ammonium	O
nitrate	O
,	O
and	O
acetonitrile	O
-	O
methanol	O
or	O
water	O
afforded	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
azidoethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	O
10	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azidoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
(	O
11	O
)	O
.	O

In	O
vitro	O
antiviral	O
activities	O
against	O
HSV	O
-	O
1	O
-	O
TK	O
(	O
+	O
)	O
(	O
KOS	O
and	O
E	O
-	O
377	O
)	O
,	O
HSV	O
-	O
1	O
-	O
TK	O
(	O
-	O
)	O
,	O
HSV	O
-	O
2	O
,	O
VZV	O
,	O
HCMV	O
,	O
and	O
DHBV	O
were	O
determined	O
.	O

Of	O
the	O
newly	O
synthesized	O
compounds	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
cyanamido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
6	O
)	O
exhibited	O
the	O
most	O
potent	O
anti	O
-	O
HSV	O
-	O
1	O
activity	O
,	O
which	O
was	O
equipotent	O
to	O
acyclovir	O
and	O
superior	O
to	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
EDU	O
)	O
.	O

In	O
addition	O
,	O
it	O
was	O
significantly	O
inhibitory	O
for	O
thymidine	O
kinase	O
deficient	O
strain	O
of	O
HSV	O
-	O
1	O
(	O
EC	O
(	O
50	O
)	O
=	O
2.3-15.3	O
microM	O
)	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
cyanamido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
haloethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
(	O
4-6	O
)	O
all	O
were	O
approximately	O
equipotent	O
against	O
HSV	O
-	O
2	O
and	O
were	O
approximately	O
1.5	O
-	O
and	O
15	O
-	O
fold	O
less	O
inhibitory	O
for	O
HSV	O
-	O
2	O
than	O
EDU	O
and	O
acyclovir	O
,	O
respectively	O
.	O

Compounds	O
4-6	O
were	O
all	O
inactive	O
against	O
HCMV	O
but	O
exhibited	O
appreciable	O
antiviral	O
activity	O
against	O
VZV	O
.	O

Their	O
anti	O
-	O
VZV	O
activity	O
was	O
similar	O
or	O
higher	O
to	O
that	O
of	O
EDU	O
and	O
approximately	O
5-12	O
-	O
fold	O
lower	O
than	O
that	O
of	O
acyclovir	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
cyanamido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
haloethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
7,8	I-IUPAC
)	I-IUPAC
analogues	I-MODIFIER
of	O
arabinouridine	O
were	O
moderately	O
inhibitory	O
for	O
VZV	O
and	O
HSV	O
-	O
1	O
(	O
strain	O
KOS	O
)	O
,	O
whereas	O
compounds	O
10	O
and	O
11	O
were	O
inactive	O
against	O
herpes	O
viruses	O
.	O

Compounds	O
5	O
and	O
6	O
also	O
demonstrated	O
modest	O
anti	O
-	O
hepatitis	O
B	O
virus	O
activity	O
against	O
DHBV	O
(	O
EC	O
(	O
50	O
)	O
=	O
19.9-23.6	O
microM	O
)	O
.	O

Interestingly	O
,	O
the	O
related	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
1n	O
)	O
analogue	O
proved	O
to	O
be	O
markedly	O
inhibitory	O
to	O
DHBV	O
replication	O
(	O
EC	O
(	O
50	O
)	O
=	O
2.6-6.6	O
microM	O
)	O
.	O

All	O
compounds	O
investigated	O
exhibited	O
low	O
host	O
cell	O
toxicity	O
to	O
several	O
stationary	O
and	O
proliferating	O
host	O
cell	O
lines	O
as	O
well	O
as	O
mitogen	O
-	O
stimulated	O
proliferating	O
human	O
T	O
lymphocytes	O
.	O

Four	O
isomers	O
of	O
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
trimethylammonium	I-IUPAC
iodide	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
muscarines	I-IUPAC
)	I-IUPAC
were	O
prepared	O
in	O
enantiomerically	O
and	O
diastereomerically	O
pure	O
form	O
from	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
sulfoxide	I-IUPAC
,	O
ethyl	O
fluoroacetate	O
,	O
and	O
allyl	O
bromide	O
.	O

Their	O
absolute	O
configurations	O
were	O
assigned	O
by	O
1H	O
NMR	O
analyses	O
.	O

The	O
four	O
optically	O
pure	O
compounds	O
were	O
tested	O
in	O
vitro	O
on	O
guinea	O
pig	O
and	O
their	O
muscarinic	O
potency	O
was	O
evaluated	O
at	O
M3	O
(	O
ileum	O
and	O
bladder	O
)	O
and	O
M2	O
(	O
heart	O
)	O
muscarinic	O
receptor	O
subtypes	O
.	O

Compound	O
1a	O
,	O
the	O
most	O
potent	O
isomer	O
of	O
the	O
series	O
,	O
was	O
also	O
tested	O
in	O
vivo	O
on	O
pithed	O
rat	O
and	O
its	O
muscarinic	O
activity	O
at	O
the	O
M1	O
receptor	O
subtype	O
was	O
compared	O
with	O
that	O
of	O
muscarine	O
.	O

Moreover	O
,	O
affinity	O
and	O
relative	O
efficacy	O
were	O
calculated	O
in	O
vitro	O
for	O
this	O
compound	O
at	O
M2	O
(	O
heart	O
force	O
and	O
rate	O
)	O
and	O
M3	O
(	O
ileum	O
and	O
bladder	O
)	O
receptors	O
in	O
order	O
to	O
investigate	O
muscarinic	O
receptor	O
heterogeneity	O
.	O

The	O
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluoromuscarines	I-IUPAC
display	O
a	O
similar	O
trend	O
of	O
potency	O
as	O
the	O
corresponding	O
muscarines	O
and	O
compound	O
1a	O
shows	O
differences	O
in	O
the	O
affinity	O
constants	O
among	O
the	O
studied	O
tissues	O
.	O

Replacement	O
of	O
a	O
hydroxyl	I-IUPAC
group	B-MODIFIER
for	O
a	O
fluorine	O
atom	O
in	O
the	O
4	O
position	O
of	O
muscarine	O
produces	O
1	O
order	O
of	O
magnitude	O
increase	O
in	O
affinity	O
for	O
cardiac	O
M2	O
muscarinic	O
receptors	O
controlling	O
rate	O
,	O
while	O
the	O
affinity	O
at	O
cardiac	O
M2	O
muscarinic	O
receptors	O
controlling	O
force	O
is	O
unchanged	O
,	O
opening	O
the	O
possibility	O
of	O
a	O
further	O
classification	O
of	O
cardiac	O
muscarinic	O
receptors	O
.	O

N5	I-IUPAC
-	I-IUPAC
Acetyl	I-IUPAC
-	I-IUPAC
N5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
(	O
1	O
)	O
,	O
the	O
key	O
constituent	O
of	O
several	O
microbial	O
siderophores	O
,	O
has	O
been	O
synthesized	O
in	O
23%	O
yield	O
overall	O
from	O
N	O
-	O
Cbz	O
-	O
L	O
-	O
glutamic	O
acid	O
1	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
ester	I-IUPAC
(	O
6	O
)	O
derived	O
from	O
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
.	O

Reduction	O
of	O
6	O
to	O
7	O
and	O
treatment	O
with	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trichloroethoxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzylhydroxylamine	I-IUPAC
(	O
8	O
)	O
,	O
and	O
diethyl	I-IUPAC
azodicarboxylate	I-IUPAC
and	O
triphenylphosphine	O
followed	O
by	O
deprotection	O
produced	O
the	O
protected	O
N5	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
N5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
derivatives	I-MODIFIER
11	O
and	O
12	O
in	O
large	O
quantities	O
(	O
10-20	O
g	O
)	O
.	O

Following	O
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
and	O
alpha	I-IUPAC
-	I-IUPAC
carboxyl	I-IUPAC
deprotections	I-MODIFIER
of	O
11	O
and	O
12	O
,	O
EEDQ	O
[	O
2	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydroquinoline	I-IUPAC
]	O
mediated	O
peptide	O
coupling	O
and	O
final	O
deprotection	O
provided	O
amino	O
acid	O
1	O
and	O
six	O
albomycin	O
-	O
like	O
peptides	O
(	O
20	O
,	O
23	O
,	O
25	O
,	O
28	O
,	O
35	O
,	O
and	O
36	O
)	O
.	O

The	O
growth	O
-	O
promoting	O
ability	O
of	O
each	O
was	O
evaluated	O
with	O
the	O
siderophore	O
biosynthesis	O
mutant	O
Shigella	O
flexneri	O
SA240	O
(	O
SA	O
100	O
iucD	O
:	O
Tn5	O
)	O
.	O

These	O
results	O
indicate	O
that	O
substantial	O
modification	O
of	O
the	O
framework	O
of	O
peptide	O
-	O
based	O
siderophores	O
can	O
be	O
tolerated	O
by	O
microbial	O
iron	O
-	O
transport	O
systems	O
.	O

4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Phenylethynyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
derivatives	I-MODIFIER
are	O
selective	O
antagonists	O
at	O
human	O
A3	O
adenosine	O
receptors	O
,	O
with	O
Ki	O
values	O
in	O
a	O
radioligand	O
binding	O
assay	O
vs	O
[	O
125I	O
]	O
AB	O
-	O
MECA	O
(	O
N6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylcarbamoyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
)	O
in	O
the	O
submicromolar	O
range	O
.	O

In	O
this	O
study	O
,	O
structure	O
-	O
activity	O
relationships	O
at	O
various	O
positions	O
of	O
the	O
dihydropyridine	O
ring	O
(	O
the	O
3	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
acyl	I-IUPAC
substituents	I-MODIFIER
,	O
the	O
4	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
substituent	I-MODIFIER
,	O
and	O
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	I-MODIFIER
)	O
were	O
probed	O
synthetically	O
.	O

Using	O
the	O
combined	O
protection	O
of	O
the	O
1	I-IUPAC
-	I-IUPAC
ethoxymethyl	I-IUPAC
and	O
the	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
ester	I-IUPAC
groups	I-MODIFIER
,	O
a	O
free	O
carboxylic	O
acid	O
was	O
formed	O
at	O
the	O
5	O
-	O
position	O
allowing	O
various	O
substitutions	O
.	O

Selectivity	O
of	O
the	O
new	O
analogues	O
for	O
cloned	O
human	O
A3	O
adenosine	O
receptors	O
was	O
determined	O
vs	O
radioligand	O
binding	O
at	O
rat	O
brain	O
A1	O
and	O
A2A	O
receptors	O
.	O

Structure	O
-	O
activity	O
analysis	O
at	O
adenosine	O
receptors	O
indicated	O
that	O
pyridyl	O
,	O
furyl	O
,	O
benzofuryl	O
,	O
and	O
thienyl	O
groups	O
at	O
the	O
4	O
-	O
position	O
resulted	O
in	O
,	O
at	O
most	O
,	O
only	O
moderate	O
selectivity	O
for	O
A3	O
adenosine	O
receptors	O
.	O

Ring	O
substitution	O
(	O
e.g.	O
,	O
4	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
)	O
of	O
the	O
4	I-IUPAC
-	I-IUPAC
phenylethylnyl	I-IUPAC
group	I-MODIFIER
did	O
not	O
provide	O
enhanced	O
selectivity	O
,	O
as	O
it	O
did	O
for	O
the	O
4	I-IUPAC
-	I-IUPAC
styryl	I-IUPAC
-	O
substituted	I-MODIFIER
dihydropyridines	B-IUPAC
.	O

At	O
the	O
3	O
-	O
position	O
of	O
the	O
dihydropyridine	O
ring	O
,	O
esters	O
were	O
much	O
more	O
selective	O
for	O
A3	O
receptors	O
than	O
closely	O
related	O
thioester	O
,	O
amide	O
,	O
and	O
ketone	O
derivatives	O
.	O

A	O
cyclic	O
3	O
-	O
keto	O
derivative	O
was	O
5	O
-	O
fold	O
more	O
potent	O
at	O
A3	O
receptors	O
than	O
a	O
related	O
open	O
-	O
ring	O
analogue	O
.	O

At	O
the	O
5	O
-	O
position	O
,	O
a	O
homologous	O
series	O
of	O
phenylalkyl	O
esters	O
and	O
a	O
series	O
of	O
substituted	I-MODIFIER
benzyl	B-IUPAC
esters	I-IUPAC
were	O
prepared	O
and	O
tested	O
.	O

(	I-PARTIUPAC
Trifluoromethyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
,	O
nitro	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
other	O
benzyl	O
esters	O
substituted	O
with	O
electron	O
-	O
withdrawing	O
groups	O
were	O
specific	O
for	O
A3	O
receptors	O
with	O
nanomolar	O
Ki	O
values	O
and	O
selectivity	O
as	O
high	O
as	O
37000	O
-	O
fold	O
.	O

A	O
functionalized	O
congener	O
bearing	O
an	O
[	I-IUPAC
(	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
group	I-MODIFIER
was	O
also	O
prepared	O
as	O
an	O
intermediate	O
in	O
the	O
synthesis	O
of	O
biologically	O
active	O
conjugates	O
.	O

The	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
1,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
pyrimidinyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
1	O
)	O
(	O
5	O
-	O
DACTHF	O
,	O
543U76	O
)	O
,	O
an	O
acyclic	O
analogue	O
of	O
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydrofolic	I-IUPAC
acid	I-IUPAC
(	O
THFA	O
)	O
,	O
are	O
described	O
.	O

The	O
key	O
intermediate	O
,	O
hemiaminal	O
8	O
,	O
was	O
prepared	O
in	O
four	O
stages	O
from	O
3	I-IUPAC
-	I-IUPAC
chloropropionaldehyde	I-IUPAC
diethyl	I-IUPAC
acetal	I-IUPAC
.	O

Reaction	O
of	O
8	O
with	O
dimethyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
gave	O
the	O
2,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
acetylamino	I-IUPAC
)	I-IUPAC
derivative	I-MODIFIER
11	O
,	O
which	O
was	O
hydrolyzed	O
with	O
1	O
N	O
sodium	O
hydroxide	O
to	O
give	O
1	O
;	O
the	O
glycine	O
analogue	O
16	O
was	O
prepared	O
in	O
a	O
similar	O
manner	O
.	O

The	O
N	O
-	O
methyl	O
analogue	O
2	O
and	O
N	O
-	O
formyl	O
analogue	O
3	O
were	O
prepared	O
from	O
11	O
and	O
1	O
,	O
respectively	O
.	O

Compounds	O
1-3	O
inhibited	O
growth	O
of	O
Detroit	O
98	O
and	O
L	O
cells	O
in	O
cell	O
culture	O
,	O
with	O
IC50s	O
ranging	O
from	O
2	O
to	O
0.018	O
microM	O
.	O

Cell	O
culture	O
toxicity	O
reversal	O
studies	O
and	O
enzyme	O
inhibition	O
tests	O
showed	O
that	O
1	O
was	O
cytotoxic	O
but	O
not	O
by	O
the	O
mechanism	O
of	O
the	O
dihydrofolate	O
reductase	O
inhibitor	O
aminopterin	O
.	O

Compound	O
1	O
and	O
its	O
polyglutamylated	O
homologues	O
inhibited	O
glycinamide	O
ribonucleotide	O
transformylase	O
(	O
GAR	O
-	O
TFase	O
)	O
and	O
aminoimidazole	O
ribonucleotide	O
transformylase	O
(	O
AICAR	O
-	O
TFase	O
)	O
,	O
the	O
folate	O
-	O
dependent	O
enzymes	O
in	O
de	O
novo	O
purine	O
biosynthesis	O
;	O
and	O
1	O
was	O
an	O
effective	O
substrate	O
for	O
mammalian	O
folyl	O
-	O
polyglutamate	O
synthetase	O
.	O

The	O
compound	O
inhibited	O
(	O
IC50	O
=	O
20	O
nM	O
)	O
the	O
conversion	O
of	O
[	O
14C	O
]	O
formate	O
to	O
[	I-IUPAC
14C	I-IUPAC
]	I-IUPAC
-	I-IUPAC
formylglycinamide	I-IUPAC
ribonucleotide	I-IUPAC
by	O
MOLT	O
-	O
4	O
cells	O
in	O
culture	O
.	O

These	O
data	O
suggest	O
that	O
the	O
site	O
of	O
action	O
of	O
1	O
is	O
inhibition	O
of	O
purine	O
de	O
novo	O
biosynthesis	O
.	O

Moderate	O
activity	O
was	O
observed	O
against	O
P388	O
leukemia	O
in	O
vivo	O
.	O

Crystal	O
structure	O
determinations	O
have	O
been	O
carried	O
out	O
for	O
the	O
following	O
seven	O
thyrotropin	O
releasing	O
hormone	O
analogues	O
:	O
I	O
,	O
(	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
6R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxothiomorpholin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylcarbonyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
histidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
proline	I-IUPAC
amide	I-IUPAC
;	O
II	O
,	O
(	I-IUPAC
3R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
oxothiomorpholin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylcarbonyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
histid	I-IUPAC
inyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
proline	I-IUPAC
amide	I-IUPAC
;	O
III	O
,	O
(	I-IUPAC
4R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxothiazolidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ylcarbonyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
histidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
prol	I-IUPAC
ine	I-IUPAC
amide	I-IUPAC
;	O
IV	O
,	O
5	I-IUPAC
-	I-IUPAC
ethylorotyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
histidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
proline	I-IUPAC
amide	I-IUPAC
;	O
V	O
,	O
5	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylorotyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
histidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
proline	I-IUPAC
amide	I-IUPAC
;	O
VI	O
,	O
5	I-IUPAC
-	I-IUPAC
bromoorotyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
histidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
proline	I-IUPAC
amide	I-IUPAC
;	O
and	O
VII	O
,	O
Phe2	O
-	O
TRH	O
.	O

A	O
surprising	O
degree	O
of	O
conformational	O
similarity	O
has	O
been	O
observed	O
for	O
the	O
peptide	O
backbone	O
.	O

All	O
peptide	O
bonds	O
are	O
found	O
to	O
be	O
trans	O
.	O

A	O
composite	O
hydrogen	O
-	O
bonding	O
environment	O
has	O
been	O
constructed	O
for	O
the	O
TRH	O
analogue	O
system	O
and	O
examined	O
for	O
its	O
inference	O
with	O
respect	O
to	O
receptor	O
binding	O
.	O

A	O
comparison	O
of	O
the	O
conformations	O
of	O
these	O
analogues	O
with	O
those	O
displayed	O
by	O
Leu5	O
-	O
enkephalin	O
has	O
also	O
been	O
made	O
,	O
and	O
unexpected	O
similarities	O
have	O
been	O
revealed	O
.	O

We	O
prepared	O
six	O
pairs	O
of	O
alpha	I-IUPAC
-	I-IUPAC
heteroaromatic	I-IUPAC
aldoximes	I-IUPAC
,	O
RC	O
(	O
=	O
NOH	O
)	O
H	O
,	O
and	O
thiohydroximates	O
,	O
RC	O
(	O
=	O
NOH	O
)	O
S	O
-	O
(	O
CH2	O
)	O
2N	O
(	O
C2H5	O
)	O
2	O
,	O
where	O
R	O
represents	O
various	O
oxadiazole	O
and	O
thiadiazole	O
rings	O
.	O

Each	O
compound	O
was	O
characterized	O
with	O
respect	O
to	O
the	O
following	O
:	O
structure	O
,	O
(	I-IUPAC
hydroxyimino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
acid	I-IUPAC
dissociation	O
constant	O
,	O
nucleophilicity	O
toward	O
trigonal	O
carbon	O
and	O
tetrahedral	O
phosphorus	O
,	O
octanol	O
-	O
buffer	O
partition	O
coefficient	O
,	O
reversible	O
inhibition	O
of	O
eel	O
acetylcholinesterase	O
(	O
AChE	O
)	O
,	O
and	O
in	O
vitro	O
reactivation	O
of	O
AChE	O
inhibited	O
by	O
ethyl	O
p	O
-	O
nitrophenyl	O
methylphosphonate	O
.	O

Eight	O
of	O
the	O
twelve	O
compounds	O
significantly	O
reactivate	O
ethyl	O
methylphosphonyl	O
-	O
AChE	O
,	O
but	O
inherent	O
reactivities	O
are	O
moderate	O
to	O
low	O
:	O
the	O
most	O
potent	O
nonquaternary	O
reactivator	O
,	O
3	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
hydroxyimino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
,	O
is	O
17	O
times	O
less	O
reactive	O
than	O
the	O
well	O
-	O
known	O
reactivator	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
hydroxyimino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylpyridinium	I-IUPAC
iodide	I-IUPAC
(	O
2	O
-	O
PAM	O
)	O
.	O

One	O
of	O
the	O
nonquaternary	O
compounds	O
,	O
3	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
oxadiazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thiohydroximic	I-IUPAC
acid	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
S	I-IUPAC
-	I-IUPAC
ester	I-IUPAC
,	O
is	O
a	O
powerful	O
reversible	O
inhibitor	O
of	O
AChE	O
(	O
I50	O
=	O
7.5	O
microM	O
)	O
.	O

The	O
observed	O
relationships	O
between	O
nonquaternary	O
compound	O
structure	O
,	O
reactivation	O
potency	O
,	O
and	O
anti	O
-	O
AChE	O
activity	O
reveal	O
important	O
molecular	O
requirements	O
for	O
high	O
reactivity	O
toward	O
phosphonylated	O
AChE	O
.	O

The	O
structural	O
basis	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
binding	O
to	O
several	O
classes	O
of	O
high	O
-	O
affinity	O
ligands	O
has	O
been	O
investigated	O
through	O
complementary	O
computational	O
and	O
experimental	O
methods	O
.	O

Employing	O
a	O
recently	O
developed	O
q	O
-	O
jumping	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulation	O
method	O
,	O
which	O
allows	O
us	O
to	O
consider	O
the	O
flexibility	O
of	O
both	O
the	O
ligands	O
and	O
the	O
receptor	O
in	O
docking	O
studies	O
,	O
we	O
predicted	O
the	O
binding	O
models	O
of	O
phorbol	I-IUPAC
-	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
,	O
phorbol	I-IUPAC
-	I-IUPAC
12,13	I-IUPAC
-	I-IUPAC
dibutyrate	I-IUPAC
(	O
PDBu	O
)	O
,	O
indolactam	O
V	O
(	O
ILV	O
)	O
,	O
ingenol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoate	I-IUPAC
,	O
and	O
thymeleatoxin	O
to	O
PKC	O
.	O

The	O
"	O
predicted	O
"	O
binding	O
model	O
for	O
phorbol	I-IUPAC
-	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
is	O
virtually	O
identical	O
to	O
the	O
experimentally	O
determined	O
binding	O
model	O
for	O
this	O
ligand	O
.	O

The	O
predicted	O
binding	O
model	O
for	O
PDBU	O
is	O
the	O
same	O
as	O
that	O
for	O
phorbol	I-IUPAC
-	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
in	O
terms	O
of	O
the	O
hydrogen	O
-	O
bonding	O
network	O
and	O
hydrophobic	O
contacts	O
.	O

The	O
predicted	O
binding	O
model	O
for	O
ILV	O
is	O
the	O
same	O
as	O
that	O
obtained	O
in	O
a	O
previous	O
docking	O
study	O
using	O
a	O
Monte	O
Carlo	O
method	O
and	O
is	O
consistent	O
with	O
the	O
structure	O
-	O
activity	O
relationships	O
for	O
this	O
class	O
of	O
ligands	O
.	O

Together	O
with	O
the	O
X	O
-	O
ray	O
structure	O
of	O
phorbol	I-IUPAC
-	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
in	O
complex	O
with	O
PKCdelta	O
C1b	O
,	O
the	O
predicted	O
binding	O
models	O
of	O
PDBu	O
,	O
ILV	O
,	O
ingenol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoate	I-IUPAC
,	O
and	O
thymeleatoxin	O
in	O
complex	O
with	O
PKC	O
showed	O
that	O
the	O
binding	O
of	O
these	O
ligands	O
to	O
PKC	O
is	O
governed	O
by	O
a	O
combination	O
of	O
several	O
highly	O
specific	O
and	O
optimal	O
hydrogen	O
bonds	O
and	O
hydrophobic	O
contacts	O
.	O

However	O
,	O
the	O
hydrogen	O
-	O
bonding	O
network	O
for	O
each	O
class	O
of	O
ligand	O
is	O
somewhat	O
different	O
and	O
the	O
number	O
of	O
hydrogen	O
bonds	O
formed	O
between	O
PKC	O
and	O
these	O
ligands	O
has	O
no	O
correlation	O
with	O
their	O
binding	O
affinities	O
.	O

To	O
provide	O
a	O
direct	O
and	O
quantitative	O
assessment	O
of	O
the	O
contributions	O
of	O
several	O
conserved	O
residues	O
around	O
the	O
binding	O
site	O
to	O
PKC	O
-	O
ligand	O
binding	O
,	O
we	O
have	O
made	O
11	O
mutations	O
and	O
measured	O
the	O
binding	O
affinities	O
of	O
the	O
high	O
-	O
affinity	O
PKC	O
ligands	O
to	O
these	O
mutants	O
.	O

The	O
results	O
obtained	O
through	O
site	O
-	O
directed	O
mutagenic	O
analysis	O
support	O
our	O
predicted	O
binding	O
models	O
for	O
these	O
ligands	O
and	O
provide	O
new	O
insights	O
into	O
PKC	O
-	O
ligand	O
binding	O
.	O

Although	O
all	O
the	O
ligands	O
have	O
high	O
affinity	O
for	O
the	O
wild	O
-	O
type	O
PKCdelta	O
C1b	O
,	O
our	O
site	O
-	O
directed	O
mutagenic	O
results	O
showed	O
that	O
ILV	O
is	O
the	O
ligand	O
most	O
sensitive	O
to	O
structural	O
perturbations	O
of	O
the	O
binding	O
site	O
while	O
ingenol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzoate	I-IUPAC
is	O
the	O
least	O
sensitive	O
among	O
the	O
four	O
classes	O
of	O
ligands	O
examined	O
here	O
.	O

Finally	O
,	O
we	O
have	O
employed	O
conventional	O
MD	O
simulations	O
to	O
investigate	O
the	O
structural	O
perturbations	O
caused	O
by	O
each	O
mutation	O
to	O
further	O
examine	O
the	O
role	O
played	O
by	O
each	O
individual	O
residue	O
in	O
PKC	O
-	O
ligand	O
binding	O
.	O

MD	O
simulations	O
revealed	O
that	O
several	O
mutations	O
,	O
including	O
Pro11	O
-	O
-	O
&	O
gt	O
;	O
Gly	O
,	O
Leu21	O
-	O
-	O
&	O
gt	O
;	O
Gly	O
,	O
Leu24	O
-	O
-	O
&	O
gt	O
;	O
Gly	O
,	O
and	O
Gln27	O
-	O
-	O
&	O
gt	O
;	O
Gly	O
,	O
cause	O
a	O
rather	O
large	O
conformational	O
alteration	O
to	O
the	O
PKC	O
binding	O
site	O
and	O
,	O
in	O
some	O
cases	O
,	O
to	O
the	O
overall	O
structure	O
of	O
the	O
protein	O
.	O

The	O
complete	O
abolishment	O
or	O
the	O
significant	O
reduction	O
in	O
PKC	O
-	O
ligand	O
binding	O
observed	O
for	O
these	O
mutants	O
thus	O
reflects	O
the	O
loss	O
of	O
certain	O
direct	O
contacts	O
between	O
the	O
side	O
chain	O
of	O
the	O
mutated	O
residue	O
in	O
PKC	O
and	O
ligands	O
as	O
well	O
as	O
the	O
large	O
conformational	O
alteration	O
to	O
the	O
binding	O
site	O
caused	O
by	O
the	O
mutation	O
.	O

Five	O
new	O
analogues	O
(	O
1c	O
-	O
g	O
)	O
of	O
the	O
antifolate	O
N10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
(	O
1a	O
)	O
are	O
described	O
in	O
which	O
the	O
benzoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
moiety	I-MODIFIER
was	O
replaced	O
by	O
benzoic	O
acid	O
(	O
desglutamyl	I-IUPAC
-	I-IUPAC
N10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5,8	I-IUPAC
-	I-IUPAC
dideazafolic	I-IUPAC
acid	I-IUPAC
)	O
,	O
benzoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
aspartate	I-IUPAC
,	O
4	I-IUPAC
-	I-IUPAC
phenylbutyrate	I-IUPAC
,	O
benzoylglycine	O
,	O
and	O
benzoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
.	O

The	O
esters	O
of	O
the	O
appropriate	O
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
(	O
benzoyl	I-PARTIUPAC
)	O
starting	O
materials	O
were	O
sequentially	O
alkylated	O
upon	O
nitrogen	O
,	O
first	O
with	O
a	O
propargyl	O
halide	O
and	O
then	O
with	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyquinazoline	I-IUPAC
hydrobromide	I-IUPAC
.	O

Saponification	O
of	O
the	O
antifolate	O
esters	O
so	O
produced	O
gave	O
the	O
desired	O
analogues	O
.	O

The	O
new	O
derivatives	O
(	O
1c	O
-	O
g	O
)	O
and	O
also	O
the	O
known	O
diethyl	O
ester	O
of	O
1a	O
(	O
1b	O
)	O
were	O
tested	O
for	O
their	O
inhibition	O
of	O
purified	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
L1210	O
cells	O
in	O
culture	O
.	O

The	O
TS	O
inhibition	O
of	O
the	O
analogues	O
1b	O
-	O
g	O
was	O
estimated	O
by	O
calculating	O
the	O
inverse	O
relative	O
potency	O
,	O
defined	O
as	O
the	O
ratio	O
IC50	O
(	O
compound	O
)	O
/	O
IC50	O
(	O
1a	O
)	O
.	O

The	O
results	O
obtained	O
were	O
as	O
follows	O
:	O
greater	O
than	O
62	O
,	O
84	O
,	O
9	O
,	O
333	O
,	O
21	O
,	O
and	O
5	O
,	O
respectively	O
.	O

All	O
were	O
thus	O
less	O
inhibitory	O
than	O
1a	O
.	O

None	O
of	O
the	O
compounds	O
improved	O
upon	O
1a	O
in	O
inhibiting	O
the	O
growth	O
of	O
L1210	O
cells	O
in	O
culture	O
.	O

The	O
syntheses	O
of	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6,7,8,9	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
,	I-IUPAC
10H	I-IUPAC
-	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
carbazol	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
8	O
)	O
,	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
7,8,9,10	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
11H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
carbazol	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
9a	O
)	O
,	O
and	O
the	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
,	I-IUPAC
11	I-IUPAC
-	I-IUPAC
trimethyl	I-IUPAC
analogue	I-MODIFIER
(	O
9b	O
)	O
are	O
described	O
.	O

The	O
in	O
vitro	O
inotropic	O
activity	O
of	O
these	O
compounds	O
,	O
as	O
well	O
as	O
the	O
known	O
cardiotonics	O
amrinone	O
and	O
7	I-IUPAC
-	I-IUPAC
hydroxycyclindole	I-IUPAC
(	O
7	O
)	O
,	O
was	O
investigated	O
.	O

Compound	O
8	O
,	O
a	O
pyrrolo	O
analogue	O
of	O
7	O
,	O
was	O
devoid	O
of	O
inotropic	O
activity	O
,	O
while	O
the	O
pyrido	I-IUPAC
analogues	B-MODIFIER
9	O
were	O
equiactive	O
to	O
7	O
and	O
amrinone	O
.	O

These	O
results	O
suggest	O
that	O
the	O
hydroxyl	O
group	O
of	O
7	O
functions	O
as	O
an	O
H	O
-	O
bond	O
acceptor	O
,	O
rather	O
than	O
a	O
donor	O
,	O
and	O
that	O
on	O
interaction	O
of	O
7	O
,	O
and	O
the	O
pyrido	O
analogues	O
9	O
,	O
with	O
a	O
common	O
receptor	O
,	O
an	O
orbital	O
occupied	O
by	O
one	O
of	O
the	O
oxygen	O
lone	O
pair	O
electrons	O
of	O
7	O
must	O
assume	O
the	O
same	O
orientation	O
as	O
the	O
orbital	O
occupied	O
by	O
the	O
pyridine	O
nitrogen	O
lone	O
pair	O
.	O

Study	O
of	O
P2	O
-	O
purinoceptor	O
subtypes	O
has	O
been	O
difficult	O
due	O
to	O
the	O
lack	O
of	O
potent	O
and	O
selective	O
ligands	O
.	O

With	O
the	O
goal	O
of	O
developing	O
high	O
affinity	O
P2	O
-	O
purinoceptor	O
-	O
selective	O
agonist	O
,	O
we	O
have	O
synthesized	O
a	O
series	O
of	O
analogues	O
of	O
adenine	O
nucleotides	O
modified	O
on	O
the	O
purine	O
ring	O
as	O
chain	O
-	O
extended	O
2	O
-	O
thioethers	O
or	O
as	O
N6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
compounds	O
.	O

Chemical	O
functionality	O
incorporated	O
in	O
the	O
thioether	O
moiety	O
included	O
cyanoalkyl	O
,	O
nitroaromatic	O
,	O
amino	I-IUPAC
,	O
thiol	I-IUPAC
,	O
cycloalkyl	O
,	O
n	O
-	O
alkyl	O
,	O
and	O
olefinic	O
groups	O
.	O

Apparent	O
affinity	O
of	O
the	O
compounds	O
for	O
P2Y	O
-	O
purinoceptors	O
was	O
established	O
by	O
measurement	O
of	O
P2Y	O
-	O
purinoceptor	O
-	O
promoted	O
phospholipase	O
C	O
activity	O
in	O
turkey	O
erythrocyte	O
membranes	O
and	O
relaxation	O
of	O
carbachol	O
-	O
contracted	O
smooth	O
muscle	O
in	O
three	O
different	O
preparations	O
(	O
guinea	O
pig	O
taenia	O
coli	O
,	O
rabbit	O
aorta	O
,	O
and	O
rabbit	O
mesenteric	O
artery	O
)	O
.	O

Activity	O
at	O
P2X	O
-	O
purinoceptors	O
was	O
established	O
by	O
measurement	O
of	O
contraction	O
of	O
rabbit	O
saphenous	O
artery	O
and	O
of	O
the	O
guinea	O
pig	O
vas	O
deferens	O
and	O
urinary	O
bladder	O
.	O

All	O
11	O
of	O
the	O
2	O
-	O
thioethers	O
of	O
ATP	O
stimulated	O
the	O
production	O
of	O
inositol	O
phosphates	O
with	O
K0	O
.5	O
values	O
of	O
1.5-770	O
nM	O
,	O
with	O
an	O
(	O
aminophenyl	O
)	O
ethyl	O
derivative	O
being	O
most	O
potent	O
.	O

Two	O
adenosine	O
diphosphate	O
analogues	O
were	O
equipotent	O
to	O
the	O
corresponding	O
ATP	O
analogues	O
.	O

Adenosine	O
monophosphate	O
analogues	O
were	O
full	O
agonists	O
,	O
although	O
generally	O
4	O
orders	O
of	O
magnitude	O
less	O
potent	O
.	O

ATP	O
2	O
-	O
thioethers	O
displayed	O
pD2	O
values	O
in	O
the	O
range	O
of	O
6-8	O
in	O
smooth	O
muscle	O
assay	O
systems	O
for	O
activity	O
at	O
P2Y	O
-	O
receptors	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
for	O
the	O
2	O
-	O
thioether	O
compounds	O
between	O
the	O
pK0	O
.5	O
values	O
for	O
inositol	O
phosphate	O
production	O
and	O
the	O
pD2	O
values	O
for	O
relaxation	O
mediated	O
via	O
the	O
P2Y	O
-	O
purinoceptors	O
in	O
the	O
guinea	O
pig	O
taenia	O
coli	O
,	O
but	O
not	O
for	O
the	O
vascular	O
P2Y	O
-	O
receptors	O
or	O
for	O
the	O
P2X	O
-	O
receptors	O
.	O

At	O
P2X	O
-	O
receptors	O
,	O
no	O
activity	O
was	O
observed	O
in	O
the	O
rabbit	O
saphenous	O
artery	O
,	O
but	O
variable	O
degrees	O
of	O
activity	O
were	O
observed	O
in	O
the	O
guinea	O
pig	O
vas	O
deferens	O
and	O
bladder	O
depending	O
on	O
distal	O
substituents	O
of	O
the	O
thioether	O
moiety	O
.	O

N6	O
-	O
Methyl	O
-	O
ATP	O
was	O
inactive	O
at	O
P2X	O
-	O
receptors	O
,	O
and	O
approximately	O
equipotent	O
to	O
ATP	O
at	O
taenia	O
coil	O
P2Y	O
-	O
receptors	O
.	O

This	O
suggested	O
that	O
hybrid	O
N6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
and	O
2	I-IUPAC
-	I-IUPAC
thioether	I-IUPAC
ATP	I-IUPAC
derivatives	I-MODIFIER
might	O
be	O
potent	O
and	O
selective	O
for	O
certain	O
P2Y	O
-	O
receptors	O
,	O
as	O
was	O
shown	O
for	O
one	O
such	O
derivative	O
,	O
N6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hexenylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ATP	I-IUPAC
.	O

1,3,5	I-MODIFIER
-	I-MODIFIER
Substituted	I-MODIFIER
indoles	O
and	O
indazoles	O
have	O
been	O
studied	O
as	O
receptor	O
antagonists	O
of	O
the	O
peptidoleukotrienes	O
.	O

The	O
best	O
of	O
these	O
compounds	O
generally	O
had	O
a	O
methyl	O
group	O
at	O
the	O
N1	O
position	O
,	O
a	O
[	I-IUPAC
(	I-IUPAC
cyclopentyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
or	O
2	I-IUPAC
-	I-IUPAC
cyclopentylacetamido	I-IUPAC
or	O
N'	I-IUPAC
-	I-IUPAC
cyclopentylureido	I-IUPAC
group	I-MODIFIER
at	O
the	O
C	O
-	O
5	O
position	O
,	O
and	O
an	O
arylsulfonyl	O
amide	O
group	O
as	O
part	O
of	O
the	O
acidic	O
chain	O
at	O
the	O
C	O
-	O
3	O
position	O
of	O
the	O
ring	O
.	O

Such	O
compounds	O
had	O
in	O
vitro	O
dissociation	O
constants	O
(	O
KB	O
)	O
in	O
the	O
range	O
10	O
(	O
-	O
9	O
)	O
-	O
10	O
(	O
-	O
11	O
)	O
M	O
on	O
guinea	O
pig	O
trachea	O
against	O
LTE4	O
as	O
agonist	O
and	O
inhibition	O
constants	O
(	O
Ki	O
)	O
less	O
than	O
or	O
equal	O
to	O
10	O
(	O
-	O
9	O
)	O
M	O
on	O
guinea	O
pig	O
parenchymal	O
membranes	O
against	O
[	O
3H	O
]	O
LTD4	O
.	O

A	O
number	O
of	O
compounds	O
were	O
orally	O
effective	O
at	O
doses	O
less	O
than	O
or	O
equal	O
to	O
1	O
mg	O
/	O
kg	O
in	O
blocking	O
LTD4	O
-	O
induced	O
"	O
dyspnea	O
"	O
in	O
guinea	O
pigs	O
.	O

Compound	O
45	O
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
cyclopentyloxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methylindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxybenzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylbenzenesulfonamide	I-IUPAC
,	O
ICI	O
204,219	O
;	O
pKB	O
=	O
9.67	O
+	O
/	O
-	O
0.13	O
,	O
Ki	O
=	O
0.3	O
+	O
/	O
-	O
0.03	O
nM	O
,	O
po	O
ED50	O
=	O
0.3	O
mg	O
/	O
kg	O
]	O
is	O
currently	O
under	O
clinical	O
investigation	O
for	O
asthma	O
.	O

In	O
the	O
indole	O
series	O
,	O
certain	O
alkylsulfonyl	O
amides	O
possessing	O
a	O
3	I-IUPAC
-	I-IUPAC
cyanobenzyl	I-IUPAC
substituent	I-MODIFIER
at	O
the	O
N	O
-	O
1	O
position	O
(	O
60	O
,	O
61	O
)	O
were	O
produced	O
that	O
had	O
KB	O
less	O
than	O
or	O
equal	O
to	O
10	O
(	O
-	O
9	O
)	O
M	O
on	O
guinea	O
pig	O
trachea	O
.	O

A	O
series	O
of	O
substituted	I-MODIFIER
dibenzo	B-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
has	O
been	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
activity	O
.	O

The	O
required	O
substituted	I-MODIFIER
dibenzo	B-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
were	O
prepared	O
by	O
a	O
variety	O
of	O
methods	O
.	O

No	O
regiospecific	O
syntheses	O
were	O
available	O
for	O
many	O
of	O
these	O
,	O
and	O
separation	O
of	O
the	O
mixtures	O
of	O
regioisomers	O
obtained	O
was	O
sometimes	O
difficult	O
.	O

The	O
dibenzo	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
are	O
active	O
against	O
wild	O
-	O
type	O
P388	O
leukemia	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
with	O
structure	O
-	O
activity	O
relationships	O
resembling	O
those	O
for	O
both	O
the	O
acridine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
and	O
phenazine	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
series	I-MODIFIER
of	O
DNA	O
-	O
intercalating	O
antitumor	O
agents	O
.	O

In	O
all	O
three	O
series	O
,	O
substituents	O
placed	O
peri	O
to	O
the	O
carboxamide	O
sidechain	O
(	O
the	O
5	O
-	O
position	O
in	O
the	O
acridines	O
,	O
and	O
the	O
9	O
-	O
position	O
in	O
the	O
phenazines	O
and	O
dibenzo	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxins	I-IUPAC
)	O
enhance	O
activity	O
and	O
potency	O
.	O

The	O
9	I-IUPAC
-	I-IUPAC
chlorodibenzodioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
was	O
also	O
curative	O
against	O
the	O
remotely	O
sited	O
Lewis	O
lung	O
carcinoma	O
.	O

Several	O
of	O
the	O
compounds	O
showed	O
much	O
lower	O
levels	O
of	O
cross	O
-	O
resistance	O
to	O
the	O
P388	O
/	O
AMSA	O
line	O
than	O
classical	O
DNA	O
-	O
intercalating	O
agents	O
,	O
which	O
suggests	O
that	O
their	O
primary	O
mechanism	O
of	O
action	O
may	O
not	O
be	O
via	O
interference	O
with	O
topoisomerase	O
II	O
alpha	O
.	O

This	O
is	O
of	O
interest	O
with	O
regard	O
to	O
the	O
development	O
of	O
drugs	O
to	O
combat	O
resistance	O
mechanisms	O
which	O
arise	O
by	O
the	O
expression	O
of	O
the	O
topo	O
II	O
beta	O
isozyme	O
.	O

Octreotide	O
,	O
an	O
analogue	O
of	O
the	O
hormone	O
somatostatin	O
,	O
has	O
applications	O
as	O
a	O
therapeutic	O
and	O
imaging	O
agent	O
for	O
somatostatin	O
-	O
positive	O
tumors	O
.	O

We	O
have	O
developed	O
a	O
generally	O
applicable	O
,	O
convenient	O
stepwise	O
solid	O
-	O
phase	O
synthetic	O
protocol	O
for	O
octreotide	O
(	O
D	O
-	O
Phe	O
-	O
Cys	O
-	O
Phe	O
-	O
D	O
-	O
Trp	O
-	O
Lys	O
-	O
Thr	O
-	O
Cys	O
-	O
threoninol	O
)	O
.	O

[	O
Cys	O
(	O
Acm	O
)	O
2	O
,	O
D	O
-	O
Trp	O
(	O
Boc	O
)	O
4	O
,	O
Lys	O
(	O
Boc	O
)	O
5	O
,	O
Thr	O
(	O
tBu	O
)	O
6	O
,	O
Cys	O
(	O
Acm	O
)	O
7	O
,	O
des	I-IUPAC
(	I-IUPAC
threoninol	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
octreotide	I-IUPAC
was	O
assembled	O
by	O
Fmoc	O
solid	O
-	O
phase	O
synthesis	O
and	O
the	O
intramolecular	O
disulfide	O
bond	O
formed	O
by	O
treatment	O
of	O
the	O
resin	O
-	O
bound	O
peptide	O
with	O
thallium	O
trifluoroacetate	O
[	O
Tl	O
(	O
Tfa	O
)	O
3	O
]	O
.	O

Side	O
-	O
chain	O
protection	O
of	O
Trp	O
by	O
the	O
Boc	O
group	O
was	O
found	O
to	O
preserve	O
Trp	O
integrity	O
during	O
Tl	O
(	O
Tfa	O
)	O
3	O
treatment	O
.	O

The	O
protected	O
peptide	O
was	O
cleaved	O
from	O
the	O
resin	O
by	O
aminolysis	O
with	O
threoninol	O
and	O
purified	O
by	O
semipreparative	O
RP	O
-	O
HPLC	O
.	O

Isolated	O
[	O
D	O
-	O
Trp	O
(	O
Boc	O
)	O
4	O
,	O
Lys	O
(	O
Boc	O
)	O
5	O
,	O
Thr	O
(	O
tBu	O
)	O
6	O
]	O
octreotide	O
had	O
the	O
correct	O
molecular	O
mass	O
(	O
[	O
M+	O
H	O
]	O
+	O
=	O
1275	O
Da	O
)	O
and	O
sequence	O
and	O
was	O
obtained	O
in	O
14%	O
yield	O
at	O
&	O
gt	O
;	O
98%	O
purity	O
.	O

[	O
D	O
-	O
Trp	O
(	O
Boc	O
)	O
4	O
,	O
Lys	O
(	O
Boc	O
)	O
5	O
,	O
Thr	O
(	O
tBu	O
)	O
6	O
]	O
octreotide	O
was	O
utilized	O
for	O
the	O
solution	O
-	O
phase	O
synthesis	O
of	O
CPTA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
,	O
where	O
CPTA	O
is	O
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
1,4,8,11	I-IUPAC
-	I-IUPAC
tetraazacyclotetradec	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
.	O

Cyclic	O
dianhydride	O
of	O
diethylenetriaminepentaacetic	O
acid	O
(	O
DTPA	O
)	O
was	O
coupled	O
to	O
a	O
portion	O
of	O
the	O
protected	O
peptide	O
-	O
resin	O
following	O
disulfide	O
bond	O
formation	O
.	O

The	O
DTPA	O
-	O
conjugated	O
,	O
side	O
-	O
chain	O
-	O
protected	O
peptide	O
was	O
cleaved	O
from	O
the	O
resin	O
by	O
aminolysis	O
with	O
threoninol	O
,	O
side	O
-	O
chain	O
deprotected	O
with	O
trifluoroacetic	O
acid	O
,	O
and	O
purified	O
by	O
semipreparative	O
RP	O
-	O
HPLC	O
.	O

The	O
isolated	O
DTPA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
had	O
the	O
correct	O
molecular	O
mass	O
(	O
[	O
M+	O
H	O
]	O
+	O
=	O
1395	O
Da	O
)	O
and	O
was	O
obtained	O
in	O
5%	O
yield	O
at	O
&	O
gt	O
;	O
90%	O
purity	O
.	O

The	O
efficiency	O
of	O
aminolysis	O
was	O
partially	O
dependent	O
upon	O
the	O
linkage	O
between	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
phenoxy	I-IUPAC
(	O
HMP	O
)	O
handles	I-MODIFIER
and	O
the	O
resin	O
and	O
/	O
or	O
resin	O
particle	O
size	O
.	O

The	O
somatostatin	O
receptor	O
binding	O
affinities	O
of	O
synthetic	O
DTPA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
and	O
CPTA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
to	O
AtT	O
-	O
20	O
mouse	O
pituitary	O
carcinoma	O
cell	O
membranes	O
were	O
examined	O
by	O
labeling	O
with	O
111In	O
and	O
64Cu	O
,	O
respectively	O
,	O
and	O
performing	O
Scatchard	O
analyses	O
.	O

The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
for	O
our	O
synthetic	O
[	O
111In	O
]	O
DTPA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
was	O
4.31	O
nM	O
,	O
which	O
is	O
comparable	O
to	O
a	O
Kd	O
=	O
5.57	O
nM	O
obtained	O
with	O
commercially	O
available	O
DTPA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
.	O

The	O
Kd	O
for	O
[	O
64Cu	O
]	O
CPTA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
was	O
78.5	O
pM	O
.	O

On	O
the	O
basis	O
of	O
the	O
criteria	O
of	O
molecular	O
mass	O
,	O
RP	O
-	O
HPLC	O
elution	O
time	O
,	O
sequence	O
analysis	O
,	O
and	O
somatostatin	O
receptor	O
binding	O
affinity	O
,	O
our	O
synthetic	O
octreotide	O
is	O
identical	O
to	O
commercially	O
available	O
octreotide	O
.	O

The	O
aminolysis	O
protocol	O
used	O
here	O
has	O
distinct	O
advantages	O
over	O
either	O
reductive	O
cleavage	O
or	O
preformed	O
linker	O
methods	O
described	O
previously	O
for	O
the	O
preparation	O
of	O
octreotide	O
.	O

The	O
antimicrobial	O
and	O
cytotoxic	O
properties	O
of	O
a	O
series	O
of	O
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrenes	I-IUPAC
structurally	O
related	O
to	O
juncusol	O
(	O
1a	O
)	O
,	O
a	O
postulated	O
phytoalexin	O
with	O
confirmed	O
cytotoxic	O
properties	O
,	O
are	O
detailed	O
.	O

Two	O
simple	O
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrenes	I-IUPAC
,	O
2,7	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
3,8	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrene	I-IUPAC
(	O
2h	O
,	O
desvinyljuncusol	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrene	I-IUPAC
(	O
3h	O
)	O
,	O
were	O
found	O
to	O
possess	O
in	O
vitro	O
antimicrobial	O
activity	O
comparable	O
with	O
that	O
of	O
the	O
natural	O
product	O
.	O

Two	O
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrenes	I-IUPAC
substituted	O
with	O
quaternary	O
ammonium	O
salts	O
,	O
2d	O
and	O
3d	O
,	O
each	O
containing	O
a	O
reactive	O
benzylic	I-MODIFIER
dimethyl	B-IUPAC
[	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
ammonio	I-IUPAC
group	I-MODIFIER
,	O
were	O
found	O
to	O
be	O
10-20	O
times	O
more	O
potent	O
than	O
juncusol	O
(	O
1a	O
)	O
.	O

Confirmed	O
in	O
vitro	O
cytotoxic	O
activity	O
that	O
parallels	O
antimicrobial	O
activity	O
was	O
found	O
for	O
juncusol	O
(	O
1a	O
)	O
,	O
desvinyljuncusol	O
(	O
2h	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrene	I-IUPAC
(	O
3h	O
)	O
,	O
and	O
the	O
quaternary	I-MODIFIER
dimethyl	B-IUPAC
[	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
ammonium	I-IUPAC
salts	I-MODIFIER
2d	O
and	O
3d	O
in	O
a	O
human	O
lymphoblastic	O
leukemia	O
cell	O
culture	O
(	O
CCRF	O
-	O
CEM	O
,	O
IC50	O
=	O
nt	O
,	O
9.3	O
,	O
nt	O
,	O
0.9	O
and	O
1.4	O
microgram	O
/	O
mL	O
,	O
respectively	O
)	O
,	O
B	O
-	O
16	O
mouse	O
melanoma	O
cell	O
culture	O
(	O
IC50	O
=	O
12.5	O
,	O
17.5	O
,	O
27.7	O
,	O
0.3	O
,	O
and	O
0.5	O
microgram	O
/	O
mL	O
,	O
respectively	O
)	O
,	O
and	O
L	O
-	O
1210	O
mouse	O
lymphocytic	O
leukemia	O
cell	O
culture	O
(	O
IC50	O
=	O
13.8	O
,	O
10.2	O
,	O
24.5	O
,	O
1.3	O
,	O
and	O
3.7	O
micrograms	O
/	O
mL	O
,	O
respectively	O
)	O
.	O

The	O
comparable	O
potency	O
and	O
spectrum	O
of	O
activity	O
of	O
juncusol	O
(	O
1a	O
)	O
,	O
desvinyljuncusol	O
(	O
2h	O
)	O
,	O
and	O
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9,10	I-IUPAC
-	I-IUPAC
dihydrophenanthrene	I-IUPAC
(	O
3h	O
)	O
suggest	O
that	O
the	O
agents	O
are	O
acting	O
as	O
simple	O
phenols	O
in	O
exerting	O
their	O
antimicrobial	O
and	O
cytotoxic	O
effects	O
.	O

A	O
number	O
of	O
17	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
alkyl	I-PARTIUPAC
/	I-PARTIUPAC
arylformamido	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
17	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	I-PARTIUPAC
N	I-PARTIUPAC
-	I-PARTIUPAC
alkyl	I-PARTIUPAC
/	I-PARTIUPAC
aryl	I-PARTIUPAC
)	I-PARTIUPAC
alkyl	I-PARTIUPAC
/	I-PARTIUPAC
arylamido	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
oxo	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
aza	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
alpha	I-PARTIUPAC
-	O
steroids	I-MODIFIER
were	O
prepared	O
from	O
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
and	O
evaluated	O
as	O
inhibitors	O
of	O
human	O
5	O
alpha	O
-	O
reductase	O
and	O
antagonists	O
of	O
the	O
androgen	O
receptor	O
.	O

Jones	O
'	O
oxidation	O
of	O
17	I-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
compounds	I-MODIFIER
gave	O
the	O
17	I-IUPAC
-	I-IUPAC
keto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
,	O
which	O
were	O
treated	O
with	O
amines	O
and	O
NaBH	O
(	O
OAc	O
)	O
3	O
/	O
NaBH3CN	O
to	O
give	O
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
arylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
10-27	O
.	O

Alternatively	O
,	O
the	O
above	O
-	O
indicated	O
compounds	O
were	O
prepared	O
from	O
amines	O
and	O
17	I-IUPAC
-	I-IUPAC
keto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
to	O
form	O
imines	O
,	O
which	O
were	O
then	O
reduced	O
with	O
NaBH4	O
.	O

Formylation	O
of	O
amines	O
10-27	O
gave	O
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkylformamides	I-IUPAC
)	I-IUPAC
28-41	O
;	O
however	O
,	O
acylation	O
afforded	O
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
aryl	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
arylamides	I-IUPAC
]	I-IUPAC
42-53	O
.	O

In	O
comparison	O
to	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
diethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
androstane	I-IUPAC
-	I-IUPAC
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
4	O
-	O
MA	O
;	O
IC50	O
=	O
4.15	O
nM	O
)	O
,	O
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkylformamido	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
were	O
potent	O
inhibitors	O
of	O
human	O
type	O
I	O
5	O
alpha	O
-	O
reductase	O
,	O
IC50	O
values	O
of	O
compounds	O
29	O
,	O
30	O
,	O
36	O
,	O
and	O
37	O
being	O
measured	O
as	O
3.05	O
,	O
0.91	O
,	O
2.19	O
,	O
and	O
2.35	O
nM	O
,	O
respectively	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
suggest	O
that	O
the	O
type	O
I	O
enzyme	O
has	O
preference	O
for	O
N	O
-	O
substituted	O
straight	O
alkyl	O
side	O
chains	O
of	O
four	O
to	O
five	O
carbon	O
atoms	O
.	O

On	O
the	O
other	O
hand	O
,	O
formamides	O
32	O
(	O
N	I-IUPAC
-	I-IUPAC
heptyl	I-IUPAC
)	O
and	O
33	O
(	O
N	I-IUPAC
-	I-IUPAC
octyl	I-IUPAC
)	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
type	O
I	O
enzyme	O
(	O
IC50s	O
=	O
9.57	O
and	O
16.9	O
nM	O
,	O
respectively	O
)	O
,	O
showed	O
also	O
strong	O
inhibitory	O
activity	O
(	O
IC50s	O
=	O
14.0	O
and	O
18.4	O
nM	O
,	O
respectively	O
)	O
for	O
human	O
type	O
II	O
5	O
alpha	O
-	O
reductase	O
,	O
in	O
comparison	O
to	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1'	I-IUPAC
,	I-IUPAC
1'	I-IUPAC
-	I-IUPAC
dimethylethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
5	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
androst	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
-	I-IUPAC
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
MK	O
-	O
906	O
;	O
IC50	O
=	O
4.53	O
nM	O
)	O
.	O

Other	O
compounds	O
in	O
this	O
series	O
showed	O
moderate	O
activities	O
(	O
IC50	O
&	O
gt	O
;	O
100	O
nM	O
)	O
on	O
the	O
type	O
II	O
enzyme	O
.	O

17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
Alkyl	I-IUPAC
/	I-IUPAC
aryl	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
arylamides	I-IUPAC
]	I-IUPAC
45	O
,	O
46	O
,	O
48	O
,	O
and	O
51	O
exhibited	O
highly	O
potent	O
inhibitory	O
activity	O
for	O
human	O
type	O
I	O
5	O
alpha	O
-	O
reductase	O
with	O
IC50s	O
of	O
1.77	O
,	O
2.42	O
,	O
2.93	O
,	O
and	O
5.44	O
nM	O
,	O
respectively	O
,	O
while	O
moderate	O
to	O
no	O
effect	O
was	O
observed	O
on	O
the	O
type	O
II	O
enzyme	O
(	O
100	O
&	O
lt	O
;	O
IC50s	O
&	O
lt	O
;	O
1000	O
nM	O
)	O
,	O
except	O
for	O
compound	O
48	O
(	O
IC50	O
=	O
3.75	O
nM	O
)	O
.	O

In	O
another	O
substitution	O
pattern	O
,	O
N	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
/	O
alkylamides	I-IUPAC
were	O
studied	O
;	O
an	O
electron	O
-	O
donating	O
group	O
increased	O
the	O
potency	O
of	O
compound	O
51	O
,	O
whereas	O
an	O
electron	O
-	O
withdrawing	O
group	O
decreased	O
the	O
potency	O
of	O
compounds	O
52	O
and	O
53	O
compared	O
to	O
parent	O
compound	O
50	O
.	O

In	O
addition	O
to	O
their	O
5	O
alpha	O
-	O
reductase	O
activities	O
,	O
17	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkylformamides	I-IUPAC
)	I-IUPAC
were	O
also	O
studied	O
for	O
their	O
inhibitory	O
activities	O
on	O
dihydrotestosterone	O
(	O
DHT	O
)	O
-	O
stimulated	O
proliferation	O
of	O
androgen	O
-	O
sensitive	O
Shionogi	O
mouse	O
mammary	O
carcinoma	O
cells	O
(	O
clone	O
SEM	O
-	O
107	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

A	O
series	O
of	O
analogues	O
of	O
the	O
conformationally	O
restricted	O
delta	O
opioid	O
receptor	O
selective	O
tetrapeptide	O
Tyr	O
-	O
c	O
[	O
D	O
-	O
Cys	O
-	O
Phe	O
-	O
D	O
-	O
Pen	O
]	O
OH	O
(	O
JOM	O
13	O
)	O
was	O
prepared	O
in	O
which	O
the	O
conformationally	O
labile	O
Tyr	O
residue	O
was	O
replaced	O
with	O
several	O
less	O
flexible	O
tyrosine	O
analogues	O
.	O

Among	O
these	O
tyrosine	O
analogues	O
were	O
the	O
bicyclic	O
structures	O
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxyisoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
HO	O
-	O
Tic	O
)	O
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxytetralin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
Hat	O
)	O
,	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxyindan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
Hai	O
)	O
in	O
which	O
rotations	O
about	O
the	O
C	O
alpha	O
-	O
C	O
beta	O
and	O
C	O
beta	O
-	O
C	O
gamma	O
bonds	O
are	O
restricted	O
due	O
to	O
cyclization	O
of	O
the	O
side	O
chain	O
to	O
the	O
backbone	O
.	O

Also	O
examined	O
were	O
analogues	O
in	O
which	O
tyrosine	O
was	O
replaced	O
with	O
either	O
trans	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
proline	I-IUPAC
(	O
t	O
-	O
Hpp	O
)	O
or	O
cis	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
proline	I-IUPAC
(	O
c	O
-	O
Hpp	O
)	O
,	O
residues	O
in	O
which	O
rotations	O
about	O
C	O
alpha	O
-	O
C	O
beta	O
,	O
but	O
not	O
C	O
beta	O
-	O
C	O
gamma	O
,	O
are	O
restricted	O
.	O

Both	O
the	O
t	O
-	O
Hpp1	O
and	O
c	O
-	O
Hpp1	O
analogues	O
displayed	O
delta	O
receptor	O
binding	O
affinity	O
similar	O
to	O
the	O
parent	O
Tyr1	O
-	O
containing	O
peptide	O
,	O
while	O
the	O
D	O
-	O
Hat1	O
,	O
L	O
-	O
Hat1	O
,	O
and	O
L	O
-	O
Hai1	O
analogues	O
exhibited	O
somewhat	O
lower	O
affinity	O
.	O

The	O
results	O
observed	O
for	O
the	O
t	O
-	O
Hpp1	O
and	O
c	O
-	O
Hpp1	O
analogues	O
are	O
particularly	O
significant	O
since	O
these	O
two	O
residues	O
have	O
little	O
accessible	O
conformational	O
space	O
in	O
common	O
.	O

Since	O
the	O
binding	O
conformation	O
of	O
residue	O
1	O
must	O
be	O
included	O
in	O
this	O
limited	O
conformational	O
intersection	O
,	O
its	O
elucidation	O
is	O
facilitated	O
.	O

Bioassay	O
results	O
from	O
guinea	O
pig	O
ileum	O
and	O
mouse	O
vas	O
deferens	O
preparations	O
are	O
in	O
general	O
agreement	O
with	O
the	O
binding	O
results	O
;	O
however	O
some	O
potency	O
discrepancies	O
are	O
observed	O
.	O

These	O
discrepancies	O
may	O
reflect	O
different	O
selectivities	O
among	O
delta	O
receptor	O
subtypes	O
for	O
the	O
analogues	O
or	O
may	O
represent	O
differing	O
efficacies	O
among	O
these	O
conformationally	O
restricted	O
peptides	O
.	O

The	O
conformational	O
properties	O
of	O
the	O
parent	O
tetrapeptide	O
and	O
the	O
residue	O
1	O
-	O
modified	O
analogues	O
were	O
studied	O
by	O
molecular	O
mechanics	O
computations	O
.	O

All	O
these	O
peptides	O
share	O
a	O
common	O
rigid	O
tripeptide	O
cycle	O
with	O
a	O
single	O
energetically	O
preferred	O
backbone	O
conformation	O
and	O
three	O
different	O
conformers	O
of	O
the	O
D	O
-	O
Cys	O
,	O
D	O
-	O
Pen	O
disulfide	O
bridge	O
,	O
two	O
of	O
which	O
are	O
observed	O
in	O
the	O
solid	O
state	O
and	O
in	O
aqueous	O
solution	O
,	O
as	O
previously	O
determined	O
from	O
X	O
-	O
ray	O
crystallography	O
and	O
1H	O
NMR	O
spectroscopy	O
data	O
(	O
Lomize	O
,	O
A	O
;	O
et	O
al.	O
J	O
.	O

Am.	O
Chem.	O
Soc	O
.	O

1994	O
,	O
116	O
,	O
429-436	O
)	O
.	O

All	O
the	O
peptides	O
have	O
similar	O
sets	O
of	O
low	O
-	O
energy	O
conformations	O
of	O
their	O
common	O
flexible	O
elements	O
,	O
the	O
Phe3	O
side	O
chain	O
and	O
the	O
peptide	O
group	O
between	O
the	O
first	O
residue	O
and	O
the	O
rigid	O
tripeptide	O
cycle	O
.	O

However	O
,	O
possible	O
conformations	O
of	O
the	O
first	O
residue	O
differ	O
and	O
depend	O
on	O
the	O
covalent	O
constraints	O
incorporated	O
into	O
the	O
side	O
chain	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
synthesis	O
and	O
sigma	O
receptor	O
affinity	O
of	O
a	O
series	O
of	O
conformationally	O
restricted	O
derivatives	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylethylenedi	I-IUPAC
amine	I-IUPAC
(	O
1	O
)	O
is	O
described	O
.	O

The	O
pyrrolidinyl	I-IUPAC
(	O
or	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
)	I-IUPAC
,	I-IUPAC
ethylenediamine	I-IUPAC
,	O
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
,	O
and	O
phenylethyl	I-IUPAC
portions	B-MODIFIER
of	O
this	O
sigma	O
receptor	O
pharmacophore	O
were	O
restricted	O
by	O
its	O
incorporation	O
into	O
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamine	I-IUPAC
-	O
,	O
pyrrolidine	I-IUPAC
-	O
,	O
piperidine	I-PARTIUPAC
-	O
,	O
homopiperidine	I-PARTIUPAC
-	O
,	O
and	O
tetrahydroisoquinoline	I-IUPAC
-	O
containing	I-MODIFIER
ligands	I-MODIFIER
.	O

The	O
sigma	O
receptor	O
binding	O
affinities	O
of	O
these	O
compounds	O
were	O
determined	O
using	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
in	O
guinea	O
pig	O
brain	O
homogenates	O
.	O

The	O
synthesis	O
of	O
all	O
but	O
one	O
class	O
was	O
achieved	O
by	O
acylation	O
and	O
alane	O
reduction	O
of	O
the	O
appropriate	O
diamine	O
precursors	O
whose	O
synthesis	O
is	O
also	O
reported	O
.	O

sigma	O
receptor	O
affinities	O
ranged	O
from	O
1.34	O
nM	O
for	O
6,7	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
(	O
12	O
)	O
to	O
455	O
nM	O
for	O
(	I-IUPAC
1R	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
cyclohexylamine	I-IUPAC
[	O
(	O
-	O
)	O
-	O
4	O
]	O
.	O

In	O
this	O
displacement	O
assay	O
,	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
exhibited	O
a	O
Ki	O
of	O
3.1	O
nM	O
while	O
DTG	O
and	O
haloperidol	O
showed	O
Ki	O
values	O
of	O
27.7	O
and	O
3.7	O
nM	O
,	O
respectively	O
.	O

The	O
conformationally	O
free	O
parent	O
compound	O
1	O
exhibited	O
a	O
Ki	O
value	O
of	O
2.1	O
nM	O
.	O

Comparison	O
of	O
both	O
the	O
sigma	O
receptor	O
affinities	O
and	O
nitrogen	O
atom	O
geometry	O
of	O
the	O
compounds	O
revealed	O
that	O
a	O
gauche	O
relation	O
of	O
the	O
nitrogen	O
atoms	O
of	O
cis	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
cyclohexanediamines	I-IUPAC
is	O
not	O
imperative	O
for	O
high	O
affinity	O
as	O
we	O
had	O
previously	O
thought	O
.	O

It	O
is	O
highly	O
likely	O
that	O
nitrogen	O
lone	O
pair	O
orientations	O
and	O
steric	O
factors	O
on	O
the	O
aliphatic	O
portions	O
of	O
these	O
ligands	O
play	O
a	O
major	O
role	O
in	O
the	O
sigma	O
receptor	O
binding	O
of	O
this	O
pharmacophore	O
.	O

The	O
design	O
of	O
analogues	O
of	O
7,8	I-IUPAC
-	I-IUPAC
dihydroretinoic	I-IUPAC
acid	I-IUPAC
(	O
7,8	O
-	O
dihydro	O
-	O
RA	O
)	O
was	O
based	O
on	O
reported	O
biological	O
activities	O
of	O
this	O
retinoid	O
and	O
its	O
dihydro	O
-	O
TMMP	O
(	O
1	O
)	O
analogue	O
and	O
on	O
structural	O
hypotheses	O
.	O

7	I-IUPAC
-	I-IUPAC
Oxa	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydroretinoids	I-IUPAC
(	O
5	O
,	O
6	O
)	O
were	O
prepared	O
by	O
O	O
-	O
alkylation	O
of	O
phenoxides	O
by	O
methyl	I-IUPAC
8	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
octatrienoate	I-IUPAC
.	O

In	O
some	O
cases	O
,	O
C	O
-	O
alkylation	O
also	O
occurred	O
.	O

7	I-IUPAC
-	I-IUPAC
Aza	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydroretinoids	I-IUPAC
(	O
12	O
,	O
13	O
)	O
were	O
synthesized	O
from	O
benzeneamines	O
and	O
the	O
acyl	I-IUPAC
cyano	I-IUPAC
or	O
bromo	I-IUPAC
derivative	B-MODIFIER
of	O
the	O
monomethyl	O
ester	O
of	O
3,7	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
octatriene	I-IUPAC
-	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
dioic	I-IUPAC
acid	I-IUPAC
.	O

These	O
monomethyl	O
ester	O
precursors	O
were	O
synthesized	O
from	O
the	O
known	O
analogous	O
aldehyde	O
via	O
an	O
O	I-IUPAC
-	I-IUPAC
trimethylsilyl	I-IUPAC
cyanohydrin	I-IUPAC
.	O

7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
Trimethylphenoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
octatrienoic	I-IUPAC
acid	I-IUPAC
(	O
6b	O
)	O
was	O
the	O
most	O
active	O
of	O
the	O
7	O
-	O
oxa	O
-	O
7,8	O
-	O
dihydro	O
-	O
RAs	O
in	O
inhibiting	O
DMBA	O
-	O
initiated	O
and	O
TPA	O
-	O
promoted	O
mouse	O
-	O
skin	O
papillomas	O
.	O

The	O
ED	O
(	O
50	O
)	O
was	O
about	O
4	O
-	O
fold	O
that	O
of	O
etretinate	O
.	O

Two	O
additional	O
7	O
-	O
oxa	O
-	O
7,8	O
-	O
dihydro	O
-	O
RAs	O
exhibited	O
modest	O
activity	O
in	O
the	O
papilloma	O
assay	O
.	O

Some	O
of	O
the	O
7	O
-	O
oxa	O
-	O
7,8	O
-	O
dihydro	O
-	O
RAs	O
bind	O
to	O
CRABP	O
and	O
RARalpha	O
.	O

Anthelmintic	O
efficacies	O
of	O
a	O
series	O
of	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
methyl	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamates	I-IUPAC
were	O
compared	O
to	O
similarly	O
substituted	I-MODIFIER
benzimidazole	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamates	I-IUPAC
.	O

With	O
only	O
one	O
exception	O
,	O
methyl	I-IUPAC
6	I-IUPAC
-	I-IUPAC
benzoylimidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
,	O
both	O
classes	O
of	O
compounds	O
exhibited	O
similar	O
activity	O
vs.	O
Nematospiroides	O
dubius	O
in	O
mice	O
.	O

Preliminary	O
screening	O
indicated	O
methyl	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,2	I-IUPAC
-	I-IUPAC
trichloroethenyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
to	O
be	O
the	O
most	O
potent	O
derivative	O
in	O
the	O
series	O
.	O

However	O
,	O
evaluation	O
in	O
sheep	O
indicated	O
that	O
its	O
anthelmintic	O
spectrum	O
was	O
inferior	O
to	O
methyl	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylsulfinyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
.	O

Methods	O
have	O
been	O
developed	O
for	O
the	O
preparation	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophenes	I-IUPAC
.	O

The	O
syntheses	O
and	O
physical	O
properties	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophene	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophene	I-IUPAC
are	O
described	O
.	O

The	O
radioiodinated	O
agents	O
are	O
of	O
interest	O
because	O
of	O
the	O
high	O
expected	O
uptake	O
and	O
prolonged	O
brain	O
retention	O
that	O
may	O
result	O
from	O
binding	O
to	O
high	O
-	O
capacity	O
,	O
relatively	O
nonspecific	O
amine	O
binding	O
sites	O
.	O

Radioiodine	O
was	O
introduced	O
into	O
the	O
5	O
-	O
position	O
of	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophene	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophene	I-IUPAC
by	O
radioiodination	O
of	O
the	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
boronic	I-IUPAC
acid	I-IUPAC
or	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trimethylstannyl	I-IUPAC
)	I-IUPAC
derivatives	I-MODIFIER
.	O

Tissue	O
distribution	O
studies	O
in	O
rats	O
with	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
iodothiophene	I-IUPAC
showed	O
high	O
brain	O
uptake	O
(	O
5	O
min	O
,	O
2.77%	O
dose	O
/	O
g	O
;	O
30	O
min	O
,	O
2.51%	O
dose	O
/	O
g	O
)	O
and	O
good	O
brain	O
/	O
blood	O
(	O
B	O
/	O
B	O
)	O
ratios	O
(	O
5	O
min	O
,	O
6/1	O
;	O
30	O
min	O
3.8/1	O
.	O

A	O
comparison	O
of	O
the	O
brain	O
uptake	O
of	O
the	O
N	I-IUPAC
-	I-IUPAC
isopropyl	I-IUPAC
derivative	I-MODIFIER
with	O
the	O
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
analogue	I-MODIFIER
demonstrated	O
higher	O
initial	O
brain	O
uptake	O
and	O
brain	O
to	O
blood	O
ratios	O
(	O
5	O
min	O
,	O
3.2%	O
dose	O
/	O
g	O
;	O
10.3/1	O
)	O
but	O
more	O
rapid	O
washout	O
(	O
30	O
min	O
,	O
1.37%	O
dose	O
;	O
2.8/1	O
)	O
.	O

These	O
data	O
suggest	O
that	O
radiolabeled	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophenes	I-IUPAC
are	O
potentially	O
useful	O
agents	O
for	O
cerebral	O
perfusion	O
imaging	O
by	O
single	O
-	O
photon	O
-	O
emission	O
computerized	O
tomography	O
(	O
SPECT	O
)	O
.	O

N	O
-	O
Substituted	O
analogues	O
of	O
trans	I-PARTIUPAC
-	I-PARTIUPAC
7	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4,4	I-IUPAC
a	I-IUPAC
,	I-IUPAC
5,6,10	I-IUPAC
b	I-IUPAC
-	I-IUPAC
octahydrobenzo	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
(	O
trans	O
-	O
7	O
-	O
and	O
trans	O
-	O
9	O
-	O
OH	O
-	O
OHBQ	O
)	O
were	O
tested	O
for	O
dopamine	O
(	O
DA	O
)	O
D2	O
receptor	O
affinity	O
by	O
using	O
in	O
vitro	O
[	O
3H	O
]	O
spiperone	O
and	O
in	O
vivo	O
5,6	O
-	O
di	O
-	O
n	O
-	O
Pr	O
-	O
ADTN	O
binding	O
assays	O
.	O

Potencies	O
at	O
central	O
pre	O
-	O
(	O
auto	O
-	O
)	O
and	O
postsynaptic	O
DA	O
receptors	O
were	O
determined	O
by	O
a	O
biochemical	O
and	O
a	O
behavioral	O
method	O
,	O
respectively	O
.	O

Corresponding	O
data	O
were	O
included	O
for	O
analogous	O
,	O
resolved	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
piperidines	I-IUPAC
and	O
a	O
few	O
other	O
substituted	O
,	O
racemic	I-MODIFIER
3	B-IUPAC
-	I-IUPAC
phenylpiperidines	I-IUPAC
.	O

Beside	O
the	O
central	O
dopaminergic	O
effects	O
of	O
these	O
compounds	O
,	O
previously	O
reported	O
sigma	O
receptor	O
affinity	O
data	O
[	O
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylpiperidine	I-IUPAC
;	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
PPP	O
]	O
were	O
also	O
taken	O
into	O
account	O
for	O
a	O
comparison	O
of	O
the	O
structure	O
-	O
activity	O
/	O
affinity	O
relationships	O
of	O
these	O
compounds	O
at	O
these	O
two	O
receptor	O
types	O
.	O

Larger	O
N	O
-	O
substituents	O
in	O
both	O
phenylpiperidines	O
and	O
OHBQs	O
increase	O
both	O
pre	O
-	O
and	O
postsynaptic	O
dopaminergic	O
activity	O
.	O

An	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	I-MODIFIER
gives	O
high	O
dopaminergic	O
efficacy	O
at	O
both	O
receptor	O
sites	O
(	O
pre	O
-	O
and	O
postsynaptic	O
)	O
in	O
all	O
series	O
.	O

However	O
,	O
even	O
higher	O
dopaminergic	O
potency	O
is	O
observed	O
for	O
trans	O
-	O
7	O
-	O
OH	O
-	O
OHBQs	O
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
piperidines	I-IUPAC
with	O
N	O
-	O
substituents	O
larger	O
than	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
.	O

In	O
contrast	O
,	O
trans	O
-	O
4	O
-	O
n	O
-	O
Bu	O
-	O
9	O
-	O
OH	O
-	O
OHBQ	O
is	O
inactive	O
,	O
and	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butylpiperidine	I-IUPAC
is	O
less	O
active	O
at	O
central	O
DA	O
receptors	O
than	O
its	O
corresponding	O
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
analogue	I-MODIFIER
.	O

This	O
implies	O
interesting	O
differences	O
in	O
N	O
-	O
substituent	O
sensitivity	O
for	O
the	O
different	O
classes	O
of	O
compounds	O
with	O
respect	O
to	O
the	O
direction	O
of	O
their	O
respective	O
N	O
-	O
substituents	O
at	O
the	O
drug	O
-	O
receptor	O
interaction	O
.	O

The	O
stereochemical	O
and	O
steric	O
demands	O
for	O
sigma	O
receptor	O
affinity	O
are	O
much	O
less	O
stringent	O
.	O

The	O
general	O
trend	O
is	O
that	O
,	O
up	O
to	O
a	O
certain	O
size	O
,	O
the	O
more	O
lipophilic	O
the	O
N	O
-	O
substituent	O
,	O
the	O
higher	O
the	O
affinity	O
for	O
sigma	O
receptor	O
sites	O
.	O

A	O
series	O
of	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
propenyl	I-IUPAC
carboxamide	I-IUPAC
derivatives	I-MODIFIER
bearing	O
an	O
unsaturated	O
bicyclic	O
moiety	O
in	O
the	O
3	O
-	O
position	O
was	O
prepared	O
and	O
evaluated	O
for	O
PAF	O
(	O
platelet	O
activating	O
factor	O
)	O
antagonist	O
activity	O
.	O

These	O
compounds	O
represent	O
conformationally	O
constrained	O
direct	O
analogues	O
of	O
the	O
corresponding	O
potent	O
5	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
pentadienecarboxamides	I-IUPAC
(	O
5	O
)	O
.	O

Most	O
of	O
the	O
new	O
compounds	O
were	O
active	O
in	O
a	O
PAF	O
-	O
binding	O
assay	O
employing	O
whole	O
,	O
washed	O
dog	O
platelets	O
as	O
the	O
receptor	O
source	O
and	O
inhibited	O
PAF	O
-	O
induced	O
bronchoconstriction	O
in	O
guinea	O
pigs	O
after	O
intravenous	O
administration	O
.	O

However	O
,	O
oral	O
activity	O
in	O
the	O
PAF	O
-	O
induced	O
bronchoconstriction	O
model	O
was	O
highly	O
sensitive	O
to	O
the	O
nature	O
and	O
substitution	O
of	O
the	O
bicyclic	O
ring	O
system	O
.	O

The	O
most	O
interesting	O
compounds	O
included	O
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propenamide	I-IUPAC
(	O
4b	O
)	O
,	O
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propenamide	I-IUPAC
(	O
4k	O
)	O
,	O
and	O
[	I-IUPAC
R	I-IUPAC
-	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
indoly	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propenamide	I-IUPAC
(	O
4l	O
)	O
which	O
inhibited	O
PAF	O
-	O
induced	O
broncho	O
-	O
constriction	O
in	O
guinea	O
pigs	O
with	O
IC50s	O
of	O
3.0-5.4	O
mg	O
/	O
kg	O
,	O
when	O
the	O
animals	O
were	O
challenged	O
2	O
h	O
after	O
drug	O
treatment	O
.	O

They	O
were	O
also	O
highly	O
effective	O
6	O
h	O
after	O
a	O
50	O
mg	O
/	O
kg	O
oral	O
dose	O
.	O

This	O
study	O
supports	O
the	O
notion	O
that	O
the	O
key	O
remote	O
aromatic	O
ring	O
present	O
in	O
the	O
5	I-IUPAC
-	I-IUPAC
arylpentadienecarboxamides	I-IUPAC
(	O
5	O
)	O
is	O
preferentially	O
coplanar	O
with	O
the	O
diene	O
system	O
for	O
good	O
PAF	O
antagonist	O
activity	O
.	O

A	O
series	O
of	O
secondary	O
and	O
tertiary	O
N	O
-	O
alkyl	O
derivatives	O
of	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorotetralin	I-IUPAC
have	O
been	O
prepared	O
.	O

The	O
affinities	O
of	O
the	O
compounds	O
for	O
[	O
3H	O
]	O
raclopride	O
-	O
labeled	O
cloned	O
human	O
dopamine	O
(	O
DA	O
)	O
D2	O
and	O
D3	O
receptors	O
as	O
well	O
as	O
[	O
3H	O
]	O
-	O
8	O
-	O
OH	O
-	O
DPAT	O
-	O
labeled	O
rat	O
hippocampal	O
5	O
-	O
HT1A	O
receptors	O
were	O
determined	O
.	O

In	O
order	O
to	O
selectively	O
determine	O
affinities	O
for	O
the	O
high	O
-	O
affinity	O
agonist	O
binding	O
site	O
at	O
DA	O
D2	O
receptors	O
,	O
the	O
agonist	O
[	O
3H	O
]	O
quinpirole	O
was	O
used	O
.	O

The	O
intrinsic	O
activities	O
of	O
the	O
compounds	O
at	O
DA	O
D2	O
and	O
D3	O
receptors	O
were	O
evaluated	O
in	O
a	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
assay	O
.	O

The	O
novel	O
compounds	O
were	O
characterized	O
as	O
dopaminergic	O
antagonists	O
or	O
inverse	O
agonists	O
.	O

The	O
antagonist	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
butylpropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorotetralin	I-IUPAC
(	O
16	O
)	O
bound	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
4.4	O
nM	O
)	O
to	O
the	O
DA	O
D3	O
receptor	O
and	O
was	O
the	O
most	O
D3	O
-	O
selective	O
compound	O
(	O
10	O
-	O
fold	O
)	O
.	O

(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
8	I-IUPAC
-	I-IUPAC
Aza	I-IUPAC
-	I-IUPAC
7	I-IUPAC
,	I-IUPAC
9	I-IUPAC
-	I-IUPAC
dioxospiro	I-IUPAC
[	I-IUPAC
4.5	I-IUPAC
]	I-IUPAC
decan	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
propylamino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorote	I-IUPAC
tralin	I-IUPAC
(	O
18	O
)	O
bound	O
with	O
very	O
high	O
affinity	O
to	O
both	O
DA	O
D3	O
and	O
5	O
-	O
HT1A	O
receptors	O
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
and	O
was	O
also	O
characterized	O
as	O
a	O
dopaminergic	O
antagonist	O
.	O

(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Benzylpropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorotetralin	I-IUPAC
(	O
10	O
)	O
behaved	O
as	O
an	O
inverse	O
agonist	O
at	O
both	O
DA	O
D2	O
and	O
D3	O
receptors	O
.	O

It	O
decreased	O
the	O
basal	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
and	O
potently	O
inhibited	O
the	O
DA	O
-	O
stimulated	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
.	O

It	O
is	O
apparent	O
that	O
the	O
intrinsic	O
activity	O
of	O
a	O
2	I-IUPAC
-	I-IUPAC
aminotetralin	I-IUPAC
derivative	I-MODIFIER
may	O
be	O
modified	O
by	O
varying	O
the	O
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
substituents	I-MODIFIER
.	O

A	O
series	O
of	O
dialkyl	I-MODIFIER
N	B-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamates	I-IUPAC
was	O
synthesized	O
by	O
treatment	O
of	O
the	O
requisite	O
m	I-IUPAC
-	I-IUPAC
phenylenediamines	I-IUPAC
with	O
an	O
alkyloxalyl	O
chloride	O
in	O
the	O
presence	O
of	O
triethylamine	O
.	O

Hydrolysis	O
with	O
sodium	O
hydroxide	O
solution	O
gave	O
the	O
corresponding	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acids	I-IUPAC
.	O

Several	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acids	I-IUPAC
were	O
synthesized	O
also	O
in	O
the	O
same	O
manner	O
starting	O
with	O
the	O
requisite	O
p	I-IUPAC
-	I-IUPAC
phenylenediamines	I-IUPAC
.	O

These	O
compounds	O
were	O
tested	O
in	O
the	O
rat	O
passive	O
cutaneous	O
anaphylaxis	O
(	O
PCA	O
)	O
assay	O
.	O

When	O
tested	O
iv	O
,	O
activity	O
was	O
found	O
in	O
the	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acids	I-IUPAC
up	O
to	O
2500	O
times	O
that	O
shown	O
by	O
disodium	O
cromoglycate	O
[	O
50%	O
inhibition	O
at	O
0.001	O
mg	O
/	O
kg	O
for	O
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acid	I-IUPAC
(	O
compound	O
61	O
)	O
]	O
.	O

Oral	O
activity	O
was	O
seen	O
in	O
this	O
series	O
of	O
compounds	O
with	O
duration	O
of	O
activity	O
up	O
to	O
120	O
min	O
.	O

Oral	O
activity	O
was	O
detected	O
in	O
diethyl	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamate	I-IUPAC
(	O
compound	O
38	O
)	O
at	O
levels	O
of	O
drug	O
as	O
low	O
as	O
0.1	O
mg	O
/	O
kg	O
.	O

Tumor	O
cell	O
migration	O
and	O
metastasis	O
in	O
cancer	O
are	O
facilitated	O
by	O
interaction	O
of	O
the	O
serine	O
protease	O
urokinase	O
type	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
with	O
its	O
receptor	O
uPAR	O
(	O
CD	O
87	O
)	O
.	O

Overexpression	O
of	O
uPA	O
and	O
uPAR	O
in	O
cancer	O
tissues	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
disease	O
recurrence	O
and	O
early	O
death	O
.	O

In	O
agreement	O
with	O
these	O
findings	O
,	O
disruption	O
of	O
the	O
protein	O
-	O
protein	O
interaction	O
between	O
uPAR	O
present	O
on	O
tumor	O
cells	O
and	O
its	O
ligand	O
uPA	O
evolved	O
as	O
an	O
attractive	O
intervention	O
strategy	O
to	O
impair	O
tumor	O
growth	O
and	O
metastasis	O
.	O

For	O
this	O
,	O
the	O
uPAR	O
antagonist	O
cyclo	O
[	O
19,31	O
]	O
[	O
D	O
-	O
Cys	O
(	O
19	O
)	O
]	O
-	O
uPA	O
(	O
19	O
)	O
(	O
-	O
)	O
(	O
31	O
)	O
was	O
optimized	O
to	O
efficiently	O
interrupt	O
binding	O
of	O
uPA	O
to	O
cellular	O
uPAR	O
.	O

First	O
,	O
the	O
disulfide	O
bridge	O
of	O
this	O
lead	O
compound	O
was	O
shifted	O
and	O
then	O
the	O
modified	O
peptide	O
was	O
shortened	O
from	O
the	O
amino	O
and	O
carboxy	O
terminus	O
to	O
generate	O
cyclo	O
[	O
21,29	O
]	O
[	O
Cys	O
(	O
21,29	O
)	O
]	O
-	O
uPA	O
(	O
21	O
)	O
(	O
-	O
)	O
(	O
30	O
)	O
.	O

Next	O
,	O
cyclo	O
[	O
21,29	O
]	O
[	O
D	O
-	O
Cys	O
(	O
21	O
)	O
Cys	O
(	O
29	O
)	O
]	O
-	O
uPA	O
(	O
21	O
)	O
(	O
-	O
)	O
(	O
30	O
)	O
was	O
yielded	O
by	O
changing	O
the	O
chirality	O
of	O
Cys	O
(	O
21	O
)	O
to	O
D	O
-	O
Cys	O
(	O
21	O
)	O
.	O

For	O
analysis	O
of	O
uPAR	O
binding	O
activity	O
,	O
we	O
employed	O
competitive	O
flow	O
cytofluorometric	O
receptor	O
binding	O
assays	O
,	O
using	O
FITC	O
-	O
uPA	O
as	O
the	O
ligand	O
and	O
U937	O
promyeloid	O
leukemia	O
cells	O
as	O
the	O
cellular	O
source	O
of	O
uPAR	O
.	O

As	O
demonstrated	O
for	O
cyclo	O
[	O
21,29	O
]	O
[	O
D	O
-	O
Cys	O
(	O
21	O
)	O
Cys	O
(	O
29	O
)	O
]	O
-	O
uPA	O
(	O
21	O
)	O
(	O
-	O
)	O
(	O
30	O
)	O
,	O
the	O
achieved	O
peptide	O
modifications	O
maintained	O
receptor	O
binding	O
activity	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.04	O
microM	O
)	O
,	O
which	O
is	O
close	O
in	O
order	O
to	O
that	O
of	O
the	O
parent	O
protein	O
ligand	O
,	O
uPA	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.01	O
microM	O
)	O
.	O

A	O
detailed	O
NMR	O
analysis	O
with	O
restrained	O
and	O
free	O
molecular	O
dynamics	O
calculations	O
in	O
explicit	O
H	O
(	O
2	O
)	O
O	O
exhibits	O
a	O
well	O
-	O
defined	O
structure	O
with	O
characteristic	O
features	O
such	O
as	O
an	O
omega	O
-	O
loop	O
with	O
two	O
betaI	O
-	O
turns	O
about	O
Lys	O
(	O
3	O
)	O
,	O
Tyr	O
(	O
4	O
)	O
,	O
Ser	O
(	O
6	O
)	O
,	O
and	O
Asn	O
(	O
7	O
)	O
.	O

Hydrophobic	O
clustering	O
of	O
the	O
side	O
chains	O
of	O
Tyr	O
(	O
4	O
)	O
,	O
Phe	O
(	O
5	O
)	O
,	O
Ile	O
(	O
8	O
)	O
,	O
and	O
Trp	O
(	O
10	O
)	O
is	O
observed	O
.	O

Side	O
chain	O
mobility	O
is	O
analyzed	O
with	O
time	O
-	O
dependent	O
distance	O
restraints	O
.	O

The	O
NMR	O
structure	O
of	O
cyclo	O
[	O
21,29	O
]	O
[	O
D	O
-	O
Cys	O
(	O
21	O
)	O
Cys	O
(	O
29	O
)	O
]	O
-	O
uPA	O
(	O
21	O
)	O
(	O
-	O
)	O
(	O
30	O
)	O
is	O
very	O
similar	O
to	O
the	O
previously	O
reported	O
structure	O
of	O
the	O
amino	O
terminal	O
fragment	O
of	O
uPA	O
.	O

Systematic	O
point	O
mutations	O
led	O
to	O
cyclo	O
[	O
21,29	O
]	O
[	O
D	O
-	O
Cys	O
(	O
21	O
)	O
Nle	O
(	O
23	O
)	O
Cys	O
(	O
29	O
)	O
]	O
-	O
uPA	O
(	O
21	O
)	O
(	O
-	O
)	O
(	O
30	O
)	O
,	O
which	O
still	O
binds	O
to	O
uPAR	O
but	O
is	O
resistant	O
to	O
proteolytic	O
cleavage	O
,	O
e.g.	O
,	O
by	O
the	O
tumor	O
-	O
associated	O
serine	O
proteases	O
uPA	O
and	O
plasmin	O
,	O
and	O
is	O
stable	O
in	O
blood	O
serum	O
or	O
plasma	O
.	O

In	O
conclusion	O
,	O
small	O
cyclic	O
peptides	O
were	O
created	O
,	O
which	O
mimic	O
the	O
structure	O
and	O
activity	O
of	O
the	O
binding	O
epitope	O
of	O
uPA	O
to	O
uPAR	O
and	O
which	O
may	O
serve	O
as	O
novel	O
therapeutic	O
agents	O
in	O
cancer	O
metastasis	O
.	O

A	O
series	O
of	O
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazole	I-IUPAC
nucleosides	I-MODIFIER
related	O
to	O
the	O
antibiotic	O
nebularine	O
and	O
the	O
highly	O
cytotoxic	O
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpurine	I-IUPAC
have	O
been	O
synthesized	O
from	O
the	O
corresponding	O
heterocycles	O
.	O

The	O
sodium	O
salt	O
glycosylation	O
of	O
the	O
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazoles	I-IUPAC
proceeded	O
smoothly	O
,	O
giving	O
mixtures	O
of	O
N	O
-	O
4	O
and	O
N	O
-	O
6	O
regioisomers	O
in	O
generally	O
good	O
yields	O
.	O

The	O
protected	O
derivatives	O
were	O
deblocked	O
using	O
standard	O
conditions	O
to	O
afford	O
the	O
desired	O
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
-	I-IUPAC
isothiazole	I-IUPAC
nucleosides	I-MODIFIER
,	O
usually	O
as	O
crystalline	O
solids	O
.	O

None	O
of	O
the	O
new	O
nucleosides	O
or	O
heterocycles	O
displayed	O
selective	O
activity	O
against	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
or	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
.	O

The	O
N	I-MODIFIER
-	I-MODIFIER
6	I-MODIFIER
glycosylated	I-MODIFIER
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazoles	I-IUPAC
were	O
completely	O
inactive	O
up	O
to	O
the	O
highest	O
concentration	O
tested	O
.	O

The	O
N	I-MODIFIER
-	I-MODIFIER
6	I-MODIFIER
glycosylated	I-MODIFIER
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazoles	I-IUPAC
also	O
were	O
inactive	O
in	O
antiproliferative	O
and	O
cytotoxicity	O
assays	O
,	O
except	O
for	O
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazole	I-IUPAC
(	O
15a	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
benzylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiaz	I-IUPAC
ole	I-IUPAC
(	O
5e	O
)	O
,	O
which	O
showed	O
moderate	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
.	O

However	O
,	O
the	O
heterocycles	O
and	O
several	O
of	O
the	O
N	O
-	O
4	O
glycosylated	O
derivatives	O
were	O
toxic	O
to	O
HFF	O
,	O
KB	O
and	O
L1210	O
cells	O
;	O
compounds	O
with	O
5	I-IUPAC
-	I-IUPAC
benzylthio	I-IUPAC
substituents	I-MODIFIER
were	O
the	O
most	O
cytotoxic	O
agents	O
in	O
this	O
series	O
.	O

In	O
order	O
to	O
obtain	O
agents	O
with	O
therapeutic	O
indices	O
superior	O
to	O
those	O
of	O
AZT	O
,	O
FLT	O
,	O
or	O
D4T	O
,	O
several	O
analogues	O
of	O
anti	O
-	O
HIV	O
-	O
1	O
nucleosides	O
were	O
synthesized	O
.	O

These	O
include	O
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
difluoro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
(	O
13	O
)	O
,	O
its	O
arabino	O
analogue	O
19	O
,	O
arabino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylcytosine	I-IUPAC
analogue	O
21	O
,	O
3'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
didehydro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluorothymidine	I-IUPAC
(	O
25	O
)	O
,	O
3'	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
(	O
29	O
)	O
,	O
2'	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
(	O
31	O
)	O
,	O
and	O
2'	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
dideoxy	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyluridine	I-IUPAC
(	O
37	O
)	O
.	O

These	O
new	O
nucleosides	O
were	O
screened	O
for	O
their	O
activity	O
against	O
HIV	O
and	O
feline	O
TLV	O
in	O
vitro	O
.	O

None	O
of	O
the	O
compounds	O
showed	O
significant	O
activity	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
such	O
a	O
small	O
modification	O
in	O
the	O
sugar	O
moiety	O
of	O
active	O
anti	O
-	O
HIV	O
nucleosides	O
(	O
i.e.	O
,	O
displacement	O
of	O
hydrogen	O
by	O
fluorine	O
)	O
almost	O
completely	O
inactivate	O
the	O
agents	O
.	O

In	O
this	O
study	O
we	O
designed	O
,	O
prepared	O
,	O
and	O
analyzed	O
a	O
water	O
-	O
soluble	O
,	O
long	O
-	O
acting	O
insulin	O
derivative	O
whose	O
protracted	O
action	O
in	O
vivo	O
is	O
based	O
on	O
a	O
new	O
principle	O
rather	O
than	O
on	O
slower	O
absorption	O
rates	O
of	O
suspended	O
insulin	O
formulations	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
prepared	O
(	O
9	O
-	O
fluorenylmethoxycarbonyl	O
-	O
SO	O
(	O
3	O
)	O
H	O
)	O
(	O
3	O
)	O
-	O
insulin	O
(	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
)	O
,	O
a	O
derivative	O
having	O
three	O
9	O
-	O
fluorenylmethoxycarbonyl	O
-	O
SO	O
(	O
3	O
)	O
H	O
(	O
FMS	O
)	O
moieties	O
covalently	O
linked	O
to	O
the	O
three	O
amino	O
side	O
chains	O
of	O
insulin	O
.	O

(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
is	O
soluble	O
in	O
aqueous	O
buffers	O
at	O
neutral	O
pH	O
,	O
at	O
a	O
concentration	O
range	O
of	O
0.15-0.60	O
mM	O
,	O
and	O
has	O
about	O
1%	O
of	O
both	O
the	O
biological	O
potency	O
and	O
the	O
receptor	O
-	O
binding	O
affinity	O
of	O
the	O
native	O
hormone	O
.	O

Upon	O
incubation	O
at	O
pH	O
7.4	O
and	O
37	O
degrees	O
C	O
,	O
it	O
undergoes	O
a	O
slow	O
hydrolysis	O
with	O
linear	O
regeneration	O
of	O
insulin	O
possessing	O
full	O
biological	O
potency	O
.	O

A	O
single	O
subcutaneous	O
administration	O
of	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
to	O
streptozocin	O
-	O
treated	O
rats	O
lowered	O
circulating	O
glucose	O
levels	O
for	O
a	O
prolonged	O
period	O
(	O
t	O
(	O
1/2	O
)	O
=	O
30	O
h	O
)	O
.	O

Similarly	O
,	O
intraperitoneal	O
administration	O
of	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
to	O
healthy	O
rats	O
had	O
a	O
prolonged	O
glucose	O
-	O
lowering	O
effect	O
.	O

In	O
this	O
experimental	O
system	O
,	O
recovery	O
from	O
hypoglycemia	O
proceeded	O
with	O
a	O
t	O
(	O
1/2	O
)	O
value	O
of	O
14	O
+	O
/	O
-	O
1	O
h	O
,	O
as	O
compared	O
with	O
t	O
(	O
1/2	O
)	O
=	O
8.0	O
+	O
/	O
-	O
1	O
h	O
for	O
native	O
insulin	O
and	O
t	O
(	O
1/2	O
)	O
=	O
10.0	O
+	O
/	O
-	O
1	O
h	O
for	O
NPH	O
-	O
insulin	O
.	O

(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
is	O
more	O
resistant	O
to	O
proteolysis	O
and	O
appears	O
to	O
be	O
nonimmunogenic	O
.	O

On	O
the	O
whole	O
,	O
(	O
FMS	O
)	O
(	O
3	O
)	O
(	O
-	O
)	O
insulin	O
represents	O
a	O
prototype	O
version	O
of	O
a	O
water	O
-	O
soluble	O
,	O
long	O
-	O
acting	O
preparation	O
of	O
insulin	O
.	O

It	O
is	O
nearly	O
inactive	O
at	O
the	O
time	O
of	O
administration	O
,	O
and	O
therefore	O
can	O
be	O
administered	O
,	O
at	O
high	O
dose	O
,	O
with	O
no	O
concern	O
for	O
hypoglycemia	O
.	O

Because	O
of	O
its	O
decreased	O
receptor	O
-	O
binding	O
affinity	O
,	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
evades	O
receptor	O
-	O
mediated	O
endocytosis	O
and	O
degradation	O
and	O
,	O
hence	O
,	O
persists	O
for	O
a	O
long	O
period	O
in	O
the	O
circulation	O
.	O

The	O
insulin	O
constituent	O
of	O
the	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
conjugate	O
undergoes	O
a	O
slow	O
,	O
spontaneous	O
activation	O
in	O
the	O
circulatory	O
system	O
,	O
manifesting	O
a	O
prolonged	O
glucose	O
-	O
lowering	O
action	O
in	O
vivo	O
.	O

According	O
to	O
the	O
data	O
presented	O
here	O
,	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
represents	O
a	O
typical	O
prodrug	O
:	O
a	O
compound	O
which	O
by	O
itself	O
shows	O
only	O
marginal	O
activity	O
but	O
over	O
time	O
it	O
is	O
chemically	O
hydrolyzed	O
to	O
the	O
fully	O
active	O
hormone	O
.	O

As	O
part	O
of	O
our	O
investigation	O
into	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
a	O
novel	O
class	O
of	O
aromatase	O
inhibitors	O
,	O
C	O
(	O
19	O
)	O
steroids	O
having	O
no	O
oxygen	O
function	O
at	O
C	O
-	O
3	O
,	O
we	O
tested	O
aromatase	O
inhibition	O
activity	O
of	O
polar	O
diol	O
compounds	O
4,19	I-IUPAC
-	I-IUPAC
dihydroxyandrost	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
25	O
and	O
27	O
)	O
and	O
6,19	I-IUPAC
-	I-IUPAC
dihydroxyandrost	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
36	O
and	O
37	O
)	O
.	O

4alpha	I-IUPAC
,	I-IUPAC
19	I-IUPAC
-	I-IUPAC
Diol	I-IUPAC
25	O
was	O
synthesized	O
from	O
tert	I-IUPAC
-	I-IUPAC
butyldimethylsilyoxyandrost	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
steroid	I-MODIFIER
(	O
9	O
)	O
through	O
its	O
OsO	O
(	O
4	O
)	O
oxidation	O
,	O
giving	O
the	O
4alpha	I-IUPAC
,	I-IUPAC
5alpha	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
derivative	I-MODIFIER
12	O
,	O
as	O
a	O
key	O
reaction	O
.	O

Acetylation	O
of	O
5beta	I-IUPAC
,	I-IUPAC
6alpha	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
19	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
30	O
and	O
its	O
5alpha	I-IUPAC
,	I-IUPAC
6beta	I-IUPAC
-	I-IUPAC
analogue	I-IUPAC
31	O
followed	O
by	O
dehydration	O
with	O
SOCl	O
(	O
2	O
)	O
and	O
alkaline	O
hydroxysis	O
gave	O
6alpha	O
,	O
19	O
-	O
diol	O
36	O
and	O
its	O
6beta	O
-	O
isomer	O
37	O
,	O
respectively	O
.	O

The	O
stereochemistry	O
of	O
a	O
hydroxy	O
group	O
at	O
C	O
-	O
4	O
of	O
compound	O
25	O
and	O
that	O
at	O
C	O
-	O
6	O
of	O
compounds	O
36	O
and	O
37	O
were	O
determined	O
on	O
the	O
basis	O
of	O
(	O
1	O
)	O
H	O
NMR	O
spectroscopy	O
in	O
each	O
case	O
.	O

4beta	I-IUPAC
,	I-IUPAC
19	I-IUPAC
-	I-IUPAC
Diol	I-IUPAC
27	O
,	O
previously	O
synthesized	O
,	O
was	O
identified	O
as	O
an	O
extremely	O
powerful	O
competitive	O
inhibitor	O
of	O
aromatase	O
(	O
K	O
(	O
i	O
)	O
=	O
3.4	O
nM	O
)	O
.	O

In	O
contrast	O
,	O
its	O
4alpha	I-IUPAC
,	I-IUPAC
19	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
isomer	I-MODIFIER
25	O
and	O
other	O
series	O
of	O
diol	O
compounds	O
,	O
6,19	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
one	I-IUPAC
steroids	I-MODIFIER
,	O
were	O
moderate	O
to	O
poor	O
competitive	O
inhibitors	O
(	O
K	O
(	O
i	O
)	O
=	O
110-800	O
nM	O
)	O
.	O

Through	O
this	O
series	O
of	O
analyses	O
,	O
it	O
was	O
concluded	O
that	O
hydrophilic	O
interaction	O
of	O
a	O
4beta	I-IUPAC
,	I-IUPAC
19	I-IUPAC
-	I-IUPAC
diol	I-IUPAC
function	I-MODIFIER
with	O
the	O
active	O
site	O
of	O
aromatase	O
plays	O
a	O
critical	O
role	O
in	O
the	O
tight	O
binding	O
of	O
3	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ene	I-IUPAC
steroids	I-MODIFIER
.	O

6	O
-	O
[	O
5	O
-	O
(	O
4	O
-	O
Amidinophenyl	O
)	O
furan	O
-	O
2	O
-	O
yl	O
]	O
nicotinamidine	O
(	O
8a	O
)	O
was	O
synthesized	O
from	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
cyanophenyl	I-IUPAC
)	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
nicotinonitrile	I-IUPAC
(	O
4a	O
)	O
,	O
through	O
the	O
bis	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetoxyamidoxime	I-IUPAC
followed	O
by	O
hydrogenation	O
.	O

Compound	O
4a	O
was	O
prepared	O
via	O
selective	O
bromination	O
of	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
nicotinonitrile	I-IUPAC
(	O
2a	O
)	O
with	O
N	I-IUPAC
-	I-IUPAC
bromosuccinimide	I-IUPAC
,	O
followed	O
by	O
Suzuki	O
coupling	O
with	O
4	I-IUPAC
-	I-IUPAC
cyanophenylboronic	I-IUPAC
acid	I-IUPAC
.	O

In	O
a	O
similar	O
way	O
,	O
diamidines	O
8b	O
and	O
8c	O
were	O
prepared	O
from	O
the	O
dicyano	I-IUPAC
derivatives	B-MODIFIER
4c	O
and	O
4d	O
,	O
respectively	O
.	O

N	I-IUPAC
-	I-IUPAC
Methoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methoxyamidino	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
furan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
nicotinamidine	I-IUPAC
(	O
6a	O
)	O
was	O
prepared	O
via	O
methylation	O
of	O
the	O
respective	O
diamidoxime	O
5a	O
with	O
dimethylsulfate	O
.	O

Prodrugs	O
6b	O
and	O
6c	O
were	O
also	O
prepared	O
by	O
methylation	O
of	O
the	O
respective	O
diamidoximes	O
5b	O
and	O
5d	O
.	O

The	O
symmetrical	O
diamidines	O
14a	O
,	O
b	O
were	O
synthesized	O
through	O
the	O
corresponding	O
bis	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetoxyamidoxime	I-IUPAC
followed	O
by	O
hydrogenation	O
.	O

The	O
key	O
compounds	O
11a	O
,	O
b	O
were	O
conveniently	O
obtained	O
by	O
Stille	O
coupling	O
between	O
2,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
butylstannyl	I-IUPAC
)	I-IUPAC
furan	I-IUPAC
and	O
the	O
corresponding	O
heteroaryl	O
halides	O
.	O

These	O
compounds	O
have	O
been	O
evaluated	O
in	O
vitro	O
for	O
activity	O
against	O
Trypanosoma	O
b	O
.	O

rhodesiense	O
(	O
T	O
.	O

b	O
.	O

r	O
.	O

)	O
and	O
P	O
.	O

falciparum	O
(	O
P	O
.	O

f	O
.	O

)	O
.	O

The	O
diamidines	O
8a	O
,	O
8c	O
,	O
and	O
14b	O
gave	O
IC	O
(	O
50	O
)	O
values	O
versus	O
T	O
.	O

b	O
.	O

r	O
.	O

of	O
less	O
than	O
10	O
nM	O
.	O

Against	O
P	O
.	O

f	O
.	O

8a	O
,	O
8b	O
,	O
and	O
14b	O
exhibited	O
IC	O
(	O
50	O
)	O
values	O
less	O
than	O
10	O
nM	O
.	O

In	O
an	O
in	O
vivo	O
mouse	O
model	O
for	O
T	O
.	O

b	O
.	O

r	O
.	O

four	O
compounds	O
6a	O
,	O
6c	O
,	O
6d	O
,	O
and	O
8a	O
were	O
curative	O
.	O

Compound	O
6a	O
produced	O
cures	O
at	O
an	O
oral	O
dosage	O
of	O
5	O
mg	O
/	O
kg	O
.	O

8,9	O
-	O
Dioxo	O
-	O
6	O
-	O
phenyl	O
-	O
1	O
-	O
aza	O
-	O
7	O
-	O
oxabicyclo	O
[	O
4.2.1	O
]	O
nonane	O
(	O
1	O
)	O
and	O
9,10	I-IUPAC
-	I-IUPAC
dioxo	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
aza	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
oxabicyclo	I-IUPAC
[	I-IUPAC
5.2.1	I-IUPAC
]	I-IUPAC
decane	I-IUPAC
(	O
2	O
)	O
,	O
examples	O
of	O
anti	O
-	O
Bredt	O
bicyclic	O
2,4	I-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
,	O
were	O
investigated	O
as	O
anticonvulsants	O
in	O
mice	O
.	O

Compound	O
2	O
was	O
the	O
more	O
potent	O
(	O
anti	O
-	O
MES	O
ED50	O
=	O
66	O
mg	O
/	O
kg	O
)	O
,	O
and	O
its	O
in	O
vivo	O
anti	O
-	O
MES	O
effect	O
was	O
consistent	O
with	O
its	O
in	O
vitro	O
potency	O
of	O
binding	O
to	O
the	O
voltage	O
-	O
sensitive	O
sodium	O
channel	O
(	O
IC50	O
=	O
160	O
microM	O
for	O
the	O
inhibition	O
of	O
binding	O
of	O
[	O
3H	O
]	O
BTX	O
-	O
B	O
)	O
,	O
suggesting	O
that	O
2	O
may	O
be	O
a	O
new	O
class	O
I	O
anticonvulsant	O
.	O

Several	O
partial	O
structures	O
of	O
2	O
,	O
either	O
monocyclic	O
lactams	O
or	O
monocyclic	O
2,4	I-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
,	O
were	O
also	O
evaluated	O
in	O
these	O
assays	O
,	O
but	O
no	O
correlation	O
was	O
observed	O
between	O
sodium	O
channel	O
binding	O
and	O
anti	O
-	O
MES	O
effects	O
.	O

A	O
significant	O
finding	O
was	O
that	O
monocyclic	O
5	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
provided	O
relatively	O
potent	O
,	O
nontoxic	O
,	O
broad	O
-	O
spectrum	O
anticonvulsants	O
.	O

The	O
peripheral	O
benzodiazepine	O
receptor	O
(	O
PBR	O
)	O
is	O
widely	O
expressed	O
in	O
peripheral	O
tissues	O
,	O
blood	O
cells	O
,	O
and	O
in	O
glia	O
cells	O
in	O
the	O
brain	O
.	O

We	O
have	O
previously	O
developed	O
two	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
ligands	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
]	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenoxyphenyl	I-IUPAC
)	I-IUPAC
acetamide	I-IUPAC
(	O
[	O
(	O
11	O
)	O
C	O
]	O
2	O
)	O
and	O
its	O
[	I-IUPAC
(	I-IUPAC
18	I-IUPAC
)	I-IUPAC
F	I-IUPAC
]	I-IUPAC
fluoroethyl	I-IUPAC
analogue	I-MODIFIER
(	O
[	O
(	O
18	O
)	O
F	O
]	O
6	O
)	O
,	O
for	O
the	O
current	O
investigation	O
of	O
PBR	O
in	O
the	O
human	O
brain	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
label	O
the	O
potent	O
PBR	O
agonist	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isopropoxybenzyl	I-IUPAC
)	I-IUPAC
acetamide	I-IUPAC
(	O
3	O
)	O
and	O
its	O
ethyl	I-IUPAC
(	O
7	O
)	O
and	O
methyl	I-IUPAC
(	O
8	O
)	O
homologues	I-MODIFIER
with	O
(	O
11	O
)	O
C	O
and	O
to	O
evaluate	O
them	O
as	O
PET	O
ligands	O
for	O
PBR	O
with	O
mice	O
,	O
rats	O
,	O
and	O
monkeys	O
.	O

Ligands	O
[	O
(	O
11	O
)	O
C	O
]	O
3	O
,	O
[	O
(	O
11	O
)	O
C	O
]	O
7	O
,	O
and	O
[	O
(	O
11	O
)	O
C	O
]	O
8	O
were	O
synthesized	O
by	O
alkylation	O
of	O
phenol	O
precursor	O
9	O
with	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
]	I-IUPAC
iodopropane	I-IUPAC
(	O
[	O
(	O
11	O
)	O
C	O
]	O
10	O
)	O
,	O
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
]	I-IUPAC
iodoethane	I-IUPAC
(	O
[	O
(	O
11	O
)	O
C	O
]	O
11	O
)	O
,	O
and	O
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
]	I-IUPAC
iodomethane	I-IUPAC
(	O
[	O
(	O
11	O
)	O
C	O
]	O
12	O
)	O
,	O
respectively	O
.	O

The	O
alkylating	O
agent	O
[	O
(	O
11	O
)	O
C	O
]	O
10	O
or	O
[	O
(	O
11	O
)	O
C	O
]	O
11	O
was	O
prepared	O
by	O
reacting	O
CH	O
(	O
3	O
)	O
MgBr	O
with	O
[	O
(	O
11	O
)	O
C	O
]	O
CO	O
(	O
2	O
)	O
,	O
followed	O
by	O
reduction	O
with	O
LiAlH	O
(	O
4	O
)	O
and	O
iodination	O
with	O
HI	O
.	O

In	O
vitro	O
quantitative	O
autoradiography	O
determined	O
that	O
3	O
,	O
7	O
,	O
and	O
8	O
had	O
potent	O
binding	O
affinities	O
(	O
K	O
(	O
i	O
)	O
=	O
0.07-0.19	O
nM	O
)	O
for	O
PBR	O
in	O
the	O
rat	O
brain	O
.	O

These	O
[	O
(	O
11	O
)	O
C	O
]	O
ligands	O
could	O
pass	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
enter	O
the	O
rat	O
brain	O
(	O
0.17-0.32%	O
of	O
injected	O
dose	O
per	O
gram	O
wet	O
tissue	O
)	O
.	O

Ex	O
vivo	O
autoradiography	O
showed	O
that	O
the	O
[	O
(	O
11	O
)	O
C	O
]	O
ligands	O
preferably	O
distributed	O
in	O
the	O
olfactory	O
bulb	O
and	O
cerebellum	O
,	O
two	O
regions	O
with	O
richer	O
PBR	O
density	O
in	O
the	O
rat	O
brain	O
.	O

The	O
co	O
-	O
injection	O
of	O
PBR	O
-	O
selective	O
2	O
reduced	O
the	O
[	O
(	O
11	O
)	O
C	O
]	O
ligand	O
binding	O
in	O
the	O
two	O
regions	O
,	O
suggesting	O
that	O
binding	O
in	O
the	O
rat	O
brain	O
was	O
specific	O
to	O
PBR	O
.	O

PET	O
study	O
determined	O
that	O
the	O
[	O
(	O
11	O
)	O
C	O
]	O
ligands	O
preferably	O
accumulate	O
in	O
the	O
occipital	O
cortex	O
of	O
the	O
monkey	O
brain	O
,	O
a	O
region	O
with	O
a	O
high	O
density	O
of	O
PBR	O
in	O
the	O
primate	O
brain	O
.	O

Moreover	O
,	O
in	O
vivo	O
binding	O
of	O
the	O
methyl	O
homologue	O
[	O
(	O
11	O
)	O
C	O
]	O
8	O
in	O
the	O
monkey	O
brain	O
could	O
be	O
inhibited	O
by	O
PBR	O
-	O
selective	O
2	O
or	O
1	O
,	O
indicating	O
that	O
some	O
of	O
the	O
[	O
(	O
11	O
)	O
C	O
]	O
8	O
binding	O
was	O
due	O
to	O
PBR	O
.	O

Metabolite	O
analysis	O
demonstrated	O
that	O
these	O
[	O
(	O
11	O
)	O
C	O
]	O
ligands	O
were	O
metabolized	O
by	O
debenzylation	O
to	O
polar	O
products	O
mainly	O
in	O
the	O
plasma	O
.	O

Vasotocin	O
(	O
AVT	O
)	O
analogues	O
with	O
tyrosine	O
or	O
phenylalanine	O
in	O
position	O
9	O
,	O
i.e.	O
,	O
[	O
9	I-IUPAC
-	I-IUPAC
tyrosine	I-IUPAC
]	O
AVT	O
,	O
[	O
2	I-IUPAC
-	I-IUPAC
phenylalanine	I-IUPAC
,	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
tyrosine	I-IUPAC
]	O
AVT	O
,	O
and	O
1	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
[	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
aminophenylalanine	I-IUPAC
)	I-IUPAC
]	I-IUPAC
AVT	O
,	O
were	O
synthesized	O
by	O
the	O
solid	O
-	O
phase	O
method	O
.	O

These	O
compounds	O
showed	O
a	O
high	O
biological	O
activity	O
in	O
the	O
hydroosmotic	O
toad	O
bladder	O
assay	O
.	O

Using	O
the	O
chemically	O
reactive	O
functional	O
groups	O
on	O
tyrosine	O
and	O
p	O
-	O
aminophenylalanine	O
in	O
position	O
9	O
,	O
we	O
prepared	O
iodinated	O
,	O
photoreactive	O
,	O
and	O
affinity	O
ligands	O
,	O
i.e.	O
,	O
[	O
2	I-IUPAC
-	I-IUPAC
phenylalanine	I-IUPAC
,	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodotyrosine	I-IUPAC
)	I-IUPAC
]	O
AVT	O
,	O
1	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
[	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
azidophenylalanine	I-IUPAC
)	I-IUPAC
]	I-IUPAC
AVT	O
,	O
and	O
1	I-IUPAC
-	I-IUPAC
desamino	I-IUPAC
[	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
biotinylphenylalanine	I-IUPAC
)	I-IUPAC
]	I-IUPAC
AVT	O
,	O
respectively	O
.	O

Half	O
-	O
maximal	O
hydroosmotic	O
responses	O
(	O
ED	O
-	O
50	O
values	O
)	O
were	O
obtained	O
with	O
2.5	O
X	O
10	O
(	O
-	O
9	O
)	O
M	O
for	O
the	O
iodinated	O
analogue	O
,	O
with	O
0.9	O
X	O
10	O
(	O
-	O
10	O
)	O
M	O
for	O
the	O
photoaffinity	O
analogue	O
,	O
and	O
with	O
1.2	O
X	O
10	O
(	O
-	O
8	O
)	O
M	O
for	O
the	O
biotinyl	O
analogue	O
.	O

The	O
hydroosmotic	O
activity	O
of	O
the	O
biotinyl	O
analogue	O
was	O
reversed	O
following	O
addition	O
of	O
avidin	O
,	O
whereas	O
the	O
photoaffinity	O
analogue	O
induced	O
a	O
persistent	O
response	O
following	O
UV	O
irradiation	O
that	O
was	O
not	O
reversed	O
upon	O
repeated	O
and	O
prolonged	O
periods	O
of	O
washout	O
.	O

These	O
analogues	O
of	O
vasotocin	O
are	O
the	O
most	O
potent	O
that	O
have	O
been	O
synthesized	O
to	O
date	O
,	O
and	O
they	O
should	O
serve	O
as	O
useful	O
probes	O
in	O
the	O
isolation	O
and	O
characterization	O
of	O
vasotocin	O
receptors	O
in	O
toad	O
bladders	O
and	O
tissues	O
from	O
other	O
species	O
that	O
use	O
vasotocin	O
as	O
an	O
antidiuretic	O
/	O
pressor	O
principle	O
.	O

The	O
photoaffinity	O
and	O
biotinyl	O
analogues	O
had	O
a	O
rat	O
antidiuretic	O
activity	O
of	O
66	O
and	O
40	O
units	O
/	O
mg	O
,	O
respectively	O
.	O

These	O
compounds	O
are	O
,	O
therefore	O
,	O
also	O
suitable	O
for	O
the	O
isolation	O
of	O
V	O
-	O
2	O
vasopressin	O
receptors	O
from	O
mammalian	O
tissues	O
.	O

trans	O
-	O
2	O
-	O
Carboxy	O
-	O
5,7	O
-	O
dichloro	O
-	O
4	O
-	O
amidotetrahydroquinolines	O
,	O
evolved	O
from	O
the	O
lead	O
5,7	I-IUPAC
-	I-IUPAC
dichlorokynurenic	I-IUPAC
acid	I-IUPAC
,	O
have	O
been	O
synthesized	O
and	O
tested	O
for	O
in	O
vitro	O
antagonist	O
activity	O
at	O
the	O
glycine	O
site	O
on	O
the	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartate	I-IUPAC
(	O
NMDA	O
)	O
receptor	O
.	O

Optimization	O
of	O
the	O
4	O
-	O
substituent	O
has	O
provided	O
antagonists	O
having	O
nanomolar	O
affinity	O
,	O
including	O
the	O
urea	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
tetrahydroquinoline	I-IUPAC
(	O
35	O
;	O
IC50	O
=	O
7.4	O
nM	O
vs	O
[	O
3H	O
]	O
glycine	O
binding	O
;	O
Kb	O
=	O
130	O
nM	O
for	O
block	O
of	O
NMDA	O
responses	O
in	O
the	O
rat	O
cortical	O
slice	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
most	O
potent	O
NMDA	O
antagonists	O
yet	O
found	O
.	O

The	O
absolute	O
stereochemical	O
requirements	O
for	O
binding	O
were	O
found	O
to	O
be	O
2S	O
,	O
4R	O
,	O
showing	O
that	O
,	O
in	O
common	O
with	O
other	O
glycine	O
-	O
site	O
NMDA	O
receptor	O
ligands	O
,	O
the	O
unnatural	O
configuration	O
at	O
the	O
alpha	O
-	O
amino	O
acid	O
center	O
is	O
required	O
.	O

The	O
preferred	O
conformation	O
of	O
the	O
trans	I-MODIFIER
-	I-MODIFIER
2,4	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
tetrahydroquinoline	I-IUPAC
system	O
,	O
as	O
shown	O
by	O
X	O
-	O
ray	O
crystallography	O
and	O
1H	O
NMR	O
studies	O
,	O
places	O
the	O
2	O
-	O
carboxyl	O
pseudoequatorial	O
and	O
the	O
4	O
-	O
substituent	O
pseudoaxial	O
.	O

Modifications	O
of	O
the	O
4	O
-	O
amide	O
show	O
that	O
bulky	O
substituents	O
are	O
tolerated	O
and	O
reveal	O
the	O
critical	O
importance	O
for	O
activity	O
of	O
correct	O
positioning	O
of	O
the	O
carbonyl	O
group	O
.	O

The	O
high	O
affinity	O
of	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoimidazolidinyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroquinoline	I-IUPAC
(	O
55	O
;	O
IC50	O
=	O
6	O
nM	O
)	O
suggests	O
that	O
the	O
Z	O
,	O
Z	O
conformer	O
of	O
the	O
phenyl	O
urea	O
moiety	O
in	O
35	O
is	O
recognized	O
by	O
the	O
receptor	O
.	O

Molecular	O
modeling	O
studies	O
show	O
that	O
the	O
4	O
-	O
carbonyl	O
groups	O
of	O
the	O
kynurenic	O
acids	O
,	O
the	O
tetrahydroquinolines	O
,	O
and	O
related	O
antagonists	O
based	O
on	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
glycine	I-IUPAC
,	O
can	O
interact	O
with	O
a	O
single	O
putative	O
H	O
-	O
bond	O
donor	O
on	O
the	O
receptor	O
.	O

The	O
results	O
allow	O
the	O
establishment	O
of	O
a	O
three	O
-	O
dimensional	O
pharmacophore	O
of	O
the	O
glycine	O
receptor	O
antagonist	O
site	O
,	O
incorporating	O
a	O
newly	O
defined	O
bulk	O
tolerance	O
/	O
hydrophobic	O
region	O
.	O

The	O
synthesis	O
and	O
sigma	O
1	O
and	O
sigma	O
2	O
binding	O
properties	O
of	O
several	O
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
benzyl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
dimethylallyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
5,9	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
benzomorphans	I-IUPAC
(	O
3	O
and	O
4	O
)	O
are	O
presented	O
.	O

In	O
agreement	O
with	O
previously	O
reported	O
binding	O
data	O
for	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
5,9	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
benzomorphans	I-IUPAC
(	O
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
N	I-IUPAC
-	I-IUPAC
normetazocine	I-IUPAC
)	O
,	O
all	O
(	O
1S	O
,	O
5S	O
,	O
9S	O
)	O
-	O
(	O
+	O
)	O
-	O
isomers	O
showed	O
higher	O
affinity	O
for	O
the	O
sigma	O
1	O
site	O
than	O
the	O
corresponding	O
(	O
1R	O
,	O
5R	O
,	O
9R	O
)	O
-	O
(	O
-	O
)	O
-	O
isomers	O
.	O

Replacement	O
of	O
the	O
2'	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
group	I-MODIFIER
of	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
5,9	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
benzomorphan	I-IUPAC
[	O
(	O
+	O
)	O
-	O
1f	O
]	O
with	O
a	O
2'	O
-	O
NH2	O
and	O
2'	O
-	O
N	O
(	O
CH3	O
)	O
2	O
[	O
(	O
+	O
)	O
-	O
3b	O
and	O
(	O
+	O
)	O
-	O
3c	O
,	O
respectively	O
]	O
had	O
only	O
a	O
small	O
effect	O
on	O
the	O
sigma	O
1	O
Ki	O
values	O
.	O

Changing	O
the	O
2'	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
group	I-MODIFIER
of	O
(	O
+	O
)	O
-	O
1f	O
to	O
an	O
H	O
,	O
F	O
,	O
Cl	O
,	O
Br	O
,	O
I	O
,	O
NHAc	O
,	O
or	O
NHSO2CH3	O
resulted	O
in	O
a	O
5	O
-	O
fold	O
or	O
greater	O
loss	O
in	O
potency	O
.	O

In	O
contrast	O
,	O
replacement	O
of	O
the	O
2'	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
group	I-MODIFIER
of	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylallyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,9	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
benzomorphan	I-IUPAC
[	O
(	O
+	O
)	O
-	O
1b	O
,	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pentazocine	I-IUPAC
]	O
with	O
a	O
2'	O
-	O
H	O
or	O
2'	O
-	O
F	O
group	O
resulted	O
in	O
a	O
2	O
-	O
fold	O
increase	O
in	O
potency	O
.	O

Conversion	O
of	O
(	O
+	O
)	O
-	O
1f	O
to	O
its	O
2'	I-IUPAC
-	I-IUPAC
desoxy	I-IUPAC
analogue	I-MODIFIER
(	O
+	O
)	O
-	O
2d	O
resulted	O
in	O
a	O
27.5	O
-	O
fold	O
loss	O
in	O
affinity	O
.	O

This	O
suggests	O
that	O
(	O
+	O
)	O
-	O
1f	O
and	O
other	O
N	O
-	O
substituted	O
benzomorphan	O
analogues	O
may	O
be	O
binding	O
to	O
single	O
sigma	O
1	O
receptors	O
in	O
a	O
different	O
way	O
or	O
to	O
different	O
sigma	O
1	O
receptors	O
.	O

(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
Pentazocine	I-IUPAC
[	O
(	O
-	O
)	O
-	O
1b	O
]	O
and	O
its	O
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
analogue	I-MODIFIER
,	O
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylallyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,9	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
benzomorphan	I-IUPAC
[	O
(	O
-	O
)	O
-	O
4a	O
]	O
showed	O
the	O
highest	O
potency	O
for	O
the	O
sigma	O
2	O
binding	O
site	O
.	O

The	O
synthesis	O
and	O
biological	O
activities	O
of	O
14	O
6	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2,4	I-IUPAC
-	I-IUPAC
diaminoquinazolines	I-IUPAC
are	O
reported	O
.	O

These	O
compounds	O
were	O
designed	O
to	O
improve	O
the	O
cell	O
penetration	O
of	O
a	O
previously	O
reported	O
series	O
of	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	O
substituted	I-MODIFIER
-	O
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
which	O
had	O
shown	O
significant	O
potency	O
and	O
remarkable	O
selectivity	O
for	O
Toxoplasma	O
gondii	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
,	O
but	O
had	O
much	O
lower	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
T	O
.	O

gondii	O
cells	O
in	O
culture	O
.	O

The	O
target	O
N9	O
-	O
H	O
analogues	O
were	O
obtained	O
via	O
regiospecific	O
reductive	O
amination	O
of	O
the	O
appropriate	O
benzaldehydes	O
with	O
2,4,6	I-IUPAC
-	I-IUPAC
triaminoquinazoline	I-IUPAC
,	O
which	O
,	O
in	O
turn	O
,	O
was	O
synthesized	O
from	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
nitroquinazoline	I-IUPAC
.	O

The	O
N9	O
-	O
CH3	O
analogues	O
were	O
synthesized	O
via	O
a	O
regiospecific	O
reductive	O
methylation	O
of	O
the	O
corresponding	O
N9	O
-	O
H	O
precursors	O
.	O

The	O
compounds	O
were	O
evaluated	O
as	O
inhibitors	O
of	O
DHFR	O
from	O
human	O
,	O
Pneumocystis	O
carinii	O
,	O
T	O
.	O

gondii	O
,	O
rat	O
liver	O
,	O
Lactobacillus	O
casei	O
,	O
and	O
Escherichia	O
coli	O
,	O
and	O
selected	O
analogues	O
were	O
evaluated	O
as	O
inhibitors	O
of	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
culture	O
.	O

These	O
analogues	O
displayed	O
potent	O
T	O
.	O

gondii	O
DHFR	O
inhibition	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
growth	O
of	O
T	O
.	O

gondii	O
cells	O
in	O
culture	O
.	O

Further	O
,	O
selected	O
analogues	O
were	O
potent	O
inhibitors	O
of	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
culture	O
in	O
the	O
in	O
vitro	O
screening	O
program	O
of	O
the	O
National	O
Cancer	O
Institute	O
with	O
GI50s	O
in	O
the	O
nanomolar	O
and	O
subnanomolar	O
range	O
.	O

Crystallographic	O
data	O
for	O
the	O
ternary	O
complex	O
of	O
hDHFR	O
-	O
NADPH	O
and	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
,	O
1c	O
,	O
reveal	O
the	O
first	O
structural	O
details	O
for	O
a	O
reversed	O
N9	O
-	O
C10	O
folate	O
bridge	O
geometry	O
as	O
well	O
as	O
the	O
first	O
conformational	O
details	O
of	O
a	O
hybrid	O
piritrexim	O
-	O
trimetrexate	O
analogue	O
.	O

A	O
novel	O
series	O
of	O
10	I-IUPAC
-	I-IUPAC
benzylidene	I-IUPAC
-	I-IUPAC
9	I-IUPAC
(	I-IUPAC
10H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
anthracenones	I-IUPAC
and	O
10	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
(	I-IUPAC
10H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
anthracenones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
antiproliferative	O
activity	O
in	O
an	O
assay	O
based	O
on	O
K562	O
leukemia	O
cells	O
.	O

The	O
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxybenzylidene	I-IUPAC
analogue	I-MODIFIER
9h	O
was	O
found	O
to	O
be	O
the	O
most	O
active	O
compound	O
(	O
IC	O
(	O
50	O
)	O
K562	O
:	O
20	O
nM	O
)	O
.	O

Structure	O
-	O
activity	O
relationships	O
are	O
also	O
considered	O
.	O

The	O
highly	O
active	O
compound	O
9h	O
and	O
the	O
2,4	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxybenzylidene	I-IUPAC
analogue	I-MODIFIER
9l	O
were	O
tested	O
against	O
five	O
tumor	O
cell	O
lines	O
using	O
the	O
XTT	O
assay	O
,	O
including	O
multidrug	O
resistant	O
phenotypes	O
.	O

Induction	O
of	O
cell	O
death	O
in	O
a	O
variety	O
of	O
tumor	O
cell	O
lines	O
was	O
determined	O
in	O
a	O
monolayer	O
assay	O
using	O
propidium	O
iodide	O
.	O

Noteworthy	O
,	O
all	O
compounds	O
within	O
the	O
series	O
induced	O
elongations	O
in	O
K562	O
cells	O
similar	O
to	O
vinblastine	O
-	O
treated	O
cells	O
.	O

The	O
effect	O
of	O
the	O
lead	O
compound	O
9h	O
on	O
K562	O
cell	O
growth	O
was	O
associated	O
with	O
cell	O
cycle	O
arrest	O
in	O
G2	O
/	O
M	O
.	O

Concentrations	O
for	O
50%	O
KB	O
/	O
HeLa	O
cells	O
arrested	O
in	O
G2	O
/	O
M	O
after	O
treatment	O
with	O
9h	O
and	O
9l	O
were	O
determined	O
and	O
found	O
to	O
be	O
in	O
the	O
range	O
of	O
0.2	O
microM	O
.	O

Additionally	O
,	O
we	O
monitored	O
the	O
dose	O
dependent	O
caspase	O
-	O
3	O
-	O
like	O
protease	O
activity	O
in	O
K562	O
cells	O
and	O
MCF	O
-	O
7	O
/	O
Casp	O
-	O
3	O
cells	O
treated	O
with	O
9h	O
,	O
indicating	O
induction	O
of	O
apoptosis	O
.	O

Western	O
blotting	O
analysis	O
demonstrated	O
that	O
9h	O
caused	O
a	O
shift	O
in	O
tubulin	O
concentration	O
from	O
the	O
polymerized	O
state	O
found	O
in	O
the	O
cell	O
pellet	O
to	O
the	O
unpolymerized	O
state	O
found	O
in	O
the	O
cell	O
supernatant	O
.	O

Seven	O
compounds	O
strongly	O
inhibited	O
tubulin	O
polymerization	O
with	O
activities	O
higher	O
or	O
comparable	O
to	O
those	O
of	O
the	O
reference	O
compounds	O
such	O
as	O
colchicine	O
,	O
podophyllotoxin	O
,	O
and	O
nocodazole	O
.	O

In	O
general	O
,	O
the	O
antiproliferative	O
activity	O
correlated	O
with	O
inhibition	O
of	O
tubulin	O
polymerization	O
.	O

The	O
most	O
active	O
compounds	O
strongly	O
displaced	O
[	O
(	O
3	O
)	O
H	O
]	O
colchicine	O
from	O
its	O
binding	O
site	O
in	O
the	O
tubulin	O
,	O
yielding	O
IC	O
(	O
50	O
)	O
values	O
3	O
-	O
to	O
4	O
-	O
fold	O
lower	O
than	O
that	O
of	O
colchicine	O
.	O

The	O
novel	O
benzylidene	I-IUPAC
-	I-IUPAC
9	I-IUPAC
(	I-IUPAC
10H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
anthracenones	I-IUPAC
described	O
in	O
the	O
present	O
study	O
constitute	O
an	O
interesting	O
group	O
of	O
highly	O
active	O
and	O
easily	O
accessible	O
antimitotic	O
agents	O
that	O
inhibit	O
tubulin	O
polymerization	O
.	O

The	O
synthesis	O
,	O
physical	O
properties	O
,	O
antitumor	O
activity	O
,	O
structure	O
-	O
activity	O
relationships	O
,	O
and	O
nephrotoxicity	O
of	O
a	O
series	O
of	O
[	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
4,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
]	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
are	O
described	O
.	O

The	O
42	O
platinum	O
(	O
II	O
)	O
complexes	O
having	O
a	O
seven	O
-	O
membered	O
ring	O
structure	O
in	O
this	O
series	O
have	O
been	O
prepared	O
and	O
characterized	O
by	O
1H	O
NMR	O
,	O
13C	O
NMR	O
,	O
IR	O
,	O
FAB	O
-	O
MS	O
,	O
and	O
elemental	O
analysis	O
.	O

All	O
members	O
of	O
the	O
series	O
were	O
designed	O
to	O
have	O
a	O
1,3	O
-	O
dioxolane	O
ring	O
moiety	O
in	O
their	O
carrier	O
ligands	O
to	O
increase	O
water	O
solubility	O
.	O

The	O
solubility	O
of	O
platinum	O
complexes	O
was	O
related	O
to	O
the	O
nature	O
of	O
leaving	O
ligands	O
and	O
2	O
-	O
substituents	O
in	O
the	O
4,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
carrier	O
ligands	O
.	O

In	O
general	O
,	O
compounds	O
having	O
two	O
different	O
R1	O
and	O
R2	O
substituents	O
in	O
the	O
4,5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dioxolane	I-IUPAC
moiety	I-MODIFIER
were	O
more	O
water	O
-	O
soluble	O
than	O
those	O
having	O
the	O
same	O
substituents	O
.	O

Most	O
members	O
of	O
this	O
series	O
showed	O
the	O
excellent	O
antitumor	O
activity	O
against	O
murine	O
L1210	O
leukemia	O
cells	O
transplanted	O
in	O
mice	O
and	O
were	O
superior	O
to	O
cisplatin	O
and	O
carboplatin	O
.	O

The	O
(	O
4R	O
,	O
5R	O
)	O
-	O
stereoisomer	O
1a	O
-	O
h	O
exhibited	O
the	O
higher	O
antitumor	O
activity	O
than	O
the	O
corresponding	O
(	O
4S	O
,	O
5S	O
)	O
-	O
stereoisomer	O
2a	O
-	O
h	O
in	O
the	O
(	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
cyclobutanedicarboxylato	I-IUPAC
)	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
.	O

The	O
(	I-IUPAC
glycolato	I-IUPAC
)	I-IUPAC
-	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	I-MODIFIER
were	O
highly	O
cytotoxic	O
toward	O
four	O
human	O
stomach	O
cancer	O
cell	O
lines	O
,	O
SNU	O
-	O
1	O
,	O
SNU	O
-	O
5	O
,	O
SNU	O
-	O
16	O
,	O
and	O
NCI	O
-	O
N87	O
,	O
and	O
among	O
them	O
,	O
complexes	O
3d	O
-	O
g	O
were	O
even	O
more	O
cytotoxic	O
than	O
cisplatin	O
.	O

The	O
(	O
malonato	O
)	O
platinum	O
(	O
II	O
)	O
complex	O
1m	O
and	O
the	O
(	O
glycolato	O
)	O
platinum	O
(	O
II	O
)	O
complexes	O
3d	O
-	O
g	O
were	O
selected	O
for	O
further	O
studies	O
based	O
on	O
the	O
greater	O
in	O
vivo	O
and	O
in	O
vitro	O
antitumor	O
activity	O
and	O
desirable	O
physical	O
properties	O
.	O

The	O
complexes	O
3e	O
-	O
g	O
were	O
almost	O
equally	O
cytotoxic	O
to	O
cisplatin	O
toward	O
human	O
stomach	O
cancer	O
cell	O
lines	O
,	O
KATO	O
-	O
III	O
and	O
MKN	O
-	O
45	O
,	O
and	O
a	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cell	O
line	O
,	O
PC14	O
.	O

In	O
contrast	O
with	O
cisplatin	O
and	O
carboplatin	O
,	O
five	O
complexes	O
selected	O
significantly	O
increased	O
in	O
life	O
span	O
in	O
mice	O
transplanted	O
with	O
cisplatin	O
-	O
resistant	O
L1210	O
cells	O
.	O

Nephrotoxicity	O
studies	O
in	O
ICR	O
mice	O
indicated	O
that	O
serum	O
BUN	O
and	O
creatinine	O
levels	O
were	O
not	O
elevated	O
when	O
five	O
complexes	O
were	O
given	O
at	O
a	O
dose	O
equal	O
to	O
1.5	O
times	O
the	O
optimal	O
dose	O
determined	O
in	O
the	O
in	O
vivo	O
L1210	O
screening	O
system	O
.	O

5	O
-	O
(	O
2	O
-	O
Acylethynyl	O
)	O
-	O
2,4	O
-	O
dimethoxypyrimidines	O
(	O
3-6	O
)	O
were	O
synthesized	O
in	O
excellent	O
yields	O
from	O
2,4	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
ethynyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
2	O
)	O
by	O
treatment	O
with	O
acid	O
chlorides	O
in	O
the	O
presence	O
of	O
anhydrous	O
aluminum	O
chloride	O
.	O

Compounds	O
3-6	O
were	O
deblocked	O
with	O
chlorotrimethylsilane	I-IUPAC
and	O
sodium	O
iodide	O
in	O
acetonitrile	O
to	O
the	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
)	I-IUPAC
vinyl	I-IUPAC
]	I-IUPAC
uracils	I-IUPAC
(	O
7-10	O
)	O
,	O
which	O
on	O
treatment	O
with	O
potassium	O
hydroxide	O
in	O
dioxane	O
yielded	O
the	O
corresponding	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acylethynyl	I-IUPAC
)	I-IUPAC
uracils	I-IUPAC
(	O
11-14	O
)	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acylethynyl	I-IUPAC
)	I-IUPAC
uracils	I-IUPAC
were	O
found	O
to	O
be	O
active	O
against	O
Ehrlich	O
ascites	O
carcinoma	O
(	O
EAC	O
)	O
cells	O
in	O
vivo	O
,	O
the	O
most	O
active	O
compounds	O
being	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzoylethynyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
11	O
)	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoylethynyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
12	O
)	O
.	O

The	O
T	O
/	O
C	O
values	O
of	O
281	O
and	O
300	O
were	O
obtained	O
for	O
compounds	O
11	O
and	O
12	O
,	O
respectively	O
,	O
in	O
the	O
case	O
of	O
mice	O
bearing	O
EAC	O
cells	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acylethynyl	I-IUPAC
)	I-IUPAC
uracils	I-IUPAC
have	O
also	O
shown	O
in	O
vitro	O
activity	O
against	O
CCRF	O
-	O
CEM	O
and	O
L1210/0	O
tumor	O
cell	O
lines	O
.	O

The	O
lead	O
compound	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoylethynyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
effectively	O
inhibited	O
thymidylate	O
synthetase	O
.	O

Chemical	O
and	O
biological	O
similarities	O
of	O
plutonium	O
(	O
IV	O
)	O
and	O
iron	O
(	O
III	O
)	O
suggested	O
that	O
octadentate	O
ligands	O
containing	O
hydroxamate	O
or	O
catecholate	O
functional	O
groups	O
,	O
which	O
are	O
found	O
in	O
microbial	O
iron	O
chelating	O
agents	O
(	O
siderophores	O
)	O
,	O
would	O
be	O
effective	O
and	O
relatively	O
selective	O
complexing	O
agents	O
for	O
actinide	O
(	O
IV	O
)	O
ions	O
.	O

However	O
,	O
their	O
usefulness	O
for	O
in	O
vivo	O
chelation	O
of	O
actinide	O
(	O
IV	O
)	O
is	O
limited	O
,	O
because	O
catechol	O
and	O
hydroxamate	O
are	O
such	O
weak	O
acids	O
that	O
the	O
potential	O
for	O
octadentate	O
binding	O
of	O
actinide	O
(	O
IV	O
)	O
cannot	O
be	O
achieved	O
at	O
physiological	O
pH	O
.	O

The	O
structurally	O
similar	O
monoprotic	O
and	O
more	O
acidic	O
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
1,2	O
-	O
HOPO	O
)	O
group	O
was	O
,	O
therefore	O
,	O
incorporated	O
into	O
multidentate	O
ligands	O
.	O

Treatment	O
of	O
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
5	O
)	O
with	O
phosgene	O
in	O
THF	O
solution	O
gives	O
the	O
active	O
ester	O
poly	I-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dioxopyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
]	I-IUPAC
,	O
which	O
upon	O
treatment	O
with	O
excess	O
anhydrous	O
dimethylamine	O
gave	O
a	O
60%	O
yield	O
of	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
6	O
)	O
.	O

A	O
similarly	O
reactive	O
intermediate	O
was	O
prepared	O
from	O
5	O
and	O
an	O
equimolar	O
amount	O
of	O
phosgene	O
in	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylacetamide	I-IUPAC
.	O

Combined	O
in	O
situ	O
with	O
1,3	I-IUPAC
-	I-IUPAC
propanediamine	I-IUPAC
,	O
benzylamine	O
,	O
spermine	O
,	O
spermidine	O
,	O
1,3,5	I-IUPAC
-	I-IUPAC
tris	I-IUPAC
(	I-IUPAC
aminomethyl	I-IUPAC
)	I-IUPAC
benzene	I-IUPAC
,	O
or	O
desferrioxamine	O
B	O
and	O
excess	O
triethylamine	O
,	O
the	O
latter	O
intermediate	O
gave	O
the	O
corresponding	O
amides	O
in	O
isolated	O
yields	O
ranging	O
from	O
16%	O
to	O
60%	O
.	O

The	O
free	O
ligands	O
,	O
their	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
and	O
the	O
ferric	O
complex	O
of	O
3,4,3	O
-	O
LIHOPO	O
were	O
administered	O
to	O
mice	O
[	O
30	O
mumol	O
/	O
kg	O
intraperitoneally	O
1	O
h	O
after	O
Pu	O
(	O
IV	O
)	O
-	O
238	O
citrate	O
,	O
kill	O
at	O
24	O
h	O
]	O
.	O

Net	O
Pu	O
removal	O
[	O
Pu	O
excretion	O
(	O
treated	O
)	O
-	O
PU	O
excretion	O
(	O
control	O
)	O
]	O
,	O
expressed	O
as	O
percent	O
of	O
injected	O
Pu	O
,	O
was	O
as	O
follows	O
:	O
Na	O
salts	O
and	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
respectively	O
,	O
of	O
3	O
-	O
LIHOPO	O
(	O
54	O
,	O
56	O
)	O
,	O
3,4	O
-	O
LIHOPO	O
(	O
58	O
,	O
60	O
)	O
,	O
3,4,3	O
-	O
LIHOPO	O
(	O
73	O
,	O
76	O
)	O
;	O
Na	O
salts	O
of	O
MEHOPO	O
(	O
46	O
)	O
,	O
DFO	O
-	O
HOPO	O
(	O
78	O
)	O
;	O
Fe	O
(	O
III	O
)	O
complex	O
of	O
3,4,3	O
-	O
LIHOPO	O
(	O
79	O
)	O
.	O

DFO	O
-	O
HOPO	O
and	O
3,4,3	O
-	O
LIHOPO	O
and	O
its	O
Zn	O
(	O
II	O
)	O
and	O
Fe	O
(	O
III	O
)	O
complexes	O
promoted	O
significantly	O
more	O
Pu	O
excretion	O
than	O
CaNa3	O
-	O
DTPA	O
(	O
61%	O
of	O
injected	O
Pu	O
)	O
.	O

Preliminary	O
findings	O
on	O
the	O
acute	O
toxicity	O
of	O
the	O
poly	O
(	O
HOPO	O
)	O
ligands	O
and	O
HOPO	O
monomers	O
are	O
presented	O
in	O
an	O
appendix	O
.	O

The	O
biological	O
data	O
indicate	O
strongly	O
that	O
the	O
aqueous	O
solubility	O
and	O
relatively	O
high	O
acidity	O
of	O
the	O
octadentate	O
HOPO	O
ligands	O
,	O
3,4,3	O
-	O
LIHOPO	O
and	O
DFO	O
-	O
HOPO	O
allow	O
them	O
to	O
form	O
complete	O
eight	O
-	O
coordinate	O
complexes	O
with	O
Pu	O
(	O
IV	O
)	O
ion	O
.	O

A	O
series	O
of	O
N	O
-	O
substituted	O
imidazolines	O
and	O
ethylenediamines	O
were	O
synthesized	O
and	O
examined	O
for	O
their	O
activity	O
in	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
systems	O
.	O

The	O
length	O
of	O
the	O
intermediate	O
side	O
chain	O
between	O
the	O
catechol	O
and	O
imidazoline	O
ring	O
or	O
the	O
amine	O
of	O
the	O
ethylenediamine	O
segment	O
was	O
shown	O
to	O
affect	O
the	O
adrenergic	O
activity	O
.	O

N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
Dihydroxyphenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
imidazoline	I-IUPAC
hydrochloride	I-IUPAC
(	O
2	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydroxyphenyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
ethylenediamine	I-IUPAC
dihydrochloride	I-IUPAC
(	O
4	O
)	O
,	O
both	O
with	O
two	O
methylene	O
groups	O
between	O
the	O
catechol	O
and	O
amine	O
segment	O
,	O
were	O
found	O
to	O
be	O
somewhat	O
selective	O
for	O
alpha	O
2	O
-	O
adrenergic	O
receptors	O
while	O
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydroxybenzyl	I-IUPAC
)	I-IUPAC
imidazoline	I-IUPAC
hydrochloride	I-IUPAC
(	O
1	O
)	O
and	O
N	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydroxybenzyl	I-IUPAC
)	I-IUPAC
ethylenediamine	I-IUPAC
dihydrochloride	I-IUPAC
(	O
3	O
)	O
,	O
both	O
with	O
one	O
methylene	I-IUPAC
group	B-MODIFIER
between	O
the	O
catechol	O
and	O
amine	O
segment	O
,	O
were	O
more	O
selective	O
for	O
alpha1	O
-	O
adrenergic	O
receptors	O
in	O
a	O
pithed	O
rat	O
model	O
.	O

Of	O
the	O
four	O
compounds	O
examined	O
,	O
only	O
compound	O
2	O
showed	O
significant	O
direct	O
activity	O
on	O
beta1	O
-	O
and	O
beta2	O
-	O
adrenergic	O
receptors	O
.	O

O	O
(	O
6	O
)	O
-	O
Substituted	O
guanine	I-IUPAC
derivatives	B-MODIFIER
are	O
powerful	O
agents	O
used	O
for	O
tumor	O
cell	O
sensitization	O
by	O
inhibition	O
of	O
the	O
DNA	O
repair	O
enzyme	O
O	O
(	O
6	O
)	O
-	O
methylguanine	O
-	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
.	O

To	O
provide	O
targeted	O
accumulation	O
of	O
MGMT	O
inhibitors	O
in	O
tumor	O
tissue	O
as	O
well	O
as	O
tools	O
for	O
in	O
vivo	O
imaging	O
,	O
we	O
synthesized	O
iodinated	O
C	O
(	O
8	O
)	O
-	O
alkyl	O
-	O
linked	O
glucose	O
conjugates	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
purine	I-IUPAC
(	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothenyl	I-IUPAC
)	I-IUPAC
guanine	I-IUPAC
,	O
ITG	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodobenzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9H	I-IUPAC
-	I-IUPAC
purine	I-IUPAC
(	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodobenzyl	I-IUPAC
)	I-IUPAC
guanine	I-IUPAC
,	O
IBG	O
)	O
.	O

These	O
compounds	O
have	O
MGMT	O
inhibitor	O
constants	O
(	O
IC	O
(	O
50	O
)	O
values	O
)	O
of	O
0.8	O
and	O
0.45	O
microM	O
for	O
ITGG	O
and	O
IBGG	O
,	O
respectively	O
,	O
as	O
determined	O
in	O
HeLa	O
S3	O
cells	O
after	O
2	O
-	O
h	O
incubation	O
with	O
inhibitor	O
.	O

To	O
substantiate	O
that	O
the	O
(	I-IUPAC
131	I-IUPAC
)	I-IUPAC
I	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hetero	I-IUPAC
)	I-IUPAC
arylmethylene	I-IUPAC
group	I-MODIFIER
at	O
the	O
O	O
(	O
6	O
)	O
-	O
position	O
of	O
guanine	O
is	O
transferred	O
to	O
MGMT	O
,	O
both	O
the	O
glucose	O
conjugated	O
inhibitors	O
ITGG	O
and	O
IBGG	O
and	O
the	O
corresponding	O
nonglucose	O
conjugated	O
compounds	O
ITG	O
and	O
IBG	O
were	O
labeled	O
with	O
iodine	O
-	O
131	O
.	O

The	O
radioiodinations	O
of	O
all	O
compounds	O
with	O
[	O
(	O
131	O
)	O
I	O
]	O
I	O
(	O
-	O
)	O
were	O
performed	O
with	O
radiochemical	O
yields	O
of	O
&	O
gt	O
;	O
70%	O
for	O
the	O
destannylation	O
of	O
the	O
corresponding	O
tri	O
-	O
n	O
-	O
butylstannylated	O
precursors	O
.	O

The	O
binding	O
ability	O
of	O
[	O
(	O
131	O
)	O
I	O
]	O
ITGG	O
,	O
[	O
(	O
131	O
)	O
]	O
IBGG	O
,	O
[	O
(	O
131	O
)	O
I	O
]	O
ITG	O
,	O
and	O
[	O
(	O
131	O
)	O
I	O
]	O
IBG	O
to	O
purified	O
MGMT	O
was	O
tested	O
.	O

All	O
radioactive	O
compounds	O
were	O
substrates	O
for	O
MGMT	O
,	O
as	O
demonstrated	O
using	O
a	O
competitive	O
repair	O
assay	O
.	O

The	O
newly	O
synthesized	O
radioactive	O
inhibitors	O
were	O
utilized	O
to	O
study	O
ex	O
vivo	O
biodistribution	O
in	O
mice	O
,	O
and	O
the	O
tumor	O
-	O
to	O
-	O
blood	O
ratio	O
of	O
tissue	O
uptake	O
of	O
[	O
(	O
131	O
)	O
I	O
]	O
IBG	O
and	O
[	O
(	O
131	O
)	O
I	O
]	O
IBGG	O
was	O
determined	O
to	O
be	O
0.24	O
and	O
0.76	O
after	O
0.5	O
h	O
,	O
respectively	O
.	O

4,5	O
-	O
Diphenyl	O
-	O
2	O
-	O
oxazolenonanoic	O
acid	O
(	O
2	O
)	O
and	O
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
diphenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxazolyl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
phenoxy	I-IUPAC
]	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
were	O
previously	O
identified	O
as	O
nonprostanoid	O
prostacyclin	O
(	O
PGI2	O
)	O
mimetics	O
that	O
inhibit	O
ADP	O
-	O
induced	O
aggregation	O
of	O
human	O
platelets	O
in	O
vitro	O
.	O

The	O
effects	O
on	O
biological	O
activity	O
of	O
substitution	O
and	O
structural	O
modification	O
of	O
the	O
4	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
rings	I-MODIFIER
of	O
3	O
was	O
examined	O
.	O

Potency	O
showed	O
a	O
marked	O
sensitivity	O
to	O
the	O
introduction	O
of	O
substituents	O
to	O
these	O
aromatic	O
rings	O
and	O
only	O
the	O
bis	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivative	I-MODIFIER
9j	O
,	O
IC50	O
=	O
0.34	O
microM	O
,	O
demonstrated	O
enhanced	O
potency	O
compared	O
to	O
the	O
parent	O
structure	O
3	O
,	O
IC50	O
=	O
1.2	O
microM	O
.	O

Substitution	O
at	O
the	O
ortho	O
or	O
meta	O
positions	O
of	O
the	O
phenyl	O
rings	O
,	O
replacement	O
by	O
thiopheneyl	O
or	O
cyclohexyl	O
moieties	O
,	O
or	O
constraining	O
in	O
a	O
planar	O
phenanthrene	O
system	O
resulted	O
in	O
compounds	O
that	O
were	O
less	O
effective	O
inhibitors	O
of	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
.	O

In	O
contrast	O
,	O
variation	O
of	O
the	O
heterocycle	O
moiety	O
revealed	O
a	O
much	O
less	O
stringent	O
SAR	O
and	O
many	O
5	O
-	O
and	O
6	O
-	O
membered	O
heterocycles	O
were	O
found	O
to	O
effectively	O
substitute	O
for	O
the	O
oxazole	O
ring	O
of	O
2	O
and	O
3	O
.	O

The	O
diphenylmethyl	O
moiety	O
functioned	O
as	O
an	O
effective	O
isostere	O
for	O
4,5	O
-	O
diphenylated	O
heterocycles	O
since	O
13aad	O
showed	O
similar	O
platelet	O
inhibitory	O
activity	O
to	O
3	O
.	O

With	O
the	O
exception	O
of	O
the	O
3,4,5	I-IUPAC
-	I-IUPAC
triphenylpyrazole	I-IUPAC
derivative	I-MODIFIER
13g	O
,	O
compounds	O
presenting	O
the	O
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
ethylphenoxy	I-IUPAC
)	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
side	I-MODIFIER
chain	I-MODIFIER
discovered	O
with	O
3	O
demonstrated	O
enhanced	O
potency	O
compared	O
to	O
the	O
analogously	O
substituted	O
alkanoic	O
acid	O
derivative	O
.	O

The	O
structure	O
-	O
activity	O
findings	O
led	O
to	O
a	O
refinement	O
of	O
a	O
model	O
of	O
the	O
nonprostanoid	O
PGI2	O
mimetic	O
pharmacophore	O
.	O

5'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Pivaloyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
dioxaphosphorinan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouridine	I-IUPAC
(	O
1c	O
)	O
was	O
designed	O
as	O
a	O
potential	O
membrane	O
-	O
permeable	O
prodrug	O
of	O
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouridine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
monophosphate	I-IUPAC
(	O
FdUMP	O
)	O
,	O
a	O
putative	O
active	O
metabolite	O
of	O
the	O
antitumor	O
drug	O
5	I-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
(	O
FU	O
)	O
.	O

It	O
was	O
anticipated	O
that	O
1c	O
would	O
be	O
hydrolyzed	O
in	O
vivo	O
by	O
carboxylate	O
esterase	O
(	O
E	O
.	O

C	O
.	O

3.1.1.1	O
)	O
to	O
the	O
labile	O
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
analogue	I-MODIFIER
2a	O
,	O
which	O
should	O
penetrate	O
cells	O
by	O
passive	O
diffusion	O
and	O
ring	O
open	O
to	O
the	O
aldehyde	O
3a	O
.	O

Spontaneous	O
elimination	O
of	O
acrolein	O
from	O
3a	O
would	O
then	O
generate	O
the	O
free	O
nucleotide	O
,	O
FdUMP	O
.	O

1c	O
might	O
also	O
penetrate	O
cells	O
directly	O
and	O
undergo	O
the	O
same	O
degradation	O
sequence	O
after	O
hydrolysis	O
by	O
cellular	O
esterases	O
.	O

1c	O
was	O
prepared	O
by	O
condensing	O
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
pivaloyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
dioxaphosphorinane	I-IUPAC
with	O
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouridine	I-IUPAC
(	O
FUdR	O
)	O
in	O
the	O
presence	O
of	O
triphenylphosphine	O
and	O
diethyl	O
azodicarboxylate	O
.	O

1c	O
was	O
moderately	O
stable	O
in	O
aqueous	O
buffers	O
over	O
the	O
pH	O
range	O
1-7.4	O
(	O
T1/2	O
&	O
gt	O
;	O
30	O
h	O
)	O
.	O

In	O
the	O
presence	O
of	O
carboxylate	O
esterase	O
,	O
however	O
,	O
it	O
was	O
degraded	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
to	O
FdUMP	O
.	O

No	O
intermediates	O
were	O
detected	O
in	O
the	O
incubation	O
mixture	O
.	O

In	O
mouse	O
plasma	O
,	O
1c	O
was	O
degraded	O
first	O
to	O
FdUMP	O
and	O
then	O
to	O
FUdR	O
.	O

The	O
latter	O
is	O
presumably	O
formed	O
by	O
dephosphorylation	O
of	O
FdUMP	O
by	O
plasma	O
5'	O
-	O
nucleotidases	O
or	O
phosphatases	O
.	O

1c	O
and	O
FU	O
inhibited	O
the	O
growth	O
of	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
in	O
culture	O
at	O
a	O
concentration	O
of	O
5	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

1c	O
was	O
equally	O
potent	O
against	O
a	O
CHO	O
variant	O
that	O
was	O
20	O
-	O
fold	O
resistant	O
to	O
FU	O
.	O

Administered	O
intraperitoneally	O
for	O
5	O
consecutive	O
days	O
,	O
1c	O
was	O
as	O
effective	O
as	O
FU	O
at	O
prolonging	O
the	O
life	O
span	O
of	O
mice	O
bearing	O
P	O
-	O
388	O
leukemia	O
.	O

In	O
the	O
presence	O
of	O
2	I-IUPAC
-	I-IUPAC
mercaptoehtanesulfonic	I-IUPAC
acid	I-IUPAC
,	O
an	O
acrolein	O
scavenger	O
,	O
1c	O
was	O
equally	O
effective	O
against	O
a	O
P	O
-	O
388	O
mutant	O
cell	O
line	O
that	O
was	O
resistant	O
to	O
FU	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
1c	O
acts	O
as	O
a	O
membrane	O
-	O
permeable	O
prodrug	O
of	O
FdUMP	O
.	O

This	O
prodrug	O
strategy	O
may	O
be	O
generally	O
useful	O
for	O
introducing	O
dianionic	O
phosphates	O
and	O
phosphonates	O
into	O
cells	O
.	O

The	O
hydrogen	O
-	O
bond	O
-	O
acceptor	O
properties	O
of	O
the	O
carbonyl	I-IUPAC
moiety	B-MODIFIER
in	O
the	O
17beta	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
group	I-MODIFIER
on	O
the	O
D	O
-	O
ring	O
of	O
the	O
anesthetic	O
steroids	O
(	I-PARTIUPAC
3alpha	I-PARTIUPAC
,	I-PARTIUPAC
5alpha	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
3alpha	I-IUPAC
,	I-IUPAC
5beta	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypregan	I-IUPAC
-	I-IUPAC
20	I-IUPAC
-	I-IUPAC
one	I-IUPAC
form	O
an	O
important	O
part	O
of	O
the	O
anesthetic	O
steroid	O
pharmacophore	O
.	O

13,24	I-IUPAC
-	I-IUPAC
Cyclo	I-IUPAC
-	I-IUPAC
18,21	I-IUPAC
-	I-IUPAC
dinorcholanes	I-IUPAC
containing	O
a	O
ketone	O
or	O
conjugated	O
ketone	O
group	O
at	O
C	O
-	O
20	O
,	O
C	O
-	O
22	O
,	O
C	O
-	O
23	O
,	O
or	O
C	O
-	O
24	O
were	O
prepared	O
as	O
conformationally	O
constrained	O
analogues	O
of	O
these	O
anesthetic	O
steroids	O
and	O
were	O
used	O
to	O
probe	O
for	O
alternate	O
locations	O
for	O
the	O
D	O
-	O
ring	O
hydrogen	O
-	O
bond	O
-	O
accepting	O
carbonyl	I-IUPAC
group	B-MODIFIER
.	O

The	O
analogues	O
were	O
evaluated	O
(	O
1	O
)	O
.	O

in	O
[	I-IUPAC
(	I-IUPAC
35	I-IUPAC
)	I-IUPAC
S	I-IUPAC
]	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butylbicyclophosphorothionate	I-IUPAC
binding	O
experiments	O
,	O
(	O
2	O
)	O
.	O

in	O
electrophysiological	O
experiments	O
using	O
rat	O
alpha	O
(	O
1	O
)	O
beta	O
(	O
2	O
)	O
gamma	O
(	O
2L	O
)	O
GABA	O
(	O
A	O
)	O
receptors	O
expressed	O
in	O
Xenopus	O
laevis	O
oocytes	O
,	O
and	O
(	O
3	O
)	O
.	O

as	O
tadpole	O
anesthetics	O
.	O

In	O
the	O
binding	O
assay	O
,	O
the	O
relative	O
order	O
of	O
potencies	O
for	O
the	O
analogues	O
in	O
the	O
5alpha	O
-	O
and	O
5beta	O
-	O
series	O
is	O
identical	O
.	O

For	O
the	O
ketones	O
,	O
the	O
order	O
is	O
24	O
-	O
one	O
&	O
gt	O
;	O
or	O
=	O
23	O
-	O
one	O
&	O
gt	O
;	O
20	O
-	O
one	O
&	O
gt	O
;	O
22	O
-	O
one	O
.	O

Likewise	O
,	O
for	O
the	O
enones	O
,	O
the	O
order	O
is	O
delta	O
(	O
22	O
)	O
-	O
24	O
-	O
one	O
&	O
gt	O
;	O
delta	O
(	O
20	O
(	O
22	O
)	O
)	O
-	O
23	O
-	O
one	O
&	O
gt	O
;	O
delta	O
(	O
22	O
)	O
-	O
20	O
-	O
one	O
&	O
gt	O
;	O
delta	O
(	O
23	O
)	O
-	O
22	O
-	O
one	O
.	O

Similar	O
relative	O
orders	O
of	O
potencies	O
are	O
also	O
found	O
in	O
the	O
other	O
two	O
bioassays	O
.	O

The	O
activities	O
of	O
the	O
24	O
-	O
one	O
and	O
delta	O
(	O
22	O
)	O
-	O
24	O
-	O
one	O
compounds	O
were	O
expected	O
to	O
be	O
very	O
low	O
,	O
because	O
the	O
carbonyl	I-IUPAC
group	B-MODIFIER
in	O
these	O
compounds	O
is	O
located	O
over	O
the	O
steroid	O
C	O
-	O
ring	O
and	O
oriented	O
toward	O
C	O
-	O
8	O
.	O

Instead	O
,	O
these	O
compounds	O
have	O
the	O
highest	O
activities	O
in	O
their	O
respective	O
series	O
,	O
with	O
the	O
delta	O
(	O
22	O
)	O
-	O
24	O
-	O
one	O
compounds	O
having	O
activities	O
comparable	O
to	O
those	O
of	O
the	O
reference	O
anesthetic	O
steroids	O
.	O

The	O
electrophysiology	O
results	O
obtained	O
with	O
the	O
24	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
cyclosteroids	I-IUPAC
suggest	O
that	O
rat	O
alpha	O
(	O
1	O
)	O
beta	O
(	O
2	O
)	O
gamma	O
(	O
2L	O
)	O
GABA	O
(	O
A	O
)	O
receptors	O
contain	O
more	O
than	O
one	O
donor	O
for	O
the	O
hydrogen	O
-	O
bond	O
-	O
acceptor	O
group	O
of	O
anesthetic	O
steroids	O
.	O

The	O
family	O
of	O
cyclosteroids	O
should	O
be	O
useful	O
for	O
future	O
structure	O
-	O
activity	O
relationship	O
studies	O
of	O
steroid	O
modulation	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
subtypes	O
.	O

Syntheses	O
of	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,3,3	I-IUPAC
-	I-IUPAC
trifluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
TFPe	O
-	O
dUrd	O
)	O
(	O
1	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,3,3	I-IUPAC
-	I-IUPAC
trifluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
11	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,3,3	I-IUPAC
-	I-IUPAC
trifluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
8	O
)	O
,	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,3,3	I-IUPAC
-	I-IUPAC
trifluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10	O
)	O
from	O
5	I-IUPAC
-	I-IUPAC
chloromercuri	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
are	O
described	O
.	O

The	O
antiviral	O
activity	O
of	O
TFPe	O
-	O
dUrd	O
was	O
determined	O
in	O
cell	O
culture	O
against	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
,	O
herpes	O
simplex	O
virus	O
type	O
2	O
(	O
HSV	O
-	O
2	O
)	O
,	O
and	O
vaccinia	O
virus	O
and	O
compared	O
concurrently	O
with	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
and	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
.	O

TFPe	O
-	O
dUrd	O
demonstrated	O
a	O
potent	O
and	O
unusually	O
selective	O
activity	O
against	O
HSV	O
-	O
1	O
,	O
with	O
a	O
2	O
-	O
log	O
reduction	O
in	O
virus	O
yield	O
at	O
0.03	O
micrograms	O
/	O
mL	O
(	O
0.09	O
microM	O
)	O
;	O
L	O
-	O
1210	O
cell	O
growth	O
was	O
inhibited	O
by	O
50%	O
only	O
at	O
290	O
micrograms	O
/	O
mL	O
.	O

Isopycnic	O
centrifugation	O
of	O
32P	O
-	O
labeled	O
DNA	O
indicated	O
that	O
if	O
0.5	O
or	O
2	O
microM	O
TFPe	O
-	O
dUrd	O
was	O
present	O
for	O
0-6	O
h	O
postinfection	O
,	O
viral	O
DNA	O
synthesis	O
was	O
reduced	O
by	O
ca.	O
50	O
and	O
85%	O
,	O
respectively	O
;	O
concomitantly	O
,	O
a	O
new	O
DNA	O
band	O
appeared	O
at	O
lower	O
density	O
than	O
normal	O
cellular	O
or	O
viral	O
DNA	O
.	O

This	O
paper	O
describes	O
the	O
synthesis	O
and	O
kappa	O
and	O
mu	O
opioid	O
receptor	O
binding	O
affinity	O
of	O
some	O
conformationally	O
restrained	O
derivatives	O
of	O
the	O
arylacetamide	O
group	O
in	O
the	O
selective	O
kappa	O
opioid	O
receptor	O
agonist	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetamide	I-IUPAC
monohydrochloride	I-IUPAC
(	O
1	O
,	O
PD117302	O
)	O
,	O
which	O
is	O
an	O
analogue	O
of	O
U	O
-	O
50	O
,	O
488	O
.	O

The	O
methyl	I-IUPAC
-	O
substituted	I-MODIFIER
derivatives	B-MODIFIER
(	B-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
benzo	I-IUPAC
-	I-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
acetamide	I-IUPAC
monohydrochloride	I-IUPAC
(	O
6a	O
,	O
b	O
)	O
possess	O
significantly	O
weaker	O
affinity	O
than	O
1	O
for	O
the	O
kappa	O
opioid	O
receptor	O
(	O
Ki	O
=	O
172	O
and	O
3.7	O
nM	O
,	O
respectively	O
)	O
.	O

It	O
is	O
proposed	O
that	O
this	O
is	O
due	O
to	O
the	O
conformational	O
restriction	O
imposed	O
by	O
the	O
methyl	I-IUPAC
group	B-MODIFIER
of	O
6	O
.	O

In	O
order	O
to	O
test	O
this	O
proposal	O
the	O
acenaphthene	O
derivative	O
and	O
the	O
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
derivative	I-MODIFIER
were	O
prepared	O
.	O

The	O
acenaphthene	I-IUPAC
derivative	B-MODIFIER
(	B-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxaspiro	I-IUPAC
[	I-IUPAC
4.5	I-IUPAC
]	I-IUPAC
dec	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
acenaphthenecarboxamide	I-IUPAC
monohydrochloride	I-IUPAC
(	O
9	O
)	O
was	O
found	O
to	O
have	O
high	O
kappa	O
opioid	O
receptor	O
affinity	O
and	O
selectivity	O
(	O
kappa	O
Ki	O
=	O
0.37	O
+	O
/	O
-	O
0.05	O
nM	O
,	O
mu	O
/	O
kappa	O
=	O
659	O
,	O
delta	O
/	O
kappa	O
=	O
1562	O
)	O
and	O
is	O
100	O
times	O
more	O
potent	O
than	O
morphine	O
as	O
an	O
analgesic	O
in	O
the	O
rat	O
paw	O
pressure	O
test	O
for	O
analgesia	O
after	O
intravenous	O
administration	O
(	O
MPE50	O
=	O
0.014	O
and	O
1.4	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
.	O

The	O
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
derivative	I-MODIFIER
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
7	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxaspiro	I-IUPAC
[	I-IUPAC
4.5	I-IUPAC
]	I-IUPAC
dec	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
naphthol	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluenesulfonate	I-IUPAC
(	O
17	O
)	O
also	O
has	O
high	O
kappa	O
opioid	O
receptor	O
affinity	O
and	O
selectivity	O
(	O
kappa	O
Ki	O
=	O
4.65	O
nM	O
,	O
mu	O
/	O
kappa	O
=	O
109	O
)	O
.	O

4	I-MODIFIER
-	I-MODIFIER
N	I-MODIFIER
-	I-MODIFIER
Substituted	B-MODIFIER
and	O
-	I-MODIFIER
unsubstituted	I-MODIFIER
3	I-PARTIUPAC
-	I-PARTIUPAC
alkyl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
thiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
were	O
synthesized	O
and	O
tested	O
vs	O
diazoxide	O
and	O
selected	O
3	I-PARTIUPAC
-	I-PARTIUPAC
alykl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzothiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
as	O
potassium	O
channel	O
openers	O
on	O
pancreatic	O
and	O
vascular	O
tissues	O
.	O

Several	O
4	I-MODIFIER
-	I-MODIFIER
N	I-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
pyridothiadiazines	I-IUPAC
and	O
some	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
chlorobenzothiadiazines	I-IUPAC
were	O
found	O
to	O
be	O
more	O
potent	O
than	O
diazoxide	O
for	O
the	O
inhibition	O
of	O
the	O
insulin	O
-	O
releasing	O
process	O
.	O

Moreover	O
,	O
the	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
pyridothiadiazines	I-IUPAC
appeared	O
to	O
be	O
more	O
selective	O
for	O
the	O
pancreatic	O
than	O
for	O
the	O
vascular	O
tissue	O
.	O

By	O
means	O
of	O
the	O
pharmacological	O
results	O
obtained	O
on	O
pancreatic	O
B	O
-	O
cells	O
,	O
structure	O
-	O
-	O
activity	O
relationships	O
were	O
deduced	O
and	O
a	O
pharmacophoric	O
model	O
for	O
the	O
interaction	O
of	O
these	O
drugs	O
with	O
their	O
receptor	O
site	O
associated	O
to	O
the	O
pancreatic	O
K	O
(	O
ATP	O
)	O
channel	O
was	O
proposed	O
.	O

According	O
to	O
their	O
selectivity	O
for	O
the	O
B	O
-	O
cell	O
(	O
endocrine	O
tissue	O
)	O
vs	O
the	O
vascular	O
(	O
smooth	O
muscle	O
tissue	O
)	O
ionic	O
channel	O
,	O
selected	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
alkylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4,3	I-IUPAC
-	I-IUPAC
e	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
,	I-IUPAC
-	I-IUPAC
thiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
may	O
serve	O
as	O
pharmacological	O
tools	O
in	O
studying	O
the	O
K	O
(	O
ATP	O
)	O
channels	O
(	O
"	O
pancreatic	O
-	O
like	O
"	O
K	O
(	O
ATP	O
)	O
channels	O
)	O
in	O
other	O
tissues	O
.	O

A	O
series	O
of	O
2,3	I-IUPAC
-	I-IUPAC
diaryl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
analogues	I-MODIFIER
substituted	B-MODIFIER
at	O
position	O
4	O
of	O
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
with	O
a	O
hydroxy	I-IUPAC
or	O
pyrrolidinoethoxy	I-IUPAC
residue	B-MODIFIER
were	O
synthesized	O
as	O
models	O
for	O
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
triarylpropenones	I-IUPAC
constrained	O
in	O
the	O
s	O
-	O
trans	O
conformation	O
.	O

The	O
prototypes	O
,	O
belonging	O
to	O
five	O
chemical	O
series	O
,	O
were	O
evaluated	O
for	O
their	O
estrogen	O
receptor	O
affinity	O
and	O
for	O
estrogen	O
agonist	O
-	O
antagonist	O
activities	O
.	O

The	O
4H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
the	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
the	O
4H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
,	O
and	O
the	O
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
derivatives	I-MODIFIER
were	O
found	O
to	O
be	O
inactive	O
or	O
only	O
marginally	O
activate	O
as	O
receptor	O
ligands	O
or	O
estrogen	O
agonists	O
-	O
antagonists	O
.	O

In	O
the	O
2H	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
category	O
the	O
parent	O
phenol	O
was	O
also	O
inactive	O
whereas	O
the	O
basic	O
ethers	O
16	O
and	O
26	O
were	O
modest	O
receptor	O
ligands	O
while	O
being	O
quite	O
active	O
as	O
antiestrogens	O
.	O

In	O
a	O
comparative	O
study	O
the	O
benzopyran	O
16	O
was	O
found	O
to	O
be	O
more	O
effective	O
antiestrogen	O
than	O
tamoxifen	O
while	O
being	O
as	O
effective	O
as	O
LY	O
-	O
117018	O
.	O

The	O
benzopyrans	O
have	O
thus	O
emerged	O
as	O
a	O
new	O
class	O
of	O
potent	O
antiestrogens	O
.	O

A	O
series	O
of	O
synthetic	O
estrogens	O
containing	O
hydroxyalkyl	O
side	O
chains	O
at	O
the	O
C	O
-	O
4	O
position	O
of	O
the	O
A	O
ring	O
were	O
designed	O
as	O
metabolically	O
stable	O
analogs	O
of	O
4	I-IUPAC
-	I-IUPAC
hydroxyestradiol	I-IUPAC
,	O
a	O
catechol	O
estrogen	O
.	O

These	O
synthetic	O
steroids	O
would	O
facilitate	O
investigations	O
on	O
the	O
potential	O
biological	O
role	O
of	O
catechol	O
estrogens	O
and	O
also	O
enable	O
further	O
examination	O
of	O
the	O
structural	O
and	O
electronic	O
constraints	O
on	O
the	O
A	O
ring	O
in	O
the	O
interaction	O
of	O
estrogens	O
with	O
the	O
estrogen	O
receptor	O
.	O

Catechol	O
estrogens	O
are	O
implicated	O
as	O
possible	O
causative	O
agents	O
in	O
estrogen	O
-	O
induced	O
tumorigenesis	O
.	O

4	I-IUPAC
-	I-IUPAC
Hydroxyestradiol	I-IUPAC
has	O
weaker	O
affinity	O
for	O
the	O
estrogen	O
receptor	O
and	O
exhibits	O
lower	O
estrogenic	O
activity	O
in	O
vivo	O
;	O
on	O
the	O
other	O
hand	O
,	O
the	O
catechol	O
estrogens	O
are	O
prone	O
to	O
further	O
oxidative	O
metabolism	O
and	O
can	O
form	O
reactive	O
intermediates	O
.	O

This	O
report	O
describes	O
the	O
synthesis	O
and	O
initial	O
biochemical	O
evaluation	O
of	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
estrogens	I-IUPAC
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
estradiols	I-IUPAC
.	O

The	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
estrogens	I-IUPAC
were	O
prepared	O
by	O
oxidative	O
hydroboration	O
of	O
4	I-IUPAC
-	I-IUPAC
alkenylestradiols	I-IUPAC
.	O

The	O
alkenylestradiols	O
were	O
obtained	O
via	O
a	O
Stille	O
cross	O
-	O
coupling	O
between	O
a	O
MOM	O
-	O
protected	O
4	I-IUPAC
-	I-IUPAC
bromoestradiol	I-IUPAC
and	O
an	O
alkenylstannane	O
.	O

The	O
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
estrogens	I-IUPAC
were	O
prepared	O
from	O
the	O
hydroxyalkyl	O
derivatives	O
with	O
phthalimide	O
under	O
Mitsunobu	O
conditions	O
.	O

The	O
substituted	O
estradiols	O
were	O
evaluated	O
for	O
estrogen	O
receptor	O
binding	O
activity	O
in	O
MCF	O
-	O
7	O
human	O
mammary	O
carcinoma	O
cells	O
,	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
estradiol	I-IUPAC
1	O
exhibited	O
the	O
highest	O
affinity	O
with	O
an	O
apparent	O
EC50	O
value	O
of	O
364	O
nM	O
.	O

The	O
relative	O
activities	O
for	O
mRNA	O
induction	O
of	O
the	O
pS2	O
gene	O
in	O
MCF	O
-	O
7	O
cell	O
cultures	O
by	O
the	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
estrogens	I-IUPAC
closely	O
parallel	O
the	O
relative	O
binding	O
affinities	O
.	O

4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Hydroxymethyl	I-IUPAC
)	I-IUPAC
estradiol	I-IUPAC
1	O
did	O
not	O
stimulate	O
the	O
growth	O
of	O
MCF	O
-	O
7	O
cells	O
at	O
concentrations	O
up	O
to	O
1	O
microM	O
.	O

Thus	O
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
estradiol	I-IUPAC
1	O
exhibited	O
similar	O
estrogen	O
receptor	O
affinity	O
as	O
the	O
catechol	O
estrogen	O
,	O
4	I-IUPAC
-	I-IUPAC
hydroxyestradiol	I-IUPAC
,	O
and	O
may	O
prove	O
useful	O
in	O
the	O
examination	O
of	O
the	O
biological	O
effects	O
of	O
4	I-IUPAC
-	I-IUPAC
hydroxyestrogens	I-IUPAC
.	O

A	O
library	O
of	O
compounds	O
were	O
prepared	O
by	O
reacting	O
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxide	I-IUPAC
(	O
5	O
)	O
with	O
commercially	O
available	O
carboxylic	O
acids	O
in	O
the	O
presence	O
of	O
potassium	O
carbonate	O
or	O
a	O
tertiary	O
amine	O
base	O
.	O

From	O
this	O
library	O
,	O
(	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
phenylmethoxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
alanate	I-IUPAC
(	O
7b	O
)	O
emerged	O
as	O
a	O
potent	O
inhibitor	O
of	O
human	O
mast	O
cell	O
tryptase	O
(	O
IC50	O
=	O
0.85	O
microM	O
)	O
.	O

Extension	O
of	O
the	O
side	O
chain	O
of	O
7b	O
by	O
two	O
carbons	O
gave	O
(	I-IUPAC
1	I-IUPAC
,	I-IUPAC
1	B-IUPAC
-	I-IUPAC
dioxido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
phenylmethoxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
pentanoate	I-IUPAC
(	O
7d	O
)	O
which	O
was	O
an	O
8	O
-	O
fold	O
more	O
potent	O
inhibitor	O
(	O
IC50	O
=	O
0.1	O
microM	O
)	O
.	O

Further	O
modification	O
of	O
this	O
series	O
produced	O
benzoic	O
acid	O
derivative	O
(	I-IUPAC
1	I-IUPAC
,	I-IUPAC
1	I-IUPAC
-	I-IUPAC
dioxido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
benzisothiazol	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
phenylmethoxy	I-IUPAC
)	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
7n	O
)	O
which	O
is	O
the	O
most	O
potent	O
inhibitor	O
identified	O
in	O
this	O
series	O
(	O
IC50	O
=	O
0.064	O
microM	O
)	O
.	O

These	O
compounds	O
exhibit	O
time	O
-	O
dependent	O
inhibition	O
consistent	O
with	O
mechanism	O
-	O
based	O
inhibition	O
.	O

For	O
7b	O
,	O
the	O
initial	O
enzyme	O
velocity	O
is	O
not	O
a	O
saturable	O
function	O
of	O
the	O
inhibitor	O
concentration	O
and	O
the	O
initial	O
Ki	O
could	O
not	O
be	O
determined	O
(	O
Ki	O
&	O
gt	O
;	O
10	O
microM	O
)	O
.	O

The	O
steady	O
-	O
state	O
rate	O
constant	O
,	O
Ki	O
,	O
was	O
determined	O
to	O
be	O
396	O
nM	O
.	O

On	O
the	O
other	O
hand	O
,	O
compounds	O
7d	O
and	O
7n	O
are	O
time	O
-	O
dependent	O
inhibitors	O
with	O
a	O
saturable	O
initial	O
complex	O
.	O

From	O
these	O
studies	O
,	O
an	O
initial	O
rate	O
constant	O
,	O
Ki	O
,	O
for	O
7d	O
and	O
7n	O
was	O
found	O
to	O
be	O
345	O
and	O
465	O
nM	O
,	O
respectively	O
.	O

The	O
steady	O
-	O
state	O
inhibition	O
constants	O
,	O
Ki	O
,	O
for	O
7d	O
and	O
7n	O
were	O
calculated	O
to	O
be	O
60	O
and	O
52	O
nM	O
,	O
respectively	O
.	O

Compound	O
7n	O
is	O
a	O
13	O
-	O
fold	O
more	O
potent	O
inhibitor	O
than	O
7b	O
,	O
and	O
these	O
kinetic	O
studies	O
indicate	O
that	O
the	O
increase	O
in	O
inhibitory	O
activity	O
is	O
due	O
to	O
an	O
increase	O
in	O
initial	O
affinity	O
toward	O
the	O
enzyme	O
and	O
not	O
an	O
increase	O
in	O
chemical	O
reactivity	O
.	O

These	O
inhibitors	O
generally	O
show	O
high	O
selectivity	O
for	O
tryptase	O
,	O
being	O
40	O
-	O
fold	O
weaker	O
inhibitors	O
of	O
elastase	O
,	O
being	O
100	O
-	O
fold	O
weaker	O
against	O
trypsin	O
,	O
and	O
showing	O
no	O
inhibition	O
against	O
thrombin	O
.	O

These	O
compounds	O
are	O
not	O
inhibitors	O
of	O
thrombin	O
,	O
plasmin	O
t	O
-	O
PA	O
,	O
urokinase	O
,	O
and	O
factor	O
Xa	O
(	O
IC50	O
&	O
gt	O
;	O
33	O
microM	O
)	O
.	O

In	O
the	O
delayed	O
-	O
type	O
hypersensitivity	O
(	O
DTH	O
)	O
mouse	O
model	O
,	O
a	O
model	O
of	O
skin	O
inflammation	O
,	O
a	O
5%	O
solution	O
of	O
7d	O
reduced	O
edema	O
by	O
69%	O
compared	O
to	O
control	O
animals	O
.	O

A	O
series	O
of	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylalkyl	I-IUPAC
)	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylglyoxylylamides	I-IUPAC
(	O
4-8	O
)	O
was	O
synthesized	O
as	O
ligands	O
of	O
the	O
benzodiazepine	O
receptor	O
(	O
BzR	O
)	O
and	O
tested	O
for	O
their	O
ability	O
to	O
displace	O
[	O
(	O
3	O
)	O
H	O
]	O
flumazenil	O
from	O
bovine	O
brain	O
membranes	O
.	O

The	O
new	O
compounds	O
,	O
bearing	O
a	O
branched	O
(	O
4	O
)	O
or	O
a	O
geometrically	O
constrained	O
benzyl	I-IUPAC
/	O
phenylethyl	I-IUPAC
amide	I-IUPAC
side	I-MODIFIER
chain	I-MODIFIER
(	O
5-8	O
)	O
,	O
represent	O
the	O
continuation	O
of	O
our	O
research	O
on	O
N	I-IUPAC
-	I-IUPAC
benzylindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylglyoxylylamides	I-IUPAC
1	O
(	O
Da	O
Settimo	O
et	O
al.	O
,	O
1996	O
)	O
,	O
N'	I-IUPAC
-	I-IUPAC
phenylindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylglyoxylohydrazides	I-IUPAC
2	O
(	O
Da	O
Settimo	O
et	O
al.	O
,	O
1998	O
)	O
,	O
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylglyoxylyl	I-IUPAC
)	I-IUPAC
alanine	I-IUPAC
derivatives	I-MODIFIER
3	O
(	O
Primofiore	O
et	O
al.	O
,	O
1989	O
)	O
.	O

A	O
few	O
indoles	O
belonging	O
to	O
the	O
previously	O
investigated	O
benzylamides	O
1	O
and	O
phenylhydrazides	O
2	O
were	O
synthesized	O
and	O
tested	O
to	O
enrich	O
the	O
SARs	O
in	O
these	O
two	O
series	O
.	O

The	O
affinities	O
and	O
the	O
GABA	O
ratios	O
of	O
selected	O
compounds	O
for	O
clonal	O
mammalian	O
alpha	O
(	O
1	O
)	O
beta	O
(	O
2	O
)	O
gamma	O
(	O
2	O
)	O
,	O
alpha	O
(	O
3	O
)	O
beta	O
(	O
2	O
)	O
gamma	O
(	O
2	O
)	O
,	O
and	O
alpha	O
(	O
5	O
)	O
beta	O
(	O
3	O
)	O
gamma	O
(	O
2	O
)	O
BzR	O
subtypes	O
were	O
also	O
determined	O
.	O

It	O
was	O
hypothesized	O
that	O
the	O
reduced	O
flexibility	O
of	O
indoles	O
4-8	O
would	O
both	O
facilitate	O
the	O
mapping	O
of	O
the	O
BzR	O
binding	O
cleft	O
and	O
increase	O
the	O
chances	O
of	O
conferring	O
selectivity	O
for	O
the	O
considered	O
receptor	O
subtypes	O
.	O

In	O
the	O
series	O
of	O
indoles	O
4	O
,	O
the	O
introduction	O
of	O
a	O
methyl	I-IUPAC
group	B-MODIFIER
on	O
the	O
benzylic	O
carbon	O
with	O
the	O
R	O
configuration	O
improved	O
affinity	O
of	O
the	O
5	O
-	O
substituted	O
(	O
5	O
-	O
Cl	O
and	O
5	O
-	O
NO	O
(	O
2	O
)	O
)	O
derivatives	O
,	O
whereas	O
it	O
was	O
detrimental	O
for	O
their	O
5	O
-	O
unsubtituted	O
(	O
5	O
-	O
H	O
)	O
counterparts	O
.	O

All	O
S	O
enantiomers	O
were	O
less	O
potent	O
than	O
the	O
R	O
ones	O
.	O

Replacement	O
of	O
the	O
methyl	O
with	O
hydrophilic	O
substituents	O
on	O
the	O
benzylic	O
carbon	O
lowered	O
affinity	O
.	O

The	O
isoindolinylamide	I-IUPAC
side	B-MODIFIER
chain	I-MODIFIER
was	O
tolerated	O
if	O
the	O
5	O
-	O
position	O
was	O
unsubstituted	O
(	O
K	O
(	O
i	O
)	O
of	O
5a	O
=	O
123	O
nM	O
)	O
,	O
otherwise	O
affinity	O
was	O
abolished	O
(	O
5b	O
,	O
c	O
)	O
.	O

All	O
the	O
2	I-IUPAC
-	I-IUPAC
indanylamides	I-IUPAC
6	O
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
indanylamides	I-IUPAC
8	O
were	O
devoid	O
of	O
any	O
appreciable	O
affinity	O
.	O

The	O
5	I-PARTIUPAC
-	I-PARTIUPAC
Cl	I-PARTIUPAC
and	O
5	I-IUPAC
-	I-IUPAC
NO	I-IUPAC
(	I-IUPAC
2	I-IUPAC
)	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
indanylamides	I-IUPAC
7b	O
(	O
K	O
(	O
i	O
)	O
80	O
nM	O
)	O
and	O
7c	O
(	O
K	O
(	O
i	O
)	O
28	O
nM	O
)	O
were	O
the	O
most	O
potent	O
among	O
the	O
indoles	O
5-8	O
geometrically	O
constrained	O
about	O
the	O
side	O
chain	O
.	O

The	O
5	I-IUPAC
-	I-IUPAC
H	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
indanylamide	I-IUPAC
7a	O
displayed	O
a	O
lower	O
affinity	O
(	O
K	O
(	O
i	O
)	O
675	O
nM	O
)	O
.	O

The	O
SARs	O
developed	O
from	O
the	O
new	O
compounds	O
,	O
together	O
with	O
those	O
collected	O
from	O
our	O
previous	O
studies	O
,	O
confirmed	O
the	O
hypothesis	O
of	O
different	O
binding	O
modes	O
for	O
5	O
-	O
substituted	O
and	O
5	O
-	O
unsubstituted	O
indoles	O
,	O
suggesting	O
that	O
the	O
shape	O
of	O
the	O
lipophilic	O
pocket	O
L	O
(	O
1	O
)	O
(	O
notation	O
in	O
accordance	O
with	O
Cook	O
's	O
BzR	O
topological	O
model	O
)	O
is	O
asymmetric	O
and	O
highlighted	O
the	O
stereoelectronic	O
and	O
conformational	O
properties	O
of	O
the	O
amide	O
side	O
chain	O
required	O
for	O
high	O
potency	O
.	O

Several	O
of	O
the	O
new	O
indoles	O
showed	O
selectivity	O
for	O
the	O
alpha	O
(	O
1	O
)	O
beta	O
(	O
2	O
)	O
gamma	O
(	O
2	O
)	O
subtype	O
compared	O
with	O
the	O
alpha	O
(	O
3	O
)	O
beta	O
(	O
2	O
)	O
gamma	O
(	O
2	O
)	O
and	O
alpha	O
(	O
5	O
)	O
beta	O
(	O
3	O
)	O
gamma	O
(	O
2	O
)	O
subtypes	O
(	O
e.g.	O
:	O
4t	O
and	O
7c	O
bind	O
to	O
these	O
three	O
BzR	O
isoforms	O
with	O
K	O
(	O
i	O
)	O
values	O
of	O
14	O
nM	O
,	O
283	O
nM	O
,	O
239	O
nM	O
,	O
and	O
9	O
nM	O
,	O
1960	O
nM	O
,	O
95	O
nM	O
,	O
respectively	O
)	O
.	O

The	O
GABA	O
ratios	O
close	O
to	O
unity	O
exhibited	O
by	O
all	O
the	O
tested	O
compounds	O
on	O
each	O
BzR	O
subtype	O
were	O
predictive	O
of	O
an	O
efficacy	O
profile	O
typical	O
of	O
antagonists	O
.	O

A	O
series	O
of	O
new	O
S	I-IUPAC
-	I-IUPAC
adenosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
(	O
AdoHcy	O
)	O
analogues	I-MODIFIER
with	O
modifications	O
to	O
amino	O
acid	O
and	O
nucleoside	O
moieties	O
was	O
prepared	O
via	O
condensation	O
of	O
appropriate	O
nucleoside	O
precursors	O
and	O
suitably	O
protected	O
L	O
-	O
homocystine	O
derivatives	O
.	O

The	O
AdoHcy	O
derivatives	O
as	O
well	O
as	O
the	O
nucleoside	O
precursors	O
were	O
evaluated	O
for	O
their	O
antiviral	O
activity	O
.	O

Some	O
of	O
the	O
compounds	O
,	O
in	O
particular	O
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
propyl	I-IUPAC
ester	I-IUPAC
(	O
36	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
isopropyl	I-IUPAC
ester	I-IUPAC
(	O
27	O
)	O
,	O
S	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxytubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
(	O
58	O
)	O
,	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoracetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
propyl	I-IUPAC
ester	I-IUPAC
(	O
26	O
)	O
,	O
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methoxyacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
ethyl	I-IUPAC
ester	I-IUPAC
(	O
31	O
)	O
showed	O
potent	O
and	O
selective	O
activity	O
against	O
HSV	O
,	O
VV	O
,	O
and	O
VSV	O
.	O

It	O
is	O
likely	O
that	O
they	O
exert	O
their	O
antiviral	O
effect	O
via	O
selective	O
inhibition	O
of	O
the	O
methyltransferases	O
which	O
are	O
required	O
for	O
the	O
maturation	O
of	O
viral	O
mRNAs	O
.	O

As	O
part	O
of	O
a	O
search	O
for	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
inhibitors	O
combining	O
the	O
high	O
potency	O
of	O
piritrexim	O
(	O
PTX	O
)	O
with	O
the	O
high	O
antiparasitic	O
vs	O
mammalian	O
selectivity	O
of	O
trimethoprim	O
(	O
TMP	O
)	O
,	O
the	O
heretofore	O
undescribed	O
2,4	I-PARTIUPAC
-	I-PARTIUPAC
diamino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2'	I-MODIFIER
,	I-MODIFIER
5'	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
benzyl	I-PARTIUPAC
)	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
2,3	I-PARTIUPAC
-	I-PARTIUPAC
d	I-PARTIUPAC
]	I-PARTIUPAC
pyrimidines	I-PARTIUPAC
6-14	O
with	O
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
or	O
omega	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
alkynyl	I-IUPAC
groups	I-MODIFIER
on	O
the	O
benzyl	I-IUPAC
moiety	B-MODIFIER
were	O
synthesized	O
and	O
tested	O
against	O
Pneumocystis	O
carinii	O
,	O
Toxoplasma	O
gondii	O
,	O
and	O
Mycobacterium	O
avium	O
DHFR	O
vs	O
rat	O
DHFR	O
.	O

Three	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diaminopteridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
alkynyl	I-IUPAC
)	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepines	I-IUPAC
(	O
19-21	O
)	O
were	O
also	O
synthesized	O
and	O
tested	O
.	O

The	O
pyridopyrimidine	O
with	O
the	O
best	O
combination	O
of	O
potency	O
and	O
selectivity	O
was	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butynyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
]	I-IUPAC
benzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
13	O
)	O
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
0.65	O
nM	O
against	O
P	O
.	O

carinii	O
DHFR	O
,	O
0.57	O
nM	O
against	O
M	O
.	O

avium	O
DHFR	O
,	O
and	O
55	O
nM	O
against	O
rat	O
DHFR	O
.	O

The	O
potency	O
of	O
13	O
against	O
P	O
.	O

carinii	O
DHFR	O
was	O
20	O
-	O
fold	O
greater	O
than	O
that	O
of	O
PTX	O
(	O
IC	O
(	O
50	O
)	O
=	O
13	O
nM	O
)	O
,	O
and	O
its	O
selectivity	O
index	O
(	O
SI	O
)	O
relative	O
to	O
rat	O
DHFR	O
was	O
85	O
,	O
whereas	O
PTX	O
was	O
nonselective	O
.	O

The	O
activity	O
of	O
13	O
against	O
P	O
.	O

carinii	O
DHFR	O
was	O
20	O
000	O
times	O
greater	O
than	O
that	O
of	O
TMP	O
,	O
with	O
an	O
SI	O
of	O
96	O
,	O
whereas	O
that	O
of	O
TMP	O
was	O
only	O
14	O
.	O

However	O
13	O
was	O
no	O
more	O
potent	O
than	O
PTX	O
against	O
M	O
.	O

avium	O
DHFR	O
,	O
and	O
its	O
SI	O
was	O
no	O
better	O
than	O
that	O
of	O
TMP	O
.	O

Molecular	O
modeling	O
dynamics	O
studies	O
using	O
compounds	O
10	O
and	O
13	O
indicated	O
a	O
slight	O
binding	O
preference	O
for	O
the	O
latter	O
,	O
in	O
qualitative	O
agreement	O
with	O
the	O
IC	O
(	O
50	O
)	O
data	O
.	O

Among	O
the	O
pteridines	O
,	O
the	O
most	O
potent	O
against	O
P	O
.	O

carinii	O
DHFR	O
and	O
M	O
.	O

avium	O
DHFR	O
was	O
the	O
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butynyl	I-IUPAC
)	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepinyl	I-IUPAC
derivative	I-MODIFIER
20	O
(	O
IC	O
(	O
50	O
)	O
=	O
2.9	O
nM	O
)	O
,	O
whereas	O
the	O
most	O
selective	O
was	O
the	O
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pentynyl	I-IUPAC
)	I-IUPAC
analogue	I-MODIFIER
21	O
,	O
with	O
SI	O
values	O
of	O
&	O
gt	O
;	O
100	O
against	O
both	O
P	O
.	O

carinii	O
and	O
M	O
.	O

avium	O
DHFR	O
relative	O
to	O
rat	O
DHFR	O
.	O

The	O
final	O
compound	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butynyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
22	O
)	O
,	O
was	O
both	O
potent	O
and	O
selective	O
against	O
M	O
.	O

avium	O
DHFR	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.47	O
nM	O
,	O
SI	O
=	O
1300	O
)	O
but	O
was	O
not	O
potent	O
or	O
selective	O
against	O
either	O
P	O
.	O

carinii	O
or	O
T	O
.	O

gondii	O
DHFR	O
.	O

6	I-IUPAC
-	I-IUPAC
Hydroxypyrimidines	I-IUPAC
substituted	I-MODIFIER
at	O
positions	O
2	O
and	O
4	O
by	O
hydrogen	O
,	O
methyl	O
,	O
amino	O
,	O
cyclopropylamino	O
,	O
dimethylamino	O
,	O
methylsulfanyl	O
,	O
or	O
hydroxyl	O
group	O
afford	O
by	O
the	O
reaction	O
with	O
diisopropyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloroethoxy	I-IUPAC
)	I-IUPAC
methylphosphonate	I-IUPAC
in	O
the	O
presence	O
of	O
NaH	O
,	O
Cs	O
(	O
2	O
)	O
CO	O
(	O
3	O
)	O
,	O
or	O
DBU	O
a	O
mixture	O
of	O
N	I-PARTIUPAC
(	I-PARTIUPAC
1	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
O	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diisopropylphosphorylmethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
isomers	I-MODIFIER
which	O
were	O
converted	O
to	O
the	O
free	O
phosphonic	O
acids	O
by	O
treatment	O
with	O
bromotrimethylsilane	O
followed	O
by	O
hydrolysis	O
.	O

Analogously	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxypyrimidine	I-IUPAC
gave	O
on	O
reaction	O
with	O
[	O
(	I-PARTIUPAC
R	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diisopropylphosphorylmethoxy	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	O
tosylate	I-MODIFIER
,	O
followed	O
by	O
deprotection	O
,	O
the	O
enantiomeric	O
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
propoxy	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O

2,4	I-IUPAC
-	I-IUPAC
Diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
sulfanylpyrimidine	I-IUPAC
gave	O
,	O
on	O
treatment	O
with	O
diisopropyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloroethoxy	I-IUPAC
)	I-IUPAC
methylphosphonate	I-IUPAC
in	O
the	O
presence	O
of	O
NaH	O
and	O
subsequent	O
deprotection	O
,	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
sulfanyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
.	O

2	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
was	O
obtained	O
from	O
the	O
appropriate	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloropyrimidine	I-IUPAC
derivative	I-MODIFIER
by	O
alkaline	O
hydrolysis	O
and	O
ester	O
cleavage	O
.	O

Direct	O
alkylation	O
of	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4,6	I-IUPAC
-	I-IUPAC
dihydroxypyrimidine	I-IUPAC
afforded	O
a	O
mixture	O
of	O
2	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
4,6	I-PARTIUPAC
-	I-PARTIUPAC
bis	I-PARTIUPAC
[	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
phosphonomethoxy	I-PARTIUPAC
)	I-PARTIUPAC
ethyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
.	O

None	O
of	O
the	O
N	I-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
isomers	I-MODIFIER
exhibited	O
any	O
antiviral	O
activity	O
against	O
DNA	O
viruses	O
or	O
RNA	O
viruses	O
tested	O
in	O
vitro	O
.	O

On	O
the	O
contrary	O
,	O
the	O
O	O
(	O
6	O
)	O
-	O
isomers	O
,	O
namely	O
the	O
compounds	O
derived	O
from	O
2,4	I-PARTIUPAC
-	I-PARTIUPAC
diamino	I-PARTIUPAC
-	I-PARTIUPAC
,	O
2	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
or	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxypyrimidine	I-IUPAC
,	O
inhibited	O
the	O
replication	O
of	O
herpes	O
viruses	O
[	O
herpes	O
simplex	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
and	O
type	O
2	O
(	O
HSV	O
-	O
2	O
)	O
,	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)	O
,	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
]	O
and	O
retroviruses	O
[	O
Moloney	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
and	O
type	O
2	O
(	O
HIV	O
-	O
2	O
)	O
]	O
,	O
their	O
activity	O
being	O
most	O
pronounced	O
against	O
the	O
latter	O
.	O

The	O
antiviral	O
activity	O
was	O
lower	O
if	O
the	O
oxygen	O
at	O
the	O
position	O
6	O
was	O
replaced	O
by	O
a	O
sulfur	O
atom	O
,	O
as	O
in	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethylsulfanyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
.	O

In	O
analogy	O
to	O
N	I-IUPAC
(	I-IUPAC
9	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
(	O
PMPDAP	O
)	O
,	O
solely	O
the	O
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
propoxy	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
exerted	O
antiviral	O
activity	O
,	O
whereas	O
its	O
(	O
S	O
)	O
-	O
enantiomer	O
was	O
essentially	O
inactive	O
.	O

Twenty	O
-	O
six	O
compounds	O
derived	O
from	O
the	O
5	I-PARTIUPAC
-	I-PARTIUPAC
deaza	I-PARTIUPAC
-	I-PARTIUPAC
and	O
5,10	I-IUPAC
-	I-IUPAC
dideazaaminopterin	I-IUPAC
series	I-MODIFIER
of	O
aminopterin	O
analogues	O
were	O
evaluated	O
for	O
antiarthritic	O
activity	O
in	O
the	O
mouse	O
type	O
II	O
collagen	O
model	O
.	O

New	O
compounds	O
in	O
the	O
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
series	I-MODIFIER
were	O
prepared	O
by	O
alkylation	O
of	O
an	O
appropriate	O
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
dialkyl	I-IUPAC
ester	I-IUPAC
or	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thenoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
diester	I-IUPAC
with	O
a	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazapteridine	I-IUPAC
.	O

The	O
resultant	O
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
diesters	I-IUPAC
were	O
saponified	O
to	O
provide	O
the	O
target	O
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogues	I-MODIFIER
.	O

5,10	I-IUPAC
-	I-IUPAC
Dideazaaminopterins	I-IUPAC
were	O
synthesized	O
by	O
similar	O
alkylation	O
of	O
the	O
carbanions	O
of	O
appropriate	O
4	I-PARTIUPAC
-	I-PARTIUPAC
carboxyphenylacetic	I-PARTIUPAC
,	O
(	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
carboxy	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
thienyl	I-PARTIUPAC
)	I-PARTIUPAC
acetic	I-PARTIUPAC
,	O
or	O
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
acetic	I-IUPAC
acid	I-IUPAC
dimethyl	I-IUPAC
esters	I-IUPAC
.	O

The	O
diesters	O
of	O
the	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acid	I-IUPAC
types	O
so	O
obtained	O
were	O
saponified	O
and	O
then	O
readily	O
decarboxylated	O
by	O
heating	O
in	O
Me2SO	O
solution	O
to	O
provide	O
the	O
2,4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5,10	I-IUPAC
-	I-IUPAC
dideazapteroic	I-IUPAC
acid	I-IUPAC
-	O
type	O
intermediates	O
.	O

Peptide	O
coupling	O
with	O
diethyl	O
L	O
-	O
glutamate	O
followed	O
by	O
ester	O
hydrolysis	O
at	O
room	O
temperature	O
afforded	O
the	O
new	O
5,10	I-IUPAC
-	I-IUPAC
dideazaaminopterin	I-IUPAC
analogues	I-MODIFIER
.	O

5	I-IUPAC
-	I-IUPAC
Deazaaminopterins	I-IUPAC
bearing	O
an	O
alkyl	O
substituent	O
at	O
the	O
5	O
-	O
position	O
were	O
generally	O
quite	O
effective	O
as	O
antiinflammatory	O
agents	O
.	O

Thus	O
5	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
propargyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
,	O
5	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazamethotrexate	I-IUPAC
,	O
and	O
2,5	I-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
thiophene	I-IUPAC
analogue	B-MODIFIER
of	O
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
showed	O
potencies	O
greater	O
than	O
methotrexate	O
by	O
intraperitoneal	O
or	O
oral	O
administration	O
and	O
were	O
active	O
over	O
a	O
considerably	O
broader	O
dose	O
range	O
.	O

Useful	O
activity	O
in	O
the	O
5,10	I-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
series	I-MODIFIER
was	O
only	O
observed	O
for	O
5,10	I-IUPAC
-	I-IUPAC
dideazaaminopterin	I-IUPAC
and	O
its	O
10	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	I-MODIFIER
.	O

Alkyl	O
substitution	O
at	O
C	O
-	O
5	O
or	O
C	O
-	O
10	O
was	O
generally	O
detrimental	O
to	O
antiinflammatory	O
activity	O
in	O
this	O
series	O
.	O

The	O
synthesis	O
and	O
pharmacological	O
activities	O
of	O
the	O
four	O
stereoisomers	O
of	O
methyl	I-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dicarboxylate	I-IUPAC
(	I-IUPAC
furnidipine	I-IUPAC
)	I-IUPAC
are	O
reported	O
.	O

The	O
four	O
isomers	O
were	O
synthesized	O
by	O
a	O
modified	O
Hantzsch	O
synthesis	O
by	O
reaction	O
of	O
(	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
or	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminocrotonate	I-IUPAC
and	O
methyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
]	I-IUPAC
acetoacetate	I-IUPAC
or	O
,	O
alternatively	O
,	O
by	O
reaction	O
of	O
(	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
or	O
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
]	I-IUPAC
acetoacetate	I-IUPAC
and	O
methyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminocrotonate	I-IUPAC
.	O

The	O
1	O
:	O
1	O
diastereomeric	O
mixtures	O
thus	O
obtained	O
were	O
separated	O
by	O
chromatography	O
,	O
using	O
poly	O
(	O
D	O
-	O
phenylglycine	O
)	O
as	O
the	O
chiral	O
stationary	O
phase	O
.	O

The	O
enantiomeric	O
purity	O
of	O
the	O
stereoisomers	O
was	O
determined	O
by	O
a	O
high	O
-	O
performance	O
liquid	O
chromatography	O
-	O
chiral	O
stationary	O
phase	O
technique	O
(	O
HPLC	O
-	O
CSP	O
)	O
.	O

Attempts	O
to	O
obtain	O
crystals	O
of	O
a	O
single	O
stereoisomer	O
failed	O
in	O
different	O
solvents	O
,	O
while	O
methanol	O
crystallization	O
of	O
the	O
product	O
obtained	O
from	O
(	I-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
]	I-IUPAC
acetoacetate	I-IUPAC
and	O
methyl	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminocrotonate	I-IUPAC
yielded	O
good	O
-	O
quality	O
crystals	O
of	O
the	O
most	O
insoluble	O
racemate	O
which	O
proved	O
to	O
be	O
a	O
mixture	O
of	O
the	O
(	O
SS	O
)	O
/	O
(	O
RR	O
)	O
enantiomers	O
by	O
X	O
-	O
ray	O
crystallography	O
.	O

Conformational	O
analysis	O
of	O
the	O
stereoisomers	O
,	O
assuming	O
rotation	O
of	O
the	O
aryl	O
substituent	O
and	O
ester	O
groups	O
,	O
shows	O
small	O
energy	O
differences	O
(	O
about	O
4	O
kcal	O
.	O

mol	O
-	O
1	O
)	O
between	O
the	O
most	O
and	O
the	O
least	O
favorable	O
conformations	O
.	O

Binding	O
studies	O
were	O
performed	O
using	O
[	O
3H	O
]	O
isradipine	O
as	O
a	O
reference	O
ligand	O
.	O

The	O
results	O
showed	O
stereospecificity	O
of	O
the	O
furnidipine	O
isomers	O
in	O
brain	O
,	O
ileum	O
,	O
and	O
cardiac	O
tissues	O
,	O
the	O
(	O
SS	O
)	O
-	O
and	O
(	O
SR	O
)	O
-	O
isomers	O
clearly	O
being	O
more	O
potent	O
than	O
their	O
(	O
RR	O
)	O
-	O
and	O
(	O
RS	O
)	O
-	O
enantiomers	O
.	O

The	O
(	O
SS	O
)	O
-	O
and	O
(	O
SR	O
)	O
-	O
isomers	O
were	O
also	O
more	O
selective	O
on	O
cerebral	O
tissue	O
when	O
compared	O
with	O
ileal	O
and	O
cardiac	O
preparations	O
.	O

Synthesis	O
and	O
biological	O
activities	O
of	O
12	O
analogs	O
of	O
N6	I-IUPAC
-	I-IUPAC
benzyladenosine	I-IUPAC
are	O
described	O
.	O

The	O
compounds	O
were	O
prepared	O
by	O
two	O
methods	O
:	O
(	O
1	O
)	O
direct	O
alkylation	O
of	O
adenosine	O
with	O
an	O
appropriately	O
substituted	O
benzyl	O
bromide	O
to	O
give	O
the	O
N1	O
-	O
substituted	O
derivative	O
which	O
was	O
then	O
rearranged	O
in	O
base	O
to	O
give	O
the	O
N6	O
-	O
substituted	O
compound	O
,	O
and	O
(	O
2	O
)	O
by	O
nucleophilic	O
displacement	O
of	O
chlorine	O
in	O
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
ribonucleoside	I-MODIFIER
,	O
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopurine	I-IUPAC
ribonucleoside	I-MODIFIER
,	O
and	O
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopurine	I-IUPAC
with	O
an	O
amine	O
.	O

These	O
analogs	O
were	O
examined	O
for	O
their	O
growth	O
inhibitory	O
effect	O
in	O
cultured	O
leukemic	O
cells	O
and	O
also	O
for	O
their	O
effect	O
on	O
adenosine	O
aminohydrolase	O
activity	O
.	O

N6	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
Nitrobenzyladenosine	I-IUPAC
and	O
its	O
2'	O
-	O
deoxy	O
analog	O
were	O
competitive	O
inhibitors	O
(	O
K1	O
65	O
,	O
22	O
MUM	O
)	O
.	O

The	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyladenine	I-IUPAC
and	O
its	O
ribonucleoside	O
were	O
found	O
to	O
be	O
noncompetitive	O
inhibitors	O
of	O
adenosine	O
aminohydrolase	O
.	O

In	O
cultured	O
L1210	O
leukemia	O
,	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzylaminopurine	I-IUPAC
and	O
the	O
corresponding	O
ribonucleoside	O
were	O
better	O
growth	O
inhibitors	O
than	O
N6	I-IUPAC
-	I-IUPAC
benzyladenosine	I-IUPAC
,	O
while	O
N6	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyladenosine	I-IUPAC
,	O
its	O
2'	O
-	O
deoxy	O
analog	O
,	O
and	O
N6	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
fluorobenzyladenosine	I-IUPAC
were	O
as	O
active	O
as	O
N6	I-IUPAC
-	I-IUPAC
benzyladenosine	I-IUPAC
.	O

Numerous	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylanilino	I-IUPAC
)	I-IUPAC
uracils	I-IUPAC
(	O
EMAU	O
)	O
have	O
been	O
synthesized	O
and	O
screened	O
for	O
their	O
capacity	O
to	O
inhibit	O
the	O
replication	O
-	O
specific	O
bacterial	O
DNA	O
polymerase	O
IIIC	O
(	O
pol	O
IIIC	O
)	O
and	O
the	O
growth	O
of	O
Gram+	O
bacteria	O
in	O
culture	O
.	O

Direct	O
alkylation	O
of	O
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyrimidone	I-IUPAC
produced	O
the	O
N3	O
-	O
substituted	O
derivatives	O
,	O
which	O
were	O
separated	O
from	O
the	O
byproduct	O
4	I-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
analogues	I-MODIFIER
.	O

The	O
N3	O
-	O
substituted	O
derivatives	O
were	O
heated	O
with	O
a	O
mixture	O
of	O
3	I-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylaniline	I-IUPAC
and	O
its	O
hydrochloride	O
to	O
effect	O
displacement	O
of	O
the	O
6	O
-	O
amino	O
group	O
and	O
simultaneous	O
demethylation	O
of	O
the	O
2	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
group	I-MODIFIER
to	O
yield	O
target	O
compounds	O
in	O
good	O
yields	O
.	O

Certain	O
intermediates	O
,	O
e.g.	O
the	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodoalkyl	I-IUPAC
)	I-IUPAC
compounds	I-MODIFIER
,	O
were	O
converted	O
to	O
a	O
variety	O
of	O
(	O
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
alkyl	I-IUPAC
)	O
-	O
EMAUs	O
by	O
displacement	O
.	O

Most	O
compounds	O
were	O
potent	O
competitive	O
inhibitors	O
of	O
pol	O
IIIC	O
(	O
K	O
(	O
i	O
)	O
s	O
0.02-0.5	O
microM	O
)	O
,	O
and	O
those	O
with	O
neutral	O
,	O
moderately	O
polar	O
3	O
-	O
substituents	O
had	O
potent	O
antibacterial	O
activity	O
against	O
Gram+	O
organisms	O
in	O
culture	O
(	O
MICs	O
0.125-10	O
microg	O
/	O
mL	O
)	O
.	O

Several	O
compounds	O
protected	O
mice	O
from	O
lethal	O
intraperitoneal	O
(	O
ip	O
)	O
infections	O
with	O
S	O
.	O

aureus	O
(	O
Smith	O
)	O
when	O
given	O
by	O
the	O
ip	O
route	O
.	O

A	O
water	O
soluble	O
derivative	O
,	O
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
morpholinylbutyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
EMAU	I-IUPAC
hydrochloride	I-IUPAC
,	O
given	O
subcutaneously	O
,	O
prolonged	O
the	O
life	O
of	O
infected	O
mice	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

The	O
synthesis	O
and	O
structure	O
-	O
activity	O
relationship	O
of	O
a	O
series	O
of	O
4	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acids	I-IUPAC
and	O
esters	I-PARTIUPAC
and	O
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acids	I-IUPAC
and	O
esters	I-PARTIUPAC
as	O
potent	O
inhibitors	O
of	O
kynurenine	O
-	O
3	O
-	O
hydroxylase	O
are	O
described	O
.	O

These	O
compounds	O
are	O
the	O
most	O
potent	O
inhibitors	O
of	O
the	O
kynurenine	O
-	O
3	O
-	O
hydroxylase	O
enzyme	O
so	O
far	O
disclosed	O
.	O

Additionally	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoate	I-IUPAC
(	O
2d	O
)	O
,	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acid	I-IUPAC
(	O
3d	O
)	O
,	O
methyl	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoate	I-IUPAC
(	O
2f	O
)	O
,	O
and	O
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acid	I-IUPAC
(	O
3f	O
)	O
prevent	O
the	O
increase	O
in	O
the	O
interferon	O
-	O
gamma	O
-	O
induced	O
synthesis	O
of	O
quinolinic	O
acid	O
in	O
primary	O
cultures	O
of	O
cultured	O
human	O
peripheral	O
blood	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

The	O
present	O
work	O
reports	O
the	O
synthesis	O
of	O
enantiomeric	O
pairs	O
of	O
the	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indene	I-IUPAC
[	O
(	O
+	O
)	O
-	O
14a	O
,	O
(	O
-	O
)	O
-	O
14a	O
]	O
and	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
H	I-IUPAC
-	I-IUPAC
indene	I-IUPAC
[	O
(	O
+	O
)	O
-	O
14b	O
,	O
(	O
-	O
)	O
-	O
14b	O
]	O
and	O
their	O
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
[	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
15a	O
,	O
b	O
]	O
,	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
[	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
16a	O
,	O
b	O
]	O
,	O
and	O
N	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
[	O
(	O
+	O
)	O
and	O
(	O
-	O
)	O
-	O
17a	O
,	O
b	O
]	O
derivatives	I-MODIFIER
obtained	O
by	O
a	O
combination	O
of	O
stereospecific	O
reactions	O
and	O
optical	O
resolution	O
.	O

The	O
new	O
compounds	O
were	O
evaluated	O
for	O
their	O
affinity	O
at	O
the	O
dopamine	O
D1	O
and	O
D2	O
receptors	O
.	O

The	O
amines	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
14a	O
,	O
incorporating	O
the	O
D1	O
pharmacophore	O
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
ethylamine	I-IUPAC
in	O
a	O
trans	O
extended	O
conformation	O
,	O
and	O
their	O
derivatives	O
displayed	O
D1	O
and	O
D2	O
affinity	O
in	O
the	O
nanomolar	O
range	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
enantiomers	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
14b	O
,	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
15b	O
displayed	O
high	O
affinity	O
and	O
selectivity	O
for	O
the	O
D1	O
receptor	O
.	O

In	O
a	O
preliminary	O
behavioral	O
study	O
on	O
rats	O
(	O
+	O
)	O
-	O
14b	O
,	O
and	O
to	O
a	O
greater	O
extent	O
(	O
+	O
)	O
-	O
15b	O
,	O
promoted	O
episodes	O
of	O
intense	O
grooming	O
,	O
thus	O
indicating	O
that	O
they	O
act	O
as	O
central	O
D1	O
agonists	O
.	O

The	O
trans	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indenes	I-IUPAC
(	O
+	O
)	O
-	O
14b	O
and	O
(	O
+	O
)	O
-	O
15b	O
represent	O
selective	O
D1	O
agonists	O
lacking	O
a	O
catechol	O
group	O
,	O
which	O
should	O
meet	O
the	O
prerequisites	O
for	O
a	O
central	O
nervous	O
system	O
penetration	O
.	O

A	O
series	O
of	O
4	I-IUPAC
-	I-IUPAC
phenylisoquinolone	I-IUPAC
derivatives	I-MODIFIER
were	O
synthesized	O
and	O
evaluated	O
for	O
NK1	O
(	O
substance	O
P	O
)	O
antagonist	O
activity	O
.	O

Highly	O
potent	O
antagonists	O
,	O
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isoquinolone	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzylcarboxamides	I-IUPAC
(	O
11	O
)	O
,	O
were	O
discovered	O
from	O
the	O
structure	O
-	O
activity	O
relationship	O
studies	O
on	O
the	O
isoquinolone	O
-	O
urea	O
lead	O
1a	O
.	O

Optimization	O
of	O
the	O
activity	O
in	O
this	O
series	O
resulted	O
in	O
the	O
development	O
of	O
5	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzylcarboxamides	I-IUPAC
(	O
30	O
)	O
which	O
are	O
highly	O
potent	O
orally	O
active	O
NK1	O
antagonists	O
.	O

Among	O
the	O
compounds	O
synthesized	O
,	O
N	I-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
3,5	I-PARTIUPAC
-	I-PARTIUPAC
bis	I-PARTIUPAC
(	I-PARTIUPAC
trifluoromethyl	I-PARTIUPAC
)	I-PARTIUPAC
benzyl	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
7,8	I-PARTIUPAC
-	I-PARTIUPAC
dihydro	I-PARTIUPAC
-	I-PARTIUPAC
N	I-PARTIUPAC
,	I-PARTIUPAC
7	I-PARTIUPAC
-	I-PARTIUPAC
dimethyl	I-PARTIUPAC
-	I-PARTIUPAC
8	I-PARTIUPAC
-	I-PARTIUPAC
oxo	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
substituted	I-MODIFIER
phenyl	B-IUPAC
)	B-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
3,4	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
pyridinecarboxamides	I-PARTIUPAC
(	O
30a	O
,	O
f	O
,	O
g	O
)	O
showed	O
excellent	O
antagonist	O
activities	O
with	O
IC50	O
values	O
(	O
in	O
vitro	O
inhibition	O
of	O
[	O
125I	O
]	O
-	O
BH	O
-	O
SP	O
binding	O
in	O
human	O
IM	O
-	O
9	O
cells	O
)	O
of	O
0.21-0.34	O
nM	O
and	O
ED50	O
values	O
(	O
in	O
vivo	O
inhibition	O
of	O
capsaicin	O
-	O
induced	O
plasma	O
extravasation	O
in	O
guinea	O
-	O
pig	O
trachea	O
,	O
iv	O
)	O
of	O
0.017-0.030	O
mg	O
/	O
kg	O
.	O

These	O
compounds	O
exhibited	O
significantly	O
potent	O
activity	O
upon	O
oral	O
administration	O
with	O
ED50	O
values	O
of	O
0.068-0.17	O
mg	O
/	O
kg	O
.	O

Conformational	O
studies	O
on	O
30g	O
indicated	O
that	O
the	O
two	O
stable	O
conformers	O
of	O
30g	O
are	O
quite	O
similar	O
to	O
those	O
of	O
CP	O
-	O
99,994	O
.	O

A	O
series	O
of	O
5	I-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
was	O
evaluated	O
for	O
anticonvulsant	O
activity	O
.	O

In	O
general	O
the	O
members	O
of	O
this	O
series	O
were	O
prepared	O
by	O
the	O
alkaline	O
cyclization	O
of	O
1	I-IUPAC
-	I-IUPAC
aroyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
alkylsemicarbazides	I-IUPAC
.	O

The	O
resulting	O
2	I-MODIFIER
-	I-MODIFIER
unsubstituted	I-MODIFIER
3H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
then	O
alkylated	O
,	O
yielding	O
2,4	I-IUPAC
-	I-IUPAC
dialkyl	I-IUPAC
-	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
compounds	O
examined	O
exhibited	O
activity	O
against	O
both	O
maximal	O
electroshock	O
-	O
and	O
pentylenetetrazole	O
-	O
induced	O
seizures	O
in	O
mice	O
.	O

Receptor	O
-	O
binding	O
studies	O
suggest	O
that	O
this	O
activity	O
was	O
not	O
a	O
consequence	O
of	O
activity	O
at	O
either	O
benzodiazepine	O
or	O
NMDA	O
-	O
type	O
glutamate	O
receptors	O
.	O

From	O
this	O
series	O
,	O
compound	O
45	O
was	O
selected	O
for	O
further	O
evaluation	O
where	O
it	O
was	O
also	O
found	O
to	O
be	O
active	O
against	O
3	I-IUPAC
-	I-IUPAC
mercaptopropionic	I-IUPAC
acid	I-IUPAC
,	O
bicuculline	O
,	O
and	O
quinolinic	O
acid	O
induced	O
seizures	O
in	O
mice	O
.	O

In	O
addition	O
,	O
45	O
also	O
protected	O
gerbils	O
from	O
hippocampal	O
neuronal	O
degeneration	O
produced	O
by	O
either	O
hypoxia	O
or	O
intrastriatal	O
quinolinic	O
acid	O
injection	O
.	O

In	O
order	O
to	O
determine	O
the	O
active	O
site	O
binding	O
orientation	O
of	O
norepinephrine	O
,	O
a	O
series	O
of	O
conformationally	O
defined	O
analogues	O
of	O
the	O
tyramines	O
,	O
in	O
which	O
the	O
ethylamine	O
side	O
chain	O
is	O
held	O
fixed	O
by	O
incorporation	O
into	O
a	O
benzonorbornene	O
skeleton	O
,	O
were	O
prepared	O
and	O
evaluated	O
for	O
phenylethanolamine	O
N	O
-	O
methyltransferase	O
(	O
PNMT	O
)	O
activity	O
.	O

While	O
exo	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
5	I-PARTIUPAC
-	I-PARTIUPAC
and	O
exo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxybenzonorbornene	I-IUPAC
(	O
7	O
and	O
10	O
,	O
respectively	O
)	O
were	O
prepared	O
from	O
5	I-IUPAC
-	I-IUPAC
methoxybenzonorbornadiene	I-IUPAC
by	O
azidomercuration	O
/	O
demercuration	O
and	O
reduction	O
,	O
it	O
was	O
necessary	O
to	O
employ	O
both	O
normal	O
(	O
inversion	O
of	O
configuration	O
)	O
and	O
abnormal	O
(	O
retention	O
of	O
configuration	O
)	O
Mitsunobu	O
reactions	O
to	O
prepare	O
,	O
stereoselectively	O
,	O
exo	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
6	I-PARTIUPAC
-	I-PARTIUPAC
and	O
exo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxybenzonorbornene	I-IUPAC
(	O
8	O
and	O
9	O
,	O
respectively	O
)	O
from	O
6	I-PARTIUPAC
-	I-PARTIUPAC
and	O
7	I-IUPAC
-	I-IUPAC
methoxybenzonorbornen	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
.	O

None	O
of	O
the	O
six	O
analogues	O
were	O
substrates	O
.	O

However	O
,	O
exo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxybenzonorbornene	I-IUPAC
(	O
8	O
)	O
and	O
anti	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
hydroxybenzonorbornene	I-IUPAC
(	O
12	O
)	O
displayed	O
significant	O
activity	O
as	O
inhibitors	O
toward	O
PNMT	O
.	O

The	O
greater	O
potency	O
of	O
8	O
and	O
12	O
,	O
as	O
compared	O
to	O
the	O
parent	O
unsubstituted	O
analogues	O
exo	I-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
amino	I-PARTIUPAC
-	I-PARTIUPAC
and	O
anti	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
benzonorbornene	I-IUPAC
(	O
4	O
and	O
5	O
,	O
respectively	O
)	O
,	O
indicates	O
the	O
presence	O
of	O
a	O
spatially	O
compact	O
hydrophilic	O
pocket	O
within	O
the	O
aromatic	O
ring	O
binding	O
region	O
of	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

Furthermore	O
,	O
the	O
greater	O
activity	O
of	O
12	O
,	O
relative	O
to	O
8	O
,	O
is	O
consistent	O
with	O
an	O
active	O
site	O
binding	O
preference	O
for	O
molecules	O
in	O
which	O
a	O
more	O
coplanar	O
relationship	O
exists	O
between	O
the	O
aromatic	O
ring	O
and	O
the	O
amine	O
nitrogen	O
.	O

From	O
the	O
findings	O
of	O
this	O
study	O
,	O
it	O
appears	O
that	O
norepinephrine	O
has	O
a	O
different	O
active	O
site	O
binding	O
orientation	O
than	O
most	O
known	O
substrates	O
and	O
competitive	O
inhibitors	O
of	O
PNMT	O
.	O

To	O
provide	O
potential	O
new	O
leads	O
for	O
the	O
treatment	O
of	O
orthopoxvirus	O
infections	O
,	O
the	O
5	O
-	O
position	O
of	O
the	O
pyrimidine	O
nucleosides	O
have	O
been	O
modified	O
with	O
a	O
gem	O
diether	O
moiety	O
to	O
yield	O
the	O
following	O
new	O
nucleosides	O
:	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
2b	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
diethoxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
3b	O
)	O
,	O
5	I-IUPAC
-	I-IUPAC
formyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
ethylene	I-IUPAC
acetal	I-IUPAC
(	O
4b	O
)	O
,	O
and	O
5	I-IUPAC
-	I-IUPAC
formyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
propylene	I-IUPAC
acetal	I-IUPAC
(	O
5b	O
)	O
.	O

These	O
were	O
evaluated	O
in	O
human	O
foreskin	O
fibroblast	O
cells	O
challenged	O
with	O
the	O
vaccinia	O
virus	O
or	O
cowpox	O
virus	O
.	O

Of	O
the	O
four	O
gem	O
diether	O
nucleosides	O
,	O
only	O
the	O
dimethyl	O
gem	O
diether	O
congener	O
showed	O
significant	O
antiviral	O
activity	O
against	O
both	O
viruses	O
.	O

This	O
antiviral	O
activity	O
did	O
not	O
appear	O
to	O
be	O
related	O
to	O
the	O
decomposition	O
to	O
the	O
5	I-IUPAC
-	I-IUPAC
formyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
which	O
was	O
itself	O
devoid	O
of	O
anti	O
-	O
orthopoxvirus	O
activity	O
in	O
these	O
assays	O
.	O

Moreover	O
,	O
at	O
the	O
pH	O
of	O
the	O
in	O
vitro	O
assays	O
,	O
2b	O
was	O
very	O
stable	O
with	O
a	O
decomposition	O
(	O
to	O
aldehyde	O
)	O
half	O
-	O
life	O
of	O
&	O
gt	O
;	O
15	O
d	O
.	O

The	O
anti	O
-	O
orthopoxvirus	O
activity	O
of	O
pyrimidine	O
may	O
be	O
favored	O
by	O
the	O
introduction	O
of	O
hydrophilic	O
moieties	O
to	O
the	O
5	O
-	O
position	O
side	O
chain	O
.	O

New	O
acylated	O
bis	I-IUPAC
-	I-IUPAC
catecholates	I-IUPAC
and	O
1,3	I-IUPAC
-	I-IUPAC
benzoxazine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
derivatives	I-MODIFIER
based	O
on	O
secondary	O
diamino	O
acids	O
(	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
glycines	I-IUPAC
,	O
N	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
,	O
and	O
N	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminovaleric	I-IUPAC
acid	I-IUPAC
)	O
,	O
on	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
aminomethyl	I-IUPAC
benzoic	I-IUPAC
acids	I-IUPAC
,	O
on	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
aminomethyl	I-IUPAC
phenoxyacetic	I-IUPAC
acids	I-IUPAC
,	O
or	O
on	O
3,5	I-IUPAC
-	I-IUPAC
diaminobenzoic	I-IUPAC
acid	I-IUPAC
were	O
synthesized	O
as	O
artificial	O
siderophores	O
.	O

The	O
corresponding	O
diamino	O
acids	O
were	O
obtained	O
from	O
the	O
diamines	O
and	O
oxocarboxylic	O
acids	O
by	O
catalytic	O
hydrogenation	O
.	O

The	O
acylated	O
bis	I-IUPAC
-	I-IUPAC
catecholates	I-IUPAC
and	O
1,3	I-IUPAC
-	I-IUPAC
benzoxazine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diones	I-IUPAC
were	O
coupled	O
with	O
ampicillin	O
or	O
amoxicillin	O
to	O
new	O
siderophore	O
aminoacylpenicillin	O
conjugates	O
.	O

These	O
conjugates	O
exhibited	O
very	O
strong	O
antibacterial	O
activity	O
in	O
vitro	O
against	O
Gram	O
-	O
negative	O
bacterial	O
pathogens	O
including	O
Pseudomonas	O
aeruginosa	O
,	O
Stenotrophomonas	O
maltophilia	O
,	O
Escherichia	O
coli	O
,	O
Klebsiella	O
pneumoniae	O
,	O
and	O
Serratia	O
marcescens	O
.	O

The	O
ampicillin	O
derivative	O
7b	O
(	O
HKI	O
9924154	O
)	O
and	O
the	O
corresponding	O
amoxicillin	O
derivative	O
8	O
(	O
HKI	O
9924155	O
)	O
represent	O
the	O
most	O
active	O
compounds	O
.	O

The	O
conjugates	O
can	O
use	O
bacterial	O
iron	O
siderophore	O
uptake	O
routes	O
to	O
penetrate	O
the	O
Gram	O
-	O
negative	O
outer	O
membrane	O
permeability	O
barrier	O
.	O

This	O
was	O
demonstrated	O
by	O
assays	O
with	O
mutants	O
deficient	O
in	O
components	O
of	O
the	O
iron	O
transport	O
systems	O
.	O

New	O
siderophore	O
penicillin	O
V	O
conjugates	O
with	O
the	O
siderophore	O
component	O
attached	O
to	O
the	O
phenyl	O
ring	O
of	O
penicillin	O
V	O
are	O
inactive	O
against	O
these	O
Gram	O
-	O
negative	O
bacteria	O
.	O

A	O
series	O
of	O
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
tyrosines	I-IUPAC
and	O
a	O
carboxy	O
terminal	O
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
tyrosine	I-IUPAC
and	O
-	I-PARTIUPAC
phenylalanine	I-PARTIUPAC
were	O
synthesized	O
as	O
potential	O
serine	O
protease	O
inhibitors	O
.	O

N	I-IUPAC
-	I-IUPAC
Acetyl	I-IUPAC
derivatives	I-MODIFIER
showed	O
irreversible	O
inactivation	O
vis	O
-	O
a	O
-	O
vis	O
subtilisin	O
,	O
while	O
the	O
N	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
ones	I-IUPAC
were	O
specific	O
toward	O
chymotrypsin	O
.	O

The	O
most	O
potent	O
inactivation	O
of	O
chymotrypsin	O
was	O
achieved	O
by	O
a	O
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
epoxybutyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosine	I-IUPAC
derivative	I-MODIFIER
.	O

The	O
inactivation	O
was	O
shown	O
to	O
be	O
stereospecific	O
since	O
a	O
D	O
derivative	O
led	O
to	O
no	O
irreversible	O
inactivation	O
.	O

Placement	O
of	O
the	O
epoxyalkyl	O
group	O
at	O
the	O
carboxy	O
terminus	O
led	O
to	O
potent	O
rapid	O
inactivation	O
.	O

Under	O
these	O
conditions	O
some	O
of	O
the	O
activity	O
was	O
later	O
recovered	O
.	O

The	O
two	O
classes	O
of	O
inactivators	O
(	O
O'	I-IUPAC
-	I-IUPAC
epoxyalkyl	I-IUPAC
and	O
carboxy	I-IUPAC
-	I-IUPAC
epoxyalkyl	I-IUPAC
)	O
appear	O
to	O
operate	O
by	O
different	O
mechanisms	O
.	O

Most	O
importantly	O
,	O
it	O
was	O
found	O
that	O
irreversible	O
inactivation	O
by	O
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosine	I-IUPAC
only	O
resulted	O
if	O
the	O
carboxy	O
terminus	O
was	O
a	O
substrate	O
(	O
i.e.	O
a	O
compound	O
with	O
free	O
carboxy	O
terminus	O
did	O
not	O
lead	O
to	O
inactivation	O
)	O
.	O

The	O
ultimate	O
activity	O
kinetic	O
assay	O
(	O
Daniels	O
,	O
S	O
.	O

B	O
.	O

;	O
et	O
al.	O
J	O
.	O

Biol.	O
Chem.	O
1983	O
,	O
258	O
,	O
15046-15053	O
.	O

)	O
indicated	O
that	O
the	O
epoxyalkyl	O
group	O
on	O
the	O
phenolic	O
oxygen	O
had	O
an	O
optimal	O
length	O
of	O
four	O
carbons	O
with	O
respect	O
to	O
the	O
turnover	O
ratio	O
(	O
the	O
ratio	O
of	O
molecules	O
undergoing	O
turnover	O
compared	O
to	O
those	O
that	O
inactivate	O
the	O
enzyme	O
)	O
for	O
chymotrypsin	O
.	O

A	O
different	O
kinetic	O
assay	O
(	O
Ashani	O
,	O
Y	O
.	O

;	O
Wins	O
,	O
P	O
.	O

;	O
Wilson	O
,	O
I	O
.	O

B	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
1972	O
,	O
284	O
,	O
427-434	O
.	O

)	O
demonstrated	O
that	O
substratelike	O
turnover	O
was	O
proceeding	O
at	O
considerably	O
slower	O
rates	O
than	O
for	O
the	O
corresponding	O
true	O
substrates	O
and	O
with	O
rate	O
-	O
limiting	O
deacylation	O
of	O
the	O
acyl	O
-	O
enzyme	O
.	O

Amino	O
acid	O
analysis	O
subsequent	O
to	O
acid	O
hydrolysis	O
demonstrated	O
that	O
Met	O
had	O
been	O
selectively	O
alkylated	O
by	O
the	O
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
tyrosine	I-IUPAC
derivative	I-MODIFIER
.	O

By	O
contrast	O
,	O
alpha	O
-	O
chymotrypsin	O
inactivated	O
with	O
N	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
Phe	I-IUPAC
-	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
epoxypropyl	I-IUPAC
ester	I-IUPAC
then	O
subjected	O
to	O
amino	O
acid	O
analysis	O
showed	O
no	O
change	O
in	O
the	O
content	O
of	O
any	O
amino	O
acid	O
that	O
would	O
serve	O
as	O
a	O
potential	O
nucleophile	O
to	O
the	O
inhibitor	O
.	O

Yet	O
,	O
the	O
L	O
-	O
Phe	O
content	O
increased	O
,	O
indicating	O
that	O
a	O
covalent	O
bond	O
had	O
been	O
formed	O
between	O
the	O
inhibitor	O
and	O
the	O
enzyme	O
.	O

Either	O
the	O
bond	O
between	O
the	O
inhibitor	O
and	O
the	O
enzyme	O
did	O
not	O
withstand	O
the	O
hydrolytic	O
conditions	O
and	O
/	O
or	O
there	O
was	O
less	O
than	O
10%	O
decrease	O
in	O
the	O
amino	O
acids	O
with	O
nucleophilic	O
side	O
chains	O
upon	O
inactivation	O
.	O

Finally	O
,	O
two	O
tripeptides	O
containing	O
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
epoxyalkyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tryosines	I-IUPAC
were	O
synthesized	O
[	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
epoxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosi	I-IUPAC
ne	I-IUPAC
ethyl	I-IUPAC
ester	I-IUPAC
and	O
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
valyl	I-IUPAC
-	I-IUPAC
O'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
epoxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
valine	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
]	O
as	O
potential	O
elastase	O
inhibitors	O
and	O
were	O
found	O
to	O
reversibly	O
and	O
competitively	O
inhibit	O
porcine	O
pancreatic	O
elastase	O
.	O

A	O
series	O
of	O
erythro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonyl	I-IUPAC
)	I-IUPAC
azole	I-IUPAC
derivatives	I-MODIFIER
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
adenosine	O
deaminase	O
(	O
ADA	O
)	O
inhibitory	O
activity	O
,	O
in	O
order	O
to	O
introduce	O
simplifications	O
in	O
the	O
ADA	O
inhibitor	O
erythro	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
(	O
EHNA	O
,	O
1a	O
)	O
.	O

The	O
synthesis	O
of	O
most	O
of	O
the	O
reported	O
compounds	O
was	O
achieved	O
by	O
reaction	O
of	O
2	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonanone	I-IUPAC
with	O
the	O
suitable	O
azole	O
followed	O
by	O
reduction	O
of	O
the	O
carbonyl	I-IUPAC
group	B-MODIFIER
to	O
give	O
a	O
diastereoisomeric	O
mixture	O
of	O
N	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonyl	I-IUPAC
)	I-IUPAC
azoles	I-IUPAC
.	O

Separation	O
of	O
diastereoisomers	O
was	O
achieved	O
by	O
HPLC	O
or	O
by	O
preparative	O
TLC	O
plates	O
.	O

The	O
results	O
of	O
the	O
enzymatic	O
test	O
indicate	O
that	O
the	O
nitrogen	O
in	O
the	O
3	O
-	O
position	O
,	O
and	O
secondly	O
,	O
the	O
nitrogen	O
in	O
the	O
5	O
-	O
position	O
are	O
very	O
important	O
for	O
the	O
interaction	O
of	O
the	O
azole	O
ring	O
with	O
the	O
inhibitory	O
site	O
on	O
the	O
enzyme	O
.	O

In	O
fact	O
,	O
the	O
pyrazole	O
and	O
the	O
2	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1,2,3	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
derivatives	I-MODIFIER
(	O
10	O
and	O
15	O
,	O
respectively	O
)	O
are	O
nearly	O
inactive	O
,	O
whereas	O
the	O
erythro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
nonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
triazole	I-IUPAC
(	O
18e	O
)	O
was	O
the	O
most	O
potent	O
ADA	O
inhibitor	O
in	O
the	O
series	O
with	O
Ki	O
=	O
0.3	O
microM	O
.	O

